
<html lang="en"     class="pb-page"  data-request-id="2dec33c9-efef-4971-85ab-dc1a6c44b7af"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2021.64.issue-6;website:website:acspubs;article:article:10.1021/acs.jmedchem.0c01851;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance" /></meta><meta name="dc.Creator" content="Zhijie  Wang" /></meta><meta name="dc.Creator" content="Jiongheng  Cai" /></meta><meta name="dc.Creator" content="Jie  Cheng" /></meta><meta name="dc.Creator" content="Wenqianzi  Yang" /></meta><meta name="dc.Creator" content="Yifan  Zhu" /></meta><meta name="dc.Creator" content="Hongmei  Li" /></meta><meta name="dc.Creator" content="Tao  Lu" /></meta><meta name="dc.Creator" content="Yadong  Chen" /></meta><meta name="dc.Creator" content="Shuai  Lu" /></meta><meta name="dc.Description" content="Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are often present in newly diagnosed acute myeloid leukemia (AML) patients with an incidence rate of approximately 30%. Recently, many FLT3 i..." /></meta><meta name="Description" content="Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are often present in newly diagnosed acute myeloid leukemia (AML) patients with an incidence rate of approximately 30%. Recently, many FLT3 i..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 10, 2021" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01851" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01851" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01851" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01851" /></link>
        
    
    

<title>FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01851" /></meta><meta property="og:title" content="FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0019.jpeg" /></meta><meta property="og:description" content="Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are often present in newly diagnosed acute myeloid leukemia (AML) patients with an incidence rate of approximately 30%. Recently, many FLT3 inhibitors have been developed and exhibit positive preclinical and clinical effects against AML. However, patients develop resistance soon after undergoing FLT3 inhibitor treatment, resulting in short durable responses and poor clinical effects. This review will discuss the main mechanisms of resistance to clinical FLT3 inhibitors and summarize the emerging strategies that are utilized to overcome drug resistance. Basically, medicinal chemistry efforts to develop new small-molecule FLT3 inhibitors offer a direct solution to this problem. Other potential strategies include the combination of FLT3 inhibitors with other therapies and the development of multitarget inhibitors. It is hoped that this review will provide inspiring insights into the discovery of new AML therapies that can eventually overcome the resistance to current FLT3 inhibitors." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01851"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01851">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01851&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01851&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01851&amp;href=/doi/10.1021/acs.jmedchem.0c01851" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 6</span><span class="cit-fg-pageRange">, 2878-2900</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/6" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01640" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c02050" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Zhijie Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhijie Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Science, China Pharmaceutical University, Nanjing 211198, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhijie++Wang">Zhijie Wang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jiongheng Cai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jiongheng Cai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Science, China Pharmaceutical University, Nanjing 211198, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jiongheng++Cai">Jiongheng Cai</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jie Cheng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jie Cheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Science, China Pharmaceutical University, Nanjing 211198, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jie++Cheng">Jie Cheng</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wenqianzi Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenqianzi Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Science, China Pharmaceutical University, Nanjing 211198, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenqianzi++Yang">Wenqianzi Yang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yifan Zhu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yifan Zhu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, China Pharmaceutical University, Nanjing 210009, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yifan++Zhu">Yifan Zhu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hongmei Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hongmei Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Science, China Pharmaceutical University, Nanjing 211198, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hongmei++Li">Hongmei Li</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tao Lu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tao Lu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, P.R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Tao Lu: phone, +86-25-86185163; fax, +86-25-86185182; email, <a href="/cdn-cgi/l/email-protection#69051c1d0806290a191c470c0d1c470a07"><span class="__cf_email__" data-cfemail="08647d7c6967486b787d266d6c7d266b66">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tao++Lu">Tao Lu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath7">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yadong Chen</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yadong Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Molecular Design and Drug Discovery, China Pharmaceutical University, Nanjing, 211198, P.R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Yadong Chen: phone, +86-25-86185169; fax, +86-25-86185170; email, <a href="/cdn-cgi/l/email-protection#abc8c3cec5d2cacfc4c5ccebccc6cac2c785c8c4c6"><span class="__cf_email__" data-cfemail="f3909b969d8a92979c9d94b3949e929a9fdd909c9e">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yadong++Chen">Yadong Chen</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath8">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2189-9356" title="Orcid link">http://orcid.org/0000-0002-2189-9356</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Shuai Lu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shuai Lu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Science, China Pharmaceutical University, Nanjing 211198, P.R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Shuai Lu: phone, +86-25-86185153; fax, +86-25-86185155; email: <a href="/cdn-cgi/l/email-protection#620e173d110a17030b220112174c0706174c010c"><span class="__cf_email__" data-cfemail="8ce0f9d3ffe4f9ede5cceffcf9a2e9e8f9a2efe2">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shuai++Lu">Shuai Lu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath9">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0169-349X" title="Orcid link">http://orcid.org/0000-0002-0169-349X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01851&amp;href=/doi/10.1021%2Facs.jmedchem.0c01851" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 6</span><span class="cit-pageRange">, 2878–2900</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 10, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>23 October 2020</li><li><span class="item_label"><b>Published</b> online</span>10 March 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 March 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01851" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01851</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2878%26pageCount%3D23%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DZhijie%2BWang%252C%2BJiongheng%2BCai%252C%2BJie%2BCheng%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D6%26contentID%3Dacs.jmedchem.0c01851%26title%3DFLT3%2BInhibitors%2Bin%2BAcute%2BMyeloid%2BLeukemia%253A%2BChallenges%2Band%2BRecent%2BDevelopments%2Bin%2BOvercoming%2BResistance%26numPages%3D23%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2900%26publicationDate%3DMarch%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01851"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1514</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01851" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Zhijie&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Jiongheng&quot;,&quot;last_name&quot;:&quot;Cai&quot;},{&quot;first_name&quot;:&quot;Jie&quot;,&quot;last_name&quot;:&quot;Cheng&quot;},{&quot;first_name&quot;:&quot;Wenqianzi&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Yifan&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Hongmei&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Tao&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Yadong&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Shuai&quot;,&quot;last_name&quot;:&quot;Lu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;10&quot;,&quot;issue&quot;:&quot;6&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;2878-2900&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01851&quot;},&quot;abstract&quot;:&quot;Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are often present in newly diagnosed acute myeloid leukemia (AML) patients with an incidence rate of approximately 30%. Recently, many FLT3 inhibitors have been developed and exhibit positive preclinical and clinical effects against AML. However, patients develop resistance soon after undergoing FLT3 inhibitor treatment, resulting in short durable responses and poor clinical effects. This review will discuss the main mechanisms of resistance to clinical FLT3 inhibitors and summarize the emerging strategies that are utilized to overcome drug resistance. Basically, medicinal chemistry efforts to develop new small-molecule FLT3 inhibitors offer a direct solution to this problem. Other potential strategies include the combination of FLT3 inhibitors with other therapies and the development of multitarget inhibitors. It is hoped that this review will provide inspiring insights into the discovery of new AML therapies that can eventually overcome the resistance &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01851&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01851" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01851&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01851" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01851&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01851" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01851&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01851&amp;href=/doi/10.1021/acs.jmedchem.0c01851" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01851" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01851" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01851%26sid%3Dliteratum%253Aachs%26pmid%3D33719439%26genre%3Darticle%26aulast%3DWang%26date%3D2021%26atitle%3DFLT3%2BInhibitors%2Bin%2BAcute%2BMyeloid%2BLeukemia%253A%2BChallenges%2Band%2BRecent%2BDevelopments%2Bin%2BOvercoming%2BResistance%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D6%26spage%3D2878%26epage%3D2900%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292227" title="Drug resistance">Drug resistance</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/6" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/jmcmar.2021.64.issue-6/20210325/jmcmar.2021.64.issue-6.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Mutations in the FMS-like tyrosine kinase 3 (<i>FLT3</i>) gene are often present in newly diagnosed acute myeloid leukemia (AML) patients with an incidence rate of approximately 30%. Recently, many FLT3 inhibitors have been developed and exhibit positive preclinical and clinical effects against AML. However, patients develop resistance soon after undergoing FLT3 inhibitor treatment, resulting in short durable responses and poor clinical effects. This review will discuss the main mechanisms of resistance to clinical FLT3 inhibitors and summarize the emerging strategies that are utilized to overcome drug resistance. Basically, medicinal chemistry efforts to develop new small-molecule FLT3 inhibitors offer a direct solution to this problem. Other potential strategies include the combination of FLT3 inhibitors with other therapies and the development of multitarget inhibitors. It is hoped that this review will provide inspiring insights into the discovery of new AML therapies that can eventually overcome the resistance to current FLT3 inhibitors.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80564" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80564" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Since FMS-like tyrosine kinase 3 (FLT3) was discovered in 1991 by Birnbaum and colleagues,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> its biological functions and therapeutic targeting have developed rapidly (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). FLT3 also known as fetal liver kinase 2 (FLK-2) or human stem cell kinase-1 (STK-1), belongs to the same type III receptor tyrosine kinase (RTK) family as FMS, KIT, and platelet-derived growth factor receptor (PDGFR) kinases, which share strong sequence similarities.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Birnbaum and colleagues cloned the human FLT3 protein structure in human CD34<sup>+</sup> hematopoietic progenitor cells in 1993.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The <i>FLT3</i> gene contains 24 codons on chromosome 13q12 and codes for a receptor-type tyrosine kinase containing 993 amino acid residues that is expressed in various lymphohematopoietic cells and tissues and is important for the normal development of stem cells and the immune system.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> FLT3 is composed of an extracellular ligand-binding portion containing five immunoglobulin-like domains, a transmembrane domain, a juxtamembrane domain, and a highly conserved intracellular kinase domain. Griffith et al. first revealed the crystal structure of the autoinhibited form of FLT3, which mainly includes the juxtamembrane domain and activation loop (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> When the FLT3 ligand (FL) binds the extracellular domain, FLT3 dimerizes and is autophosphorylated and subsequently activates its downstream signaling pathways, including signal transducer and activator of transcription 5A (STAT5A),<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> RAS/mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3 kinase (PI3K)/AKT pathways, promoting the growth, proliferation, survival, and differentiation of myeloid cells.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Timeline of key advances relating to the biology and therapeutic targeting of FLT3.<a onclick="showRef(event, 'ref1 ref2 ref3 ref11 ref13 ref20 ref24 ref26 ref29 ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref11 ref13 ref20 ref24 ref26 ref29 ref30 ref31 ref32">(1−3,11,13,20,24,26,29−32)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure of FLT3 kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB">1RJB</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Acute myeloid leukemia (AML) is a hematopoietic stem cell malignancy characterized by dysfunction of the bone marrow hematopoietic system, excessive growth, and proliferation of hematopoietic stem cells and the obstruction of differentiation and apoptosis.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> Many clinical studies indicate that mutations of the <i>FLT3</i> gene exist in 25%–45% of AML patients<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> and are divided into two forms.</div><div class="NLM_p">Internal tandem duplications (ITDs) in the juxtamembrane domain of FLT3 were first described by Nakao and colleagues in 1996<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and occur in approximately 25% of AML patients.<a onclick="showRef(event, 'ref2 ref10'); return false;" href="javascript:void(0);" class="ref ref2 ref10">(2,10)</a> The length and position of ITD mutations are variable, ranging in size from 3 to 1236 nucleotides. The different sizes of ITD mutations have unequal prognostic significance in AML patients; the longer the size is, the lower the overall survival (OS) rate of AML patients is.<a onclick="showRef(event, 'ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13">(11−13)</a> Furthermore, patients who have a high FLT3-ITD burden easily relapse even if the condition is relieved after chemotherapy or after receiving allohematopoietic stem cell transplantation (alloHSCT).<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> FLT3-ITD mutations can ligand-independently and constitutively activate FLT3 signaling pathways and suppress CCAAT/estradiol-binding protein alpha (c/EBPalpha) and Pu.1, which are transcription factors that can promote the differentiation of myeloid cells.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> Recently, both the National Comprehensive Cancer Network and European LeukemiaNet have listed FLT3-ITD as a high-risk mutation in AML and suggested screening for it at the time of diagnosis.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a></div><div class="NLM_p last">The other form of FLT3 mutation is a missense point mutation in a highly conserved structure of FLT3 kinase, the activation loop of the tyrosine kinase domain (TKD), including substitutions, deletions, and insertions in the activation loop, which is found in approximately 7% of patients with AML.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> The most commonly occurring TKD mutations are substitutions of aspartic acid at position 835, such as D835Y, D835V, D835H, D835E, and D835N.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> Similar to the ITD mutation, the TKD mutation can lead to ligand-independent dimerization and autophosphorylation and constitutively activate FLT3 signaling pathways, including the PI3K/AKT and MEK/ERK pathways but not STAT5 signaling pathways. In addition, the TKD mutation does not suppress c/EBPalpha and Pu.1.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Although the TKD mutation alone can upregulate the kinase activity of FLT3, its relationship with the pathogenesis and prognosis of AML is still not particularly clear.<a onclick="showRef(event, 'ref20 ref22'); return false;" href="javascript:void(0);" class="ref ref20 ref22">(20,22)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  FLT3 Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84362" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84362" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Because of the close correlations of FLT3 mutation and the poor prognosis, high relapse, and mortality rates of AML patients,<a onclick="showRef(event, 'ref14 ref20'); return false;" href="javascript:void(0);" class="ref ref14 ref20">(14,20)</a> FLT3 has become a promising drug target for AML therapy.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Primary drugs against FLT3 mutations are small-molecule inhibitors, although Williams et al. developed fully internalizing human antagonistic antibodies against FLT3 to suppress leukemia cell growth.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><div class="NLM_p">Small-molecule FLT3 inhibitors compete with ATP to interact with the ATP-binding site of the intracellular TKD, preventing receptor autophosphorylation and the subsequent activation of downstream signaling.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> According to their specificity against FLT3, FLT3 inhibitors are classified into two generations<a onclick="showRef(event, 'ref22 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref24">(22,24)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The first-generation inhibitors are nonselective and multitarget inhibitors, such as midostaurin (<b>1</b>), lestaurtinib (<b>2</b>), sunitinib (<b>3</b>), sorafenib (<b>4</b>), and tandutinib (<b>5</b>). Second-generation inhibitors, such as quizartinib (<b>6</b>), gilteritinib (<b>7</b>), and crenolanib (<b>8</b>), have improved selectivity against FLT3. Both generations of inhibitors have strong inhibitory effects on the FLT3-ITD mutation. In addition, according to the bound conformation of the FLT3 TKD, the inhibitors can be divided into type I inhibitors (midostaurin, lestaurtinib, gilteritinib, and crenolanib) that bind the DFG-in conformation (active conformation) and type II inhibitors (sorafenib, quizartinib, and tandutinib) that bind the DFG-out conformation (inactive conformation). The DFG motif of FLT3 includes residues D829, F830, and G831, and the orientation of these three amino acid residues indicates the conformation of FLT3 kinase. In the DFG-in (active) conformation, the side chain of D829 is directed into the ATP-binding site, and the aromatic ring in the side chain of F830 is positioned in the back cleft. In the DFG-out (inactive) conformation, the aromatic ring in the side chain of F830 is directed into the ATP-binding site, and the side chain of D829 is positioned in the back cleft, generating an extra hydrophobic region adjacent to the ATP-binding site. Type II inhibitors occupy this region, while type I inhibitors do not.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> FLT3 inhibitors alone or in combination with other therapies can alleviate the symptoms of AML and prolong the OS of patients with AML. However, patients will develop drug resistance soon after receiving such treatments, resulting in a shorter response period for FLT3 inhibitors. The causes of drug resistance are complex and diverse, and this obstacle urgently needs to be addressed to improve the treatment effect and survival of patients.<a onclick="showRef(event, 'ref24 ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref24 ref26 ref27 ref28">(24,26−28)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. First- and Second-Generation FLT3 Inhibitors<a onclick="showRef(event, 'ref24 ref29 ref30 ref32 ref33 ref34 ref35 ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref24 ref29 ref30 ref32 ref33 ref34 ref35 ref36 ref37 ref38">(24,29,30,32−38)</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0018.gif" alt="" id="fx1" /></img><div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">3.  Resistance to FLT3 Inhibitor</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56718" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56718" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Although FLT3 inhibitors have made positive clinical progresses, there are still some significant problems. Among them, drug resistance is urgent to overcome, as it often results in a short durable response to FLT3 inhibitors.<a onclick="showRef(event, 'ref18 ref29 ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref18 ref29 ref39 ref40 ref41">(18,29,39−41)</a></div><div class="NLM_p">Resistance for FLT3 inhibitors in AML patients may occur by on-target or off-target mechanisms (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Secondary point mutations in the TKD of FLT3-ITD confer on-target drug resistance to FLT3 inhibitors.<a onclick="showRef(event, 'ref27 ref29 ref42'); return false;" href="javascript:void(0);" class="ref ref27 ref29 ref42">(27,29,42)</a> For instance, mutation of the D835 residue in the kinase activation loop weakens the efficacy of type II FLT3 inhibitors (such as quizartinib and sorafenib) because this mutation induces a DFG-in conformation that hinders the binding of type II inhibitors.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> Another common mutation related to on-target resistance occurs on the F691 residue of FLT3-ITD, the “gatekeeper” residue, which confers resistance to quizartinib due to the disappearance of edge-to-face interactions between it and FLT3.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Essentially, all secondary mutations decrease the affinity between FLT3 and its inhibitors, resulting in resistance to FLT3 inhibitors.<a onclick="showRef(event, 'ref27 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref27 ref42 ref43">(27,42,43)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Mechanisms of Resistance to FLT3 Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">on-target</th><th class="colsep0 rowsep0" align="center">off-target</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">such as D835V/Y/F/H, F691L/I, N676D, Y842C/H</td><td class="colsep0 rowsep0" align="left">activation of FLT3 downstream signaling pathways (JAK/STAT5, PI3K/AKT/mTOR)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">specific mutations such as TET2, RAS, IDH1/2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">activation of SYK</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">activation of AXL</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">upregulation of Pim</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">upregulation of FL</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">protection of bone marrow microenvironment</td></tr></tbody></table></div></div><div class="NLM_p">Mechanisms of off-target resistance consist of the compensatory activation of other progrowth and prosurvival signaling pathways, the upregulation of FL expression, and the formation of a protective bone marrow microenvironment.<a onclick="showRef(event, 'ref26 ref46 ref47 ref48 ref49 ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref26 ref46 ref47 ref48 ref49 ref50 ref51">(26,46−51)</a> Aberrant activation of FLT3 downstream signaling pathways, such as the JAK/STAT5 or PI3K/AKT/mTOR pathway, in FLT3-mutated cells has been widely reported, and these changes eventually decrease the cytotoxic effects of FLT3 inhibitors (midostaurin, sorafenib, quizartinib) on AML cells.<a onclick="showRef(event, 'ref46 ref47 ref52'); return false;" href="javascript:void(0);" class="ref ref46 ref47 ref52">(46,47,52)</a> In a recent study, whole-exome sequencing of AML patient samples showed that TET2, RAS pathway, and IDH1/2 mutations promoted crenolanib resistance.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> An in vivo study demonstrated that spleen tyrosine kinase (SYK) activation conferred resistance to quizartinib by transactivating FLT3 via direct binding.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The level of AXL phosphorylation was enhanced significantly in MV4-11 and primary AML cells with FLT3-ITD after treatment with FLT3 inhibitors (midostaurin and quizartinib), which caused resistance to these two inhibitors.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Pim kinases are frequently overexpressed in various tumors, including AML. Green and colleagues found that the level of Pim expression was upregulated in sorafenib-resistant primary AML cells and that the upregulation of Pim contributed to FLT3 inhibitor (sorafenib and quizartinib) resistance.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> In addition to activating the compensatory pathways, multiple studies indicated that the upregulation of FL levels impeded the effects of FLT3 inhibitors (lestaurtinib, midostaurin, sorafenib, KW-2449, and quizartinib).<a onclick="showRef(event, 'ref51 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref51 ref54 ref55">(51,54,55)</a> Consistently, clinical trials also showed that enhanced plasma FL levels after chemotherapy conferred resistance to lestaurtinib.<a onclick="showRef(event, 'ref51 ref54'); return false;" href="javascript:void(0);" class="ref ref51 ref54">(51,54)</a> An in vitro study also illustrated that increased FL levels activated WT-FLT3 but not FLT3-ITD, resulting in resistance to quizartinib.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Moreover, the protection of AML cells in the bone marrow microenvironment is conducive to FLT3 inhibitor resistance,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> mainly through the upregulation of various cytokines and growth factors in this specific microenvironment. For example, fibroblast growth factor 2 (FGF2) in bone marrow stromal cells was upregulated in AML patients harboring FLT3-ITD after treatment with quizartinib, and its level peaked prior to obvious clinical relapse and detection of resistance-conferring mutations.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> An in vitro study demonstrated that exogenous FGF2 protected MOLM14 cells from quizartinib by activating FGFR1 and downstream MAPK effectors.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Furthermore, Jones and colleagues found that the expression of CYP3A4 in bone marrow stromal cells decreased the efficacies of quizartinib, sorafenib, and gilteritinib against AML cells harboring FLT3-ITD.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></div><div class="NLM_p">Correspondingly, a variety of new compounds or combination therapies have been studied to antagonize the proposed molecular mechanisms related to resistance to FLT3 inhibitors, and these new strategies are categorized as the new-generation FLT3 inhibitors, combination therapies with FLT3 inhibitors and multitarget inhibitors (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). These strategies are discussed in detail as follows.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Primary strategy to overcome FLT3 inhibitor resistance.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">3.1.  Develop New FLT3 Inhibitors That Are Effective against FLT3-ITD-TKD Mutations</h3><div class="NLM_p">Researchers have made considerable efforts to overcome the existing problems of FLT3 inhibitors such as their limited and transient efficacy.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> To overcome on-target resistance, medicinal chemists chose to develop new FLT3 inhibitors that are effective against FLT3-ITD-TKD mutations via ingenious molecular design rationales.</div><div class="NLM_p">Pexidartinib (PLX3397, <b>9</b>) is a triple-kinase inhibitor of KIT (half-maximal inhibitory concentration [IC<sub>50</sub>]: 27 nM), CSF1R (IC<sub>50</sub>: 13 nM), and FLT3-ITD (IC<sub>50</sub>: 11 nM). Pexidartinib has a shorter linker (methyl amine) between the middle and tail pyridine rings than other common type II inhibitors<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). The molecular docking simulation by Shah and colleagues<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> showed that pexidartinib did not interact with the gatekeeper residue of FLT3 and formed two hydrogen bonds with E692 and D829 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B). The hydrogen bond between pexidartinib and D829 sequestered pexidartinib away from F691, thus avoiding the adverse influence of the F691L mutation, which may contribute to overcoming the effect of the secondary FLT3-F691L mutation. Pexidartinib inhibited the proliferation of BaF3-FLT3-ITD (IC<sub>50</sub>: 130 nM), BaF3-FLT3-ITD-F691L (IC<sub>50</sub>: 97 nM), MOLM14 (IC<sub>50</sub>: 350 nM), and MOLM14-F691L (IC<sub>50</sub>: 670 nM) cells. Moreover, the levels of FLT3 and STAT5 phosphorylation inhibition by pexidartinib were equivalent to those in the FLT3-F691L-transformed MOLM14 and parental MOLM14 cells in the presence of human plasma. In an analysis of clinical patient samples after pexidartinib treatment, the FLT3-F691L mutation was not detected. However, the efficacy of pexidartinib was vulnerable to other residue mutations, particularly the residue located in the activation loop, such as D835 (BaF3-FLT3-ITD-D835Y IC<sub>50</sub>: 4700 nM).<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Chemical structure of pexidartinib. (B) Docking of pexidartinib into FLT3 kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>). The red dashed lines represent hydrogen bonds; the carbon atoms of the residues and the ligand are shown in yellow and green, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Ge and colleagues discovered a novel type II FLT3 inhibitor, MZH29 (<b>10</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A), that showed potent inhibitory activities against BaF3-FLT3-ITD and BaF3-FLT3-ITD-F691L (IC<sub>50</sub>: 0.22 and 1.1 nM, respectively). Molecular docking simulation showed that four hydrogen bonds formed between MZH29 and E661, C694 and D829, and a π–π stacking interaction formed between MZH29 and F830 in the MZH29-FLT3-F691L model (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B), which may contribute to the stable binding of MZH29 and further explained why MZH29 was effective in cells with the F691L mutation. Although MZH29 exhibited excellent inhibitory activity against BaF3-FLT3-D835Y/H/V cells (IC<sub>50</sub>: 0.19, 0.17, and 2.5 nM, respectively), its efficacy against cells with the FLT3-ITD-D835Y mutation was weakened (IC<sub>50</sub>: 22 nM).<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Chemical structure of MZH29. (B) Docking of MZH29 into FLT3 kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>). The red dashed lines represent hydrogen bonds; the yellow dashed line represents π–π interactions; the carbon atoms of the residues and the ligand are shown in yellow and green, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Cabozantinib (<b>11</b>) is a multitarget inhibitor targeting FLT3, AXL, MET, VEGFR, and KIT and exhibits positive clinical efficacy in AML patients harboring FLT3-ITD mutations (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). In vitro, cabozantinib potently inhibited FLT3 phosphorylation in FLT3-ITD-positive cells under both medium and plasma conditions (IC<sub>50</sub>: 0.6 and 34 nM, respectively). Unlike the type II inhibitor quizartinib, cabozantinib also effectively suppressed FLT3 phosphorylation in BaF3-FLT3-ITD-F691L cells in both medium and plasma, with an IC<sub>50</sub> value of 2.86 nM in media, indicating that the F691L mutation hardly affects the binding of the inhibitor with FLT3. In the docking binding model, the middle phenylamine moiety of cabozantinib maintained a remote distance from F691 and formed a hydrogen bond with D829 opposite F691 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B), which partly supports its potent inhibitory activity in FLT3-ITD-F691L cells. However, consistent with most type II FLT3 inhibitors, the efficacy of cabozantinib was vulnerable to D835 mutations.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Chemical structure of cabozantinib. (B) Docking of cabozantinib into FLT3 kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>). The red dashed lines represent hydrogen bonds; the carbon atoms of the residues and the ligand are shown in yellow and green, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the basis of the irreversible BTK kinase inhibitor ibrutinib (<b>12</b>), Liu and colleagues developed the selective FLT3 inhibitor CHMFL-FLT3-122 (<b>13</b>), which potently inhibited BaF3-FLT3-ITD (half-maximal growth-inhibitory concentration [GI<sub>50</sub>]: 11 nM). However, the efficacy of CHMFL-FLT3-122 was weakened in cells with FLT3-ITD-TKD mutations, such as BaF3-FLT3-ITD-D835Y (GI<sub>50</sub>: 170 nM) and BaF3-FLT3-ITD-F691L (GI<sub>50</sub>: 220 nM).<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Hence, they further discovered a type II FLT3 inhibitor, CHMFL-FLT3-213 (<b>14</b>), derived from CHMFL-FLT3-122 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A),<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> that showed potent inhibitory activity against secondary mutations of FLT3-ITD, such as BaF3-FLT3-ITD-D835Y/N/G/A (GI<sub>50</sub>: 0.3–9.3 nM) and BaF3-FLT3-ITD-F691L (GI<sub>50</sub>: 2 nM). It was speculated that the <i>O</i>-linked benzene ring of CHMFL-FLT3-122 formed a π–π interaction with the gatekeeper residue F691 of FLT3 kinase. However, in the case of the FLT3-F691L mutation, the favorable π–π interaction was lost, and the unfavorable steric clash between the benzene ring and residue leucine may hinder the binding of CHMFL-FLT3-122 with FLT3. As the molecular docking result for CHMFL-FLT3-213 showed, the urea moiety formed three hydrogen bonds with E661 and D829, which sequestered the benzene ring away from L691 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B,C), avoiding the adverse influence of the F691L mutation. Furthermore, CHMFL-FLT3-213 was also effective in cells with FLT3-ITD-D835Y mutations, which often confer drug resistance to type II FLT3 inhibitors.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Chemical structure and design strategy for compound CHMFL-FLT3-213. (B) CHMFL-FLT3-213 docked into FLT3 kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XUF">4XUF</a>). (C) Docking of CHMFL-FLT3-213 into the homology model of DFG-out conformation of FLT3-F691L mutant (site mutation from PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XUF">4XUF</a>). The red dashed lines represent hydrogen bonds; the carbon atoms of the residues and the ligand are shown in yellow and green, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">However, CHMFL-FLT3-213 exhibited low selectivity over c-KIT, and the simultaneous inhibition of FLT3 and c-KIT may induce myelosuppression toxicity. Therefore, Chen and colleagues developed a new compound, chen-9u (<b>15</b>), based on CHMFL-FLT3-213 (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A). Compound chen-9u maintained excellent inhibitory activities against cells with the BaF3-FLT3-ITD-D835V (IC<sub>50</sub>: 20.71 nM) and BaF3-FLT3-ITD-F691L (IC<sub>50</sub>: 12.99 nM) mutations with improved selectivity over c-KIT compared with CHMFL-FLT3-213 (>40-fold vs 0.9-fold) and improved bioavailability (<i>F</i> = 59.5% vs <i>F</i> = 18.8%). The binding pattern of compound chen-9u was similar to that of CHMFL-FLT3-213 in FLT3, which explained its potent inhibitory efficacies against cells with FLT3-ITD-D835V and FLT3-ITD-F691L mutations (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B).<a onclick="showRef(event, 'ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref61 ref62">(61,62)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Chemical structure and design strategy for compound chen-9u. (B) Compound chen-9u docked into FLT3 kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XUF">4XUF</a>). The red dashed lines represent hydrogen bonds; the carbon atoms of the residues and the ligand are shown in yellow and green, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">FN-1501 (<b>16</b>) is a multiple- kinase inhibitor under phase I clinical evaluation (NCT03690154) for advanced solid tumors that shows potent inhibitory activities against FLT3 (IC<sub>50</sub>: 0.27 nM), CDK2 (IC<sub>50</sub>: 2.47 nM), CDK4 (IC<sub>50</sub>: 0.85 nM), and CDK6 (IC<sub>50</sub>: 1.96 nM) and exhibits excellent antileukemic efficacy in MV4-11 cell xenograft mouse models.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> To improve the FLT3 inhibitory potency and selectivity, Lu and colleagues obtained compound Lu-50 (<b>17</b>) through a rational structure–activity relationship design strategy<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A). Compound Lu-50 maintained the potent inhibitory activity against FLT3 (IC<sub>50</sub>: 0.21 nM) but decreased inhibitory activity against CDK2 and CDK6 (inhibitory rate: 13.70% and 8.75% at 123 nM concentration, respectively). Molecular docking analysis showed that the pyrazole ring formed two crucial hydrogen bonds with E692 and C694 in the hinge region of FLT3, while the carboxamide moiety formed a hydrogen bond with C694. In addition, the pyrimidine moiety formed two hydrogen bonds with K644 and D829. Moreover, in the hydrophilic pocket, the methyl group at position 2 of the pyrimidine may allow favorable van der Waals interactions with FLT3 (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B), which explains the importance of the methyl group in the improvement of the selectivity for FLT3. Further study found that compound Lu-50 possessed potent binding affinity against FLT3 mutations, including the FLT3-ITD-D835V (<i>K</i><sub>d</sub>: 3.7 nM) and FLT3-ITD-F691L (<i>K</i><sub>d</sub>: 13.12 nM) resistance-conferring mutations.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Chemical structure and design strategy for <b>Lu-50</b>. (B) Compound <b>Lu-50</b> docked into a homology mode of FLT3 (based on the crystal structure of c-KIT, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG">1PKG</a>). The red dashed lines represent hydrogen bonds; the carbon atoms of the residues and the ligand are shown in yellow and green, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Starczynowski and colleagues obtained compound NCGC1481 (<b>18</b>) through continued structure optimization when they were developing dual FLT3/IRAK inhibitors.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Further study<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> showed that NCGC1481 (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A) exhibited superior binding affinity against FLT3-ITD (<i>K</i><sub>d</sub>: 0.36 nM) and FLT3-TKD mutations, including common D835H/V/Y mutations (<i>K</i><sub>d</sub>: 0.29–0.01 nM) and uncommon K663Q (<i>K</i><sub>d</sub>: 5.4 nM), N841I (<i>K</i><sub>d</sub>: 0.33 nM), and R834Q (<i>K</i><sub>d</sub>: 0.3 nM) mutations. Moreover, the binding affinities of NCGC1481 with FLT3-ITD-D835V (<i>K</i><sub>d</sub>: 0.01 nM) and FLT3-ITD-F691L (<i>K</i><sub>d</sub>: 0.012 nM) mutations were still significantly potent. The cocrystal structure showed that NCGC1481 was a type I kinase inhibitor, but FLT3 presented a DFG-out conformation and the pyrrolidin-3-amine moiety of NCGC1481 was missing (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>B). Crucial hydrogen bonding interactions between D835 and S838 of FLT3 play an important role in stabilizing the DFG-out conformation. When D835 was mutated to other residues, the function of the vital hydrogen bonds diminished, resulting in the equilibrium shifting toward the DFG-in conformation of FLT3. Therefore, unlike quizartinib, NCGC1481 averted the decrease in binding potency with FLT3-D835 mutations.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Shah and colleagues<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> showed that the edge-to-face aromatic interactions between the phenyl ring of quizartinib and the F691 and F830 residues of FLT3 were important for quizartinib-FLT3 binding, and D835 influenced the conformation of the DFG motif and the orientation of F830. Thus, when F691 and D835 were mutated, the edge-to-face interactions were destroyed, conferring clinical resistance to quizartinib.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> However, NCGC1481 was only proximal to F691 with a modest edge interaction (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>B); therefore, the F691 mutation weakly affected NCGC1481. NCGC1481 effectively inhibited the growth of MOLM14 cells expressing FLT3-ITD, FLT3-ITD-D835Y, or FLT3-ITD-F691L mutations as well as patient-derived AML cells expressing FLT3-ITD or FLT3-D835E/Y mutations and had no effect on AML cells without FLT3 mutations or healthy hematopoietic cells. More importantly, NCGC1481 demonstrated remarkable antileukemic activity in mice xenografted with FLT3-ITD-D835Y cells, extending the OS of mice.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) Chemical structure of compound NCGC1481. (B) Cocrystal binding mode of the scaffold of NCGC1481 with FLT3 kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6IL3">6IL3</a>). The red dashed line represents hydrogen bonds; the carbon atoms of the residues and the ligand are shown in yellow and green, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Targeted covalent inhibitors have attracted the enormous attention of researchers, and great progress has been made in enhancing the binding affinity and overcoming drug resistance.<a onclick="showRef(event, 'ref66 ref67 ref68 ref69'); return false;" href="javascript:void(0);" class="ref ref66 ref67 ref68 ref69">(66−69)</a> By targeting conserved amino acids, many covalent inhibitors of kinases have been developed, such as BTK,<a onclick="showRef(event, 'ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref70 ref71">(70,71)</a> EGFR,<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> FGFR,<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> JAK3,<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> and KRAS inhibitors.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> In terms of FLT3 inhibitors, the first reported covalent inhibitor, FF-10101 (<b>19</b>, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>A), is in a phase I clinical trial to treat refractory or relapsed AML patients in the US. The cocrystal structure of FLT3 with FF-10101<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> shows that two hydrogen bonds formed between the pyrimidinamine moiety and the E692 and C694 residues located in the hinge region, and another hydrogen bond formed between the middle carbonyl moiety and C695, while a covalent bond was generated between the warhead of FF-10101 and the “SH” of C695 (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>B). In vitro, FF-10101 exhibited potent growth inhibitory activities against FLT3-ITD- (GI<sub>50</sub>: 1.9 nM), FLT3-D835Y/H- (GI<sub>50</sub>: 0.32, 1.1 nM, respectively), FLT3-ITD-D835Y- (GI<sub>50</sub>: 0.81 nM), FLT3-ITD-Y842C/H- (GI<sub>50</sub>: 3.5, 5.3 nM, respectively), and FLT3-ITD-F691L- (GI<sub>50</sub>: 10 nM) expressing 32D cells. Furthermore, oral administration of FF-10101 showed potent inhibitory effects in NOD/SCID mice inoculated subcutaneously with FLT3-ITD- and FLT3-ITD-D835Y-expressing 32D cells and slightly weaker effects against FLT3-ITD-F691L (but still stronger effects than quizartinib).<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (A) Chemical structure of compound FF-10101. (B) Binding mode of FF-10101 with FLT3 kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5X02">5X02</a>). The red dashed lines represent hydrogen bonds; the yellow solid line represents covalent bonds; the carbon atoms of the residues and the ligand are shown in yellow and green, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although the discovery of FF-10101 reveals that the C695 residue of FLT3 is a feasible nucleophile to attack with covalent inhibitors, researchers have still explored other available cysteine residues in designing diverse irreversible inhibitors. By targeting the highly conserved C828 residue preceding the DFG motif of FLT3, Schmidt discovered an irreversible covalent FLT3 inhibitor Schmidt-4b (<b>20</b>, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>A) based on sunitinib,<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> which showed excellent affinities against FLT3-ITD-D835V (<i>K</i><sub>d</sub>: 0.83 nM) and FLT3-ITD-F691L (<i>K</i><sub>d</sub>: 1.5 nM) and displayed superior potential to overcome drug resistance-conferring FLT3 mutations. Molecular docking analysis showed that Schmidt-4b bound to FLT3 in a similar pattern to that of sunitinib, while a covalent bond was generated between the warhead of Schmidt-4b and “SH” of C828 (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>B). Furthermore, compound Schmidt-4b showed improved selectivity against FLT3 in comparison with sunitinib and exhibited superior cytotoxicity against MV4-11 cells (IC<sub>50</sub>: 6 nM) compared with sunitinib (IC<sub>50</sub>: 54 nM) while maintaining selectivity over FLT3-wild-type THP1 cells (IC<sub>50</sub>: >1 μM). In addition, compound Schmidt-4b showed excellent safety in a <i>Danio rerio</i> embryo toxicity assay.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Overall, the studies of these two compounds (FF-10101 and Schmidt-4b) suggest that covalent inhibitors might serve as an effective strategy for improving selectivity and overcoming drug resistance.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. (A) Chemical structure and design strategy for compound Schmidt-4b. (B) Compound Schmidt-4b docked into a homology mode of FLT3 (c-KIT, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG">1PKG</a>). The red dashed lines represent hydrogen bonds; the yellow solid line represents covalent bonds; the carbon atoms of the residues and the ligand are shown in yellow and green, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">3.2.  Combination Therapy to Overcome Resistance</h3><div class="NLM_p">The use of FLT3 inhibitors as AML monotherapies frequently leads to drug resistance, short durable response periods, and poor clinical effects due to complex pathological changes, in part including compensatory activation of FLT3 downstream pathways, protection of the bone marrow microenvironment, specific gene mutations, and activation of other proteins. In view of these findings, combining other drugs with FLT3 inhibitors has been intensely evaluated, and the combinations have demonstrated positive preclinical or clinical effects (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>), indicating that simultaneously inhibiting multiple synergetic signaling pathways can contribute to improving the efficacy and overcoming the resistance to FLT3 inhibitors. Furthermore, researchers may be inspired by the structures of these agents (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) to develop more effective anti-AML drugs.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Primary Mechanisms of Combination Therapies</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">agents<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">mechanism</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ATO and FLT3 inhibitor</td><td class="colsep0 rowsep0" align="left">activating Bak, Bax through activating GSK-3β</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BET inhibitor and FLT3 inhibitor</td><td class="colsep0 rowsep0" align="left">increasing p21, Bim, cl-PARP, HEXIM1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC inhibitor and FLT3 inhibitor</td><td class="colsep0 rowsep0" align="left">inducing FLT3 proteasomal degradation and further decreasing p-AKT, p-ERK1/2, p-STAT5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DNA methyltransferase inhibitor and FLT3 inhibitor</td><td class="colsep0 rowsep0" align="left">increasing SHP1, decreasing FLT3 ligand, and p-STAT3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">metformin and FLT3 inhibitor</td><td class="colsep0 rowsep0" align="left">increasing mTOR-mediated apoptosis and autophagy</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">all-<i>trans</i> retinoic acid and FLT3 inhibitor</td><td class="colsep0 rowsep0" align="left">decreasing Bcl6 and CHK1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CHK1 inhibitor</td><td class="colsep0 rowsep0" align="left">impairing DDR</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pim inhibitor and FLT3 inhibitor</td><td class="colsep0 rowsep0" align="left">decreasing Pim and Mcl-1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">proteasome inhibitor and FLT3 inhibitor</td><td class="colsep0 rowsep0" align="left">inducing FLT3 autophagy degradation</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">melatonin and FLT3 inhibitor</td><td class="colsep0 rowsep0" align="left">increasing ROS</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PP2A activator and FLT3 inhibitor</td><td class="colsep0 rowsep0" align="left">decreasing p-ERK and p-AKT through activating PP2A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SET inhibitor and FLT3 inhibitor</td><td class="colsep0 rowsep0" align="left">activating PP2A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hedgehog inhibitor and FLT3 inhibitor</td><td class="colsep0 rowsep0" align="left">decreasing p-STAT5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK inhibitor and FLT3 inhibitor</td><td class="colsep0 rowsep0" align="left">impairing stromal protection through downregulating p-STAT5 levels</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">STAT5 inhibitor and FLT3 inhibitor</td><td class="colsep0 rowsep0" align="left">decreasing p-STAT5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PI3K/mTOR inhibitor and FLT3 inhibitor</td><td class="colsep0 rowsep0" align="left">blocking PI3K/AKT pathway</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AKT inhibitor and FLT3 inhibitor</td><td class="colsep0 rowsep0" align="left">impairing stromal protection</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SYK inhibitor and FLT3 inhibitor</td><td class="colsep0 rowsep0" align="left">decreasing p-SYK, p-FLT3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">References shown in the text.</p></div></div></div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Structure of related agents involved in combination therapy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec3_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10">3.2.1.  Arsenic Trioxide (ATO) and FLT3 Inhibitor Combination</h4><div class="NLM_p last">ATO exhibited superior effects in the treatment of acute promyelocytic leukemia (APL), and therapy combining all-<i>trans</i> retinoic acid (ATRA) effectively prolonged the OS of APL patients.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> In addition, ATO showed a high complete hematologic response (CHR) rate and favorable OS rates in APL patients with FLT3-ITD or FLT3-D835V mutations.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> An in vivo study<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> showed that ATO could also induce FLT3-ITD degradation in MOLM13 cells by obstructing the HDAC6/HSP90/FLT3-ITD axis. Furthermore, the combination of sorafenib, an inhibitor of FLT3-ITD, and ATO enhanced apoptosis in FLT3-ITD AML cell lines and primary AML cells. The mechanistic study demonstrated that this combination treatment activated GSK-3β, reduced Mcl-1 levels and increased Bim levels, resulting in the activation of proapoptotic proteins Bak and Bax. Consistently, the upregulation of the antiapoptotic protein Mcl-1 has been proven to be a mechanism of resistance to FLT3 inhibitors in AML cells.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Compared with sorafenib alone, this combination also increased the antitumor effect in NSG mice xenografted with FLT3-ITD-positive MOLM13 cells.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a></div></div><div id="sec3_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11">3.2.2.  Bromodomain and Extra Terminal (BET) Inhibitor and FLT3 Inhibitor Combination</h4><div class="NLM_p last">The BET family proteins are important bromodomain proteins, which act as epigenetic “readers” that recognize and bind acetylated lysine in the process of histone acetylation modification. Many studies have shown that BET proteins are closely related to the occurrence and development of tumors, and BET inhibitors have exhibited positive preclinical and clinical effects in the treatment of tumors.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Moreover, Bhalla and colleagues found that the BET inhibitor JQ1 induced apoptosis of BaF3 cells expressing FLT3-ITD, FLT3-ITD-D835V, or FLT3-ITD-F691L by downregulating c-MYC and upregulating HEXIM1 and Bim. Furthermore, JQ1 maintained superior efficacies against quizartinib- and ponatinib-resistant MOLM13 cells, which were attributed to the upregulation of the levels of p21, HEXIM1, Bim, and cleaved PARP. The combination of JQ1 and quizartinib or ponatinib synergistically and significantly increased the apoptosis rate of MV4-11, MOLM13, and primary AML blast progenitor cells expressing FLT3-ITD compared to that of cells treated with either agent alone. The combination therapy more potently attenuated of the levels of c-MYC, BCL2, CDK4, and CDK6, as well as the phosphorylation of AKT, ERK1/2, and STAT5 and increased the levels of p21, Bim, and cleaved PARP in the cells mentioned above.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a></div></div><div id="sec3_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12">3.2.3.  Histone Deacetylase (HDAC) Inhibitor and FLT3 Inhibitor Combination</h4><div class="NLM_p last">HDAC inhibitors exhibit significant activity against hematologic malignancies as epigenetic anticancer drugs.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> The combination of HDAC inhibitors and other drugs, including kinase inhibitors, has illustrated better therapeutic efficacy than either drug alone in a variety of clinical trials or in vitro studies.<a onclick="showRef(event, 'ref85 ref86'); return false;" href="javascript:void(0);" class="ref ref85 ref86">(85,86)</a> The relationships between HDAC and FLT3 have been reported from different aspects.<a onclick="showRef(event, 'ref83 ref87'); return false;" href="javascript:void(0);" class="ref ref83 ref87">(83,87)</a> Bhalla and colleagues found that the levels of HDAC1/2/3/6 increased in quizartinib- and ponatinib-resistant MOLM13 cells compared to parental MOLM13 cells.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> In a recent study, HDAC8 was upregulated through FOXO1- and FOXO3-mediated transactivation in MV4-11 and MOLM13 cells after receiving quizartinib treatment, and this upregulation conferred resistance to quizartinib.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Furthermore, the synergetic antitumor effects of FLT3 inhibitors with HDAC inhibitors on FLT3-ITD-positive cells have been widely demonstrated.<a onclick="showRef(event, 'ref88 ref89 ref90 ref91 ref92 ref93 ref94 ref95'); return false;" href="javascript:void(0);" class="ref ref88 ref89 ref90 ref91 ref92 ref93 ref94 ref95">(88−95)</a> Yokoyama and colleagues showed that HDAC inhibitor MS-275 caused ubiquitin-proteasome-mediated degradation of FLT3 by inducing the acetylation of heat acetylation shock protein 90 (HSP90) and the ubiquitination of FLT3.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Krämer and colleagues also found that HDAC inhibitor LBH589 induced degradation of FLT3-ITD by the HDACinhibitor-inducible E2 ubiquitin conjugase UBCH8 and the E3 ligase SIAH1 in AML cells.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> In addition, the combination of LBH589 and different FLT3 inhibitors synergistically induced the apoptosis of AML cells expressing FLT3-ITD.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Bhalla and colleagues reported that cotreatment with HDAC inhibitor LAQ824 enhanced the growth inhibitory efficacy of midostaurin on AML cells with FLT3 mutations by greater attenuation of p-FLT3, FLT3, p-AKT, p-ERK1/2, and p-STAT5.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> HDAC inhibitor SAHA was demonstrated to increase the radiosensitivity of AML cells with FLT3 mutations.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> In addition, SAHA was further demonstrated to enhance the activity of the FLT3 inhibitor BPR1J-340 against FLT3-ITD mutant cells.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> The combination of the FLT3 inhibitor ABT-869 and SAHA was shown to synergistically kill AML cells with FLT3 mutations and suppress colony formation by downregulating phosphatase of regenerating liver-3 (PRL-3), a potential downstream target of FLT3 signaling and a useful therapeutic target in AML.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> Crotonside, a natural product with FLT3 and HDAC3/6 inhibitory activities, exhibited selective inhibitory efficacy against AML cell lines, such as MV4-11 and MOLM13, and impeded tumor progression in the subcutaneous MV4-11 xenograft model of NOD-SCID mice.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> In addition to preclinical studies, clinical trials of such combination therapies are also being conducted. Currently, the combination of sorafenib and SAHA in poor-risk AML and high-risk myelodysplastic syndrome (MDS) is in a phase I clinical trial (NCT00875745). The combination of sorafenib, SAHA, and bortezomib for the treatment of AML with complex- or poor-risk (monosomy 5/7) cytogenetics or the FLT3-ITD-positive genotype is in a phase I/II trial (NCT01534260).</div></div><div id="sec3_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13">3.2.4.  DNA Methyltransferase (DNMT) Inhibitor and FLT3 Inhibitor Combination</h4><div class="NLM_p last">DNA methylation is an important epigenetic mechanism, and abnormal DNA methylation levels have been found in various tumors. DNMT inhibitors exhibit excellent antileukemic activity by inhibiting the activation of DNA methylation in preclinical and clinical studies.<a onclick="showRef(event, 'ref96 ref97'); return false;" href="javascript:void(0);" class="ref ref96 ref97">(96,97)</a> In preclinical studies, the combination of DNMT inhibitor decitabine (DEC) or 5-azacitidine (AZA) and quizartinib synergistically induced the apoptosis, growth inhibition, and terminal myeloid differentiation of MOLM14 cells and primary AML cells derived from newly diagnosed or relapsed patients with FLT3-ITD mutation patients in vitro.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> Cotreatment with AZA and lestaurtinib increased the expression of tumor suppressor src homology-2 (SH2)-containing protein-tyrosine phosphatase 1 (SHP1) and inhibit phosphorylation of STAT3, which contributed to increasing sensitivity of MV4-11 cells to lestaurtinib.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> In clinical trials, cotreatment with AZA and sorafenib for patients with relapsed and refractory AML expressing FLT3-ITD showed favorable effects (NCT01254890).<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> In addition, the combination of quizartinib with AZA or low-dose cytarabine in patients with FLT3-ITD-positive myeloid leukemias showed a higher response rate than either agent alone (NCT01892371).<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a></div></div><div id="sec3_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14">3.2.5.  Metformin and FLT3 Inhibitor Combination</h4><div class="NLM_p last">Recently, the oral diabetes medicine metformin has been shown to inhibit the proliferation of tumor cells. For example, metformin inhibits the proliferation of MCF-7 cells by activating AMP-activated protein kinase (AMPK), further suppressing mammalian target of rapamycin (mTOR) and subsequent translation initiation.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Metformin inhibits the proliferation of A431 cells by blocking the PI3K/AKT signaling pathway.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> Jia and colleagues demonstrated that metformin could synergistically enhance the activity of sorafenib against FLT3-ITD-positive AML cells by increasing mTOR-mediated apoptosis and autophagy; in this process, light chain 3 (LC3), an autophagy marker, was upregulated and p-mTOR, p-P70S6K, and p-4EBP1 were downregulated.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></div></div><div id="sec3_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15">3.2.6.  All-<i>trans</i> Retinoic Acid (ATRA) and FLT3 Inhibitor Combination</h4><div class="NLM_p last">ATRA has demonstrated therapeutic effects in several kinds of tumors, especially APL.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> In AML, Liu and colleagues reported that ATRA inhibited growth and induced cell cycle arrest and apoptosis in FLT3-ITD AML cells by downregulating checkpoint kinase 1 (CHK1), a key regulator of the DNA damage response (DDR). Moreover, combining ATRA and the DNA damage drug SN38 showed synergistic anti-AML effects in vitro and in vivo.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Small and colleagues<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> directly revealed the synergistic effects of ATRA and FLT3 inhibitors (quizartinib, sorafenib, TTT-3002) in MOLM14, MV4-11, and FLT3-ITD-positive primary AML cells by decreasing the expression of the antiapoptotic protein Bcl6, which was upregulated with FLT3 inhibitors alone. Moreover, this combination therapy effectively eliminated FLT3-ITD-positive leukemia stem cells (LSCs) in vitro and in vivo and improved the survival of mice xenografted with FLT3-ITD AML cells. Another preliminary study showed that cotreatment with ATRA and sorafenib led to durable responses in three AML patients with FLT3-ITD and NPM1 mutations.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a></div></div><div id="sec3_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16">3.2.7.  Checkpoint Kinase 1 (CHK1) Inhibitor and FLT3 Inhibitor Combination</h4><div class="NLM_p last">CHK1 belongs to the serine-threonine protein kinase family and is recognized as an important factor in inducing cell cycle arrest in response to DNA damage. Overexpression of CHK1 has been found in triple-negative breast cancer, colon carcinoma, etc.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Recently, CHK1 has been demonstrated to play a key role in FLT3-ITD AML cell proliferation, and resistance. Correspondingly, CHK1 inhibitors potently reduced the proliferation of MV4-11 and FLT3-ITD-positive primary AML cells.<a onclick="showRef(event, 'ref109 ref110'); return false;" href="javascript:void(0);" class="ref ref109 ref110">(109,110)</a> Targeting CHK1 may be a promising therapeutic strategy for AML.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Cotreatment with a CHK1 inhibitor and FLT3 inhibitor for AML needs to be evaluated.</div></div><div id="sec3_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17">3.2.8.  Pim Inhibitor and FLT3 Inhibitor Combination</h4><div class="NLM_p last">Pim kinases belong to the serine-threonine protein kinase family and are frequently overexpressed in human tumors, including FLT3-ITD-positive tumor cells. Increased Pim proteins, especially Pim-1, reduce the sensitivity of FLT3 inhibitors, impair the apoptotic effects of FLT3 inhibitors and eventually confer resistance to FLT3 inhibitors in FLT3-ITD AML cells.<a onclick="showRef(event, 'ref50 ref111'); return false;" href="javascript:void(0);" class="ref ref50 ref111">(50,111)</a> The synergistic effects of Pim inhibitors and FLT3 inhibitors have been reported. Cotreatment with these two kinds of inhibitors induced more intense apoptosis in FLT3-ITD-positive cells<a onclick="showRef(event, 'ref50 ref112'); return false;" href="javascript:void(0);" class="ref ref50 ref112">(50,112)</a> and abrogated resistance to FLT3 inhibitors in FLT3-ITD-F691L-mutated cells.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> In another study, the combination of the Pim inhibitor AZD1208 and FLT3 inhibitors not only arrested cell cycle progression and induced apoptosis in AML cells expressing FLT3-ITD in vitro but also impeded tumor progression in MV4-11 cell xenograft mouse models, which was attributed to the enhanced proteasomal degradation of Mcl-1.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a></div></div><div id="sec3_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18">3.2.9.  Proteasome Inhibitor and FLT3 Inhibitor Combination</h4><div class="NLM_p last">Proteasome inhibitors have demonstrated superior antitumor effects by decreasing the levels of proteasome activity in tumor cells.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> In addition, the proteasome inhibitor bortezomib potently inhibited FLT3 phosphorylation and induced cell death in MV4-11, MOLM14, and primary AML cells expressing FLT3-ITD. In terms of molecular mechanisms, bortezomib induced the degradation of FLT3-ITD through an autophagy-dependent mechanism and thus inhibited its downstream signaling pathways. Moreover, bortezomib overcame the secondary D835Y resistance-conferring mutation that conferred resistance to quizartinib in vitro and improved OS in MV4-11, MOLM14, and MOLM14/D835Y cell xenograft tumors in mouse models.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> In a completed phase I clinical trial, cotreatment with midostaurin, bortezomib, and chemotherapies (mitoxantrone, etoposide, and cytarabine) for refractory/relapsed AML showed a 56.5% complete remission (CR) rate and an 82.5% overall response rate (NCT01174888).<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a></div></div><div id="sec3_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19">3.2.10.  Melatonin and FLT3 Inhibitor Combination</h4><div class="NLM_p last">Melatonin shows excellent antitumor activity in various cancers, including breast, lung, gastrointestinal cancers, leukemia, etc., by inducing apoptosis and cell cycle arrest.<a onclick="showRef(event, 'ref117 ref118 ref119 ref120'); return false;" href="javascript:void(0);" class="ref ref117 ref118 ref119 ref120">(117−120)</a> Deng and colleagues reported that melatonin inhibited cellular growth and induced apoptosis in FLT3-ITD-positive cells by enhancing the levels of reactive oxygen species (ROS). Moreover, melatonin intensified the cytotoxicity of sorafenib in AML cells expressing FLT3-ITD due to the overproduction of ROS and exhibited synergistic antileukemic activity with sorafenib in vitro and in vivo.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a></div></div><div id="sec3_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20">3.2.11.  Protein Phosphatase 2A (PP2A) Activator and FLT3 Inhibitor Combination</h4><div class="NLM_p last">The activity of PP2A, a tumor suppressor, was decreased by FLT3 induction in FLT3-mutated cells. Conversely, PP2A activators, such as FTY720 and AAL, induced apoptosis and blocked colony formation in FLT3-ITD-positive cells by downregulating the levels of p-ERK and p-AKT. Moreover, the combination of PP2A activators and FLT3 inhibitors showed more potent cytotoxicity against FLT3-ITD mutant cells than individual drugs.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a></div></div><div id="sec3_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21">3.2.12.  SET Inhibitor and FLT3 Inhibitor Combination</h4><div class="NLM_p last">The SET oncoprotein is an endogenous inhibitor of PP2A, and the levels of the SET protein are increased in AML cells. The SET inhibitor OP449 hindered the growth of MOLM14 and primary AML cells expressing FLT3-ITD. A mechanistic study showed that OP449 increased the activity of PP2A and decreased the levels of p-AKT, p-STAT5, and p-S6 (ribosomal) in MOLM14 cells. Furthermore, cotreatment with OP449 and quizartinib exhibited stronger inhibition of cell growth in MOLM14 cells than either drug alone.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a></div></div><div id="sec3_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22">3.2.13.  Hedgehog (Hh) Inhibitor and FLT3 Inhibitor Combination</h4><div class="NLM_p last">The Hh signaling pathway is necessary for normal embryonic development and is usually inactivated in most adult tissues. However, many studies have demonstrated that the Hh signaling pathway is reactivated in several tumor cells, and inhibitors that target the Hh signaling pathway have exhibited excellent antitumor efficacy.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> Matsui and colleagues found that the Hh signaling pathway was abnormally activated in FLT3-ITD-positive malignant cells, marked by the upregulation of GLI2, a major effector of the Hh pathway. In fact, the constitutive activation of the Hh pathway enhanced the level of STAT5 signaling and the proliferation of bone marrow myeloid progenitors and eventually accelerated the development of AML.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> Furthermore, the combination of the Hh pathway inhibitor IPI-926 and sorafenib exhibited more potent antileukemic activity in vitro and in vivo than either agent alone.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> In addition, the FDA approved the Hh pathway inhibitor glasdegib for AML treatment in 2018.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a></div></div><div id="sec3_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23">3.2.14.  JAK Inhibitor and FLT3 Inhibitor Combination</h4><div class="NLM_p last">As mentioned above, the bone marrow microenvironment can diminish the effects of FLT3 inhibitors, conferring AML cell resistance to FLT3 inhibitors. Gray and colleagues found that JAK inhibitors had the ability to overcome stromal protection and reverse microenvironment-induced resistance to FLT3 inhibitors. In vitro, JAK inhibitors (INCB-18424, AZD-1480, tofacitinib) significantly enhanced the cytotoxicity of midostaurin and quizartinib against MOLM13 and MV4-11 cells in the presence of stromal-conditioned media (SCM). In addition, the JAK inhibitor INCB-18424 and midostaurin demonstrated synergistic inhibitory effects in AML patient cells harboring FLT3-ITD.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div></div><div id="sec3_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24">3.2.15.  STAT5 Inhibitor and FLT3 Inhibitor Combination</h4><div class="NLM_p last">STAT5 serves as the key downstream effector of the FLT3 signaling pathway, and its aberrant activation contributes to the survival and growth of FLT3-ITD AML cells.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> Therefore, the STAT5 inhibitor pimozide inhibited the growth of FLT3-ITD mutant cells in vitro by directly downregulating the levels of p-STAT5. Pimozide reduced the tumor burden and prolonged survival compared with midostaurin in a mouse model of AML harboring FLT3-ITD. Furthermore, pimozide and FLT3 inhibitor (midostaurin or sunitinib) combinations showed more potent antileukemic efficacy in FLT3-ITD-positive cells, as indicated by a more significant reduction in p-STAT5 than that with either drug alone.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div></div><div id="sec3_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25">3.2.16.  PI3K/mTOR/AKT Pathway Inhibitor and FLT3 Inhibitor Combination</h4><div class="NLM_p last">The PI3K/mTOR/AKT pathway plays a crucial role in regulating cell growth and proliferation. Abnormal activation of this pathway has been found in various diseases, especially cancers. Moreover, as one of the downstream pathways of FLT3, this pathway is abnormally activated when FLT3 is mutated.<a onclick="showRef(event, 'ref47 ref127'); return false;" href="javascript:void(0);" class="ref ref47 ref127">(47,127)</a> Kazi and colleagues found that upregulation of the PI3K/mTOR pathway conferred resistance to sorafenib in MV4-11 and MOLM13 cells. Moreover, the PI3K/mTOR inhibitor gedatolisib showed equal cytotoxicity against sorafenib-sensitive and sorafenib-resistant MOLM13 cells and had the ability to inhibit colony formation in the above-mentioned resistant cells. Gedatolisib also exhibited an inhibitory effect and prolonged survival in sorafenib-resistant AML cell xenograft mouse models.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> In another study,<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> the mTOR inhibitor rapamycin maintained inhibitory activity against cells with FLT3-ITD-F691I, which confers resistance to midostaurin. Further, the combination of rapamycin and midostaurin enhanced the inhibitory effect on proliferation compared with that of either drug alone in BaF3-FLT3-ITD and BaF3-FLT3-ITD-F691I cells.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> Until recently, cotreatment with everolimus (RAD001) and midostaurin for patients with relapsed, refractory, or poor prognosis AML or MDS is being evaluated in a phase I trial (NCT00819546). As a key member of the PI3K pathway, AKT was also aberrantly activated in FLT3-mutated cells,<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> while AKT inhibitors contributed to overcoming the protection of the bone marrow microenvironment in AML. Moreover, the combination of a panel of selective AKT inhibitors (MK2206, AT7867, etc.) and FLT3 inhibitors (midostaurin or quizartinib) synergistically inhibited growth and cell cycle progression and induced apoptosis in FLT3-ITD-positive cells with or without stromal protection.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a></div></div><div id="sec3_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26">3.2.17.  SYK Inhibitor and FLT3 Inhibitor Combination</h4><div class="NLM_p last">SYK is a member of the nonreceptor tyrosine kinase family and is highly expressed in hematopoietic cells. SYK plays a critical role in mediating the signal transduction of a number of classical immune receptors such as the B-cell receptor. SYK has become a potential therapeutic target for various diseases, including cancers and autoimmune diseases.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> Stegmaier and colleagues<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> found that SYK was highly activated in primary AML cells expressing FLT3-ITD and played an important role in the development of FLT3-ITD-induced myeloid neoplasia. Furthermore, the enhanced activation of SYK increased quizartinib resistance. The combination of the SYK inhibitor PRT062607 and quizartinib showed synergistic antileukemic effects in vitro and in vivo and prolonged survival of mice with AML.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27">3.3.  Application of Multitarget Inhibitors to Overcome Resistance</h3><div class="NLM_p">Although combinations of FLT3 inhibitors with other therapies have shown positive preclinical and clinical efficacies, the complex pharmacokinetic profiles, drug–drug interactions, and poor patient compliance may hinder the further development of such combination treatments. On the other hand, multitarget inhibitors have exhibited good antitumor effects and have the ability to overcome resistance by simultaneously suppressing multiple hallmark features of tumors.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> In fact, the advantages of multitarget inhibitors against AML, including their abilities to overcome drug resistance, have been widely reported.<a onclick="showRef(event, 'ref38 ref53 ref65 ref131 ref132 ref133 ref134 ref135 ref136 ref137 ref138 ref139 ref140'); return false;" href="javascript:void(0);" class="ref ref38 ref53 ref65 ref131 ref132 ref133 ref134 ref135 ref136 ref137 ref138 ref139 ref140">(38,53,65,131−140)</a> It should be noted that some multitarget inhibitors discussed below also have inhibitory activities against other targets that are not reported to be related to FLT3 inhibitor resistance (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Target Information for the Multitarget Inhibitors in <a class="ref internalNav" href="#sec3_3" aria-label="Section 3.3">Section 3.3</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">multitarget inhibitor</th><th class="colsep0 rowsep0" align="center">targets related to overcoming resistance</th><th class="colsep0 rowsep0" align="center">other targets</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gilteritinib</td><td class="colsep0 rowsep0" align="left">FLT3, 0.29 nM;<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> AXL, 0.73 nM<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">LTK, 0.35 nM;<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> ALK, 1.2 nM<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left">         </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pacritinib</td><td class="colsep0 rowsep0" align="left">FLT3, 22 nM;<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> JAK2, 23 nM<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">JAK1, 1280 nM;<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> JAK3, 520 nM;<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> TYK2, 50 nM<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left">         </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Yan-14j</td><td class="colsep0 rowsep0" align="left">FLT3, 30 nM;<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> JAK2, 27 nM<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">not reported</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left">         </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCT241736</td><td class="colsep0 rowsep0" align="left">FLT3, 6.2 nM;<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a> Aurora A, 7.5 nM;<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a> Aurora B, 48 nM<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">not reported</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left">         </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AMG925</td><td class="colsep0 rowsep0" align="left">FLT3, 1 nM;<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> CDK4, 3 nM<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">CDK6, 8 nM;<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> CDK2, 375 nM<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left">         </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCGC1481</td><td class="colsep0 rowsep0" align="left">FLT3, <0.5 nM;<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> IRAK1, 22.6 nM;<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> IRAK4, 0.8 nM<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">ABL1, 0.6 nM;<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> CHK2, 5.1 nM;<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> DDR1, 8.5 nM;<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> FGR, <0.5 nM;<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> FLT4, 1.0 nM;<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> VEGFR2, 5.0 nM;<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a>; PDGFRα, 1.1 nM;<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> TrkC, 0.7 nM<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last"><i>K</i><sub>d</sub> values.</p></div></div></div><div id="sec3_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29">3.3.1.  Dual FLT3 and AXL Inhibitor</h4><div class="NLM_p last">A preclinical study showed that the phosphorylation of AXL was significantly increased in FLT3-ITD-positive cells after treatment with midostaurin or quizartinib, while the activation of AXL conferred resistance to midostaurin and quizartinib.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> The AXL inhibitor TP-0903 remained cytotoxic to resistant cells, implying that inhibition of AXL activation contributed to overcoming FLT3 inhibitor resistance.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Gilteritinib is an efficient FLT3/AXL inhibitor (IC<sub>50</sub>: 0.29 and 0.73 nM, respectively) and exhibits potent and equivalent inhibitory activity against BaF3-FLT3-ITD (IC<sub>50</sub>: 1.8 nM) and BaF3-FLT3-ITD-D835Y (IC<sub>50</sub>: 2.1 nM); meanwhile, gilteritinib also potently inhibits LTK (IC<sub>50</sub>: 0.35 nM) and ALK (IC<sub>50</sub>: 1.2 nM).<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> Moreover, gilteritinib demonstrates potent antitumor activity against FLT3-driven AML in xenograft mouse models, including FLT3-ITD and FLT3-ITD-D835Y.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> In 2018, gilteritinib was approved by the FDA due to its significant improvement in the median OS, remission rate, and safety profiles over salvage chemotherapy in patients with FLT3-mutated relapsed/refractory AML from a phase III ADMIRAL trial.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The success of gilteritinib provides an applicable example for the discovery of multitarget inhibitors with more potent anti-AML efficacy and the potential to overcome resistance.</div></div><div id="sec3_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30">3.3.2.  Dual FLT3 and JAK2 Inhibitors</h4><div class="NLM_p">JAK2 is a member of Janus kinase (JAK) family. Exhaustive studies have shown that the aberrant activation of JAK2 is closely associated with multiple hematological malignancies.<a onclick="showRef(event, 'ref141 ref142'); return false;" href="javascript:void(0);" class="ref ref141 ref142">(141,142)</a> In vitro, the levels of JAK2 were significantly increased after treatment with FLT3 inhibitors in MV4-11 cells, conferring resistance to FLT3 inhibitors.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> Correspondingly, Gray and colleagues found that the selective JAK2 inhibitor AZD-1480 synergistically enhanced the antitumor effects of midostaurin and quizartinib in the presence of SCM.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> These studies indicated that inhibition of JAK2 was helpful to overcome FLT3 inhibitor resistance. Currently, some dual-target inhibitors of FLT3 and JAK2 have been reported.<a onclick="showRef(event, 'ref132 ref133 ref134'); return false;" href="javascript:void(0);" class="ref ref132 ref133 ref134">(132−134)</a> Pacritinib (SB1518) (<b>21</b>, <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a> left), which has strong FLT3 and JAK2 inhibitory potencies (IC<sub>50</sub>: 22 and 23 nM, respectively) and relatively moderate activities against other JAK family proteins (IC<sub>50</sub> for JAK1, JAK3, TYK2: 1280, 520, 50 nM, respectively), showed nearly no effects on growth inhibitory activity in linifanib- or sunitinib-resistant MV4-11 cells.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> In another study, pacritinib maintained equivalent sensitivity against BaF3-FLT3-ITD (IC<sub>50</sub>: 133 nM) and BaF3-FLT3-ITD-D835H/Y (IC<sub>50</sub>: 306 nM, 434 nM, respectively), as well as BaF3-FLT3-ITD-F691L (IC<sub>50</sub>: 291 nM) cells. The same result was observed in MOLM13 (IC<sub>50</sub>: 73 nM) and MOLM13-D835Y (IC<sub>50</sub>: 173 nM) cells.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> In clinical trials, pacritinib showed preliminary antileukemic activity when combined with chemotherapy in patients with FLT3 mutations.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> In addition to pacritinib, the Yan group reported a series of dual FLT3 and JAK2 inhibitors, and compound Yan-14j (<b>22</b>, <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a> right) showed the most balanced inhibitory activities against FLT3 (IC<sub>50</sub>: 30 nM) and JAK2 (IC<sub>50</sub>: 27 nM) among the reported inhibitors.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a></div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Chemical structures of compounds pacritinib (SB1518, left) and Yan-14j (right).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31">3.3.3.  Dual FLT3 and Aurora Inhibitor</h4><div class="NLM_p">Aurora kinases, consisting of Aurora A, Aurora B, and Aurora C, belong to the family of serine-threonine protein kinases and play an important role in mitosis. It has been widely reported that Aurora A and Aurora B are associated with the poor prognosis of various tumors, including leukemia, and multiple Aurora inhibitors have been found to have clinical antitumor activity in AML patients.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Recently, CCT241736 (<b>23</b>, <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>), a potent and selective dual inhibitor of FLT3 and Aurora kinases (<i>K</i><sub>d</sub> for Aurora A, Aurora B, FLT3: 7.5, 48, and 6.2 nM, respectively) was disclosed to have the ability to overcome resistance to FLT3 inhibitors (tandutinib, quizartinib) caused by FLT3-TKD mutations or increased FL expression. For instance, in MOLM13 cells resistant to tandutinib, a point mutation at D835 was detected, yet CCT241736 equivalently inhibited the growth of MOLM13 (GI<sub>50</sub>: 100 nM) and MOLM13-resistant cells (GI<sub>50</sub>: 180 nM). Unlike that of quizartinib and sorafenib, the cellular efficacy of CCT241736 was slightly influenced by FLT3-TKD mutations (F691L, Y842C/H, D835V/Y) in BaF3 cells expressing those FLT3 mutations. Moreover, in MOLM13 cells exposed to endogenous 10 ng/mL FL, the efficacies of quizartinib and tandutinib were seriously affected by these high FL levels, but CCT241736 was effective even with high levels of FL. In vivo, CCT241736 exhibited significant antiproliferation potency in MV4-11, MOLM13, MOLM13-resistant, and BaF3-FLT3-ITD-F691L cell xenograft mouse models. Western blot analysis demonstrated that the antitumor activity of CCT241736 was attributed to the decrease in the levels of p-STAT5 and p-Aurora A.<a onclick="showRef(event, 'ref135 ref136'); return false;" href="javascript:void(0);" class="ref ref135 ref136">(135,136)</a></div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Chemical structure of CCT241736.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32">3.3.4.  FLT3 and CDK4/6 Multitarget Inhibitor</h4><div class="NLM_p">Cyclin-dependent kinases (CDKs) are highly involved in the modulation of the cell cycle and in tumor progression. Among the numerous CDK inhibitors, specific CDK4/6 inhibitors have emerged as blockbuster drugs in breast cancer therapies.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> The CDK4-retinoblastoma protein (RB) pathway, a downstream target of the FLT3 signaling pathway, has also been demonstrated to be responsible for the development of hematologic malignancies.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> Hence, the CDK4/6 inhibitor PD0332991 showed synergistic antitumor activity with FLT3 inhibitors in AML cells expressing FLT3-ITD.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> AMG925 (<b>24</b>, <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>), a dual FLT3/CDK4 inhibitor (IC<sub>50</sub>: 1 and 3 nM, respectively), showed potent growth inhibitory activity in MOLM13 xenograft tumor models by downregulating the phosphorylation levels of STAT5 and RB. Furthermore, AMG925 has the potential to combat resistance to several clinical FLT3 inhibitors (such as quizartinib and sorafenib). For instance, AMG925 exhibited comparable inhibitory activities against MOLM13 (IC<sub>50</sub>: 19 nM) and MOLM13-D835Y cells (IC<sub>50</sub>: 23 nM),<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> as well as against MV4-11 (IC<sub>50</sub>: 18 nM) and MV4-11-D835V cells (IC<sub>50</sub>: 9 nM).<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> Notably, when incubated with AMG925 for over 8 months, MOLM13 and MV4-11 AML cells only developed partial and reversible resistance to AMG925; moreover, no secondary resistance-conferring mutations in FLT3 were identified, although the total levels of FLT3 increased in AMG925-resistant cells.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a></div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Chemical structure of AMG925.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33">3.3.5.  FLT3 and IRAK1/4 Multitarget Inhibitor</h4><div class="NLM_p">Recently, Starczynowski and colleagues found that the compensatory activation of the innate immune stress response pathway conferred resistance to FLT3 inhibitors as a target-independent mechanism. In particular, activation of IL-1 receptor-associated kinase 1 (IRAK1) and IRAK4 was essential for the above adaptive resistance. Therefore, they developed NCGC1481<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>), which simultaneously inhibits FLT3 (IC<sub>50</sub>: <0.5 nM) and IRAK1/4 (IC<sub>50</sub>: 22.6 and 0.8 nM, respectively); this compound also has potent inhibitory activity against other targets, such as ABL1, CHK2, FLT4, VEGFR2, etc. Western blot analysis showed that NCGC1481 decreased the phosphorylation levels of FLT3 and IRAK4. In contrast, quizartinib attenuated FLT3 phosphorylation but elevated IRAK4 phosphorylation, resulting in resistance to quizartinib. In quizartinib-resistant or gilteritinib-resistant AML cells, NCGC1481, rather than a selective IRAK inhibitor, overcame adaptive resistance and potently impeded cell proliferation, suggesting that this dual inhibition mechanism was indispensable for decreasing the viability of resistant AML cells. In vivo, NCGC1481 exhibited potent antitumor activity and prolonged the median OS time in mice xenografted with both parental and quizartinib-resistant AML cells.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Chemical structure of NCGC1481.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">4.  Conclusions and Perspective</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56551" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56551" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">FLT3 mutations are frequent in AML, with an incidence rate of approximately 30%; they confer a poor prognosis, with a high relapse rate and short OS. Luckily, FLT3 inhibitors have made great clinical progress. Midostaurin was the first approved FLT3 inhibitor (by the FDA in 2017) for the treatment of adult patients with newly diagnosed FLT3-mutated AML,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> and then gilteritinib was approved in 2018 for the treatment of adult patients with FLT3-mutated relapsed or refractory AML.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Subsequently, quizartinib was approved in Japan for the treatment of adult patients with FLT3-ITD-positive relapsed or refractory AML in 2019.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> In addition, numerous FLT3 inhibitors are in the preclinical or clinical stages. Unfortunately, resistance to FLT3 inhibitors is reported frequently, as is the case with most kinase inhibitors. Resistance eventually results in a short clinical response and fast disease relapse. For example, in the analysis of clinical samples from AML patients who relapsed after midostaurin treatment, the mutation of N676 to K676 mainly contributed to drug resistance.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The quizartinib-resistant FLT3-ITD-positive AML patients all had secondary point mutations of FLT3, including activation loop mutations D835Y, D835V, and D835F and the gatekeeper mutation F691L.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> Pasquet and colleagues also found that activation of AXL hindered the response to quizartinib in FLT3-ITD AML primary samples.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> In addition, the high expression of CYP3A4 in bone marrow stromal cells hampered the efficacies of quizartinib, sorafenib, and gilteritinib against AML cells harboring FLT3-ITD.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> In general, the causes of drug resistance are complex and diverse, and this obstacle urgently needs to be addressed to improve the treatment effect and survival of AML patients.</div><div class="NLM_p">Therefore, developing novel strategies to overcome resistance has become a research hotspot in the field of FLT3 inhibitor research, in which plentiful exciting achievements have arisen. New-generation FLT3 inhibitors have been developed to address on-target resistance mechanisms, and most of them have exhibited excellent preclinical activity. From the structural perspective, the main reasons for the resistance to type II inhibitors are that the mutation of some amino acid residues directly reduces the binding force or promotes the conversion from the DFG-out conformation to the DFG-in conformation, ultimately leading to a reduction in the binding force. Type I inhibitors, which bind to the conserved DFG-in conformation, are mainly affected by the decrease in binding force caused by amino acid mutations around the inhibitors. For example, the efficacies of type II inhibitors are vulnerable to mutations at D835 that contributes to stabilizing the DFG-out conformation, while those of type I inhibitors are mostly unaffected. Therefore, the spectrum of resistance-causing TKD mutations for type I may be narrower.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> Given the circumstances described above, avoiding steric hindrance with the mutated residues or introducing additional favorable interactions may be effective strategies for overcoming resistance; the development of pexidartinib is an example of this strategy.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> In addition, the reasonable use of hydrophobic regions generated by the DFG motif shift also shows great advantages in overcoming resistance, as exhibited by the development of CHMFL-FLT3-213.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Moreover, the FLT3 amino acid residues with nucleophilic side chains have also been greatly utilized to design covalent inhibitors that can overcome secondary point mutation resistance, such as FF-10101, which targets C695,<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> and Schmidt-4b, which targets C828;<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> the efficacy of these compounds can be partially attributed to the increasing target action time of covalent inhibitors.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> The approval of numerous covalent inhibitors, such as ibrutinib, neratinib, osimertinib, etc., proves their feasibility and effectiveness. Nevertheless, the off-target toxicity of covalent inhibitors due to their lack of specificity and selectivity still needs to be addressed.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Recently, several proteolysis-targeting chimeras (PROTACs) aiming to degrade FLT3 were reported,<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> and this may represent a new direction for addressing FLT3 inhibitor resistance. Moreover, allosteric inhibitors also exhibit significant potential in overcoming secondary point mutation resistance.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Deininger and colleagues found that a BCR-ABL1 allosteric inhibitor (asciminib) was insensitive to point mutations at the ATP site, and the combination of asciminib and the ATP competitive inhibitor ponatinib effectively overcame ponatinib resistance and suppressed the emergence of resistance-conferring point mutations.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Although some good results have been achieved in efforts to overcome resistance due to a single point mutation in FLT3, polyclonal resistance point mutations may represent another stubborn obstacle, as one relapsed AML patient harboring the FLT3-ITD mutation after quizartinib treatment exhibited both the F691L and D835V mutations.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a></div><div class="NLM_p">Combination therapies that inhibit multiple signaling pathways are believed to exert collaborative functions to overcome resistance and increase the short duration of response to single FLT3 inhibitors. Although some of those combination therapies obtained positive clinical effects, unpredictable drug–drug interactions, pharmacokinetic properties, and cumulative toxicity may impede their further development. On the other hand, rational design of inhibitors that simultaneously target multiple relevant signaling pathways could be motivated by successful combination strategies. If the designed multitarget inhibitors could have efficacy equivalent to that of combination therapy, then the pharmacokinetics and toxicity concerns may be alleviated to some extent.</div><div class="NLM_p">Multitarget drugs have the potential to remove the obstacles of combination therapies and retain the characteristics of inhibiting multiple pathways. Indeed, some preclinical multitarget inhibitors have revealed exciting potential in combating resistance to FLT3 inhibitors. However, their selectivity is still not satisfactory, and their effectiveness needs to be elaboratively verified in clinical trials. The design of new multitarget inhibitors inspired by emerging combination therapies with FLT3 inhibitors could lead to the development of drugs with higher specificity for the expected targets. Antibody–drug conjugates (ADCs) can recognize specific tumor cells utilizing antibodies that are specific against tumor cell surface proteins and thus should have decreased adverse effects and increased selectivity and potency.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> This strategy might be another way for multitarget inhibitors to overcome drug resistance while avoiding off-target toxicity. Moreover, studies on combination therapies and multitarget inhibitors will mutually inspire further research on these topics to give rise to more scientific ideas of clinical value.</div><div class="NLM_p last">Drug resistance limits the effectiveness of FLT3 inhibitors and seriously affects the survival of treated patients. The estimated five-year OS rate of AML patients is less than 50%,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and resistance and relapse may be responsible for their unsatisfactory prognosis. A thorough understanding of the specific mutations or genetic changes that cause drug resistance will aid in the development of more effective therapeutic strategies, and current knowledge on the resistance mechanisms may still be superficial. Hence, further mechanistic studies are needed to gain full insight into the complex regulatory systems in drug-resistant cells. Correspondingly, the existing strategies to overcome resistance need to keep evolving to battle resistance with a new mechanism. It is believed that the rapid and fruitful development of new-generation FLT3 inhibitors and combination therapies and multitarget inhibitors involving FLT3 will undoubtedly solve the temporary dilemma of FLT3 resistance.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01851" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57528" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57528" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tao Lu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, China
Pharmaceutical University, Nanjing 210009, P.R. China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#aec2dbdacfc1eecddedb80cbcadb80cdc0"><span class="__cf_email__" data-cfemail="cca0b9b8ada38cafbcb9e2a9a8b9e2afa2">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yadong Chen</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Molecular Design and Drug Discovery, China Pharmaceutical University, Nanjing, 211198, P.R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2189-9356" title="Orcid link">http://orcid.org/0000-0002-2189-9356</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d2b1bab7bcabb3b6bdbcb592b5bfb3bbbefcb1bdbf"><span class="__cf_email__" data-cfemail="97f4fff2f9eef6f3f8f9f0d7f0faf6fefbb9f4f8fa">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuai Lu</span> - <span class="hlFld-Affiliation affiliation">School
of Science, China Pharmaceutical University, Nanjing 211198, P.R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0169-349X" title="Orcid link">http://orcid.org/0000-0002-0169-349X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a5c9d0fad6cdd0c4cce5c6d5d08bc0c1d08bc6cb"><span class="__cf_email__" data-cfemail="412d341e3229342028012231346f2425346f222f">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhijie Wang</span> - <span class="hlFld-Affiliation affiliation">School
of Science, China Pharmaceutical University, Nanjing 211198, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiongheng Cai</span> - <span class="hlFld-Affiliation affiliation">School
of Science, China Pharmaceutical University, Nanjing 211198, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jie Cheng</span> - <span class="hlFld-Affiliation affiliation">School
of Science, China Pharmaceutical University, Nanjing 211198, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenqianzi Yang</span> - <span class="hlFld-Affiliation affiliation">School
of Science, China Pharmaceutical University, Nanjing 211198, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yifan Zhu</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, China Pharmaceutical University, Nanjing 210009, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hongmei Li</span> - <span class="hlFld-Affiliation affiliation">School
of Science, China Pharmaceutical University, Nanjing 211198, P.R. China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Z. W. and S.L. are responsible for writing the manuscript. All authors are responsible for verification and revisions.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00060" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00060" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Zhijie Wang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=bio1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Zhijie Wang</b> received his Bachelor’s degree from Hebei Medical University in 2017. He is currently a doctoral candidate at the Department of Chemistry, China Pharmaceutical University, under the supervision of Professor Yadong Chen. His research mainly concentrates on the design, synthesis, and biological evaluations of potent FLT3 inhibitors that targeting FLT3 resistant mutations.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Jiongheng Cai</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=bio2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jiongheng Cai</b> received his Bachelor’s degree from China Pharmaceutical University in 2019. He is currently a postgraduate student at the Department of Chemistry, China Pharmaceutical University, under the supervision of Professor Tao Lu. His master’s study mainly focuses on the synthesis and biological evaluations of covalent and irreversible FLT3 inhibitors.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Jie Cheng</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=bio3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jie Cheng</b> obtained her Bachelor’s degree from Shenyang Pharmaceutical University in 2019. Currently, she studies for a Master’s degree under the supervision of Professor Tao Lu at China Pharmaceutical University, majoring in Medicinal Chemistry. Her research mainly focuses on the synthesis and biological evaluations of RIPK1 and FLT3 inhibitors.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Wenqianzi Yang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=bio4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Wenqianzi Yang</b> is currently an undergraduate and will get her Bachelor’s degree from China Pharmaceutical University soon. She participates in College Students Innovation Project for the synthesis of FLT3 inhibitors.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Yifan Zhu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=bio5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yifan Zhu</b> is currently an undergraduate and will get her Bachelor’s degree from China Pharmaceutical University soon. She participates in College Students Innovation Project for the synthesis of FLT3 inhibitors.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Hongmei Li</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=bio6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Hongmei Li</b> obtained her Bachelor’s degree from China Pharmaceutical University. She then received her Ph.D. degree in Medicinal Chemistry at the same institute under the supervision of Professor Tao Lu. She is currently a lecturer at China Pharmaceutical University. Her research mainly focuses on the drug discovery and development of new cancer therapies.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Tao Lu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=bio7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Tao Lu</b> received his Ph.D. degree in Medicinal Chemistry from China Pharmaceutical University in 2001. He worked as a Sino–US joint Ph.D. in the research of telomerase inhibitors at the University of Texas at Austin under the supervision of Professor Laurence H. Hurley from 1989 to 2000. He is currently a professor and serves as vice-President of China Pharmaceutical University in 2013. The antitumor drug FN-1501 was independently developed by his team and then was transferred to Shanghai Fosun Pharmaceutical Ltd for phase I clinical studies in the United States, Australia, and China. His research mainly focuses on the discovery of new antitumor drugs.</p></figure></div><div class="bio" rid="ath8"><figure id="ath8" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Yadong Chen</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=bio8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yadong Chen</b> received his Ph.D. degree in Medicinal Chemistry from China Pharmaceutical University under the supervision of Professor Qidong You in 2009. He worked at the Comprehensive Cancer Center of University of Michigan School of Medicine as a visiting scholar under the supervision of Dr. Shaomeng Wang. Currently, he is a professor at China Pharmaceutical University and focuses on the discovery of novel small-molecule drugs for major diseases as well as the research of molecular design based on the artificial intelligence.</p></figure></div><div class="bio" rid="ath9"><figure id="ath9" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Shuai Lu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=bio9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Shuai Lu</b> obtained his Ph.D. degree in Medicinal Chemistry from China Pharmaceutical University under the supervision of Professor Tao Lu in 2012. He worked at the ITDD of University of Minnesota as a visiting scholar under the supervision of Dr. Gunda I. Georg from 2016 to 2017. Currently, he is an associate professor at China Pharmaceutical University. His research interests mainly focus on the discovery of the targeted antitumor drugs including FLT3 inhibitors, RIPK1 inhibitors and SHP2 inhibitors.</p></figure></div><div class="ack" id="ACK-d7e2098-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i45">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71000" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71000" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work is supported by the Natural Science Foundation of Jiangsu Province (SBK2016020485 and BK20180573), the National Natural Science Foundation of China (81502925), the “Double First-Class University Project” (CPU2018GF02) of China Pharmaceutical University for financial support. Wenqianzi Yang and Yifan Zhu appreciate the College Students Innovation Project for the R&D of Novel Drugs (J1310032) from the National Found for Fostering Talents of Basic Science (NFFTBS).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">FMS-like tyrosine kinase 3</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">FLK2</td><td class="NLM_def"><p class="first last">fetal liver kinase 2</p></td></tr><tr><td class="NLM_term">STK-1</td><td class="NLM_def"><p class="first last">stem cell kinase-1</p></td></tr><tr><td class="NLM_term">RTKs</td><td class="NLM_def"><p class="first last">receptor tyrosine kinases</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">FL</td><td class="NLM_def"><p class="first last">FLT3 ligand</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphatidylinositol 3 kinase</p></td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">ITD</td><td class="NLM_def"><p class="first last">internal tandem duplication</p></td></tr><tr><td class="NLM_term">OS</td><td class="NLM_def"><p class="first last">overall survival</p></td></tr><tr><td class="NLM_term">HSCT</td><td class="NLM_def"><p class="first last">hematopoietic stem cell transplantation</p></td></tr><tr><td class="NLM_term">c/EBPalpha</td><td class="NLM_def"><p class="first last">CCAAT/estradiol-binding protein alpha</p></td></tr><tr><td class="NLM_term">TKD</td><td class="NLM_def"><p class="first last">tyrosine kinase domain</p></td></tr><tr><td class="NLM_term">MEK</td><td class="NLM_def"><p class="first last">mitogen-activated extracellular signal-regulated kinases</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular regulated protein kinases</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">PKC</td><td class="NLM_def"><p class="first last">protein kinase C</p></td></tr><tr><td class="NLM_term">SYK</td><td class="NLM_def"><p class="first last">spleen tyrosine kinase</p></td></tr><tr><td class="NLM_term">PKA</td><td class="NLM_def"><p class="first last">protein kinase A</p></td></tr><tr><td class="NLM_term">PDGF</td><td class="NLM_def"><p class="first last">platelet-derived growth factor</p></td></tr><tr><td class="NLM_term">VEGFR</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor</p></td></tr><tr><td class="NLM_term">Trk</td><td class="NLM_def"><p class="first last">tropomyosin receptor kinase</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">ALK</td><td class="NLM_def"><p class="first last">anaplastic lymphoma kinase</p></td></tr><tr><td class="NLM_term">LTK</td><td class="NLM_def"><p class="first last">leukocyte tyrosine kinase</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">TET2</td><td class="NLM_def"><p class="first last">ten-11 translocation</p></td></tr><tr><td class="NLM_term">IDH1/2</td><td class="NLM_def"><p class="first last">isocitrate dehydrogenase 1/2</p></td></tr><tr><td class="NLM_term">FGF2</td><td class="NLM_def"><p class="first last">fibroblast growth factor 2</p></td></tr><tr><td class="NLM_term">FGFR</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximal inhibitory concentration</p></td></tr><tr><td class="NLM_term">CSF1R</td><td class="NLM_def"><p class="first last">colony stimulating factor 1 receptor</p></td></tr><tr><td class="NLM_term">MET</td><td class="NLM_def"><p class="first last">mesenchymal-epithelial transition factor</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">GI<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximal growth-inhibitory concentration</p></td></tr><tr><td class="NLM_term">CDK</td><td class="NLM_def"><p class="first last">cyclin-dependent kinases</p></td></tr><tr><td class="NLM_term">IRAK</td><td class="NLM_def"><p class="first last">IL-1 receptor-associated kinase</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">ATO</td><td class="NLM_def"><p class="first last">arsenic trioxide</p></td></tr><tr><td class="NLM_term">CHR</td><td class="NLM_def"><p class="first last">complete hematologic response</p></td></tr><tr><td class="NLM_term">OS</td><td class="NLM_def"><p class="first last">overall survival</p></td></tr><tr><td class="NLM_term">APL</td><td class="NLM_def"><p class="first last">acute promyelocytic leukemia</p></td></tr><tr><td class="NLM_term">BET</td><td class="NLM_def"><p class="first last">bromodomain and extra terminal</p></td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetylase</p></td></tr><tr><td class="NLM_term">HSP90</td><td class="NLM_def"><p class="first last">heat shock protein 90</p></td></tr><tr><td class="NLM_term">GSK-3β</td><td class="NLM_def"><p class="first last">glycogen synthase kinase-3β</p></td></tr><tr><td class="NLM_term">Mcl-1</td><td class="NLM_def"><p class="first last">myeloid cell leukemia 1</p></td></tr><tr><td class="NLM_term">BET</td><td class="NLM_def"><p class="first last">bromodomain and extra terminal domain</p></td></tr><tr><td class="NLM_term">PARP</td><td class="NLM_def"><p class="first last">poly(ADP-ribose) polymerase</p></td></tr><tr><td class="NLM_term">BCL</td><td class="NLM_def"><p class="first last">B-cell lymphoma</p></td></tr><tr><td class="NLM_term">PRL-3</td><td class="NLM_def"><p class="first last">phosphatase of regenerating liver-3</p></td></tr><tr><td class="NLM_term">MDS</td><td class="NLM_def"><p class="first last">myelodysplastic syndrome</p></td></tr><tr><td class="NLM_term">DNMT</td><td class="NLM_def"><p class="first last">DNA methyltransferase</p></td></tr><tr><td class="NLM_term">DEC</td><td class="NLM_def"><p class="first last">decitabine</p></td></tr><tr><td class="NLM_term">AZA</td><td class="NLM_def"><p class="first last">5-azacitidine</p></td></tr><tr><td class="NLM_term">SHP1</td><td class="NLM_def"><p class="first last">src homology-2 (SH2)-containing protein-tyrosine phosphatase 1</p></td></tr><tr><td class="NLM_term">AMPK</td><td class="NLM_def"><p class="first last">AMP-activated protein kinase</p></td></tr><tr><td class="NLM_term">LC3</td><td class="NLM_def"><p class="first last">light chain 3</p></td></tr><tr><td class="NLM_term">ATRA</td><td class="NLM_def"><p class="first last">All-<i>trans</i> retinoic acid</p></td></tr><tr><td class="NLM_term">CHK</td><td class="NLM_def"><p class="first last">checkpoint kinase</p></td></tr><tr><td class="NLM_term">DDR</td><td class="NLM_def"><p class="first last">DNA damage response</p></td></tr><tr><td class="NLM_term">LSCs</td><td class="NLM_def"><p class="first last">leukemia stem cells</p></td></tr><tr><td class="NLM_term">Pim</td><td class="NLM_def"><p class="first last">proviral insertion site in Moloney murine leukemia virus</p></td></tr><tr><td class="NLM_term">CR</td><td class="NLM_def"><p class="first last">complete remission</p></td></tr><tr><td class="NLM_term">ROS</td><td class="NLM_def"><p class="first last">reactive oxygen species</p></td></tr><tr><td class="NLM_term">PP2A</td><td class="NLM_def"><p class="first last">protein phosphatase 2A</p></td></tr><tr><td class="NLM_term">Hh</td><td class="NLM_def"><p class="first last">hedgehog</p></td></tr><tr><td class="NLM_term">SCM</td><td class="NLM_def"><p class="first last">stromal-conditioned media</p></td></tr><tr><td class="NLM_term">DDR1</td><td class="NLM_def"><p class="first last">discoidin domain receptor 1</p></td></tr><tr><td class="NLM_term">FLT4</td><td class="NLM_def"><p class="first last">FMS-like tyrosine kinase 4</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">RB</td><td class="NLM_def"><p class="first last">retinoblastoma protein</p></td></tr><tr><td class="NLM_term">PROTACs</td><td class="NLM_def"><p class="first last">proteolysis-targeting chimeras</p></td></tr><tr><td class="NLM_term">ADCs</td><td class="NLM_def"><p class="first last">antibody–drug conjugates</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i47">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02821" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02821" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 149 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosnet, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchetto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">deLapeyriere, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birnbaum, D.</span></span> <span> </span><span class="NLM_article-title">Murine FLT3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1641</span>– <span class="NLM_lpage">1650</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1656368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADyaK38XmsVKhu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1991&pages=1641-1650&issue=9&author=O.+Rosnetauthor=S.+Marchettoauthor=O.+deLapeyriereauthor=D.+Birnbaum&title=Murine+FLT3%2C+a+gene+encoding+a+novel+tyrosine+kinase+receptor+of+the+PDGFR%2FCSF1R+family"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family</span></div><div class="casAuthors">Rosnet, Olivier; Marchetto, Sylvie; DeLapeyriere, Odile; Birnbaum, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1641-50</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    </div><div class="casAbstract">Receptor-type tyrosine kinases presenting an extracellular region with 5 Ig-like domains, and strongly related by sequence similarities in the intracellular region, constitute a family of receptors involved in development and function of various cell lineages.  The mouse Flt3 gene, encoding the sixth member of this family was isolated and characterized.  The Flt3 gene possesses an open reading frame of 3000 nucleotides, and therefore appears to code for a protein of 1000 amino acids.  The deduced structure of the FLT3 protein presents all the characteristics of a receptor-type kinase of this family.  The gene is expressed in placenta, in various adult tissues including gonads and brain, and in hematopoietic cells.  The Flt3 transcript is 3.7 kb long, except in the testis, where 2 shorter post-meiotic transcripts are detected.  These results suggest a role for this novel receptor and its yet unidentified ligand in placenta, gonads and hematopoietic and nervous systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9ZZA6MOS37LVg90H21EOLACvtfcHk0lhd9uVgGCN4Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XmsVKhu7Y%253D&md5=db8f1899ab6517815304a14a8e741f1f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRosnet%26aufirst%3DO.%26aulast%3DMarchetto%26aufirst%3DS.%26aulast%3DdeLapeyriere%26aufirst%3DO.%26aulast%3DBirnbaum%26aufirst%3DD.%26atitle%3DMurine%2520FLT3%252C%2520a%2520gene%2520encoding%2520a%2520novel%2520tyrosine%2520kinase%2520receptor%2520of%2520the%2520PDGFR%252FCSF1R%2520family%26jtitle%3DOncogene%26date%3D1991%26volume%3D6%26issue%3D9%26spage%3D1641%26epage%3D1650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">The roles of FLT3 in hematopoiesis and leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>100</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1532</span>– <span class="NLM_lpage">1542</span>, <span class="refDoi"> DOI: 10.1182/blood-2002-02-0492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2002-02-0492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=12176867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslyhsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2002&pages=1532-1542&issue=5&author=D.+G.+Gillilandauthor=J.+D.+Griffin&title=The+roles+of+FLT3+in+hematopoiesis+and+leukemia&doi=10.1182%2Fblood-2002-02-0492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The roles of FLT3 in hematopoiesis and leukemia</span></div><div class="casAuthors">Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1532-1542</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">FLT3 is a receptor tyrosine kinase expressed by immature hematopoietic cells and is important for the normal development of stem cells and the immune system.  The ligand for FLT3 is expressed by marrow stromal cells and other cells and synergized with other growth factors to stimulate proliferation of stem cells, progenitor cells, dendritic cells, and natural killer cells.  Mutations of FLT3 have been detected in about 30% of patients with acute myelogenous leukemia and a small no. of patients with acute lymphocytic leukemia or myelodysplastic syndrome.  Patients with FLT3 mutations tend to have a poor prognosis.  The mutations most often involve small tandem duplications of amino acids within the juxtamembrane domain of the receptor and result in constitutive tyrosine kinase activity.  Expression of a mutant FLT3 receptor in murine marrow cells results in a lethal myeloproliferative syndrome and preliminary studies suggest that mutant FLT3 cooperates with other leukemia oncogenes to confer a more aggressive phenotype.  Taken together, these results suggest that FLT3 is an attractive therapeutic target for kinase inhibitors or other approaches for patients with mutations of this gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYQc2WkC8EQbVg90H21EOLACvtfcHk0lhd9uVgGCN4Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslyhsLc%253D&md5=f6d04b227f5c5baf5c22cfba6e693ff1</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1182%2Fblood-2002-02-0492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2002-02-0492%26sid%3Dliteratum%253Aachs%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DThe%2520roles%2520of%2520FLT3%2520in%2520hematopoiesis%2520and%2520leukemia%26jtitle%3DBlood%26date%3D2002%26volume%3D100%26issue%3D5%26spage%3D1532%26epage%3D1542%26doi%3D10.1182%2Fblood-2002-02-0492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosnet, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pebusque, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchetto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonnelle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toiron, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birnbaum, D.</span></span> <span> </span><span class="NLM_article-title">Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>82</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1110</span>– <span class="NLM_lpage">1119</span>, <span class="refDoi"> DOI: 10.1182/blood.V82.4.1110.1110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood.V82.4.1110.1110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=8394751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADyaK2cXhvVSj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1993&pages=1110-1119&issue=4&author=O.+Rosnetauthor=C.+Schiffauthor=M.+J.+Pebusqueauthor=S.+Marchettoauthor=C.+Tonnelleauthor=Y.+Toironauthor=F.+Birgauthor=D.+Birnbaum&title=Human+FLT3%2FFLK2+gene%3A+cDNA+cloning+and+expression+in+hematopoietic+cells&doi=10.1182%2Fblood.V82.4.1110.1110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells</span></div><div class="casAuthors">Rosnet, Olivier; Schiff, Claudine; Pebusque, Marie Josephe; Marchetto, Sylvie; Tonnelle, Cecile; Toiron, Yves; Birg, Francoise; Birnbaum, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1110-19</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    </div><div class="casAbstract">The human FLT3 cDNA was cloned from a pre-B-cell line and characterized.  The deduced amino acid sequence shows that FLT3 codes for a receptor-type tyrosine kinase of 993 residues, presenting a strong similarity with the corresponding mouse FLT3/FLK2 protein as well as with the receptors for colony-stimulating factor 1 (CSF1R/FMS) and steel locus factor (SLFR/KIT).  An anal. of the expression of the gene using amplification of reverse transcribed FLT3 mRNA by polymerase chain reaction shows that FLT3 is expressed in various lymphohematopoietic cells and tissues, including a series of immature cell lines and leukemias of lymphocytic origin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6jBgqseYA5bVg90H21EOLACvtfcHk0lhd9uVgGCN4Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhvVSj&md5=02c1749a20d00231ce7d8bb5e95ec137</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1182%2Fblood.V82.4.1110.1110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V82.4.1110.1110%26sid%3Dliteratum%253Aachs%26aulast%3DRosnet%26aufirst%3DO.%26aulast%3DSchiff%26aufirst%3DC.%26aulast%3DPebusque%26aufirst%3DM.%2BJ.%26aulast%3DMarchetto%26aufirst%3DS.%26aulast%3DTonnelle%26aufirst%3DC.%26aulast%3DToiron%26aufirst%3DY.%26aulast%3DBirg%26aufirst%3DF.%26aulast%3DBirnbaum%26aufirst%3DD.%26atitle%3DHuman%2520FLT3%252FFLK2%2520gene%253A%2520cDNA%2520cloning%2520and%2520expression%2520in%2520hematopoietic%2520cells%26jtitle%3DBlood%26date%3D1993%26volume%3D82%26issue%3D4%26spage%3D1110%26epage%3D1119%26doi%3D10.1182%2Fblood.V82.4.1110.1110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faerman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swenson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, K.</span></span> <span> </span><span class="NLM_article-title">The structural basis for autoinhibition of FLT3 by the juxtamembrane domain</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">178</span>, <span class="refDoi"> DOI: 10.1016/S1097-2765(03)00505-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2FS1097-2765%2803%2900505-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=14759363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2004&pages=169-178&issue=2&author=J.+Griffithauthor=J.+Blackauthor=C.+Faermanauthor=L.+Swensonauthor=M.+Wynnauthor=F.+Luauthor=J.+Lippkeauthor=K.+Saxena&title=The+structural+basis+for+autoinhibition+of+FLT3+by+the+juxtamembrane+domain&doi=10.1016%2FS1097-2765%2803%2900505-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis for autoinhibition of FLT3 by the juxtamembrane domain</span></div><div class="casAuthors">Griffith, James; Black, James; Faerman, Carlos; Swenson, Lora; Wynn, Michael; Lu, Fan; Lippke, Judith; Saxena, Kumkum</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-178</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">FLT3 is a type III receptor tyrosine kinase that is thought to play a key role in hematopoiesis.  Certain classes of FLT3 mutations cause constitutively activated forms of the receptor that are found in significant nos. of patients with acute myelogenous leukemia (AML).  The mutations occur either in the activation loop, for example, as point mutations of Asp835 or as internal tandem duplication (ITD) sequences in the juxtamembrane (JM) domain.  To further understand the nature of FLT3 autoinhibition and regulation, we have detd. the crystal structure of the autoinhibited form of FLT3.  This structure shows the autoinhibitory conformation of a complete JM domain in this class of receptor tyrosine kinases.  The detailed inhibitory mechanism of the JM domain is revealed, which is likely utilized by other members of type III receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJAabT6TBxpLVg90H21EOLACvtfcHk0liUxrq6tRkSPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D&md5=d1df4a37aac59f5b59ca242fc8ccd6da</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2803%2900505-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252803%252900505-7%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DJ.%26aulast%3DBlack%26aufirst%3DJ.%26aulast%3DFaerman%26aufirst%3DC.%26aulast%3DSwenson%26aufirst%3DL.%26aulast%3DWynn%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DF.%26aulast%3DLippke%26aufirst%3DJ.%26aulast%3DSaxena%26aufirst%3DK.%26atitle%3DThe%2520structural%2520basis%2520for%2520autoinhibition%2520of%2520FLT3%2520by%2520the%2520juxtamembrane%2520domain%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D13%26issue%3D2%26spage%3D169%26epage%3D178%26doi%3D10.1016%2FS1097-2765%2803%2900505-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangoc, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spolski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broxmeyer, H. E.</span></span> <span> </span><span class="NLM_article-title">Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>192</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">719</span>– <span class="NLM_lpage">728</span>, <span class="refDoi"> DOI: 10.1084/jem.192.5.719</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1084%2Fjem.192.5.719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10974037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtlegtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2000&pages=719-728&issue=5&author=S.+Zhangauthor=S.+Fukudaauthor=Y.+Leeauthor=G.+Hangocauthor=S.+Cooperauthor=R.+Spolskiauthor=W.+J.+Leonardauthor=H.+E.+Broxmeyer&title=Essential+role+of+signal+transducer+and+activator+of+transcription+%28Stat%295a+but+not+Stat5b+for+Flt3-dependent+signaling&doi=10.1084%2Fjem.192.5.719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling</span></div><div class="casAuthors">Zhang, Shuli; Fukuda, Seiji; Lee, Younghee; Hangoc, Giao; Cooper, Scott; Spolski, Rosanne; Leonard, Warren J.; Broxmeyer, Hal E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">719-728</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase Flt3 plays an important role in proliferation and survival of hematopoietic stem and progenitor cells.  Although some post-receptor signaling events of Flt3 have been characterized, the involvement of the Janus kinase/signal transducer and activator of transcription (Jak/Stat) pathway in Flt3 signaling has not been thoroughly evaluated.  To this aim, the authors examd. whether Flt3 activates the Jak/Stat pathway in Baf3/Flt3 cells, a line stably expressing human Flt3 receptor.  Stat5a, but not Stats 1-4, 5b, or 6, was potently activated by Flt3 ligand (FL) stimulation.  Interestingly, FL did not activate any Jaks.  Activation of Stat5a required the kinase activity of Flt3.  A selective role for Stat5a in the proliferative response of primary hematopoietic progenitor cells to FL was documented, as FL did not act on progenitors from marrows of Stat5a-/- mice, but did stimulate/costimulate proliferation of these cells from Stat5a+/+, Stat5b-/-, and Stat5b+/+ mice.  Thus, Stat5a is essential for at least certain effects of FL.  The authors' data also confirm that Stat5a and Stat5b are not redundant, but rather are at least partially distinctive in their function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPiElN3OIS8rVg90H21EOLACvtfcHk0liUxrq6tRkSPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtlegtrw%253D&md5=f8ba557376b2c7fe86dcd821ffb1ae97</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1084%2Fjem.192.5.719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.192.5.719%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DFukuda%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DHangoc%26aufirst%3DG.%26aulast%3DCooper%26aufirst%3DS.%26aulast%3DSpolski%26aufirst%3DR.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26aulast%3DBroxmeyer%26aufirst%3DH.%2BE.%26atitle%3DEssential%2520role%2520of%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%2520%2528Stat%25295a%2520but%2520not%2520Stat5b%2520for%2520Flt3-dependent%2520signaling%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2000%26volume%3D192%26issue%3D5%26spage%3D719%26epage%3D728%26doi%3D10.1084%2Fjem.192.5.719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gucky, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reznickova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radosova Muchova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klejova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malinkova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazgier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepsik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divoky, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystof, V.</span></span> <span> </span><span class="NLM_article-title">Discovery of <i>N</i><sup>2</sup>-(4-amino-cyclohexyl)-9-cyclopentyl-<i>N</i><sup>6</sup>-(4-morpholin-4-ylmethyl-phenyl)-9<i>H</i>-purine-2,6-diamine as a potent FLT3 kinase inhibitor for acute myeloid leukemia with FLT3 mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3855</span>– <span class="NLM_lpage">3869</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01529</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01529" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotVahsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3855-3869&issue=9&author=T.+Guckyauthor=E.+Reznickovaauthor=T.+Radosova+Muchovaauthor=R.+Jordaauthor=Z.+Klejovaauthor=V.+Malinkovaauthor=K.+Berkaauthor=V.+Bazgierauthor=H.+Ajaniauthor=M.+Lepsikauthor=V.+Divokyauthor=V.+Krystof&title=Discovery+of+N2-%284-amino-cyclohexyl%29-9-cyclopentyl-N6-%284-morpholin-4-ylmethyl-phenyl%29-9H-purine-2%2C6-diamine+as+a+potent+FLT3+kinase+inhibitor+for+acute+myeloid+leukemia+with+FLT3+mutations&doi=10.1021%2Facs.jmedchem.7b01529"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N2-(4-Amino-cyclohexyl)-9-cyclopentyl-N6-(4-morpholin-4-ylmethyl-phenyl)-9H-purine-2,6-diamine as a Potent FLT3 Kinase Inhibitor for Acute Myeloid Leukemia with FLT3 Mutations</span></div><div class="casAuthors">Gucky, Tomas; Reznickova, Eva; Radosova Muchova, Tereza; Jorda, Radek; Klejova, Zuzana; Malinkova, Veronika; Berka, Karel; Bazgier, Vaclav; Ajani, Haresh; Lepsik, Martin; Divoky, Vladimir; Krystof, Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3855-3869</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">FLT3 tyrosine kinase is a potential drug target in acute myeloid leukemia (AML) because patients with FLT3-ITD mutations respond poorly to std. cytotoxic agents and there is a clear link between the disease and the oncogenic properties of FLT3.  We present novel 2,6,9-trisubstituted purine derivs. with potent FLT3 inhibitory activity.  The lead compd. 7d displays nanomolar activity in biochem. assays and selectively blocks proliferation of AML cell lines harboring FLT3-ITD mutations, whereas other transformed and normal human cells are several orders of magnitude less sensitive.  The MV4-11 cells treated with 7d suppressed the phosphorylation of FLT3 and its downstream signaling pathways, with subsequent G1 cell cycle arrest and apoptosis.  Addnl., a single dose of 7d in mice with s.c. MV4-11 xenografts caused sustained inhibition of FLT3 and STAT5 phosphorylation over 48 h, in contrast to the shorter effect obsd. after administration of the ref. FLT3 inhibitor quizartinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ88Wx0YxwWLVg90H21EOLACvtfcHk0li3KLfB7XK2LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotVahsr0%253D&md5=cbc982a08f1905840e273e23c825a134</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01529%26sid%3Dliteratum%253Aachs%26aulast%3DGucky%26aufirst%3DT.%26aulast%3DReznickova%26aufirst%3DE.%26aulast%3DRadosova%2BMuchova%26aufirst%3DT.%26aulast%3DJorda%26aufirst%3DR.%26aulast%3DKlejova%26aufirst%3DZ.%26aulast%3DMalinkova%26aufirst%3DV.%26aulast%3DBerka%26aufirst%3DK.%26aulast%3DBazgier%26aufirst%3DV.%26aulast%3DAjani%26aufirst%3DH.%26aulast%3DLepsik%26aufirst%3DM.%26aulast%3DDivoky%26aufirst%3DV.%26aulast%3DKrystof%26aufirst%3DV.%26atitle%3DDiscovery%2520of%2520N2-%25284-amino-cyclohexyl%2529-9-cyclopentyl-N6-%25284-morpholin-4-ylmethyl-phenyl%2529-9H-purine-2%252C6-diamine%2520as%2520a%2520potent%2520FLT3%2520kinase%2520inhibitor%2520for%2520acute%2520myeloid%2520leukemia%2520with%2520FLT3%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D9%26spage%3D3855%26epage%3D3869%26doi%3D10.1021%2Facs.jmedchem.7b01529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dohner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisdorf, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomfield, C. D.</span></span> <span> </span><span class="NLM_article-title">Acute myeloid leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1136</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1056/NEJMra1406184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1056%2FNEJMra1406184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=26376137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BC283jt1Shsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=1136-1152&issue=12&author=H.+Dohnerauthor=D.+J.+Weisdorfauthor=C.+D.+Bloomfield&title=Acute+myeloid+leukemia&doi=10.1056%2FNEJMra1406184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Acute Myeloid Leukemia</span></div><div class="casAuthors">Dohner Hartmut; Weisdorf Daniel J; Bloomfield Clara D</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1136-52</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7_lmkXqa4eckU0YCbOU3EfW6udTcc2eZ9Pkrd-yKzr7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283jt1Shsw%253D%253D&md5=a22a9f8b7b0e31e1084d2e76281bb35a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1406184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1406184%26sid%3Dliteratum%253Aachs%26aulast%3DDohner%26aufirst%3DH.%26aulast%3DWeisdorf%26aufirst%3DD.%2BJ.%26aulast%3DBloomfield%26aufirst%3DC.%2BD.%26atitle%3DAcute%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26issue%3D12%26spage%3D1136%26epage%3D1152%26doi%3D10.1056%2FNEJMra1406184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Short, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rytting, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J. E.</span></span> <span> </span><span class="NLM_article-title">Acute myeloid leukaemia</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>392</i></span> (<span class="NLM_issue">10147</span>),  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">606</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(18)31041-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2FS0140-6736%2818%2931041-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=30078459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ltF2jtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=392&publication_year=2018&pages=593-606&issue=10147&author=N.+J.+Shortauthor=M.+E.+Ryttingauthor=J.+E.+Cortes&title=Acute+myeloid+leukaemia&doi=10.1016%2FS0140-6736%2818%2931041-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Acute myeloid leukaemia</span></div><div class="casAuthors">Short Nicholas J; Rytting Michael E; Cortes Jorge E</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">392</span>
        (<span class="NLM_cas:issue">10147</span>),
    <span class="NLM_cas:pages">593-606</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">For several decades, few substantial therapeutic advances have been made for patients with acute myeloid leukaemia.  However, since 2017 unprecedented growth has been seen in the number of drugs available for the treatment of acute myeloid leukaemia, with several new drugs receiving regulatory approval.  In addition to advancing our therapeutic armamentarium, an increased understanding of the biology and genomic architecture of acute myeloid leukaemia has led to refined risk assessment of this disease, with consensus risk stratification guidelines now incorporating a growing number of recurrent molecular aberrations that aid in the selection of risk-adapted management strategies.  Despite this promising recent progress, the outcomes of patients with acute myeloid leukaemia remain unsatisfactory, with more than half of patients ultimately dying from their disease.  Enrolment of patients into clinical trials that evaluate novel drugs and rational combination therapies is imperative to continuing this progress and further improving the outcomes of patients with acute myeloid leukaemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-2ehJOMY27yA3UY9EwTNrfW6udTcc2eZ9Pkrd-yKzr7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ltF2jtA%253D%253D&md5=212ad7a55f4f9e1e1d90f2e265987f3c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2818%2931041-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252818%252931041-9%26sid%3Dliteratum%253Aachs%26aulast%3DShort%26aufirst%3DN.%2BJ.%26aulast%3DRytting%26aufirst%3DM.%2BE.%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26atitle%3DAcute%2520myeloid%2520leukaemia%26jtitle%3DLancet%26date%3D2018%26volume%3D392%26issue%3D10147%26spage%3D593%26epage%3D606%26doi%3D10.1016%2FS0140-6736%2818%2931041-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stirewalt, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radich, J. P.</span></span> <span> </span><span class="NLM_article-title">The role of FLT3 in haematopoietic malignancies</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">650</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1038/nrc1169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fnrc1169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=12951584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvVWlu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=650-665&issue=9&author=D.+L.+Stirewaltauthor=J.+P.+Radich&title=The+role+of+FLT3+in+haematopoietic+malignancies&doi=10.1038%2Fnrc1169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The role of FLT3 in hematopoietic malignancies</span></div><div class="casAuthors">Stirewalt, Derek L.; Radich, Jerald P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">650-665</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Normal haematopoietic cells use complex systems to control proliferation, differentiation and cell death.  The control of proliferation is, in part, accomplished through the ligand-induced stimulation of receptor tyrosine kinases, which signal to downstream effectors through the RAS pathway.  Recently, mutations in the FMS-like tyrosine kinase 3 (FLT3) gene, which encodes a receptor tyrosine kinase, have been found to be the most common genetic lesion in acute myeloid leukemia (AML), occurring in ∼25% of cases.  Exploring the mechanism by which these FLT3 mutations cause uncontrolled proliferation might lead to a better understanding of how cells become cancerous and provide insights for the development of new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRONPQkpemorVg90H21EOLACvtfcHk0li3KLfB7XK2LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvVWlu7c%253D&md5=97183b7a6087fafe20bfc695f403825b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrc1169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1169%26sid%3Dliteratum%253Aachs%26aulast%3DStirewalt%26aufirst%3DD.%2BL.%26aulast%3DRadich%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520role%2520of%2520FLT3%2520in%2520haematopoietic%2520malignancies%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26issue%3D9%26spage%3D650%26epage%3D665%26doi%3D10.1038%2Fnrc1169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fromm, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erhardt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krauter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brossart, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundgen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salih, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulf, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertenstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wattad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotze, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraemer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinicke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girschikofsky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derigs, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horst, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gohring, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teleanu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullinger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thol, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidzik, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paschka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, R. F.</span></span> <span> </span><span class="NLM_article-title">Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)</span>. <i>Ann. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>96</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1993</span>– <span class="NLM_lpage">2003</span>, <span class="refDoi"> DOI: 10.1007/s00277-017-3150-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1007%2Fs00277-017-3150-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=29090343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BC1M7msVymug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2017&pages=1993-2003&issue=12&author=G.+Nagelauthor=D.+Weberauthor=E.+Frommauthor=S.+Erhardtauthor=M.+Lubbertauthor=W.+Fiedlerauthor=T.+Kindlerauthor=J.+Krauterauthor=P.+Brossartauthor=A.+Kundgenauthor=H.+R.+Salihauthor=J.+Westermannauthor=G.+Wulfauthor=B.+Hertensteinauthor=M.+Wattadauthor=K.+Gotzeauthor=D.+Kraemerauthor=T.+Heinickeauthor=M.+Girschikofskyauthor=H.+G.+Derigsauthor=H.+A.+Horstauthor=C.+Rudolphauthor=M.+Heuserauthor=G.+Gohringauthor=V.+Teleanuauthor=L.+Bullingerauthor=F.+Tholauthor=V.+I.+Gaidzikauthor=P.+Paschkaauthor=K.+Dohnerauthor=A.+Ganserauthor=H.+Dohnerauthor=R.+F.+Schlenk&title=Epidemiological%2C+genetic%2C+and+clinical+characterization+by+age+of+newly+diagnosed+acute+myeloid+leukemia+based+on+an+academic+population-based+registry+study+%28AMLSG+BiO%29&doi=10.1007%2Fs00277-017-3150-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)</span></div><div class="casAuthors">Nagel Gabriele; Fromm E; Erhardt S; Weber D; Rudolph C; Teleanu V; Bullinger L; Gaidzik V I; Paschka P; Dohner K; Dohner Hartmut; Schlenk R F; Lubbert M; Fiedler W; Kindler T; Krauter J; Brossart P; Kundgen A; Salih H R; Westermann J; Wulf G; Hertenstein B; Wattad M; Gotze K; Kraemer D; Heinicke T; Girschikofsky M; Derigs H G; Horst H A; Heuser M; Thol F; Ganser A; Gohring G; Schlenk R F</div><div class="citationInfo"><span class="NLM_cas:title">Annals of hematology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1993-2003</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We describe genetic and clinical characteristics of acute myeloid leukemia (AML) patients according to age from an academic population-based registry.  Adult patients with newly diagnosed AML at 63 centers in Germany and Austria were followed within the AMLSG BiO registry (NCT01252485).  Between January 1, 2012, and December 31, 2014, data of 3525 patients with AML (45% women) were collected.  The median age was 65 years (range 18-94).  The comparison of age-specific AML incidence rates with epidemiological cancer registries revealed excellent coverage in patients < 70 years old and good coverage up to the age of 80.  The distribution according to the European LeukemiaNet (ELN) risk categorization from 2010 was 20% favorable, 31% intermediate-1, 28% intermediate-2, and 21% adverse.  With increasing age, the relative but not the absolute prevalence of patients with ELN favorable and intermediate-1 risk (p < 0.001), with activating FLT3 mutations (p < 0.001), with ECOG performance status < 2 (p < 0.001), and with HCT-CI comorbidity index < 3 (p < 0.001) decreased.  Regarding treatment, obesity and favorable risk were associated with an intensive treatment, whereas adverse risk, higher age, and comorbidity index > 0 were associated with non-intensive treatment or best supportive care.  The AMLSG BiO registry provides reliable population-based distributions of genetic, clinical, and treatment characteristics according to age.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTfcgM0Frwgo4YPsCkJIw00fW6udTcc2ea3Ig47phtlMLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7msVymug%253D%253D&md5=3e1e417ca1378864da1bbb89c4759bb6</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs00277-017-3150-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00277-017-3150-3%26sid%3Dliteratum%253Aachs%26aulast%3DNagel%26aufirst%3DG.%26aulast%3DWeber%26aufirst%3DD.%26aulast%3DFromm%26aufirst%3DE.%26aulast%3DErhardt%26aufirst%3DS.%26aulast%3DLubbert%26aufirst%3DM.%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DKindler%26aufirst%3DT.%26aulast%3DKrauter%26aufirst%3DJ.%26aulast%3DBrossart%26aufirst%3DP.%26aulast%3DKundgen%26aufirst%3DA.%26aulast%3DSalih%26aufirst%3DH.%2BR.%26aulast%3DWestermann%26aufirst%3DJ.%26aulast%3DWulf%26aufirst%3DG.%26aulast%3DHertenstein%26aufirst%3DB.%26aulast%3DWattad%26aufirst%3DM.%26aulast%3DGotze%26aufirst%3DK.%26aulast%3DKraemer%26aufirst%3DD.%26aulast%3DHeinicke%26aufirst%3DT.%26aulast%3DGirschikofsky%26aufirst%3DM.%26aulast%3DDerigs%26aufirst%3DH.%2BG.%26aulast%3DHorst%26aufirst%3DH.%2BA.%26aulast%3DRudolph%26aufirst%3DC.%26aulast%3DHeuser%26aufirst%3DM.%26aulast%3DGohring%26aufirst%3DG.%26aulast%3DTeleanu%26aufirst%3DV.%26aulast%3DBullinger%26aufirst%3DL.%26aulast%3DThol%26aufirst%3DF.%26aulast%3DGaidzik%26aufirst%3DV.%2BI.%26aulast%3DPaschka%26aufirst%3DP.%26aulast%3DDohner%26aufirst%3DK.%26aulast%3DGanser%26aufirst%3DA.%26aulast%3DDohner%26aufirst%3DH.%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26atitle%3DEpidemiological%252C%2520genetic%252C%2520and%2520clinical%2520characterization%2520by%2520age%2520of%2520newly%2520diagnosed%2520acute%2520myeloid%2520leukemia%2520based%2520on%2520an%2520academic%2520population-based%2520registry%2520study%2520%2528AMLSG%2520BiO%2529%26jtitle%3DAnn.%2520Hematol.%26date%3D2017%26volume%3D96%26issue%3D12%26spage%3D1993%26epage%3D2003%26doi%3D10.1007%2Fs00277-017-3150-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiike, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonoda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misawa, S.</span></span> <span> </span><span class="NLM_article-title">Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1911</span>– <span class="NLM_lpage">1918</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=8946930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADyaK2s7gt1Kqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1996&pages=1911-1918&issue=12&author=M.+Nakaoauthor=S.+Yokotaauthor=T.+Iwaiauthor=H.+Kanekoauthor=S.+Horiikeauthor=K.+Kashimaauthor=Y.+Sonodaauthor=T.+Fujimotoauthor=S.+Misawa&title=Internal+tandem+duplication+of+the+FLT3+gene+found+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Internal tandem duplication of the flt3 gene found in acute myeloid leukemia</span></div><div class="casAuthors">Nakao M; Yokota S; Iwai T; Kaneko H; Horiike S; Kashima K; Sonoda Y; Fujimoto T; Misawa S</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1911-8</span>
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    </div><div class="casAbstract">We analyzed mRNA expression of the flt3 gene in 30 patients with acute myeloid leukemia (AML) and 50 with acute lymphoblastic leukemia (ALL).  Using reverse transcriptase-polymerase chain reaction (RT-PCR), expression of flt3 was observed in 61 patients; 22 (73%) with AML and 39 (78%) with ALL.  Among these, five patients with AML (one M2, two M4, and two M5) showed unexpected longer transcripts with a primer combination which could amplify the transmembrane (TM) domain through the juxtamembrane (JM) domain.  For those patients who expressed flt3 mRNA, the extracellular domain of the flt3 gene was also examined by RT-PCR, but no length abnormality was seen in this region.  We further analyzed the TM domain through the second tyrosine kinase domain by genomic amplifications.  The five patients who showed aberrant flt3 transcripts exhibited abnormal longer PCR products in addition to the germline products at a region corresponding to the JM through the first TK (TK1) domains.  Sequence analyses of the abnormal RT-PCR products demonstrated that partial sequences were tandemly duplicated.  Because all these altered transcripts were in-frame, deduced protein products could be expected.  Sequence analyses of the genomic DNA revealed that three of the five patients showed a simple internal duplication within exon 11; one had an internal duplication (26 bp) with a 4-bp insertion; and in the fifth patient, a 136-bp sequence from the 3' part of exon 11 to intron 11 and the first 16-bp sequence of exon 12 were each duplicated with 1-bp insertion.  In order to confirm the tumor specificity of these alterations, DNA samples obtained at complete remission were also analyzed in the three patients harboring an flt3 duplication, but no abnormal PCR product other than germline was detected in any of the samples.  Our results suggest that an internal tandem duplication at the JM/TK1 domains of the flt3 gene is a somatic change detected preferentially in AML, possibly containing a monocytic component.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQL5G2hUkeODSA3UY9EwTNrfW6udTcc2ea3Ig47phtlMLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s7gt1Kqsg%253D%253D&md5=da0c7f21e6c4daf68bd4b1ae38a92891</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNakao%26aufirst%3DM.%26aulast%3DYokota%26aufirst%3DS.%26aulast%3DIwai%26aufirst%3DT.%26aulast%3DKaneko%26aufirst%3DH.%26aulast%3DHoriike%26aufirst%3DS.%26aulast%3DKashima%26aufirst%3DK.%26aulast%3DSonoda%26aufirst%3DY.%26aulast%3DFujimoto%26aufirst%3DT.%26aulast%3DMisawa%26aufirst%3DS.%26atitle%3DInternal%2520tandem%2520duplication%2520of%2520the%2520FLT3%2520gene%2520found%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D1996%26volume%3D10%26issue%3D12%26spage%3D1911%26epage%3D1918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stirewalt, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopecky, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meshinchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogosova-Agadjanyan, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linsley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slovak, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willman, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radich, J. P.</span></span> <span> </span><span class="NLM_article-title">Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>107</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3724</span>– <span class="NLM_lpage">3726</span>, <span class="refDoi"> DOI: 10.1182/blood-2005-08-3453</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2005-08-3453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=16368883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD28Xkt1Giu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2006&pages=3724-3726&issue=9&author=D.+L.+Stirewaltauthor=K.+J.+Kopeckyauthor=S.+Meshinchiauthor=J.+H.+Engelauthor=E.+L.+Pogosova-Agadjanyanauthor=J.+Linsleyauthor=M.+L.+Slovakauthor=C.+L.+Willmanauthor=J.+P.+Radich&title=Size+of+FLT3+internal+tandem+duplication+has+prognostic+significance+in+patients+with+acute+myeloid+leukemia&doi=10.1182%2Fblood-2005-08-3453"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia</span></div><div class="casAuthors">Stirewalt, Derek L.; Kopecky, Kenneth J.; Meshinchi, Soheil; Engel, Julia H.; Pogosova-Agadjanyan, Era L.; Linsley, Jeremy; Slovak, Marilyn L.; Willman, Cheryl L.; Radich, Jerald P.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3724-3726</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">FLT3 internal tandem duplications (FLT3/ITDs) in the juxtamembrane domain are found in approx. 25% of acute myeloid leukemia (AML) patients, ranging in size from 3 to hundreds of nucleotides.  We examd. whether the sizes of FLT3/ITDs were assocd. with clin. outcomes in 151 AML patients enrolled in Southwest Oncol. Group studies: S9333 and S9500.  FLT3/ITDs were identified in 32% of patients (median ITD size = 39 nucleotides; range, 15-153 nucleotides).  The CR rates were 35%, 67%, and 52% for patients with large (≥ 40), small (< 40), and no ITDs, resp. (P =.19).  Increasing ITD size was assocd. with decreasing OS (estd. 5-yr OS: large = 13%, small = 26%, and no ITD = 21%, P =.072) and RFS (estd. 5-yr RFS: large = 13%, small = 27%, and no ITD = 34%, P =.017).  These studies suggest that ITD size may have prognostic significance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbTynIbwo_AbVg90H21EOLACvtfcHk0li1EHrK2ar-Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xkt1Giu7s%253D&md5=5cfa50e4ac5aedf32d6afaab8d658c65</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-08-3453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-08-3453%26sid%3Dliteratum%253Aachs%26aulast%3DStirewalt%26aufirst%3DD.%2BL.%26aulast%3DKopecky%26aufirst%3DK.%2BJ.%26aulast%3DMeshinchi%26aufirst%3DS.%26aulast%3DEngel%26aufirst%3DJ.%2BH.%26aulast%3DPogosova-Agadjanyan%26aufirst%3DE.%2BL.%26aulast%3DLinsley%26aufirst%3DJ.%26aulast%3DSlovak%26aufirst%3DM.%2BL.%26aulast%3DWillman%26aufirst%3DC.%2BL.%26aulast%3DRadich%26aufirst%3DJ.%2BP.%26atitle%3DSize%2520of%2520FLT3%2520internal%2520tandem%2520duplication%2520has%2520prognostic%2520significance%2520in%2520patients%2520with%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2006%26volume%3D107%26issue%3D9%26spage%3D3724%26epage%3D3726%26doi%3D10.1182%2Fblood-2005-08-3453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schnittger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haferlach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alpermann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haferlach, T.</span></span> <span> </span><span class="NLM_article-title">Diversity of the juxtamembrane and TKD1 mutations (exons 13–15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data</span>. <i>Genes, Chromosomes Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">910</span>– <span class="NLM_lpage">924</span>, <span class="refDoi"> DOI: 10.1002/gcc.21975</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1002%2Fgcc.21975" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=22674490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvFOqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=910-924&issue=10&author=S.+Schnittgerauthor=U.+Bacherauthor=C.+Haferlachauthor=T.+Alpermannauthor=W.+Kernauthor=T.+Haferlach&title=Diversity+of+the+juxtamembrane+and+TKD1+mutations+%28exons+13%E2%80%9315%29+in+the+FLT3+gene+with+regards+to+mutant+load%2C+sequence%2C+length%2C+localization%2C+and+correlation+with+biological+data&doi=10.1002%2Fgcc.21975"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Diversity of the juxtamembrane and TKD1 mutations (Exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data</span></div><div class="casAuthors">Schnittger, Susanne; Bacher, Ulrike; Haferlach, Claudia; Alpermann, Tamara; Kern, Wolfgang; Haferlach, Torsten</div><div class="citationInfo"><span class="NLM_cas:title">Genes, Chromosomes & Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">910-924</span>CODEN:
                <span class="NLM_cas:coden">GCCAES</span>;
        ISSN:<span class="NLM_cas:issn">1045-2257</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">In acute myeloid leukemia (AML) mutations in the juxtamembrane and tyrosine kinase 1 domain (exons 13-15) of the FLT3 gene (FLT3-ITD/LM) are heterogeneous with respect to mutation load, size, and localization.  We characterized length and structure of these mutations by fragment anal. and sequencing in 689 AML which were identified among 3,365 (20.5%) newly diagnosed AML (1,803 males, 1,562 females; 15.8-91.8 years).  Mutations were heterogeneous in length (median: 63, range: 3-1,236 nucleotides; nt).  Most frequent were sizes of 21 (8.4%) or 24 nt (6.0%).  Ninety-one different insertion sites were obsd. (between nt 1,788 and 1,934, according to accession "FLT3 [Ensembl/Havana merge: ENSG00000122025]" with nt 1,856 (n = 41) and 1,863 (n = 35) being most frequent.  In addn., 89 different insertion end points were obsd. between nt 1,790 and 1,994.  FLT3-mutation/wild-type ratio was available in 615 patients (median, 0.80; range 0.03-181.73). 128 Patients (20.8%) had ratios <0.3, 334 (54.3%) had ratio ≥0.3 <1, 118 (19.2%) ≥1, and 35 (5.7%) showed complete loss of the FLT3-wild-type allele.  Overall (OS) and event-free (EFS) survival were better for FLT3-neg. than FLT3mut normal karyotype patients (P = 0.078 and P = 0.004, resp.) and patients with low level FLT3-mutations had significantly longer OS and EFS compared with high level mutations (FLT3-mutation/wild-type ratio ≥1) (P < 0.001 and P = 0.002, resp.).  The length of the mutation had no prognostic impact.  Mutations localized more 5' were assocd. with better outcome than more 3'mutations, but no strict assocn. to certain functional domains was detected.  In conclusion, FLT3-mutations are extremely heterogenous with mutation load being the most relevant parameter. © 2012 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvkqizY7W9trVg90H21EOLACvtfcHk0li1EHrK2ar-Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvFOqtb8%253D&md5=1ba64ad96edcf3aca579f5b7a1861a99</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fgcc.21975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fgcc.21975%26sid%3Dliteratum%253Aachs%26aulast%3DSchnittger%26aufirst%3DS.%26aulast%3DBacher%26aufirst%3DU.%26aulast%3DHaferlach%26aufirst%3DC.%26aulast%3DAlpermann%26aufirst%3DT.%26aulast%3DKern%26aufirst%3DW.%26aulast%3DHaferlach%26aufirst%3DT.%26atitle%3DDiversity%2520of%2520the%2520juxtamembrane%2520and%2520TKD1%2520mutations%2520%2528exons%252013%25E2%2580%259315%2529%2520in%2520the%2520FLT3%2520gene%2520with%2520regards%2520to%2520mutant%2520load%252C%2520sequence%252C%2520length%252C%2520localization%252C%2520and%2520correlation%2520with%2520biological%2520data%26jtitle%3DGenes%252C%2520Chromosomes%2520Cancer%26date%3D2012%26volume%3D51%26issue%3D10%26spage%3D910%26epage%3D924%26doi%3D10.1002%2Fgcc.21975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullinger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobbe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casper, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringhoffer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Held, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brossart, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salih, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horst, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulf, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nachbaur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotze, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamparter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paschka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidzik, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teleanu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krauter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohner, K.</span></span> <span> </span><span class="NLM_article-title">Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">3441</span>– <span class="NLM_lpage">3449</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-05-578070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2014-05-578070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=25270908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitV2nsbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=3441-3449&issue=23&author=R.+F.+Schlenkauthor=S.+Kayserauthor=L.+Bullingerauthor=G.+Kobbeauthor=J.+Casperauthor=M.+Ringhofferauthor=G.+Heldauthor=P.+Brossartauthor=M.+Lubbertauthor=H.+R.+Salihauthor=T.+Kindlerauthor=H.+A.+Horstauthor=G.+Wulfauthor=D.+Nachbaurauthor=K.+Gotzeauthor=A.+Lamparterauthor=P.+Paschkaauthor=V.+I.+Gaidzikauthor=V.+Teleanuauthor=D.+Spathauthor=A.+Bennerauthor=J.+Krauterauthor=A.+Ganserauthor=H.+Dohnerauthor=K.+Dohner&title=Differential+impact+of+allelic+ratio+and+insertion+site+in+FLT3-ITD-positive+AML+with+respect+to+allogeneic+transplantation&doi=10.1182%2Fblood-2014-05-578070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation</span></div><div class="casAuthors">Schlenk, Richard F.; Kayser, Sabine; Bullinger, Lars; Kobbe, Guido; Casper, Jochen; Ringhoffer, Mark; Held, Gerhard; Brossart, Peter; Luebbert, Michael; Salih, Helmut R.; Kindler, Thomas; Horst, Heinz A.; Wulf, Gerald; Nachbaur, David; Goetze, Katharina; Lamparter, Alexander; Paschka, Peter; Gaidzik, Verena I.; Teleanu, Veronica; Spaeth, Daniela; Benner, Axel; Krauter, Juergen; Ganser, Arnold; Doehner, Hartmut; Doehner, Konstanze</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3441-3449</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The objective was to evaluate the prognostic and predictive impact of allelic ratio and insertion site (IS) of internal tandem duplications (ITDs), as well as concurrent gene mutations, with regard to postremission therapy in 323 patients with FLT3-ITD-pos. acute myeloid leukemia (AML).  Increasing FLT3-ITD allelic ratio (P = .004) and IS in the tyrosine kinase domain 1 (TKD1, P = .06) were assocd. with low complete remission (CR) rates.  After postremission therapy including intensive chemotherapy (n = 121) or autologous hematopoietic stem cell transplantation (HSCT, n = 17), an allelic ratio ≥ 0.51 was assocd. with an unfavorable relapse-free (RFS, P = .0008) and overall survival (OS, P = .004); after allogeneic HSCT (n = 93), outcome was significantly improved in patients with a high allelic ratio (RFS, P = .02; OS, P = .03), whereas no benefit was seen in patients with a low allelic ratio (RFS, P = .38; OS, P = .64).  Multivariable analyses revealed a high allelic ratio as a predictive factor for the beneficial effect of allogeneic HSCT; ITD IS in TKD1 remained an unfavorable factor, whereas no prognostic impact of concurrent gene mutations was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-3OpzDAfbwLVg90H21EOLACvtfcHk0li1EHrK2ar-Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitV2nsbbN&md5=d505ffab0eb1820edec6d5657d17db41</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-05-578070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-05-578070%26sid%3Dliteratum%253Aachs%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26aulast%3DKayser%26aufirst%3DS.%26aulast%3DBullinger%26aufirst%3DL.%26aulast%3DKobbe%26aufirst%3DG.%26aulast%3DCasper%26aufirst%3DJ.%26aulast%3DRinghoffer%26aufirst%3DM.%26aulast%3DHeld%26aufirst%3DG.%26aulast%3DBrossart%26aufirst%3DP.%26aulast%3DLubbert%26aufirst%3DM.%26aulast%3DSalih%26aufirst%3DH.%2BR.%26aulast%3DKindler%26aufirst%3DT.%26aulast%3DHorst%26aufirst%3DH.%2BA.%26aulast%3DWulf%26aufirst%3DG.%26aulast%3DNachbaur%26aufirst%3DD.%26aulast%3DGotze%26aufirst%3DK.%26aulast%3DLamparter%26aufirst%3DA.%26aulast%3DPaschka%26aufirst%3DP.%26aulast%3DGaidzik%26aufirst%3DV.%2BI.%26aulast%3DTeleanu%26aufirst%3DV.%26aulast%3DSpath%26aufirst%3DD.%26aulast%3DBenner%26aufirst%3DA.%26aulast%3DKrauter%26aufirst%3DJ.%26aulast%3DGanser%26aufirst%3DA.%26aulast%3DDohner%26aufirst%3DH.%26aulast%3DDohner%26aufirst%3DK.%26atitle%3DDifferential%2520impact%2520of%2520allelic%2520ratio%2520and%2520insertion%2520site%2520in%2520FLT3-ITD-positive%2520AML%2520with%2520respect%2520to%2520allogeneic%2520transplantation%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26issue%3D23%26spage%3D3441%26epage%3D3449%26doi%3D10.1182%2Fblood-2014-05-578070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ley, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koboldt, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welch, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchey, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamprecht, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMichael, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dooling, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalicki-Veizer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magrini, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendl, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Link, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasson, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payton, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westervelt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graubert, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPersio, J. F.</span></span> <span> </span><span class="NLM_article-title">Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>481</i></span> (<span class="NLM_issue">7382</span>),  <span class="NLM_fpage">506</span>– <span class="NLM_lpage">510</span>, <span class="refDoi"> DOI: 10.1038/nature10738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fnature10738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=22237025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsF2jtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=481&publication_year=2012&pages=506-510&issue=7382&author=L.+Dingauthor=T.+J.+Leyauthor=D.+E.+Larsonauthor=C.+A.+Millerauthor=D.+C.+Koboldtauthor=J.+S.+Welchauthor=J.+K.+Ritcheyauthor=M.+A.+Youngauthor=T.+Lamprechtauthor=M.+D.+McLellanauthor=J.+F.+McMichaelauthor=J.+W.+Wallisauthor=C.+Luauthor=D.+Shenauthor=C.+C.+Harrisauthor=D.+J.+Doolingauthor=R.+S.+Fultonauthor=L.+L.+Fultonauthor=K.+Chenauthor=H.+Schmidtauthor=J.+Kalicki-Veizerauthor=V.+J.+Magriniauthor=L.+Cookauthor=S.+D.+McGrathauthor=T.+L.+Vickeryauthor=M.+C.+Wendlauthor=S.+Heathauthor=M.+A.+Watsonauthor=D.+C.+Linkauthor=M.+H.+Tomassonauthor=W.+D.+Shannonauthor=J.+E.+Paytonauthor=S.+Kulkarniauthor=P.+Westerveltauthor=M.+J.+Walterauthor=T.+A.+Graubertauthor=E.+R.+Mardisauthor=R.+K.+Wilsonauthor=J.+F.+DiPersio&title=Clonal+evolution+in+relapsed+acute+myeloid+leukaemia+revealed+by+whole-genome+sequencing&doi=10.1038%2Fnature10738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing</span></div><div class="casAuthors">Ding, Li; Ley, Timothy J.; Larson, David E.; Miller, Christopher A.; Koboldt, Daniel C.; Welch, John S.; Ritchey, Julie K.; Young, Margaret A.; Lamprecht, Tamara; McLellan, Michael D.; McMichael, Joshua F.; Wallis, John W.; Lu, Charles; Shen, Dong; Harris, Christopher C.; Dooling, David J.; Fulton, Robert S.; Fulton, Lucinda L.; Chen, Ken; Schmidt, Heather; Kalicki-Veizer, Joelle; Magrini, Vincent J.; Cook, Lisa; McGrath, Sean D.; Vickery, Tammi L.; Wendl, Michael C.; Heath, Sharon; Watson, Mark A.; Link, Daniel C.; Tomasson, Michael H.; Shannon, William D.; Payton, Jacqueline E.; Kulkarni, Shashikant; Westervelt, Peter; Walter, Matthew J.; Graubert, Timothy A.; Mardis, Elaine R.; Wilson, Richard K.; DiPersio, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">481</span>
        (<span class="NLM_cas:issue">7382</span>),
    <span class="NLM_cas:pages">506-510</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The sequencing of AML genomes of eight patients before and after relapse reveals two major patterns of clonal evolution, with chemotherapy appearing to have a role in both patterns.  Most patients with acute myeloid leukemia (AML) die from progressive disease after relapse, which is assocd. with clonal evolution at the cytogenetic level.  To det. the mutational spectrum assocd. with relapse, we sequenced the primary tumor and relapse genomes from eight AML patients, and validated hundreds of somatic mutations using deep sequencing; this allowed us to define clonality and clonal evolution patterns precisely at relapse.  In addn. to discovering novel, recurrently mutated genes (for example, WAC, SMC3, DIS3,DDX41 and DAXX) in AML, we also found two major clonal evolution patterns during AML relapse: (1) the founding clone in the primary tumor gained mutations and evolved into the relapse clone, or (2) a subclone of the founding clone survived initial therapy, gained addnl. mutations and expanded at relapse.  In all cases, chemotherapy failed to eradicate the founding clone.  The comparison of relapse-specific vs. primary tumor mutations in all eight cases revealed an increase in transversions, probably due to DNA damage caused by cytotoxic chemotherapy.  These data demonstrate that AML relapse is assocd. with the addn. of new mutations and clonal evolution, which is shaped, in part, by the chemotherapy that the patients receive to establish and maintain remissions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkAtZJP8nda7Vg90H21EOLACvtfcHk0lhytSmCC4-Eag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsF2jtw%253D%253D&md5=572898dafabbe7f75054c2e07bd64a74</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnature10738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10738%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DL.%26aulast%3DLey%26aufirst%3DT.%2BJ.%26aulast%3DLarson%26aufirst%3DD.%2BE.%26aulast%3DMiller%26aufirst%3DC.%2BA.%26aulast%3DKoboldt%26aufirst%3DD.%2BC.%26aulast%3DWelch%26aufirst%3DJ.%2BS.%26aulast%3DRitchey%26aufirst%3DJ.%2BK.%26aulast%3DYoung%26aufirst%3DM.%2BA.%26aulast%3DLamprecht%26aufirst%3DT.%26aulast%3DMcLellan%26aufirst%3DM.%2BD.%26aulast%3DMcMichael%26aufirst%3DJ.%2BF.%26aulast%3DWallis%26aufirst%3DJ.%2BW.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DD.%26aulast%3DHarris%26aufirst%3DC.%2BC.%26aulast%3DDooling%26aufirst%3DD.%2BJ.%26aulast%3DFulton%26aufirst%3DR.%2BS.%26aulast%3DFulton%26aufirst%3DL.%2BL.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DSchmidt%26aufirst%3DH.%26aulast%3DKalicki-Veizer%26aufirst%3DJ.%26aulast%3DMagrini%26aufirst%3DV.%2BJ.%26aulast%3DCook%26aufirst%3DL.%26aulast%3DMcGrath%26aufirst%3DS.%2BD.%26aulast%3DVickery%26aufirst%3DT.%2BL.%26aulast%3DWendl%26aufirst%3DM.%2BC.%26aulast%3DHeath%26aufirst%3DS.%26aulast%3DWatson%26aufirst%3DM.%2BA.%26aulast%3DLink%26aufirst%3DD.%2BC.%26aulast%3DTomasson%26aufirst%3DM.%2BH.%26aulast%3DShannon%26aufirst%3DW.%2BD.%26aulast%3DPayton%26aufirst%3DJ.%2BE.%26aulast%3DKulkarni%26aufirst%3DS.%26aulast%3DWestervelt%26aufirst%3DP.%26aulast%3DWalter%26aufirst%3DM.%2BJ.%26aulast%3DGraubert%26aufirst%3DT.%2BA.%26aulast%3DMardis%26aufirst%3DE.%2BR.%26aulast%3DWilson%26aufirst%3DR.%2BK.%26aulast%3DDiPersio%26aufirst%3DJ.%2BF.%26atitle%3DClonal%2520evolution%2520in%2520relapsed%2520acute%2520myeloid%2520leukaemia%2520revealed%2520by%2520whole-genome%2520sequencing%26jtitle%3DNature%26date%3D2012%26volume%3D481%26issue%3D7382%26spage%3D506%26epage%3D510%26doi%3D10.1038%2Fnature10738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwable, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandts, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tickenbrock, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sargin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdel, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller-Tidow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serve, H.</span></span> <span> </span><span class="NLM_article-title">AML-associated FLT3 kinase domain mutations show signal transduction differences compared with FLT3 ITD mutations</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>106</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.1182/blood-2004-07-2942</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2004-07-2942" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=15769897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvVWjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=265-273&issue=1&author=C.+Choudharyauthor=J.+Schwableauthor=C.+Brandtsauthor=L.+Tickenbrockauthor=B.+Sarginauthor=T.+Kindlerauthor=T.+Fischerauthor=W.+E.+Berdelauthor=C.+Muller-Tidowauthor=H.+Serve&title=AML-associated+FLT3+kinase+domain+mutations+show+signal+transduction+differences+compared+with+FLT3+ITD+mutations&doi=10.1182%2Fblood-2004-07-2942"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations</span></div><div class="casAuthors">Choudhary, Chunaram; Schwaeble, Joachim; Brandts, Christian; Tickenbrock, Lara; Sargin, Buelent; Kindler, Thomas; Fischer, Thomas; Berdel, Wolfgang E.; Mueller-Tidow, Carsten; Serve, Hubert</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">265-273</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Activating mutations of Flt3 are found in approx. 1/3 of patients with acute myeloid leukemia (AML) and are an attractive drug target.  Two classes of Flt3 mutations occur: internal tandem duplications (ITDs) in the juxtamembrane and point mutations in the tyrosine kinase domain (TKD).  We and others have shown that Flt3-ITD induced aberrant signaling including strong activation of signal transducer and activator of transcription 5 (STAT5) and repression of CCAAT/estradiol-binding protein α (c/EBPα) and Pu.1.  Here, we compared the signaling properties of Flt3-ITD vs. Flt3-TKD in myeloid progenitor cells.  We demonstrate that Flt3-TKD mutations induced autonomous growth of 32D cells in suspension cultures.  However, in contrast to Flt3-ITD and similar to wild-type Flt3 (Flt3-WT), Flt3-TKD cannot support colony formation in semisolid media.  Also, in contrast to Flt3-ITD, neither Flt3-WT nor Flt3-TKD induced activation or induction of STAT5 target genes.  Flt3-TKD also failed to repress c/EBPα and Pu.1.  No significant differences were obsd. in receptor autophosphorylation and the phosphorylation of Erk-1 and -2, Akt, and Shc.  Importantly, TKD but not ITD mutations were a log power more sensitive toward the tyrosine kinase inhibitor protein kinase C 412 (PKC412) than Flt3-WT.  In conclusion, Flt3-ITD and Flt3-TKD mutations display differences in their signaling properties that could have important implications for their transforming capacity and for the design of mutation-specific therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK50hyr7RAoLVg90H21EOLACvtfcHk0lhytSmCC4-Eag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvVWjtrw%253D&md5=a70850e3d6fe00e8316cc8d79c2d3016</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1182%2Fblood-2004-07-2942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2004-07-2942%26sid%3Dliteratum%253Aachs%26aulast%3DChoudhary%26aufirst%3DC.%26aulast%3DSchwable%26aufirst%3DJ.%26aulast%3DBrandts%26aufirst%3DC.%26aulast%3DTickenbrock%26aufirst%3DL.%26aulast%3DSargin%26aufirst%3DB.%26aulast%3DKindler%26aufirst%3DT.%26aulast%3DFischer%26aufirst%3DT.%26aulast%3DBerdel%26aufirst%3DW.%2BE.%26aulast%3DMuller-Tidow%26aufirst%3DC.%26aulast%3DServe%26aufirst%3DH.%26atitle%3DAML-associated%2520FLT3%2520kinase%2520domain%2520mutations%2520show%2520signal%2520transduction%2520differences%2520compared%2520with%2520FLT3%2520ITD%2520mutations%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26issue%3D1%26spage%3D265%26epage%3D273%26doi%3D10.1182%2Fblood-2004-07-2942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandts, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohmer, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerke, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt-Arras, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdel, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller-Tidow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serve, H.</span></span> <span> </span><span class="NLM_article-title">Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">326</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2009.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.molcel.2009.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=19854140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFWht7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2009&pages=326-339&issue=2&author=C.+Choudharyauthor=J.+V.+Olsenauthor=C.+Brandtsauthor=J.+Coxauthor=P.+N.+Reddyauthor=F.+D.+Bohmerauthor=V.+Gerkeauthor=D.+E.+Schmidt-Arrasauthor=W.+E.+Berdelauthor=C.+Muller-Tidowauthor=M.+Mannauthor=H.+Serve&title=Mislocalized+activation+of+oncogenic+RTKs+switches+downstream+signaling+outcomes&doi=10.1016%2Fj.molcel.2009.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes</span></div><div class="casAuthors">Choudhary, Chunaram; Olsen, Jesper V.; Brandts, Christian; Cox, Juergen; Reddy, Pavankumar N. G.; Boehmer, Frank D.; Gerke, Volker; Schmidt-Arras, Dirk-E.; Berdel, Wolfgang E.; Mueller-Tidow, Carsten; Mann, Matthias; Serve, Hubert</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">326-339</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inappropriate activation of oncogenic kinases at intracellular locations is frequently obsd. in human cancers, but its effects on global signaling are incompletely understood.  Here, we show that the oncogenic mutant of Flt3 (Flt3-ITD), when localized at the endoplasmic reticulum (ER), aberrantly activates STAT5 and upregulates its targets, Pim-1/2, but fails to activate PI3K and MAPK signaling.  Conversely, membrane targeting of Flt3-ITD strongly activates the MAPK and PI3K pathways, with diminished phosphorylation of STAT5.  Global phosphoproteomics quantified 12,186 phosphorylation sites, confirmed compartment-dependent activation of these pathways and discovered many addnl. components of Flt3-ITD signaling.  The differential activation of Akt and Pim kinases by ER-retained Flt3-ITD helped to identify their putative targets.  Surprisingly, we find spatial regulation of tyrosine phosphorylation patterns of the receptor itself.  Thus, intracellular activation of RTKs by oncogenic mutations in the biosynthetic route may exploit cellular architecture to initiate aberrant signaling cascades, thus evading neg. regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrovh7aN2JkVrVg90H21EOLACvtfcHk0lgm1B3DZIbNtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFWht7vL&md5=3312964e2c3ad2fde98220675c8fab96</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2009.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2009.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DChoudhary%26aufirst%3DC.%26aulast%3DOlsen%26aufirst%3DJ.%2BV.%26aulast%3DBrandts%26aufirst%3DC.%26aulast%3DCox%26aufirst%3DJ.%26aulast%3DReddy%26aufirst%3DP.%2BN.%26aulast%3DBohmer%26aufirst%3DF.%2BD.%26aulast%3DGerke%26aufirst%3DV.%26aulast%3DSchmidt-Arras%26aufirst%3DD.%2BE.%26aulast%3DBerdel%26aufirst%3DW.%2BE.%26aulast%3DMuller-Tidow%26aufirst%3DC.%26aulast%3DMann%26aufirst%3DM.%26aulast%3DServe%26aufirst%3DH.%26atitle%3DMislocalized%2520activation%2520of%2520oncogenic%2520RTKs%2520switches%2520downstream%2520signaling%2520outcomes%26jtitle%3DMol.%2520Cell%26date%3D2009%26volume%3D36%26issue%3D2%26spage%3D326%26epage%3D339%26doi%3D10.1016%2Fj.molcel.2009.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abboud, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appelbaum, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bixby, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fathi, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foran, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gore, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maness, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollyea, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shami, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickland, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieduwilt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogba, N.</span></span> <span> </span><span class="NLM_article-title">Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology</span>. <i>J. Natl. Compr. Cancer Network</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">926</span>– <span class="NLM_lpage">957</span>, <span class="refDoi"> DOI: 10.6004/jnccn.2017.0116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.6004%2Fjnccn.2017.0116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=28687581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BC1cjlsFGrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=926-957&issue=7&author=M.+R.+O%E2%80%99Donnellauthor=M.+S.+Tallmanauthor=C.+N.+Abboudauthor=J.+K.+Altmanauthor=F.+R.+Appelbaumauthor=D.+A.+Arberauthor=V.+Bhattauthor=D.+Bixbyauthor=W.+Blumauthor=S.+E.+Coutreauthor=M.+De+Limaauthor=A.+T.+Fathiauthor=M.+Fiorellaauthor=J.+M.+Foranauthor=S.+D.+Goreauthor=A.+C.+Hallauthor=P.+Kropfauthor=J.+Lancetauthor=L.+J.+Manessauthor=G.+Marcucciauthor=M.+G.+Martinauthor=J.+O.+Mooreauthor=R.+Olinauthor=D.+Pekerauthor=D.+A.+Pollyeaauthor=K.+Pratzauthor=F.+Ravandiauthor=P.+J.+Shamiauthor=R.+M.+Stoneauthor=S.+A.+Stricklandauthor=E.+S.+Wangauthor=M.+Wieduwiltauthor=K.+Gregoryauthor=N.+Ogba&title=Acute+myeloid+leukemia%2C+version+3.2017%2C+NCCN+clinical+practice+guidelines+in+oncology&doi=10.6004%2Fjnccn.2017.0116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology</span></div><div class="casAuthors">O'Donnell Margaret R; Tallman Martin S; Abboud Camille N; Altman Jessica K; Appelbaum Frederick R; Arber Daniel A; Bhatt Vijaya; Bixby Dale; Blum William; Coutre Steven E; De Lima Marcos; Fathi Amir T; Fiorella Melanie; Foran James M; Gore Steven D; Hall Aric C; Kropf Patricia; Lancet Jeffrey; Maness Lori J; Marcucci Guido; Martin Michael G; Moore Joseph O; Olin Rebecca; Peker Deniz; Pollyea Daniel A; Pratz Keith; Ravandi Farhad; Shami Paul J; Stone Richard M; Strickland Stephen A; Wang Eunice S; Wieduwilt Matthew; Gregory Kristina; Ogba Ndiya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Comprehensive Cancer Network : JNCCN</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">926-957</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States.  This portion of the NCCN Guidelines for AML focuses on management and provides recommendations on the workup, diagnostic evaluation, and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2aszz8ssiQXl8icjszYl0fW6udTcc2eZo16l1nbp09rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjlsFGrtA%253D%253D&md5=6d087e673a8e9556532bdede9151f2e2</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.6004%2Fjnccn.2017.0116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.6004%252Fjnccn.2017.0116%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DM.%2BR.%26aulast%3DTallman%26aufirst%3DM.%2BS.%26aulast%3DAbboud%26aufirst%3DC.%2BN.%26aulast%3DAltman%26aufirst%3DJ.%2BK.%26aulast%3DAppelbaum%26aufirst%3DF.%2BR.%26aulast%3DArber%26aufirst%3DD.%2BA.%26aulast%3DBhatt%26aufirst%3DV.%26aulast%3DBixby%26aufirst%3DD.%26aulast%3DBlum%26aufirst%3DW.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DDe%2BLima%26aufirst%3DM.%26aulast%3DFathi%26aufirst%3DA.%2BT.%26aulast%3DFiorella%26aufirst%3DM.%26aulast%3DForan%26aufirst%3DJ.%2BM.%26aulast%3DGore%26aufirst%3DS.%2BD.%26aulast%3DHall%26aufirst%3DA.%2BC.%26aulast%3DKropf%26aufirst%3DP.%26aulast%3DLancet%26aufirst%3DJ.%26aulast%3DManess%26aufirst%3DL.%2BJ.%26aulast%3DMarcucci%26aufirst%3DG.%26aulast%3DMartin%26aufirst%3DM.%2BG.%26aulast%3DMoore%26aufirst%3DJ.%2BO.%26aulast%3DOlin%26aufirst%3DR.%26aulast%3DPeker%26aufirst%3DD.%26aulast%3DPollyea%26aufirst%3DD.%2BA.%26aulast%3DPratz%26aufirst%3DK.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DShami%26aufirst%3DP.%2BJ.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DStrickland%26aufirst%3DS.%2BA.%26aulast%3DWang%26aufirst%3DE.%2BS.%26aulast%3DWieduwilt%26aufirst%3DM.%26aulast%3DGregory%26aufirst%3DK.%26aulast%3DOgba%26aufirst%3DN.%26atitle%3DAcute%2520myeloid%2520leukemia%252C%2520version%25203.2017%252C%2520NCCN%2520clinical%2520practice%2520guidelines%2520in%2520oncology%26jtitle%3DJ.%2520Natl.%2520Compr.%2520Cancer%2520Network%26date%3D2017%26volume%3D15%26issue%3D7%26spage%3D926%26epage%3D957%26doi%3D10.6004%2Fjnccn.2017.0116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dohner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estey, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimwade, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amadori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appelbaum, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dombret, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenaux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo-Coco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niederwieser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ossenkoppele, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sierra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tien, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowenberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomfield, C. D.</span></span> <span> </span><span class="NLM_article-title">Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">424</span>– <span class="NLM_lpage">447</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-08-733196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2016-08-733196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=27895058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BC2sjht1ShsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=424-447&issue=4&author=H.+Dohnerauthor=E.+Esteyauthor=D.+Grimwadeauthor=S.+Amadoriauthor=F.+R.+Appelbaumauthor=T.+Buchnerauthor=H.+Dombretauthor=B.+L.+Ebertauthor=P.+Fenauxauthor=R.+A.+Larsonauthor=R.+L.+Levineauthor=F.+Lo-Cocoauthor=T.+Naoeauthor=D.+Niederwieserauthor=G.+J.+Ossenkoppeleauthor=M.+Sanzauthor=J.+Sierraauthor=M.+S.+Tallmanauthor=H.+F.+Tienauthor=A.+H.+Weiauthor=B.+Lowenbergauthor=C.+D.+Bloomfield&title=Diagnosis+and+management+of+AML+in+adults%3A+2017+ELN+recommendations+from+an+international+expert+panel&doi=10.1182%2Fblood-2016-08-733196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel</span></div><div class="casAuthors">Dohner Hartmut; Estey Elihu; Appelbaum Frederick R; Grimwade David; Amadori Sergio; Lo-Coco Francesco; Buchner Thomas; Dombret Herve; Ebert Benjamin L; Fenaux Pierre; Larson Richard A; Levine Ross L; Tallman Martin S; Naoe Tomoki; Niederwieser Dietger; Ossenkoppele Gert J; Sanz Miguel; Sierra Jorge; Tien Hwei-Fang; Wei Andrew H; Wei Andrew H; Lowenberg Bob; Bloomfield Clara D</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">424-447</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML.  Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations.  The recommendations include a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTjTcxQJDkes9NTrvPZP1IpfW6udTcc2ea5kvU7XnIUjLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjht1ShsQ%253D%253D&md5=9dc44be2424ca51a6083c9e4edd34238</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-08-733196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-08-733196%26sid%3Dliteratum%253Aachs%26aulast%3DDohner%26aufirst%3DH.%26aulast%3DEstey%26aufirst%3DE.%26aulast%3DGrimwade%26aufirst%3DD.%26aulast%3DAmadori%26aufirst%3DS.%26aulast%3DAppelbaum%26aufirst%3DF.%2BR.%26aulast%3DBuchner%26aufirst%3DT.%26aulast%3DDombret%26aufirst%3DH.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26aulast%3DFenaux%26aufirst%3DP.%26aulast%3DLarson%26aufirst%3DR.%2BA.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DLo-Coco%26aufirst%3DF.%26aulast%3DNaoe%26aufirst%3DT.%26aulast%3DNiederwieser%26aufirst%3DD.%26aulast%3DOssenkoppele%26aufirst%3DG.%2BJ.%26aulast%3DSanz%26aufirst%3DM.%26aulast%3DSierra%26aufirst%3DJ.%26aulast%3DTallman%26aufirst%3DM.%2BS.%26aulast%3DTien%26aufirst%3DH.%2BF.%26aulast%3DWei%26aufirst%3DA.%2BH.%26aulast%3DLowenberg%26aufirst%3DB.%26aulast%3DBloomfield%26aufirst%3DC.%2BD.%26atitle%3DDiagnosis%2520and%2520management%2520of%2520AML%2520in%2520adults%253A%25202017%2520ELN%2520recommendations%2520from%2520an%2520international%2520expert%2520panel%26jtitle%3DBlood%26date%3D2017%26volume%3D129%26issue%3D4%26spage%3D424%26epage%3D447%26doi%3D10.1182%2Fblood-2016-08-733196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyoi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyawaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagasaki, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimazaki, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motoji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeshita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoe, T.</span></span> <span> </span><span class="NLM_article-title">Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>97</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2434</span>– <span class="NLM_lpage">2439</span>, <span class="refDoi"> DOI: 10.1182/blood.V97.8.2434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood.V97.8.2434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=11290608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFOgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2001&pages=2434-2439&issue=8&author=Y.+Yamamotoauthor=H.+Kiyoiauthor=Y.+Nakanoauthor=R.+Suzukiauthor=Y.+Koderaauthor=S.+Miyawakiauthor=N.+Asouauthor=K.+Kuriyamaauthor=F.+Yagasakiauthor=C.+Shimazakiauthor=H.+Akiyamaauthor=K.+Saitoauthor=M.+Nishimuraauthor=T.+Motojiauthor=K.+Shinagawaauthor=A.+Takeshitaauthor=H.+Saitoauthor=R.+Uedaauthor=R.+Ohnoauthor=T.+Naoe&title=Activating+mutation+of+D835+within+the+activation+loop+of+FLT3+in+human+hematologic+malignancies&doi=10.1182%2Fblood.V97.8.2434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies</span></div><div class="casAuthors">Yamamoto, Yukiya; Kiyoi, Hitoshi; Nakano, Yasuyuki; Suzuki, Ritsuro; Kodera, Yoshihisa; Miyawaki, Shuichi; Asou, Norio; Kuriyama, Kazutaka; Yagasaki, Fumiharu; Shimazaki, Chihiro; Akiyama, Hideki; Saito, Kenji; Nishimura, Miki; Motoji, Toshiko; Shinagawa, Katsuji; Takeshita, Akihiro; Saito, Hidehiko; Ueda, Ryuzo; Ohno, Ryuzo; Naoe, Tomoki</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2434-2439</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Mutations of receptor tyrosine kinases are implicated in the constitutive activation and development of human malignancy.  An internal tandem duplication (ITD) of the juxtamembrane (JM) domain-coding sequence of the FLT3 gene (FLT3/ITD) is found in 20% of patients with acute myeloid leukemia (AML) and is strongly assocd. with leukocytosis and a poor prognosis.  On the other hand, mutations of the c-KIT gene, which have been found in mast cell leukemia and AML, are clustered in 2 distinct regions, the JM domain and D816 within the activation loop.  This study was designed to analyze the mutation of D835 of FLT3, which corresponds to D816 of c-KIT, in a large series of human hematol. malignancies.  Several kinds of missense mutations were found in 30 of the 429 (7.0%) AML cases, 1 of the 29 (3.4%) myelodysplastic syndrome (MDS) cases, and 1 of the 36 (2.8%) acute lymphocytic leukemia patients.  The D835Y mutation was most frequently found (22 of the 32 D835 mutations), followed by the D835V (5), and D835H (1), D835E (1), and D835N (1) mutations.  Of note is that D835 mutations occurred independently of FLT3/ITD.  An anal. in the 201 patients newly diagnosed with AML (excluding M3) revealed that, in contrast to the FLT3/ITD mutation, D835 mutations were not significantly related to the leukocytosis, but tended to worsen disease-free survival.  All D835-mutant FLT3 were constitutively tyrosine-phosphorylated and transformed 32D cells, suggesting these mutations were constitutively active.  These results demonstrate that the FLT3 gene is the target most frequently mutated to become constitutively active in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrydJnPT47K17Vg90H21EOLACvtfcHk0lh3plBO3Y24cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFOgtbk%253D&md5=646e1b1a04c570f4094e7d83723d47fb</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1182%2Fblood.V97.8.2434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V97.8.2434%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DKodera%26aufirst%3DY.%26aulast%3DMiyawaki%26aufirst%3DS.%26aulast%3DAsou%26aufirst%3DN.%26aulast%3DKuriyama%26aufirst%3DK.%26aulast%3DYagasaki%26aufirst%3DF.%26aulast%3DShimazaki%26aufirst%3DC.%26aulast%3DAkiyama%26aufirst%3DH.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DNishimura%26aufirst%3DM.%26aulast%3DMotoji%26aufirst%3DT.%26aulast%3DShinagawa%26aufirst%3DK.%26aulast%3DTakeshita%26aufirst%3DA.%26aulast%3DSaito%26aufirst%3DH.%26aulast%3DUeda%26aufirst%3DR.%26aulast%3DOhno%26aufirst%3DR.%26aulast%3DNaoe%26aufirst%3DT.%26atitle%3DActivating%2520mutation%2520of%2520D835%2520within%2520the%2520activation%2520loop%2520of%2520FLT3%2520in%2520human%2520hematologic%2520malignancies%26jtitle%3DBlood%26date%3D2001%26volume%3D97%26issue%3D8%26spage%3D2434%26epage%3D2439%26doi%3D10.1182%2Fblood.V97.8.2434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abu-Duhier, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodeve, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Care, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peake, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, J. T.</span></span> <span> </span><span class="NLM_article-title">Identification of novel FLT3 Asp835 mutations in adult acute myeloid leukemia</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>113</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">983</span>– <span class="NLM_lpage">988</span>, <span class="refDoi"> DOI: 10.1046/j.1365-2141.2001.02850.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1046%2Fj.1365-2141.2001.02850.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=11442493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlslalsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2001&pages=983-988&issue=4&author=F.+M.+Abu-Duhierauthor=A.+C.+Goodeveauthor=G.+A.+Wilsonauthor=R.+S.+Careauthor=I.+R.+Peakeauthor=J.+T.+Reilly&title=Identification+of+novel+FLT3+Asp835+mutations+in+adult+acute+myeloid+leukemia&doi=10.1046%2Fj.1365-2141.2001.02850.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia</span></div><div class="casAuthors">Abu-Duhier, F. M.; Goodeve, A. C.; Wilson, G. A.; Care, R. S.; Peake, I. R.; Reilly, J. T.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">983-988</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">Genomic DNA from 97 cases of adult de novo acute myeloid leukemia (AML) was screened using polymerase chain reaction (PCR) and conformation-sensitive gel electrophoresis (CSGE) for FLT3 exon 20 mutations.  Initial sequencing of four cases, representing the spectrum of CSGE abnormalities, revealed changes affecting codon Asp835 in three cases and also an intron 20 A to G change.  In order to identify all possible Asp835 alterations, as well as the frequency of the intronic change nucleotide 2541+57 A→G, the patient PCR products were digested with EcoRV and NlaIII resp.  Seven cases (7.2%) possessed a mutation affecting Asp835; these were identified, following DNA sequencing, as Asp835Tyr (n = 5), Asp835His (n = 1) and Asp835del (n = 1).  Alterations affecting Asp835 were not found in 80 normal control DNA samples.  In contrast, the nucleotide 2541+57 A→G change was shown to be a polymorphism, with an allelic frequency of 0.24 for the G and 0.76 for the A allele.  This study reports, for the first time, point mutations in the human FLT3 gene that, because of their homol. with other class III receptor tyrosine kinase mutations, probably result in constitutive activation of the receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyMMv-RBFxCbVg90H21EOLACvtfcHk0li1FEBLGzL9cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlslalsbg%253D&md5=7989d20d19f76954dbeaf2fde89d8add</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2141.2001.02850.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2141.2001.02850.x%26sid%3Dliteratum%253Aachs%26aulast%3DAbu-Duhier%26aufirst%3DF.%2BM.%26aulast%3DGoodeve%26aufirst%3DA.%2BC.%26aulast%3DWilson%26aufirst%3DG.%2BA.%26aulast%3DCare%26aufirst%3DR.%2BS.%26aulast%3DPeake%26aufirst%3DI.%2BR.%26aulast%3DReilly%26aufirst%3DJ.%2BT.%26atitle%3DIdentification%2520of%2520novel%2520FLT3%2520Asp835%2520mutations%2520in%2520adult%2520acute%2520myeloid%2520leukemia%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2001%26volume%3D113%26issue%3D4%26spage%3D983%26epage%3D988%26doi%3D10.1046%2Fj.1365-2141.2001.02850.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daver, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span> <span> </span><span class="NLM_article-title">Targeting FLT3 mutations in AML: review of current knowledge and evidence</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1038/s41375-018-0357-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fs41375-018-0357-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=30651634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVyrsbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=299-312&issue=2&author=N.+Daverauthor=R.+F.+Schlenkauthor=N.+H.+Russellauthor=M.+J.+Levis&title=Targeting+FLT3+mutations+in+AML%3A+review+of+current+knowledge+and+evidence&doi=10.1038%2Fs41375-018-0357-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting FLT3 mutations in AML: review of current knowledge and evidence</span></div><div class="casAuthors">Daver, Naval; Schlenk, Richard F.; Russell, Nigel H.; Levis, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">299-312</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Genomic investigations of acute myeloid leukemia (AML) have demonstrated that several genes are recurrently mutated, leading to new genomic classifications, predictive biomarkers, and new therapeutic targets.  Mutations of the FMS-like tyrosine kinase 3 (FLT3) gene occur in approx. 30% of all AML cases, with the internal tandem duplication (ITD) representing the most common type of FLT3 mutation (FLT3-ITD; approx. 25% of all AML cases).  FLT3-ITD is a common driver mutation that presents with a high leukemic burden and confers a poor prognosis in patients with AML.  The prognostic value of a FLT3 mutation in the tyrosine kinase domain (FLT3-TKD), which has a lower incidence in AML (approx. 7-10% of all cases), is uncertain.  Accumulating evidence demonstrates that FLT3 mutational status evolves throughout the disease continuum.  This so-called clonal evolution, together with the identification of FLT3-ITD as a neg. prognostic marker, serves to highlight the importance of FLT3-ITD testing at diagnosis and again at relapse.  Earlier identification of FLT3 mutations will help provide a better understanding of the patient's disease and enable targeted treatment that may help patients achieve longer and more durable remissions.  First-generation FLT3 inhibitors developed for clin. use are broad-spectrum, multikinase inhibitors; however, next-generation FLT3 inhibitors are more specific, more potent, and have fewer toxicities assocd. with off-target effects.  Primary and secondary acquired resistance to FLT3 inhibitors remains a challenge and provides a rationale for combining FLT3 inhibitors with other therapies, both conventional and investigational.  This review focuses on the pathol. and prognostic role of FLT3 mutations in AML, clin. classification of the disease, recent progress with next-generation FLT3 inhibitors, and mechanisms of resistance to FLT3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjK_p2nZ_9j7Vg90H21EOLACvtfcHk0li1FEBLGzL9cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVyrsbbI&md5=25ea007d2f7b670aaddeb02866f15c69</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fs41375-018-0357-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-018-0357-9%26sid%3Dliteratum%253Aachs%26aulast%3DDaver%26aufirst%3DN.%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26aulast%3DRussell%26aufirst%3DN.%2BH.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26atitle%3DTargeting%2520FLT3%2520mutations%2520in%2520AML%253A%2520review%2520of%2520current%2520knowledge%2520and%2520evidence%26jtitle%3DLeukemia%26date%3D2019%26volume%3D33%26issue%3D2%26spage%3D299%26epage%3D312%26doi%3D10.1038%2Fs41375-018-0357-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balderes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span> <span> </span><span class="NLM_article-title">Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1432</span>– <span class="NLM_lpage">1438</span>, <span class="refDoi"> DOI: 10.1038/sj.leu.2403825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fsj.leu.2403825" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=15931264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtlSjs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=1432-1438&issue=8&author=B.+Williamsauthor=A.+Atkinsauthor=H.+Zhangauthor=D.+Luauthor=X.+Jimenezauthor=H.+Liauthor=M.+N.+Wangauthor=D.+Ludwigauthor=P.+Balderesauthor=L.+Witteauthor=Y.+Liauthor=Z.+Zhu&title=Cell-based+selection+of+internalizing+fully+human+antagonistic+antibodies+directed+against+FLT3+for+suppression+of+leukemia+cell+growth&doi=10.1038%2Fsj.leu.2403825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth</span></div><div class="casAuthors">Williams, B.; Atkins, A.; Zhang, H.; Lu, D.; Jimenez, X.; Li, H.; Wang, M-N.; Ludwig, D.; Balderes, P.; Witte, L.; Li, Y.; Zhu, Z.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1432-1438</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">FMS-like tyrosine kinase 3 (FLT3) receptor is highly expressed in an array of hematol. malignancies including ∼90% of acute myelogenous leukemia (AML).  Ligand stimulation of the receptor promotes the survival and proliferation of leukemia cells.  Strategies targeting FLT3 using monoclonal antibodies may therefore constitute an effective therapeutic approach for these leukemia.  Towards this, the authors selected a naive antibody phage display library on both recombinant FLT3 receptor protein and FLT3-expressing leukemia cells using a tailored selection scheme that was designed to isolate antagonistic phage antibodies that not only interfere with receptor/ligand binding but also trigger receptor internalization upon cell surface binding.  Phage antibodies were screened first for their ability to bind to cell surface receptor and induce receptor internalization, followed by their activity in blocking ligand-receptor interaction and neutralizing ligand-stimulated receptor activation and cell proliferation.  The authors identified three fully human antibodies, EB10, A2IN, and D4-3, which bound specifically to both sol. and cell surface-expressed FLT3.  All three antibodies were shown to be internalized upon binding to cell surface-expressed receptor in a time-dependent fashion.  EB10 and D4-3 blocked ligand binding to the receptor with IC50s of 14 and 7 nM, resp.  Further, EB10 and D4-3 inhibited FLT3 ligand-induced receptor phosphorylation and cell proliferation in EOL-1 leukemia cells.  Taken together, these results suggest that both EB10 and D4-3 may represent excellent therapeutic candidates for the treatment of FLT3-expressing human leukemia, both as unmodified antibodies and as conjugates of cytotoxic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxE-FdjIl3s7Vg90H21EOLACvtfcHk0li1FEBLGzL9cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtlSjs7o%253D&md5=a331d3fb53ce026cb97dda46eab46015</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2403825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2403825%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DB.%26aulast%3DAtkins%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DJimenez%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DM.%2BN.%26aulast%3DLudwig%26aufirst%3DD.%26aulast%3DBalderes%26aufirst%3DP.%26aulast%3DWitte%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DZ.%26atitle%3DCell-based%2520selection%2520of%2520internalizing%2520fully%2520human%2520antagonistic%2520antibodies%2520directed%2520against%2520FLT3%2520for%2520suppression%2520of%2520leukemia%2520cell%2520growth%26jtitle%3DLeukemia%26date%3D2005%26volume%3D19%26issue%3D8%26spage%3D1432%26epage%3D1438%26doi%3D10.1038%2Fsj.leu.2403825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larrosa-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, M. R.</span></span> <span> </span><span class="NLM_article-title">FLT3 inhibitors in acute myeloid leukemia: current status and future directions</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">991</span>– <span class="NLM_lpage">1001</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F1535-7163.MCT-16-0876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=28576946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Shsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=991-1001&issue=6&author=M.+Larrosa-Garciaauthor=M.+R.+Baer&title=FLT3+inhibitors+in+acute+myeloid+leukemia%3A+current+status+and+future+directions&doi=10.1158%2F1535-7163.MCT-16-0876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions</span></div><div class="casAuthors">Larrosa-Garcia, Maria; Baer, Maria R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">991-1001</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase fms-like tyrosine kinase 3 (FLT3), involved in regulating survival, proliferation, and differentiation of hematopoietic stem/progenitor cells, is expressed on acute myeloid leukemia (AML) cells in most patients.  Mutations of FLT3 resulting in constitutive signaling are common in AML, including internal tandem duplication (ITD) in the juxtamembrane domain in 25% of patients and point mutations in the tyrosine kinase domain in 5%.  Patients with AML with FLT3-ITD have a high relapse rate and short relapse-free and overall survival after chemotherapy and after transplant.  A no. of inhibitors of FLT3 signaling have been identified and are in clin. trials, both alone and with chemotherapy, with the goal of improving clin. outcomes in patients with AML with FLT3 mutations.  While inhibitor monotherapy produces clin. responses, they are usually incomplete and transient, and resistance develops rapidly.  Diverse combination therapies have been suggested to potentiate the efficacy of FLT3 inhibitors and to prevent development of resistance or overcome resistance.  Combinations with epigenetic therapies, proteasome inhibitors, downstream kinase inhibitors, phosphatase activators, and other drugs that alter signaling are being explored.  This review summarizes the current status of translational and clin. research on FLT3 inhibitors in AML, and discusses novel combination approaches.  Mol Cancer Ther; 16(6); 991-1001. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvp5t3cNnh3bVg90H21EOLACvtfcHk0ljy_2-y6kDWSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Shsbs%253D&md5=7105f50a6f38c3ce41be4adb82a62413</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0876%26sid%3Dliteratum%253Aachs%26aulast%3DLarrosa-Garcia%26aufirst%3DM.%26aulast%3DBaer%26aufirst%3DM.%2BR.%26atitle%3DFLT3%2520inhibitors%2520in%2520acute%2520myeloid%2520leukemia%253A%2520current%2520status%2520and%2520future%2520directions%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26issue%3D6%26spage%3D991%26epage%3D1001%26doi%3D10.1158%2F1535-7163.MCT-16-0876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J. J.</span></span> <span> </span><span class="NLM_article-title">Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">409</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1021/jm0608107</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0608107" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Cmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=409-424&issue=3&author=J.+J.+Liao&title=Molecular+recognition+of+protein+kinase+binding+pockets+for+design+of+potent+and+selective+kinase+inhibitors&doi=10.1021%2Fjm0608107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors</span></div><div class="casAuthors">Liao, Jeffrey Jie-Lou</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">409-424</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Many kinase inhibitors have failed in preclin. or clin. development because of the lack of such selectivity that induces intolerable side effects, mostly because the catalytic cleft is highly conserved in sequence and conformation.  Systematic anal. of the crystal structures of protein kinases can offer insight into the design of highly selective kinase inhibitors to overcome these effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroDTl2SBUfbbVg90H21EOLACvtfcHk0ljy_2-y6kDWSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Cmsg%253D%253D&md5=77542d3ba589bd834a0d2b97a24eea05</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm0608107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0608107%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DJ.%2BJ.%26atitle%3DMolecular%2520recognition%2520of%2520protein%2520kinase%2520binding%2520pockets%2520for%2520design%2520of%2520potent%2520and%2520selective%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26issue%3D3%26spage%3D409%26epage%3D424%26doi%3D10.1021%2Fjm0608107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghiaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of resistance to FLT3 inhibitors and the role of the bone marrow microenvironment</span>. <i>Hematol Oncol Clin North Am.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.1016/j.hoc.2017.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.hoc.2017.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=28673395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BC1cjktFCmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=681-692&issue=4&author=G.+Ghiaurauthor=M.+Levis&title=Mechanisms+of+resistance+to+FLT3+inhibitors+and+the+role+of+the+bone+marrow+microenvironment&doi=10.1016%2Fj.hoc.2017.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment</span></div><div class="casAuthors">Ghiaur Gabriel; Levis Mark</div><div class="citationInfo"><span class="NLM_cas:title">Hematology/oncology clinics of North America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">681-692</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The presence of FLT3 mutations in acute myeloid leukemia (AML) carries a particularly poor prognosis, making the development of FLT3 inhibitors an imperative goal.  The last decade has seen an abundance of clinical trials using these drugs alone or in combination with chemotherapy.  This culminated with the recent approval by the US Food and Drug Administration of Midostaurin for the treatment of FLT3-mutated AML.  Initial success has been followed by the emergence of clinical resistance.  Although novel FLT3 inhibitors are being developed, studies into mechanisms of resistance raise hope of new strategies to prevent emergence of resistance and eliminate minimal residual disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRBg2yQ4XqfsTEC-75aqa5AfW6udTcc2ebPenhMla1eFrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjktFCmtg%253D%253D&md5=8b20010c4ef8fa3be85964287b6bb74e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.hoc.2017.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.hoc.2017.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DGhiaur%26aufirst%3DG.%26aulast%3DLevis%26aufirst%3DM.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520FLT3%2520inhibitors%2520and%2520the%2520role%2520of%2520the%2520bone%2520marrow%2520microenvironment%26jtitle%3DHematol%2520Oncol%2520Clin%2520North%2520Am.%26date%3D2017%26volume%3D31%26issue%3D4%26spage%3D681%26epage%3D692%26doi%3D10.1016%2Fj.hoc.2017.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daver, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopleva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span> <span> </span><span class="NLM_article-title">Secondary mutations as mediators of resistance to targeted therapy in leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>125</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">3236</span>– <span class="NLM_lpage">3245</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-10-605808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2014-10-605808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=25795921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVOru73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=3236-3245&issue=21&author=N.+Daverauthor=J.+Cortesauthor=F.+Ravandiauthor=K.+P.+Patelauthor=J.+A.+Burgerauthor=M.+Konoplevaauthor=H.+Kantarjian&title=Secondary+mutations+as+mediators+of+resistance+to+targeted+therapy+in+leukemia&doi=10.1182%2Fblood-2014-10-605808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Secondary mutations as mediators of resistance to targeted therapy in leukemia</span></div><div class="casAuthors">Daver, Naval; Cortes, Jorge; Ravandi, Farhad; Patel, Keyur P.; Burger, Jan A.; Konopleva, Marina; Kantarjian, Hagop</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3236-3245</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The advent of small mol.-based targeted therapy has improved the treatment of both acute and chronic leukemias.  Resistance to small mol. inhibitors has emerged as a common theme.  The most frequent mode of acquired resistance is the acquisition of point mutations in the kinase domain.  FLT3 inhibitors have improved response rates in FLT3-mutated acute myeloid leukemia (AML).  The occurrence of the ATP-binding site and activation loop mutations confers varying degrees of resistance to the individual FLT3 inhibitors.  Second-generation FLT3 inhibitors such as crenolanib may overcome the resistance of these mutations.  Furthermore, nonmutational mechanisms of resistance such as prosurvival pathways and bone marrow signaling may be upregulated in FLT3 inhibitor-resistant AML with secondary kinase domain mutations.  More recently, point mutations conferring resistance to the Bruton tyrosine kinase inhibitor ibrutinib in chronic lymphocytic leukemia, arsenic trioxide in acute promyelocytic leukemia, and the BH3-mimetic ABT199 in lymphoma have been identified.  In chronic myeloid leukemia, the emergence of tyrosine kinase domain mutations has historically been the dominant mechanism of resistance.  The early identification of secondary point mutations and their downstream effects along with the development of second- or third-generation inhibitors and rationally designed small mol. combinations are potential strategies to overcome mutation-mediated resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN52qqT0ZLQrVg90H21EOLACvtfcHk0ljy_2-y6kDWSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVOru73N&md5=03a65603c787ea7ee0957398bfd64c0c</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-10-605808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-10-605808%26sid%3Dliteratum%253Aachs%26aulast%3DDaver%26aufirst%3DN.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DPatel%26aufirst%3DK.%2BP.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DKantarjian%26aufirst%3DH.%26atitle%3DSecondary%2520mutations%2520as%2520mediators%2520of%2520resistance%2520to%2520targeted%2520therapy%2520in%2520leukemia%26jtitle%3DBlood%26date%3D2015%26volume%3D125%26issue%3D21%26spage%3D3236%26epage%3D3245%26doi%3D10.1182%2Fblood-2014-10-605808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elshoury, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przespolewski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. S.</span></span> <span> </span><span class="NLM_article-title">Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors</span>. <i>Expert Rev. Anticancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">286</span>, <span class="refDoi"> DOI: 10.1080/14737140.2019.1573679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1080%2F14737140.2019.1573679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=30681373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFynt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=273-286&issue=3&author=A.+Elshouryauthor=A.+Przespolewskiauthor=J.+Baronauthor=E.+S.+Wang&title=Advancing+treatment+of+acute+myeloid+leukemia%3A+the+future+of+FLT3+inhibitors&doi=10.1080%2F14737140.2019.1573679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors</span></div><div class="casAuthors">Elshoury, Amro; Przespolewski, Amanda; Baron, Jeffrey; Wang, Eunice S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-286</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Mutations of the FLT3 gene are among most common genetic abnormalities occurring in acute myeloid leukemia (AML) and are assocd. with dismal prognosis.  Tremendous effort has been devoted to developing clin. effective FLT3 inhibitors.  First generation inhibitors consisted of multi-kinase inhibitors (sorafenib, lestaurtinib, midostaurin), which blocked FLT3 as well as multiple other kinase receptors.  The failure of these agents to induce durable responses led to the development of second generation FLT3 tyrosine kinase inhibitors (quizartinib, crenolinib, gilteritinib) exhibiting high potency and specificity for mutant FLT3 kinases and sustained invivo FLT3 inhibition.  These myriad FLT3 inhibitors possess diverse kinase inhibitory properties, toxicity profiles, and pharmacokinetics, which impact on their incorporation into therapeutic regimens.: This article reviews the medical literature on current and future FLT3 inhibitors for AML therapy.  We provide algorithms for which kinase inhibitor should be utilized for different FLT3 mutations (ITD±TKD) and clin. scenarios (de novo, relapsed/refractory, fit vs. unfit) and discuss novel FLT3 targeted therapeutic approaches.: Integration of clin. active FLT3 inhibitors into all stages of therapy for all individuals with FLT3 mutant AML promises to significantly improve outcomes for this poor prognosis disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWsY02GcCSXLVg90H21EOLACvtfcHk0liXnU33eEbt0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFynt7s%253D&md5=3b0ee9e9837357f4a82e138151b47c13</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1080%2F14737140.2019.1573679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737140.2019.1573679%26sid%3Dliteratum%253Aachs%26aulast%3DElshoury%26aufirst%3DA.%26aulast%3DPrzespolewski%26aufirst%3DA.%26aulast%3DBaron%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DE.%2BS.%26atitle%3DAdvancing%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%253A%2520the%2520future%2520of%2520FLT3%2520inhibitors%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2019%26volume%3D19%26issue%3D3%26spage%3D273%26epage%3D286%26doi%3D10.1080%2F14737140.2019.1573679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leahy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span> <span> </span><span class="NLM_article-title">Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1038/leu.2012.191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fleu.2012.191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=22858906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVCgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=48-55&issue=1&author=A.+B.+Williamsauthor=B.+Nguyenauthor=L.+Liauthor=P.+Brownauthor=M.+Levisauthor=D.+Leahyauthor=D.+Small&title=Mutations+of+FLT3%2FITD+confer+resistance+to+multiple+tyrosine+kinase+inhibitors&doi=10.1038%2Fleu.2012.191"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors</span></div><div class="casAuthors">Williams, A. B.; Nguyen, B.; Li, L.; Brown, P.; Levis, M.; Leahy, D.; Small, D.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-55</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">FMS-like tyrosine kinase 3 (FLT3) normally functions in the survival/proliferation of hematopoietic stem/progenitor cells, but its constitutive activation by internal tandem duplication (ITD) mutations correlates with a poor prognosis in AML.  The development of FLT3 tyrosine kinase inhibitors (TKI) is a promising strategy, but resistance that arises during the course of treatment caused by secondary mutations within the mutated gene itself poses a significant challenge.  In an effort to predict FLT3 resistance mutations that might develop in patients, we used satn. mutagenesis of FLT3/ITD followed by selection of transfected cells in FLT3 TKI.  We identified F621L, A627P, F691L and Y842C mutations in FLT3/ITD that confer varying levels of resistance to FLT3 TKI.  Western blotting confirmed that some FLT3 TKI were ineffective at inhibiting FLT3 autophosphorylation and signaling through MAP kinase, STAT5 and AKT in some mutants.  Balb/c mice transplanted with the FLT3/ITD Y842C mutation confirmed resistance to sorafenib in vivo but not to lestaurtinib.  These results indicate a growing no. of FLT3 mutations that are likely to be encountered in patients.  Such knowledge, combined with known remaining sensitivity to other FLT3 TKI, will be important to establish as secondary drug treatments that can be substituted when these mutants are encountered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPSwpRBLJiTbVg90H21EOLACvtfcHk0liXnU33eEbt0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVCgsA%253D%253D&md5=fcdbe55897826bb883841aad04b6ebda</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fleu.2012.191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2012.191%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DA.%2BB.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DBrown%26aufirst%3DP.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DLeahy%26aufirst%3DD.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DMutations%2520of%2520FLT3%252FITD%2520confer%2520resistance%2520to%2520multiple%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DLeukemia%26date%3D2013%26volume%3D27%26issue%3D1%26spage%3D48%26epage%3D55%26doi%3D10.1038%2Fleu.2012.191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, R. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z. H.</span></span> <span> </span><span class="NLM_article-title">Small-molecule Fms-like tyrosine kinase 3 inhibitors: an attractive and efficient method for the treatment of acute myeloid leukemia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">12403</span>– <span class="NLM_lpage">12428</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00696</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00696" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlOqu7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=12403-12428&issue=21&author=Y.+Zhongauthor=R.+Z.+Qiuauthor=S.+L.+Sunauthor=C.+Zhaoauthor=T.+Y.+Fanauthor=M.+Chenauthor=N.+G.+Liauthor=Z.+H.+Shi&title=Small-molecule+Fms-like+tyrosine+kinase+3+inhibitors%3A+an+attractive+and+efficient+method+for+the+treatment+of+acute+myeloid+leukemia&doi=10.1021%2Facs.jmedchem.0c00696"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia</span></div><div class="casAuthors">Zhong, Yue; Qiu, Run-Ze; Sun, Shan-Liang; Zhao, Chao; Fan, Tian-Yuan; Chen, Min; Li, Nian-Guang; Shi, Zhi-Hao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">12403-12428</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Fms-like tyrosine kinase 3 (FLT3) is an important member of the class III receptor tyrosine kinase (RTK) family, which is involved in the proliferation of hematopoietic cells and lymphocytes.  In recent years, increasing evidence have demonstrated that the activation and mutation of FLT3 is closely implicated in the occurrence and development of acute myeloid leukemia (AML).  The exploration of small-mol. inhibitors targeting FLT3 has aroused wide interest of pharmaceutical chemists and is expected to bring new hope for AML therapy.  In this review, we specifically highlighted FLT3 mediated JAK/STAT, RAS/MAPK, and PI3K/AKT/mTOR signaling.  The structural properties and biol. activities of representative FLT3 inhibitors reported from 2014 to the present were also summarized.  In addn., the major challenges in the current advance of novel FLT3 inhibitors were further analyzed, with the aim to guide future drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8JNly0RbiqrVg90H21EOLACvtfcHk0liXnU33eEbt0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlOqu7rP&md5=7fd352a4bb173b1303302dfa58707b56</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00696%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DQiu%26aufirst%3DR.%2BZ.%26aulast%3DSun%26aufirst%3DS.%2BL.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DFan%26aufirst%3DT.%2BY.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DN.%2BG.%26aulast%3DShi%26aufirst%3DZ.%2BH.%26atitle%3DSmall-molecule%2520Fms-like%2520tyrosine%2520kinase%25203%2520inhibitors%253A%2520an%2520attractive%2520and%2520efficient%2520method%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D21%26spage%3D12403%26epage%3D12428%26doi%3D10.1021%2Facs.jmedchem.0c00696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiyoi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawashima, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span> <span> </span><span class="NLM_article-title">FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>111</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">312</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1111/cas.14274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1111%2Fcas.14274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=31821677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFSjt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2020&pages=312-322&issue=2&author=H.+Kiyoiauthor=N.+Kawashimaauthor=Y.+Ishikawa&title=FLT3+mutations+in+acute+myeloid+leukemia%3A+Therapeutic+paradigm+beyond+inhibitor+development&doi=10.1111%2Fcas.14274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development</span></div><div class="casAuthors">Kiyoi, Hitoshi; Kawashima, Naomi; Ishikawa, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">312-322</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  FMS-like tyrosine kinase 3 (FLT3) is a type III receptor tyrosine kinase that plays an important role in hematopoietic cell survival, proliferation and differentiation.  The most clin. important point is that mutation of the FLT3 gene is the most frequent genetic alteration and a poor prognostic factor in acute myeloid leukemia (AML) patients.  There are two major types of FLT3 mutations: internal tandem duplication mutations in the juxtamembrane domain (FLT3-ITD) and point mutations or deletion in the tyrosine kinase domain (FLT3-TKD).  Both mutant FLT3 mols. are activated through ligand-independent dimerization and trans-phosphorylation.  Mutant FLT3 induces the activation of multiple intracellular signaling pathways, mainly STAT5, MAPK and AKT signals, leading to cell proliferation and anti-apoptosis.  Because high-dose chemotherapy and allogeneic hematopoietic stem cell transplantation cannot sufficiently improve the prognosis, clin. development of FLT3 kinase inhibitors expected.  Although several FLT3 inhibitors have been developed, it takes more than 20 years from the first identification of FLT3 mutations until FLT3 inhibitors become clin. available for AML patients with FLT3 mutations.  To date, three FLT3 inhibitors have been clin. approved as monotherapy or combination therapy with conventional chemotherapeutic agents in Japan and/or Europe and United states.  However, several mechanisms of resistance to FLT3 inhibitors have already become apparent during their clin. trials.  The resistance mechanisms are complex and emerging resistant clones are heterogenous.  Further basic and clin. studies are required to establish the best therapeutic strategy for AML patients with FLT3 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv_Q3ByI5dqLVg90H21EOLACvtfcHk0litwLQ52IZwVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFSjt7vP&md5=79c7656f1836b2deda2b8c1203ad9719</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1111%2Fcas.14274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.14274%26sid%3Dliteratum%253Aachs%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DKawashima%26aufirst%3DN.%26aulast%3DIshikawa%26aufirst%3DY.%26atitle%3DFLT3%2520mutations%2520in%2520acute%2520myeloid%2520leukemia%253A%2520Therapeutic%2520paradigm%2520beyond%2520inhibitor%2520development%26jtitle%3DCancer%2520Sci.%26date%3D2020%26volume%3D111%26issue%3D2%26spage%3D312%26epage%3D322%26doi%3D10.1111%2Fcas.14274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span> <span> </span><span class="NLM_article-title">Quizartinib (AC220): a promising option for acute myeloid leukemia</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1125</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S198950</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.2147%2FDDDT.S198950" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=31114157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVaisr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=1117-1125&author=F.+Zhouauthor=Z.+Geauthor=B.+Chen&title=Quizartinib+%28AC220%29%3A+a+promising+option+for+acute+myeloid+leukemia&doi=10.2147%2FDDDT.S198950"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Quizartinib (AC220): a promising option for acute myeloid leukemia</span></div><div class="casAuthors">Zhou, Fang; Ge, Zheng; Chen, Baoan</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1117-1125</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Quizartinib is an effective therapy for patients with FLT3-ITD acute myeloid leukemia (AML) by continuing to inhibit the activity of FLT3 gene, leading to apoptosis of tumor cells.  Multiple clin. trials have proved that it is effective in relapsed or refractory AML with an FLT3-ITD mutation.  In this review, we focus on the characteristics of FLT3/ITD mutations, the mechanism and pharmacokinetics of quizartinib, and the mechanisms of resistance to quizartinib.  We also summarize clin. experiences and adverse effects with quizartinib and recommend crucial approaches of quizartinib in the therapy of patients with newly diagnosed AML and patients with relapsed/refractory AML, particularly those with FLT3-ITD mutation.  Quizartinib presents its advantages as a very promising agent in the treatment of AML, esp. in patients with FLT3-ITD mutations.  FLT3/ITD mutation can lead to constitutive autophosphorylation of FLT3 and activation of its downstream effectors including RAS/RAF/MEK, MAPK/ERK, PI3K/AKT/mTOR and JAK/STAT5 signal pathways, while Quizartinib can inhibit these downstream pathways through specific FLT3 inhibition.  Quizartinib has received US Food and Drug Administration breakthrough therapy designation in patients with relapsed/refractory FLT3-ITD AML based on clin. trials.  A larger sample of clin. trials are needed to verify its safety and efficacy, and the efficacy of quizartinib combined with chemotherapy or allogeneic hematopoietic cell transplantation should also be estd. in clin. trials.  Meanwhile, for the side effects of quizartinib, further studies are needed to find a way to reduce its toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdQbluP81wNLVg90H21EOLACvtfcHk0litwLQ52IZwVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVaisr7K&md5=c172240b673571ce14933fa6de086b10</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S198950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S198950%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DGe%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DB.%26atitle%3DQuizartinib%2520%2528AC220%2529%253A%2520a%2520promising%2520option%2520for%2520acute%2520myeloid%2520leukemia%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2019%26volume%3D13%26spage%3D1117%26epage%3D1125%26doi%3D10.2147%2FDDDT.S198950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span> <span> </span><span class="NLM_article-title">Midostaurin approved for FLT3-mutated AML</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">3403</span>– <span class="NLM_lpage">3406</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-05-782292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2017-05-782292" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=28546144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFamt7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=3403-3406&issue=26&author=M.+Levis&title=Midostaurin+approved+for+FLT3-mutated+AML&doi=10.1182%2Fblood-2017-05-782292"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Midostaurin approved for FLT3-mutated AML</span></div><div class="casAuthors">Levis, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3403-3406</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Midostaurin was recently approved by the US Food and Drug Administration for the treatment of FLT3-mutant acute myeloid leukemia (AML).  This is the first drug to receive regulatory approval for AML in the United States since the year 2000.  Midostaurin is a small-mol. kinase inhibitor with activity against the receptor tyrosine kinase FLT3, and its approval will hopefully mark the beginning of an era of targeted agents for the treatment of molecularly defined subtypes of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiE1vcI_B3uLVg90H21EOLACvtfcHk0litwLQ52IZwVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFamt7vM&md5=8e6eda0e807f1611ef4b90d7c1959ef4</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-05-782292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-05-782292%26sid%3Dliteratum%253Aachs%26aulast%3DLevis%26aufirst%3DM.%26atitle%3DMidostaurin%2520approved%2520for%2520FLT3-mutated%2520AML%26jtitle%3DBlood%26date%3D2017%26volume%3D129%26issue%3D26%26spage%3D3403%26epage%3D3406%26doi%3D10.1182%2Fblood-2017-05-782292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knapper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilkes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hills, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavenagh, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjeldsen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunwald, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnett, A. K.</span></span> <span> </span><span class="NLM_article-title">A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1143</span>– <span class="NLM_lpage">1154</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-07-730648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2016-07-730648" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=27872058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVWgtL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=1143-1154&issue=9&author=S.+Knapperauthor=N.+Russellauthor=A.+Gilkesauthor=R.+K.+Hillsauthor=R.+E.+Galeauthor=J.+D.+Cavenaghauthor=G.+Jonesauthor=L.+Kjeldsenauthor=M.+R.+Grunwaldauthor=I.+Thomasauthor=H.+Konigauthor=M.+J.+Levisauthor=A.+K.+Burnett&title=A+randomized+assessment+of+adding+the+kinase+inhibitor+lestaurtinib+to+first-line+chemotherapy+for+FLT3-mutated+AML&doi=10.1182%2Fblood-2016-07-730648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML</span></div><div class="casAuthors">Knapper, Steven; Russell, Nigel; Gilkes, Amanda; Hills, Robert K.; Gale, Rosemary E.; Cavenagh, James D.; Jones, Gail; Kjeldsen, Lars; Grunwald, Michael R.; Thomas, Ian; Konig, Heiko; Levis, Mark J.; Burnett, Alan K.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1143-1154</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The clin. benefit of adding FMS-like tyrosine kinase-3 (FLT3)-directed small mol. therapy to std. first-line treatment of acute myeloid leukemia (AML) has not yet been established.  As part of the UK AML15 and AML17 trials, patients with previously untreated AML and confirmed FLT3-activating mutations, mostly younger than 60 years, were randomly assigned either to receive oral lestaurtinib (CEP701) or not after each of 4 cycles of induction and consolidation chemotherapy.  Lestaurtinib was commenced 2 days after completing chemotherapy and administered in cycles of up to 28 days.  The trials ran consecutively.  Primary endpoints were overall survival inAML15 and relapse-free survival in AML17; outcome data were meta-analyzed.  Five hundred patients were randomly assigned between lestaurtinib and control: 74% had FLT3-internal tandemduplicationmutations, 23% FLT3-tyrosine kinase domain pointmutations, and 2%both types.No significant differences were seen in either 5-yr overall survival (lestaurtinib 46% vs control 45%; hazard ratio, 0.90; 95% CI 0.70-1.15;P=.3) or 5-yr relapse-free survival (40% vs 36%; hazard ratio, 0.88; 95%CI 0.69-1.12;P=.3).  Exploratory subgroup anal. suggested survival benefit with lestaurtinib in patients receiving concomitant azole antifungal prophylaxis and gemtuzumab ozogamicin with the first course of chemotherapy.  Correlative studies included anal. of in vivo FLT3 inhibition by plasma inhibitory activity assay and indicated improved overall survival and significantly reduced rates of relapse in lestaurtinib-treated patients who achieved sustained greater than 85% FLT3 inhibition.  In conclusion, combining lestaurtinib with intensive chemotherapy proved feasible in younger patients with newly diagnosed FLT3-mutated AML, but yielded no overall clin. benefit.  The improved clin. outcomes seen in patients achieving sustained FLT3 inhibition encourage continued evaluation of FLT3-directed therapy alongside front-line AML treatment.  The UK AML15 and AML17 trials are registered at www.isrctn.com/ISRCTN17161961 and www.isrctn.com/ISRCTN55675535 resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZEyQZJRTBUbVg90H21EOLACvtfcHk0litwLQ52IZwVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVWgtL7F&md5=54c984612a70cf995de092ff91482319</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-07-730648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-07-730648%26sid%3Dliteratum%253Aachs%26aulast%3DKnapper%26aufirst%3DS.%26aulast%3DRussell%26aufirst%3DN.%26aulast%3DGilkes%26aufirst%3DA.%26aulast%3DHills%26aufirst%3DR.%2BK.%26aulast%3DGale%26aufirst%3DR.%2BE.%26aulast%3DCavenagh%26aufirst%3DJ.%2BD.%26aulast%3DJones%26aufirst%3DG.%26aulast%3DKjeldsen%26aufirst%3DL.%26aulast%3DGrunwald%26aufirst%3DM.%2BR.%26aulast%3DThomas%26aufirst%3DI.%26aulast%3DKonig%26aufirst%3DH.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DBurnett%26aufirst%3DA.%2BK.%26atitle%3DA%2520randomized%2520assessment%2520of%2520adding%2520the%2520kinase%2520inhibitor%2520lestaurtinib%2520to%2520first-line%2520chemotherapy%2520for%2520FLT3-mutated%2520AML%26jtitle%3DBlood%26date%3D2017%26volume%3D129%26issue%3D9%26spage%3D1143%26epage%3D1154%26doi%3D10.1182%2Fblood-2016-07-730648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weis, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marini, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bixby, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perissinotti, A. J.</span></span> <span> </span><span class="NLM_article-title">Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia</span>. <i>Crit Rev. Oncol Hematol</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2019.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.critrevonc.2019.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=31279288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BB3MzkslersA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2019&pages=125-138&author=T.+M.+Weisauthor=B.+L.+Mariniauthor=D.+L.+Bixbyauthor=A.+J.+Perissinotti&title=Clinical+considerations+for+the+use+of+FLT3+inhibitors+in+acute+myeloid+leukemia&doi=10.1016%2Fj.critrevonc.2019.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia</span></div><div class="casAuthors">Weis Taylor M; Marini Bernard L; Bixby Dale L; Perissinotti Anthony J</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">125-138</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Internal tandem duplications and tyrosine kinase mutations in the fms-like tyrosine kinase 3 (FLT3) receptor can occur in acute myeloid leukemia (AML) and portend a poor prognosis.  Midostaurin, a multikinase inhibitor that targets FLT3, demonstrated a survival benefit in FLT3-mutated AML in combination with front-line chemotherapy.  Despite this advancement, the use of FLT3 inhibitors in clinical practice is complicated by significant drug-drug interactions and uncertainty about optimal timing, duration, and sequencing of therapy.  As monotherapy, the utility of FLT3 inhibitors was initially limited by incomplete and transient clinical responses and the development of acquired resistance.  This led to the development of more potent and selective FLT3 inhibitors designed to overcome common resistance mechanisms.  One of these second generation FLT3 inhibitors, gilteritinib, is now FDA-approved for the treatment of relapsed or refractory AML.  Now that multiple FLT3 inhibitors are commercially available, it is important to further delineate the role of these agents in the AML population.  This review aims to provide a comprehensive overview of the role of FLT3 inhibitors in AML and apply the current literature to clinical practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLHgPcBNhpCCM8MEzWGjS9fW6udTcc2eaUPnENjk1LKbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzkslersA%253D%253D&md5=d4ae236b21409087d7226b1a6df8bd2a</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2019.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2019.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DWeis%26aufirst%3DT.%2BM.%26aulast%3DMarini%26aufirst%3DB.%2BL.%26aulast%3DBixby%26aufirst%3DD.%2BL.%26aulast%3DPerissinotti%26aufirst%3DA.%2BJ.%26atitle%3DClinical%2520considerations%2520for%2520the%2520use%2520of%2520FLT3%2520inhibitors%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DCrit%2520Rev.%2520Oncol%2520Hematol%26date%3D2019%26volume%3D141%26spage%3D125%26epage%3D138%26doi%3D10.1016%2Fj.critrevonc.2019.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLachlan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvaro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enjeti, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verrills, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dun, M. D.</span></span> <span> </span><span class="NLM_article-title">Targeting oncogenic signaling in mutant FLT3 acute myeloid leukemia: the path to least resistance</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">3198</span>, <span class="refDoi"> DOI: 10.3390/ijms19103198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.3390%2Fijms19103198" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntlymtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=3198&issue=10&author=D.+Staudtauthor=H.+C.+Murrayauthor=T.+McLachlanauthor=F.+Alvaroauthor=A.+K.+Enjetiauthor=N.+M.+Verrillsauthor=M.+D.+Dun&title=Targeting+oncogenic+signaling+in+mutant+FLT3+acute+myeloid+leukemia%3A+the+path+to+least+resistance&doi=10.3390%2Fijms19103198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting oncogenic signaling in mutant FLT3 acute myeloid leukemia: the path to least resistance</span></div><div class="casAuthors">Staudt, Dilana; Murray, Heather C.; McLachlan, Tabitha; Alvaro, Frank; Enjeti, Anoop K.; Verrills, Nicole M.; Dun, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3198/1-3198/26</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The identification of recurrent driver mutations in genes encoding tyrosine kinases has resulted in the development of molecularly-targeted treatment strategies designed to improve outcomes for patients diagnosed with acute myeloid leukemia (AML).  The receptor tyrosine kinase FLT3 is the most commonly mutated gene in AML, with internal tandem duplications within the juxtamembrane domain (FLT3-ITD) or missense mutations in the tyrosine kinase domain (FLT3-TKD) present in 30-35% of AML patients at diagnosis.  An established driver mutation and marker of poor prognosis, the FLT3 tyrosine kinase has emerged as an attractive therapeutic target, and thus, encouraged the development of FLT3 tyrosine kinase inhibitors (TKIs).  However, the therapeutic benefit of FLT3 inhibition, particularly as a monotherapy, frequently results in the development of treatment resistance and disease relapse.  Commonly, FLT3 inhibitor resistance occurs by the emergence of secondary lesions in the FLT3 gene, particularly in the second tyrosine kinase domain (TKD) at residue Asp835 (D835) to form a 'dual mutation' (ITD-D835).  Individual FLT3-ITD and FLT3-TKD mutations influence independent signaling cascades; however, little is known about which divergent signaling pathways are controlled by each of the FLT3 specific mutations, particularly in the context of patients harboring dual ITD-D835 mutations.  This review provides a comprehensive anal. of the known discrete and cooperative signaling pathways deregulated by each of the FLT3 specific mutations, as well as the therapeutic approaches that hold the most promise of more durable and personalized therapeutic approaches to improve treatments of FLT3 mutant AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpa4ET_f5LGqbVg90H21EOLACvtfcHk0li5CsQtycHJJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntlymtr8%253D&md5=534da5dfc80804ed501f8aa95454b1cc</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.3390%2Fijms19103198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19103198%26sid%3Dliteratum%253Aachs%26aulast%3DStaudt%26aufirst%3DD.%26aulast%3DMurray%26aufirst%3DH.%2BC.%26aulast%3DMcLachlan%26aufirst%3DT.%26aulast%3DAlvaro%26aufirst%3DF.%26aulast%3DEnjeti%26aufirst%3DA.%2BK.%26aulast%3DVerrills%26aufirst%3DN.%2BM.%26aulast%3DDun%26aufirst%3DM.%2BD.%26atitle%3DTargeting%2520oncogenic%2520signaling%2520in%2520mutant%2520FLT3%2520acute%2520myeloid%2520leukemia%253A%2520the%2520path%2520to%2520least%2520resistance%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26issue%3D10%26spage%3D3198%26doi%3D10.3390%2Fijms19103198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traer, E.</span></span> <span> </span><span class="NLM_article-title">Profile of quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD-positive acute myeloid leukemia: evidence to date</span>. <i>Cancer Manage. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.2147/CMAR.S196568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.2147%2FCMAR.S196568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=32021432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVCjsrnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=151-163&author=L.+Fletcherauthor=S.+K.+Joshiauthor=E.+Traer&title=Profile+of+quizartinib+for+the+treatment+of+adult+patients+with+relapsed%2Frefractory+FLT3-ITD-positive+acute+myeloid+leukemia%3A+evidence+to+date&doi=10.2147%2FCMAR.S196568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Profile of quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD-positive acute myeloid leukemia: evidence to date</span></div><div class="casAuthors">Fletcher, Luke; Joshi, Sunil K.; Traer, Elie</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Management and Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">151-163</span>CODEN:
                <span class="NLM_cas:coden">CMRACP</span>;
        ISSN:<span class="NLM_cas:issn">1179-1322</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) is a clonal hematol. neoplasm characterized by rapid, uncontrolled cell growth of immature myeloid cells (blasts).  There are numerous genetic abnormalities in AML, many of which are prognostic, but an increasing no. are targets for drug therapy.  One of the most common genetic abnormalities in AML are activating mutations in the FMS-like tyrosine kinase 3 receptor (FLT3).  As a receptor tyrosine kinase, FLT3 was the first targetable genetic abnormality in AML.  The first generation of FLT3 inhibitors were broad-spectrum kinase inhibitors that inhibited FLT3 among other proteins.  Although clin. active, first-generation FLT3 inhibitors had limited success as single agents.  This led to the development of a second generation of more selective FLT3 inhibitors.  This review focuses on quizartinib, a potent second-generation FLT3 inhibitor.  We discuss the clin. trial development, mechanisms of resistance, and the recent FDA decision to deny approval for quizartinib as a single agent in relapsed/refractory AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMBOdx7nPXwrVg90H21EOLACvtfcHk0li5CsQtycHJJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVCjsrnE&md5=06f5bc8d10d0e2d4a8cd540d5af751e2</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.2147%2FCMAR.S196568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCMAR.S196568%26sid%3Dliteratum%253Aachs%26aulast%3DFletcher%26aufirst%3DL.%26aulast%3DJoshi%26aufirst%3DS.%2BK.%26aulast%3DTraer%26aufirst%3DE.%26atitle%3DProfile%2520of%2520quizartinib%2520for%2520the%2520treatment%2520of%2520adult%2520patients%2520with%2520relapsed%252Frefractory%2520FLT3-ITD-positive%2520acute%2520myeloid%2520leukemia%253A%2520evidence%2520to%2520date%26jtitle%3DCancer%2520Manage.%2520Res.%26date%3D2020%26volume%3D12%26spage%3D151%26epage%3D163%26doi%3D10.2147%2FCMAR.S196568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perl, A. E.</span></span> <span> </span><span class="NLM_article-title">Gilteritinib: potent targeting of FLT3 mutations in AML</span>. <i>Blood Adv.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1178</span>– <span class="NLM_lpage">1191</span>, <span class="refDoi"> DOI: 10.1182/bloodadvances.2019000174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fbloodadvances.2019000174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=32208491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BB3cXis12ktrjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2020&pages=1178-1191&issue=6&author=M.+Levisauthor=A.+E.+Perl&title=Gilteritinib%3A+potent+targeting+of+FLT3+mutations+in+AML&doi=10.1182%2Fbloodadvances.2019000174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Gilteritinib: potent targeting of FLT3 mutations in AML</span></div><div class="casAuthors">Levis, Mark; Perl, Alexander E.</div><div class="citationInfo"><span class="NLM_cas:title">Blood Advances</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1178-1191</span>CODEN:
                <span class="NLM_cas:coden">BALDBA</span>;
        ISSN:<span class="NLM_cas:issn">2473-9537</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Since the discovery of FMS-like tyrosine kinase-3 (FLT3)-activating mutations as genetic drivers in acute myeloid leukemia (AML), investigators have tried to develop tyrosine kinase inhibitors that could effectively target FLT3 and alter the disease trajectory.  Giltertinib (formerly known as ASP2215) is a novel compd. that entered the field late, but moved through the developmental process with remarkable speed.  In many ways, this drug's rapid development was facilitated by the large body of knowledge gained over the years from efforts to develop other FLT3 inhibitors.  Single-agent gilteritinib, a potent and selective oral FLT3 inhibitor, improved the survival of patients with relapsed or refractory FLT3-mutated AML compared with std. chemotherapy.  This continues to validate the approach of targeting FLT3 itself and establishes a new backbone for testing combination regimens.  This review will frame the preclin. and clin. development of gilteritinib in the context of the lessons learned from its predecessors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOB-jGZCX9A7Vg90H21EOLACvtfcHk0ljQe-UGXnzktQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXis12ktrjK&md5=a293d32efa1833dbc74aef6cbbf06ae2</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1182%2Fbloodadvances.2019000174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fbloodadvances.2019000174%26sid%3Dliteratum%253Aachs%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26atitle%3DGilteritinib%253A%2520potent%2520targeting%2520of%2520FLT3%2520mutations%2520in%2520AML%26jtitle%3DBlood%2520Adv.%26date%3D2020%26volume%3D4%26issue%3D6%26spage%3D1178%26epage%3D1191%26doi%3D10.1182%2Fbloodadvances.2019000174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khaled, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perl, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganguly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dombret, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogge, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonas, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montesinos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radsak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sica, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arunachalam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namuyinga, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yver, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span> <span> </span><span class="NLM_article-title">Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">984</span>– <span class="NLM_lpage">997</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(19)30150-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2FS1470-2045%2819%2930150-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=31175001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFGqtrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=984-997&issue=7&author=J.+E.+Cortesauthor=S.+Khaledauthor=G.+Martinelliauthor=A.+E.+Perlauthor=S.+Gangulyauthor=N.+Russellauthor=A.+Kramerauthor=H.+Dombretauthor=D.+Hoggeauthor=B.+A.+Jonasauthor=A.+Y.+Leungauthor=P.+Mehtaauthor=P.+Montesinosauthor=M.+Radsakauthor=S.+Sicaauthor=M.+Arunachalamauthor=M.+Holmesauthor=K.+Kobayashiauthor=R.+Namuyingaauthor=N.+Geauthor=A.+Yverauthor=Y.+Zhangauthor=M.+J.+Levis&title=Quizartinib+versus+salvage+chemotherapy+in+relapsed+or+refractory+FLT3-ITD+acute+myeloid+leukaemia+%28QuANTUM-R%29%3A+a+multicentre%2C+randomised%2C+controlled%2C+open-label%2C+phase+3+trial&doi=10.1016%2FS1470-2045%2819%2930150-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial</span></div><div class="casAuthors">Cortes, Jorge E.; Khaled, Samer; Martinelli, Giovanni; Perl, Alexander E.; Ganguly, Siddhartha; Russell, Nigel; Kramer, Alwin; Dombret, Herve; Hogge, Donna; Jonas, Brian A.; Leung, Anskar Yu-Hung; Mehta, Priyanka; Montesinos, Pau; Radsak, Markus; Sica, Simona; Arunachalam, Meena; Holmes, Melissa; Kobayashi, Ken; Namuyinga, Ruth; Ge, Nanxiang; Yver, Antoine; Zhang, Yufen; Levis, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">984-997</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Patients with relapsed or refractory FLT3 internal tandem duplication (FLT3-ITD)-pos. acute myeloid leukemia have a poor prognosis, including high frequency of relapse, poorer response to salvage therapy, and shorter overall survival than those with FLT3 wild-type disease.  We aimed to assess whether single-agent quizartinib, an oral, highly potent and selective type II FLT3 inhibitor, improves overall survival vs. salvage chemotherapy.  QuANTUM-R is a randomized, controlled, phase 3 trial done at 152 hospitals and cancer centers in 19 countries.  Eligible patients aged 18 years or older with ECOG performance status 0-2 with relapsed or refractory (duration of first composite complete remission ≤6 mo) FLT3-ITD acute myeloid leukemia after std. therapy with or without allogeneic hemopoietic stem-cell transplantation were randomly assigned (2:1; permuted block size of 6; stratified by response to previous therapy and choice of chemotherapy via a phone-based and web-based interactive response system) to quizartinib (60 mg [30 mg lead-in] orally once daily) or investigator's choice of preselected chemotherapy: s.c. low-dose cytarabine (s.c. injection of cytarabine 20 mg twice daily on days 1-10 of 28-day cycles); i.v. infusions of mitoxantrone (8 mg/m2 per day), etoposide (100 mg/m2 per day), and cytarabine (1000 mg/m2 per day on days 1-5 of up to two 28-day cycles); or i.v. granulocyte colony-stimulating factor (300μg/m2 per day or 5μg/kg per day s.c. on days 1-5), fludarabine (i.v. infusion 30 mg/m2 per day on days 2-6), cytarabine (i.v. infusion 2000 mg/m2 per day on days 2-6), and idarubicin (i.v. infusion 10 mg/m2 per day on days 2-4 in up to two 28-day cycles).  Patients proceeding to hemopoietic stem-cell transplantation after quizartinib could resume quizartinib after hemopoietic stem-cell transplantation.  The primary endpoint was overall survival in the intention-to-treat population.  This trial is registered with ClinicalTrials.gov, no. NCT02039726, and follow-up is ongoing.  Between May 7, 2014, and Sept 13, 2017, 367 patients were enrolled, of whom 245 were randomly allocated to quizartinib and 122 to chemotherapy.  Four patients in the quizartinib group and 28 in the chemotherapy group were not treated.  Median follow-up was 23.5 mo (IQR 15.4-32.3).  Overall survival was longer for quizartinib than for chemotherapy (hazard ratio 0.76 [95% CI 0.58-0.98; p = 0.02]).  Median overall survival was 6.2 mo (5.3-7.2) in the quizartinib group and 4.7 mo (4.0-5.5) in the chemotherapy group.  The most common non-haematol. grade 3-5 treatment-emergent adverse events (within ≤30 days of last dose or >30 days if suspected to be a treatment-related event) for quizartinib (241 patients) and chemotherapy (94 patients) were sepsis or septic shock (46 patients [19%] for quizartinib vs 18 [19%] for chemotherapy), pneumonia (29 [12%] vs eight [9%]), and hypokalemia (28 [12%] vs eight [9%]).  The most frequent treatment-related serious adverse events were febrile neutropenia (18 patients [7%]), sepsis or septic shock (11 [5%]), QT prolongation (five [2%]), and nausea (five [2%]) in the quizartinib group, and febrile neutropenia (five [5%]), sepsis or septic shock (four [4%]), pneumonia (two [2%]), and pyrexia (two [2%]) in the chemotherapy group.  Grade 3 QT prolongation in the quizartinib group was uncommon (eight [3%] by central reading, ten [4%] by investigator report); no grade 4 events occurred.  There were 80 (33%) treatment-emergent deaths in the quizartinib group (31 [13%] of which were due to adverse events) and 16 (17%) in the chemotherapy group (nine [10%] of which were due to adverse events).  Treatment with quizartinib had a survival benefit vs. salvage chemotherapy and had a manageable safety profile in patients with rapidly proliferative disease and very poor prognosis.  Quizartinib could be considered a new std. of care.  Given that there are only a few available treatment options, this study highlights the value of targeting the FLT3-ITD driver mutation with a highly potent and selective FLT3 inhibitor.Daiichi Sankyo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGcMb6SW1_b7Vg90H21EOLACvtfcHk0ljQe-UGXnzktQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFGqtrzM&md5=63619aa2e4ea4fcc29b74d2aef43f224</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2819%2930150-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252819%252930150-0%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26aulast%3DKhaled%26aufirst%3DS.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26aulast%3DGanguly%26aufirst%3DS.%26aulast%3DRussell%26aufirst%3DN.%26aulast%3DKramer%26aufirst%3DA.%26aulast%3DDombret%26aufirst%3DH.%26aulast%3DHogge%26aufirst%3DD.%26aulast%3DJonas%26aufirst%3DB.%2BA.%26aulast%3DLeung%26aufirst%3DA.%2BY.%26aulast%3DMehta%26aufirst%3DP.%26aulast%3DMontesinos%26aufirst%3DP.%26aulast%3DRadsak%26aufirst%3DM.%26aulast%3DSica%26aufirst%3DS.%26aulast%3DArunachalam%26aufirst%3DM.%26aulast%3DHolmes%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DK.%26aulast%3DNamuyinga%26aufirst%3DR.%26aulast%3DGe%26aufirst%3DN.%26aulast%3DYver%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26atitle%3DQuizartinib%2520versus%2520salvage%2520chemotherapy%2520in%2520relapsed%2520or%2520refractory%2520FLT3-ITD%2520acute%2520myeloid%2520leukaemia%2520%2528QuANTUM-R%2529%253A%2520a%2520multicentre%252C%2520randomised%252C%2520controlled%252C%2520open-label%252C%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2019%26volume%3D20%26issue%3D7%26spage%3D984%26epage%3D997%26doi%3D10.1016%2FS1470-2045%2819%2930150-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandrekar, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanford, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laumann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomfield, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiede, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prior, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo-Coco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klisovic, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sierra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandwein, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Witte, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niederwieser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appelbaum, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medeiros, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krauter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serve, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehninger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amadori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohner, H.</span></span> <span> </span><span class="NLM_article-title">Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">464</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1614359</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1056%2FNEJMoa1614359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=28644114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlyksrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=454-464&issue=5&author=R.+M.+Stoneauthor=S.+J.+Mandrekarauthor=B.+L.+Sanfordauthor=K.+Laumannauthor=S.+Geyerauthor=C.+D.+Bloomfieldauthor=C.+Thiedeauthor=T.+W.+Priorauthor=K.+Dohnerauthor=G.+Marcucciauthor=F.+Lo-Cocoauthor=R.+B.+Klisovicauthor=A.+Weiauthor=J.+Sierraauthor=M.+A.+Sanzauthor=J.+M.+Brandweinauthor=T.+de+Witteauthor=D.+Niederwieserauthor=F.+R.+Appelbaumauthor=B.+C.+Medeirosauthor=M.+S.+Tallmanauthor=J.+Krauterauthor=R.+F.+Schlenkauthor=A.+Ganserauthor=H.+Serveauthor=G.+Ehningerauthor=S.+Amadoriauthor=R.+A.+Larsonauthor=H.+Dohner&title=Midostaurin+plus+chemotherapy+for+acute+myeloid+leukemia+with+a+FLT3+mutation&doi=10.1056%2FNEJMoa1614359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation</span></div><div class="casAuthors">Stone, R. M.; Mandrekar, S. J.; Sanford, B. L.; Laumann, K.; Geyer, S.; Bloomfield, C. D.; Thiede, C.; Prior, T. W.; Dohner, K.; Marcucci, G.; Lo-Coco, F.; Klisovic, R. B.; Wei, A.; Sierra, J.; Sanz, M. A.; Brandwein, J. M.; de Witte, T.; Niederwieser, D.; Appelbaum, F. R.; Medeiros, B. C.; Tallman, M. S.; Krauter, J.; Schlenk, R. F.; Ganser, A.; Serve, H.; Ehninger, G.; Amadori, S.; Larson, R. A.; Dohner, H.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">454-464</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes.  We conducted a phase 3 trial to det. whether the addn. of midostaurin - an oral multitargeted kinase inhibitor that is active in patients with a FLT3 mutation - to std. chemotherapy would prolong overall survival in this population.  Methods: We screened 3277 patients, 18 to 59 years of age, who had newly diagnosed AML for FLT3 mutations.  Patients were randomly assigned to receive std. chemotherapy (induction therapy with daunorubicin and cytarabine and consolidation therapy with high-dose cytarabine) plus either midostaurin or placebo; those who were in remission after consolidation therapy entered a maintenance phase in which they received either midostaurin or placebo.  Randomization was stratified according to subtype of FLT3 mutation: point mutation in the tyrosine kinase domain (TKD) or internal tandem duplication (ITD) mutation with either a high ratio (>0.7) or a low ratio (0.05 to 0.7) of mutant to wild-type alleles (ITD [high] and ITD [low], resp.).  Allogeneic transplantation was allowed.  The primary end point was overall survival.  Results: A total of 717 patients underwent randomization; 360 were assigned to the midostaurin group, and 357 to the placebo group.  The FLT3 subtype was ITD (high) in 214 patients, ITD (low) in 341 patients, and TKD in 162 patients.  The treatment groups were well balanced with respect to age, race, FLT3 subtype, cytogenetic risk, and blood counts but not with respect to sex (51.7% in the midostaurin group vs. 59.4% in the placebo group were women, P = 0.04).  Overall survival was significantly longer in the midostaurin group than in the placebo group (hazard ratio for death, 0.78; one-sided P = 0.009), as was event-free survival (hazard ratio for event or death, 0.78; one-sided P = 0.002).  In both the primary anal. and an anal. in which data for patients who underwent transplantation were censored, the benefit of midostaurin was consistent across all FLT3 subtypes.  The rate of severe adverse events was similar in the two groups.  Conclusions: The addn. of the multitargeted kinase inhibitor midostaurin to std. chemotherapy significantly prolonged overall and event-free survival among patients with AML and a FLT3 mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9IT8JULCk7bVg90H21EOLACvtfcHk0limLo3TImmfIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlyksrbK&md5=9b0b003122a307b4d92f05826745cb8c</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1614359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1614359%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DMandrekar%26aufirst%3DS.%2BJ.%26aulast%3DSanford%26aufirst%3DB.%2BL.%26aulast%3DLaumann%26aufirst%3DK.%26aulast%3DGeyer%26aufirst%3DS.%26aulast%3DBloomfield%26aufirst%3DC.%2BD.%26aulast%3DThiede%26aufirst%3DC.%26aulast%3DPrior%26aufirst%3DT.%2BW.%26aulast%3DDohner%26aufirst%3DK.%26aulast%3DMarcucci%26aufirst%3DG.%26aulast%3DLo-Coco%26aufirst%3DF.%26aulast%3DKlisovic%26aufirst%3DR.%2BB.%26aulast%3DWei%26aufirst%3DA.%26aulast%3DSierra%26aufirst%3DJ.%26aulast%3DSanz%26aufirst%3DM.%2BA.%26aulast%3DBrandwein%26aufirst%3DJ.%2BM.%26aulast%3Dde%2BWitte%26aufirst%3DT.%26aulast%3DNiederwieser%26aufirst%3DD.%26aulast%3DAppelbaum%26aufirst%3DF.%2BR.%26aulast%3DMedeiros%26aufirst%3DB.%2BC.%26aulast%3DTallman%26aufirst%3DM.%2BS.%26aulast%3DKrauter%26aufirst%3DJ.%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26aulast%3DGanser%26aufirst%3DA.%26aulast%3DServe%26aufirst%3DH.%26aulast%3DEhninger%26aufirst%3DG.%26aulast%3DAmadori%26aufirst%3DS.%26aulast%3DLarson%26aufirst%3DR.%2BA.%26aulast%3DDohner%26aufirst%3DH.%26atitle%3DMidostaurin%2520plus%2520chemotherapy%2520for%2520acute%2520myeloid%2520leukemia%2520with%2520a%2520FLT3%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26issue%3D5%26spage%3D454%26epage%3D464%26doi%3D10.1056%2FNEJMoa1614359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heidel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solem, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breitenbuecher, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipka, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiede, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandts, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serve, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roesel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giles, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehninger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, T.</span></span> <span> </span><span class="NLM_article-title">Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>107</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">300</span>, <span class="refDoi"> DOI: 10.1182/blood-2005-06-2469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2005-06-2469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=16150941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsVGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2006&pages=293-300&issue=1&author=F.+Heidelauthor=F.+K.+Solemauthor=F.+Breitenbuecherauthor=D.+B.+Lipkaauthor=S.+Kasperauthor=M.+H.+Thiedeauthor=C.+Brandtsauthor=H.+Serveauthor=J.+Roeselauthor=F.+Gilesauthor=E.+Feldmanauthor=G.+Ehningerauthor=G.+J.+Schillerauthor=S.+Nimerauthor=R.+M.+Stoneauthor=Y.+Wangauthor=T.+Kindlerauthor=P.+S.+Cohenauthor=C.+Huberauthor=T.+Fischer&title=Clinical+resistance+to+the+kinase+inhibitor+PKC412+in+acute+myeloid+leukemia+by+mutation+of+Asn-676+in+the+FLT3+tyrosine+kinase+domain&doi=10.1182%2Fblood-2005-06-2469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain</span></div><div class="casAuthors">Heidel, Florian; Solem, Fian K.; Breitenbuecher, Frank; Lipka, Daniel B.; Kasper, Stefan; Thiede, M. H.; Brandts, Christian; Serve, Hubert; Roesel, Johannes; Giles, Francis; Feldman, Eric; Ehninger, Gerhard; Schille, Gary J.; Nimer, Stephen; Stone, Richard M.; Wang, Yanfeng; Kindler, Thomas; Cohen, Pamela S.; Huber, Christoph; Fischer, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">293-300</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Activating mutations in the FLT3 tyrosine kinase (TK) occur in approx. 35% of patients with acute myeloid leukemia (AML).  Therefore, targeting mutated FLT3 is an attractive therapeutic strategy, and early clin. trials testing FLT3 TK inhibitors (TKI) showed measurable clin. responses.  Most of these responses were transient; however, in a subset of patients blast recurrence was preceded by an interval of prolonged remission.  The etiol. of clin. resistance to FLT3-TKI in AML is unclear but is of major significance for the development of future therapeutic strategies.  We searched for mechanisms of resistance in 6 patients with AML who had relapses upon PKC412 treatment.  In an index AML patient, an algorithm of analyses was applied using clin. material.  In vivo and in vitro investigation of primary blasts at relapse revealed persistent TK phosphorylation of FLT3 despite sufficient PKC412 serum levels.  Through addnl. mol. analyses, we identified a single amino acid substitution at position 676 (N676K) within the FLT3 kinase domain as the sole cause of resistance of PKC412 in this patient.  Reconstitution expts. expressing the N676K mutant in 32D cells demonstrated that FLT3-ITD-N676K was sufficient to confer an intermediate level of resistance to PKC412 in vitro.  These studies point out that a genetically complex malignancy such as AML may retain dependence on a single oncogenic signal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNW2s1mxXfzLVg90H21EOLACvtfcHk0limLo3TImmfIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsVGlsQ%253D%253D&md5=be1fc50b4c74553a330fa9bd48cb2a22</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-06-2469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-06-2469%26sid%3Dliteratum%253Aachs%26aulast%3DHeidel%26aufirst%3DF.%26aulast%3DSolem%26aufirst%3DF.%2BK.%26aulast%3DBreitenbuecher%26aufirst%3DF.%26aulast%3DLipka%26aufirst%3DD.%2BB.%26aulast%3DKasper%26aufirst%3DS.%26aulast%3DThiede%26aufirst%3DM.%2BH.%26aulast%3DBrandts%26aufirst%3DC.%26aulast%3DServe%26aufirst%3DH.%26aulast%3DRoesel%26aufirst%3DJ.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DFeldman%26aufirst%3DE.%26aulast%3DEhninger%26aufirst%3DG.%26aulast%3DSchiller%26aufirst%3DG.%2BJ.%26aulast%3DNimer%26aufirst%3DS.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKindler%26aufirst%3DT.%26aulast%3DCohen%26aufirst%3DP.%2BS.%26aulast%3DHuber%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DT.%26atitle%3DClinical%2520resistance%2520to%2520the%2520kinase%2520inhibitor%2520PKC412%2520in%2520acute%2520myeloid%2520leukemia%2520by%2520mutation%2520of%2520Asn-676%2520in%2520the%2520FLT3%2520tyrosine%2520kinase%2520domain%26jtitle%3DBlood%26date%3D2006%26volume%3D107%26issue%3D1%26spage%3D293%26epage%3D300%26doi%3D10.1182%2Fblood-2005-06-2469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alvarado, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luthra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Manero, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopleva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrov, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreeff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J. E.</span></span> <span> </span><span class="NLM_article-title">Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>120</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">2142</span>– <span class="NLM_lpage">2149</span>, <span class="refDoi"> DOI: 10.1002/cncr.28705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1002%2Fcncr.28705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=24737502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFSmtrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2014&pages=2142-2149&issue=14&author=Y.+Alvaradoauthor=H.+M.+Kantarjianauthor=R.+Luthraauthor=F.+Ravandiauthor=G.+Borthakurauthor=G.+Garcia-Maneroauthor=M.+Konoplevaauthor=Z.+Estrovauthor=M.+Andreeffauthor=J.+E.+Cortes&title=Treatment+with+FLT3+inhibitor+in+patients+with+FLT3-mutated+acute+myeloid+leukemia+is+associated+with+development+of+secondary+FLT3-tyrosine+kinase+domain+mutations&doi=10.1002%2Fcncr.28705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations</span></div><div class="casAuthors">Alvarado, Yesid; Kantarjian, Hagop M.; Luthra, Rajyalakshmi; Ravandi, Farhad; Borthakur, Gautam; Garcia-Manero, Guillermo; Konopleva, Marina; Estrov, Zeev; Andreeff, Michael; Cortes, Jorge E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2142-2149</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND : FLT3-internal tandem duplication (ITD) mutations are found in approx. 30% of patients with acute myeloid leukemia (AML).  FLT3 inhibitors have shown clin. activity in AML with FLT3-ITD, but responses are usually short-lived.  METHODS : This study examd. 69 FLT3-mutated patients with AML, who were treated with different FLT3 inhibitors to analyze emergence of new mutations.  RESULTS : At baseline, 87% of patients had an ITD mutation, 7% had a D835/I836 mutation, and 6% had combined ITD and D835/I836 mutations.  Responses occurred in 32% of patients, all with FLT3-ITD; none of the patients with D835/I836 or ITD+D835/I836 responded.  Mutational assessment at the time of FLT3 inhibitor discontinuation showed that 68% of patients were unchanged, 10% had become undetectable, and 22% of patients progressed from a single ITD to have combined ITD+D835/I836 mutations.  In those patients with unchanged FLT3 mutation at progression, the median survival was 5 mo, whereas in those with undetectable and with combined ITD+D835/I836 mutations, the median survival was 7 mo, resp.  CONCLUSIONS : These data confirm in vitro observations that a secondary tyrosine kinase domain mutation may arise after the use of FLT3 inhibitors in patients with single FLT3-ITD mutated AML, a phenomenon that is assocd. with resistance and a poor prognosis.  Cancer 2014;120:2142-2149. © 2014 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6wrXS8kVYurVg90H21EOLACvtfcHk0limLo3TImmfIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFSmtrzN&md5=b16b32e2b79500ca3dabb70a1d9b0a3a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fcncr.28705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.28705%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarado%26aufirst%3DY.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DLuthra%26aufirst%3DR.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DAndreeff%26aufirst%3DM.%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26atitle%3DTreatment%2520with%2520FLT3%2520inhibitor%2520in%2520patients%2520with%2520FLT3-mutated%2520acute%2520myeloid%2520leukemia%2520is%2520associated%2520with%2520development%2520of%2520secondary%2520FLT3-tyrosine%2520kinase%2520domain%2520mutations%26jtitle%3DCancer%26date%3D2014%26volume%3D120%26issue%3D14%26spage%3D2142%26epage%3D2149%26doi%3D10.1002%2Fcncr.28705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stecula, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. P.</span></span> <span> </span><span class="NLM_article-title">FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2390</span>– <span class="NLM_lpage">2392</span>, <span class="refDoi"> DOI: 10.1038/leu.2015.165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fleu.2015.165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=26108694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Wrtb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=2390-2392&issue=12&author=C.+C.+Smithauthor=K.+Linauthor=A.+Steculaauthor=A.+Saliauthor=N.+P.+Shah&title=FLT3+D835+mutations+confer+differential+resistance+to+type+II+FLT3+inhibitors&doi=10.1038%2Fleu.2015.165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors</span></div><div class="casAuthors">Smith, C. C.; Lin, K.; Stecula, A.; Sali, A.; Shah, N. P.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2390-2392</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activating mutations in FLT3 occur in ∼30% of adult acute myeloid leukemia, primarily consisting of internal tandem duplication (ITD) mutations (∼25%) and point mutations in the tyrosine kinase domain (∼5%), commonly at the activation loop residue D835.  Secondary kinase domain mutations in FLT3-ITD, particularly at the D835 residue are frequently assocd. with acquired clin. resistance to effective FLT3 tyrosine kinase inhibitors (TKIs).  Mol. docking studies have suggested that D835 mutations primarily confer resistance by stabilizing an active Asp-Phe-Gly in ('DFG-in') kinase conformation unfavorable to the binding of type II FLT3 TKIs, which target a 'DFG-out' inactive conformation.  We profiled the activity of active type II FLT3 TKIs against D835 kinase domain mutants that have been clin. detected to date.  We found that type II inhibitors (quizartinib, sorafenib, ponatinib and PLX3397) retain activity against specific D835 substitutions.  Modeling studies suggest that bulky hydrophobic substitutions (D835Y/V/I/F) at this residue are particularly resistant, whereas mutations that preserve interactions between D835 and S838 are relatively sensitive (D835E/N).  All mutants retain sensitivity to the type I inhibitor crenolanib.  These results suggest that patients with relatively sensitive D835 mutations should be included in clin. trials of type II FLT3 TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQhZ7jQYhBcbVg90H21EOLACvtfcHk0liWztjRuOoWNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Wrtb%252FJ&md5=f6de44ca15604b8429a5dab811fe8eeb</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.165%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DStecula%26aufirst%3DA.%26aulast%3DSali%26aufirst%3DA.%26aulast%3DShah%26aufirst%3DN.%2BP.%26atitle%3DFLT3%2520D835%2520mutations%2520confer%2520differential%2520resistance%2520to%2520type%2520II%2520FLT3%2520inhibitors%26jtitle%3DLeukemia%26date%3D2015%26volume%3D29%26issue%3D12%26spage%3D2390%26epage%3D2392%26doi%3D10.1038%2Fleu.2015.165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melgar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolanos, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hueneman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawa, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyt, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunderlich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perentesis, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starczynowski, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span> <span> </span><span class="NLM_article-title">Targeting AML-associated FLT3 mutations with a type I kinase inhibitor</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>130</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">2017</span>– <span class="NLM_lpage">2023</span>, <span class="refDoi"> DOI: 10.1172/JCI127907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1172%2FJCI127907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=32149729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsFGlurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2020&pages=2017-2023&issue=4&author=L.+M.+Jonesauthor=K.+Melgarauthor=L.+Bolanosauthor=K.+Huenemanauthor=M.+M.+Walkerauthor=J.+K.+Jiangauthor=K.+M.+Wilsonauthor=X.+Zhangauthor=J.+Shenauthor=F.+Jiangauthor=P.+Sutterauthor=A.+Wangauthor=X.+Xuauthor=G.+J.+Tawaauthor=S.+B.+Hoytauthor=M.+Wunderlichauthor=E.+O%E2%80%99Brienauthor=J.+P.+Perentesisauthor=D.+T.+Starczynowskiauthor=C.+J.+Thomas&title=Targeting+AML-associated+FLT3+mutations+with+a+type+I+kinase+inhibitor&doi=10.1172%2FJCI127907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting AML-associated FLT3 mutations with a type I kinase inhibitor</span></div><div class="casAuthors">Jones, LaQuita M.; Melgar, Katelyn; Bolanos, Lyndsey; Hueneman, Kathleen; Walker, Morgan M.; Jiang, Jian-Kang; Wilson, Kelli M.; Zhang, Xiaohu; Shen, Jian; Jiang, Fan; Sutter, Patrick; Wang, Amy; Xu, Xin; Tawa, Gregory J.; Hoyt, Scott B.; Wunderlich, Mark; O'Brien, Eric; Perentesis, John P.; Starczynowski, Daniel T.; Thomas, Craig J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2017-2023</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">1558-8238</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Tyrosine kinase domain (TKD) mutations contribute to acquired resistance to FMS-like tyrosine kinase 3 (FLT3) inhibitors used to treat FLT3-mutant acute myeloid leukemia (AML).  We report a cocrystal structure of FLT3 with a type I inhibitor, NCGC1481, that retained potent binding and activity against FLT3 TKD and gatekeeper mutations.  Relative to the current generation of advanced FLT3 inhibitors, NCGC1481 exhibited superior antileukemic activity against the common, clin. relevant FLT3-mutant AML cells in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU_p8IYcvTBrVg90H21EOLACvtfcHk0liWztjRuOoWNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsFGlurk%253D&md5=d1c6d0eb4baf22ef9d3da642a3f71e45</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1172%2FJCI127907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI127907%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DL.%2BM.%26aulast%3DMelgar%26aufirst%3DK.%26aulast%3DBolanos%26aufirst%3DL.%26aulast%3DHueneman%26aufirst%3DK.%26aulast%3DWalker%26aufirst%3DM.%2BM.%26aulast%3DJiang%26aufirst%3DJ.%2BK.%26aulast%3DWilson%26aufirst%3DK.%2BM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DSutter%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DTawa%26aufirst%3DG.%2BJ.%26aulast%3DHoyt%26aufirst%3DS.%2BB.%26aulast%3DWunderlich%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DE.%26aulast%3DPerentesis%26aufirst%3DJ.%2BP.%26aulast%3DStarczynowski%26aufirst%3DD.%2BT.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26atitle%3DTargeting%2520AML-associated%2520FLT3%2520mutations%2520with%2520a%2520type%2520I%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2020%26volume%3D130%26issue%3D4%26spage%3D2017%26epage%3D2023%26doi%3D10.1172%2FJCI127907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasater, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damon, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendleton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasarskis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carias, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matusow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spevak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. P.</span></span> <span> </span><span class="NLM_article-title">Characterizing and overriding the structural mechanism of the quizartinib-resistant FLT3 ″gatekeeper″ F691L mutation with PLX3397</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">668</span>– <span class="NLM_lpage">679</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F2159-8290.CD-15-0060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=25847190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2MXps1Cgsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=668-679&issue=6&author=C.+C.+Smithauthor=C.+Zhangauthor=K.+C.+Linauthor=E.+A.+Lasaterauthor=Y.+Zhangauthor=E.+Massiauthor=L.+E.+Damonauthor=M.+Pendletonauthor=A.+Bashirauthor=R.+Sebraauthor=A.+Perlauthor=A.+Kasarskisauthor=R.+Shellooeauthor=G.+Tsangauthor=H.+Cariasauthor=B.+Powellauthor=E.+A.+Burtonauthor=B.+Matusowauthor=J.+Zhangauthor=W.+Spevakauthor=P.+N.+Ibrahimauthor=M.+H.+Leauthor=H.+H.+Hsuauthor=G.+Habetsauthor=B.+L.+Westauthor=G.+Bollagauthor=N.+P.+Shah&title=Characterizing+and+overriding+the+structural+mechanism+of+the+quizartinib-resistant+FLT3+%E2%80%B3gatekeeper%E2%80%B3+F691L+mutation+with+PLX3397&doi=10.1158%2F2159-8290.CD-15-0060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397</span></div><div class="casAuthors">Smith, Catherine C.; Zhang, Chao; Lin, Kimberly C.; Lasater, Elisabeth A.; Zhang, Ying; Massi, Evan; Damon, Lauren E.; Pendleton, Matthew; Bashir, Ali; Sebra, Robert; Perl, Alexander; Kasarskis, Andrew; Shellooe, Rafe; Tsang, Garson; Carias, Heidi; Powell, Ben; Burton, Elizabeth A.; Matusow, Bernice; Zhang, Jiazhong; Spevak, Wayne; Ibrahim, Prabha N.; Le, Mai H.; Hsu, Henry H.; Habets, Gaston; West, Brian L.; Bollag, Gideon; Shah, Neil P.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">668-679</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PLX3397 inhibits the growth of quizartinib-resistant FLT3-ITD+ AML cells expressing the gatekeeper F691L mutation in vitro and in vivo, but not cells expressing kinase domain mutations in the FLT3 activation loop.  Tyrosine kinase domain mutations are a common cause of acquired clin. resistance to tyrosine kinase inhibitors (TKI) used to treat cancer, including the FLT3 inhibitor quizartinib.  Mutation of kinase "gatekeeper" residues, which control access to an allosteric pocket adjacent to the ATP-binding site, has been frequently implicated in TKI resistance.  The mol. underpinnings of gatekeeper mutation-mediated resistance are incompletely understood.  We report the first cocrystal structure of FLT3 with the TKI quizartinib, which demonstrates that quizartinib binding relies on essential edge-to-face arom. interactions with the gatekeeper F691 residue, and F830 within the highly conserved Asp-Phe-Gly motif in the activation loop.  This reliance makes quizartinib critically vulnerable to gatekeeper and activation loop substitutions while minimizing the impact of mutations elsewhere.  Moreover, we identify PLX3397, a novel FLT3 inhibitor that retains activity against the F691L mutant due to a binding mode that depends less vitally on specific interactions with the gatekeeper position.  Significance: We report the first cocrystal structure of FLT3 with a kinase inhibitor, elucidating the structural mechanism of resistance due to the gatekeeper F691L mutation.  PLX3397 is a novel FLT3 inhibitor with in vitro activity against this mutation but is vulnerable to kinase domain mutations in the FLT3 activation loop.  Cancer Discov; 5(6); 668-79. cpr2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9oYwTJ6cznrVg90H21EOLACvtfcHk0liWztjRuOoWNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXps1Cgsb4%253D&md5=7e76b2892a49a6e4701f534fce212ca4</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0060%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DK.%2BC.%26aulast%3DLasater%26aufirst%3DE.%2BA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DMassi%26aufirst%3DE.%26aulast%3DDamon%26aufirst%3DL.%2BE.%26aulast%3DPendleton%26aufirst%3DM.%26aulast%3DBashir%26aufirst%3DA.%26aulast%3DSebra%26aufirst%3DR.%26aulast%3DPerl%26aufirst%3DA.%26aulast%3DKasarskis%26aufirst%3DA.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DCarias%26aufirst%3DH.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DMatusow%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DLe%26aufirst%3DM.%2BH.%26aulast%3DHsu%26aufirst%3DH.%2BH.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DShah%26aufirst%3DN.%2BP.%26atitle%3DCharacterizing%2520and%2520overriding%2520the%2520structural%2520mechanism%2520of%2520the%2520quizartinib-resistant%2520FLT3%2520%25E2%2580%25B3gatekeeper%25E2%2580%25B3%2520F691L%2520mutation%2520with%2520PLX3397%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26issue%3D6%26spage%3D668%26epage%3D679%26doi%3D10.1158%2F2159-8290.CD-15-0060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Natan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharbanda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolais, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, D. A.</span></span> <span> </span><span class="NLM_article-title">The STAT5 inhibitor pimozide displays efficacy in models of acute myelogenous leukemia driven by FLT3 mutations</span>. <i>Genes Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">7–8</span>),  <span class="NLM_fpage">503</span>– <span class="NLM_lpage">511</span>, <span class="refDoi"> DOI: 10.1177/1947601912466555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1177%2F1947601912466555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=23264850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtleitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=503-511&issue=7%E2%80%938&author=E.+A.+Nelsonauthor=S.+R.+Walkerauthor=M.+Xiangauthor=E.+Weisbergauthor=M.+Bar-Natanauthor=R.+Barrettauthor=S.+Liuauthor=S.+Kharbandaauthor=A.+L.+Christieauthor=M.+Nicolaisauthor=J.+D.+Griffinauthor=R.+M.+Stoneauthor=A.+L.+Kungauthor=D.+A.+Frank&title=The+STAT5+inhibitor+pimozide+displays+efficacy+in+models+of+acute+myelogenous+leukemia+driven+by+FLT3+mutations&doi=10.1177%2F1947601912466555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The STAT5 inhibitor pimozide displays efficacy in models of acute myelogenous leukemia driven by FLT3 mutations</span></div><div class="casAuthors">Nelson, Erik A.; Walker, Sarah R.; Xiang, Michael; Weisberg, Ellen; Bar-Natan, Michal; Barrett, Rosemary; Liu, Suiyang; Kharbanda, Surender; Christie, Amanda L.; Nicolais, Maria; Griffin, James D.; Stone, Richard M.; Kung, Andrew L.; Frank, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">503-511, 9</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Activation of the transcription factor STAT5 is essential for the pathogenesis of acute myelogenous leukemia (AML) contg. the FLT3 internal tandem duplication (ITD) mutation.  FLT3 ITD is a constitutively active tyrosine kinase that drives the activation of STAT5, leading to the growth and survival of AML cells.  Although there has been some success in identifying tyrosine kinase inhibitors that block the function of FLT3 ITD, there remains a continued need for effective treatment of this disease.  We have identified the psychotropic drug pimozide as an effective inhibitor of STAT5 function.  Pimozide inhibits the tyrosine phosphorylation of STAT5, leading to the death of AML cells through the induction of apoptosis.  Pimozide shows a combinatorial effect with the tyrosine kinase inhibitors midostaurin (PKC412) and sunitinib in the inhibition of STAT5 tyrosine phosphorylation and the induction of apoptosis.  Significantly, pimozide reduces the tumor burden in a mouse model of FLT3-driven AML.  Therefore, identifying STAT5 inhibitors may provide a new avenue for the treatment of AML, and these may be effective alone or in combination with tyrosine kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY6fwT1Dx0qrVg90H21EOLACvtfcHk0lhkUM0HV2Am_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtleitLs%253D&md5=c6a237d42ce26413f162b3eac9571c3f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1177%2F1947601912466555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601912466555%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DE.%2BA.%26aulast%3DWalker%26aufirst%3DS.%2BR.%26aulast%3DXiang%26aufirst%3DM.%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DBar-Natan%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DKharbanda%26aufirst%3DS.%26aulast%3DChristie%26aufirst%3DA.%2BL.%26aulast%3DNicolais%26aufirst%3DM.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DFrank%26aufirst%3DD.%2BA.%26atitle%3DThe%2520STAT5%2520inhibitor%2520pimozide%2520displays%2520efficacy%2520in%2520models%2520of%2520acute%2520myelogenous%2520leukemia%2520driven%2520by%2520FLT3%2520mutations%26jtitle%3DGenes%2520Cancer%26date%3D2012%26volume%3D3%26issue%3D7%25E2%2580%25938%26spage%3D503%26epage%3D511%26doi%3D10.1177%2F1947601912466555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindblad, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordero, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puissant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macaulay, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabir, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallon-Christersson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haraldsson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemann, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levander, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmaier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietras, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronnstrand, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazi, J. U.</span></span> <span> </span><span class="NLM_article-title">Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">39</span>),  <span class="NLM_fpage">5119</span>– <span class="NLM_lpage">5131</span>, <span class="refDoi"> DOI: 10.1038/onc.2016.41</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fonc.2016.41" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=26999641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC28XksVykurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=5119-5131&issue=39&author=O.+Lindbladauthor=E.+Corderoauthor=A.+Puissantauthor=L.+Macaulayauthor=A.+Ramosauthor=N.+N.+Kabirauthor=J.+Sunauthor=J.+Vallon-Christerssonauthor=K.+Haraldssonauthor=M.+T.+Hemannauthor=A.+Borgauthor=F.+Levanderauthor=K.+Stegmaierauthor=K.+Pietrasauthor=L.+Ronnstrandauthor=J.+U.+Kazi&title=Aberrant+activation+of+the+PI3K%2FmTOR+pathway+promotes+resistance+to+sorafenib+in+AML&doi=10.1038%2Fonc.2016.41"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML</span></div><div class="casAuthors">Lindblad, O.; Cordero, E.; Puissant, A.; Macaulay, L.; Ramos, A.; Kabir, N. N.; Sun, J.; Vallon-Christersson, J.; Haraldsson, K.; Hemann, M. T.; Borg, Aa; Levander, F.; Stegmaier, K.; Pietras, K.; Roennstrand, L.; Kazi, J. U.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">5119-5131</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Therapy directed against oncogenic FLT3 has been shown to induce response in patients with acute myeloid leukemia (AML), but these responses are almost always transient.  To address the mechanism of FLT3 inhibitor resistance, we generated two resistant AML cell lines by sustained treatment with the FLT3 inhibitor sorafenib.  Parental cell lines carry the FLT3-ITD (tandem duplication) mutation and are highly responsive to FLT3 inhibitors, whereas resistant cell lines display resistance to multiple FLT3 inhibitors.  Sanger sequencing and protein mass-spectrometry did not identify any acquired mutations in FLT3 in the resistant cells.  Moreover, sorafenib treatment effectively blocked FLT3 activation in resistant cells, whereas it was unable to block colony formation or cell survival, suggesting that the resistant cells are no longer FLT3 dependent.  Gene expression anal. of sensitive and resistant cell lines, as well as of blasts from patients with sorafenib-resistant AML, suggested an enrichment of the PI3K/mTOR pathway in the resistant phenotype, which was further supported by next-generation sequencing and phospho-specific-antibody array anal.  Furthermore, a selective PI3K/mTOR inhibitor, gedatolisib, efficiently blocked proliferation, colony and tumor formation, and induced apoptosis in resistant cell lines.  Gedatolisib significantly extended survival of mice in a sorafenib-resistant AML patient-derived xenograft model.  Taken together, our data suggest that aberrant activation of the PI3K/mTOR pathway in FLT3-ITD-dependent AML results in resistance to drugs targeting FLT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCfp1049FgsbVg90H21EOLACvtfcHk0lhkUM0HV2Am_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksVykurw%253D&md5=94a7570e240d12c506af0850819c77d9</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fonc.2016.41&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2016.41%26sid%3Dliteratum%253Aachs%26aulast%3DLindblad%26aufirst%3DO.%26aulast%3DCordero%26aufirst%3DE.%26aulast%3DPuissant%26aufirst%3DA.%26aulast%3DMacaulay%26aufirst%3DL.%26aulast%3DRamos%26aufirst%3DA.%26aulast%3DKabir%26aufirst%3DN.%2BN.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DVallon-Christersson%26aufirst%3DJ.%26aulast%3DHaraldsson%26aufirst%3DK.%26aulast%3DHemann%26aufirst%3DM.%2BT.%26aulast%3DBorg%26aufirst%3DA.%26aulast%3DLevander%26aufirst%3DF.%26aulast%3DStegmaier%26aufirst%3DK.%26aulast%3DPietras%26aufirst%3DK.%26aulast%3DRonnstrand%26aufirst%3DL.%26aulast%3DKazi%26aufirst%3DJ.%2BU.%26atitle%3DAberrant%2520activation%2520of%2520the%2520PI3K%252FmTOR%2520pathway%2520promotes%2520resistance%2520to%2520sorafenib%2520in%2520AML%26jtitle%3DOncogene%26date%3D2016%26volume%3D35%26issue%3D39%26spage%3D5119%26epage%3D5131%26doi%3D10.1038%2Fonc.2016.41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottomly, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segerdell, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilmot, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McWeeney, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eide, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nechiporuk, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Searles, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Follit, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lind, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Manero, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buelow, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyner, J. W.</span></span> <span> </span><span class="NLM_article-title">Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">244</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-08263-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fs41467-018-08263-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=30651561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BB3cjit1GisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=244&issue=1&author=H.+Zhangauthor=S.+Savageauthor=A.+R.+Schultzauthor=D.+Bottomlyauthor=L.+Whiteauthor=E.+Segerdellauthor=B.+Wilmotauthor=S.+K.+McWeeneyauthor=C.+A.+Eideauthor=T.+Nechiporukauthor=A.+Carlosauthor=R.+Hensonauthor=C.+Linauthor=R.+Searlesauthor=H.+Hoauthor=Y.+L.+Lamauthor=R.+Sweatauthor=C.+Follitauthor=V.+Jainauthor=E.+Lindauthor=G.+Borthakurauthor=G.+Garcia-Maneroauthor=F.+Ravandiauthor=H.+M.+Kantarjianauthor=J.+Cortesauthor=R.+Collinsauthor=D.+R.+Buelowauthor=S.+D.+Bakerauthor=B.+J.+Drukerauthor=J.+W.+Tyner&title=Clinical+resistance+to+crenolanib+in+acute+myeloid+leukemia+due+to+diverse+molecular+mechanisms&doi=10.1038%2Fs41467-018-08263-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms</span></div><div class="casAuthors">Zhang Haijiao; Savage Samantha; Schultz Anna Reister; Nechiporuk Tamilla; Tyner Jeffrey W; Zhang Haijiao; Savage Samantha; Schultz Anna Reister; Eide Christopher A; Nechiporuk Tamilla; Druker Brian J; Tyner Jeffrey W; Bottomly Daniel; White Libbey; Segerdell Erik; Wilmot Beth; McWeeney Shannon K; Eide Christopher A; Druker Brian J; Carlos Amy; Henson Rachel; Lin Chenwei; Searles Robert; Ho Hoang; Lam Yee Ling; Sweat Richard; Follit Courtney; Jain Vinay; Lind Evan; Borthakur Gautam; Garcia-Manero Guillermo; Ravandi Farhad; Kantarjian Hagop M; Cortes Jorge; Collins Robert; Buelow Daelynn R; Baker Sharyn D</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">244</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">FLT3 mutations are prevalent in AML patients and confer poor prognosis.  Crenolanib, a potent type I pan-FLT3 inhibitor, is effective against both internal tandem duplications and resistance-conferring tyrosine kinase domain mutations.  While crenolanib monotherapy has demonstrated clinical benefit in heavily pretreated relapsed/refractory AML patients, responses are transient and relapse eventually occurs.  Here, to investigate the mechanisms of crenolanib resistance, we perform whole exome sequencing of AML patient samples before and after crenolanib treatment.  Unlike other FLT3 inhibitors, crenolanib does not induce FLT3 secondary mutations, and mutations of the FLT3 gatekeeper residue are infrequent.  Instead, mutations of NRAS and IDH2 arise, mostly as FLT3-independent subclones, while TET2 and IDH1 predominantly co-occur with FLT3-mutant clones and are enriched in crenolanib poor-responders.  The remaining patients exhibit post-crenolanib expansion of mutations associated with epigenetic regulators, transcription factors, and cohesion factors, suggesting diverse genetic/epigenetic mechanisms of crenolanib resistance.  Drug combinations in experimental models restore crenolanib sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1TvmXT9vLcb5oR8RchjrrfW6udTcc2eYE5OBe2eOWLrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjit1GisA%253D%253D&md5=8e3b63a5ef84182a0df6229bd5c99bc9</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-08263-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-08263-x%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSavage%26aufirst%3DS.%26aulast%3DSchultz%26aufirst%3DA.%2BR.%26aulast%3DBottomly%26aufirst%3DD.%26aulast%3DWhite%26aufirst%3DL.%26aulast%3DSegerdell%26aufirst%3DE.%26aulast%3DWilmot%26aufirst%3DB.%26aulast%3DMcWeeney%26aufirst%3DS.%2BK.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DNechiporuk%26aufirst%3DT.%26aulast%3DCarlos%26aufirst%3DA.%26aulast%3DHenson%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DSearles%26aufirst%3DR.%26aulast%3DHo%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DY.%2BL.%26aulast%3DSweat%26aufirst%3DR.%26aulast%3DFollit%26aufirst%3DC.%26aulast%3DJain%26aufirst%3DV.%26aulast%3DLind%26aufirst%3DE.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DBuelow%26aufirst%3DD.%2BR.%26aulast%3DBaker%26aufirst%3DS.%2BD.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26atitle%3DClinical%2520resistance%2520to%2520crenolanib%2520in%2520acute%2520myeloid%2520leukemia%2520due%2520to%2520diverse%2520molecular%2520mechanisms%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26issue%3D1%26spage%3D244%26doi%3D10.1038%2Fs41467-018-08263-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Puissant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenouille, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pikman, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassil, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazi, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luciano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronnstrand, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aster, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galinsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeAngelo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemann, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmaier, K.</span></span> <span> </span><span class="NLM_article-title">SYK is a critical regulator of FLT3 in acute myeloid leukemia</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">226</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2014.01.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.ccr.2014.01.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=24525236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitlCisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=226-242&issue=2&author=A.+Puissantauthor=N.+Fenouilleauthor=G.+Alexeauthor=Y.+Pikmanauthor=C.+F.+Bassilauthor=S.+Mehtaauthor=J.+Duauthor=J.+U.+Kaziauthor=F.+Lucianoauthor=L.+Ronnstrandauthor=A.+L.+Kungauthor=J.+C.+Asterauthor=I.+Galinskyauthor=R.+M.+Stoneauthor=D.+J.+DeAngeloauthor=M.+T.+Hemannauthor=K.+Stegmaier&title=SYK+is+a+critical+regulator+of+FLT3+in+acute+myeloid+leukemia&doi=10.1016%2Fj.ccr.2014.01.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia</span></div><div class="casAuthors">Puissant, Alexandre; Fenouille, Nina; Alexe, Gabriela; Pikman, Yana; Bassil, Christopher F.; Mehta, Swapnil; Du, Jinyan; Kazi, Julhash U.; Luciano, Frederic; Ronnstrand, Lars; Kung, Andrew L.; Aster, Jon C.; Galinsky, Ilene; Stone, Richard M.; De Angelo, Daniel J.; Hemann, Michael T.; Stegmaier, Kimberly</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">226-242</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Cooperative dependencies between mutant oncoproteins and wild-type proteins are crit. in cancer pathogenesis and therapy resistance.  Although spleen tyrosine kinase (SYK) has been implicated in hematol. malignancies, it is rarely mutated.  We used kinase activity profiling to identify collaborators of SYK in acute myeloid leukemia (AML) and detd. that FMS-like tyrosine kinase 3 (FLT3) is transactivated by SYK via direct binding.  Highly activated SYK is predominantly found in FLT3-ITD pos. AML and cooperates with FLT3-ITD to activate MYC transcriptional programs.  FLT3-ITD AML cells are more vulnerable to SYK suppression than FLT3 wild-type counterparts.  In a FLT3-ITD in vivo model, SYK is indispensable for myeloproliferative disease (MPD) development, and SYK overexpression promotes overt transformation to AML and resistance to FLT3-ITD-targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLCsPtJvlk9bVg90H21EOLACvtfcHk0lhNXGV5S1syZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitlCisrw%253D&md5=a529b289d6d920b2506df30c658b4d0e</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2014.01.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2014.01.022%26sid%3Dliteratum%253Aachs%26aulast%3DPuissant%26aufirst%3DA.%26aulast%3DFenouille%26aufirst%3DN.%26aulast%3DAlexe%26aufirst%3DG.%26aulast%3DPikman%26aufirst%3DY.%26aulast%3DBassil%26aufirst%3DC.%2BF.%26aulast%3DMehta%26aufirst%3DS.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DKazi%26aufirst%3DJ.%2BU.%26aulast%3DLuciano%26aufirst%3DF.%26aulast%3DRonnstrand%26aufirst%3DL.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DAster%26aufirst%3DJ.%2BC.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DHemann%26aufirst%3DM.%2BT.%26aulast%3DStegmaier%26aufirst%3DK.%26atitle%3DSYK%2520is%2520a%2520critical%2520regulator%2520of%2520FLT3%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D25%26issue%3D2%26spage%3D226%26epage%3D242%26doi%3D10.1016%2Fj.ccr.2014.01.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Green, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciel, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hospital, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazed, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilorge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paubelle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacquel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zylbersztejn, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decroocq, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulain, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sujobert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacque, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">So, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosmider, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auberger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermine, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstock, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacombe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayeux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanasse, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moura, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouscary, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamburini, J.</span></span> <span> </span><span class="NLM_article-title">Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia</span>. <i>Sci. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">e1500221</span>, <span class="refDoi"> DOI: 10.1126/sciadv.1500221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1126%2Fsciadv.1500221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=26601252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtl2itrnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=e1500221&issue=8&author=A.+S.+Greenauthor=T.+T.+Macielauthor=M.+A.+Hospitalauthor=C.+Yinauthor=F.+Mazedauthor=E.+C.+Townsendauthor=S.+Pilorgeauthor=M.+Lambertauthor=E.+Paubelleauthor=A.+Jacquelauthor=F.+Zylbersztejnauthor=J.+Decroocqauthor=L.+Poulainauthor=P.+Sujobertauthor=N.+Jacqueauthor=K.+Adamauthor=J.+C.+Soauthor=O.+Kosmiderauthor=P.+Aubergerauthor=O.+Hermineauthor=D.+M.+Weinstockauthor=C.+Lacombeauthor=P.+Mayeuxauthor=G.+J.+Vanasseauthor=A.+Y.+Leungauthor=I.+C.+Mouraauthor=D.+Bouscaryauthor=J.+Tamburini&title=Pim+kinases+modulate+resistance+to+FLT3+tyrosine+kinase+inhibitors+in+FLT3-ITD+acute+myeloid+leukemia&doi=10.1126%2Fsciadv.1500221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia</span></div><div class="casAuthors">Green, Alexa S.; Maciel, Thiago T.; Hospital, Marie-Anne; Yin, Chae; Mazed, Fetta; Townsend, Elizabeth C.; Pilorge, Sylvain; Lambert, Mireille; Paubelle, Etienne; Jacquel, Arnaud; Zylbersztejn, Florence; Decroocq, Justine; Poulain, Laury; Sujobert, Pierre; Jacque, Nathalie; Adam, Kevin; So, Jason C. C.; Kosmider, Olivier; Auberger, Patrick; Hermine, Olivier; Weinstock, David M.; Lacombe, Catherine; Mayeux, Patrick; Vanasse, Gary J.; Leung, Anskar Y.; Moura, Ivan C.; Bouscary, Didier; Tamburini, Jerome</div><div class="citationInfo"><span class="NLM_cas:title">Science Advances</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e1500221/1-e1500221/13</span>CODEN:
                <span class="NLM_cas:coden">SACDAF</span>;
        ISSN:<span class="NLM_cas:issn">2375-2548</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) is frequently detected in acute myeloid leukemia (AML) patients and is assocd. with a dismal long-term prognosis.  FLT3 tyrosine kinase inhibitors provide shortterm disease control, but relapse invariably occurs within months.  Pim protein kinases are oncogenic FLT3-ITD targets expressed in AML cells.  We show that increased Pim kinase expression is found in relapse samples from AML patients treated with FLT3 inhibitors.  Ectopic Pim-2 expression induces resistance to FLT3 inhibition in both FLT3- ITD-induced myeloproliferative neoplasm and AML models in mice.  Strikingly, we found that Pim kinases govern FLT3-ITD signaling and that their pharmacol. or genetic inhibition restores cell sensitivity to FLT3 inhibitors.  Finally, dual inhibition of FLT3 and Pimkinases eradicates FLT3-ITD+ cells including primary AML cells.  Concomitant Pim and FLT3 inhibition represents a promising new avenue for AML therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT6JcWV2N-6bVg90H21EOLACvtfcHk0lj92Kuaqh3TEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtl2itrnM&md5=16641fd4236f453104f40e6e80e20b13</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1126%2Fsciadv.1500221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciadv.1500221%26sid%3Dliteratum%253Aachs%26aulast%3DGreen%26aufirst%3DA.%2BS.%26aulast%3DMaciel%26aufirst%3DT.%2BT.%26aulast%3DHospital%26aufirst%3DM.%2BA.%26aulast%3DYin%26aufirst%3DC.%26aulast%3DMazed%26aufirst%3DF.%26aulast%3DTownsend%26aufirst%3DE.%2BC.%26aulast%3DPilorge%26aufirst%3DS.%26aulast%3DLambert%26aufirst%3DM.%26aulast%3DPaubelle%26aufirst%3DE.%26aulast%3DJacquel%26aufirst%3DA.%26aulast%3DZylbersztejn%26aufirst%3DF.%26aulast%3DDecroocq%26aufirst%3DJ.%26aulast%3DPoulain%26aufirst%3DL.%26aulast%3DSujobert%26aufirst%3DP.%26aulast%3DJacque%26aufirst%3DN.%26aulast%3DAdam%26aufirst%3DK.%26aulast%3DSo%26aufirst%3DJ.%2BC.%26aulast%3DKosmider%26aufirst%3DO.%26aulast%3DAuberger%26aufirst%3DP.%26aulast%3DHermine%26aufirst%3DO.%26aulast%3DWeinstock%26aufirst%3DD.%2BM.%26aulast%3DLacombe%26aufirst%3DC.%26aulast%3DMayeux%26aufirst%3DP.%26aulast%3DVanasse%26aufirst%3DG.%2BJ.%26aulast%3DLeung%26aufirst%3DA.%2BY.%26aulast%3DMoura%26aufirst%3DI.%2BC.%26aulast%3DBouscary%26aufirst%3DD.%26aulast%3DTamburini%26aufirst%3DJ.%26atitle%3DPim%2520kinases%2520modulate%2520resistance%2520to%2520FLT3%2520tyrosine%2520kinase%2520inhibitors%2520in%2520FLT3-ITD%2520acute%2520myeloid%2520leukemia%26jtitle%3DSci.%2520Adv.%26date%3D2015%26volume%3D1%26issue%3D8%26spage%3De1500221%26doi%3D10.1126%2Fsciadv.1500221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galkin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnett, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span> <span> </span><span class="NLM_article-title">FLT3 ligand impedes the efficacy of FLT3 inhibitors <i>in vitro</i> and <i>in vivo</i></span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>117</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3286</span>– <span class="NLM_lpage">3293</span>, <span class="refDoi"> DOI: 10.1182/blood-2010-01-266742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2010-01-266742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=21263155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslams70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=3286-3293&issue=12&author=T.+Satoauthor=X.+Yangauthor=S.+Knapperauthor=P.+Whiteauthor=B.+D.+Smithauthor=S.+Galkinauthor=D.+Smallauthor=A.+Burnettauthor=M.+Levis&title=FLT3+ligand+impedes+the+efficacy+of+FLT3+inhibitors+in+vitro+and+in+vivo&doi=10.1182%2Fblood-2010-01-266742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo</span></div><div class="casAuthors">Sato, Takashi; Yang, Xiaochuan; Knapper, Steven; White, Paul; Smith, B. Douglas; Galkin, Steven; Small, Donald; Burnett, Alan; Levis, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3286-3293</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">We examd. in vivo FLT3 inhibition in acute myeloid leukemia patients treated with chemotherapy followed by the FLT3 inhibitor lestaurtinib, comparing newly diagnosed acute myeloid leukemia patients with relapsed patients.  Because we noted that in vivo FLT3 inhibition by lestaurtinib was less effective in the relapsed patients compared with the newly diagnosed patients, we investigated whether plasma FLT3 ligand (FL) levels could influence the efficacy of FLT3 inhibition in these patients.  After intensive chemotherapy, FL levels rose to a mean of 488 pg/mL on day 15 of induction therapy for newly diagnosed patients, whereas they rose to a mean of 1148 pg/mL in the relapsed patients.  FL levels rose even higher with successive courses of chemotherapy, to a mean of 3251 pg/mL after the fourth course.  In vitro, exogenous FL at concns. similar to those obsd. in patients mitigated FLT3 inhibition and cytotoxicity for each of 5 different FLT3 inhibitors (lestaurtinib, midostaurin, sorafenib, KW-2449, and AC220).  The dramatic increase in FL level after chemotherapy represents a possible obstacle to inhibiting FLT3 in this clin. setting.  These findings could have important implications regarding the design and outcome of trials of FLT3 inhibitors and furthermore suggest a rationale for targeting FL as a therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZGxLbAzmoObVg90H21EOLACvtfcHk0lj92Kuaqh3TEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslams70%253D&md5=0cc4092386152ccdafb174772165e5a9</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-01-266742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-01-266742%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DKnapper%26aufirst%3DS.%26aulast%3DWhite%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DGalkin%26aufirst%3DS.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DBurnett%26aufirst%3DA.%26aulast%3DLevis%26aufirst%3DM.%26atitle%3DFLT3%2520ligand%2520impedes%2520the%2520efficacy%2520of%2520FLT3%2520inhibitors%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26issue%3D12%26spage%3D3286%26epage%3D3293%26doi%3D10.1182%2Fblood-2010-01-266742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daley, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galinsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N.</span></span> <span> </span><span class="NLM_article-title">Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2233</span>– <span class="NLM_lpage">2244</span>, <span class="refDoi"> DOI: 10.1038/leu.2012.96</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fleu.2012.96" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=22469781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSgurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=2233-2244&issue=10&author=E.+Weisbergauthor=Q.+Liuauthor=E.+Nelsonauthor=A.+L.+Kungauthor=A.+L.+Christieauthor=R.+Bronsonauthor=M.+Sattlerauthor=T.+Sandaauthor=Z.+Zhaoauthor=W.+Hurauthor=C.+Mitsiadesauthor=R.+Smithauthor=J.+F.+Daleyauthor=R.+Stoneauthor=I.+Galinskyauthor=J.+D.+Griffinauthor=N.+Gray&title=Using+combination+therapy+to+override+stromal-mediated+chemoresistance+in+mutant+FLT3-positive+AML%3A+synergism+between+FLT3+inhibitors%2C+dasatinib%2Fmulti-targeted+inhibitors+and+JAK+inhibitors&doi=10.1038%2Fleu.2012.96"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors</span></div><div class="casAuthors">Weisberg, E.; Liu, Q.; Nelson, Erik; Kung, A. L.; Christie, A. L.; Bronson, R.; Sattler, M.; Sanda, T.; Zhao, Z.; Hur, W.; Mitsiades, C.; Smith, R.; Daley, J. F.; Stone, R.; Galinsky, I.; Griffin, J. D.; Gray, N.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2233-2244</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) progenitors are frequently characterized by activating mutations in the receptor tyrosine kinase Fms-like tyrosine kinase-3 (FLT3).  Protein tyrosine kinases are integral components of signaling cascades that have a role in both FLT3-mediated transformation as well as viability pathways that are advantageous to leukemic cell survival.  The bone marrow microenvironment can diminish AML sensitivity to tyrosine kinase inhibitors.  We hypothesized that inhibition of protein kinases in addn. to FLT3 may be effective in overriding drug resistance in AML.  We used a cell-based model mimicking stromal protection as part of an unbiased high-throughput chem. screen to identify kinase inhibitors with the potential to override microenvironment-mediated drug resistance in mutant FLT3-pos. AML.  Several related multi-targeted kinase inhibitors, including dasatinib, with the capability of reversing microenvironment-induced resistance to FLT3 inhibition were identified and validated.  We validated synergy in vitro and demonstrated effective combination potential in vivo.  In particular Janus kinase inhibitors were effective in overriding stromal protection and potentiating FLT3 inhibition in primary AML and cell lines.  These results hint at a novel concept of using combination therapy to override drug resistance in mutant FLT3-pos. AML in the bone marrow niche and suppress or eradicate residual disease.  Leukemia (2012) 26, 2233-2244; doi:10.1038/leu.2012.96; published online 1 May 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr06E1HAXSPQrVg90H21EOLACvtfcHk0lj92Kuaqh3TEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSgurfN&md5=8bb4fcb2f4d911f1c32057b94d450419</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fleu.2012.96&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2012.96%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DNelson%26aufirst%3DE.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DChristie%26aufirst%3DA.%2BL.%26aulast%3DBronson%26aufirst%3DR.%26aulast%3DSattler%26aufirst%3DM.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DMitsiades%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DDaley%26aufirst%3DJ.%2BF.%26aulast%3DStone%26aufirst%3DR.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DGray%26aufirst%3DN.%26atitle%3DUsing%2520combination%2520therapy%2520to%2520override%2520stromal-mediated%2520chemoresistance%2520in%2520mutant%2520FLT3-positive%2520AML%253A%2520synergism%2520between%2520FLT3%2520inhibitors%252C%2520dasatinib%252Fmulti-targeted%2520inhibitors%2520and%2520JAK%2520inhibitors%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26issue%3D10%26spage%3D2233%26epage%3D2244%26doi%3D10.1038%2Fleu.2012.96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundy-Bosse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitman, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bearss, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligiuri, M. A.</span></span> <span> </span><span class="NLM_article-title">Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2382</span>– <span class="NLM_lpage">2389</span>, <span class="refDoi"> DOI: 10.1038/leu.2015.147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fleu.2015.147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=26172401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOisrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=2382-2389&issue=12&author=I.+K.+Parkauthor=B.+Mundy-Bosseauthor=S.+P.+Whitmanauthor=X.+Zhangauthor=S.+L.+Warnerauthor=D.+J.+Bearssauthor=W.+Blumauthor=G.+Marcucciauthor=M.+A.+Caligiuri&title=Receptor+tyrosine+kinase+Axl+is+required+for+resistance+of+leukemic+cells+to+FLT3-targeted+therapy+in+acute+myeloid+leukemia&doi=10.1038%2Fleu.2015.147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia</span></div><div class="casAuthors">Park, I.-K.; Mundy-Bosse, B.; Whitman, S. P.; Zhang, X.; Warner, S. L.; Bearss, D. J.; Blum, W.; Marcucci, G.; Caligiuri, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2382-2389</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In acute myeloid leukemia (AML), about 25-30% of patients harbor a constitutively active receptor tyrosine kinase (RTK) FLT3 encoded by a FLT3 allele harboring internal tandem duplication (FLT3-ITD) mutation.  The presence of FLT3-ITD correlates with poor prognosis in AML and it makes FLT3 an attractive therapeutic target in AML.  Unfortunately, to date small-mol. inhibitors of FLT3 have resulted in only partial and transient clin. responses with residual leukemic blasts resistant to FLT3 inhibitors detected in blood or bone marrow.  In this study, we investigated whether the RTK Axl is responsible for resistance of FLT3-ITD+ AML cells to PKC412 and AC220, FLT3 inhibitors currently under clin. trials for FLT3-ITD+ AML patients.  Upon treatment with PKC412 or AC220, phosphorylation of Axl was significantly enhanced in the FLT3-ITD+ MV4-11 AML cell line and in primary blasts from a FLT3-ITD+ AML patient.  Consistently, a PKC412-resistant AML cell line and PKC412-resistant primary blasts from FLT3-ITD+ AML patients had significantly higher levels of constitutively phosphorylated Axl and total Axl when compared with a PKC412-sensitive AML cell line and PKC412-sensitive primary blasts from FLT3-ITD+ AML patients.  We also found that resistance of AML cells against the FLT3 inhibitor PKC412 and AC220 was substantially diminished by the inhibition of Axl via a small-mol. inhibitor TP-0903, a sol. receptor Axl fusion protein Axl-Fc or knockdown of Axl gene expression by shRNA.  Collectively, our study suggests that Axl is required for resistance of FLT3-ITD+ AML cells against the FLT3 inhibitor PKC412 and AC220, and that inhibition of Axl activation may overcome resistance to FLT3-targeted therapy in FLT3-ITD+ AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeDvBUXvGLubVg90H21EOLACvtfcHk0lhtvhSBdmO0wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOisrvI&md5=a9f83832544a12ccdb85215e9e26cabc</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.147%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DI.%2BK.%26aulast%3DMundy-Bosse%26aufirst%3DB.%26aulast%3DWhitman%26aufirst%3DS.%2BP.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26aulast%3DBlum%26aufirst%3DW.%26aulast%3DMarcucci%26aufirst%3DG.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26atitle%3DReceptor%2520tyrosine%2520kinase%2520Axl%2520is%2520required%2520for%2520resistance%2520of%2520leukemic%2520cells%2520to%2520FLT3-targeted%2520therapy%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2015%26volume%3D29%26issue%3D12%26spage%3D2382%26epage%3D2389%26doi%3D10.1038%2Fleu.2015.147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erba, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baccarani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cripe, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meloni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godley, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amadori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiktor-Jedrzejczak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juliusson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litzow, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersdorf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremmel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bensen-Kennedy, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. D.</span></span> <span> </span><span class="NLM_article-title">Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>117</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3294</span>– <span class="NLM_lpage">3301</span>, <span class="refDoi"> DOI: 10.1182/blood-2010-08-301796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2010-08-301796" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=21270442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslams7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=3294-3301&issue=12&author=M.+Levisauthor=F.+Ravandiauthor=E.+S.+Wangauthor=M.+R.+Baerauthor=A.+Perlauthor=S.+Coutreauthor=H.+Erbaauthor=R.+K.+Stuartauthor=M.+Baccaraniauthor=L.+D.+Cripeauthor=M.+S.+Tallmanauthor=G.+Meloniauthor=L.+A.+Godleyauthor=A.+A.+Langstonauthor=S.+Amadoriauthor=I.+D.+Lewisauthor=A.+Naglerauthor=R.+Stoneauthor=K.+Yeeauthor=A.+Advaniauthor=D.+Douerauthor=W.+Wiktor-Jedrzejczakauthor=G.+Juliussonauthor=M.+R.+Litzowauthor=S.+Petersdorfauthor=M.+Sanzauthor=H.+M.+Kantarjianauthor=T.+Satoauthor=L.+Tremmelauthor=D.+M.+Bensen-Kennedyauthor=D.+Smallauthor=B.+D.+Smith&title=Results+from+a+randomized+trial+of+salvage+chemotherapy+followed+by+lestaurtinib+for+patients+with+FLT3+mutant+AML+in+first+relapse&doi=10.1182%2Fblood-2010-08-301796"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse</span></div><div class="casAuthors">Levis, Mark; Ravandi, Farhad; Wang, Eunice S.; Baer, Maria R.; Perl, Alexander; Coutre, Steven; Erba, Harry; Stuart, Robert K.; Baccarani, Michele; Cripe, Larry D.; Tallman, Martin S.; Meloni, Giovanna; Godley, Lucy A.; Langston, Amelia A.; Amadori, Sergio; Lewis, Ian D.; Nagler, Arnon; Stone, Richard; Yee, Karen; Advani, Anjali; Douer, Dan; Wiktor-Jedrzejczak, W.; Juliusson, Gunnar; Litzow, Mark R.; Petersdorf, Stephen; Sanz, Miguel; Kantarjian, Hagop M.; Sato, Takashi; Tremmel, Lothar; Bensen-Kennedy, Debra M.; Small, Donald; Smith, B. Douglas</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3294-3301</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">In a randomized trial of therapy for FMS-like tyrosine kinase-3 (FLT3) mutant acute myeloid leukemia in first relapse, 224 patients received chemotherapy alone or followed by 80 mg of the FLT3 inhibitor lestaurtinib twice daily.  Endpoints included complete remission or complete remission with incomplete platelet recovery (CR/CRp), overall survival, safety, and tolerability.  Correlative studies included pharmacokinetics and anal. of in vivo FLT3 inhibition.  There were 29 patients with CR/CRp in the lestaurtinib arm and 23 in the control arm (26% vs 21%; P = .35), and no difference in overall survival between the 2 arms.  There was evidence of toxicity in the lestaurtinib-treated patients, particularly those with plasma levels in excess of 20μM.  In the lestaurtinib arm, FLT3 inhibition was highly correlated with remission rate, but target inhibition on day 15 was achieved in only 58% of patients receiving lestaurtinib.  Given that such a small proportion of patients on this trial achieved sustained FLT3 inhibition in vivo, any conclusions regarding the efficacy of combining FLT3 inhibition with chemotherapy are limited.  Overall, lestaurtinib treatment after chemotherapy did not increase response rates or prolong survival of patients with FLT3 mutant acute myeloid leukemia in first relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNtYr30842srVg90H21EOLACvtfcHk0lhtvhSBdmO0wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslams7o%253D&md5=7e3647298bb0ee66ac72786f103d8f3b</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-08-301796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-08-301796%26sid%3Dliteratum%253Aachs%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DE.%2BS.%26aulast%3DBaer%26aufirst%3DM.%2BR.%26aulast%3DPerl%26aufirst%3DA.%26aulast%3DCoutre%26aufirst%3DS.%26aulast%3DErba%26aufirst%3DH.%26aulast%3DStuart%26aufirst%3DR.%2BK.%26aulast%3DBaccarani%26aufirst%3DM.%26aulast%3DCripe%26aufirst%3DL.%2BD.%26aulast%3DTallman%26aufirst%3DM.%2BS.%26aulast%3DMeloni%26aufirst%3DG.%26aulast%3DGodley%26aufirst%3DL.%2BA.%26aulast%3DLangston%26aufirst%3DA.%2BA.%26aulast%3DAmadori%26aufirst%3DS.%26aulast%3DLewis%26aufirst%3DI.%2BD.%26aulast%3DNagler%26aufirst%3DA.%26aulast%3DStone%26aufirst%3DR.%26aulast%3DYee%26aufirst%3DK.%26aulast%3DAdvani%26aufirst%3DA.%26aulast%3DDouer%26aufirst%3DD.%26aulast%3DWiktor-Jedrzejczak%26aufirst%3DW.%26aulast%3DJuliusson%26aufirst%3DG.%26aulast%3DLitzow%26aufirst%3DM.%2BR.%26aulast%3DPetersdorf%26aufirst%3DS.%26aulast%3DSanz%26aufirst%3DM.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DSato%26aufirst%3DT.%26aulast%3DTremmel%26aufirst%3DL.%26aulast%3DBensen-Kennedy%26aufirst%3DD.%2BM.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26atitle%3DResults%2520from%2520a%2520randomized%2520trial%2520of%2520salvage%2520chemotherapy%2520followed%2520by%2520lestaurtinib%2520for%2520patients%2520with%2520FLT3%2520mutant%2520AML%2520in%2520first%2520relapse%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26issue%3D12%26spage%3D3294%26epage%3D3301%26doi%3D10.1182%2Fblood-2010-08-301796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyoi, H.</span></span> <span> </span><span class="NLM_article-title">Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">30</span>),  <span class="NLM_fpage">47018</span>– <span class="NLM_lpage">47032</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.10147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.18632%2Foncotarget.10147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=27331411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BC2s7isFKhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=47018-47032&issue=30&author=F.+Chenauthor=Y.+Ishikawaauthor=A.+Akashiauthor=T.+Naoeauthor=H.+Kiyoi&title=Co-expression+of+wild-type+FLT3+attenuates+the+inhibitory+effect+of+FLT3+inhibitor+on+FLT3+mutated+leukemia+cells&doi=10.18632%2Foncotarget.10147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells</span></div><div class="casAuthors">Chen Fangli; Ishikawa Yuichi; Akashi Akimi; Kiyoi Hitoshi; Naoe Tomoki</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">47018-47032</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">FLT3 mutation is found in about 30% of acute myeloid leukemia (AML) patients and is associated with a poor prognosis.  Several FLT3 inhibitors are undergoing investigation, while their clinical efficacies were lower than expected and several resistant mechanisms to FLT3 inhibitors have been demonstrated.  Although most AML cells harboring FLT3 mutation co-express wild-type (Wt)-FLT3, it is not fully understood how Wt-FLT3 expression is associated with the resistance to FLT3 inhibitors.  In this study, we elucidated a resistant mechanism by which FL-dependent Wt-FLT3 activation reduced inhibitory effects of FLT3 inhibitors.  We demonstrated that FL-stimulation much more strongly reduced growth inhibitory effects of FLT3 inhibitors on Wt- and mutant-FLT3 co-expressing cells than sole mutant-FLT3 expressing cells both in vitro and in vivo.  It was also confirmed that FL impaired the anti-leukemia effects of FLT3 inhibitors on primary AML cells.  We elucidated that FL impeded the inhibitory effects of FLT3 inhibitors mainly through the activation of Wt-FLT3, but not mutated FLT3, in the Wt- and ITD-FLT3 co-expressing cells.  Furthermore, FL-induced activation of Wt-FLT3-MAPK axis was the dominant pathway for the resistance, and the glycosylation of Wt-FLT3 was also vital for FL-dependent kinase activation and following resistance to FLT3 inhibitors.  Thus, we clarified the importance of co-expressing Wt-FLT3 in resistance to FLT3 inhibitors.  These findings provide us with important implications for clinical application and new strategies to improve clinical outcomes of FLT3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRyBiRvpDlPv_SAs_PE1QvifW6udTcc2eYGYvU1XYiWnrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7isFKhtQ%253D%253D&md5=95b7de22ecd33946cb95e4b22f68fe78</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.10147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.10147%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DF.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAkashi%26aufirst%3DA.%26aulast%3DNaoe%26aufirst%3DT.%26aulast%3DKiyoi%26aufirst%3DH.%26atitle%3DCo-expression%2520of%2520wild-type%2520FLT3%2520attenuates%2520the%2520inhibitory%2520effect%2520of%2520FLT3%2520inhibitor%2520on%2520FLT3%2520mutated%2520leukemia%2520cells%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26issue%3D30%26spage%3D47018%26epage%3D47032%26doi%3D10.18632%2Foncotarget.10147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Traer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javidi-Sharifi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunlap, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">English, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacsovics, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span> <span> </span><span class="NLM_article-title">FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">6471</span>– <span class="NLM_lpage">6482</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-3569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F0008-5472.CAN-15-3569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=27671675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVCjt7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=6471-6482&issue=22&author=E.+Traerauthor=J.+Martinezauthor=N.+Javidi-Sharifiauthor=A.+Agarwalauthor=J.+Dunlapauthor=I.+Englishauthor=T.+Kovacsovicsauthor=J.+W.+Tynerauthor=M.+Wongauthor=B.+J.+Druker&title=FGF2+from+marrow+microenvironment+promotes+resistance+to+FLT3+inhibitors+in+acute+myeloid+leukemia&doi=10.1158%2F0008-5472.CAN-15-3569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia</span></div><div class="casAuthors">Traer, Elie; Martinez, Jacqueline; Javidi-Sharifi, Nathalie; Agarwal, Anupriya; Dunlap, Jennifer; English, Isabel; Kovacsovics, Tibor; Tyner, Jeffrey W.; Wong, Melissa; Druker, Brian J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6471-6482</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Potent FLT3 inhibitors, such as quizartinib (AC220), have shown promise in treating acute myeloid leukemia (AML) contg. FLT3 internal tandem duplication (ITD) mutations.  However, responses are not durable and resistance develops within months.  In this study, we outline a two-step model of resistance whereby extrinsic microenvironmental proteins FLT3 ligand (FL) and fibroblast growth factor 2 (FGF2) protect FLT3-ITD+ MOLM14 cells from AC220, providing time for subsequent accumulation of ligand-independent resistance mechanisms.  FL directly attenuated AC220 inhibition of FLT3, consistent with previous reports.  Conversely, FGF2 promoted resistance through activation of FGFR1 and downstream MAPK effectors; these resistant cells responded synergistically to combinatorial inhibition of FGFR1 and FLT3.  Removing FL or FGF2 from ligand-dependent resistant cultures transiently restored sensitivity to AC220, but accelerated acquisition of secondary resistance via reactivation of FLT3 and RAS/MAPK signaling.  FLT3-ITD AML patients treated with AC220 developed increased FGF2 expression in marrow stromal cells, which peaked prior to overt clin. relapse and detection of resistance mutations.  Overall, these results support a strategy of early combination therapy to target early survival signals from the bone marrow microenvironment, in particular FGF2, to improve the depth of response in FLT3-ITD AML.  Cancer Res; 76(22); 6471-82. cpr2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW1JQ4QAjsZbVg90H21EOLACvtfcHk0lhK9ddLe1zW5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVCjt7rE&md5=ad8ad0fc77302b1d31d5927e25c51604</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-3569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-3569%26sid%3Dliteratum%253Aachs%26aulast%3DTraer%26aufirst%3DE.%26aulast%3DMartinez%26aufirst%3DJ.%26aulast%3DJavidi-Sharifi%26aufirst%3DN.%26aulast%3DAgarwal%26aufirst%3DA.%26aulast%3DDunlap%26aufirst%3DJ.%26aulast%3DEnglish%26aufirst%3DI.%26aulast%3DKovacsovics%26aufirst%3DT.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DWong%26aufirst%3DM.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DFGF2%2520from%2520marrow%2520microenvironment%2520promotes%2520resistance%2520to%2520FLT3%2520inhibitors%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26issue%3D22%26spage%3D6471%26epage%3D6482%26doi%3D10.1158%2F0008-5472.CAN-15-3569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. J.</span></span> <span> </span><span class="NLM_article-title">Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors</span>. <i>Blood Adv.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">908</span>– <span class="NLM_lpage">916</span>, <span class="refDoi"> DOI: 10.1182/bloodadvances.2018022921</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fbloodadvances.2018022921" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=30898762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1ahs7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2019&pages=908-916&issue=6&author=Y.+T.+Changauthor=D.+Hernandezauthor=S.+Alonsoauthor=M.+Gaoauthor=M.+Suauthor=G.+Ghiaurauthor=M.+J.+Levisauthor=R.+J.+Jones&title=Role+of+CYP3A4+in+bone+marrow+microenvironment-mediated+protection+of+FLT3%2FITD+AML+from+tyrosine+kinase+inhibitors&doi=10.1182%2Fbloodadvances.2018022921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors</span></div><div class="casAuthors">Chang, Yu-Ting; Hernandez, Daniela; Alonso, Salvador; Gao, Minling; Su, Meng; Ghiaur, Gabriel; Levis, Mark J.; Jones, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">Blood Advances</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">908-916</span>CODEN:
                <span class="NLM_cas:coden">BALDBA</span>;
        ISSN:<span class="NLM_cas:issn">2473-9537</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">An intriguing aspect of the clin. activity of FMS-like tyrosine kinase 3 inhibitors (FLT3 TKIs) is their apparent higher activity against peripheral blasts from FLT3/internal tandem duplication (ITD) acute myeloid leukemia than marrow disease in the same patients.  Accordingly, studies showed that the bone marrow microenvironment plays a role in FLT3 TKI resistance, although the underlying mechanisms are unclear.  We recently identified a previously undescribed mechanism by which the bone marrow microenvironment can contribute to drug resistance: expression of cytochrome P 450 enzymes (CYPs).  In fact, bone marrow stromal cells (BMSCs) expressed most CYPs, including CYP3A4.  Because hepatic CYP3A4 plays a role in the inactivation of several FLT3 TKIs, we explored the potential role of CYP3A4 in bone marrow microenvironment-mediated FLT3 TKI resistance.  We found that CYP3A4 plays a major role in BMSC-mediated inhibition in the activity of 3 different FLT3 TKIs (sorafenib, quizartinib, and gilteritinib) against FLT3/ITD acute myeloid leukemia (AML).  Furthermore, clarithromycin, a clin. active CYP3A4 inhibitor, significantly reversed the protective effects of BMSCs.  We show, for the first time, that bone marrow stromal CYP3A4 contributes to FLT3 TKI resistance in the bone marrow.  These results suggest that combining FLT3 TKIs with CYP3A4 inhibitors could be a promising strategy toward improving the activity of FLT3 TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiUvvLQPJXqrVg90H21EOLACvtfcHk0lhLUL6bGUJufw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1ahs7%252FM&md5=b6e068417dec6eaa20321697024c31fe</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1182%2Fbloodadvances.2018022921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fbloodadvances.2018022921%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DY.%2BT.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DAlonso%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DGhiaur%26aufirst%3DG.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DJones%26aufirst%3DR.%2BJ.%26atitle%3DRole%2520of%2520CYP3A4%2520in%2520bone%2520marrow%2520microenvironment-mediated%2520protection%2520of%2520FLT3%252FITD%2520AML%2520from%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBlood%2520Adv.%26date%3D2019%26volume%3D3%26issue%3D6%26spage%3D908%26epage%3D916%26doi%3D10.1182%2Fbloodadvances.2018022921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, W.</span></span> <span> </span><span class="NLM_article-title">MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">913</span>– <span class="NLM_lpage">921</span>, <span class="refDoi"> DOI: 10.1038/leu.2016.297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fleu.2016.297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=27773927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCjt7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=913-921&issue=4&author=B.+Xuauthor=Y.+Zhaoauthor=X.+Wangauthor=P.+Gongauthor=W.+Ge&title=MZH29+is+a+novel+potent+inhibitor+that+overcomes+drug+resistance+FLT3+mutations+in+acute+myeloid+leukemia&doi=10.1038%2Fleu.2016.297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia</span></div><div class="casAuthors">Xu, B.; Zhao, Y.; Wang, X.; Gong, P.; Ge, W.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">913-921</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">More than one-third of patients with acute myeloid leukemia (AML) harbor aberrant mutations in Fms-like tyrosine kinase 3 (FLT3).  Among them, the internal tandem duplication (ITD) mutation predicts poor prognosis.  MZH29 is a novel FLT3 inhibitor synthesized in our lab. that showed that cellular and kinase assays sustained inhibitory effects on wild-type and mutant FLT3, including the FLT3-ITD, FLT3-D835H/Y/V and FLT3-K663Q mutants.  More importantly, MZH29 retained its potent inhibitory effect against the FLT3-ITD/F691L mutation, a drug resistance mutation against the well-known FLT3 inhibitor, AC220.  MZH29 is a type II FLT3 inhibitor that tolerated the F691L mutation in mol. docking studies.  Oral administration of 10 mg/kg MZH29 caused complete tumor regression and extended survival in a mouse model of AML with less toxicity.  Subsequent proteomics study revealed less proteome perturbation in the MZH29-treated group than in the AC220-treated group.  MZH29 demonstrates potential and potent novel FLT3 inhibitory effects for the treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqypie-S2V6M7Vg90H21EOLACvtfcHk0lhLUL6bGUJufw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCjt7fI&md5=76a4ff225ff13fc14e810826e75572fc</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1038%2Fleu.2016.297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2016.297%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DGe%26aufirst%3DW.%26atitle%3DMZH29%2520is%2520a%2520novel%2520potent%2520inhibitor%2520that%2520overcomes%2520drug%2520resistance%2520FLT3%2520mutations%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2017%26volume%3D31%26issue%3D4%26spage%3D913%26epage%3D921%26doi%3D10.1038%2Fleu.2016.297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fathi, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blonquist, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amrein, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballen, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMasters, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avigan, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobbs, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behnan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Som, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rae, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishman, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuberg, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span> <span> </span><span class="NLM_article-title">Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>124</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">306</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1002/cncr.31038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1002%2Fcncr.31038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=28960265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1Wgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2018&pages=306-314&issue=2&author=A.+T.+Fathiauthor=T.+M.+Blonquistauthor=D.+Hernandezauthor=P.+C.+Amreinauthor=K.+K.+Ballenauthor=M.+McMastersauthor=D.+E.+Aviganauthor=R.+Joyceauthor=E.+K.+Loganauthor=G.+Hobbsauthor=A.+M.+Brunnerauthor=C.+Josephauthor=A.+M.+Perryauthor=M.+Burkeauthor=T.+Behnanauthor=J.+Fosterauthor=M.+K.+Bergeronauthor=J.+A.+Moranauthor=A.+Y.+Ramosauthor=T.+T.+Somauthor=J.+Raeauthor=K.+M.+Fishmanauthor=K.+L.+McGregorauthor=C.+Connollyauthor=D.+S.+Neubergauthor=M.+J.+Levis&title=Cabozantinib+is+well+tolerated+in+acute+myeloid+leukemia+and+effectively+inhibits+the+resistance-conferring+FLT3%2Ftyrosine+kinase+domain%2FF691+mutation&doi=10.1002%2Fcncr.31038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation</span></div><div class="casAuthors">Fathi, Amir T.; Blonquist, Traci M.; Hernandez, Daniela; Amrein, Philip C.; Ballen, Karen K.; McMasters, Malgorzata; Avigan, David E.; Joyce, Robin; Logan, Emma K.; Hobbs, Gabriela; Brunner, Andrew M.; Joseph, Christelle; Perry, Ashley M.; Burke, Meghan; Behnan, Tanya; Foster, Julia; Bergeron, Meghan K.; Moran, Jenna A.; Ramos, Aura Y.; Som, Tina T.; Rae, Jessica; Fishman, Kaitlyn M.; McGregor, Kristin L.; Connolly, Christine; Neuberg, Donna S.; Levis, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">306-314</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND : Cabozantinib, a tyrosine kinase inhibitor of FMS-like tyrosine kinase 3 (FLT3), MET, AXL, vascular endothelial growth factor receptor, and KIT, is approved for use in multiple malignancies.  We assessed the safety and tolerability of cabozantinib in AML, given up-regulation of multiple relevant pathways.  METHODS : Adults were eligible if they were 18 years old or older with relapsed/refractory AML or if they were 70 years old or older with newly diagnosed AML but were ineligible for conventional therapy.  Cabozantinib was administered in 28-day cycles, and dose escalation occurred via cohorts.  A pharmacodynamic evaluation of serial plasma samples via a plasma inhibitory assay (PIA) was used to assess FLT3-inhibitory activity in FLT3-mutant cell lines.  RESULTS : Among 18 patients enrolled, 5 were found to harbor FLT3/ITD mutations.  Sixteen patients (89%) had relapsed/refractory AML, and most were treated with 2 or more lines of prior treatment.  No dose-limiting toxicities (DLTs) were detected at the first dose level (40 mg daily), but 2 patients experienced DLTs at the next level (60 mg daily).  The remaining patients were then dosed at 40 mg daily, the max. tolerated dose (MTD).  Addnl. grade 2 or higher toxicities, possibly/probably related to cabozantinib, included fatigue, nausea, transaminitis, and electrolyte imbalance.  No patients had a marrow response according to formal criteria, but 4 had peripheral blast redns.; 2 of these 4 patients transiently cleared circulating blasts.  One patient experienced a redn. in marrow blasts, and 1 had stable disease.  The FLT3-inhibitory activity of plasma samples, as assessed with the PIA, revealed potent and sustained inhibition in FLT3/ITD and, notably, F691 tyrosine kinase domain (TKD)-mutant cells.  CONCLUSIONS : Cabozantinib is well tolerated in AML patients at an MTD of 40 mg daily and is a potent inhibitor of FLT3/ITD- and F691 TKD-altered tyrosine kinases.  Cancer 2018;124:306-14. © 2017 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF-_oxC3SsXbVg90H21EOLACvtfcHk0lhYOigVdYr6lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1Wgsg%253D%253D&md5=ad24e48ef3222951bc1c8e3d445b4b8f</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2Fcncr.31038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.31038%26sid%3Dliteratum%253Aachs%26aulast%3DFathi%26aufirst%3DA.%2BT.%26aulast%3DBlonquist%26aufirst%3DT.%2BM.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DAmrein%26aufirst%3DP.%2BC.%26aulast%3DBallen%26aufirst%3DK.%2BK.%26aulast%3DMcMasters%26aufirst%3DM.%26aulast%3DAvigan%26aufirst%3DD.%2BE.%26aulast%3DJoyce%26aufirst%3DR.%26aulast%3DLogan%26aufirst%3DE.%2BK.%26aulast%3DHobbs%26aufirst%3DG.%26aulast%3DBrunner%26aufirst%3DA.%2BM.%26aulast%3DJoseph%26aufirst%3DC.%26aulast%3DPerry%26aufirst%3DA.%2BM.%26aulast%3DBurke%26aufirst%3DM.%26aulast%3DBehnan%26aufirst%3DT.%26aulast%3DFoster%26aufirst%3DJ.%26aulast%3DBergeron%26aufirst%3DM.%2BK.%26aulast%3DMoran%26aufirst%3DJ.%2BA.%26aulast%3DRamos%26aufirst%3DA.%2BY.%26aulast%3DSom%26aufirst%3DT.%2BT.%26aulast%3DRae%26aufirst%3DJ.%26aulast%3DFishman%26aufirst%3DK.%2BM.%26aulast%3DMcGregor%26aufirst%3DK.%2BL.%26aulast%3DConnolly%26aufirst%3DC.%26aulast%3DNeuberg%26aufirst%3DD.%2BS.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26atitle%3DCabozantinib%2520is%2520well%2520tolerated%2520in%2520acute%2520myeloid%2520leukemia%2520and%2520effectively%2520inhibits%2520the%2520resistance-conferring%2520FLT3%252Ftyrosine%2520kinase%2520domain%252FF691%2520mutation%26jtitle%3DCancer%26date%3D2018%26volume%3D124%26issue%3D2%26spage%3D306%26epage%3D314%26doi%3D10.1002%2Fcncr.31038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3–122) as a potent and orally available FLT3 kinase inhibitor for FLT3-ITD positive acute myeloid leukemia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">9625</span>– <span class="NLM_lpage">9638</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01611</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01611" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGnsL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9625-9638&issue=24&author=X.+Liauthor=A.+Wangauthor=K.+Yuauthor=Z.+Qiauthor=C.+Chenauthor=W.+Wangauthor=C.+Huauthor=H.+Wuauthor=J.+Wuauthor=Z.+Zhaoauthor=J.+Liuauthor=F.+Zouauthor=L.+Wangauthor=B.+Wangauthor=W.+Wangauthor=S.+Zhangauthor=J.+Liuauthor=Q.+Liu&title=Discovery+of+%28R%29-1-%283-%284-amino-3-%284-phenoxyphenyl%29-1H-pyrazolo%5B3%2C4-d%5Dpyrimidin-1-yl%29piperidin-1-yl%29-2-%28dimethylamino%29ethanone+%28CHMFL-FLT3%E2%80%93122%29+as+a+potent+and+orally+available+FLT3+kinase+inhibitor+for+FLT3-ITD+positive+acute+myeloid+leukemia&doi=10.1021%2Facs.jmedchem.5b01611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia</span></div><div class="casAuthors">Li, Xixiang; Wang, Aoli; Yu, Kailin; Qi, Ziping; Chen, Cheng; Wang, Wenchao; Hu, Chen; Wu, Hong; Wu, Jiaxin; Zhao, Zheng; Liu, Juan; Zou, Fengming; Wang, Li; Wang, Beilei; Wang, Wei; Zhang, Shanchun; Liu, Jing; Liu, Qingsong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9625-9638</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">FLT3-ITD mutant has been obsd. in about 30% of AML patients and extensively studied as a drug discovery target.  On the basis of the structure of PCI-32765 (ibrutinib), a BTK kinase inhibitor that was recently reported to bear FLT3 kinase activity through a structure-guided drug design approach, the authors have discovered compd. 18 (CHMFL-FLT3-122, I), which displayed an IC50 of 40 nM against FLT3 kinase and achieved selectivity over BTK kinase (over 10-fold).  It significantly inhibited the proliferation of FLT3-ITD pos. AML cancer cell lines MV4-11 (GIC50 = 22 nM), MOLM13/14 (GIC50 = 21 nM/42 nM).  More importantly, compd. 18 demonstrated 170-fold selectivity between FLT3 kinase and c-KIT kinase (GIC50 = 11 nM vs. 1900 nM) in the TEL-fusion isogenic BaF3 cells indicating a potential to avoid the FLT3/c-KIT dual inhibition induced myelosuppression toxicity.  In the cellular context it strongly affected FLT3-ITD mediated signaling pathways and induced apoptosis by arresting the cell cycle into the G0/G1 phase.  In the in vivo studies compd. 18 demonstrated a good bioavailability (30%) and significantly suppressed the tumor growth in MV4-11 cell inoculated xenograft model (50 mg/kg) without exhibiting obvious toxicity.  Compd. 18 might be a potential drug candidate for FLT3-ITD pos. AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotxBPmnbEZ17Vg90H21EOLACvtfcHk0lhYOigVdYr6lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGnsL%252FJ&md5=f0d6f5f767f35c4aed3b20c02de06e86</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01611%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DQi%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520%2528R%2529-1-%25283-%25284-amino-3-%25284-phenoxyphenyl%2529-1H-pyrazolo%255B3%252C4-d%255Dpyrimidin-1-yl%2529piperidin-1-yl%2529-2-%2528dimethylamino%2529ethanone%2520%2528CHMFL-FLT3%25E2%2580%2593122%2529%2520as%2520a%2520potent%2520and%2520orally%2520available%2520FLT3%2520kinase%2520inhibitor%2520for%2520FLT3-ITD%2520positive%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D24%26spage%3D9625%26epage%3D9638%26doi%3D10.1021%2Facs.jmedchem.5b01611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-(4-(4-amino-3-(4-(2-morpholinoethoxy)phenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a highly potent type II FLT3 kinase inhibitor capable of overcoming a variety of FLT3 kinase mutants in FLT3-ITD positive AML</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">8407</span>– <span class="NLM_lpage">8424</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00840</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00840" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOmu7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8407-8424&issue=20&author=A.+Wangauthor=X.+Liauthor=C.+Chenauthor=H.+Wuauthor=Z.+Qiauthor=C.+Huauthor=K.+Yuauthor=J.+Wuauthor=J.+Liuauthor=X.+Liuauthor=Z.+Huauthor=W.+Wangauthor=W.+Wangauthor=W.+Wangauthor=L.+Wangauthor=B.+Wangauthor=Q.+Liuauthor=L.+Liauthor=J.+Geauthor=T.+Renauthor=S.+Zhangauthor=R.+Xiaauthor=J.+Liuauthor=Q.+Liu&title=Discovery+of+1-%284-%284-amino-3-%284-%282-morpholinoethoxy%29phenyl%29-1H-pyrazolo%5B3%2C4-d%5Dpyrimidin-1-yl%29phenyl%29-3-%285-%28tert-butyl%29isoxazol-3-yl%29urea+%28CHMFL-FLT3-213%29+as+a+highly+potent+type+II+FLT3+kinase+inhibitor+capable+of+overcoming+a+variety+of+FLT3+kinase+mutants+in+FLT3-ITD+positive+AML&doi=10.1021%2Facs.jmedchem.7b00840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML</span></div><div class="casAuthors">Wang, Aoli; Li, Xixiang; Chen, Cheng; Wu, Hong; Qi, Ziping; Hu, Chen; Yu, Kailin; Wu, Jiaxin; Liu, Juan; Liu, Xiaochuan; Hu, Zhenquan; Wang, Wei; Wang, Wenliang; Wang, Wenchao; Wang, Li; Wang, Beilei; Liu, Qingwang; Li, Lili; Ge, Jian; Ren, Tao; Zhang, Shanchun; Xia, Ruixiang; Liu, Jing; Liu, Qingsong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8407-8424</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">FLT3-ITD mutant has been obsd. in about 30% of AML patients and extensively studied as a drug discovery target.  On the basis of our previous study that ibrutinib exhibited selective and moderate inhibitory activity against FLT3-ITD pos. AML cells, through a structure-guided drug design approach, we have discovered a new type II FLT3 kinase inhibitor, compd. I (CHMFL-FLT3-213), which exhibited highly potent inhibitory effects against FLT3-ITD mutant and assocd. oncogenic mutations (including FLT3-D835Y/H/V, FLT3-ITD-D835Y/I/N/A/G/Del, and FLT3-ITD-F691L).  In the cellular context I strongly affected FLT3-ITD mediated signaling pathways and induced apoptosis by arresting cell cycle into G0/G1 phase.  In the in vivo studies I demonstrated an acceptable bioavailability (F = 19%) and significantly suppressed the tumor growth in MV4-11 cell inoculated xenograft model (15 mg kg-1 day-1, TGI = 97%) without exhibiting obvious toxicity.  Compd. I might be a potential drug candidate for FLT3-ITD pos. AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1tbOp_Bxu-LVg90H21EOLACvtfcHk0lhYOigVdYr6lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOmu7fN&md5=e4f3a47069f8ea615a3e1543b24a19b9</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00840%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DQi%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DXia%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%25201-%25284-%25284-amino-3-%25284-%25282-morpholinoethoxy%2529phenyl%2529-1H-pyrazolo%255B3%252C4-d%255Dpyrimidin-1-yl%2529phenyl%2529-3-%25285-%2528tert-butyl%2529isoxazol-3-yl%2529urea%2520%2528CHMFL-FLT3-213%2529%2520as%2520a%2520highly%2520potent%2520type%2520II%2520FLT3%2520kinase%2520inhibitor%2520capable%2520of%2520overcoming%2520a%2520variety%2520of%2520FLT3%2520kinase%2520mutants%2520in%2520FLT3-ITD%2520positive%2520AML%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D20%26spage%3D8407%26epage%3D8424%26doi%3D10.1021%2Facs.jmedchem.7b00840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Identification of pyrrolo[2,3- d]pyrimidine-based derivatives as potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3) inhibitors for treating acute myelogenous leukemia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">4158</span>– <span class="NLM_lpage">4173</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00223</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00223" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms1ajt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4158-4173&issue=8&author=X.+Yuanauthor=Y.+Chenauthor=W.+Zhangauthor=J.+Heauthor=L.+Leiauthor=M.+Tangauthor=J.+Liuauthor=M.+Liauthor=C.+Douauthor=T.+Yangauthor=L.+Yangauthor=S.+Yangauthor=Y.+Weiauthor=A.+Pengauthor=T.+Niuauthor=M.+Xiangauthor=H.+Yeauthor=L.+Chen&title=Identification+of+pyrrolo%5B2%2C3-+d%5Dpyrimidine-based+derivatives+as+potent+and+orally+effective+Fms-like+tyrosine+receptor+kinase+3+%28FLT3%29+inhibitors+for+treating+acute+myelogenous+leukemia&doi=10.1021%2Facs.jmedchem.9b00223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Pyrrolo[2,3-d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia</span></div><div class="casAuthors">Yuan, Xue; Chen, Yong; Zhang, Wanhua; He, Jun; Lei, Lei; Tang, Minghai; Liu, Jiang; Li, Muzhou; Dou, Caixia; Yang, Tao; Yang, Linyu; Yang, Shengyong; Wei, Yuquan; Peng, Aihua; Niu, Ting; Xiang, Mingli; Ye, Haoyu; Chen, Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4158-4173</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of pyrrolo[2,3-d]pyrimidine derivs. were prepd. and optimized for cytotoxic activities against FLT3-ITD mutant cancer cells.  Among them, compd. I possessed nanomolar FLT3 inhibitory activities and subnanomolar inhibitory activities against MV4-11 and Molm-13 cells.  It also showed excellent inhibitory activities in FLT3-ITD-D835V and FLT3-ITD-F691L cells which were resistant to quizartinib.  Furthermore, I exhibited over 40-fold selectivity toward FLT3 relative to c-Kit kinase, which might reduce myelosuppression toxicity.  Cellular assays demonstrated that I inhibited phosphorylated FLT3 and downstream signaling factors and also induced cell cycle arrest in the G0/G1 stage and apoptosis in MV4-11 and Molm-13 cells.  Oral administration of I at 10 mg/kg could achieve rapid tumor extinction in the MV4-11 xenograft model and significantly inhibit the tumor growth in the MOLM-13 xenograft model with a tumor growth inhibitory rate of 96% without obvious toxicity.  Addnl., I demonstrated high bioavailability (F = 59.5%) and suitable eliminated half-life time (T1/2 = 2.06 h), suggesting that I may be a potent candidate for treating acute myelogenous leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc5FKDBj_PA7Vg90H21EOLACvtfcHk0ljCx-xnu5U4pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms1ajt7s%253D&md5=37666941adb79cb2a5d8a4115ddd2519</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00223%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DLei%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DDou%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DA.%26aulast%3DNiu%26aufirst%3DT.%26aulast%3DXiang%26aufirst%3DM.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DIdentification%2520of%2520pyrrolo%255B2%252C3-%2520d%255Dpyrimidine-based%2520derivatives%2520as%2520potent%2520and%2520orally%2520effective%2520Fms-like%2520tyrosine%2520receptor%2520kinase%25203%2520%2528FLT3%2529%2520inhibitors%2520for%2520treating%2520acute%2520myelogenous%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D8%26spage%3D4158%26epage%3D4173%26doi%3D10.1021%2Facs.jmedchem.9b00223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-((7<i>H</i>-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase inhibitor with potentially high efficiency against acute myelocytic leukemia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1499</span>– <span class="NLM_lpage">1518</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01261</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01261" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1499-1518&issue=4&author=Y.+Wangauthor=Y.+Zhiauthor=Q.+Jinauthor=S.+Luauthor=G.+Linauthor=H.+Yuanauthor=T.+Yangauthor=Z.+Wangauthor=C.+Yaoauthor=J.+Lingauthor=H.+Guoauthor=T.+Liauthor=J.+Jinauthor=B.+Liauthor=L.+Zhangauthor=Y.+Chenauthor=T.+Lu&title=Discovery+of+4-%28%287H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29amino%29-N-%284-%28%284-methylpiperazin-1-yl%29methyl%29phenyl%29-1H-pyrazole-3-carboxamide+%28FN-1501%29%2C+an+FLT3-+and+CDK-Kinase+inhibitor+with+potentially+high+efficiency+against+acute+myelocytic+leukemia&doi=10.1021%2Facs.jmedchem.7b01261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia</span></div><div class="casAuthors">Wang, Yue; Zhi, Yanle; Jin, Qiaomei; Lu, Shuai; Lin, Guowu; Yuan, Haoliang; Yang, Taotao; Wang, Zhanwei; Yao, Chao; Ling, Jun; Guo, Hao; Li, Tonghui; Jin, Jianlin; Li, Baoquan; Zhang, Li; Chen, Yadong; Lu, Tao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1499-1518</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 1-H-pyrazole-3-carboxamide derivs. have been designed and synthesized that exhibit excellent FLT3 and CDK inhibition and antiproliferative activities.  A structure-activity-relationship study illustrates that the incorporation of a pyrimidine-fused heterocycle at position 4 of the pyrazole is crit. for FLT3 and CDK inhibition.  Compd. 50 (FN-1501), which possesses potent inhibitory activities against FLT3, CDK2, CDK4, and CDK6 with IC50 values in the nanomolar range, shows antiproliferative activities against MV4-11 cells (IC50: 0.008 μM), which correlates with the suppression of retinoblastoma phosphorylation, FLT3, ERK, AKT, and STAT5 and the onset of apoptosis.  Acute-toxicity studies in mice show that compd. I (LD50: 186 mg/kg) is safer than AT7519 (32 mg/kg).  In MV4-11 xenografts in a nude-mouse model, compd. I can induce tumor regression at the dose of 15 mg/kg, which is more efficient than cytarabine (50 mg/kg).  Taken together, these results demonstrate the potential of this unique compd. for further development into a drug applied in acute-myeloid-leukemia (AML) therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfX9S4QkGccbVg90H21EOLACvtfcHk0ljCx-xnu5U4pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyqurg%253D&md5=2757ad7559e655c5d96f0a8af8c74aa5</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01261%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhi%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DC.%26aulast%3DLing%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DT.%26atitle%3DDiscovery%2520of%25204-%2528%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%2529-N-%25284-%2528%25284-methylpiperazin-1-yl%2529methyl%2529phenyl%2529-1H-pyrazole-3-carboxamide%2520%2528FN-1501%2529%252C%2520an%2520FLT3-%2520and%2520CDK-Kinase%2520inhibitor%2520with%2520potentially%2520high%2520efficiency%2520against%2520acute%2520myelocytic%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D4%26spage%3D1499%26epage%3D1518%26doi%3D10.1021%2Facs.jmedchem.7b01261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of the selective and efficacious inhibitors of FLT3 mutations</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.ejmech.2018.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=29894944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFaltbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2018&pages=303-315&author=Y.+Zhiauthor=B.+Liauthor=C.+Yaoauthor=H.+Liauthor=P.+Chenauthor=J.+Baoauthor=T.+Qinauthor=Y.+Wangauthor=T.+Luauthor=S.+Lu&title=Discovery+of+the+selective+and+efficacious+inhibitors+of+FLT3+mutations&doi=10.1016%2Fj.ejmech.2018.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the selective and efficacious inhibitors of FLT3 mutations</span></div><div class="casAuthors">Zhi, Yanle; Li, Baoquan; Yao, Chao; Li, Hongmei; Chen, Puzhou; Bao, Jiyin; Qin, Tianren; Wang, Yue; Lu, Tao; Lu, Shuai</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">303-315</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Fms-like tyrosine kinase 3 (FLT3) is among the most frequently mutated protein in acute myeloid leukemia (AML), which has been confirmed as an important drug target for AML chemotherapy.  Starting from the lead compd. LT-106-175, a series of 1-H-pyrazole-3-carboxamide derivs. were synthesized to improve the FLT3 inhibitory potency and selectivity.  Among them, compd. 50 (4-((2-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)amino)-N-(4-(piperazin-1-yl)phenyl)-1H-pyrazole-3-carboxamide) was identified as a highly potent and selective FLT3 inhibitor (IC50 = 0.213 nM), which showed equal activities against various mutants of FLT3 including FLT3 (ITD)-D835V and FLT3 (ITD)-F691L that is resistant to quizartinib.  Compd. 50 also exhibited efficacy against the human AML cell line MV4-11 (IC50 = 16.1 nM) harboring FLT3-ITD mutants.  Inversely, compd. 50 displayed no cytotoxicity to FLT3-independent cells, and the biochem. analyses showed that its effects were related to the inhibition of FLT3 signal pathways.  Addnl., compd. 50 induced apoptosis in MV4-11 cell as demonstrated by flow cytometry.  Moreover, compd. 50 showed enhanced metabolic stability.  Altogether, it was concluded that compd. 50 could be a promising FLT3 inhibitor for further developing therapeutic remedy of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUFIlbd1kxabVg90H21EOLACvtfcHk0li_rXs2Z7PbPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFaltbzJ&md5=8b82ebdbf00f4693a7e7b94b32c9f1b7</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DZhi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DYao%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DBao%26aufirst%3DJ.%26aulast%3DQin%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520the%2520selective%2520and%2520efficacious%2520inhibitors%2520of%2520FLT3%2520mutations%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D155%26spage%3D303%26epage%3D315%26doi%3D10.1016%2Fj.ejmech.2018.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Melgar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolanos, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hueneman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunderlich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorimer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abendroth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyt, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Famulare, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulloy, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perentesis, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starczynowski, D. T.</span></span> <span> </span><span class="NLM_article-title">Overcoming adaptive therapy resistance in AML by targeting immune response pathways</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">508</span>),  <span class="NLM_fpage">eaaw8828</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aaw8828</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1126%2Fscitranslmed.aaw8828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=31484791" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=eaaw8828&issue=508&author=K.+Melgarauthor=M.+M.+Walkerauthor=L.+M.+Jonesauthor=L.+C.+Bolanosauthor=K.+Huenemanauthor=M.+Wunderlichauthor=J.+K.+Jiangauthor=K.+M.+Wilsonauthor=X.+Zhangauthor=P.+Sutterauthor=A.+Wangauthor=X.+Xuauthor=K.+Choiauthor=G.+Tawaauthor=D.+Lorimerauthor=J.+Abendrothauthor=E.+O%E2%80%99Brienauthor=S.+B.+Hoytauthor=E.+Bermanauthor=C.+A.+Famulareauthor=J.+C.+Mulloyauthor=R.+L.+Levineauthor=J.+P.+Perentesisauthor=C.+J.+Thomasauthor=D.+T.+Starczynowski&title=Overcoming+adaptive+therapy+resistance+in+AML+by+targeting+immune+response+pathways&doi=10.1126%2Fscitranslmed.aaw8828"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaw8828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaw8828%26sid%3Dliteratum%253Aachs%26aulast%3DMelgar%26aufirst%3DK.%26aulast%3DWalker%26aufirst%3DM.%2BM.%26aulast%3DJones%26aufirst%3DL.%2BM.%26aulast%3DBolanos%26aufirst%3DL.%2BC.%26aulast%3DHueneman%26aufirst%3DK.%26aulast%3DWunderlich%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DJ.%2BK.%26aulast%3DWilson%26aufirst%3DK.%2BM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSutter%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DChoi%26aufirst%3DK.%26aulast%3DTawa%26aufirst%3DG.%26aulast%3DLorimer%26aufirst%3DD.%26aulast%3DAbendroth%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DE.%26aulast%3DHoyt%26aufirst%3DS.%2BB.%26aulast%3DBerman%26aufirst%3DE.%26aulast%3DFamulare%26aufirst%3DC.%2BA.%26aulast%3DMulloy%26aufirst%3DJ.%2BC.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DPerentesis%26aufirst%3DJ.%2BP.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DStarczynowski%26aufirst%3DD.%2BT.%26atitle%3DOvercoming%2520adaptive%2520therapy%2520resistance%2520in%2520AML%2520by%2520targeting%2520immune%2520response%2520pathways%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2019%26volume%3D11%26issue%3D508%26spage%3Deaaw8828%26doi%3D10.1126%2Fscitranslmed.aaw8828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Kinase inhibitors: the road ahead</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fnrd.2018.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=29545548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1cXks12ktbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=353-377&issue=5&author=F.+M.+Fergusonauthor=N.+S.+Gray&title=Kinase+inhibitors%3A+the+road+ahead&doi=10.1038%2Fnrd.2018.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase inhibitors: the road ahead</span></div><div class="casAuthors">Ferguson, Fleur M.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">353-377</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinase signaling pathways have been successfully targeted to inhibit proliferation and angiogenesis for cancer therapy.  However, kinase deregulation has been firmly demonstrated to play an essential role in virtually all major disease areas.  Kinase inhibitor drug discovery programs have recently broadened their focus to include an expanded range of kinase targets and therapeutic areas.  In this Review, we provide an overview of the novel targets, biol. processes and disease areas that kinase-targeting small mols. are being developed against, highlight the assocd. challenges and assess the strategies and technologies that are enabling efficient generation of highly optimized kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZPospb1TP7Vg90H21EOLACvtfcHk0li_rXs2Z7PbPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXks12ktbg%253D&md5=34e42911d8a70301905460c3507e737a</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.21%26sid%3Dliteratum%253Aachs%26aulast%3DFerguson%26aufirst%3DF.%2BM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DKinase%2520inhibitors%253A%2520the%2520road%2520ahead%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26issue%3D5%26spage%3D353%26epage%3D377%26doi%3D10.1038%2Fnrd.2018.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harki, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummond, K. M.</span></span> <span> </span><span class="NLM_article-title">Covalent modifiers: a chemical perspective on the reactivity of alpha,beta-unsaturated carbonyls with thiols via hetero-michael addition reactions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">839</span>– <span class="NLM_lpage">885</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC28XitV2rtbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=839-885&issue=3&author=P.+A.+Jacksonauthor=J.+C.+Widenauthor=D.+A.+Harkiauthor=K.+M.+Brummond&title=Covalent+modifiers%3A+a+chemical+perspective+on+the+reactivity+of+alpha%2Cbeta-unsaturated+carbonyls+with+thiols+via+hetero-michael+addition+reactions&doi=10.1021%2Facs.jmedchem.6b00788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions</span></div><div class="casAuthors">Jackson, Paul A.; Widen, John C.; Harki, Daniel A.; Brummond, Kay M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">839-885</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Although Michael acceptors display a potent and broad spectrum of bioactivity, they have largely been ignored in drug discovery because of their presumed indiscriminate reactivity.  As such, a dearth of information exists relevant to the thiol reactivity of natural products and their analogs possessing this moiety.  In the midst of recently approved acrylamide-contg. drugs, it is clear that a good understanding of the hetero-Michael addn. reaction and the relative reactivities of biol. thiols with Michael acceptors under physiol. conditions is needed for the design and use of these compds. as biol. tools and potential therapeutics.  This Perspective provides information that will contribute to this understanding, such as kinetics of thiol addn. reactions, bioactivities, as well as steric and electronic factors that influence the electrophilicity and reversibility of Michael acceptors.  This Perspective is focused on α,β-unsatd. carbonyls given their preponderance in bioactive natural products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn4jDqxoos17Vg90H21EOLACvtfcHk0liSMN4WV1jfGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitV2rtbnM&md5=36d3be5bf688c4e4a8cf4bcf42073009</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00788%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DP.%2BA.%26aulast%3DWiden%26aufirst%3DJ.%2BC.%26aulast%3DHarki%26aufirst%3DD.%2BA.%26aulast%3DBrummond%26aufirst%3DK.%2BM.%26atitle%3DCovalent%2520modifiers%253A%2520a%2520chemical%2520perspective%2520on%2520the%2520reactivity%2520of%2520alpha%252Cbeta-unsaturated%2520carbonyls%2520with%2520thiols%2520via%2520hetero-michael%2520addition%2520reactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D3%26spage%3D839%26epage%3D885%26doi%3D10.1021%2Facs.jmedchem.6b00788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gehringer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Emerging and re-emerging warheads for targeted covalent Inhibitors: applications in medicinal chemistry and chemical biology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5673</span>– <span class="NLM_lpage">5724</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01153</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01153" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFKiur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5673-5724&issue=12&author=M.+Gehringerauthor=S.+A.+Laufer&title=Emerging+and+re-emerging+warheads+for+targeted+covalent+Inhibitors%3A+applications+in+medicinal+chemistry+and+chemical+biology&doi=10.1021%2Facs.jmedchem.8b01153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology</span></div><div class="casAuthors">Gehringer, Matthias; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5673-5724</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Targeted covalent inhibitors (TCIs) are designed to bind poorly conserved amino acids by means of reactive groups, the so-called warheads.  Currently, targeting noncatalytic cysteine residues with acrylamides and other α,β-unsatd. carbonyl compds. is the predominant strategy in TCI development.  The recent ascent of covalent drugs has stimulated considerable efforts to characterize alternative warheads for the covalent-reversible and irreversible engagement of noncatalytic cysteine residues as well as other amino acids.  This Perspective article provides an overview of warheads-beyond α,β-unsatd. amides-recently used in the design of targeted covalent ligands.  Promising reactive groups that have not yet demonstrated their utility in TCI development are also highlighted.  Special emphasis is placed on the discussion of reactivity and of case studies illustrating applications in medicinal chem. and chem. biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDhc4PWV293LVg90H21EOLACvtfcHk0liSMN4WV1jfGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFKiur%252FL&md5=4623733558ff99aadebfc13950b816ad</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01153%26sid%3Dliteratum%253Aachs%26aulast%3DGehringer%26aufirst%3DM.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DEmerging%2520and%2520re-emerging%2520warheads%2520for%2520targeted%2520covalent%2520Inhibitors%253A%2520applications%2520in%2520medicinal%2520chemistry%2520and%2520chemical%2520biology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D12%26spage%3D5673%26epage%3D5724%26doi%3D10.1021%2Facs.jmedchem.8b01153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lonsdale, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of targeted covalent inhibitors</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3816</span>– <span class="NLM_lpage">3830</span>, <span class="refDoi"> DOI: 10.1039/C7CS00220C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1039%2FC7CS00220C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=29620097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVGiurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2018&pages=3816-3830&issue=11&author=R.+Lonsdaleauthor=R.+A.+Ward&title=Structure-based+design+of+targeted+covalent+inhibitors&doi=10.1039%2FC7CS00220C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of targeted covalent inhibitors</span></div><div class="casAuthors">Lonsdale, Richard; Ward, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3816-3830</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Covalent inhibition is a rapidly growing discipline within drug discovery.  Many historical covalent inhibitors were discovered by serendipity, with such a mechanism of action often regarded as undesirable due to potential toxicity issues.  Recent progress has seen a major shift in this outlook, as covalent inhibition shows promise for targets where previous efforts to identify non-covalent small mol. inhibitors have failed.  Targeted covalent inhibitors (TCIs) can offer drug discovery scientists the ability to increase the potency and/or selectivity of small mol. inhibitors, by attachment of reactive functional groups designed to covalently bind to specific sites in a target.  In this tutorial review we introduce the broader concept of covalent inhibition, discuss the potential benefits and challenges of such an approach, and provide an overview of the current status of the field.  We also describe some strategies and computational tools to enable successful covalent drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnSIGMuS3vm7Vg90H21EOLACvtfcHk0liSMN4WV1jfGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVGiurs%253D&md5=a7e31b23cf8ecfcad1397ad10ea10b7b</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1039%2FC7CS00220C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7CS00220C%26sid%3Dliteratum%253Aachs%26aulast%3DLonsdale%26aufirst%3DR.%26aulast%3DWard%26aufirst%3DR.%2BA.%26atitle%3DStructure-based%2520design%2520of%2520targeted%2520covalent%2520inhibitors%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2018%26volume%3D47%26issue%3D11%26spage%3D3816%26epage%3D3830%26doi%3D10.1039%2FC7CS00220C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Angst, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gessier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janser, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walchli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beerli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littlewood-Evans, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuesslein-Hildesheim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieczorek, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheufler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinniger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerlin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funhoff, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cenni, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of LOU064 (remibrutinib), a potent and highly selective covalent inhibitor of Bruton’s tyrosine kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">5102</span>– <span class="NLM_lpage">5118</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01916</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01916" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjs1KiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=5102-5118&issue=10&author=D.+Angstauthor=F.+Gessierauthor=P.+Janserauthor=A.+Vulpettiauthor=R.+Walchliauthor=C.+Beerliauthor=A.+Littlewood-Evansauthor=J.+Dawsonauthor=B.+Nuesslein-Hildesheimauthor=G.+Wieczorekauthor=S.+Gutmannauthor=C.+Scheuflerauthor=A.+Hinnigerauthor=A.+Zimmerlinauthor=E.+G.+Funhoffauthor=R.+Pulzauthor=B.+Cenni&title=Discovery+of+LOU064+%28remibrutinib%29%2C+a+potent+and+highly+selective+covalent+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1021%2Facs.jmedchem.9b01916"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase</span></div><div class="casAuthors">Angst, Daniela; Gessier, Francois; Janser, Philipp; Vulpetti, Anna; Walchli, Rudolf; Beerli, Christian; Littlewood-Evans, Amanda; Dawson, Janet; Nuesslein-Hildesheim, Barbara; Wieczorek, Grazyna; Gutmann, Sascha; Scheufler, Clemens; Hinniger, Alexandra; Zimmerlin, Alfred; Funhoff, Enrico G.; Pulz, Robert; Cenni, Bruno</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5102-5118</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases.  The use of currently marketed covalent BTK inhibitors is limited to oncol. indications based on their suboptimal kinase selectivity.  We describe the discovery and preclin. profile of LOU064 (remibrutinib, 25), a potent, highly selective covalent BTK inhibitor.  LOU064 exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for a best-in-class covalent BTK inhibitor for the treatment of autoimmune diseases.  It demonstrates potent in vivo target occupancy with an EC90 of 1.6 mg/kg and dose-dependent efficacy in rat collagen-induced arthritis.  LOU064 is currently being tested in phase 2 clin. studies for chronic spontaneous urticaria and Sjoegren's syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBR_esJ38IMrVg90H21EOLACvtfcHk0lga3sOoVEThqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjs1KiurY%253D&md5=9122b310c294d6071ae7cd73cdb91b3d</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01916%26sid%3Dliteratum%253Aachs%26aulast%3DAngst%26aufirst%3DD.%26aulast%3DGessier%26aufirst%3DF.%26aulast%3DJanser%26aufirst%3DP.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DWalchli%26aufirst%3DR.%26aulast%3DBeerli%26aufirst%3DC.%26aulast%3DLittlewood-Evans%26aufirst%3DA.%26aulast%3DDawson%26aufirst%3DJ.%26aulast%3DNuesslein-Hildesheim%26aufirst%3DB.%26aulast%3DWieczorek%26aufirst%3DG.%26aulast%3DGutmann%26aufirst%3DS.%26aulast%3DScheufler%26aufirst%3DC.%26aulast%3DHinniger%26aufirst%3DA.%26aulast%3DZimmerlin%26aufirst%3DA.%26aulast%3DFunhoff%26aufirst%3DE.%2BG.%26aulast%3DPulz%26aufirst%3DR.%26aulast%3DCenni%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520LOU064%2520%2528remibrutinib%2529%252C%2520a%2520potent%2520and%2520highly%2520selective%2520covalent%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D10%26spage%3D5102%26epage%3D5118%26doi%3D10.1021%2Facs.jmedchem.9b01916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin
Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elzinga, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westhouse, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catlett, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pokross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allentoff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of branebrutinib (BMS-986195): a strategy for identifying a highly potent and selective covalent inhibitor providing rapid <i>in vivo</i> inactivation of Bruton’s tyrosine kinase (BTK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3228</span>– <span class="NLM_lpage">3250</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00167</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00167" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXls1aks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3228-3250&issue=7&author=S.+H.+Wattersonauthor=Q.+Liuauthor=M.+Beaudoin%0ABertrandauthor=D.+G.+Battauthor=L.+Liauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=L.+Chengauthor=M.+T.+Obermeierauthor=R.+Mooreauthor=Z.+Yangauthor=R.+Vickeryauthor=P.+A.+Elzingaauthor=L.+Discenzaauthor=C.+D%E2%80%99Arienzoauthor=K.+M.+Gilloolyauthor=T.+L.+Taylorauthor=C.+Pulicicchioauthor=Y.+Zhangauthor=E.+Heimrichauthor=K.+W.+McIntyreauthor=Q.+Ruanauthor=R.+A.+Westhouseauthor=I.+M.+Catlettauthor=N.+Zhengauthor=C.+Chaudhryauthor=J.+Daiauthor=M.+A.+Galellaauthor=A.+J.+Tebbenauthor=M.+Pokrossauthor=J.+Liauthor=R.+Zhaoauthor=D.+Smithauthor=R.+Rampullaauthor=A.+Allentoffauthor=M.+A.+Wallaceauthor=A.+Mathurauthor=L.+Salter-Cidauthor=J.+E.+Macorauthor=P.+H.+Carterauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+A.+Tino&title=Discovery+of+branebrutinib+%28BMS-986195%29%3A+a+strategy+for+identifying+a+highly+potent+and+selective+covalent+inhibitor+providing+rapid+in+vivo+inactivation+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29&doi=10.1021%2Facs.jmedchem.9b00167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK)</span></div><div class="casAuthors">Watterson, Scott H.; Liu, Qingjie; Beaudoin Bertrand, Myra; Batt, Douglas G.; Li, Ling; Pattoli, Mark A.; Skala, Stacey; Cheng, Lihong; Obermeier, Mary T.; Moore, Robin; Yang, Zheng; Vickery, Rodney; Elzinga, Paul A.; Discenza, Lorell; D'Arienzo, Celia; Gillooly, Kathleen M.; Taylor, Tracy L.; Pulicicchio, Claudine; Zhang, Yifan; Heimrich, Elizabeth; McIntyre, Kim W.; Ruan, Qian; Westhouse, Richard A.; Catlett, Ian M.; Zheng, Naiyu; Chaudhry, Charu; Dai, Jun; Galella, Michael A.; Tebben, Andrew J.; Pokross, Matt; Li, Jianqing; Zhao, Rulin; Smith, Daniel; Rampulla, Richard; Allentoff, Alban; Wallace, Michael A.; Mathur, Arvind; Salter-Cid, Luisa; Macor, John E.; Carter, Percy H.; Fura, Aberra; Burke, James R.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3228-3250</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a non-receptor tyrosine kinase, is a member of the Tec family of kinases and is essential for B cell receptor (BCR) mediated signaling.  BTK also plays a crit. role in the downstream signaling pathways for the Fcγ receptor in monocytes, the Fcε receptor in granulocytes, and the RANK receptor in osteoclasts.  As a result, pharmacol. inhibition of BTK is anticipated to provide an effective strategy for the clin. treatment of autoimmune diseases such as rheumatoid arthritis and lupus.  This article will outline the evolution of our strategy to identify a covalent, irreversible inhibitor of BTK that has the intrinsic potency, selectivity, and pharmacokinetic properties necessary to provide a rapid rate of inactivation systemically following a very low dose.  With excellent in vivo efficacy and a very desirable tolerability profile, 5a (branebrutinib, BMS-986195) has advanced into clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGr5oQEoebirVg90H21EOLACvtfcHk0lga3sOoVEThqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXls1aks7w%253D&md5=2d521ec7c06d503f940cb44d381af58d</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00167%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DElzinga%26aufirst%3DP.%2BA.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DWesthouse%26aufirst%3DR.%2BA.%26aulast%3DCatlett%26aufirst%3DI.%2BM.%26aulast%3DZheng%26aufirst%3DN.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DPokross%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DAllentoff%26aufirst%3DA.%26aulast%3DWallace%26aufirst%3DM.%2BA.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%2520branebrutinib%2520%2528BMS-986195%2529%253A%2520a%2520strategy%2520for%2520identifying%2520a%2520highly%2520potent%2520and%2520selective%2520covalent%2520inhibitor%2520providing%2520rapid%2520in%2520vivo%2520inactivation%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D7%26spage%3D3228%26epage%3D3250%26doi%3D10.1021%2Facs.jmedchem.9b00167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lelais, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epple, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, Y. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anumolu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badiger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juarez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manuia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groessl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasibhatla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isbell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spraggon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P. Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of (R,E)-<i>N</i>-(7-chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1<i>H</i>-benzo[d]imid azol-2-yl)-2-methylisonicotinamide (EGF816), a novel, potent, and WT sparing covalent inhibitor of oncogenic (L858R, ex19del) and resistant (T790M) EGFR mutants for the treatment of EGFR mutant non-small-cell lung cancers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">6671</span>– <span class="NLM_lpage">6689</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01985</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01985" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOgu77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6671-6689&issue=14&author=G.+Lelaisauthor=R.+Eppleauthor=T.+H.+Marsiljeauthor=Y.+O.+Longauthor=M.+McNeillauthor=B.+Chenauthor=W.+Luauthor=J.+Anumoluauthor=S.+Badigerauthor=B.+Bursulayaauthor=M.+DiDonatoauthor=R.+Fongauthor=J.+Juarezauthor=J.+Liauthor=M.+Manuiaauthor=D.+E.+Masonauthor=P.+Gordonauthor=T.+Groesslauthor=K.+Johnsonauthor=Y.+Jiaauthor=S.+Kasibhatlaauthor=C.+Liauthor=J.+Isbellauthor=G.+Spraggonauthor=S.+Benderauthor=P.+Y.+Michellys&title=Discovery+of+%28R%2CE%29-N-%287-chloro-1-%281-%5B4-%28dimethylamino%29but-2-enoyl%5Dazepan-3-yl%29-1H-benzo%5Bd%5Dimid+azol-2-yl%29-2-methylisonicotinamide+%28EGF816%29%2C+a+novel%2C+potent%2C+and+WT+sparing+covalent+inhibitor+of+oncogenic+%28L858R%2C+ex19del%29+and+resistant+%28T790M%29+EGFR+mutants+for+the+treatment+of+EGFR+mutant+non-small-cell+lung+cancers&doi=10.1021%2Facs.jmedchem.5b01985"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers</span></div><div class="casAuthors">Lelais, Gerald; Epple, Robert; Marsilje, Thomas H.; Long, Yun O.; McNeill, Matthew; Chen, Bei; Lu, Wenshuo; Anumolu, Jaganmohan; Badiger, Sangamesh; Bursulaya, Badry; DiDonato, Michael; Fong, Rina; Juarez, Jose; Li, Jie; Manuia, Mari; Mason, Daniel E.; Gordon, Perry; Groessl, Todd; Johnson, Kevin; Jia, Yong; Kasibhatla, Shailaja; Li, Chun; Isbell, John; Spraggon, Glen; Bender, Steven; Michellys, Pierre-Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6671-6689</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Over the past decade, first and second generation EGFR inhibitors have significantly improved outcomes for lung cancer patients with activating mutations in EGFR.  However, both resistance through a secondary T790M mutation at the gatekeeper residue and dose-limiting toxicities from wild-type (WT) EGFR inhibition ultimately limit the full potential of these therapies to control mutant EGFR-driven tumors and new therapies are urgently needed.  Herein, we describe our approach toward the discovery of 47 (EGF816, nazartinib), a novel, covalent mutant-selective EGFR inhibitor with equipotent activity on both oncogenic and T790M-resistant EGFR mutations.  Through mol. docking studies we converted a mutant-selective high-throughput screening hit (7) into a no. of targeted covalent EGFR inhibitors with equipotent activity across mutants EGFR and good WT-EGFR selectivity.  We used an abbreviated in vivo efficacy study for prioritizing compds. with good tolerability and efficacy that ultimately led to the selection of 47 as the clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpcKsqbwkyp7Vg90H21EOLACvtfcHk0lh8eBePz8yh_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOgu77P&md5=c106545d878ab3d675644b47099668a0</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01985%26sid%3Dliteratum%253Aachs%26aulast%3DLelais%26aufirst%3DG.%26aulast%3DEpple%26aufirst%3DR.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DLong%26aufirst%3DY.%2BO.%26aulast%3DMcNeill%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DAnumolu%26aufirst%3DJ.%26aulast%3DBadiger%26aufirst%3DS.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DFong%26aufirst%3DR.%26aulast%3DJuarez%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DManuia%26aufirst%3DM.%26aulast%3DMason%26aufirst%3DD.%2BE.%26aulast%3DGordon%26aufirst%3DP.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DKasibhatla%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DIsbell%26aufirst%3DJ.%26aulast%3DSpraggon%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26atitle%3DDiscovery%2520of%2520%2528R%252CE%2529-N-%25287-chloro-1-%25281-%255B4-%2528dimethylamino%2529but-2-enoyl%255Dazepan-3-yl%2529-1H-benzo%255Bd%255Dimid%2520azol-2-yl%2529-2-methylisonicotinamide%2520%2528EGF816%2529%252C%2520a%2520novel%252C%2520potent%252C%2520and%2520WT%2520sparing%2520covalent%2520inhibitor%2520of%2520oncogenic%2520%2528L858R%252C%2520ex19del%2529%2520and%2520resistant%2520%2528T790M%2529%2520EGFR%2520mutants%2520for%2520the%2520treatment%2520of%2520EGFR%2520mutant%2520non-small-cell%2520lung%2520cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D14%26spage%3D6671%26epage%3D6689%26doi%3D10.1021%2Facs.jmedchem.5b01985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brameld, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venetsanakos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaStant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughhead, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karr, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerritsen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J. O.</span></span> <span> </span><span class="NLM_article-title">Discovery of the irreversible covalent FGFR inhibitor 8-(3-(4-acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8<i>H</i>)-one (PRN1371) for the treatment of solid tumors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">6516</span>– <span class="NLM_lpage">6527</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00360</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00360" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVykt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6516-6527&issue=15&author=K.+A.+Brameldauthor=T.+D.+Owensauthor=E.+Vernerauthor=E.+Venetsanakosauthor=J.+M.+Bradshawauthor=V.+T.+Phanauthor=D.+Tamauthor=K.+Leungauthor=J.+Shuauthor=J.+LaStantauthor=D.+G.+Loughheadauthor=T.+Tonauthor=D.+E.+Karrauthor=M.+E.+Gerritsenauthor=D.+M.+Goldsteinauthor=J.+O.+Funk&title=Discovery+of+the+irreversible+covalent+FGFR+inhibitor+8-%283-%284-acryloylpiperazin-1-yl%29propyl%29-6-%282%2C6-dichloro-3%2C5-dimethoxyphenyl%29-2-%28methylamino%29pyrido%5B2%2C3-d%5Dpyrimidin-7%288H%29-one+%28PRN1371%29+for+the+treatment+of+solid+tumors&doi=10.1021%2Facs.jmedchem.7b00360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors</span></div><div class="casAuthors">Brameld, Ken A.; Owens, Timothy D.; Verner, Erik; Venetsanakos, Eleni; Bradshaw, J. Michael; Phan, Vernon T.; Tam, Danny; Leung, Kwan; Shu, Jin; LaStant, Jacob; Loughhead, David G.; Ton, Tony; Karr, Dane E.; Gerritsen, Mary E.; Goldstein, David M.; Funk, Jens Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6516-6527</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aberrant signaling of the FGF/FGFR pathway occurs frequently in cancers and is an oncogenic driver in many solid tumors.  Clin. validation of FGFR as a therapeutic target has been demonstrated in bladder, liver, lung, breast, and gastric cancers.  Our goal was to develop an irreversible covalent inhibitor of FGFR1-4 for use in oncol. indications.  An irreversible covalent binding mechanism imparts many desirable pharmacol. benefits including high potency, selectivity, and prolonged target inhibition.  Herein we report the structure-based design, medicinal chem. optimization, and unique ADME assays of our irreversible covalent drug discovery program which culminated in the discovery of compd. 34 (PRN1371), a highly selective and potent FGFR1-4 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpklTuvm1niy7Vg90H21EOLACvtfcHk0lh8eBePz8yh_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVykt7fK&md5=987069b645d5e0e36ccda5e5c81520b9</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00360%26sid%3Dliteratum%253Aachs%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DVenetsanakos%26aufirst%3DE.%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26aulast%3DPhan%26aufirst%3DV.%2BT.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLeung%26aufirst%3DK.%26aulast%3DShu%26aufirst%3DJ.%26aulast%3DLaStant%26aufirst%3DJ.%26aulast%3DLoughhead%26aufirst%3DD.%2BG.%26aulast%3DTon%26aufirst%3DT.%26aulast%3DKarr%26aufirst%3DD.%2BE.%26aulast%3DGerritsen%26aufirst%3DM.%2BE.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26atitle%3DDiscovery%2520of%2520the%2520irreversible%2520covalent%2520FGFR%2520inhibitor%25208-%25283-%25284-acryloylpiperazin-1-yl%2529propyl%2529-6-%25282%252C6-dichloro-3%252C5-dimethoxyphenyl%2529-2-%2528methylamino%2529pyrido%255B2%252C3-d%255Dpyrimidin-7%25288H%2529-one%2520%2528PRN1371%2529%2520for%2520the%2520treatment%2520of%2520solid%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D15%26spage%3D6516%26epage%3D6527%26doi%3D10.1021%2Facs.jmedchem.7b00360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery of an orally available Janus kinase 3 selective covalent inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">1054</span>– <span class="NLM_lpage">1066</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01823</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01823" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjs1Ghug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1054-1066&issue=2&author=L.+Shiauthor=Z.+Zhongauthor=X.+Liauthor=Y.+Zhouauthor=Z.+Pan&title=Discovery+of+an+orally+available+Janus+kinase+3+selective+covalent+inhibitor&doi=10.1021%2Facs.jmedchem.8b01823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Orally Available Janus Kinase 3 Selective Covalent Inhibitor</span></div><div class="casAuthors">Shi, Liyang; Zhong, Zhenpeng; Li, Xitao; Zhou, Yiqing; Pan, Zhengying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1054-1066</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">JAK family kinases are important mediators of immune cell signaling and Janus Kinase 3 (JAK3) has long been indicated as a potential target for autoimmune disorders.  Intensive efforts to develop highly selective JAK3 inhibitors have been underway for many years.  However, because of JAK3's strong binding preference to ATP (ATP), a no. of inhibitors exhibit large gaps between enzymic and cellular potency, which hampers efforts to dissect the roles of JAK3 in cellular settings.  Using a targeted covalent inhibitor approach, we discovered compd. 32, which overcame ATP competition (1 mM) in the enzymic assay, and demonstrated significantly improved inhibitory activity for JAK3-dependent signaling in mouse CTLL-2 and human peripheral blood mononuclear cells.  Compd. 32 also exhibited high selectivity within the JAK family and good pharmacokinetic properties.  Thus, it may serve as a highly valuable tool mol. to study the overlapping roles of JAK family kinases in complex biol. settings.  Our study also suggested that for covalent kinase inhibitors, esp. those targeting kinases with low Km ATP values, the reversible interactions between mols. and proteins should be carefully optimized to improve the overall potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZd2JO9l7Q4LVg90H21EOLACvtfcHk0lh8eBePz8yh_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjs1Ghug%253D%253D&md5=17792310c69501e5a645a63b79aa4826</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01823%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DL.%26aulast%3DZhong%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DPan%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520an%2520orally%2520available%2520Janus%2520kinase%25203%2520selective%2520covalent%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D2%26spage%3D1054%26epage%3D1066%26doi%3D10.1021%2Facs.jmedchem.8b01823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amegadzie, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frohn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopecky, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minatti, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickrell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegmund, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tegley, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walton, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurz, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achanta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiki, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volak, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zech, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipford, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cee, V. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of a covalent inhibitor of KRAS(G12C) (AMG 510) for the treatment of solid tumors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">52</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01180</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01180" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlGitrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=52-65&issue=1&author=B.+A.+Lanmanauthor=J.+R.+Allenauthor=J.+G.+Allenauthor=A.+K.+Amegadzieauthor=K.+S.+Ashtonauthor=S.+K.+Bookerauthor=J.+J.+Chenauthor=N.+Chenauthor=M.+J.+Frohnauthor=G.+Goodmanauthor=D.+J.+Kopeckyauthor=L.+Liuauthor=P.+Lopezauthor=J.+D.+Lowauthor=V.+Maauthor=A.+E.+Minattiauthor=T.+T.+Nguyenauthor=N.+Nishimuraauthor=A.+J.+Pickrellauthor=A.+B.+Reedauthor=Y.+Shinauthor=A.+C.+Siegmundauthor=N.+A.+Tamayoauthor=C.+M.+Tegleyauthor=M.+C.+Waltonauthor=H.+L.+Wangauthor=R.+P.+Wurzauthor=M.+Xueauthor=K.+C.+Yangauthor=P.+Achantaauthor=M.+D.+Bartbergerauthor=J.+Canonauthor=L.+S.+Hollisauthor=J.+D.+McCarterauthor=C.+Mohrauthor=K.+Rexauthor=A.+Y.+Saikiauthor=T.+San+Miguelauthor=L.+P.+Volakauthor=K.+H.+Wangauthor=D.+A.+Whittingtonauthor=S.+G.+Zechauthor=J.+R.+Lipfordauthor=V.+J.+Cee&title=Discovery+of+a+covalent+inhibitor+of+KRAS%28G12C%29+%28AMG+510%29+for+the+treatment+of+solid+tumors&doi=10.1021%2Facs.jmedchem.9b01180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors</span></div><div class="casAuthors">Lanman, Brian A.; Allen, Jennifer R.; Allen, John G.; Amegadzie, Albert K.; Ashton, Kate S.; Booker, Shon K.; Chen, Jian Jeffrey; Chen, Ning; Frohn, Michael J.; Goodman, Guy; Kopecky, David J.; Liu, Longbin; Lopez, Patricia; Low, Jonathan D.; Ma, Vu; Minatti, Ana E.; Nguyen, Thomas T.; Nishimura, Nobuko; Pickrell, Alexander J.; Reed, Anthony B.; Shin, Youngsook; Siegmund, Aaron C.; Tamayo, Nuria A.; Tegley, Christopher M.; Walton, Mary C.; Wang, Hui-Ling; Wurz, Ryan P.; Xue, May; Yang, Kevin C.; Achanta, Pragathi; Bartberger, Michael D.; Canon, Jude; Hollis, L. Steven; McCarter, John D.; Mohr, Christopher; Rex, Karen; Saiki, Anne Y.; San Miguel, Tisha; Volak, Laurie P.; Wang, Kevin H.; Whittington, Douglas A.; Zech, Stephan G.; Lipford, J. Russell; Cee, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">52-65</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">KRASG12C has emerged as a promising target in the treatment of solid tumors.  Covalent inhibitors targeting the mutant cysteine-12 residue have been shown to disrupt signaling by this long-"undruggable" target; however clin. viable inhibitors have yet to be identified.  Here, we report efforts to exploit a cryptic pocket (H95/Y96/Q99) we identified in KRASG12C to identify inhibitors suitable for clin. development.  Structure-based design efforts leading to the identification of a novel quinazolinone scaffold are described, along with optimization efforts that overcame a configurational stability issue arising from restricted rotation about an axially chiral biaryl bond.  Biopharmaceutical optimization of the resulting leads culminated in the identification of AMG 510, a highly potent, selective, and well-tolerated KRASG12C inhibitor currently in phase I clin. trials (NCT03600883).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGeWqRRXX6lbVg90H21EOLACvtfcHk0lirf6SXJGbrhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlGitrrK&md5=d973189be70bb913020edb4989f6ba7d</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01180%26sid%3Dliteratum%253Aachs%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DAllen%26aufirst%3DJ.%2BR.%26aulast%3DAllen%26aufirst%3DJ.%2BG.%26aulast%3DAmegadzie%26aufirst%3DA.%2BK.%26aulast%3DAshton%26aufirst%3DK.%2BS.%26aulast%3DBooker%26aufirst%3DS.%2BK.%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26aulast%3DChen%26aufirst%3DN.%26aulast%3DFrohn%26aufirst%3DM.%2BJ.%26aulast%3DGoodman%26aufirst%3DG.%26aulast%3DKopecky%26aufirst%3DD.%2BJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLopez%26aufirst%3DP.%26aulast%3DLow%26aufirst%3DJ.%2BD.%26aulast%3DMa%26aufirst%3DV.%26aulast%3DMinatti%26aufirst%3DA.%2BE.%26aulast%3DNguyen%26aufirst%3DT.%2BT.%26aulast%3DNishimura%26aufirst%3DN.%26aulast%3DPickrell%26aufirst%3DA.%2BJ.%26aulast%3DReed%26aufirst%3DA.%2BB.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DSiegmund%26aufirst%3DA.%2BC.%26aulast%3DTamayo%26aufirst%3DN.%2BA.%26aulast%3DTegley%26aufirst%3DC.%2BM.%26aulast%3DWalton%26aufirst%3DM.%2BC.%26aulast%3DWang%26aufirst%3DH.%2BL.%26aulast%3DWurz%26aufirst%3DR.%2BP.%26aulast%3DXue%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DK.%2BC.%26aulast%3DAchanta%26aufirst%3DP.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DCanon%26aufirst%3DJ.%26aulast%3DHollis%26aufirst%3DL.%2BS.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DMohr%26aufirst%3DC.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DSaiki%26aufirst%3DA.%2BY.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DVolak%26aufirst%3DL.%2BP.%26aulast%3DWang%26aufirst%3DK.%2BH.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DZech%26aufirst%3DS.%2BG.%26aulast%3DLipford%26aufirst%3DJ.%2BR.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26atitle%3DDiscovery%2520of%2520a%2520covalent%2520inhibitor%2520of%2520KRAS%2528G12C%2529%2520%2528AMG%2520510%2529%2520for%2520the%2520treatment%2520of%2520solid%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D1%26spage%3D52%26epage%3D65%26doi%3D10.1021%2Facs.jmedchem.9b01180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamaura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurokawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujikawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Date, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terada, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyoi, H.</span></span> <span> </span><span class="NLM_article-title">A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>131</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-05-786657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2017-05-786657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=29187377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1CqsbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2018&pages=426-438&issue=4&author=T.+Yamauraauthor=T.+Nakataniauthor=K.+Udaauthor=H.+Oguraauthor=W.+Shinauthor=N.+Kurokawaauthor=K.+Saitoauthor=N.+Fujikawaauthor=T.+Dateauthor=M.+Takasakiauthor=D.+Teradaauthor=A.+Hiraiauthor=A.+Akashiauthor=F.+Chenauthor=Y.+Adachiauthor=Y.+Ishikawaauthor=F.+Hayakawaauthor=S.+Hagiwaraauthor=T.+Naoeauthor=H.+Kiyoi&title=A+novel+irreversible+FLT3+inhibitor%2C+FF-10101%2C+shows+excellent+efficacy+against+AML+cells+with+FLT3+mutations&doi=10.1182%2Fblood-2017-05-786657"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations</span></div><div class="casAuthors">Yamaura, Takeshi; Nakatani, Toshiyuki; Uda, Ken; Ogura, Hayato; Shin, Wigyon; Kurokawa, Naoya; Saito, Koichi; Fujikawa, Norie; Date, Tomomi; Takasaki, Masaru; Terada, Daisuke; Hirai, Atsushi; Akashi, Akimi; Chen, Fangli; Adachi, Yoshiya; Ishikawa, Yuichi; Hayakawa, Fumihiko; Hagiwara, Shinji; Naoe, Tomoki; Kiyoi, Hitoshi</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">426-438</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">An activating mutation of Fms-like tyrosine kinase 3 (FLT3) is the most frequent genetic alteration assocd. with poor prognosis in acute myeloid leukemia (AML).  Although many FLT3 inhibitors have been clin. developed, no first-generation inhibitors have demonstrated clin. efficacy by monotherapy, due to poor pharmacokinetics or unfavorable safety profiles possibly assocd. with low selectivity against FLT3 kinase.  Recently, a selective FLT3 inhibitor, quizartinib, demonstrated favorable outcomes in clin. studies.  However, several resistant mutations emerged during the disease progression.  To overcome these problems, we developed a novel FLT3 inhibitor, FF-10101, designed to possess selective and irreversible FLT3 inhibition.  The co-crystal structure of FLT3 protein bound to FF-10101 revealed the formation of a covalent bond between FF-10101 and the cysteine residue at 695 of FLT3.  The unique binding brought high selectivity and inhibitory activity against FLT3 kinase.  FF-10101 showed potent growth inhibitory effects on human AML cell lines harboring FLT3 internal tandem duplication (FLT3-ITD), MOLM-13, MOLM-14, and MV4-11, and all tested types of mutant FLT3-expressing 32D cells including quizartinib-resistant mutations at D835, Y842, and F691 residues in the FLT3 kinase domain.  In mouse s.c. implantation models, orally administered FF-10101 showed significant growth inhibitory effect on FLT3-ITD-D835Y- and FLT3-ITD-F691L-expressing 32D cells.  Furthermore, FF-10101 potently inhibited growth of primary AML cells harboring either FLT3-ITD or FLT3-D835 mutation in vitro and in vivo.  These results indicate that FF-10101 is a promising agent for the treatment of patients with AML with FLT3 mutations, including the activation loop mutations clin. identified as quizartinib-resistant mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrNdcWgLnPALVg90H21EOLACvtfcHk0lirf6SXJGbrhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1CqsbnE&md5=6812be0253e393c018ad5f7b47b9ec02</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-05-786657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-05-786657%26sid%3Dliteratum%253Aachs%26aulast%3DYamaura%26aufirst%3DT.%26aulast%3DNakatani%26aufirst%3DT.%26aulast%3DUda%26aufirst%3DK.%26aulast%3DOgura%26aufirst%3DH.%26aulast%3DShin%26aufirst%3DW.%26aulast%3DKurokawa%26aufirst%3DN.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DFujikawa%26aufirst%3DN.%26aulast%3DDate%26aufirst%3DT.%26aulast%3DTakasaki%26aufirst%3DM.%26aulast%3DTerada%26aufirst%3DD.%26aulast%3DHirai%26aufirst%3DA.%26aulast%3DAkashi%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DAdachi%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DHayakawa%26aufirst%3DF.%26aulast%3DHagiwara%26aufirst%3DS.%26aulast%3DNaoe%26aufirst%3DT.%26aulast%3DKiyoi%26aufirst%3DH.%26atitle%3DA%2520novel%2520irreversible%2520FLT3%2520inhibitor%252C%2520FF-10101%252C%2520shows%2520excellent%2520efficacy%2520against%2520AML%2520cells%2520with%2520FLT3%2520mutations%26jtitle%3DBlood%26date%3D2018%26volume%3D131%26issue%3D4%26spage%3D426%26epage%3D438%26doi%3D10.1182%2Fblood-2017-05-786657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bensinger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubba, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cremer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohl, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wassmer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engemann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmaier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, B.</span></span> <span> </span><span class="NLM_article-title">Virtual screening identifies irreversible FMS-like tyrosine kinase 3 inhibitors with activity toward resistance-conferring mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2428</span>– <span class="NLM_lpage">2446</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01714</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01714" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisl2lsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2428-2446&issue=5&author=D.+Bensingerauthor=D.+Stubbaauthor=A.+Cremerauthor=V.+Kohlauthor=T.+Wassmerauthor=J.+Stuckertauthor=V.+Engemannauthor=K.+Stegmaierauthor=K.+Schmitzauthor=B.+Schmidt&title=Virtual+screening+identifies+irreversible+FMS-like+tyrosine+kinase+3+inhibitors+with+activity+toward+resistance-conferring+mutations&doi=10.1021%2Facs.jmedchem.8b01714"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations</span></div><div class="casAuthors">Bensinger, Dennis; Stubba, Daniel; Cremer, Anjali; Kohl, Vanessa; Wassmer, Theresa; Stuckert, Johanna; Engemann, Victoria; Stegmaier, Kimberly; Schmitz, Katja; Schmidt, Boris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2428-2446</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The use of covalent irreversible binding inhibitors is an established concept for drug development.  Usually, the discovery of new irreversible kinase inhibitors occurs serendipitously, showing that efficient rational approaches for the rapid discovery of new drugs are needed.  Herein, the authors report a virtual screening strategy that led to the discovery of irreversible inhibitors of FMS-like tyrosine kinase 3 (FLT3) involved in the pathogenesis of acute myeloid leukemia.  A virtual screening library was designed to target the highly conserved Cys828 residue preceding the DFG motif by modification of reported reversible inhibitors with chem. reactive groups.  Prospective covalent docking allowed the identification of two lead series, resulting in a massive increase in inhibition of kinase activity and cell viability by irreversible inhibitors compared to the corresponding reversible scaffolds.  Lead compd. I (BSc5371) displays superior cytotoxicity in FLT3-dependent cell lines to compds. in recent clin. trials and overcomes drug-resistant mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquy_8BkIpJILVg90H21EOLACvtfcHk0lgKnXQ3Bn2pUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisl2lsro%253D&md5=336bed5b86809d78cfaf8b74d934ef68</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01714%26sid%3Dliteratum%253Aachs%26aulast%3DBensinger%26aufirst%3DD.%26aulast%3DStubba%26aufirst%3DD.%26aulast%3DCremer%26aufirst%3DA.%26aulast%3DKohl%26aufirst%3DV.%26aulast%3DWassmer%26aufirst%3DT.%26aulast%3DStuckert%26aufirst%3DJ.%26aulast%3DEngemann%26aufirst%3DV.%26aulast%3DStegmaier%26aufirst%3DK.%26aulast%3DSchmitz%26aufirst%3DK.%26aulast%3DSchmidt%26aufirst%3DB.%26atitle%3DVirtual%2520screening%2520identifies%2520irreversible%2520FMS-like%2520tyrosine%2520kinase%25203%2520inhibitors%2520with%2520activity%2520toward%2520resistance-conferring%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D5%26spage%3D2428%26epage%3D2446%26doi%3D10.1021%2Facs.jmedchem.8b01714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daver, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinardo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pemmaraju, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Manero, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrajoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popat, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosing, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderlini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span> <span> </span><span class="NLM_article-title">Clinical characteristics and outcomes in patients with acute promyelocytic leukemia and hyperleucocytosis</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>168</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">646</span>– <span class="NLM_lpage">653</span>, <span class="refDoi"> DOI: 10.1111/bjh.13189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1111%2Fbjh.13189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=25312977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitlOjs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2015&pages=646-653&issue=5&author=N.+Daverauthor=H.+Kantarjianauthor=G.+Marcucciauthor=S.+Pierceauthor=M.+Brandtauthor=C.+Dinardoauthor=N.+Pemmarajuauthor=G.+Garcia-Maneroauthor=S.+O%E2%80%99Brienauthor=A.+Ferrajoliauthor=S.+Verstovsekauthor=U.+Popatauthor=C.+Hosingauthor=P.+Anderliniauthor=G.+Borthakurauthor=T.+Kadiaauthor=J.+Cortesauthor=F.+Ravandi&title=Clinical+characteristics+and+outcomes+in+patients+with+acute+promyelocytic+leukemia+and+hyperleucocytosis&doi=10.1111%2Fbjh.13189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis</span></div><div class="casAuthors">Daver, Naval; Kantarjian, Hagop; Marcucci, Guido; Pierce, Sherry; Brandt, Mark; Dinardo, Courtney; Pemmaraju, Naveen; Garcia-Manero, Guillermo; O'Brien, Susan; Ferrajoli, Alessandra; Verstovsek, Srdan; Popat, Uday; Hosing, Chitra; Anderlini, Paolo; Borthakur, Gautam; Kadia, Tapan; Cortes, Jorge; Ravandi, Farhad</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">646-653</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary: The clin. characteristics, treatment options and outcomes in patients with acute promyelocytic leukemia (APL) and hyperleucocytosis remain poorly defined.  This study reviewed 242 consecutive patients with APL; 29 patients (12%) had a white blood cell count (WBC) ≥ 50 × 109/l at presentation (median WBC 85·5 × 109/l).  Patients with hyperleucocytosis had inferior complete remission (CR) rates (69% vs. 88%; P = 0·004) and higher 4-wk mortality (24% vs. 9%; P = 0·018) compared to patients without hyperleucocytosis.  We noted a trend towards inferior 3-yr disease-free survival (DFS) (69% vs. 80%; P = 0·057) and inferior 3-yr overall survival (OS) (74% vs. 92%; P = 0·2) for patients with hyperleucocytosis.  Leukapheresis was performed in 11 (38%) of the 29 patients with hyperleucocytosis.  CR rate and 3-yr OS were not significantly improved in patients who received leukapheresis.  CR rate and 3-yr OS for the 15 patients with hyperleucocytosis treated with all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) plus cytotoxic therapy (idarubicin or gemtuzumab ozogamicin) combinations were 100% and 100% vs. 57% and 35% for the 14 patients treated with non-ATRA/ATO combinations (P = 0·004 and P = 0·002).  Leukapheresis does not improve the outcomes in patients with APL presenting with hyperleucocytosis.  ATRA/ATO-based combinations are superior to other regimens in these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryVkJHaNGBWLVg90H21EOLACvtfcHk0lgKnXQ3Bn2pUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitlOjs70%253D&md5=c53c1fb35e1fbfc0ec12ddb0140f3ebd</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1111%2Fbjh.13189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.13189%26sid%3Dliteratum%253Aachs%26aulast%3DDaver%26aufirst%3DN.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DMarcucci%26aufirst%3DG.%26aulast%3DPierce%26aufirst%3DS.%26aulast%3DBrandt%26aufirst%3DM.%26aulast%3DDinardo%26aufirst%3DC.%26aulast%3DPemmaraju%26aufirst%3DN.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DFerrajoli%26aufirst%3DA.%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DPopat%26aufirst%3DU.%26aulast%3DHosing%26aufirst%3DC.%26aulast%3DAnderlini%26aufirst%3DP.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DKadia%26aufirst%3DT.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DRavandi%26aufirst%3DF.%26atitle%3DClinical%2520characteristics%2520and%2520outcomes%2520in%2520patients%2520with%2520acute%2520promyelocytic%2520leukemia%2520and%2520hyperleucocytosis%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2015%26volume%3D168%26issue%3D5%26spage%3D646%26epage%3D653%26doi%3D10.1111%2Fbjh.13189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandy, M.</span></span> <span> </span><span class="NLM_article-title">Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>92</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">994</span>– <span class="NLM_lpage">995</span>, <span class="refDoi"> DOI: 10.3324/haematol.10802</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.3324%2Fhaematol.10802" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=17606455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFGqu7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2007&pages=994-995&issue=7&author=V.+Mathewsauthor=M.+Thomasauthor=V.+M.+Srivastavaauthor=B.+Georgeauthor=A.+Srivastavaauthor=M.+Chandy&title=Impact+of+FLT3+mutations+and+secondary+cytogenetic+changes+on+the+outcome+of+patients+with+newly+diagnosed+acute+promyelocytic+leukemia+treated+with+a+single+agent+arsenic+trioxide+regimen&doi=10.3324%2Fhaematol.10802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen</span></div><div class="casAuthors">Mathews, Vikram; Thomas, Maria; Srivastava, Vivi M.; George, Biju; Srivastava, Alok; Chandy, Mammen</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">994-995</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">0390-6078</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">Ninety-eight newly diagnosed cases of PML-RARα pos. APL were treated with a regimen of single agent ATO.  FLT3 activating mutations were seen in 33% and an addnl. cytogenetic finding was noted in 23.2%.  FLT3 activating mutations were significantly assocd. with a bcr3 PML-RARα isoform (p = 0.012) and a delay in achieving a mol. remission (p = 0.022).  Neither FLT3 activating mutations nor secondary cytogenetic changes had an impact on clin. outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyjF_niTK9BbVg90H21EOLACvtfcHk0ljIzsNVCnyV2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFGqu7vE&md5=808914d910f31c37950491b98411e63b</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.10802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.10802%26sid%3Dliteratum%253Aachs%26aulast%3DMathews%26aufirst%3DV.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DSrivastava%26aufirst%3DV.%2BM.%26aulast%3DGeorge%26aufirst%3DB.%26aulast%3DSrivastava%26aufirst%3DA.%26aulast%3DChandy%26aufirst%3DM.%26atitle%3DImpact%2520of%2520FLT3%2520mutations%2520and%2520secondary%2520cytogenetic%2520changes%2520on%2520the%2520outcome%2520of%2520patients%2520with%2520newly%2520diagnosed%2520acute%2520promyelocytic%2520leukemia%2520treated%2520with%2520a%2520single%2520agent%2520arsenic%2520trioxide%2520regimen%26jtitle%3DHaematologica%26date%3D2007%26volume%3D92%26issue%3D7%26spage%3D994%26epage%3D995%26doi%3D10.3324%2Fhaematol.10802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabrilove, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waxman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Y.</span></span> <span> </span><span class="NLM_article-title">Arsenic trioxide and sorafenib induce synthetic lethality of FLT3-ITD acute myeloid leukemia cells</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1871</span>– <span class="NLM_lpage">1880</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-17-0298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F1535-7163.MCT-17-0298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=29959200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit12qtLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=1871-1880&issue=9&author=R.+Wangauthor=Y.+Liauthor=P.+Gongauthor=J.+Gabriloveauthor=S.+Waxmanauthor=Y.+Jing&title=Arsenic+trioxide+and+sorafenib+induce+synthetic+lethality+of+FLT3-ITD+acute+myeloid+leukemia+cells&doi=10.1158%2F1535-7163.MCT-17-0298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Arsenic trioxide and sorafenib induce synthetic lethality of FLT3-ITD acute myeloid leukemia cells</span></div><div class="casAuthors">Wang, Rui; Lie, Ying; Gong, Ping; Gabrilove, Janice; Waxman, Samuel; Jing, Yongkui</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1871-1880</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) with Fms-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutation is notoriously hard to treat.  We identified two drugs that together form an effective combination therapy against FLT3-ITD AML.  One of the drugs, Sorafenib, an inhibitor of FLT3-ITD and other kinase activity, produces an impressive but short-lived remission in FLT3-ITD AML patients.  The second, arsenic trioxide (ATO), at therapeutically achievable concns., reduces the level of FLT3-ITD and Mcl-1 proteins, and induces apoptosis in leukemic cell lines and in primary cells expressing FLT3-ITD.  We linked this relative sensitivity to ATO to low levels of reduced glutathione.  While producing proapoptotic effects, ATO treatment also has an unwanted effect whereby it causes the accumulation of the phosphorylated (inactive) form of glycogen synthase kinase 3β, a kinase necessary for apoptosis.  When ATO is combined with Sorafenib, GSK-3β is activated, Mcl-1 is further reduced, and proapoptotic proteins Bak and Bax are activated.  Mice xenografted with FLT3-ITD MOLM13 cell line treated with the Sorafenib/ATO combination have significantly improved survival.  This combination has potential to improve the therapeutic outcome of FLT3-ITD targeted therapy of AML patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSa8hhWaOsyrVg90H21EOLACvtfcHk0ljIzsNVCnyV2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit12qtLrL&md5=092c29dab1f5e12e30fc97bebf4b9222</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0298%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DGabrilove%26aufirst%3DJ.%26aulast%3DWaxman%26aufirst%3DS.%26aulast%3DJing%26aufirst%3DY.%26atitle%3DArsenic%2520trioxide%2520and%2520sorafenib%2520induce%2520synthetic%2520lethality%2520of%2520FLT3-ITD%2520acute%2520myeloid%2520leukemia%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26issue%3D9%26spage%3D1871%26epage%3D1880%26doi%3D10.1158%2F1535-7163.MCT-17-0298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Breitenbuecher, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markova, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carius, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauder, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohmer, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronnstrand, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, T.</span></span> <span> </span><span class="NLM_article-title">A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>113</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">4063</span>– <span class="NLM_lpage">4073</span>, <span class="refDoi"> DOI: 10.1182/blood-2007-11-126664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2007-11-126664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=19144992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsVWrtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=4063-4073&issue=17&author=F.+Breitenbuecherauthor=B.+Markovaauthor=S.+Kasperauthor=B.+Cariusauthor=T.+Stauderauthor=F.+D.+Bohmerauthor=K.+Massonauthor=L.+Ronnstrandauthor=C.+Huberauthor=T.+Kindlerauthor=T.+Fischer&title=A+novel+molecular+mechanism+of+primary+resistance+to+FLT3-kinase+inhibitors+in+AML&doi=10.1182%2Fblood-2007-11-126664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML</span></div><div class="casAuthors">Breitenbuecher, Frank; Markova, Boyka; Kasper, Stefan; Carius, Birgit; Stauder, Torsten; Boehmer, Frank D.; Masson, Kristina; Roennstrand, Lars; Huber, Christoph; Kindler, Thomas; Fischer, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4063-4073</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Currently, FLT3 tyrosine kinase inhibitors (TKIs) are emerging as the most promising drug therapy to overcome the dismal prognosis of acute myelogenous leukemia (AML) patients harboring internal tandem duplications (ITDs) of FLT3.  However, up-front drug resistance occurs in approx. 30% of patients, and mol. mechanisms of resistance are poorly understood.  Here, we have uncovered a novel mechanism of primary resistance to FLT3 TKIs in AML: an FLT3 receptor harboring a nonjuxtamembrane ITD atypically integrating into the β-2 sheet of the first kinase domain (FLT3_ITD627E) induces dramatic up-regulation of the anti-apoptotic myeloid cell leukemia 1 protein (MCL-1).  Using RNA interference technol., deregulated MCL-1 protein expression was shown to play a major role in conferring the resistance phenotype of 32D_ITD627E cells.  Enhanced and sustained binding of the adaptor protein GRB-2 to the FLT3_ITD627E receptor is involved in MCL-1 up-regulation and is independent from TKI (PKC412)-induced inhibition of the receptor kinase.  Thus, we describe a new mechanism of primary resistance to TKIs, which operates by reprogramming local and distant signal transduction events of the FLT3 tyrosine kinase.  The data presented suggest that particular ITDs of FLT3 may be assocd. with rewired signaling and differential responsiveness to TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkDPfslG_wk7Vg90H21EOLACvtfcHk0ljIzsNVCnyV2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsVWrtr8%253D&md5=a741ab3c322f5ac83712fa097bf22704</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-11-126664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-11-126664%26sid%3Dliteratum%253Aachs%26aulast%3DBreitenbuecher%26aufirst%3DF.%26aulast%3DMarkova%26aufirst%3DB.%26aulast%3DKasper%26aufirst%3DS.%26aulast%3DCarius%26aufirst%3DB.%26aulast%3DStauder%26aufirst%3DT.%26aulast%3DBohmer%26aufirst%3DF.%2BD.%26aulast%3DMasson%26aufirst%3DK.%26aulast%3DRonnstrand%26aufirst%3DL.%26aulast%3DHuber%26aufirst%3DC.%26aulast%3DKindler%26aufirst%3DT.%26aulast%3DFischer%26aufirst%3DT.%26atitle%3DA%2520novel%2520molecular%2520mechanism%2520of%2520primary%2520resistance%2520to%2520FLT3-kinase%2520inhibitors%2520in%2520AML%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26issue%3D17%26spage%3D4063%26epage%3D4073%26doi%3D10.1182%2Fblood-2007-11-126664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Q.</span></span> <span> </span><span class="NLM_article-title">Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1833</span>, <span class="refDoi"> DOI: 10.1038/s41467-020-15290-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fs41467-020-15290-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=32286255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntFOiu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1833&issue=1&author=M.+Yinauthor=Y.+Guoauthor=R.+Huauthor=W.+L.+Caiauthor=Y.+Liauthor=S.+Peiauthor=H.+Sunauthor=C.+Pengauthor=J.+Liauthor=R.+Yeauthor=Q.+Yangauthor=N.+Wangauthor=Y.+Taoauthor=X.+Chenauthor=Q.+Yan&title=Potent+BRD4+inhibitor+suppresses+cancer+cell-macrophage+interaction&doi=10.1038%2Fs41467-020-15290-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction</span></div><div class="casAuthors">Yin, Mingzhu; Guo, Ying; Hu, Rui; Cai, Wesley L.; Li, Yao; Pei, Shiyao; Sun, Hongyin; Peng, Cong; Li, Jiali; Ye, Rui; Yang, Qiaohong; Wang, Nenghui; Tao, Yongguang; Chen, Xiang; Yan, Qin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1833</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Small mol. inhibitor of the bromodomain and extraterminal domain (BET) family proteins is a promising option for cancer treatment.  However, current BET inhibitors are limited by their potency or oral bioavailability.  Here we report the discovery and characterization of NHWD-870, a BET inhibitor that is more potent than three major clin. stage BET inhibitors BMS-986158, OTX-015, and GSK-525762.  NHWD-870 causes tumor shrinkage or significantly suppresses tumor growth in nine xenograft or syngeneic models.  In addn. to its ability to downregulate c-MYC and directly inhibit tumor cell proliferation, NHWD-870 blocks the proliferation of tumor assocd. macrophages (TAMs) through multiple mechanisms, partly by reducing the expression and secretion of macrophage colony-stimulating factor CSF1 by tumor cells.  NHWD-870 inhibits CSF1 expression through suppressing BRD4 and its target HIF1α.  Taken together, these results reveal a mechanism by which BRD4 inhibition suppresses tumor growth, and support further development of NHWD-870 to treat solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTJ-5bp_10QrVg90H21EOLACvtfcHk0lh5VhJR_wLpzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntFOiu70%253D&md5=20b5ac123381a3ca75164a5e53a64c18</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1038%2Fs41467-020-15290-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-020-15290-0%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DR.%26aulast%3DCai%26aufirst%3DW.%2BL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DPei%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DTao%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DYan%26aufirst%3DQ.%26atitle%3DPotent%2520BRD4%2520inhibitor%2520suppresses%2520cancer%2520cell-macrophage%2520interaction%26jtitle%3DNat.%2520Commun.%26date%3D2020%26volume%3D11%26issue%3D1%26spage%3D1833%26doi%3D10.1038%2Fs41467-020-15290-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fiskus, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devaraj, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leveque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portier, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhalla, K. N.</span></span> <span> </span><span class="NLM_article-title">BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2315</span>– <span class="NLM_lpage">2327</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F1535-7163.MCT-14-0258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=25053825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yisb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2315-2327&issue=10&author=W.+Fiskusauthor=S.+Sharmaauthor=J.+Qiauthor=B.+Shahauthor=S.+G.+Devarajauthor=C.+Levequeauthor=B.+P.+Portierauthor=S.+Iyerauthor=J.+E.+Bradnerauthor=K.+N.+Bhalla&title=BET+protein+antagonist+JQ1+is+synergistically+lethal+with+FLT3+tyrosine+kinase+inhibitor+%28TKI%29+and+overcomes+resistance+to+FLT3-TKI+in+AML+cells+expressing+FLT-ITD&doi=10.1158%2F1535-7163.MCT-14-0258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD</span></div><div class="casAuthors">Fiskus, Warren; Sharma, Sunil; Qi, Jun; Shah, Bhavin; Devaraj, Santhana G. T.; Leveque, Christopher; Portier, Bryce P.; Iyer, Swaminathan; Bradner, James E.; Bhalla, Kapil N.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2315-2327</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Recently, treatment with bromodomain and extraterminal protein antagonist (BA) such as JQ1 has been shown to inhibit growth and induce apoptosis of human acute myelogenous leukemia (AML) cells, including those expressing FLT3-ITD.  Here, we demonstrate that cotreatment with JQ1 and the FLT3 tyrosine kinase inhibitor (TKI) ponatinib or AC220 synergistically induce apoptosis of cultured and primary CD34+ human AML blast progenitor cells (BPC) expressing FLT3-ITD.  Concomitantly, as compared with each agent alone, cotreatment with JQ1 and the FLT3-TKI caused greater attenuation of c-MYC, BCL2, and CDK4/6.  Simultaneously, cotreatment with JQ1 and the FLT3-TKI increased the levels of p21, BIM, and cleaved PARP, as well as mediated marked attenuation of p-STAT5, p-AKT, and p-ERK1/2 levels in AML BPCs.  Conversely, cotreatment with JQ1 and FLT3-TKI was significantly less active against CD34+ normal bone marrow progenitor cells.  Knockdown of BRD4 by short hairpin RNA also sensitized AML cells to FLT3-TKI.  JQ1 treatment induced apoptosis of mouse Ba/F3 cells ectopically expressing FLT3-ITD with or without FLT3-TKI-resistant mutations F691L and D835V.  Compared with the parental human AML FLT3-ITD-expressing MOLM13, MOLM13-TKIR cells resistant to AC220 were markedly more sensitive to JQ1-induced apoptosis.  Furthermore, cotreatment with JQ1 and the pan-histone deacetylase inhibitor (HDI) panobinostat synergistically induced apoptosis of FLT3-TKI-resistant MOLM13-TKIR and MV4-11-TKIR cells.  Collectively, these findings support the rationale for detg. the in vivo activity of combined therapy with BA and FLT3-TKI against human AML cells expressing FLT3-ITD or with BA and HDI against AML cells resistant to FLT3-TKI.  Mol Cancer Ther; 13(10); 2315-27. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9PTZkTs8dmLVg90H21EOLACvtfcHk0lh5VhJR_wLpzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yisb%252FI&md5=86b07b19b740ed314bd042a472507766</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0258%26sid%3Dliteratum%253Aachs%26aulast%3DFiskus%26aufirst%3DW.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DB.%26aulast%3DDevaraj%26aufirst%3DS.%2BG.%26aulast%3DLeveque%26aufirst%3DC.%26aulast%3DPortier%26aufirst%3DB.%2BP.%26aulast%3DIyer%26aufirst%3DS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DBhalla%26aufirst%3DK.%2BN.%26atitle%3DBET%2520protein%2520antagonist%2520JQ1%2520is%2520synergistically%2520lethal%2520with%2520FLT3%2520tyrosine%2520kinase%2520inhibitor%2520%2528TKI%2529%2520and%2520overcomes%2520resistance%2520to%2520FLT3-TKI%2520in%2520AML%2520cells%2520expressing%2520FLT-ITD%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26issue%3D10%26spage%3D2315%26epage%3D2327%26doi%3D10.1158%2F1535-7163.MCT-14-0258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Tilburg, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milde, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ecker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hielscher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenk, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhl, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riehl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruhwald, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pekrun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieland, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flotho, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kordes, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruhn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linderkamp, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahm, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freitag, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burhenne, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foerster, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meid, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karapanagiotou-Schenkel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span> <span> </span><span class="NLM_article-title">Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia</span>. <i>Clin. Epigenet.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">188</span>, <span class="refDoi"> DOI: 10.1186/s13148-019-0775-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1186%2Fs13148-019-0775-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=31823832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVyktbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=188&issue=1&author=C.+M.+van%0ATilburgauthor=T.+Mildeauthor=R.+Wittauthor=J.+Eckerauthor=T.+Hielscherauthor=A.+Seitzauthor=J.+P.+Schenkauthor=J.+L.+Buhlauthor=D.+Riehlauthor=M.+C.+Fruhwaldauthor=A.+Pekrunauthor=C.+Rossigauthor=R.+Wielandauthor=C.+Flothoauthor=U.+Kordesauthor=B.+Gruhnauthor=T.+Simonauthor=C.+Linderkampauthor=F.+Sahmauthor=L.+Taylorauthor=A.+Freitagauthor=J.+Burhenneauthor=K.+I.+Foersterauthor=A.+D.+Meidauthor=S.+M.+Pfisterauthor=I.+Karapanagiotou-Schenkelauthor=O.+Witt&title=Phase+I%2FII+intra-patient+dose+escalation+study+of+vorinostat+in+children+with+relapsed+solid+tumor%2C+lymphoma%2C+or+leukemia&doi=10.1186%2Fs13148-019-0775-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia</span></div><div class="casAuthors">van Tilburg, Cornelis M.; Milde, Till; Witt, Ruth; Ecker, Jonas; Hielscher, Thomas; Seitz, Angelika; Schenk, Jens-Peter; Buhl, Juliane L.; Riehl, Dennis; Fruehwald, Michael C.; Pekrun, Arnulf; Rossig, Claudia; Wieland, Regina; Flotho, Christian; Kordes, Uwe; Gruhn, Bernd; Simon, Thorsten; Linderkamp, Christin; Sahm, Felix; Taylor, Lenka; Freitag, Angelika; Burhenne, Juergen; Foerster, Kathrin I.; Meid, Andreas D.; Pfister, Stefan M.; Karapanagiotou-Schenkel, Irini; Witt, Olaf</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Epigenetics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">188</span>CODEN:
                <span class="NLM_cas:coden">CELPCI</span>;
        ISSN:<span class="NLM_cas:issn">1868-7083</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">In the current pediatric trial, we applied an intra-patient dose escalation design.  The purpose of this trial was to det. a safe dose recommendation (SDR) of single-agent vorinostat for intra-patient dose escalation, pharmacokinetic analyses (PK), and activity evaluation in children (3-18 years) with relapsed or therapy-refractory malignancies.  Results: A phase I intra-patient dose (de)escalation was performed until individual max. tolerated dose (MTD).  The starting dose was 180 mg/m2/day with weekly dose escalations of 50 mg/m2 until DLT/max. dose.  After MTD detn., patients seamlessly continued in phase II with disease assessments every 3 mo.  An SDR of 130 mg/m2/day was detd. (max., 580 mg/m2/day). n = 46/50 (92%) patients experienced treatment-related AEs which were mostly reversible and included thrombocytopenia, fatigue, nausea, diarrhea, anemia, and vomiting. n = 6/50 (12%) had treatment-related SAEs.  Five patients achieved prolonged disease control (> 12 mo) and showed a higher Cmax (> 270 ng/mL) and MTDs.  Conclusion: An SDR of 130 mg/m2/day for individual dose escalation was detd.  Higher drug exposure was assocd. with responses and long-term disease stabilization with manageable toxicity.  Patients with low expression of plasma cytokine levels at baseline were able to tolerate higher doses of vorinostat and benefited from treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAK3quYz2RfrVg90H21EOLACvtfcHk0lh5VhJR_wLpzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVyktbfF&md5=7b89e399083307382870d15a844e11ef</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1186%2Fs13148-019-0775-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13148-019-0775-1%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BTilburg%26aufirst%3DC.%2BM.%26aulast%3DMilde%26aufirst%3DT.%26aulast%3DWitt%26aufirst%3DR.%26aulast%3DEcker%26aufirst%3DJ.%26aulast%3DHielscher%26aufirst%3DT.%26aulast%3DSeitz%26aufirst%3DA.%26aulast%3DSchenk%26aufirst%3DJ.%2BP.%26aulast%3DBuhl%26aufirst%3DJ.%2BL.%26aulast%3DRiehl%26aufirst%3DD.%26aulast%3DFruhwald%26aufirst%3DM.%2BC.%26aulast%3DPekrun%26aufirst%3DA.%26aulast%3DRossig%26aufirst%3DC.%26aulast%3DWieland%26aufirst%3DR.%26aulast%3DFlotho%26aufirst%3DC.%26aulast%3DKordes%26aufirst%3DU.%26aulast%3DGruhn%26aufirst%3DB.%26aulast%3DSimon%26aufirst%3DT.%26aulast%3DLinderkamp%26aufirst%3DC.%26aulast%3DSahm%26aufirst%3DF.%26aulast%3DTaylor%26aufirst%3DL.%26aulast%3DFreitag%26aufirst%3DA.%26aulast%3DBurhenne%26aufirst%3DJ.%26aulast%3DFoerster%26aufirst%3DK.%2BI.%26aulast%3DMeid%26aufirst%3DA.%2BD.%26aulast%3DPfister%26aufirst%3DS.%2BM.%26aulast%3DKarapanagiotou-Schenkel%26aufirst%3DI.%26aulast%3DWitt%26aufirst%3DO.%26atitle%3DPhase%2520I%252FII%2520intra-patient%2520dose%2520escalation%2520study%2520of%2520vorinostat%2520in%2520children%2520with%2520relapsed%2520solid%2520tumor%252C%2520lymphoma%252C%2520or%2520leukemia%26jtitle%3DClin.%2520Epigenet.%26date%3D2019%26volume%3D11%26issue%3D1%26spage%3D188%26doi%3D10.1186%2Fs13148-019-0775-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fiskus, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pranpat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bali, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumaraswamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyapalle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giles, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhalla, K.</span></span> <span> </span><span class="NLM_article-title">Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>108</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">645</span>– <span class="NLM_lpage">652</span>, <span class="refDoi"> DOI: 10.1182/blood-2005-11-4639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2005-11-4639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=16537804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFehtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=645-652&issue=2&author=W.+Fiskusauthor=M.+Pranpatauthor=P.+Baliauthor=M.+Balasisauthor=S.+Kumaraswamyauthor=S.+Boyapalleauthor=K.+Rochaauthor=J.+Wuauthor=F.+Gilesauthor=P.+W.+Manleyauthor=P.+Atadjaauthor=K.+Bhalla&title=Combined+effects+of+novel+tyrosine+kinase+inhibitor+AMN107+and+histone+deacetylase+inhibitor+LBH589+against+Bcr-Abl-expressing+human+leukemia+cells&doi=10.1182%2Fblood-2005-11-4639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells</span></div><div class="casAuthors">Fiskus, Warren; Pranpat, Michael; Bali, Purva; Balasis, Maria; Kumaraswamy, Sandhya; Boyapalle, Sandhya; Rocha, Kathy; Wu, Jie; Giles, Francis; Manley, Paul W.; Atadja, Peter; Bhalla, Kapil</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">645-652</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">AMN107 (Novartis Pharmaceuticals, Basel, Switzerland) has potent in vitro and in vivo activity against the unmutated and most common mutant forms of Bcr-Abl.  Treatment with the histone deacetylase inhibitor LBH589 (Novartis) depletes Bcr-Abl levels.  We detd. the effects of AMN107 and/or LBH589 in Bcr-Abl-expressing human K562 and LAMA-84 cells, as well as in primary chronic myelogenous leukemia (CML) cells.  AMN107 was more potent than imatinib mesylate (IM) in inhibiting Bcr-Abl tyrosine kinase (TK) activity and attenuating p-STAT5, p-AKT, Bcl-xL, and c-Myc levels in K562 and LAMA-84 cells.  Cotreatment with LBH589 and AMN107 exerted synergistic apoptotic effects with more attenuation of p-STAT5, p-ERK1/2, c-Myc, and Bcl-xL and increases in p27 and Bim levels.  LBH589 attenuated Bcr-Abl levels and induced apoptosis of mouse pro-B BaF3 cells contg. ectopic expression of Bcr-Abl or the IM-resistant, point-mutant Bcr-AblT315l and Bcr-AblE255K.  Treatment with LBH589 also depleted Bcr-Abl levels and induced apoptosis of IM-resistant primary human CML cells, including those with expression of Bcr-AblT315l.  As compared with either agent alone, cotreatment with AMN107 and LBH589 induced more loss of cell viability of primary IM-resistant CML cells.  Thus, cotreatment with LBH589 and AMN107 is active against cultured or primary IM-resistant CML cells, including those with expression of Bcr-AblT315l.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGzSAxnzx4SrVg90H21EOLACvtfcHk0lhILqr01XJPGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFehtbk%253D&md5=cc73f2b19bbc3bbd8cbac6b8c24c994f</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-11-4639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-11-4639%26sid%3Dliteratum%253Aachs%26aulast%3DFiskus%26aufirst%3DW.%26aulast%3DPranpat%26aufirst%3DM.%26aulast%3DBali%26aufirst%3DP.%26aulast%3DBalasis%26aufirst%3DM.%26aulast%3DKumaraswamy%26aufirst%3DS.%26aulast%3DBoyapalle%26aufirst%3DS.%26aulast%3DRocha%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DBhalla%26aufirst%3DK.%26atitle%3DCombined%2520effects%2520of%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520AMN107%2520and%2520histone%2520deacetylase%2520inhibitor%2520LBH589%2520against%2520Bcr-Abl-expressing%2520human%2520leukemia%2520cells%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26issue%3D2%26spage%3D645%26epage%3D652%26doi%3D10.1182%2Fblood-2005-11-4639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hof, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fichtner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henze, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Stackelberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shalapour, S.</span></span> <span> </span><span class="NLM_article-title">Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-kappaB</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1445</span>– <span class="NLM_lpage">1457</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-1511</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F1078-0432.CCR-12-1511" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=23357978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFKktrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1445-1457&issue=6&author=L.+Bastianauthor=J.+Hofauthor=M.+Pfauauthor=I.+Fichtnerauthor=C.+Eckertauthor=G.+Henzeauthor=J.+Pradaauthor=A.+von+Stackelbergauthor=K.+Seegerauthor=S.+Shalapour&title=Synergistic+activity+of+bortezomib+and+HDACi+in+preclinical+models+of+B-cell+precursor+acute+lymphoblastic+leukemia+via+modulation+of+p53%2C+PI3K%2FAKT%2C+and+NF-kappaB&doi=10.1158%2F1078-0432.CCR-12-1511"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-κB</span></div><div class="casAuthors">Bastian, Lorenz; Hof, Jana; Pfau, Madlen; Fichtner, Iduna; Eckert, Cornelia; Henze, Guenter; Prada, Javier; von Stackelberg, Arend; Seeger, Karl; Shalapour, Shabnam</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1445-1457</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Relapse of disease and subsequent resistance to established therapies remains a major challenge in the treatment of childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL).  New therapeutic options, such as proteasome and histone deacetylase inhibitors (HDACi) with a toxicity profile differing from that of conventional cytotoxic agents, are needed for these extensively pretreated patients.  Exptl. Design: Antiproliferative and proapoptotic effects of combined HDACi/proteasome inhibitor treatments were analyzed using BCP-ALL monocultures, cocultures with primary mesenchymal stroma cells from patients with ALL, and xenograft mouse models.  The underlying mol. mechanisms assocd. with combined treatment were detd. by gene expression profiling and protein validation.  Results: We identified the proteasome inhibitor bortezomib as a promising combination partner for HDACi due to the substantial synergistic antileukemic activity in BCP-ALL cells after concomitant application.  This effect was maintained or even increased in the presence of chemotherapeutic agents.  The synergistic effect of combined HDACi/BTZ treatment was assocd. with the regulation of genes involved in cell cycle, JUN/MAPK, PI3K/AKT, p53, ubiquitin/proteasome, and NF-κB pathways.  We obsd. an activation of NF-κB after bortezomib treatment and the induction of apoptosis-related NF-κB target genes such as TNFαRs after concomitant treatment, indicating a possible involvement of NF-κB as proapoptotic mediator.  In this context, significantly lower NF-κB subunits gene expression was detected in leukemia cells from patients who developed a relapse during frontline chemotherapy, compared with those who relapsed after cessation of frontline therapy.  Conclusion: These results provide a rationale for the integration of HDACi/BTZ combinations into current childhood BCP-ALL treatment protocols.  Clin Cancer Res; 19(6); 1445-57. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB99eJz7h77bVg90H21EOLACvtfcHk0lhILqr01XJPGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFKktrk%253D&md5=1ba986aa293b8726bb4757ea8f147d3f</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-1511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-1511%26sid%3Dliteratum%253Aachs%26aulast%3DBastian%26aufirst%3DL.%26aulast%3DHof%26aufirst%3DJ.%26aulast%3DPfau%26aufirst%3DM.%26aulast%3DFichtner%26aufirst%3DI.%26aulast%3DEckert%26aufirst%3DC.%26aulast%3DHenze%26aufirst%3DG.%26aulast%3DPrada%26aufirst%3DJ.%26aulast%3Dvon%2BStackelberg%26aufirst%3DA.%26aulast%3DSeeger%26aufirst%3DK.%26aulast%3DShalapour%26aufirst%3DS.%26atitle%3DSynergistic%2520activity%2520of%2520bortezomib%2520and%2520HDACi%2520in%2520preclinical%2520models%2520of%2520B-cell%2520precursor%2520acute%2520lymphoblastic%2520leukemia%2520via%2520modulation%2520of%2520p53%252C%2520PI3K%252FAKT%252C%2520and%2520NF-kappaB%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26issue%3D6%26spage%3D1445%26epage%3D1457%26doi%3D10.1158%2F1078-0432.CCR-12-1511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span> <span> </span><span class="NLM_article-title">FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD<sup>+</sup> acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>135</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">1472</span>– <span class="NLM_lpage">1483</span>, <span class="refDoi"> DOI: 10.1182/blood.2019003538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood.2019003538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=32315388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BB38zns12kug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2020&pages=1472-1483&issue=17&author=J.+Longauthor=M.+Y.+Jiaauthor=W.+Y.+Fangauthor=X.+J.+Chenauthor=L.+L.+Muauthor=Z.+Y.+Wangauthor=Y.+Shenauthor=R.+F.+Xiangauthor=L.+N.+Wangauthor=L.+Wangauthor=C.+H.+Jiangauthor=J.+L.+Jiangauthor=W.+J.+Zhangauthor=Y.+D.+Sunauthor=L.+Changauthor=W.+H.+Gaoauthor=Y.+Wangauthor=J.+M.+Liauthor=D.+L.+Hongauthor=A.+B.+Liangauthor=J.+Hu&title=FLT3+inhibition+upregulates+HDAC8+via+FOXO+to+inactivate+p53+and+promote+maintenance+of+FLT3-ITD%2B+acute+myeloid+leukemia&doi=10.1182%2Fblood.2019003538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia</span></div><div class="casAuthors">Long Jun; Zhang Wen-Jun; Liang Ai-Bin; Long Jun; Jia Ming-Yuan; Fang Wei-Yue; Chen Xin-Jie; Wang Zhong-Yu; Xiang Ru-Fang; Wang Li-Ning; Wang Ling; Jiang Chuan-He; Jiang Jie-Ling; Sun Yi-Dan; Chang Li; Gao Wen-Hui; Wang Ying; Li Jun-Min; Hu Jiong; Jia Ming-Yuan; Fang Wei-Yue; Chen Xin-Jie; Wang Ying; Mu Li-Li; Hong Deng-Li; Shen Yan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1472-1483</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Internal tandem duplication (ITD) mutations within the FMS-like receptor tyrosine kinase-3 (FLT3) can be found in up to 25% to 30% of acute myeloid leukemia (AML) patients and confer a poor prognosis.  Although FLT3 tyrosine kinase inhibitors (TKIs) have shown clinical responses, they cannot eliminate primitive FLT3-ITD+ AML cells, which are potential sources of relapse.  Therefore, elucidating the mechanisms underlying FLT3-ITD+ AML maintenance and drug resistance is essential to develop novel effective treatment strategies.  Here, we demonstrate that FLT3 inhibition induces histone deacetylase 8 (HDAC8) upregulation through FOXO1- and FOXO3-mediated transactivation in FLT3-ITD+ AML cells.  Upregulated HDAC8 deacetylates and inactivates p53, leading to leukemia maintenance and drug resistance upon TKI treatment.  Genetic or pharmacological inhibition of HDAC8 reactivates p53, abrogates leukemia maintenance, and significantly enhances TKI-mediated elimination of FLT3-ITD+ AML cells.  Importantly, in FLT3-ITD+ AML patient-derived xenograft models, the combination of FLT3 TKI (AC220) and an HDAC8 inhibitor (22d) significantly inhibits leukemia progression and effectively reduces primitive FLT3-ITD+ AML cells.  Moreover, we extend these findings to an AML subtype harboring another tyrosine kinase-activating mutation.  In conclusion, our study demonstrates that HDAC8 upregulation is an important mechanism to resist TKIs and promote leukemia maintenance and suggests that combining HDAC8 inhibition with TKI treatment could be a promising strategy to treat FLT3-ITD+ AML and other tyrosine kinase mutation-harboring leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLBFLp-jEpumGmni0r9GoKfW6udTcc2eblalq0g7kqMrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38zns12kug%253D%253D&md5=a68a319748e3483ac7b69faeb2770ed2</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1182%2Fblood.2019003538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.2019003538%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DJ.%26aulast%3DJia%26aufirst%3DM.%2BY.%26aulast%3DFang%26aufirst%3DW.%2BY.%26aulast%3DChen%26aufirst%3DX.%2BJ.%26aulast%3DMu%26aufirst%3DL.%2BL.%26aulast%3DWang%26aufirst%3DZ.%2BY.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DR.%2BF.%26aulast%3DWang%26aufirst%3DL.%2BN.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DC.%2BH.%26aulast%3DJiang%26aufirst%3DJ.%2BL.%26aulast%3DZhang%26aufirst%3DW.%2BJ.%26aulast%3DSun%26aufirst%3DY.%2BD.%26aulast%3DChang%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DW.%2BH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%2BM.%26aulast%3DHong%26aufirst%3DD.%2BL.%26aulast%3DLiang%26aufirst%3DA.%2BB.%26aulast%3DHu%26aufirst%3DJ.%26atitle%3DFLT3%2520inhibition%2520upregulates%2520HDAC8%2520via%2520FOXO%2520to%2520inactivate%2520p53%2520and%2520promote%2520maintenance%2520of%2520FLT3-ITD%252B%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2020%26volume%3D135%26issue%3D17%26spage%3D1472%26epage%3D1483%26doi%3D10.1182%2Fblood.2019003538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishioka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikezoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeffler, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, A.</span></span> <span> </span><span class="NLM_article-title">MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1382</span>– <span class="NLM_lpage">1392</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2008.02.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.leukres.2008.02.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=18394702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvF2qtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2008&pages=1382-1392&issue=9&author=C.+Nishiokaauthor=T.+Ikezoeauthor=J.+Yangauthor=S.+Takeuchiauthor=H.+P.+Koefflerauthor=A.+Yokoyama&title=MS-275%2C+a+novel+histone+deacetylase+inhibitor+with+selectivity+against+HDAC1%2C+induces+degradation+of+FLT3+via+inhibition+of+chaperone+function+of+heat+shock+protein+90+in+AML+cells&doi=10.1016%2Fj.leukres.2008.02.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells</span></div><div class="casAuthors">Nishioka, Chie; Ikezoe, Takayuki; Yang, Jing; Takeuchi, Seisho; Koeffler, H. Phillip; Yokoyama, Akihito</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1382-1392</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">This study explored the effect of MS-275, a novel histone deacetylase inhibitor (HDACI), against a variety of human leukemia cells with defined genetic alterations.  MS-275 profoundly induced growth arrest of acute myelogenous leukemia (AML) MOLM13 and biphenotypic leukemia MV4-11 cells, which possess internal tandem duplication mutation in the fms-like tyrosine kinase 3 (FLT3) gene (FLT3-ITD), with IC50s less than 1 μM, as measured by 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay on day two of culture.  Exposure of these cells to MS-275 decreased levels of total, as well as, phosphorylated forms of FLT3, resulting in inactivation of its downstream signal pathways, including Akt, ERK, and STAT5.  Further studies found that MS-275 induced acetylation of heat shock protein 90 (HSP90) in conjunction with ubiquitination of FLT3, leading to degrdn. of FLT3 proteins in these cells.  This was blunted by treatment with the proteasome inhibitor bortezomib, confirming that FLT was degraded via ubiquitin/proteasome pathway.  Moreover, we found that further inhibition of MEK/ERK signaling potentiated the action of MS-275 in leukemia cells.  Taken together, MS-275 may be useful for treatment of individuals with leukemia possessing activating mutation of FLT3 gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFFu5NS0Ijg7Vg90H21EOLACvtfcHk0liBhCiuqpxQyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvF2qtb0%253D&md5=b7af7f332be3efcac4f117470376e6ca</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2008.02.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2008.02.018%26sid%3Dliteratum%253Aachs%26aulast%3DNishioka%26aufirst%3DC.%26aulast%3DIkezoe%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DTakeuchi%26aufirst%3DS.%26aulast%3DKoeffler%26aufirst%3DH.%2BP.%26aulast%3DYokoyama%26aufirst%3DA.%26atitle%3DMS-275%252C%2520a%2520novel%2520histone%2520deacetylase%2520inhibitor%2520with%2520selectivity%2520against%2520HDAC1%252C%2520induces%2520degradation%2520of%2520FLT3%2520via%2520inhibition%2520of%2520chaperone%2520function%2520of%2520heat%2520shock%2520protein%252090%2520in%2520AML%2520cells%26jtitle%3DLeuk.%2520Res.%26date%3D2008%26volume%3D32%26issue%3D9%26spage%3D1382%26epage%3D1392%26doi%3D10.1016%2Fj.leukres.2008.02.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietschmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohmer, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinzel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, O. H.</span></span> <span> </span><span class="NLM_article-title">Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1412</span>– <span class="NLM_lpage">1421</span>, <span class="refDoi"> DOI: 10.1038/leu.2010.114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fleu.2010.114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=20508617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVSmurzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=1412-1421&issue=8&author=M.+Buchwaldauthor=K.+Pietschmannauthor=J.+P.+Mullerauthor=F.+D.+Bohmerauthor=T.+Heinzelauthor=O.+H.+Kramer&title=Ubiquitin+conjugase+UBCH8+targets+active+FMS-like+tyrosine+kinase+3+for+proteasomal+degradation&doi=10.1038%2Fleu.2010.114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation</span></div><div class="casAuthors">Buchwald, M.; Pietschmann, K.; Mueller, J. P.; Boehmer, F. D.; Heinzel, T.; Kraemer, O. H.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1412-1421</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The class III receptor tyrosine kinase FMS-like tyrosine kinase 3 (FLT3) regulates normal hematopoiesis and immunol. functions.  Nonetheless, constitutively active mutant FLT3 (FLT3-ITD) causally contributes to transformation and is assocd. with poor prognosis of acute myeloid leukemia (AML) patients.  Histone deacetylase inhibitors (HDACi) can counteract deregulated gene expression profiles and decrease oncoprotein stability, which renders them candidate drugs for AML treatment.  However, these drugs have pleiotropic effects and it is often unclear how they correct oncogenic transcriptomes and proteomes.  We report here that treatment of AML cells with the HDACi LBH589 induces the ubiquitin-conjugating enzyme UBCH8 and degrdn. of FLT3-ITD.  Gain- and loss-of-function approaches show that UBCH8 and the ubiquitin-ligase SIAH1 phys. interact with and target FLT3-ITD for proteasomal degrdn.  These ubiquitinylating enzymes though have a significantly lesser effect on wild-type FLT3.  Furthermore, physiol. and pharmacol. stimulation of FLT3 phosphorylation, inhibition of FLT3-ITD autophosphorylation and anal. of kinase-inactive FLT3-ITD revealed that tyrosine phosphorylation dets. degrdn. of FLT3 and FLT3-ITD by the proteasome.  These results provide novel insights into antileukemic activities of HDACi and position UBCH8, which have been implicated primarily in processes in the nucleus, as a previously unrecognized important modulator of FLT3-ITD stability and leukemic cell survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLyKAo8s7C0bVg90H21EOLACvtfcHk0liBhCiuqpxQyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVSmurzE&md5=1e7a09004da360e385f01ecfb9178157</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2Fleu.2010.114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2010.114%26sid%3Dliteratum%253Aachs%26aulast%3DBuchwald%26aufirst%3DM.%26aulast%3DPietschmann%26aufirst%3DK.%26aulast%3DMuller%26aufirst%3DJ.%2BP.%26aulast%3DBohmer%26aufirst%3DF.%2BD.%26aulast%3DHeinzel%26aufirst%3DT.%26aulast%3DKramer%26aufirst%3DO.%2BH.%26atitle%3DUbiquitin%2520conjugase%2520UBCH8%2520targets%2520active%2520FMS-like%2520tyrosine%2520kinase%25203%2520for%2520proteasomal%2520degradation%26jtitle%3DLeukemia%26date%3D2010%26volume%3D24%26issue%3D8%26spage%3D1412%26epage%3D1421%26doi%3D10.1038%2Fleu.2010.114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pietschmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolck, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spielberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polzer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiekermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bug, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinzel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohmer, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, O. H.</span></span> <span> </span><span class="NLM_article-title">Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2373</span>– <span class="NLM_lpage">2383</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F1535-7163.MCT-12-0129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=22942377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1CksrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=2373-2383&issue=11&author=K.+Pietschmannauthor=H.+A.+Bolckauthor=M.+Buchwaldauthor=S.+Spielbergauthor=H.+Polzerauthor=K.+Spiekermannauthor=G.+Bugauthor=T.+Heinzelauthor=F.+D.+Bohmerauthor=O.+H.+Kramer&title=Breakdown+of+the+FLT3-ITD%2FSTAT5+axis+and+synergistic+apoptosis+induction+by+the+histone+deacetylase+inhibitor+panobinostat+and+FLT3-specific+inhibitors&doi=10.1158%2F1535-7163.MCT-12-0129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Breakdown of the FLT3-ITD/STAT5 Axis and Synergistic Apoptosis Induction by the Histone Deacetylase Inhibitor Panobinostat and FLT3-Specific Inhibitors</span></div><div class="casAuthors">Pietschmann, Kristin; Bolck, Hella Anna; Buchwald, Marc; Spielberg, Steffi; Polzer, Harald; Spiekermann, Karsten; Bug, Gesine; Heinzel, Thorsten; Boehmer, Frank-Dietmar; Kraemer, Oliver H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2373-2383</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activating mutations of the class III receptor tyrosine kinase FLT3 are the most frequent mol. aberration in acute myeloid leukemia (AML).  Mutant FLT3 accelerates proliferation, suppresses apoptosis, and correlates with poor prognosis.  Therefore, it is a promising therapeutic target.  Here, the authors show that RNA interference against FLT3 with an internal tandem duplication (FLT3-ITD) potentiates the efficacy of the histone deacetylase inhibitor (HDACi) panobinostat (LBH589) against AML cells expressing FLT3-ITD.  Similar to RNA interference, tyrosine kinase inhibitors (TKI; AC220/cpd.102/PKC412) in combination with LBH589 exhibit superior activity against AML cells.  Median dose-effect analyses of drug-induced apoptosis rates of AML cells (MV4-11 and MOLM-13) revealed combination index (CI) values indicating strong synergism.  AC220, the most potent and FLT3-specific TKI, shows highest synergism with LBH589 in the low nanomolar range.  A 4-h exposure to LBH589 + AC220 already generates more than 50% apoptosis after 24 h.  Different cell lines lacking FLT3-ITD as well as normal peripheral blood mononuclear cells are not significantly affected by LBH589 + TKI, showing the specificity of this treatment regimen.  Immunoblot analyses show that LBH589 + TKI induce apoptosis via degrdn. of FLT3-ITD and its prosurvival target STAT5.  Previously, the authors showed the LBH589-induced proteasomal degrdn. of FLT3-ITD.  Here, the authors show that activated caspase-3 also contributes to the degrdn. of FLT3-ITD and that STAT5 is a direct target of this protease.  The authors' data strongly emphasize HDACi/TKI drug combinations as promising modality for the treatment of FLT3-ITD-pos. AMLs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobrrwTwrumvLVg90H21EOLACvtfcHk0lgFOS6d6bMTQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1CksrfF&md5=cd0825ddafad9c60143015f1d69deaa9</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0129%26sid%3Dliteratum%253Aachs%26aulast%3DPietschmann%26aufirst%3DK.%26aulast%3DBolck%26aufirst%3DH.%2BA.%26aulast%3DBuchwald%26aufirst%3DM.%26aulast%3DSpielberg%26aufirst%3DS.%26aulast%3DPolzer%26aufirst%3DH.%26aulast%3DSpiekermann%26aufirst%3DK.%26aulast%3DBug%26aufirst%3DG.%26aulast%3DHeinzel%26aufirst%3DT.%26aulast%3DBohmer%26aufirst%3DF.%2BD.%26aulast%3DKramer%26aufirst%3DO.%2BH.%26atitle%3DBreakdown%2520of%2520the%2520FLT3-ITD%252FSTAT5%2520axis%2520and%2520synergistic%2520apoptosis%2520induction%2520by%2520the%2520histone%2520deacetylase%2520inhibitor%2520panobinostat%2520and%2520FLT3-specific%2520inhibitors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26issue%3D11%26spage%3D2373%26epage%3D2383%26doi%3D10.1158%2F1535-7163.MCT-12-0129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bali, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigua, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishvanath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scuto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annavarapu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiskus, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moscinski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhalla, K.</span></span> <span> </span><span class="NLM_article-title">Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT3</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">4991</span>– <span class="NLM_lpage">4997</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-0210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F1078-0432.CCR-04-0210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=15297399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtlSitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=4991-4997&issue=15&author=P.+Baliauthor=P.+Georgeauthor=P.+Cohenauthor=J.+Taoauthor=F.+Guoauthor=C.+Siguaauthor=A.+Vishvanathauthor=A.+Scutoauthor=S.+Annavarapuauthor=W.+Fiskusauthor=L.+Moscinskiauthor=P.+Atadjaauthor=K.+Bhalla&title=Superior+activity+of+the+combination+of+histone+deacetylase+inhibitor+LAQ824+and+the+FLT-3+kinase+inhibitor+PKC412+against+human+acute+myelogenous+leukemia+cells+with+mutant+FLT3&doi=10.1158%2F1078-0432.CCR-04-0210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 Kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3</span></div><div class="casAuthors">Bali, Purva; George, Prince; Cohen, Pamela; Tao, Jianguo; Guo, Fei; Sigua, Celia; Vishvanath, Anasuya; Scuto, Anna; Annavarapu, Srinivas; Fiskus, Warren; Moscinski, Lynn; Atadja, Peter; Bhalla, Kapil</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4991-4997</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mutant FLT-3 receptor tyrosine kinase is a client protein of the mol. chaperone heat shock protein 90 and is commonly present and contributes to the leukemia phenotype in acute myelogenous leukemia (AML).  LAQ824, a cinnamyl hydroxamate histone deacetylase inhibitor, is known to induce acetylation and inhibition of heat shock protein 90.  Here, we detd. the effects of LAQ824 and/or PKC412 (a FLT-3 kinase inhibitor) on the levels of mutant FLT-3 and its downstream signaling, as well as growth arrest and cell-death of cultured and primary human AML cells.  The effect of LAQ824 and/or PKC412 treatment was detd. on the levels of FLT-3 and phosphorylated (p)-FLT-3, on downstream pro-growth and pro-survival effectors, e.g., p-STAT5, p-AKT, and p-extracellular signal-regulated kinase (ERK) 1/2, and on the cell cycle status and apoptosis in the cultured MV4-11 and primary AML cells with mutant FLT-3.  Treatment with LAQ824 promoted proteasomal degrdn. and attenuation of the levels of FLT-3 and p-FLT-3, assocd. with cell cycle G1-phase accumulation and apoptosis of MV4-11 cells.  This was accompanied by attenuation of p-STAT5, p-AKT, and p-ERK1/2 levels.  STAT-5 DNA-binding activity and the levels of c-Myc and oncostatin M were also down-regulated.  Cotreatment with LAQ824 and PKC412 synergistically induced apoptosis of MV4-11 cells and induced more apoptosis of the primary AML cells expressing mutant FLT-3.  This was also assocd. with more attenuation of p-FLT-3, p-AKT, p-ERK1/2, and p-STAT5.  The combination of LAQ824 and PKC412 is highly active against human AML cells with mutant FLT-3, which merits in vivo studies of the combination against human AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPJeLfYNFiTbVg90H21EOLACvtfcHk0lgFOS6d6bMTQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtlSitrs%253D&md5=375c881c176bfec9a1ddf8b5616d576d</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-0210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-0210%26sid%3Dliteratum%253Aachs%26aulast%3DBali%26aufirst%3DP.%26aulast%3DGeorge%26aufirst%3DP.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DTao%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DF.%26aulast%3DSigua%26aufirst%3DC.%26aulast%3DVishvanath%26aufirst%3DA.%26aulast%3DScuto%26aufirst%3DA.%26aulast%3DAnnavarapu%26aufirst%3DS.%26aulast%3DFiskus%26aufirst%3DW.%26aulast%3DMoscinski%26aufirst%3DL.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DBhalla%26aufirst%3DK.%26atitle%3DSuperior%2520activity%2520of%2520the%2520combination%2520of%2520histone%2520deacetylase%2520inhibitor%2520LAQ824%2520and%2520the%2520FLT-3%2520kinase%2520inhibitor%2520PKC412%2520against%2520human%2520acute%2520myelogenous%2520leukemia%2520cells%2520with%2520mutant%2520FLT3%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26issue%3D15%26spage%3D4991%26epage%3D4997%26doi%3D10.1158%2F1078-0432.CCR-04-0210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radany, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. Y.</span></span> <span> </span><span class="NLM_article-title">Suberoylanilide hydroxamic acid induces hypersensitivity to radiation therapy in acute myelogenous leukemia cells expressing constitutively active FLT3 mutants</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">e84515</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0084515</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1371%2Fjournal.pone.0084515" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=24367670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFelsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e84515&issue=12&author=X.+Chenauthor=E.+H.+Radanyauthor=P.+Wongauthor=S.+Maauthor=K.+Wuauthor=B.+Wangauthor=J.+Y.+Wong&title=Suberoylanilide+hydroxamic+acid+induces+hypersensitivity+to+radiation+therapy+in+acute+myelogenous+leukemia+cells+expressing+constitutively+active+FLT3+mutants&doi=10.1371%2Fjournal.pone.0084515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Suberoylanilide hydroxamic acid induces hypersensitivity to radiation therapy in acute myelogenous leukemia cells expressing constitutively active FLT3 mutants</span></div><div class="casAuthors">Chen, Xufeng; Radany, Eric H.; Wong, Patty; Ma, Shenglin; Wu, Kan; Wang, Bing; Wong, Jeffrey Y. C.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e84515/1-e84515/14, 14 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDIs) have shown promise as candidate radiosensitizer for many types of cancers.  However, the mechanisms of action are not well understood, and whether they could have clin. impact on radiotherapy for leukemia is unclear.  In this study, we demonstrate that suberoylanilide hydroxamic acid (SAHA) can increase radiosensitivity of acute myeloid leukemia (AML) cells through posttranslational modification of Rad51 protein responses and selective inhibition of the homol.-directed repair (HDR) pathway.  Our data also showed that AML cells with mutant, constitutively active FMS-like tyrosine kinase-3 (FLT3) were more radiation sensitive, caused by compromised non-homologous end joining (NHEJ) repair.  Furthermore, SAHA-induced radiosensitization were enhanced in AML cells with expression of these FLT3 mutants.  The results of this study suggest that SAHA, a recently approved HDI in clin. trials, may act as a candidate component for novel conditioning regimens to improve efficacy for AML patients undergoing radiotherapy and chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrzXL5huZIy7Vg90H21EOLACvtfcHk0lgFOS6d6bMTQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFelsb8%253D&md5=49e370ef178feae3db7bf0534211d754</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0084515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0084515%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DRadany%26aufirst%3DE.%2BH.%26aulast%3DWong%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWong%26aufirst%3DJ.%2BY.%26atitle%3DSuberoylanilide%2520hydroxamic%2520acid%2520induces%2520hypersensitivity%2520to%2520radiation%2520therapy%2520in%2520acute%2520myelogenous%2520leukemia%2520cells%2520expressing%2520constitutively%2520active%2520FLT3%2520mutants%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26issue%3D12%26spage%3De84515%26doi%3D10.1371%2Fjournal.pone.0084515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiaang, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">e83160</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0083160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1371%2Fjournal.pone.0083160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=24416160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFOjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e83160&issue=1&author=W.+H.+Linauthor=T.+K.+Yehauthor=W.+T.+Jiaangauthor=K.+J.+Yenauthor=C.+H.+Chenauthor=C.+T.+Huangauthor=S.+C.+Yenauthor=S.+Y.+Hsiehauthor=L.+H.+Chouauthor=C.+P.+Chenauthor=C.+H.+Chiuauthor=L.+C.+Kaoauthor=Y.+S.+Chaoauthor=C.+T.+Chenauthor=J.+T.+Hsu&title=Evaluation+of+the+antitumor+effects+of+BPR1J-340%2C+a+potent+and+selective+FLT3+inhibitor%2C+alone+or+in+combination+with+an+HDAC+inhibitor%2C+vorinostat%2C+in+AML+cancer&doi=10.1371%2Fjournal.pone.0083160"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer</span></div><div class="casAuthors">Lin, Wen-Hsing; Yeh, Teng-Kuang; Jiaang, Weir-Torn; Yen, Kuei-Jung; Chen, Chun-Hwa; Huang, Chin-Ting; Yen, Shih-Chieh; Hsieh, Shu-Yi; Chou, Ling-Hui; Chen, Ching-Ping; Chiu, Chun-Hsien; Kao, Li-Chun; Chao, Yu-Sheng; Chen, Chiung-Tong; Hsu, John T.-A.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e83160/1-e83160/9, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Overexpression or/and activating mutation of FLT3 kinase play a major driving role in the pathogenesis of acute myeloid leukemia (AML).  Hence, pharmacol. inhibitors of FLT3 are of therapeutic potential for AML treatment.  In this study, BPR1J-340 was identified as a novel potent FLT3 inhibitor by biochem. kinase activity (IC50 approx. 25 nM) and cellular proliferation (GC50 approx. 5 nM) assays.  BPR1J-340 inhibited the phosphorylation of FLT3 and STAT5 and triggered apoptosis in FLT3-ITD+ AML cells.  The pharmacokinetic parameters of BPR1J-340 in rats were detd.  BPR1J-340 also demonstrated pronounced tumor growth inhibition and regression in FLT3-ITD+ AML murine xenograft models.  The combination treatment of the HDAC inhibitor vorinostat (SAHA) with BPR1J-340 synergistically induced apoptosis via Mcl-1 down-regulation in MOLM-13 AML cells, indicating that the combination of selective FLT3 kinase inhibitors and HDAC inhibitors could exhibit clin. benefit in AML therapy.  Our results suggest that BPR1J-340 may be further developed in the preclin. and clin. studies as therapeutics in AML treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppUyYs9NC-LbVg90H21EOLACvtfcHk0ljG-Rre8ziqXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFOjsrc%253D&md5=d16dce70aa0d0978df3570db62559b90</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0083160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0083160%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DW.%2BH.%26aulast%3DYeh%26aufirst%3DT.%2BK.%26aulast%3DJiaang%26aufirst%3DW.%2BT.%26aulast%3DYen%26aufirst%3DK.%2BJ.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DHuang%26aufirst%3DC.%2BT.%26aulast%3DYen%26aufirst%3DS.%2BC.%26aulast%3DHsieh%26aufirst%3DS.%2BY.%26aulast%3DChou%26aufirst%3DL.%2BH.%26aulast%3DChen%26aufirst%3DC.%2BP.%26aulast%3DChiu%26aufirst%3DC.%2BH.%26aulast%3DKao%26aufirst%3DL.%2BC.%26aulast%3DChao%26aufirst%3DY.%2BS.%26aulast%3DChen%26aufirst%3DC.%2BT.%26aulast%3DHsu%26aufirst%3DJ.%2BT.%26atitle%3DEvaluation%2520of%2520the%2520antitumor%2520effects%2520of%2520BPR1J-340%252C%2520a%2520potent%2520and%2520selective%2520FLT3%2520inhibitor%252C%2520alone%2520or%2520in%2520combination%2520with%2520an%2520HDAC%2520inhibitor%252C%2520vorinostat%252C%2520in%2520AML%2520cancer%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26issue%3D1%26spage%3De83160%26doi%3D10.1371%2Fjournal.pone.0083160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. S.</span></span> <span> </span><span class="NLM_article-title">PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">e19798</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0019798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1371%2Fjournal.pone.0019798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=21589872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtlKksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e19798&issue=5&author=J.+Zhouauthor=C.+Biauthor=W.+J.+Chngauthor=L.+L.+Cheongauthor=S.+C.+Liuauthor=S.+Maharaauthor=K.+G.+Tayauthor=Q.+Zengauthor=J.+Liauthor=K.+Guoauthor=C.+P.+Tanauthor=H.+Yuauthor=D.+H.+Albertauthor=C.+S.+Chen&title=PRL-3%2C+a+metastasis+associated+tyrosine+phosphatase%2C+is+involved+in+FLT3-ITD+signaling+and+implicated+in+anti-AML+therapy&doi=10.1371%2Fjournal.pone.0019798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy</span></div><div class="casAuthors">Zhou, Jianbiao; Bi, Chonglei; Chng, Wee-Joo; Cheong, Lip-Lee; Liu, Shaw-Cheng; Mahara, Sylvia; Tay, Kian-Ghee; Zeng, Qi; Li, Jie; Guo, Ke; Tan, Cheng Peow Bobby; Yu, Hanry; Albert, Daniel H.; Chen, Chien-Shing</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e19798</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Combination with other small mol. drugs represents a promising strategy to improve therapeutic efficacy of FLT3 inhibitors in the clinic.  We demonstrated that combining ABT-869, a FLT3 inhibitor, with SAHA, a HDAC inhibitor, led to synergistic killing of the AML cells with FLT3 mutations and suppression of colony formation.  We identified a core gene signature that is uniquely induced by the combination treatment in 2 different leukemia cell lines.  Among these, we showed that downregulation of PTP4A3 (PRL-3) played a role in this synergism.  PRL-3 is downstream of FLT3 signaling and ectopic expression of PRL-3 conferred therapeutic resistance through upregulation of STAT (signal transducers and activators of transcription) pathway activity and anti-apoptotic Mcl-1 protein.  PRL-3 interacts with HDAC4 and SAHA downregulates PRL-3 via a proteasome dependent pathway.  In addn., PRL-3 protein was identified in 47% of AML cases, but was absent in myeloid cells in normal bone marrows.  Our results suggest such combination therapies may significantly improve the therapeutic efficacy of FLT3 inhibitors.  PRL-3 plays a potential pathol. role in AML and it might be a useful therapeutic target in AML, and warrant clin. investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjpYGhMVUgIbVg90H21EOLACvtfcHk0ljG-Rre8ziqXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtlKksrw%253D&md5=a31d6fabae78504afd1549b8bf110e6a</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0019798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0019798%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DBi%26aufirst%3DC.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DCheong%26aufirst%3DL.%2BL.%26aulast%3DLiu%26aufirst%3DS.%2BC.%26aulast%3DMahara%26aufirst%3DS.%26aulast%3DTay%26aufirst%3DK.%2BG.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DK.%26aulast%3DTan%26aufirst%3DC.%2BP.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DChen%26aufirst%3DC.%2BS.%26atitle%3DPRL-3%252C%2520a%2520metastasis%2520associated%2520tyrosine%2520phosphatase%252C%2520is%2520involved%2520in%2520FLT3-ITD%2520signaling%2520and%2520implicated%2520in%2520anti-AML%2520therapy%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26issue%3D5%26spage%3De19798%26doi%3D10.1371%2Fjournal.pone.0019798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z. X.</span></span> <span> </span><span class="NLM_article-title">Crotonoside exhibits selective post-inhibition effect in AML cells via inhibition of FLT3 and HDAC3/6</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">61</span>),  <span class="NLM_fpage">103087</span>– <span class="NLM_lpage">103099</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.20710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.18632%2Foncotarget.20710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=29262547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BC1Mzjs1antw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=103087-103099&issue=61&author=Y.+Z.+Liauthor=S.+Yuauthor=P.+A.+Yanauthor=D.+Y.+Gongauthor=F.+L.+Wuauthor=Z.+Heauthor=Y.+Y.+Yuanauthor=A.+Y.+Zhaoauthor=X.+Tangauthor=R.+Q.+Zhangauthor=C.+Pengauthor=Z.+X.+Cao&title=Crotonoside+exhibits+selective+post-inhibition+effect+in+AML+cells+via+inhibition+of+FLT3+and+HDAC3%2F6&doi=10.18632%2Foncotarget.20710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Crotonoside exhibits selective post-inhibition effect in AML cells via inhibition of FLT3 and HDAC3/6</span></div><div class="casAuthors">Li Yu-Zhi; Yu Si; Yan Pei-Ao; Gong Dao-Yin; Tang Xue; Zhang Ruo-Qi; Peng Cheng; Cao Zhi-Xing; Wu Fang-Li; He Zhi; Yuan Yu-Yao; Zhao An-Yan</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">61</span>),
    <span class="NLM_cas:pages">103087-103099</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Targeted therapies for the treatment of acute myeloid leukemia (AML), specifically the FLT3 inhibitors, have shown promising results.  Nevertheless, it is very unlikely that inhibitors which target a single pathway will provide long-term disease control.  Here, we report the characterization of crotonoside, a natural product extracted from Chinese medicinal herb, Croton, for the treatment of AML via inhibition of FLT3 and HDAC3/6.  In vitro, crotonoside exhibited selective inhibition in AML cells.  In vivo, crotonoside treatment at 70 and 35 mg/kg/d produced significant AML tumor inhibition rates of 93.5% and 73.6%, respectively.  Studies on the anti-AML mechanism of crotonoside demonstrated a significant inhibition of FLT3 signaling, cell cycle arrest in G0/G1 phase, and apoptosis.  In contrast to classic FLT3 inhibitor; sunitinib, crotonoside was able to selectively suppress the expression of HDAC3 and HDAC6 without altering the expression of other HDAC isoforms.  Inhibitors of HDAC3 and HDAC6; RGFP966 and HPOB, respectively, also exhibited selective inhibition in AML cells.  Furthermore, we established novel signaling pathways including HDAC3/NF-κB-p65 and HDAC6/c-Myc besides FLT3/c-Myc which are aberrantly regulated in the progression of AML.  In addition, crotonoside alone or the combination of sunitinib/RFP966/HPOB exhibited a significant post-inhibition effect in AML cells by the inhibition of FLT3 and HDAC3/6.  Inhibitors targeting the FLT3 and HDAC3/6 might provide a more effective treatment strategy for AML.  Taken together, the present study suggests that crotonoside could be a promising candidate for the treatment of AML, and deserves further investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJ7MGLt-1wSEQ0lWbKiCflfW6udTcc2eb9shdHg1URMbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mzjs1antw%253D%253D&md5=353a8403064b1a9ce553d76d712cfe88</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.20710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.20710%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%2BZ.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DYan%26aufirst%3DP.%2BA.%26aulast%3DGong%26aufirst%3DD.%2BY.%26aulast%3DWu%26aufirst%3DF.%2BL.%26aulast%3DHe%26aufirst%3DZ.%26aulast%3DYuan%26aufirst%3DY.%2BY.%26aulast%3DZhao%26aufirst%3DA.%2BY.%26aulast%3DTang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DR.%2BQ.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DZ.%2BX.%26atitle%3DCrotonoside%2520exhibits%2520selective%2520post-inhibition%2520effect%2520in%2520AML%2520cells%2520via%2520inhibition%2520of%2520FLT3%2520and%2520HDAC3%252F6%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D61%26spage%3D103087%26epage%3D103099%26doi%3D10.18632%2Foncotarget.20710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganguly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajkhowa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gocke, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konig, H.</span></span> <span> </span><span class="NLM_article-title">The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1025</span>– <span class="NLM_lpage">1032</span>, <span class="refDoi"> DOI: 10.1038/leu.2015.346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fleu.2015.346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=26686245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC28Xps1Snug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=1025-1032&issue=5&author=E.+Changauthor=S.+Gangulyauthor=T.+Rajkhowaauthor=C.+D.+Gockeauthor=M.+Levisauthor=H.+Konig&title=The+combination+of+FLT3+and+DNA+methyltransferase+inhibition+is+synergistically+cytotoxic+to+FLT3%2FITD+acute+myeloid+leukemia+cells&doi=10.1038%2Fleu.2015.346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells</span></div><div class="casAuthors">Chang, E.; Ganguly, S.; Rajkhowa, T.; Gocke, C. D.; Levis, M.; Konig, H.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1025-1032</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Effective treatment regimens for elderly acute myeloid leukemia (AML) patients harboring internal tandem duplication mutations in the FMS-like tyrosine kinase-3 (FLT3) gene (FLT3/ITD) are lacking and represent a significant unmet need.  Recent data on the effects of FLT3 tyrosine kinase inhibitors on FLT3/ITD+ AML showed promising clin. activity, including in elderly patients.  DNA methyltransferase (DNMT) inhibitors such as decitabine (5-aza-2-deoxycytidine, DEC) and 5-azacitidine (AZA) demonstrated clin. benefit in AML, are well tolerated and are assocd. with minimal increases in FLT3 ligand, which can represent a potential resistance mechanism to FLT3 inhibitors.  In addn., both FLT3 and DNMT inhibition are assocd. with the induction of terminal differentiation of myeloid blasts.  Consequently, there is a strong theor. rationale for combining FLT3 and DNMT inhibition for FLT3/ITD+ AML.  We therefore sought to study the anti-leukemic effects of DEC, AZA and FLT3 inhibitors, either as single agents or in combination, on AML cell lines and primary cells derived from newly diagnosed and relapsed AML patients.  Our studies indicate that combined treatment using FLT3 inhibition and hypomethylation confers synergistic anti-leukemic effects, including apoptosis, growth inhibition and differentiation.  The simultaneous administration of AZA and FLT3 inhibition appears to be the most efficacious combination in this regard.  These drugs may provide a novel therapeutic approach for FLT3/ITD+ AML, in particular for older patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsoMdnpAgygrVg90H21EOLACvtfcHk0lgQE0-yU4Ut7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xps1Snug%253D%253D&md5=c7b5c4d85f330db28f6bb7a9388370f2</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.346%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DE.%26aulast%3DGanguly%26aufirst%3DS.%26aulast%3DRajkhowa%26aufirst%3DT.%26aulast%3DGocke%26aufirst%3DC.%2BD.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DKonig%26aufirst%3DH.%26atitle%3DThe%2520combination%2520of%2520FLT3%2520and%2520DNA%2520methyltransferase%2520inhibition%2520is%2520synergistically%2520cytotoxic%2520to%2520FLT3%252FITD%2520acute%2520myeloid%2520leukemia%2520cells%26jtitle%3DLeukemia%26date%3D2016%26volume%3D30%26issue%3D5%26spage%3D1025%26epage%3D1032%26doi%3D10.1038%2Fleu.2015.346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lubbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruter, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmoor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germing, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuendgen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rethwisch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platzbecker, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galm, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brugger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heil, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackanson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagemeijer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijermans, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohner, H.</span></span> <span> </span><span class="NLM_article-title">A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>97</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">401</span>, <span class="refDoi"> DOI: 10.3324/haematol.2011.048231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.3324%2Fhaematol.2011.048231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=22058219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BC383nsFSrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2012&pages=393-401&issue=3&author=M.+Lubbertauthor=B.+H.+Ruterauthor=R.+Clausauthor=C.+Schmoorauthor=M.+Schmidauthor=U.+Germingauthor=A.+Kuendgenauthor=V.+Rethwischauthor=A.+Ganserauthor=U.+Platzbeckerauthor=O.+Galmauthor=W.+Bruggerauthor=G.+Heilauthor=B.+Hackansonauthor=B.+Deschlerauthor=K.+Dohnerauthor=A.+Hagemeijerauthor=P.+W.+Wijermansauthor=H.+Dohner&title=A+multicenter+phase+II+trial+of+decitabine+as+first-line+treatment+for+older+patients+with+acute+myeloid+leukemia+judged+unfit+for+induction+chemotherapy&doi=10.3324%2Fhaematol.2011.048231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy</span></div><div class="casAuthors">Lubbert Michael; Ruter Bjorn H; Claus Rainer; Schmoor Claudia; Schmid Mathias; Germing Ulrich; Kuendgen Andrea; Rethwisch Volker; Ganser Arnold; Platzbecker Uwe; Galm Oliver; Brugger Wolfram; Heil Gerhard; Hackanson Bjorn; Deschler Barbara; Dohner Konstanze; Hagemeijer Anne; Wijermans Pierre W; Dohner Hartmut</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">393-401</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The treatment of acute myeloid leukemia of older, medically non-fit patients still poses a highly unmet clinical need, and only few large, prospective studies have been performed in this setting.  Given the established activity of hypomethylating agents such as 5-aza-2'-deoxycytidine (decitabine) in myelodysplastic syndromes and acute myeloid leukemia with 20-30% bone marrow blasts, we investigated whether this drug is also active in patients with more than 30% blasts.  DESIGN AND METHODS:  To evaluate the efficacy and toxicity of decitabine in patients over 60 years old with untreated acute myeloid leukemia ineligible for induction chemotherapy, 227 patients (median age, 72 years), many with comorbidities, adverse cytogenetics and/or preceding myelodysplastic syndrome were treated with this hypomethylating agent.  During the initial decitabine treatment (135 mg/m(2) total dose infused intravenously over 72 hours every 6 weeks), a median of two cycles was administered (range, 1-4).  All-trans retinoic acid was administered to 100 patients during course 2.  Fifty-two patients who completed four cycles of treatment subsequently received a median of five maintenance courses (range, 1-19) with a lower dose of decitabine (20 mg/m(2)) infused over 1 hour on 3 consecutive days every 4-6 weeks.  RESULTS:  The complete and partial remission rate was 26%, 95% CI (20%, 32%), and an antileukemic effect was noted in 26% of patients.  Response rates did not differ between patients with or without adverse cytogenetics; patients with monosomal karyotypes also responded.  The median overall survival from the start of decitabine treatment was 5.5 months (range, 0-57.5+) and the 1-year survival rate was 28%, 95%CI (22%,34%).  Toxicities were predominantly hematologic.  CONCLUSIONS:  Decitabine is well tolerated by older, medically non-fit patients with acute myeloid leukemia; myelosuppression is the major toxicity.  The response rate and overall survival were not adversely influenced by poor-risk cytogenetics or myelodysplastic syndrome.  Because of these encouraging results, randomized studies evaluating single-agent decitabine versus conventional treatment are warranted.  The study is registered with the German Clinical Trials Registry, number DRKS00000069.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTewgQWGB3nkO98rul4nhSdfW6udTcc2eZkbs_Az4XYmbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383nsFSrtA%253D%253D&md5=be52b886b97d95c66f3d803ccba55985</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2011.048231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2011.048231%26sid%3Dliteratum%253Aachs%26aulast%3DLubbert%26aufirst%3DM.%26aulast%3DRuter%26aufirst%3DB.%2BH.%26aulast%3DClaus%26aufirst%3DR.%26aulast%3DSchmoor%26aufirst%3DC.%26aulast%3DSchmid%26aufirst%3DM.%26aulast%3DGerming%26aufirst%3DU.%26aulast%3DKuendgen%26aufirst%3DA.%26aulast%3DRethwisch%26aufirst%3DV.%26aulast%3DGanser%26aufirst%3DA.%26aulast%3DPlatzbecker%26aufirst%3DU.%26aulast%3DGalm%26aufirst%3DO.%26aulast%3DBrugger%26aufirst%3DW.%26aulast%3DHeil%26aufirst%3DG.%26aulast%3DHackanson%26aufirst%3DB.%26aulast%3DDeschler%26aufirst%3DB.%26aulast%3DDohner%26aufirst%3DK.%26aulast%3DHagemeijer%26aufirst%3DA.%26aulast%3DWijermans%26aufirst%3DP.%2BW.%26aulast%3DDohner%26aufirst%3DH.%26atitle%3DA%2520multicenter%2520phase%2520II%2520trial%2520of%2520decitabine%2520as%2520first-line%2520treatment%2520for%2520older%2520patients%2520with%2520acute%2520myeloid%2520leukemia%2520judged%2520unfit%2520for%2520induction%2520chemotherapy%26jtitle%3DHaematologica%26date%3D2012%26volume%3D97%26issue%3D3%26spage%3D393%26epage%3D401%26doi%3D10.3324%2Fhaematol.2011.048231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Jamal, H. A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mat Jusoh, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johan, M. F.</span></span> <span> </span><span class="NLM_article-title">Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">869</span>, <span class="refDoi"> DOI: 10.1186/s12885-015-1695-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1186%2Fs12885-015-1695-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=26547689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVGlsLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=869&author=H.+A.+N.+Al-Jamalauthor=S.+A.+Mat+Jusohauthor=R.+Hassanauthor=M.+F.+Johan&title=Enhancing+SHP-1+expression+with+5-azacytidine+may+inhibit+STAT3+activation+and+confer+sensitivity+in+lestaurtinib+%28CEP-701%29-resistant+FLT3-ITD+positive+acute+myeloid+leukemia&doi=10.1186%2Fs12885-015-1695-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia</span></div><div class="casAuthors">Al-Jamal, Hamid Ali Nagi; Jusoh, Siti Asmaa Mat; Hassan, Rosline; Johan, Muhammad Farid</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">869/1-869/11</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Tumor-suppressor genes are inactivated by methylation in several cancers including acute myeloid leukemia (AML).  Src homol.-2 (SH2)-contg. protein-tyrosine phosphatase 1 (SHP-1) is a neg. regulator of the JAK/STAT pathway.  Transcriptional silencing of SHP-1 plays a crit. role in the development and progression of cancers through STAT3 activation. 5-Azacytidine (5-Aza) is a DNA methyltransferase inhibitor that causes DNA demethylation resulting in re-expression of silenced SHP-1.  Lestaurtinib (CEP-701) is a multi-targeted tyrosine kinase inhibitor that potently inhibits FLT3 tyrosine kinase and induces hematol. remission in AML patients harboring the internal tandem duplication of the FLT3 gene (FLT3-ITD).  However, the majority of patients in clin. trials developed resistance to CEP-701.  Therefore, the aim of this study, was to assess the effect of re-expression of SHP-1 on sensitivity to CEP-701 in resistant AML cells.  Methods: Resistant cells harboring the FLT3-ITD were developed by overexposure of MV4-11 to CEP-701, and the effects of 5-Aza treatment were investigated.  Apoptosis and cytotoxicity of CEP-701 were detd. using Annexin V and MTS assays, resp.  Gene expression was performed by quant. real-time PCR.  STATs activity was examd. by western blotting and the methylation profile of SHP-1 was studied using MS-PCR and pyrosequencing anal.  Repeated-measures ANOVA and Kruskal-Wallis tests were used for statistical anal.  Results: The cytotoxic dose of CEP-701 on resistant cells was significantly higher in comparison with parental and MV4-11R-cep + 5-Aza cells (p = 0.004).  The resistant cells showed a significant higher viability and lower apoptosis compared with other cells (p < 0.001).  Expression of SHP-1 was 7-fold higher in MV4-11R-cep + 5-Aza cells compared to parental and resistant cells (p = 0.011).  STAT3 was activated in resistant cells.  Methylation of SHP-1 was significantly decreased in MV4-11R-cep + 5-Aza cells (p = 0.002).  Conclusions: The restoration of SHP-1 expression induces sensitivity towards CEP-701 and could serve as a target in the treatment of AML.  Our findings support the hypothesis that, the tumor-suppressor effect of SHP-1 is lost due to epigenetic silencing and its re-expression might play an important role in re-inducing sensitivity to TKIs.  Thus, SHP-1 is a plausible candidate for a role in the development of CEP-701 resistance in FLT3-ITD+ AML patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRvpZF_EfRyrVg90H21EOLACvtfcHk0lgQE0-yU4Ut7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVGlsLrM&md5=edfd98edbe255dd426424ef67aaf401b</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1186%2Fs12885-015-1695-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-015-1695-x%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Jamal%26aufirst%3DH.%2BA.%2BN.%26aulast%3DMat%2BJusoh%26aufirst%3DS.%2BA.%26aulast%3DHassan%26aufirst%3DR.%26aulast%3DJohan%26aufirst%3DM.%2BF.%26atitle%3DEnhancing%2520SHP-1%2520expression%2520with%25205-azacytidine%2520may%2520inhibit%2520STAT3%2520activation%2520and%2520confer%2520sensitivity%2520in%2520lestaurtinib%2520%2528CEP-701%2529-resistant%2520FLT3-ITD%2520positive%2520acute%2520myeloid%2520leukemia%26jtitle%3DBMC%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D869%26doi%3D10.1186%2Fs12885-015-1695-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alattar, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunwald, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudek, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajkhowa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richie, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daver, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Manero, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faderl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nazha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopleva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellasala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreeff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span> <span> </span><span class="NLM_article-title">Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT3 internal tandem duplication mutation</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>121</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">4655</span>– <span class="NLM_lpage">4662</span>, <span class="refDoi"> DOI: 10.1182/blood-2013-01-480228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2013-01-480228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=23613521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpsFWktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2013&pages=4655-4662&issue=23&author=F.+Ravandiauthor=M.+L.+Alattarauthor=M.+R.+Grunwaldauthor=M.+A.+Rudekauthor=T.+Rajkhowaauthor=M.+A.+Richieauthor=S.+Pierceauthor=N.+Daverauthor=G.+Garcia-Maneroauthor=S.+Faderlauthor=A.+Nazhaauthor=M.+Konoplevaauthor=G.+Borthakurauthor=J.+Burgerauthor=T.+Kadiaauthor=S.+Dellasalaauthor=M.+Andreeffauthor=J.+Cortesauthor=H.+Kantarjianauthor=M.+Levis&title=Phase+2+study+of+azacytidine+plus+sorafenib+in+patients+with+acute+myeloid+leukemia+and+FLT3+internal+tandem+duplication+mutation&doi=10.1182%2Fblood-2013-01-480228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation</span></div><div class="casAuthors">Ravandi, Farhad; Alattar, Mona Lisa; Grunwald, Michael R.; Rudek, Michelle A.; Rajkhowa, Trivikram; Richie, Mary Ann; Pierce, Sherry; Daver, Naval; Garcia-Manero, Guillermo; Faderl, Stefan; Nazha, Aziz; Konopleva, Marina; Borthakur, Gautam; Burger, Jan; Kadia, Tapan; Dellasala, Sara; Andreeff, Michael; Cortes, Jorge; Kantarjian, Hagop; Levis, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4655-4662</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Patients received 5-azacytidine (AZA) 75 mg/m2 i.v. daily for 7 days and sorafenib 400 mg orally twice daily continuously; cycles were repeated at ∼1-mo intervals.  Forty-three acute myeloid leukemia (AML) patients with a median age of 64 years (range, 24-87 years) were enrolled; 37 were evaluable for response.  FMS-like tyrosine kinase-3 (FLT3)-internal tandem duplication (ITD) mutation was detected in 40 (93%) patients, with a median allelic ratio of 0.32 (range, 0.009-0.93).  They had received a median of 2 prior treatment regimens (range, 0-7); 9 had failed prior therapy with a FLT3 kinase inhibitor.  The response rate was 46%, including 10 (27%) complete response with incomplete count recovery (CRi), 6 (16%) complete responses (CR), and 1 (3%) partial response.  The median time to achieve CR/CRi was 2 cycles (range, 1-4), and the median duration of CR/CRi was 2.3 mo (range, 1-14.3 mo).  Sixty-four percent of patients achieved adequate (defined as >85%) FLT3 inhibition during their first cycle of therapy.  The degree of FLT3 inhibition correlated with plasma sorafenib concns.  FLT3 ligand levels did not rise to levels seen in prior studies of patients receiving cytotoxic chemotherapy.  The combination of AZA and sorafenib is effective for patients with relapsed AML and FLT-3-ITD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx7FK4wFoKk7Vg90H21EOLACvtfcHk0ljZet2RITEZfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpsFWktbo%253D&md5=cb763c746906ccd682cbe8faa5ec6f67</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-01-480228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-01-480228%26sid%3Dliteratum%253Aachs%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DAlattar%26aufirst%3DM.%2BL.%26aulast%3DGrunwald%26aufirst%3DM.%2BR.%26aulast%3DRudek%26aufirst%3DM.%2BA.%26aulast%3DRajkhowa%26aufirst%3DT.%26aulast%3DRichie%26aufirst%3DM.%2BA.%26aulast%3DPierce%26aufirst%3DS.%26aulast%3DDaver%26aufirst%3DN.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DFaderl%26aufirst%3DS.%26aulast%3DNazha%26aufirst%3DA.%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DBurger%26aufirst%3DJ.%26aulast%3DKadia%26aufirst%3DT.%26aulast%3DDellasala%26aufirst%3DS.%26aulast%3DAndreeff%26aufirst%3DM.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DLevis%26aufirst%3DM.%26atitle%3DPhase%25202%2520study%2520of%2520azacytidine%2520plus%2520sorafenib%2520in%2520patients%2520with%2520acute%2520myeloid%2520leukemia%2520and%2520FLT3%2520internal%2520tandem%2520duplication%2520mutation%26jtitle%3DBlood%26date%3D2013%26volume%3D121%26issue%3D23%26spage%3D4655%26epage%3D4662%26doi%3D10.1182%2Fblood-2013-01-480228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daver, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohanian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNardo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrov, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrajoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Manero, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopleva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreeff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pemmaraju, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabbour, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarado, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinsoy, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span> <span> </span><span class="NLM_article-title">The combination of quizartinib with azacitidine or Low dose cytarabine is highly active in patients (Pts) with FLT3-ITD mutated myeloid leukemias: interim report of a phase I/II trial</span>. <i>Clinical Lymphoma Myeloma and Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">S3</span>, <span class="refDoi"> DOI: 10.1016/j.clml.2017.09.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.clml.2017.09.027" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=S3&issue=10&author=M.+Swaminathanauthor=H.+Kantarjianauthor=N.+Daverauthor=G.+Borthakurauthor=M.+Ohanianauthor=T.+Kadiaauthor=C.+DiNardoauthor=N.+Jainauthor=Z.+Estrovauthor=A.+Ferrajoliauthor=G.+Garcia-Maneroauthor=M.+Konoplevaauthor=M.+Andreeffauthor=N.+Pemmarajuauthor=E.+Jabbourauthor=Y.+Alvaradoauthor=W.+Wierdaauthor=M.+R.+Pinsoyauthor=F.+Ravandiauthor=J.+Cortes&title=The+combination+of+quizartinib+with+azacitidine+or+Low+dose+cytarabine+is+highly+active+in+patients+%28Pts%29+with+FLT3-ITD+mutated+myeloid+leukemias%3A+interim+report+of+a+phase+I%2FII+trial&doi=10.1016%2Fj.clml.2017.09.027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.clml.2017.09.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clml.2017.09.027%26sid%3Dliteratum%253Aachs%26aulast%3DSwaminathan%26aufirst%3DM.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DDaver%26aufirst%3DN.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DOhanian%26aufirst%3DM.%26aulast%3DKadia%26aufirst%3DT.%26aulast%3DDiNardo%26aufirst%3DC.%26aulast%3DJain%26aufirst%3DN.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DFerrajoli%26aufirst%3DA.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DAndreeff%26aufirst%3DM.%26aulast%3DPemmaraju%26aufirst%3DN.%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DAlvarado%26aufirst%3DY.%26aulast%3DWierda%26aufirst%3DW.%26aulast%3DPinsoy%26aufirst%3DM.%2BR.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DThe%2520combination%2520of%2520quizartinib%2520with%2520azacitidine%2520or%2520Low%2520dose%2520cytarabine%2520is%2520highly%2520active%2520in%2520patients%2520%2528Pts%2529%2520with%2520FLT3-ITD%2520mutated%2520myeloid%2520leukemias%253A%2520interim%2520report%2520of%2520a%2520phase%2520I%252FII%2520trial%26jtitle%3DClinical%2520Lymphoma%2520Myeloma%2520and%2520Leukemia%26date%3D2017%26volume%3D17%26issue%3D10%26spage%3DS3%26doi%3D10.1016%2Fj.clml.2017.09.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dowling, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakikhani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantus, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span> <span> </span><span class="NLM_article-title">Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10804</span>– <span class="NLM_lpage">10812</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-2310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F0008-5472.CAN-07-2310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=18006825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlSls7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=10804-10812&issue=22&author=R.+J.+Dowlingauthor=M.+Zakikhaniauthor=I.+G.+Fantusauthor=M.+Pollakauthor=N.+Sonenberg&title=Metformin+inhibits+mammalian+target+of+rapamycin-dependent+translation+initiation+in+breast+cancer+cells&doi=10.1158%2F0008-5472.CAN-07-2310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin Inhibits Mammalian Target of Rapamycin-Dependent Translation Initiation in Breast Cancer Cells</span></div><div class="casAuthors">Dowling, Ryan J. O.; Zakikhani, Mahvash; Fantus, I. George; Pollak, Michael; Sonenberg, Nahum</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10804-10812</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Metformin is used for the treatment of type 2 diabetes because of its ability to lower blood glucose.  The effects of metformin are explained by the activation of AMP-activated protein kinase (AMPK), which regulates cellular energy metab.  Recently, we showed that metformin inhibits the growth of breast cancer cells through the activation of AMPK.  Here, we show that metformin inhibits translation initiation.  In MCF-7 breast cancer cells, metformin treatment led to a 30% decrease in global protein synthesis.  Metformin caused a dose-dependent specific decrease in cap-dependent translation, with a maximal inhibition of 40%.  Polysome profile anal. showed an inhibition of translation initiation as metformin treatment of MCF-7 cells led to a shift of mRNAs from heavy to light polysomes and a concomitant increase in the amt. of 80S ribosomes.  The decrease in translation caused by metformin was assocd. with mammalian target of rapamycin (mTOR) inhibition, and a decrease in the phosphorylation of S6 kinase, ribosomal protein S6, and eIF4E-binding protein 1.  The effects of metformin on translation were mediated by AMPK, as treatment of cells with the AMPK inhibitor compd. C prevented the inhibition of translation.  Furthermore, translation in MDA-MB-231 cells, which lack the AMPK kinase LKB1, and in tuberous sclerosis complex 2 null (TSC2-/-) mouse embryonic fibroblasts was unaffected by metformin, indicating that LKB1 and TSC2 are involved in the mechanism of action of metformin.  These results show that metformin-mediated AMPK activation leads to inhibition of mTOR and a redn. in translation initiation, thus providing a possible mechanism of action of metformin in the inhibition of cancer cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJqVcwq27NFbVg90H21EOLACvtfcHk0ljZet2RITEZfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlSls7fI&md5=3a7bcbef8eda124f387ceb5526a3efb4</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-2310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-2310%26sid%3Dliteratum%253Aachs%26aulast%3DDowling%26aufirst%3DR.%2BJ.%26aulast%3DZakikhani%26aufirst%3DM.%26aulast%3DFantus%26aufirst%3DI.%2BG.%26aulast%3DPollak%26aufirst%3DM.%26aulast%3DSonenberg%26aufirst%3DN.%26atitle%3DMetformin%2520inhibits%2520mammalian%2520target%2520of%2520rapamycin-dependent%2520translation%2520initiation%2520in%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26issue%3D22%26spage%3D10804%26epage%3D10812%26doi%3D10.1158%2F0008-5472.CAN-07-2310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W.</span></span> <span> </span><span class="NLM_article-title">Metformin inhibits the proliferation of A431 cells by modulating the PI3K/Akt signaling pathway</span>. <i>Exp. Ther. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1401</span>– <span class="NLM_lpage">1406</span>, <span class="refDoi"> DOI: 10.3892/etm.2015.2220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.3892%2Fetm.2015.2220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=25780442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnvValsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=1401-1406&issue=4&author=Y.+Liuauthor=Y.+Zhangauthor=K.+Jiaauthor=Y.+Dongauthor=W.+Ma&title=Metformin+inhibits+the+proliferation+of+A431+cells+by+modulating+the+PI3K%2FAkt+signaling+pathway&doi=10.3892%2Fetm.2015.2220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin inhibits the proliferation of A431 cells by modulating the PI3K/Akt signaling pathway</span></div><div class="casAuthors">Liu, Yingshan; Zhang, Yan; Jia, Kun; Dong, Yuhao; Ma, Weiyuan</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and Therapeutic Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1401-1406</span>CODEN:
                <span class="NLM_cas:coden">ETMXA2</span>;
        ISSN:<span class="NLM_cas:issn">1792-0981</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The ability of metformin, an antidiabetic drug with wide applications, to inhibit tumor cell growth has recently been discovered.  The PI3K/Akt signaling pathway has been found to play an important role in the survival, proliferation and apoptosis of tumor cells.  The aim of the present study was to explore the effect of metformin on the proliferation of A431 human squamous cell carcinoma cells and the underlying mol. mechanisms.  A431 cells in the logarithmic growth phase were treated with 0, 15, 30, 45 and 60 mM metformin for 12, 24 and 36 h, resp.  Cell morphol. with 45 mM metformin treatment for 24 h was obsd. under a microscope.  The proliferation of A431 cells was detected by the Cell Counting kit-8 colorimetric method.  The mRNA expression levels of PI3K and Akt were detected by reverse transcription-polymerase chain reaction (RT-PCR).  The protein expression levels of PI3K, Akt and phosphorylated (p)-Akt were detected by western blot anal.  Metformin treatment caused morphol. change in A431 cells and inhibited their proliferation in a significant time- and dose-dependent manner.  RT-PCR results showed that the mRNA expression of PI3K was inhibited by metformin in a time- and dose-dependent manner (P<0.05).  However, there was no significant change in the mRNA expression of Akt following metformin treatment (P>0.05).  Western blotting results showed that the protein expression levels of PI3K and p-Akt were inhibited by metformin in a time- and dose-dependent manner (P<0.05).  In conclusion, metformin significantly inhibited the proliferation of A431 cells in the current study, which may be strongly assocd. with the inhibition of the PI3K/Akt signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr663vfSlEIhrVg90H21EOLACvtfcHk0lgOv-H8Cwta-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnvValsr4%253D&md5=f54c303907ea5ca73bc84e99cf70c242</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.3892%2Fetm.2015.2220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fetm.2015.2220%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DW.%26atitle%3DMetformin%2520inhibits%2520the%2520proliferation%2520of%2520A431%2520cells%2520by%2520modulating%2520the%2520PI3K%252FAkt%2520signaling%2520pathway%26jtitle%3DExp.%2520Ther.%2520Med.%26date%3D2015%26volume%3D9%26issue%3D4%26spage%3D1401%26epage%3D1406%26doi%3D10.3892%2Fetm.2015.2220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span> <span> </span><span class="NLM_article-title">Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1421</span>– <span class="NLM_lpage">1427</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2015.09.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.leukres.2015.09.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=26505133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslSjsb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2015&pages=1421-1427&issue=12&author=F.+Wangauthor=Z.+Liuauthor=J.+Zengauthor=H.+Zhuauthor=J.+Liauthor=X.+Chengauthor=T.+Jiangauthor=L.+Zhangauthor=C.+Zhangauthor=T.+Chenauthor=T.+Liuauthor=Y.+Jia&title=Metformin+synergistically+sensitizes+FLT3-ITD-positive+acute+myeloid+leukemia+to+sorafenib+by+promoting+mTOR-mediated+apoptosis+and+autophagy&doi=10.1016%2Fj.leukres.2015.09.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy</span></div><div class="casAuthors">Wang, Fangfang; Liu, Zuofeng; Zeng, Jisha; Zhu, Hongyan; Li, Jingjing; Cheng, Xiaomin; Jiang, Tao; Zhang, Li; Zhang, Chuanfen; Chen, Tie; Liu, Ting; Jia, Yongqian</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1421-1427</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Mutations of Fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD), accounting for approx. 30% of patients with acute myeloid leukemia (AML), results in poor therapeutic efficacy and short survival.  Sorafenib, an oral multikinase inhibitor, can inhibit FLT3 and improve clin. outcome of FLT3 mutated leukemia.  Our current studies have shown that, the antidiabetic drug metformin also exerts anti-leukemic effect by activating p-AMPK and synergistically sensitizes FLT3 mutated AML to sorafenib.  Both agents suppress cell proliferation in a dose-dependent manner and induce apoptosis via cell cycle arrest, but does not obviously modulate autophagy marker, light chain 3 (LC3).  Mechanistically, in the presence of metformin, the anticancer potential of sorafenib, accompanying with increased LC3 levels, is found to be synergistically enhanced with the remarkably reduced protein expression of the mTOR/p70S6K/4EBP1 pathway, while not appreciably altering cell cycle.  Overall, these results show metformin in aid of sorafenib may represent a promising and attractive strategy for the treatment of FLT3-ITD mutated AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1PhDpLHlTjLVg90H21EOLACvtfcHk0lgOv-H8Cwta-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslSjsb%252FI&md5=c9f09d1129f9c72f86d126f9831a2bd9</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2015.09.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2015.09.016%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DZeng%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DJia%26aufirst%3DY.%26atitle%3DMetformin%2520synergistically%2520sensitizes%2520FLT3-ITD-positive%2520acute%2520myeloid%2520leukemia%2520to%2520sorafenib%2520by%2520promoting%2520mTOR-mediated%2520apoptosis%2520and%2520autophagy%26jtitle%3DLeuk.%2520Res.%26date%3D2015%26volume%3D39%26issue%3D12%26spage%3D1421%26epage%3D1427%26doi%3D10.1016%2Fj.leukres.2015.09.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. J.</span></span> <span> </span><span class="NLM_article-title">The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2017.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.leukres.2017.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=29232592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFGlsrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2018&pages=14-19&author=H.+H.+Zhuauthor=Z.+P.+Guoauthor=J.+S.+Jiaauthor=Q.+Jiangauthor=H.+Jiangauthor=X.+J.+Huang&title=The+impact+of+oral+arsenic+and+all-trans-retinoic+acid+on+coagulopathy+in+acute+promyelocytic+leukemia&doi=10.1016%2Fj.leukres.2017.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia</span></div><div class="casAuthors">Zhu, Hong-Hu; Guo, Zhi-Ping; Jia, Jin-Song; Jiang, Qian; Jiang, Hao; Huang, Xiao-Jun</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14-19</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The aim of our study was to evaluate the impact of oral arsenic (the realgar-indigo naturalis formula, RIF) and all-trans retinoic acid (ATRA) on coagulopathy in acute promyelocytic leukemia (APL) compared with i.v. arsenic trioxide (ATO) and ATRA during induction.  Mitoxantrone was added to all the patients at a dose of 1.4 mg/m2 per day for 5-7 days.  D-dimer levels, prothrombin time (PT), fibrinogen (Fbg) levels and the platelet count were comparably analyzed among 83 newly diagnosed APL patients treated with RIF (n = 45) or with ATO (n = 38).  Since induction therapy with RIF and ATRA, the median levels of Fbg, PT and platelets were recovered to the normal range within 4 days, 10 days and 28 days, resp.  The last day of platelet and plasma transfusion was day 12 (range: 0-24 days) and day 3 (range: 0-27 days), resp.  Among the 42 patients with a disseminated intravascular coagulation (DIC) score = 4, the consumption of transfused platelets was less in the RIF group than that in the ATO group (P = 0.037).  In the 17 patients with a DIC score <4, prompt recovery of Fbg levels (P = 0.028) was obsd. in the RIF group compared with that in the ATO group (P = 0.401).  RIF and ATO showed similar effects on the recovery of coagulopathy in APL patients.  RIF had a potential beneficial effect in accelerating the recovery of thrombocytopenia and hypofibrinogenemia for subclin. DIC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaPZ3N9Bihf7Vg90H21EOLACvtfcHk0lgOv-H8Cwta-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFGlsrfL&md5=87885249348fc3492fa2a6a8c5cd660b</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2017.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2017.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DH.%2BH.%26aulast%3DGuo%26aufirst%3DZ.%2BP.%26aulast%3DJia%26aufirst%3DJ.%2BS.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DX.%2BJ.%26atitle%3DThe%2520impact%2520of%2520oral%2520arsenic%2520and%2520all-trans-retinoic%2520acid%2520on%2520coagulopathy%2520in%2520acute%2520promyelocytic%2520leukemia%26jtitle%3DLeuk.%2520Res.%26date%3D2018%26volume%3D65%26spage%3D14%26epage%3D19%26doi%3D10.1016%2Fj.leukres.2017.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">All-trans retinoic acid exerts selective anti-FLT3-ITD acute myeloid leukemia efficacy through downregulating Chk1 kinase</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>473</i></span>,  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2019.12.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.canlet.2019.12.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=31904486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BB3cXotVemtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=473&publication_year=2020&pages=130-138&author=W.+Wangauthor=Z.+Jiangauthor=L.+Wangauthor=A.+Wangauthor=J.+Liuauthor=C.+Chenauthor=K.+Yuauthor=F.+Zouauthor=W.+Wangauthor=J.+Liuauthor=Q.+Liu&title=All-trans+retinoic+acid+exerts+selective+anti-FLT3-ITD+acute+myeloid+leukemia+efficacy+through+downregulating+Chk1+kinase&doi=10.1016%2Fj.canlet.2019.12.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">All-trans retinoic acid exerts selective anti-FLT3-ITD acute myeloid leukemia efficacy through downregulating Chk1 kinase</span></div><div class="casAuthors">Wang, Wenliang; Jiang, Zongru; Wang, Li; Wang, Aoli; Liu, Juan; Chen, Cheng; Yu, Kailin; Zou, Fengming; Wang, Wenchao; Liu, Jing; Liu, Qingsong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">473</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">130-138</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">All-trans retinoic acid (ATRA) is known to be a potent inhibitor of FLT3-ITD acute myeloid leukemia (AML) cells, although the exact mechanism remains unclear.  In this work, we report that ATRA causes fatal mitotic catastrophe in FLT3-ITD AML cells by degrading Chk1 kinase, and therefore preventing DNA damage repair.  In order to explore a further enhancement in the inhibitory effect of ATRA on FLT3-ITD AML cells, we investigated the suitability of a combination of ATRA and DNA damage drug SN38.  In vitro expts. showed that this combinatorial approach effectively inhibited the proliferation of FLT3-ITD cells and induced cell apoptosis in AML.  In vivo expts. confirmed that the combination could substantially improve the anti-tumor effect of SN38.  Taken together, our results indicate that ATRA down-regulates Chk1 in FLT3-ITD AML cells, and the combination of ATRA and SN38 significantly improves the anti-tumor effect of either ATRA or SN38 when used alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKcigTNTfpvbVg90H21EOLACvtfcHk0ljHMq2_yXLPkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXotVemtr4%253D&md5=64cdca227a01b66ea4375c0be20ed337</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2019.12.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2019.12.045%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DZou%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DAll-trans%2520retinoic%2520acid%2520exerts%2520selective%2520anti-FLT3-ITD%2520acute%2520myeloid%2520leukemia%2520efficacy%2520through%2520downregulating%2520Chk1%2520kinase%26jtitle%3DCancer%2520Lett.%26date%3D2020%26volume%3D473%26spage%3D130%26epage%3D138%26doi%3D10.1016%2Fj.canlet.2019.12.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenblatt, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirley, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffield, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruner, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aplan, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span> <span> </span><span class="NLM_article-title">All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD<sup>+</sup> leukemia stem cells <i>in vitro</i> and <i>in vivo</i></span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">2867</span>– <span class="NLM_lpage">2878</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-05-646786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2015-05-646786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=27103744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1ars7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=2867-2878&issue=23&author=H.+S.+Maauthor=S.+M.+Greenblattauthor=C.+M.+Shirleyauthor=A.+S.+Duffieldauthor=J.+K.+Brunerauthor=L.+Liauthor=B.+Nguyenauthor=E.+Jungauthor=P.+D.+Aplanauthor=G.+Ghiaurauthor=R.+J.+Jonesauthor=D.+Small&title=All-trans+retinoic+acid+synergizes+with+FLT3+inhibition+to+eliminate+FLT3%2FITD%2B+leukemia+stem+cells+in+vitro+and+in+vivo&doi=10.1182%2Fblood-2015-05-646786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo</span></div><div class="casAuthors">Ma, Hayley S.; Greenblatt, Sarah M.; Shirley, Courtney M.; Duffield, Amy S.; Bruner, J. Kyle; Li, Li; Nguyen, Bao; Jung, Eric; Aplan, Peter D.; Ghiaur, Gabriel; Jones, Richard J.; Small, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2867-2878</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">FMS-like tyrosine kinase 3 (FLT3)-mutant acute myeloid leukemia (AML) portends a poor prognosis, and ineffective targeting of the leukemic stem cell (LSC) population remains one of several obstacles in treating this disease.  All-trans retinoic acid (ATRA) has been used in several clin. trials for the treatment of nonpromyelocytic AML with limited clin. activity obsd.  FLT3 tyrosine kinase inhibitors (TKIs) used as monotherapy also achieve limited clin. responses and are thus far unable to affect cure rates in AML patients.  We explored the efficacy of combining ATRA and FLT3 TKIs to eliminate FLT3/internal tandem duplication (ITD)+ LSCs.  Our studies reveal highly synergistic drug activity, preferentially inducing apoptosis in FLT3/ITD+ cell lines and patient samples.  Colony-forming unit assays further demonstrate decreased clonogenicity of FLT3/ITD+ cells upon treatment with ATRA and TKI.  Most importantly, the drug combination depletes FLT3/ITD+ LSCs in a genetic mouse model of AML, and prolongs survival of leukemic mice.  Furthermore, engraftment of primary FLT3/ITD+ patient samples is reduced in mice following treatment with FLT3 TKI and ATRA in combination, with evidence of cellular differentiation occurring in vivo.  Mechanistically, we provide evidence that the synergism of ATRA and FLT3 TKIs is at least in part due to the observation that FLT3 TKI treatment upregulates the antiapoptotic protein Bcl6, limiting the drug's apoptotic effect.  However, cotreatment with ATRA reduces Bcl6 expression to baseline levels through suppression of interleukin-6 receptor signaling.  These studies provide evidence of the potential of this drug combination to eliminate FLT3/ITD+ LSCs and reduce the rate of relapse in AML patients with FLT3 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZPpO6zBVIsLVg90H21EOLACvtfcHk0ljHMq2_yXLPkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1ars7zE&md5=4f0e624bfcb71998230c304074beda38</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-05-646786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-05-646786%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DH.%2BS.%26aulast%3DGreenblatt%26aufirst%3DS.%2BM.%26aulast%3DShirley%26aufirst%3DC.%2BM.%26aulast%3DDuffield%26aufirst%3DA.%2BS.%26aulast%3DBruner%26aufirst%3DJ.%2BK.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DJung%26aufirst%3DE.%26aulast%3DAplan%26aufirst%3DP.%2BD.%26aulast%3DGhiaur%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DR.%2BJ.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DAll-trans%2520retinoic%2520acid%2520synergizes%2520with%2520FLT3%2520inhibition%2520to%2520eliminate%2520FLT3%252FITD%252B%2520leukemia%2520stem%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26issue%3D23%26spage%3D2867%26epage%3D2878%26doi%3D10.1182%2Fblood-2015-05-646786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guenounou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delabesse, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recher, C.</span></span> <span> </span><span class="NLM_article-title">Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations</span>. <i>Eur. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>93</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">536</span>, <span class="refDoi"> DOI: 10.1111/ejh.12334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1111%2Fejh.12334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=24689895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFCqu7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2014&pages=533-536&issue=6&author=S.+Guenounouauthor=E.+Delabesseauthor=C.+Recher&title=Sorafenib+plus+all-trans+retinoic+acid+for+AML+patients+with+FLT3-ITD+and+NPM1+mutations&doi=10.1111%2Fejh.12334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations</span></div><div class="casAuthors">Guenounou, Sarah; Delabesse, Eric; Recher, Christian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Haematology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">533-536</span>CODEN:
                <span class="NLM_cas:coden">EJHAEC</span>;
        ISSN:<span class="NLM_cas:issn">0902-4441</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Knowledge of the mol. basis of acute myeloid leukemia has increased considerably in the past few years, and therapies targeting specific mol. defects of this disease are intensively investigated.  Patients with both NPM1 and FLT3-ITD mutations encompass 20% of cytogenetically normal AML.  The multikinase and FLT3 inhibitor, sorafenib, has shown some efficacy in patients with relapsed FLT3-ITD+ AML.  In addn., it is suggested that all-trans retinoic acid (ATRA) used in combination with chemotherapy has shown to improve outcome of patients harboring NPM1 mutations.  We report here the clin. course of three patients with refractory or relapsed FLT3-ITD+/NPM1+ AML who achieved significant response upon sorafenib and ATRA combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJW3OjlJDixbVg90H21EOLACvtfcHk0ljHMq2_yXLPkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFCqu7nM&md5=266b24a8c5b745a24af876b34ea56526</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1111%2Fejh.12334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fejh.12334%26sid%3Dliteratum%253Aachs%26aulast%3DGuenounou%26aufirst%3DS.%26aulast%3DDelabesse%26aufirst%3DE.%26aulast%3DRecher%26aufirst%3DC.%26atitle%3DSorafenib%2520plus%2520all-trans%2520retinoic%2520acid%2520for%2520AML%2520patients%2520with%2520FLT3-ITD%2520and%2520NPM1%2520mutations%26jtitle%3DEur.%2520J.%2520Haematol.%26date%3D2014%26volume%3D93%26issue%3D6%26spage%3D533%26epage%3D536%26doi%3D10.1111%2Fejh.12334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Speers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsimelzon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrick, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culhane, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quackenbush, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilsenbeck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P.</span></span> <span> </span><span class="NLM_article-title">Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">6327</span>– <span class="NLM_lpage">6340</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-1107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F1078-0432.CCR-09-1107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=19808870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlyqsLfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=6327-6340&issue=20&author=C.+Speersauthor=A.+Tsimelzonauthor=K.+Sextonauthor=A.+M.+Herrickauthor=C.+Gutierrezauthor=A.+Culhaneauthor=J.+Quackenbushauthor=S.+Hilsenbeckauthor=J.+Changauthor=P.+Brown&title=Identification+of+novel+kinase+targets+for+the+treatment+of+estrogen+receptor-negative+breast+cancer&doi=10.1158%2F1078-0432.CCR-09-1107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer</span></div><div class="casAuthors">Speers, Corey; Tsimelzon, Anna; Sexton, Krystal; Herrick, Ashley M.; Gutierrez, Carolina; Culhane, Aedin; Quackenbush, John; Hilsenbeck, Susan; Chang, Jenny; Brown, Powel</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6327-6340</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Previous gene expression profiling studies of breast cancer have focused on the entire genome to identify genes differentially expressed between estrogen receptor (ER) α-pos. and ER-α-neg. cancers.  Exptl. Design: Here, the authors used gene expression microarray profiling to identify a distinct kinase gene expression profile that identifies ER-neg. breast tumors and subsets ER-neg. breast tumors into four distinct subtypes.  Results: Based on the types of kinases expressed in these clusters, the authors identify a cell cycle regulatory subset, a S6 kinase pathway cluster, an immunomodulatory kinase-expressing cluster, and a mitogen-activated protein kinase pathway cluster.  Furthermore, the authors show that this specific kinase profile is validated using independent sets of human tumors and is also seen in a panel of breast cancer cell lines.  Kinase expression knockdown studies show that many of these kinases are essential for the growth of ER-neg., but not ER-pos., breast cancer cell lines.  Finally, survival anal. of patients with breast cancer shows that the S6 kinase pathway signature subtype of ER-neg. cancers confers an extremely poor prognosis, whereas patients whose tumors express high levels of immunomodulatory kinases have a significantly better prognosis.  Conclusions: This study identifies a list of kinases that are prognostic and may serve as druggable targets for the treatment of ER-neg. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_rbJqzatV3bVg90H21EOLACvtfcHk0ljXHUV5jYDmPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlyqsLfK&md5=5c3d1bc319129b47ae96fe07b635c29a</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-1107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-1107%26sid%3Dliteratum%253Aachs%26aulast%3DSpeers%26aufirst%3DC.%26aulast%3DTsimelzon%26aufirst%3DA.%26aulast%3DSexton%26aufirst%3DK.%26aulast%3DHerrick%26aufirst%3DA.%2BM.%26aulast%3DGutierrez%26aufirst%3DC.%26aulast%3DCulhane%26aufirst%3DA.%26aulast%3DQuackenbush%26aufirst%3DJ.%26aulast%3DHilsenbeck%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DP.%26atitle%3DIdentification%2520of%2520novel%2520kinase%2520targets%2520for%2520the%2520treatment%2520of%2520estrogen%2520receptor-negative%2520breast%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26issue%3D20%26spage%3D6327%26epage%3D6340%26doi%3D10.1158%2F1078-0432.CCR-09-1107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dozier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Didier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamburini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manenti, S.</span></span> <span> </span><span class="NLM_article-title">Targeting CHK1 inhibits cell proliferation in FLT3-ITD positive acute myeloid leukemia</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1342</span>– <span class="NLM_lpage">1349</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2014.08.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.leukres.2014.08.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=25281057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFGltLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2014&pages=1342-1349&issue=11&author=L.+L.+Yuanauthor=A.+Greenauthor=L.+Davidauthor=C.+Dozierauthor=C.+Recherauthor=C.+Didierauthor=J.+Tamburiniauthor=S.+Manenti&title=Targeting+CHK1+inhibits+cell+proliferation+in+FLT3-ITD+positive+acute+myeloid+leukemia&doi=10.1016%2Fj.leukres.2014.08.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CHK1 inhibits cell proliferation in FLT3-ITD positive acute myeloid leukemia</span></div><div class="casAuthors">Yuan, Ling Li; Green, Alexa; David, Laure; Dozier, Christine; Recher, Christian; Didier, Christine; Tamburini, Jerome; Manenti, Stephane</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1342-1349</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">CHK1 Ser/Thr kinase, a well characterized regulator of DNA damage response, is also involved in normal cell cycle progression.  In this study, we investigate how CHK1 participates to proliferation of acute myeloid leukemia cells expressing the mutated FLT3-ITD tyrosine kinase receptor.  Pharmacol. inhibition of CHK1 as well as its shRNA mediated down regulation reduced the proliferation rate of FLT-ITD expressing leukemic cell lines in a cytostatic manner.  Flow cytometry anal. revealed no accumulation in a specific phase of the cell cycle upon CHK1 inhibition.  Accordingly, lentiviral-mediated CHK1 overexpression increased the proliferation rate of FLT3-ITD expressing cells, as judged by cell viability and [3H] thymidine incorporation expts.  By contrast, expression of a ser280 mutant did not, suggesting that phosphorylation of this residue is an important determinant of CHK1 proliferative function.  Clonogenic growth of primary leukemic cells from patients in semi-solid medium was reduced upon CHK1 inhibition, confirming the data obtained with leukemic established cell lines.  Surprisingly, 3 out of 4 CHK1 inhibitory compds. tested in this study were also potent inhibitors of the FLT3-ITD tyrosine kinase receptor.  Altogether, these data identify CHK1 as a regulator of FLT3-ITD-pos. leukemic cells proliferation, and they open interesting perspectives in terms of new therapeutic strategies for these pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXfsrSR7FvhLVg90H21EOLACvtfcHk0ljXHUV5jYDmPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFGltLfL&md5=98e88982e5d5142c10993192e2abba9b</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2014.08.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2014.08.020%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DL.%2BL.%26aulast%3DGreen%26aufirst%3DA.%26aulast%3DDavid%26aufirst%3DL.%26aulast%3DDozier%26aufirst%3DC.%26aulast%3DRecher%26aufirst%3DC.%26aulast%3DDidier%26aufirst%3DC.%26aulast%3DTamburini%26aufirst%3DJ.%26aulast%3DManenti%26aufirst%3DS.%26atitle%3DTargeting%2520CHK1%2520inhibits%2520cell%2520proliferation%2520in%2520FLT3-ITD%2520positive%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeuk.%2520Res.%26date%3D2014%26volume%3D38%26issue%3D11%26spage%3D1342%26epage%3D1349%26doi%3D10.1016%2Fj.leukres.2014.08.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimal, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansat-De
Mas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dozier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamburini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Didier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manenti, S.</span></span> <span> </span><span class="NLM_article-title">Pim kinases phosphorylate Chk1 and regulate its functions in acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1038/leu.2013.168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fleu.2013.168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=23748345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsl2jt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=293-301&issue=2&author=L.+L.+Yuanauthor=A.+S.+Greenauthor=S.+Bertoliauthor=F.+Grimalauthor=V.+Mansat-De%0AMasauthor=C.+Dozierauthor=J.+Tamburiniauthor=C.+Recherauthor=C.+Didierauthor=S.+Manenti&title=Pim+kinases+phosphorylate+Chk1+and+regulate+its+functions+in+acute+myeloid+leukemia&doi=10.1038%2Fleu.2013.168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Pim kinases phosphorylate Chk1 and regulate its functions in acute myeloid leukemia</span></div><div class="casAuthors">Yuan, L. L.; Green, A. S.; Bertoli, S.; Grimal, F.; Mansat-De Mas, V.; Dozier, C.; Tamburini, J.; Recher, C.; Didier, C.; Manenti, S.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">293-301</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Phosphorylation by Akt on Ser 280 was reported to induce cytoplasmic retention and inactivation of CHK1 with consequent genetic instability in PTEN-/- cells.  In acute myeloid leukemia cells carrying the FLT3-internal tandem duplication (ITD) mutation, we obsd. high rates of FLT3-ITD-dependent CHK1 Ser 280 phosphorylation.  Pharmacol. inhibition and RNA interference identified Pim1/2, not Akt, as effectors of this phosphorylation.  Pim1 catalyzed Ser 280 phosphorylation in vitro and ectopic expression of Pim1/2-induced CHK1 phosphorylation.  Ser 280 phosphorylation did not modify CHK1 localization, but facilitated its cell cycle and resistance functions in leukemic cells.  FLT3, PIM or CHK1 inhibitors synergized with DNA-damaging agents to induce apoptosis, allowing cells to bypass the etoposide-induced G2/M arrest.  Consistently, etoposide-induced CHK1-dependent phosphorylations of CDC25C on Ser 216 and histone H3 on Thr11 were decreased upon FLT3 inhibition.  Accordingly, ectopic expression of CHK1 improved the resistance of FLT3-ITD cells and maintained histone H3 phosphorylation in response to DNA damage, whereas expression of unphosphorylated Ser 280Ala mutant did not.  Finally, FLT3- and Pim-dependent phosphorylation of CHK1 on Ser 280 was confirmed in primary blasts from patients.  These results identify a new pathway involved in the resistance of FLT3-ITD leukemic cells to genotoxic agents, and they constitute the first report of CHK1 Ser 280 regulation in myeloid malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRb_6wUbp7YrVg90H21EOLACvtfcHk0ljXHUV5jYDmPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsl2jt7w%253D&md5=bec5f52a33e196a13350b18a3b920e5e</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1038%2Fleu.2013.168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2013.168%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DL.%2BL.%26aulast%3DGreen%26aufirst%3DA.%2BS.%26aulast%3DBertoli%26aufirst%3DS.%26aulast%3DGrimal%26aufirst%3DF.%26aulast%3DMansat-De%2BMas%26aufirst%3DV.%26aulast%3DDozier%26aufirst%3DC.%26aulast%3DTamburini%26aufirst%3DJ.%26aulast%3DRecher%26aufirst%3DC.%26aulast%3DDidier%26aufirst%3DC.%26aulast%3DManenti%26aufirst%3DS.%26atitle%3DPim%2520kinases%2520phosphorylate%2520Chk1%2520and%2520regulate%2520its%2520functions%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2014%26volume%3D28%26issue%3D2%26spage%3D293%26epage%3D301%26doi%3D10.1038%2Fleu.2013.168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lilly, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span> <span> </span><span class="NLM_article-title">Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>105</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1759</span>– <span class="NLM_lpage">1767</span>, <span class="refDoi"> DOI: 10.1182/blood-2004-05-2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2004-05-2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=15498859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsVGjs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=1759-1767&issue=4&author=K.+T.+Kimauthor=K.+Bairdauthor=J.+Y.+Ahnauthor=P.+Meltzerauthor=M.+Lillyauthor=M.+Levisauthor=D.+Small&title=Pim-1+is+up-regulated+by+constitutively+activated+FLT3+and+plays+a+role+in+FLT3-mediated+cell+survival&doi=10.1182%2Fblood-2004-05-2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival</span></div><div class="casAuthors">Kim, Kyu-Tae; Baird, Kristin; Ahn, Joon-Young; Meltzer, Paul; Lilly, Michael; Levis, Mark; Small, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1759-1767</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Constitutively activating internal tandem duplication (ITD) mutations of the receptor tyrosine kinase FLT3 (Fms-like tyrosine kinase 3) play an important role in leukemogenesis, and their presence is assocd. with poor prognosis in acute myeloid leukemia (AML).  To better understand FLT3 signaling in leukemogenesis, the authors have examd. the changes in gene expression induced by FLT3/ITD or constitutively activated wild-type FLT3 expression.  Microarrays were used with RNA harvested before and after inhibition of FLT3 signaling.  Pim-1 was one of the most significantly down-regulated genes upon FLT3 inhibition.  Pim-1 is a proto-oncogene and is known to be up-regulated by signal transducer and activator of transcription 5 (STAT5), which itself is a downstream target of FLT3 signaling.  Quant. polymerase chain reaction (QPCR) confirmed the microarray results and demonstrated approx. 10-fold decreases in Pim-1 expression in response to FLT3 inhibition.  Pim-1 protein also decreased rapidly in parallel with decreasing autophosphorylation activity of FLT3.  Enforced expression of either the 44-kDa or 33-kDa Pim-1 isotypes resulted in increased resistance to FLT3 inhibition-mediated cytotoxicity and apoptosis.  In contrast, expression of a dominant-neg. Pim-1 construct accelerated cytotoxicity in response to FLT3 inhibition and inhibited colony growth of FLT3/ITD-transformed BaF3 cells.  These findings demonstrate that constitutively activated FLT3 signaling up-regulates Pim-1 expression in leukemia cells.  This up-regulation contributes to the proliferative and antiapoptotic pathways induced by FLT3 signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqaPXq1gUo1bVg90H21EOLACvtfcHk0lhhfRKhcwzLQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsVGjs7k%253D&md5=003846bdd51d90c5efc2613954b3b185</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1182%2Fblood-2004-05-2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2004-05-2006%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BT.%26aulast%3DBaird%26aufirst%3DK.%26aulast%3DAhn%26aufirst%3DJ.%2BY.%26aulast%3DMeltzer%26aufirst%3DP.%26aulast%3DLilly%26aufirst%3DM.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DPim-1%2520is%2520up-regulated%2520by%2520constitutively%2520activated%2520FLT3%2520and%2520plays%2520a%2520role%2520in%2520FLT3-mediated%2520cell%2520survival%26jtitle%3DBlood%26date%3D2005%26volume%3D105%26issue%3D4%26spage%3D1759%26epage%3D1767%26doi%3D10.1182%2Fblood-2004-05-2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burcu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linn, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, M. R.</span></span> <span> </span><span class="NLM_article-title">Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">e74653</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0074653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1371%2Fjournal.pone.0074653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=24040307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVGiu7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e74653&issue=9&author=K.+Natarajanauthor=Y.+Xieauthor=M.+Burcuauthor=D.+E.+Linnauthor=Y.+Qiuauthor=M.+R.+Baer&title=Pim-1+kinase+phosphorylates+and+stabilizes+130+kDa+FLT3+and+promotes+aberrant+STAT5+signaling+in+acute+myeloid+leukemia+with+FLT3+internal+tandem+duplication&doi=10.1371%2Fjournal.pone.0074653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication</span></div><div class="casAuthors">Natarajan, Karthika; Xie, Yingqiu; Burcu, Mehmet; Linn, Douglas E.; Qiu, Yun; Baer, Maria R.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e74653</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The type III receptor tyrosine kinase fms-like tyrosine kinase 3 (FLT3) is expressed on both normal hematopoietic stem cells and acute myeloid leukemia (AML) cells and regulates their proliferation.  Internal tandem duplication (ITD) mutation of FLT3 is present in a third of AML cases, results in constitutive activation and aberrant signaling of FLT3, and is assocd. with adverse treatment outcomes.  While wild-type (WT) FLT3 is predominantly a 150 kDa complex glycosylated cell surface protein, FLT3-ITD is partially retained in the endoplasmic reticulum as a 130 kDa underglycosylated species assocd. with the chaperones calnexin and heat shock protein (HSP) 90, and mediates aberrant STAT5 signaling, which upregulates the oncogenic serine/threonine kinase Pim-1.  FLT3 contains a Pim-1 substrate consensus serine phosphorylation site, and we hypothesized that it might be a Pim-1 substrate.  Pim-1 was indeed found to directly interact with and serine-phosphorylate FLT3.  Pim-1 inhibition decreased the expression and half-life of 130 kDa FLT3, with partial abrogation by proteasome inhibition, in assocn. with decreased FLT3 binding to calnexin and HSP90, and increased 150 kDa FLT3 expression and half-life, with abrogation by inhibition of glycosylation.  These findings were consistent with Pim-1 stabilizing FLT3-ITD as a 130 kDa species assocd. with calnexin and HSP90 and inhibiting its glycosylation to form the 150 kDa species.  Pim-1 knockdown effects were similar.  Pim-1 inhibition also decreased phosphorylation of FLT3 at tyrosine 591 and of STAT5, and expression of Pim-1 itself, consistent with inhibition of the FLT3-ITD-STAT5 signaling pathway.  Finally, Pim-1 inhibition synergized with FLT3 inhibition in inducing apoptosis of FLT3-ITD cells.  This is, to our knowledge, the first demonstration of a role of Pim-1 in a pos. feedback loop promoting aberrant signaling in malignant cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr42kk5fFOnOrVg90H21EOLACvtfcHk0lhhfRKhcwzLQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVGiu7vI&md5=01126b1c9bb585e6c514e85c0cd7a637</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0074653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0074653%26sid%3Dliteratum%253Aachs%26aulast%3DNatarajan%26aufirst%3DK.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DBurcu%26aufirst%3DM.%26aulast%3DLinn%26aufirst%3DD.%2BE.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DBaer%26aufirst%3DM.%2BR.%26atitle%3DPim-1%2520kinase%2520phosphorylates%2520and%2520stabilizes%2520130%2520kDa%2520FLT3%2520and%2520promotes%2520aberrant%2520STAT5%2520signaling%2520in%2520acute%2520myeloid%2520leukemia%2520with%2520FLT3%2520internal%2520tandem%2520duplication%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26issue%3D9%26spage%3De74653%26doi%3D10.1371%2Fjournal.pone.0074653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kapoor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doshi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapidus, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathias, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trotta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davila, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tron, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrotti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, M. R.</span></span> <span> </span><span class="NLM_article-title">Concurrent inhibition of Pim and FLT3 kinases enhances apoptosis of FLT3-ITD acute myeloid leukemia cells through increased Mcl-1 proteasomal degradation</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">234</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-1629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F1078-0432.CCR-17-1629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=29074603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVWntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=234-247&issue=1&author=S.+Kapoorauthor=K.+Natarajanauthor=P.+R.+Baldwinauthor=K.+A.+Doshiauthor=R.+G.+Lapidusauthor=T.+J.+Mathiasauthor=M.+Scarpaauthor=R.+Trottaauthor=E.+Davilaauthor=M.+Krausauthor=D.+Huszarauthor=A.+E.+Tronauthor=D.+Perrottiauthor=M.+R.+Baer&title=Concurrent+inhibition+of+Pim+and+FLT3+kinases+enhances+apoptosis+of+FLT3-ITD+acute+myeloid+leukemia+cells+through+increased+Mcl-1+proteasomal+degradation&doi=10.1158%2F1078-0432.CCR-17-1629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation</span></div><div class="casAuthors">Kapoor, Shivani; Natarajan, Karthika; Baldwin, Patrick R.; Doshi, Kshama A.; Lapidus, Rena G.; Mathias, Trevor J.; Scarpa, Mario; Trotta, Rossana; Davila, Eduardo; Kraus, Manfred; Huszar, Dennis; Tron, Adriana E.; Perrotti, Danilo; Baer, Maria R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">234-247</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) is present in 30% of acute myeloid leukemia (AML), and these patients have short disease-free survival.  FLT3 inhibitors have limited and transient clin. activity, and concurrent treatment with inhibitors of parallel or downstream signaling may improve responses.  The oncogenic serine/threonine kinase Pim-1 is upregulated downstream of FLT3-ITD and also promotes its signaling in a pos. feedback loop, suggesting benefit of combined Pim and FLT3 inhibition.  Combinations of clin. active Pim and FLT3 inhibitors were studied in vitro and in vivo.  Concurrent treatment with the pan-Pim inhibitor AZD1208 and FLT3 inhibitors at clin. applicable concns. abrogated in vitro growth of FLT3-ITD, but not wild-type FLT3 (FLT3-WT), cell lines.  AZD1208 cotreatment increased FLT3 inhibitor-induced apoptosis of FLT3-ITD, but not FLT3-WT, cells measured by sub-G1 fraction, annexin V labeling, mitochondrial membrane potential, and PARP and caspase-3 cleavage.  Concurrent treatment with AZD1208 and the FLT3 inhibitor quizartinib decreased growth of MV4-11 cells, with FLT3-ITD, in mouse xenografts, and prolonged survival, enhanced apoptosis of FLT3-ITD primary AML blasts, but not FLT3-WT blasts or remission marrow cells, and decreased FLT3-ITD AML blast colony formation.  Mechanistically, AZD1208 and quizartinib cotreatment decreased expression of the antiapoptotic protein Mcl-1.  Decrease in Mcl-1 protein expression was abrogated by treatment with the proteasome inhibitor MG132, and was preceded by downregulation of the Mcl-1 deubiquitinase USP9X, a novel mechanism of Mcl-1 regulation in AML.  The data support clin. testing of Pim and FLT3 inhibitor combination therapy for FLT3-ITD AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqej4YfGVBGLVg90H21EOLACvtfcHk0lhhfRKhcwzLQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVWntg%253D%253D&md5=f20b78a3d8a7a5f14d3256219e4a83eb</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-1629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-1629%26sid%3Dliteratum%253Aachs%26aulast%3DKapoor%26aufirst%3DS.%26aulast%3DNatarajan%26aufirst%3DK.%26aulast%3DBaldwin%26aufirst%3DP.%2BR.%26aulast%3DDoshi%26aufirst%3DK.%2BA.%26aulast%3DLapidus%26aufirst%3DR.%2BG.%26aulast%3DMathias%26aufirst%3DT.%2BJ.%26aulast%3DScarpa%26aufirst%3DM.%26aulast%3DTrotta%26aufirst%3DR.%26aulast%3DDavila%26aufirst%3DE.%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DHuszar%26aufirst%3DD.%26aulast%3DTron%26aufirst%3DA.%2BE.%26aulast%3DPerrotti%26aufirst%3DD.%26aulast%3DBaer%26aufirst%3DM.%2BR.%26atitle%3DConcurrent%2520inhibition%2520of%2520Pim%2520and%2520FLT3%2520kinases%2520enhances%2520apoptosis%2520of%2520FLT3-ITD%2520acute%2520myeloid%2520leukemia%2520cells%2520through%2520increased%2520Mcl-1%2520proteasomal%2520degradation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26issue%3D1%26spage%3D234%26epage%3D247%26doi%3D10.1158%2F1078-0432.CCR-17-1629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parlati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouffet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackinnon, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshaies, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of an inhibitor of the proteasome subunit rpn11</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1343</span>– <span class="NLM_lpage">1361</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01379</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01379" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisVGlsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1343-1361&issue=4&author=C.+Perezauthor=J.+Liauthor=F.+Parlatiauthor=M.+Rouffetauthor=Y.+Maauthor=A.+L.+Mackinnonauthor=T.+F.+Chouauthor=R.+J.+Deshaiesauthor=S.+M.+Cohen&title=Discovery+of+an+inhibitor+of+the+proteasome+subunit+rpn11&doi=10.1021%2Facs.jmedchem.6b01379"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Inhibitor of the Proteasome Subunit Rpn11</span></div><div class="casAuthors">Perez, Christian; Li, Jing; Parlati, Francesco; Rouffet, Matthieu; Ma, Yuyong; Mackinnon, Andrew L.; Chou, Tsui-Fen; Deshaies, Raymond J.; Cohen, Seth M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1343-1361</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The proteasome plays a crucial role in degrdn. of normal proteins that happen to be constitutively or inducibly unstable, and in this capacity it plays a regulatory role.  Addnl., it degrades abnormal/damaged/mutant/misfolded proteins, which serves a quality-control function.  Inhibitors of the proteasome have been validated in the treatment of multiple myeloma, with several FDA-approved therapeutics.  Rpn11 is a Zn2+-dependent metallo-isopeptidase that hydrolyzes ubiquitin from tagged proteins that are trafficked to the proteasome for degrdn.  A fragment-based drug discovery (FBDD) approach was utilized to identify fragments with activity against Rpn11.  Screening of a library of metal-binding pharmacophores (MBPs) revealed that 8-thioquinoline (8TQ, IC50 value ∼2.5 μM) displayed strong inhibition of Rpn11.  Further synthetic elaboration of 8TQ yielded a small mol. compd. I (IC50 value ∼300 nM) that is a potent and selective inhibitor of Rpn11 that blocks proliferation of tumor cells in culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVoqv0GBUXK7Vg90H21EOLACvtfcHk0lhm6JXYhkLHqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisVGlsLk%253D&md5=375924a352599bba41888915b77e2159</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01379%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DRouffet%26aufirst%3DM.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DMackinnon%26aufirst%3DA.%2BL.%26aulast%3DChou%26aufirst%3DT.%2BF.%26aulast%3DDeshaies%26aufirst%3DR.%2BJ.%26aulast%3DCohen%26aufirst%3DS.%2BM.%26atitle%3DDiscovery%2520of%2520an%2520inhibitor%2520of%2520the%2520proteasome%2520subunit%2520rpn11%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D4%26spage%3D1343%26epage%3D1361%26doi%3D10.1021%2Facs.jmedchem.6b01379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larrue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saland, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boutzen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joffre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hospital, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamburini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delabesse, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manenti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarry, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recher, C.</span></span> <span> </span><span class="NLM_article-title">Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">882</span>– <span class="NLM_lpage">892</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-05-646497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2015-05-646497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=26286850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1KjtrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=882-892&issue=7&author=C.+Larrueauthor=E.+Salandauthor=H.+Boutzenauthor=F.+Vergezauthor=M.+Davidauthor=C.+Joffreauthor=M.+A.+Hospitalauthor=J.+Tamburiniauthor=E.+Delabesseauthor=S.+Manentiauthor=J.+E.+Sarryauthor=C.+Recher&title=Proteasome+inhibitors+induce+FLT3-ITD+degradation+through+autophagy+in+AML+cells&doi=10.1182%2Fblood-2015-05-646497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells</span></div><div class="casAuthors">Larrue, Clement; Saland, Estelle; Boutzen, Helena; Vergez, Francois; David, Marion; Joffre, Carine; Hospital, Marie-Anne; Tamburini, Jerome; Delabesse, Eric; Manenti, Stephane; Sarry, Jean Emmanuel; Recher, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">882-892</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Internal tandem duplication of the Fms-like tyrosine kinase-3 receptor (FLT3) internal tandem duplication (ITD) is found in 30% of acute myeloid leukemia (AML) and is assocd. with a poor outcome.  In addn. to tyrosine kinase inhibitors, therapeutic strategies that modulate the expression of FLT3-ITD are also promising.  We show that AML samples bearing FLT3-ITD mutations are more sensitive to proteasome inhibitors than wild-type samples and this sensitivity is strongly correlated with a higher FLT3-ITD allelic burden.  Using pharmacol. inhibitors of autophagy, specific downregulation of key autophagy proteins including Vps34, autophagy gene (Atg)5, Atg12, Atg13, biochem., and microscopy studies, we demonstrated that proteasome inhibitors induced cytotoxic autophagy in AML cells.  FLT3-ITD mols. were detectable within autophagosomes after bortezomib treatment indicating that autophagy induction was responsible for the early degrdn. of FLT3-ITD, which preceded the inhibition of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), PI3K/AKT, and STAT5 pathways, and subsequent activation of cell death.  Moreover, proteasome inhibitors overcome resistance to quizartinib induced by mutations in the kinase domain of FLT3, suggesting that these compoundsmay prevent the emergence of mutant clones arising from tyrosine kinase inhibitor treatments.  In xenograft mice models, bortezomib stimulated the conversion of LC3-I to LC3-II, indicating induction of autophagy in vivo, downregulated FLT3-ITD protein expression and improved overall survival.  Therefore, selecting patients according to FLT3-ITD mutations could be anewwayto detect a significant clin. activity of proteasome inhibitors in AML patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotz1aMaqxvG7Vg90H21EOLACvtfcHk0lhm6JXYhkLHqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1KjtrzP&md5=0f71d67246259ff440b9da749df29447</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-05-646497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-05-646497%26sid%3Dliteratum%253Aachs%26aulast%3DLarrue%26aufirst%3DC.%26aulast%3DSaland%26aufirst%3DE.%26aulast%3DBoutzen%26aufirst%3DH.%26aulast%3DVergez%26aufirst%3DF.%26aulast%3DDavid%26aufirst%3DM.%26aulast%3DJoffre%26aufirst%3DC.%26aulast%3DHospital%26aufirst%3DM.%2BA.%26aulast%3DTamburini%26aufirst%3DJ.%26aulast%3DDelabesse%26aufirst%3DE.%26aulast%3DManenti%26aufirst%3DS.%26aulast%3DSarry%26aufirst%3DJ.%2BE.%26aulast%3DRecher%26aufirst%3DC.%26atitle%3DProteasome%2520inhibitors%2520induce%2520FLT3-ITD%2520degradation%2520through%2520autophagy%2520in%2520AML%2520cells%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26issue%3D7%26spage%3D882%26epage%3D892%26doi%3D10.1182%2Fblood-2015-05-646497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatnagar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garzon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canning, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devine, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klisovic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcucci, G.</span></span> <span> </span><span class="NLM_article-title">Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia</span>. <i>Leuk. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2100</span>– <span class="NLM_lpage">2108</span>, <span class="refDoi"> DOI: 10.3109/10428194.2015.1135435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.3109%2F10428194.2015.1135435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=26784138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFKhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=2100-2108&issue=9&author=A.+R.+Walkerauthor=H.+Wangauthor=K.+Walshauthor=B.+Bhatnagarauthor=S.+Vasuauthor=R.+Garzonauthor=R.+Canningauthor=S.+Geyerauthor=Y.+Z.+Wuauthor=S.+M.+Devineauthor=R.+Klisovicauthor=W.+Blumauthor=G.+Marcucci&title=Midostaurin%2C+bortezomib+and+MEC+in+relapsed%2Frefractory+acute+myeloid+leukemia&doi=10.3109%2F10428194.2015.1135435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia</span></div><div class="casAuthors">Walker, Alison R.; Wang, Hongyan; Walsh, Katherine; Bhatnagar, Bhavana; Vasu, Sumithira; Garzon, Ramiro; Canning, Renee; Geyer, Susan; Wu, Yue-Zhong; Devine, Steven M.; Klisovic, Rebecca; Blum, William; Marcucci, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2100-2108</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1029-2403</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Targeting aberrant tyrosine kinase activity may impact clin. outcome in acute myeloid leukemia (AML).  We conducted a phase I study of the tyrosine kinase inhibitor midostaurin with bortezomib alone and in combination with chemotherapy in patients with AML.  Patients on dose levels 1 and 2 (DL1 & 2) received midostaurin 50 mg bid and escalating doses of bortezomib (1 to 1.3 mg/m2).  Patients on DL3 or higher received midostaurin and bortezomib following chemotherapy with mitoxantrone, etoposide, cytarabine (MEC).  None of the patients enrolled to DL1 & 2 had dose-limiting toxicities (DLTs) or a clin. response.  Among patients enrolled to DL3 or higher, DLTs were peripheral neuropathy, decrease in ejection fraction and diarrhea.  A 56.5% CR rate and 82.5% overall response rate (CR + CR with incomplete neutrophil or platelet count recovery) were obsd.  The midostaurin/bortezomib/MEC combination is active in refractory/relapsed AML, but is assocd. with expected drug-related toxicities (NCT01174888).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY3jHRB7_JQrVg90H21EOLACvtfcHk0lgrIF0I8H-ZVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFKhtrY%253D&md5=29a42c74b9da814d367152a0d78ebd90</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.3109%2F10428194.2015.1135435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10428194.2015.1135435%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DA.%2BR.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWalsh%26aufirst%3DK.%26aulast%3DBhatnagar%26aufirst%3DB.%26aulast%3DVasu%26aufirst%3DS.%26aulast%3DGarzon%26aufirst%3DR.%26aulast%3DCanning%26aufirst%3DR.%26aulast%3DGeyer%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DY.%2BZ.%26aulast%3DDevine%26aufirst%3DS.%2BM.%26aulast%3DKlisovic%26aufirst%3DR.%26aulast%3DBlum%26aufirst%3DW.%26aulast%3DMarcucci%26aufirst%3DG.%26atitle%3DMidostaurin%252C%2520bortezomib%2520and%2520MEC%2520in%2520relapsed%252Frefractory%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2016%26volume%3D57%26issue%3D9%26spage%3D2100%26epage%3D2108%26doi%3D10.3109%2F10428194.2015.1135435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, S. M.</span></span> <span> </span><span class="NLM_article-title">Alteration of the MT1 melatonin receptor gene and its expression in primary human breast tumors and breast cancer cell lines</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>118</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1007/s10549-008-0220-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1007%2Fs10549-008-0220-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=18979234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Ons7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2009&pages=293-305&issue=2&author=L.+Laiauthor=L.+Yuanauthor=Q.+Chengauthor=C.+Dongauthor=L.+Maoauthor=S.+M.+Hill&title=Alteration+of+the+MT1+melatonin+receptor+gene+and+its+expression+in+primary+human+breast+tumors+and+breast+cancer+cell+lines&doi=10.1007%2Fs10549-008-0220-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Alteration of the MT1 melatonin receptor gene and its expression in primary human breast tumors and breast cancer cell lines</span></div><div class="casAuthors">Lai, Ling; Yuan, Lin; Cheng, Qi; Dong, Chunmin; Mao, Lulu; Hill, Steven Marc</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">293-305</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The MT1 melatonin receptor is bound and activated by the pineal hormone melatonin.  This G protein-coupled melatonin receptor is expressed in human breast tumor cell lines, and when activated, mediates the growth-suppressive and steroid hormone/nuclear receptor modulatory actions of melatonin on breast tumor cells.  In the current studies, we have examd. the expression of the MT1 receptor in breast cancer cell lines and primary human breast tumors and correlated MT1 receptor expression with the deletion, rearrangement and amplification of the MT1 gene and established markers of breast cancer such as tumor size, stage, estrogen receptor alpha (ERα) and progesterone receptor (PR) expression.  Theses studies suggest amplification of the MT1 gene in some breast tumors and an inverse correlation with ERα, PR and MT1 protein expression.  Furthermore, these approaches employing immunohistochem. and immunofluorescent/confocal microscopic studies demonstrate that the MT1 receptor is localized to the caveoli and that MT1 expression in MCF-7 breast cancer cells can be repressed by estradiol and melatonin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTLKjLnW2DArVg90H21EOLACvtfcHk0lgrIF0I8H-ZVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Ons7zP&md5=7f60f4169056958cf5131f96fb87b9b1</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1007%2Fs10549-008-0220-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-008-0220-1%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DQ.%26aulast%3DDong%26aufirst%3DC.%26aulast%3DMao%26aufirst%3DL.%26aulast%3DHill%26aufirst%3DS.%2BM.%26atitle%3DAlteration%2520of%2520the%2520MT1%2520melatonin%2520receptor%2520gene%2520and%2520its%2520expression%2520in%2520primary%2520human%2520breast%2520tumors%2520and%2520breast%2520cancer%2520cell%2520lines%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2009%26volume%3D118%26issue%3D2%26spage%3D293%26epage%3D305%26doi%3D10.1007%2Fs10549-008-0220-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plaimee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weerapreeyakul, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barusrux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johns, N. P.</span></span> <span> </span><span class="NLM_article-title">Melatonin potentiates cisplatin-induced apoptosis and cell cycle arrest in human lung adenocarcinoma cells</span>. <i>Cell Proliferation</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1111/cpr.12158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1111%2Fcpr.12158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=25580987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslWgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2015&pages=67-77&issue=1&author=P.+Plaimeeauthor=N.+Weerapreeyakulauthor=S.+Barusruxauthor=N.+P.+Johns&title=Melatonin+potentiates+cisplatin-induced+apoptosis+and+cell+cycle+arrest+in+human+lung+adenocarcinoma+cells&doi=10.1111%2Fcpr.12158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin potentiates cisplatin-induced apoptosis and cell cycle arrest in human lung adenocarcinoma cells</span></div><div class="casAuthors">Plaimee, P.; Weerapreeyakul, N.; Barusrux, S.; Johns, N. P.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Proliferation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-77</span>CODEN:
                <span class="NLM_cas:coden">CPROEM</span>;
        ISSN:<span class="NLM_cas:issn">0960-7722</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Objectives : Melatonin produces anti-cancer effects via several mechanisms, including by induction of apoptosis.  In this way, it has been shown to be of use, in combination with chemotherapeutic drugs, for cancer treatment.  The study described here has evaluated effects of melatonin on cytotoxicity, apoptosis and cell cycle arrest induced with the chemotherapeutic agent cisplatin, in human lung adenocarcinoma cisplatin-sensitive cell line (SK-LU-1), which previously had only limit data.  Materials and methods : Cells of the SK-LU-1 line were treated with melatonin alone at 1-5 mm concn. or cisplatin alone 10-200 μm, for 48 h in culture.  Cytotoxicity was measured by MTT redn. assay.  Apoptosis induction was detected by annexin V/PI staining using flow cytometric anal. and DAPI nuclear staining.  Change in mitochondrial membrane potential (ΔΨm) was quantified using DiOC6(3) reagent and activities of caspases-3/7 were also investigated.  DNA fractions were measured using propidium iodide (PI) staining.  Results : Melatonin or cisplatin alone had 50% (IC50) cytotoxicity at 5 mm or 34 μm concns. resp.  Combination of 1 or 2 mm melatonin and cisplatin significantly augmented cytotoxicity of cisplatin by reducing its IC50 to 11 and 4 μm, resp.  Consistently, combined treatment increased population of apoptotic cells by elevating mitochondrial membrane depolarization, activating caspases-3/7 and inducing cell cycle arrest in the S phase, compared to treatment with cisplatin alone.  Conclusion : These data demonstrate that melatonin enhanced cisplatin-induced cytotoxicity and apoptosis in SK-LU-1 lung cancer cells.  SK-LU-1 cell population growth inhibition was mediated by cell cycle arrest in the S phase.  These findings suggest that melatonin has the potential to be used for NSCLC treatment in combination with a chemotherapeutic agent such as cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOwyaIbAwG6bVg90H21EOLACvtfcHk0lgrIF0I8H-ZVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslWgsQ%253D%253D&md5=6533ab83ae36d7d2c61dad01130bdcb2</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1111%2Fcpr.12158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcpr.12158%26sid%3Dliteratum%253Aachs%26aulast%3DPlaimee%26aufirst%3DP.%26aulast%3DWeerapreeyakul%26aufirst%3DN.%26aulast%3DBarusrux%26aufirst%3DS.%26aulast%3DJohns%26aufirst%3DN.%2BP.%26atitle%3DMelatonin%2520potentiates%2520cisplatin-induced%2520apoptosis%2520and%2520cell%2520cycle%2520arrest%2520in%2520human%2520lung%2520adenocarcinoma%2520cells%26jtitle%3DCell%2520Proliferation%26date%3D2015%26volume%3D48%26issue%3D1%26spage%3D67%26epage%3D77%26doi%3D10.1111%2Fcpr.12158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krestinina, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fadeev, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomovsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baburina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobyakova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akatov, V.</span></span> <span> </span><span class="NLM_article-title">Melatonin can strengthen the effect of retinoic acid in HL-60 cells</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2873</span>, <span class="refDoi"> DOI: 10.3390/ijms19102873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.3390%2Fijms19102873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntVKku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=2873&issue=10&author=O.+Krestininaauthor=R.+Fadeevauthor=A.+Lomovskyauthor=Y.+Baburinaauthor=M.+Kobyakovaauthor=V.+Akatov&title=Melatonin+can+strengthen+the+effect+of+retinoic+acid+in+HL-60+cells&doi=10.3390%2Fijms19102873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin can strengthen the effect of retinoic acid in HL-60 cells</span></div><div class="casAuthors">Krestinina, Olga; Fadeev, Roman; Lomovsky, Alexey; Baburina, Yulia; Kobyakova, Margarita; Akatov, Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2873/1-2873/13</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Melatonin is produced by the pineal gland.  It can be regarded as an anticancer agent and used for combined therapy, owing to its oncostatic, antioxidant, and immunoregulatory activities.  Retinoic acid is widely used for the treatment of acute promyelocytic leukemia; however, it has adverse effects on the human organism.  We investigated the effect of melatonin and reduced concns. of retinoic acid on the activation of proliferation in acute promyelocytic leukemiaon a cell model HL-60.  The combined effect of these compds. leads to a redn. in the no. of cells by 70% and the index of mitotic activity by 64%.  Combined treatment with melatonin and retinoic acid decreased the expression of the Bcl-2.  The mitochondrial isoform VDAC1 can be a target in the treatment of different tumors.  The combined effect of and retinoic acid at a low concn. (10 nM) decreased VDAC1 expression.  Melatonin in combination with retinoic acid produced a similar effect on the expression of the translocator protein.  The copptn. of VDAC with 2',3'-cyclonucleotide-3'-phosphodiesterase implies a possible role of its in cancer development.  The combined effect of retinoic acid and melatonin decreased the activity of the electron transport chain complexes.  The changes in the activation of proliferation in HL-60 cells, the mitotic index, and Bcl-2 expression under combined effect of retinoic acid (10 nM) with melatonin (1 mM) are similar to changes that are induced by 1 μM retinoic acid.  Our results suggest that MEL is able to improve the action the other chemotherapeutic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRIZPiXu93trVg90H21EOLACvtfcHk0ljnXqC1VXa7sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntVKku7s%253D&md5=dbf9c36fca75b7651d10a61094de49b7</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.3390%2Fijms19102873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19102873%26sid%3Dliteratum%253Aachs%26aulast%3DKrestinina%26aufirst%3DO.%26aulast%3DFadeev%26aufirst%3DR.%26aulast%3DLomovsky%26aufirst%3DA.%26aulast%3DBaburina%26aufirst%3DY.%26aulast%3DKobyakova%26aufirst%3DM.%26aulast%3DAkatov%26aufirst%3DV.%26atitle%3DMelatonin%2520can%2520strengthen%2520the%2520effect%2520of%2520retinoic%2520acid%2520in%2520HL-60%2520cells%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26issue%3D10%26spage%3D2873%26doi%3D10.3390%2Fijms19102873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosales-Corral, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, D. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acuna-Castroviejo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span> <span> </span><span class="NLM_article-title">Melatonin, a full service anti-cancer agent: inhibition of initiation, progression and metastasis</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">843</span>, <span class="refDoi"> DOI: 10.3390/ijms18040843</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.3390%2Fijms18040843" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFGjs7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=843&issue=4&author=R.+J.+Reiterauthor=S.+A.+Rosales-Corralauthor=D.+X.+Tanauthor=D.+Acuna-Castroviejoauthor=L.+Qinauthor=S.+F.+Yangauthor=K.+Xu&title=Melatonin%2C+a+full+service+anti-cancer+agent%3A+inhibition+of+initiation%2C+progression+and+metastasis&doi=10.3390%2Fijms18040843"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin, a full service anti-cancer agent: inhibition of initiation, progression and metastasis</span></div><div class="casAuthors">Reiter, Russel J.; Rosales-Corral, Sergio A.; Tan, Dun-Xian; Acuna-Castroviejo, Dario; Qin, Lilan; Yang, Shun-Fa; Xu, Kexin</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">843/1-843/47</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">There is highly credible evidence that melatonin mitigates cancer at the initiation, progression and metastasis phases.  In many cases, the mol. mechanisms underpinning these inhibitory actions have been proposed.  What is rather perplexing, however, is the large no. of processes by which melatonin reportedly restrains cancer development and growth.  These diverse actions suggest that what is being obsd. are merely epiphenomena of an underlying more fundamental action of melatonin that remains to be disclosed.  Some of the arresting actions of melatonin on cancer are clearly membrane receptor-mediated while others are membrane receptor-independent and involve direct intracellular actions of this ubiquitously-distributed mol.  While the emphasis of melatonin/cancer research has been on the role of the indoleamine in restraining breast cancer, this is changing quickly with many cancer types having been shown to be susceptible to inhibition by melatonin.  There are several facets of this research which could have immediate applications at the clin. level.  Many studies have shown that melatonin's co-administration improves the sensitivity of cancers to inhibition by conventional drugs.  Even more important are the findings that melatonin renders cancers previously totally resistant to treatment sensitive to these same therapies.  Melatonin also inhibits mol. processes assocd. with metastasis by limiting the entrance of cancer cells into the vascular system and preventing them from establishing secondary growths at distant sites.  This is of particular importance since cancer metastasis often significantly contributes to death of the patient.  Another area that deserves addnl. consideration is related to the capacity of melatonin in reducing the toxic consequences of anti-cancer drugs while increasing their efficacy.  Although this information has been available for more than a decade, it has not been adequately exploited at the clin. level.  Even if the only beneficial actions of melatonin in cancer patients are its ability to attenuate acute and long-term drug toxicity, melatonin should be used to improve the phys. wellbeing of the patients.  The exptl. findings, however, suggest that the advantages of using melatonin as a co-treatment with conventional cancer therapies would far exceed improvements in the wellbeing of the patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozdzwNs8nI5bVg90H21EOLACvtfcHk0ljnXqC1VXa7sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFGjs7bP&md5=1bb28bdff4aa4e971c76c069cc72f341</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.3390%2Fijms18040843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18040843%26sid%3Dliteratum%253Aachs%26aulast%3DReiter%26aufirst%3DR.%2BJ.%26aulast%3DRosales-Corral%26aufirst%3DS.%2BA.%26aulast%3DTan%26aufirst%3DD.%2BX.%26aulast%3DAcuna-Castroviejo%26aufirst%3DD.%26aulast%3DQin%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DS.%2BF.%26aulast%3DXu%26aufirst%3DK.%26atitle%3DMelatonin%252C%2520a%2520full%2520service%2520anti-cancer%2520agent%253A%2520inhibition%2520of%2520initiation%252C%2520progression%2520and%2520metastasis%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26issue%3D4%26spage%3D843%26doi%3D10.3390%2Fijms18040843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tian, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Manero, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span> <span> </span><span class="NLM_article-title">Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3768</span>– <span class="NLM_lpage">3779</span>, <span class="refDoi"> DOI: 10.7150/thno.34327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.7150%2Fthno.34327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=31281512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1ertLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=3768-3779&issue=13&author=T.+Tianauthor=J.+Liauthor=Y.+Liauthor=Y.+X.+Luauthor=Y.+L.+Tangauthor=H.+Wangauthor=F.+Zhengauthor=D.+Shiauthor=Q.+Longauthor=M.+Chenauthor=G.+Garcia-Maneroauthor=Y.+Huauthor=L.+Qinauthor=W.+Deng&title=Melatonin+enhances+sorafenib-induced+cytotoxicity+in+FLT3-ITD+acute+myeloid+leukemia+cells+by+redox+modification&doi=10.7150%2Fthno.34327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification</span></div><div class="casAuthors">Tian, Tian; Li, Jiajun; Li, Yizhuo; Lu, Yun-Xin; Tang, Yan-Lai; Wang, Hua; Zheng, Fufu; Shi, Dingbo; Long, Qian; Chen, Miao; Garcia-Manero, Guillermo; Hu, Yumin; Qin, Lijun; Deng, Wuguo</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3768-3779</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) with an internal tandem duplication in Fms-related tyrosine kinase 3 (FLT3-ITD) is identified as a subgroup with poor outcome and intrinsic resistance to chemotherapy and therefore urgent need for development of novel therapeutic strategies.  The antitumor effects of melatonin alone or combined with sorafenib were evaluated via flow cytometry and immunoblotting assays in FLT-ITD AML cells.  Also, the ex vivo and in vivo models were used to test the synergistic effects of melatonin and sorafenib against leukemia with FLT3/ITD mutation.  Our study shows for the first time that melatonin inhibits proliferation and induces apoptosis in FLT3/ITD-pos. leukemia cells.  Mechanistically, melatonin preferentially causes overprodn. of reactive oxygen species (ROS) and ultimately massive cell death in FLT3-ITD AML cells.  Moreover, melatonin significantly enhances the cytotoxicity induced by the FLT3 tyrosine kinase inhibitor sorafenib in AML cells with FLT3/ITD through redox modification.  Importantly, combination of melatonin and sorafenib exhibited highly synergistic therapeutic activity in MV4-11 xenografts and a murine model bearing FLT3/ITD leukemia.  This study indicates that melatonin, alone or in combination with sorafenib, has potential to improve the therapeutic outcome of AML patients with FLT3-ITD mutation that merits further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSlsD6-46i5rVg90H21EOLACvtfcHk0ljnXqC1VXa7sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1ertLjE&md5=ad88dd7b7f757bc568e06142486c39e7</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.7150%2Fthno.34327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.34327%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DY.%2BX.%26aulast%3DTang%26aufirst%3DY.%2BL.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DF.%26aulast%3DShi%26aufirst%3DD.%26aulast%3DLong%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DQin%26aufirst%3DL.%26aulast%3DDeng%26aufirst%3DW.%26atitle%3DMelatonin%2520enhances%2520sorafenib-induced%2520cytotoxicity%2520in%2520FLT3-ITD%2520acute%2520myeloid%2520leukemia%2520cells%2520by%2520redox%2520modification%26jtitle%3DTheranostics%26date%3D2019%26volume%3D9%26issue%3D13%26spage%3D3768%26epage%3D3779%26doi%3D10.7150%2Fthno.34327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dun, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panicker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mashkani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Don, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toop, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lock, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guthridge, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashman, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skelding, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enjeti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verrills, N. M.</span></span> <span> </span><span class="NLM_article-title">Activation of protein phosphatase 2A in FLT3<sup>+</sup> acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">30</span>),  <span class="NLM_fpage">47465</span>– <span class="NLM_lpage">47478</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.10167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.18632%2Foncotarget.10167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=27329844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BC2s7isFeguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=47465-47478&issue=30&author=A.+M.+Smithauthor=M.+D.+Dunauthor=E.+M.+Leeauthor=C.+Harrisonauthor=R.+Kahlauthor=H.+Flanaganauthor=N.+Panickerauthor=B.+Mashkaniauthor=A.+S.+Donauthor=J.+Morrisauthor=H.+Toopauthor=R.+B.+Lockauthor=J.+A.+Powellauthor=D.+Thomasauthor=M.+A.+Guthridgeauthor=A.+Mooreauthor=L.+K.+Ashmanauthor=K.+A.+Skeldingauthor=A.+Enjetiauthor=N.+M.+Verrills&title=Activation+of+protein+phosphatase+2A+in+FLT3%2B+acute+myeloid+leukemia+cells+enhances+the+cytotoxicity+of+FLT3+tyrosine+kinase+inhibitors&doi=10.18632%2Foncotarget.10167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors</span></div><div class="casAuthors">Smith Amanda M; Dun Matthew D; Harrison Celeste; Kahl Richard; Flanagan Hayley; Panicker Nikita; Mashkani Baratali; Ashman Leonie K; Skelding Kathryn A; Enjeti Anoop; Verrills Nicole M; Smith Amanda M; Dun Matthew D; Harrison Celeste; Kahl Richard; Flanagan Hayley; Panicker Nikita; Mashkani Baratali; Ashman Leonie K; Skelding Kathryn A; Enjeti Anoop; Verrills Nicole M; Smith Amanda M; Lee Erwin M; Lock Richard B; Mashkani Baratali; Don Anthony S; Morris Jonathan; Toop Hamish; Powell Jason A; Thomas Daniel; Thomas Daniel; Guthridge Mark A; Moore Andrew; Enjeti Anoop</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">47465-47478</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Constitutive activation of the receptor tyrosine kinase Fms-like tyrosine kinase 3 (FLT3), via co-expression of its ligand or by genetic mutation, is common in acute myeloid leukemia (AML).  In this study we show that FLT3 activation inhibits the activity of the tumor suppressor, protein phosphatase 2A (PP2A).  Using BaF3 cells transduced with wildtype or mutant FLT3, we show that FLT3-induced PP2A inhibition sensitizes cells to the pharmacological PP2A activators, FTY720 and AAL(S).  FTY720 and AAL(S) induced cell death and inhibited colony formation of FLT3 activated cells.  Furthermore, PP2A activators reduced the phosphorylation of ERK and AKT, downstream targets shared by both FLT3 and PP2A, in FLT3/ITD+ BaF3 and MV4-11 cell lines.  PP2A activity was lower in primary human bone marrow derived AML blasts compared to normal bone marrow, with blasts from FLT3-ITD patients displaying lower PP2A activity than WT-FLT3 blasts.  Reduced PP2A activity was associated with hyperphosphorylation of the PP2A catalytic subunit, and reduced expression of PP2A structural and regulatory subunits.  AML patient blasts were also sensitive to cell death induced by FTY720 and AAL(S), but these compounds had minimal effect on normal CD34+ bone marrow derived monocytes.  Finally, PP2A activating compounds displayed synergistic effects when used in combination with tyrosine kinase inhibitors in FLT3-ITD+ cells.  A combination of Sorafenib and FTY720 was also synergistic in the presence of a protective stromal microenvironment.  Thus combining a PP2A activating compound and a FLT3 inhibitor may be a novel therapeutic approach for treating AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTxTjCLYqx9S2xpATR2EQURfW6udTcc2eY-P_AgQl6l3bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7isFeguw%253D%253D&md5=691727b8e4d3b270933bdda014f6a7f7</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.10167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.10167%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DDun%26aufirst%3DM.%2BD.%26aulast%3DLee%26aufirst%3DE.%2BM.%26aulast%3DHarrison%26aufirst%3DC.%26aulast%3DKahl%26aufirst%3DR.%26aulast%3DFlanagan%26aufirst%3DH.%26aulast%3DPanicker%26aufirst%3DN.%26aulast%3DMashkani%26aufirst%3DB.%26aulast%3DDon%26aufirst%3DA.%2BS.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DToop%26aufirst%3DH.%26aulast%3DLock%26aufirst%3DR.%2BB.%26aulast%3DPowell%26aufirst%3DJ.%2BA.%26aulast%3DThomas%26aufirst%3DD.%26aulast%3DGuthridge%26aufirst%3DM.%2BA.%26aulast%3DMoore%26aufirst%3DA.%26aulast%3DAshman%26aufirst%3DL.%2BK.%26aulast%3DSkelding%26aufirst%3DK.%2BA.%26aulast%3DEnjeti%26aufirst%3DA.%26aulast%3DVerrills%26aufirst%3DN.%2BM.%26atitle%3DActivation%2520of%2520protein%2520phosphatase%25202A%2520in%2520FLT3%252B%2520acute%2520myeloid%2520leukemia%2520cells%2520enhances%2520the%2520cytotoxicity%2520of%2520FLT3%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26issue%3D30%26spage%3D47465%26epage%3D47478%26doi%3D10.18632%2Foncotarget.10167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKenzie, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pippa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eide, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oddo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sears, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitek, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odero, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span> <span> </span><span class="NLM_article-title">Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2092</span>– <span class="NLM_lpage">2103</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-2575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F1078-0432.CCR-13-2575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=24436473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtl2msLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2092-2103&issue=8&author=A.+Agarwalauthor=R.+J.+MacKenzieauthor=R.+Pippaauthor=C.+A.+Eideauthor=J.+Oddoauthor=J.+W.+Tynerauthor=R.+Searsauthor=M.+P.+Vitekauthor=M.+D.+Oderoauthor=D.+J.+Christensenauthor=B.+J.+Druker&title=Antagonism+of+SET+using+OP449+enhances+the+efficacy+of+tyrosine+kinase+inhibitors+and+overcomes+drug+resistance+in+myeloid+leukemia&doi=10.1158%2F1078-0432.CCR-13-2575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia</span></div><div class="casAuthors">Agarwal, Anupriya; MacKenzie, Ryan J.; Pippa, Raffaella; Eide, Christopher A.; Oddo, Jessica; Tyner, Jeffrey W.; Sears, Rosalie; Vitek, Michael P.; Odero, Maria D.; Christensen, Dale J.; Druker, Brian J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2092-2103</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The SET oncoprotein, a potent inhibitor of the protein phosphatase 2A (PP2A), is overexpressed in leukemia.  We evaluated the efficacy of SET antagonism in chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) cell lines, a murine leukemia model, and primary patient samples using OP449, a specific, cell-penetrating peptide that antagonizes SET's inhibition of PP2A.  Exptl. Design: In vitro cytotoxicity and specificity of OP449 in CML and AML cell lines and primary samples were measured using proliferation, apoptosis, and clonogenic assays.  Efficacy of target inhibition by OP449 was evaluated by immunoblotting and PP2A assay.  In vivo antitumor efficacy of OP449 was measured in human HL-60 xenografted murine model.  Results: We obsd. that OP449 inhibited growth of CML cells including those from patients with blastic phase disease and patients harboring highly drug-resistant BCR-ABL1 mutations.  Combined treatment with OP449 and ABL1 tyrosine kinase inhibitors was significantly more cytotoxic to K562 cells and primary CD34+ CML cells.  SET protein levels remained unchanged with OP449 treatment, but BCR-ABL1-mediated downstream signaling was significantly inhibited with the degrdn. of key signaling mols. such as BCR-ABL1, STAT5, and AKT.  Similarly, AML cell lines and primary patient samples with various genetic lesions showed inhibition of cell growth after treatment with OP449 alone or in combination with resp. kinase inhibitors.  Finally, OP449 reduced the tumor burden of mice xenografted with human leukemia cells.  Conclusions: We demonstrate a novel therapeutic paradigm of SET antagonism using OP449 in combination with tyrosine kinase inhibitors for the treatment of CML and AML.  Clin Cancer Res; 20(8); 2092-103. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPqhh_v9-eq7Vg90H21EOLACvtfcHk0lj1r52dq8Xpvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtl2msLY%253D&md5=22aab4e8cb861c5be37a596dbf6ce8e7</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-2575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-2575%26sid%3Dliteratum%253Aachs%26aulast%3DAgarwal%26aufirst%3DA.%26aulast%3DMacKenzie%26aufirst%3DR.%2BJ.%26aulast%3DPippa%26aufirst%3DR.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DOddo%26aufirst%3DJ.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DSears%26aufirst%3DR.%26aulast%3DVitek%26aufirst%3DM.%2BP.%26aulast%3DOdero%26aufirst%3DM.%2BD.%26aulast%3DChristensen%26aufirst%3DD.%2BJ.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DAntagonism%2520of%2520SET%2520using%2520OP449%2520enhances%2520the%2520efficacy%2520of%2520tyrosine%2520kinase%2520inhibitors%2520and%2520overcomes%2520drug%2520resistance%2520in%2520myeloid%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26issue%3D8%26spage%3D2092%26epage%3D2103%26doi%3D10.1158%2F1078-0432.CCR-13-2575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gondek, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huso, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foerster, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchionni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGovern, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peacock, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merchant, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsui, W.</span></span> <span> </span><span class="NLM_article-title">Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">291</span>),  <span class="NLM_fpage">291ra96</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aaa5731</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1126%2Fscitranslmed.aaa5731" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=26062848" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=291ra96&issue=291&author=Y.+Limauthor=L.+Gondekauthor=L.+Liauthor=Q.+Wangauthor=H.+Maauthor=E.+Changauthor=D.+L.+Husoauthor=S.+Foersterauthor=L.+Marchionniauthor=K.+McGovernauthor=D.+N.+Watkinsauthor=C.+D.+Peacockauthor=M.+Levisauthor=B.+D.+Smithauthor=A.+A.+Merchantauthor=D.+Smallauthor=W.+Matsui&title=Integration+of+Hedgehog+and+mutant+FLT3+signaling+in+myeloid+leukemia&doi=10.1126%2Fscitranslmed.aaa5731"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaa5731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaa5731%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DY.%26aulast%3DGondek%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DChang%26aufirst%3DE.%26aulast%3DHuso%26aufirst%3DD.%2BL.%26aulast%3DFoerster%26aufirst%3DS.%26aulast%3DMarchionni%26aufirst%3DL.%26aulast%3DMcGovern%26aufirst%3DK.%26aulast%3DWatkins%26aufirst%3DD.%2BN.%26aulast%3DPeacock%26aufirst%3DC.%2BD.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DMerchant%26aufirst%3DA.%2BA.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DMatsui%26aufirst%3DW.%26atitle%3DIntegration%2520of%2520Hedgehog%2520and%2520mutant%2520FLT3%2520signaling%2520in%2520myeloid%2520leukemia%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2015%26volume%3D7%26issue%3D291%26spage%3D291ra96%26doi%3D10.1126%2Fscitranslmed.aaa5731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohl, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullinger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rucker, F. G.</span></span> <span> </span><span class="NLM_article-title">New targeted agents in acute myeloid leukemia: new hope on the rise</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1983</span>, <span class="refDoi"> DOI: 10.3390/ijms20081983</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.3390%2Fijms20081983" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFKjt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1983&issue=8&author=S.+R.+Bohlauthor=L.+Bullingerauthor=F.+G.+Rucker&title=New+targeted+agents+in+acute+myeloid+leukemia%3A+new+hope+on+the+rise&doi=10.3390%2Fijms20081983"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">New targeted agents in acute myeloid leukemia: new hope on the rise</span></div><div class="casAuthors">Bohl, Stephan R.; Bullinger, Lars; Ruecker, Frank G.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1983</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The therapeutic approach for acute myeloid leukemia (AML) remains challenging, since over the last four decades a stagnation in std. cytotoxic treatment has been obsd.  But within recent years, remarkable advances in the understanding of the mol. heterogeneity and complexity of this disease have led to the identification of novel therapeutic targets.  In the last two years, seven new targeted agents (midostaurin, gilteritinib, enasidenib, ivosidenib, glasdegib, venetoclax and gemtuzumab ozogamicin) have received US Food and Drug Administration (FDA) approval for the treatment of AML.  These drugs did not just prove to have a clin. benefit as single agents but have esp. improved AML patient outcomes if they are combined with conventional therapy.  In this review, we will focus on currently approved and promising upcoming agents and we will discuss controversial aspects and limitations of targeted treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQK8hg1LfxhbVg90H21EOLACvtfcHk0lj1r52dq8Xpvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFKjt7o%253D&md5=f698f250c6c5edcfd8b871016ebbe75e</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.3390%2Fijms20081983&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20081983%26sid%3Dliteratum%253Aachs%26aulast%3DBohl%26aufirst%3DS.%2BR.%26aulast%3DBullinger%26aufirst%3DL.%26aulast%3DRucker%26aufirst%3DF.%2BG.%26atitle%3DNew%2520targeted%2520agents%2520in%2520acute%2520myeloid%2520leukemia%253A%2520new%2520hope%2520on%2520the%2520rise%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26issue%3D8%26spage%3D1983%26doi%3D10.3390%2Fijms20081983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, S.</span></span> <span> </span><span class="NLM_article-title">Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">13</span>, <span class="refDoi"> DOI: 10.1186/1756-8722-4-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1186%2F1756-8722-4-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=21453545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltV2htLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=13&author=S.+Takahashi&title=Downstream+molecular+pathways+of+FLT3+in+the+pathogenesis+of+acute+myeloid+leukemia%3A+biology+and+therapeutic+implications&doi=10.1186%2F1756-8722-4-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications</span></div><div class="casAuthors">Takahashi, Shinichiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  FLT3 is a type III receptor tyrosine kinase.  Mutations of FLT3 comprise one of the most frequently identified types of genetic alterations in acute myeloid leukemia.  One-third of acute myeloid leukemia patients have mutations of this gene, and the majority of these mutations involve an internal tandem duplication in the juxtamembrane region of FLT3, leading to constitutive activation of downstream signaling pathways and aberrant cell growth.  This review summarizes the current understanding of the effects of the downstream mol. signaling pathways after FLT3 activation, with a particular focus on the effects on transcription factors.  Moreover, this review describes novel FLT3-targeted therapies, as well as efficient combination therapies for FLT3-mutated leukemia cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSWuiPhmUfabVg90H21EOLACvtfcHk0lgvw-T0nwqShQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltV2htLk%253D&md5=c9fc883616d38b64a3ce16dc1c9f28cb</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-4-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-4-13%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DS.%26atitle%3DDownstream%2520molecular%2520pathways%2520of%2520FLT3%2520in%2520the%2520pathogenesis%2520of%2520acute%2520myeloid%2520leukemia%253A%2520biology%2520and%2520therapeutic%2520implications%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2011%26volume%3D4%26spage%3D13%26doi%3D10.1186%2F1756-8722-4-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohi, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sternberg, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3130</span>– <span class="NLM_lpage">3135</span>, <span class="refDoi"> DOI: 10.1073/pnas.0400063101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1073%2Fpnas.0400063101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=14976243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitlWhtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=3130-3135&issue=9&author=M.+G.+Mohiauthor=C.+Boultonauthor=T.+L.+Guauthor=D.+W.+Sternbergauthor=D.+Neubergauthor=J.+D.+Griffinauthor=D.+G.+Gillilandauthor=B.+G.+Neel&title=Combination+of+rapamycin+and+protein+tyrosine+kinase+%28PTK%29+inhibitors+for+the+treatment+of+leukemias+caused+by+oncogenic+PTKs&doi=10.1073%2Fpnas.0400063101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs</span></div><div class="casAuthors">Mohi, M. Golam; Boulton, Christina; Gu, Ting-Lei; Sternberg, David W.; Neuberg, Donna; Griffin, James D.; Gilliland, D. Gary; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3130-3135</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Abnormal protein tyrosine kinases (PTKs) cause many human leukemias.  For example, BCR/ABL causes chronic myelogenous leukemia (CML), whereas FLT3 mutations contribute to the pathogenesis of acute myelogenous leukemia.  The ABL inhibitor Imatinib (Gleevec, STI571) has remarkable efficacy for treating chronic phase CML, and FLT3 inhibitors (e.g., PKC412) show similar promise in preclin. studies.  However, resistance to PTK inhibitors is a major emerging problem that may limit long-term therapeutic efficacy.  Development of rational combination therapies will probably be required to effect cures of these and other neoplastic disorders.  Here, we report that the mTOR inhibitor rapamycin synergizes with Imatinib against BCR/ABL-transformed myeloid and lymphoid cells and increases survival in a murine CML model.  Rapamycin/Imatinib combinations also inhibit Imatinib-resistant mutants of BCR/ABL, and rapamycin plus PKC412 synergistically inhibits cells expressing PKC412-sensitive or -resistant leukemogenic FLT3 mutants.  Biochem. analyses raise the possibility that inhibition of 4E-BP1 phosphorylation may be particularly important for the synergistic effects of PTK inhibitor/rapamycin combinations.  Addn. of a mitogen-activated protein kinase kinase inhibitor to rapamycin or rapamycin plus PTK inhibitor further increases efficacy.  Our results suggest that simultaneous targeting of more than one signaling pathway required by leukemogenic PTKs may improve the treatment of primary and relapsed CML and/or acute myelogenous leukemia caused by FLT3 mutations.  Similar strategies may be useful for treating solid tumors assocd. with mutant and/or overexpressed PTKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFh_qyVxb2rrVg90H21EOLACvtfcHk0lgvw-T0nwqShQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitlWhtL0%253D&md5=fdf6c963832e6a9eab8bbb964d9db5a4</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0400063101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0400063101%26sid%3Dliteratum%253Aachs%26aulast%3DMohi%26aufirst%3DM.%2BG.%26aulast%3DBoulton%26aufirst%3DC.%26aulast%3DGu%26aufirst%3DT.%2BL.%26aulast%3DSternberg%26aufirst%3DD.%2BW.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DCombination%2520of%2520rapamycin%2520and%2520protein%2520tyrosine%2520kinase%2520%2528PTK%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520leukemias%2520caused%2520by%2520oncogenic%2520PTKs%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26issue%3D9%26spage%3D3130%26epage%3D3135%26doi%3D10.1073%2Fpnas.0400063101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolais, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galinsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N.</span></span> <span> </span><span class="NLM_article-title">Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">e56473</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0056473</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1371%2Fjournal.pone.0056473" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=23437141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjs12ns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e56473&issue=2&author=E.+Weisbergauthor=Q.+Liuauthor=X.+Zhangauthor=E.+Nelsonauthor=M.+Sattlerauthor=F.+Liuauthor=M.+Nicolaisauthor=J.+Zhangauthor=C.+Mitsiadesauthor=R.+W.+Smithauthor=R.+Stoneauthor=I.+Galinskyauthor=A.+Nonamiauthor=J.+D.+Griffinauthor=N.+Gray&title=Selective+Akt+inhibitors+synergize+with+tyrosine+kinase+inhibitors+and+effectively+override+stroma-associated+cytoprotection+of+mutant+FLT3-positive+AML+cells&doi=10.1371%2Fjournal.pone.0056473"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells</span></div><div class="casAuthors">Weisberg, Ellen; Liu, Qingsong; Zhang, Xin; Nelson, Erik; Sattler, Martin; Liu, Feiyang; Nicolais, Maria; Zhang, Jianming; Mitsiades, Constantine; Smith, Robert W.; Stone, Richard; Galinsky, Ilene; Nonami, Atsushi; Griffin, James D.; Gray, Nathanael</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e56473</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Objectives: Tyrosine kinase inhibitor (TKI)-treated acute myeloid leukemia (AML) patients commonly show rapid and significant peripheral blood blast cell redn., however a marginal decrease in bone marrow blasts.  This suggests a protective environment and highlights the demand for a better understanding of stromal:leukemia cell communication.  As a strategy to improve clin. efficacy, we searched for novel agents capable of potentiating the stroma-diminished effects of TKI treatment of mutant FLT3-expressing cells.  Methods: We designed a combinatorial high throughput drug screen using well-characterized kinase inhibitor-focused libraries to identify novel kinase inhibitors capable of overriding stromal-mediated resistance to TKIs, such as PKC412 and AC220.  Std. liq. culture proliferation assays, cell cycle and apoptosis anal., and immunoblotting were carried out with cell lines or primary AML to validate putative candidates from the screen and characterize the mechanism(s) underlying obsd. synergy.  Results and Conclusions: Our study led to the observation of synergy between selective Akt inhibitors and FLT3 inhibitors against mutant FLT3-pos. AML in either the absence or presence of stroma.  Our findings are consistent with evidence that Akt activation is characteristic of mutant FLT3-transformed cells, as well as obsd. residual Akt activity following FLT3 inhibitor treatment.  In conclusion, our study highlights the potential importance of Akt as a signaling factor in leukemia survival, and supports the use of the co-culture chem. screen to identify agents able to potentiate TKI anti-leukemia activity in a cytoprotective microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoghH_zJn-FM7Vg90H21EOLACvtfcHk0lgvw-T0nwqShQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjs12ns7k%253D&md5=195d2a5870780230bdfdad9da26cd501</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0056473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0056473%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DNelson%26aufirst%3DE.%26aulast%3DSattler%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DNicolais%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DMitsiades%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DR.%2BW.%26aulast%3DStone%26aufirst%3DR.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DNonami%26aufirst%3DA.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DGray%26aufirst%3DN.%26atitle%3DSelective%2520Akt%2520inhibitors%2520synergize%2520with%2520tyrosine%2520kinase%2520inhibitors%2520and%2520effectively%2520override%2520stroma-associated%2520cytoprotection%2520of%2520mutant%2520FLT3-positive%2520AML%2520cells%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26issue%3D2%26spage%3De56473%26doi%3D10.1371%2Fjournal.pone.0056473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamorska-Dyga, A.</span></span> <span> </span><span class="NLM_article-title">Syk inhibitors in clinical development for hematological malignancies</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">145</span>, <span class="refDoi"> DOI: 10.1186/s13045-017-0512-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1186%2Fs13045-017-0512-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=28754125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2gsrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=145&issue=1&author=D.+Liuauthor=A.+Mamorska-Dyga&title=Syk+inhibitors+in+clinical+development+for+hematological+malignancies&doi=10.1186%2Fs13045-017-0512-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Syk inhibitors in clinical development for hematological malignancies</span></div><div class="casAuthors">Liu, Delong; Mamorska-Dyga, Aleksandra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">145/1-145/7</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Spleen tyrosine kinase (Syk) is a cytosolic non-receptor protein tyrosine kinase (PTK) and is mainly expressed in hematopoietic cells.  Syk was recognized as a crit. element in the B-cell receptor signaling pathway.  Syk is also a key component in signal transduction from other immune receptors like Fc receptors and adhesion receptors.  Several oral Syk inhibitors including fostamatinib (R788), entospletinib (GS-9973), cerdulatinib (PRT062070), and TAK-659 are being assessed in clin. trials.  The second generation compd., entospletinib, showed promising results in clin. trials against B-cell malignancies, mainly chronic lymphoid leukemia.  Syk inhibitors are being evaluated in combination regimens in multiple malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI4gAk4MLv-7Vg90H21EOLACvtfcHk0liTxxiN7N41CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2gsrbJ&md5=ed423c793913414c2966af15bd4457c4</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1186%2Fs13045-017-0512-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-017-0512-1%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DMamorska-Dyga%26aufirst%3DA.%26atitle%3DSyk%2520inhibitors%2520in%2520clinical%2520development%2520for%2520hematological%2520malignancies%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2017%26volume%3D10%26issue%3D1%26spage%3D145%26doi%3D10.1186%2Fs13045-017-0512-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Megias-Vericat, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballesta-Lopez, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barragan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Cuadron, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montesinos, P.</span></span> <span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors for acute myeloid leukemia: a step toward disease control?</span>. <i>Blood Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">100675</span>, <span class="refDoi"> DOI: 10.1016/j.blre.2020.100675</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.blre.2020.100675" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=32147087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkslClur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2020&pages=100675&author=J.+E.+Megias-Vericatauthor=O.+Ballesta-Lopezauthor=E.+Barraganauthor=D.+Martinez-Cuadronauthor=P.+Montesinos&title=Tyrosine+kinase+inhibitors+for+acute+myeloid+leukemia%3A+a+step+toward+disease+control%3F&doi=10.1016%2Fj.blre.2020.100675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control</span></div><div class="casAuthors">Megias-Vericat, Juan Eduardo; Ballesta-Lopez, Octavio; Barragan, Eva; Martinez-Cuadron, David; Montesinos, Pau</div><div class="citationInfo"><span class="NLM_cas:title">Blood Reviews</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">100675</span>CODEN:
                <span class="NLM_cas:coden">BLOREB</span>;
        ISSN:<span class="NLM_cas:issn">0268-960X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Dysregulation of tyrosine kinases (TKs) may play a role in leukemogenesis by promoting survival and proliferation of acute myeloid leukemia (AML) cells.  In AML, the main TKs mutations are produced in Fms-like tyrosine kinase 3 (FLT3), KIT and Janus kinase (JAK) genes, and with less frequency in BCR-ABL.  The striking results with TK Inhibitors (TKIs) therapy in BCR-ABL1 chronic myeloid leukemias has paved the way for its clin. development in AML.  However, the AML biol. complexity seems to prevent TKI therapy from being proposed as a strong shift in the treatment paradigm and prognosis.  While some FLT3 inhibitors have shown efficacy in well-designed studies, an increasing no. of AML patients are being treated with TKIs as a new std. of care, compassionate use, or in clin. trials.  We will review the current clin. evidence concerning the use of TKIs in different subsets of AML (BCR-ABL1, Core Binding Factor, FLT3 mutated, and FLT3 wild-type) to address the main topics concerning these targeted therapies for AML: 1) optimal place (upfront, relapsed/refractory or maintenance); 2) monotherapy or combination; 3) efficacy in TK mutated vs. wild-type patients; 4) differences between selective and multi-targeted TKIs.  In the next years, clin. trials and real-world data will help answer these questions and establish the impact of TKIs on outcomes of AML patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_GLCI_CMJlLVg90H21EOLACvtfcHk0liTxxiN7N41CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkslClur0%253D&md5=42fffc2fef25f79d95324b1944fc4718</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.blre.2020.100675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.blre.2020.100675%26sid%3Dliteratum%253Aachs%26aulast%3DMegias-Vericat%26aufirst%3DJ.%2BE.%26aulast%3DBallesta-Lopez%26aufirst%3DO.%26aulast%3DBarragan%26aufirst%3DE.%26aulast%3DMartinez-Cuadron%26aufirst%3DD.%26aulast%3DMontesinos%26aufirst%3DP.%26atitle%3DTyrosine%2520kinase%2520inhibitors%2520for%2520acute%2520myeloid%2520leukemia%253A%2520a%2520step%2520toward%2520disease%2520control%253F%26jtitle%3DBlood%2520Rev.%26date%3D2020%26volume%3D44%26spage%3D100675%26doi%3D10.1016%2Fj.blre.2020.100675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuromitsu, S.</span></span> <span> </span><span class="NLM_article-title">Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">556</span>– <span class="NLM_lpage">565</span>, <span class="refDoi"> DOI: 10.1007/s10637-017-0470-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1007%2Fs10637-017-0470-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=28516360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvV2isrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=556-565&issue=5&author=M.+Moriauthor=N.+Kanekoauthor=Y.+Uenoauthor=M.+Yamadaauthor=R.+Tanakaauthor=R.+Saitoauthor=I.+Shimadaauthor=K.+Moriauthor=S.+Kuromitsu&title=Gilteritinib%2C+a+FLT3%2FAXL+inhibitor%2C+shows+antileukemic+activity+in+mouse+models+of+FLT3+mutated+acute+myeloid+leukemia&doi=10.1007%2Fs10637-017-0470-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia</span></div><div class="casAuthors">Mori, Masamichi; Kaneko, Naoki; Ueno, Yoko; Yamada, Masaki; Tanaka, Ruriko; Saito, Rika; Shimada, Itsuro; Mori, Kenichi; Kuromitsu, Sadao</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">556-565</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Advances in the understanding of the mol. basis for acute myeloid leukemia (AML) have generated new potential targets for treatment.  Fms-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in AML and mutations in this gene are assocd. with poor overall survival.  AXL plays a role in the activation of FLT3 and has been implicated in the pathogenesis of AML.  The studies reported here evaluated the ability of a novel FLT3/AXL inhibitor, gilteritinib, to block mutated FLT3 in cellular and animal models of AML.  Initial kinase studies showed that gilteritinib, a type I tyrosine kinase inhibitor, was highly selective for both FLT3 and AXL while having weak activity against c-KIT.  Gilteritinib demonstrated potent inhibitory activity against the internal tandem duplication (FLT3-ITD) and FLT3-D835Y point mutations in cellular assays using MV4-11 and MOLM-13 cells as well as Ba/F3 cells expressing mutated FLT3.  Gilteritinib also inhibited FLT3-F691 mutations, although to a lesser degree, in these assays.  Furthermore, gilteritinib decreased the phosphorylation levels of FLT3 and its downstream targets in both cellular and animal models.  In vivo, gilteritinib was distributed at high levels in xenografted tumors after oral administration.  The decreased FLT3 activity and high intratumor distribution of gilteritinib translated to tumor regression and improved survival in xenograft and intra-bone marrow transplantation models of FLT3-driven AML.  No overt toxicity was seen in mouse models treated with gilteritinib.  These results indicate that gilteritinib may be an important next-generation FLT3 inhibitor for use in the treatment of FLT3 mutation-pos. AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMaOcOB0-DOrVg90H21EOLACvtfcHk0liTxxiN7N41CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvV2isrc%253D&md5=ffdf8ee1887cd2c6623dda70bb98a464</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1007%2Fs10637-017-0470-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-017-0470-z%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DM.%26aulast%3DKaneko%26aufirst%3DN.%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DYamada%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DR.%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DShimada%26aufirst%3DI.%26aulast%3DMori%26aufirst%3DK.%26aulast%3DKuromitsu%26aufirst%3DS.%26atitle%3DGilteritinib%252C%2520a%2520FLT3%252FAXL%2520inhibitor%252C%2520shows%2520antileukemic%2520activity%2520in%2520mouse%2520models%2520of%2520FLT3%2520mutated%2520acute%2520myeloid%2520leukemia%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2017%26volume%3D35%26issue%3D5%26spage%3D556%26epage%3D565%26doi%3D10.1007%2Fs10637-017-0470-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amalini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia</span>. <i>Blood Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">e44</span>, <span class="refDoi"> DOI: 10.1038/bcj.2011.43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fbcj.2011.43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=22829080" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=e44&issue=11&author=S.+Hartauthor=K.+C.+Gohauthor=V.+Novotny-Diermayrauthor=Y.+C.+Tanauthor=B.+Madanauthor=C.+Amaliniauthor=L.+C.+Ongauthor=B.+Khengauthor=A.+Cheongauthor=J.+Zhouauthor=W.+J.+Chngauthor=J.+M.+Wood&title=Pacritinib+%28SB1518%29%2C+a+JAK2%2FFLT3+inhibitor+for+the+treatment+of+acute+myeloid+leukemia&doi=10.1038%2Fbcj.2011.43"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2011.43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2011.43%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DS.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DAmalini%26aufirst%3DC.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DKheng%26aufirst%3DB.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DPacritinib%2520%2528SB1518%2529%252C%2520a%2520JAK2%252FFLT3%2520inhibitor%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%2520Cancer%2520J.%26date%3D2011%26volume%3D1%26issue%3D11%26spage%3De44%26doi%3D10.1038%2Fbcj.2011.43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buelow, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phelps, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mims, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behbehani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blachly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klisovic, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garzon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatnagar, B.</span></span> <span> </span><span class="NLM_article-title">Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">349</span>, <span class="refDoi"> DOI: 10.1007/s10637-019-00786-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1007%2Fs10637-019-00786-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=31102119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFert7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=340-349&issue=2&author=J.+Y.+Jeonauthor=Q.+Zhaoauthor=D.+R.+Buelowauthor=M.+Phelpsauthor=A.+R.+Walkerauthor=A.+S.+Mimsauthor=S.+Vasuauthor=G.+Behbehaniauthor=J.+Blachlyauthor=W.+Blumauthor=R.+B.+Klisovicauthor=J.+C.+Byrdauthor=R.+Garzonauthor=S.+D.+Bakerauthor=B.+Bhatnagar&title=Preclinical+activity+and+a+pilot+phase+I+study+of+pacritinib%2C+an+oral+JAK2%2FFLT3+inhibitor%2C+and+chemotherapy+in+FLT3-ITD-positive+AML&doi=10.1007%2Fs10637-019-00786-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positve AML</span></div><div class="casAuthors">Jeon, Jae Yoon; Zhao, Qiuhong; Buelow, Daelynn R.; Phelps, Mitch; Walker, Alison R.; Mims, Alice S.; Vasu, Sumithira; Behbehani, Gregory; Blachly, James; Blum, William; Klisovic, Rebecca B.; Byrd, John C.; Garzon, Ramiro; Baker, Sharyn D.; Bhatnagar, Bhavana</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">340-349</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Activating FLT3 internal tandem duplication (FLT3-ITD) mutations in acute myeloid leukemia (AML) assoc. with inferior outcomes.  We detd. that pacritinib, a JAK2/FLT3 inhibitor, has in vitro activity against FLT3-ITD and tyrosine kinase domain (TKD) mutations.  Therefore, we conducted a phase I study of pacritinib in combination with chemotherapy in AML patients with FLT3 mutations to det. the pharmacokinetics and preliminary toxicity and clin. activity.  Pacritinib was administered at a dose of 100 mg or 200 mg twice daily following a 3 + 3 dose-escalation in combination with cytarabine and daunorubicin (cohort A) or with decitabine induction (cohort B).  A total of thirteen patients were enrolled (five in cohort A; eight in cohort B).  Dose limiting toxicities include hemolytic anemia and grade 3 QTc prolongation in two patients who received 100 mg.  Complete remission was achieved in two patients in cohort A, one of whom had a minor D835Y clone at baseline.  One patient in cohort B achieved morphol. leukemia free state.  Seven patients (two in cohort A; five in cohort B) had stable disease.  In conclusion, pacritinib, an inhibitor of FLT3-ITD and resistant-conferring TKD mutations, was well tolerated and demonstrated preliminary anti-leukemic activity in combination with chemotherapy in patients with FLT3 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_5v94xwTkvbVg90H21EOLACvtfcHk0ljbe-VJj3FXhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFert7jM&md5=8bd832581ae6d52b56fb0df21074be16</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1007%2Fs10637-019-00786-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-019-00786-4%26sid%3Dliteratum%253Aachs%26aulast%3DJeon%26aufirst%3DJ.%2BY.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DBuelow%26aufirst%3DD.%2BR.%26aulast%3DPhelps%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DA.%2BR.%26aulast%3DMims%26aufirst%3DA.%2BS.%26aulast%3DVasu%26aufirst%3DS.%26aulast%3DBehbehani%26aufirst%3DG.%26aulast%3DBlachly%26aufirst%3DJ.%26aulast%3DBlum%26aufirst%3DW.%26aulast%3DKlisovic%26aufirst%3DR.%2BB.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DGarzon%26aufirst%3DR.%26aulast%3DBaker%26aufirst%3DS.%2BD.%26aulast%3DBhatnagar%26aufirst%3DB.%26atitle%3DPreclinical%2520activity%2520and%2520a%2520pilot%2520phase%2520I%2520study%2520of%2520pacritinib%252C%2520an%2520oral%2520JAK2%252FFLT3%2520inhibitor%252C%2520and%2520chemotherapy%2520in%2520FLT3-ITD-positive%2520AML%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2020%26volume%3D38%26issue%3D2%26spage%3D340%26epage%3D349%26doi%3D10.1007%2Fs10637-019-00786-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">111590</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.ejmech.2019.111590" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=31408808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFyjsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2019&pages=111590&author=Y.+Liauthor=T.+Yeauthor=L.+Xuauthor=Y.+Dongauthor=Y.+Luoauthor=C.+Wangauthor=Y.+Hanauthor=K.+Chenauthor=M.+Qinauthor=Y.+Liuauthor=Y.+Zhao&title=Discovery+of+4-piperazinyl-2-aminopyrimidine+derivatives+as+dual+inhibitors+of+JAK2+and+FLT3&doi=10.1016%2Fj.ejmech.2019.111590"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3</span></div><div class="casAuthors">Li, Yingxiu; Ye, Tianyu; Xu, Le; Dong, Yuhong; Luo, Yong; Wang, Chu; Han, Yufei; Chen, Ke; Qin, Mingze; Liu, Yajing; Zhao, Yanfang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111590</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Hybridization strategy is an effective strategy to obtain multi-target inhibitors in drug design.  In this study, we assembled the pharmacophores of momelotinib and tandutinib to get a series of 4-piperazinyl-2-aminopyrimidine derivs.  All compds. were tested for the inhibition of JAK2 and FLT3 enzymes, of which, compds. with potent enzyme activities were assayed for antiproliferative activities against three cancer cell lines (HEL, MV4-11, and HL60).  The structure-activity relationship studies were conducted through variations in two regions, the "A" Ph ring and "B" Ph ring.  Compd. 14j showed the most balanced in vitro inhibitory activity against JAK2 and FLT3 (JAK2 IC50 = 27 nM, FLT3 IC50 = 30 nM), and it also showed potent inhibition against the above tested cell lines.  In the cellular context, 14j strongly induced apoptosis by arresting cell cycle in the G1/S phase, and was selected as a promising JAK2/FLT3 dual inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs61BoDk0-lbVg90H21EOLACvtfcHk0ljbe-VJj3FXhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFyjsLnO&md5=787f97231f5494a8f85f581521486b25</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111590%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DQin%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DY.%26atitle%3DDiscovery%2520of%25204-piperazinyl-2-aminopyrimidine%2520derivatives%2520as%2520dual%2520inhibitors%2520of%2520JAK2%2520and%2520FLT3%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D181%26spage%3D111590%26doi%3D10.1016%2Fj.ejmech.2019.111590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bavetsias, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crumpler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atrash, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faisal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosmopoulou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheldrake, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Haven Brandon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayliss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linardopoulos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span> <span> </span><span class="NLM_article-title">Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">8721</span>– <span class="NLM_lpage">8734</span>, <span class="refDoi"> DOI: 10.1021/jm300952s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300952s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVOhsrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8721-8734&issue=20&author=V.+Bavetsiasauthor=S.+Crumplerauthor=C.+Sunauthor=S.+Averyauthor=B.+Atrashauthor=A.+Faisalauthor=A.+S.+Mooreauthor=M.+Kosmopoulouauthor=N.+Brownauthor=P.+W.+Sheldrakeauthor=K.+Bushauthor=A.+Henleyauthor=G.+Boxauthor=M.+Valentiauthor=A.+de+Haven+Brandonauthor=F.+I.+Raynaudauthor=P.+Workmanauthor=S.+A.+Ecclesauthor=R.+Baylissauthor=S.+Linardopoulosauthor=J.+Blagg&title=Optimization+of+imidazo%5B4%2C5-b%5Dpyridine-based+kinase+inhibitors%3A+identification+of+a+dual+FLT3%2FAurora+kinase+inhibitor+as+an+orally+bioavailable+preclinical+development+candidate+for+the+treatment+of+acute+myeloid+leukemia&doi=10.1021%2Fjm300952s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Imidazo[4,5-b]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia</span></div><div class="casAuthors">Bavetsias, Vassilios; Crumpler, Simon; Sun, Chongbo; Avery, Sian; Atrash, Butrus; Faisal, Amir; Moore, Andrew S.; Kosmopoulou, Magda; Brown, Nathan; Sheldrake, Peter W.; Bush, Katherine; Henley, Alan; Box, Gary; Valenti, Melanie; Brandon, Alexis de Haven; Raynaud, Florence I.; Workman, Paul; Eccles, Suzanne A.; Bayliss, Richard; Linardopoulos, Spiros; Blagg, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8721-8734</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Optimization of the imidazo[4,5-b]pyridine-based series of Aurora kinase inhibitors led to the identification of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine (I), a potent inhibitor of Aurora kinases (Aurora-A Kd = 7.5 nM, Aurora-B Kd = 48 nM), FLT3 kinase (Kd = 6.2 nM), and FLT3 mutants including FLT3-ITD (Kd = 38 nM) and FLT3(D835Y) (Kd = 14 nM).  FLT3-ITD causes constitutive FLT3 kinase activation and is detected in 20-35% of adults and 15% of children with acute myeloid leukemia (AML), conferring a poor prognosis in both age groups.  In an in vivo setting, I strongly inhibited the growth of a FLT3-ITD-pos. AML human tumor xenograft (MV4-11) following oral administration, with in vivo biomarker modulation and plasma free drug exposures consistent with dual FLT3 and Aurora kinase inhibition.  Compd. I, an orally bioavailable dual FLT3 and Aurora kinase inhibitor, was selected as a preclin. development candidate for the treatment of human malignancies, in particular AML, in adults and children.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr33FrCMOQBC7Vg90H21EOLACvtfcHk0lg2O9MFaT1xcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVOhsrzK&md5=4fcd67f24f682f6421d058723b9e89df</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1021%2Fjm300952s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300952s%26sid%3Dliteratum%253Aachs%26aulast%3DBavetsias%26aufirst%3DV.%26aulast%3DCrumpler%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DAvery%26aufirst%3DS.%26aulast%3DAtrash%26aufirst%3DB.%26aulast%3DFaisal%26aufirst%3DA.%26aulast%3DMoore%26aufirst%3DA.%2BS.%26aulast%3DKosmopoulou%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DN.%26aulast%3DSheldrake%26aufirst%3DP.%2BW.%26aulast%3DBush%26aufirst%3DK.%26aulast%3DHenley%26aufirst%3DA.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3Dde%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DBayliss%26aufirst%3DR.%26aulast%3DLinardopoulos%26aufirst%3DS.%26aulast%3DBlagg%26aufirst%3DJ.%26atitle%3DOptimization%2520of%2520imidazo%255B4%252C5-b%255Dpyridine-based%2520kinase%2520inhibitors%253A%2520identification%2520of%2520a%2520dual%2520FLT3%252FAurora%2520kinase%2520inhibitor%2520as%2520an%2520orally%2520bioavailable%2520preclinical%2520development%2520candidate%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D20%26spage%3D8721%26epage%3D8734%26doi%3D10.1021%2Fjm300952s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moore, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faisal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, G. W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miraki-Moud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bavetsias, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallsworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Haven Brandon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xavier, C. P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stronge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, A. D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taussig, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linardopoulos, S.</span></span> <span> </span><span class="NLM_article-title">Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736</span>. <i>Blood Adv.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1478</span>– <span class="NLM_lpage">1491</span>, <span class="refDoi"> DOI: 10.1182/bloodadvances.2019000986</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fbloodadvances.2019000986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=32282883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BB3cXis12ksr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2020&pages=1478-1491&issue=7&author=A.+S.+Mooreauthor=A.+Faisalauthor=G.+W.+Y.+Makauthor=F.+Miraki-Moudauthor=V.+Bavetsiasauthor=M.+Valentiauthor=G.+Boxauthor=A.+Hallsworthauthor=A.+de+Haven+Brandonauthor=C.+P.+R.+Xavierauthor=R.+Strongeauthor=A.+D.+J.+Pearsonauthor=J.+Blaggauthor=F.+I.+Raynaudauthor=R.+Chopraauthor=S.+A.+Ecclesauthor=D.+C.+Taussigauthor=S.+Linardopoulos&title=Quizartinib-resistant+FLT3-ITD+acute+myeloid+leukemia+cells+are+sensitive+to+the+FLT3-Aurora+kinase+inhibitor+CCT241736&doi=10.1182%2Fbloodadvances.2019000986"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736</span></div><div class="casAuthors">Moore, Andrew S.; Faisal, Amir; Mak, Grace W. Y.; Miraki-Moud, Farideh; Bavetsias, Vassilios; Valenti, Melanie; Box, Gary; Hallsworth, Albert; Brandon, Alexis de Haven; Xavier, Cristina P. R.; Stronge, Randal; Pearson, Andrew D. J.; Blagg, Julian; Raynaud, Florence I.; Chopra, Rajesh; Eccles, Suzanne A.; Taussig, David C.; Linardopoulos, Spiros</div><div class="citationInfo"><span class="NLM_cas:title">Blood Advances</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1478-1491</span>CODEN:
                <span class="NLM_cas:coden">BALDBA</span>;
        ISSN:<span class="NLM_cas:issn">2473-9537</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Internal tandem duplication of FLT3 (FLT3-ITD) is one of the most common somatic mutations in acute myeloid leukemia (AML); it causes constitutive activation of FLT3 kinase and is assocd. with high relapse rates and poor survival.  Small-mol. inhibition of FLT3 represents an attractive therapeutic strategy for this subtype of AML, although resistance from secondary FLT3 tyrosine kinase domain (FLT3-TKD) mutations is an emerging clin. problem.  CCT241736 is an orally bioavailable, selective, and potent dual inhibitor of FLT3 and Aurora kinases.  FLT3-ITD+ cells with secondary FLT3-TKD mutations have high in vitro relative resistance to the FLT3 inhibitors quizartinib and sorafenib, but not to CCT241736.  The mechanism of action of CCT241736 results in significant in vivo efficacy, with inhibition of tumor growth obsd. in efficacy studies in FLT3-ITD and FLT3-ITD-TKD human tumor xenograft models.  The efficacy of CCT241736 was also confirmed in primary samples from AML patients, including those with quizartinib-resistant disease, which induces apoptosis through inhibition of both FLT3 and Aurora kinases.  The unique combination of CCT241736 properties based on robust potency, dual selectivity, and significant in vivo activity indicate that CCT241736 is a bona fide clin. drug candidate for FLT3-ITD and TKD AML patients with resistance to current drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3khkwzjI8mbVg90H21EOLACvtfcHk0lg2O9MFaT1xcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXis12ksr3K&md5=a911f89f608c505eeb6ffcfd14113bfc</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1182%2Fbloodadvances.2019000986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fbloodadvances.2019000986%26sid%3Dliteratum%253Aachs%26aulast%3DMoore%26aufirst%3DA.%2BS.%26aulast%3DFaisal%26aufirst%3DA.%26aulast%3DMak%26aufirst%3DG.%2BW.%2BY.%26aulast%3DMiraki-Moud%26aufirst%3DF.%26aulast%3DBavetsias%26aufirst%3DV.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DHallsworth%26aufirst%3DA.%26aulast%3Dde%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DXavier%26aufirst%3DC.%2BP.%2BR.%26aulast%3DStronge%26aufirst%3DR.%26aulast%3DPearson%26aufirst%3DA.%2BD.%2BJ.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DChopra%26aufirst%3DR.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DTaussig%26aufirst%3DD.%2BC.%26aulast%3DLinardopoulos%26aufirst%3DS.%26atitle%3DQuizartinib-resistant%2520FLT3-ITD%2520acute%2520myeloid%2520leukemia%2520cells%2520are%2520sensitive%2520to%2520the%2520FLT3-Aurora%2520kinase%2520inhibitor%2520CCT241736%26jtitle%3DBlood%2520Adv.%26date%3D2020%26volume%3D4%26issue%3D7%26spage%3D1478%26epage%3D1491%26doi%3D10.1182%2Fbloodadvances.2019000986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksterowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribble, M. W.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alba, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connors, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeGraffenreid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deignan, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquette, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huard, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaizerman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lively, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMinn, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihalic, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattabiraman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piper, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Queva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragains, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suchomel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wanska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehn, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickramasinghe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3430</span>– <span class="NLM_lpage">3449</span>, <span class="refDoi"> DOI: 10.1021/jm500118j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500118j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3430-3449&issue=8&author=Z.+Liauthor=X.+Wangauthor=J.+Eksterowiczauthor=M.+W.+Gribbleauthor=G.+Q.+Albaauthor=M.+Ayresauthor=T.+J.+Carlsonauthor=A.+Chenauthor=X.+Chenauthor=R.+Choauthor=R.+V.+Connorsauthor=M.+DeGraffenreidauthor=J.+T.+Deignanauthor=J.+Duquetteauthor=P.+Fanauthor=B.+Fisherauthor=J.+Fuauthor=J.+N.+Huardauthor=J.+Kaizermanauthor=K.+S.+Keeganauthor=C.+Liauthor=K.+Liauthor=Y.+Liauthor=L.+Liangauthor=W.+Liuauthor=S.+E.+Livelyauthor=M.+C.+Loauthor=J.+Maauthor=D.+L.+McMinnauthor=J.+T.+Mihalicauthor=K.+Modiauthor=R.+Ngoauthor=K.+Pattabiramanauthor=D.+E.+Piperauthor=C.+Quevaauthor=M.+L.+Ragainsauthor=J.+Suchomelauthor=S.+Thibaultauthor=N.+Walkerauthor=X.+Wangauthor=Z.+Wangauthor=M.+Wanskaauthor=P.+M.+Wehnauthor=M.+F.+Weidnerauthor=A.+J.+Zhangauthor=X.+Zhaoauthor=A.+Kambauthor=D.+Wickramasingheauthor=K.+Daiauthor=L.+R.+McGeeauthor=J.+C.+Medina&title=Discovery+of+AMG+925%2C+a+FLT3+and+CDK4+dual+kinase+inhibitor+with+preferential+affinity+for+the+activated+state+of+FLT3&doi=10.1021%2Fjm500118j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3</span></div><div class="casAuthors">Li, Zhihong; Wang, Xianghong; Eksterowicz, John; Gribble, Michael W.; Alba, Grace Q.; Ayres, Merrill; Carlson, Timothy J.; Chen, Ada; Chen, Xiaoqi; Cho, Robert; Connors, Richard V.; DeGraffenreid, Michael; Deignan, Jeffrey T.; Duquette, Jason; Fan, Pingchen; Fisher, Benjamin; Fu, Jiasheng; Huard, Justin N.; Kaizerman, Jacob; Keegan, Kathleen S.; Li, Cong; Li, Kexue; Li, Yunxiao; Liang, Lingming; Liu, Wen; Lively, Sarah E.; Lo, Mei-Chu; Ma, Ji; McMinn, Dustin L.; Mihalic, Jeffrey T.; Modi, Kriti; Ngo, Rachel; Pattabiraman, Kanaka; Piper, Derek E.; Queva, Christophe; Ragains, Mark L.; Suchomel, Julia; Thibault, Steve; Walker, Nigel; Wang, Xiaodong; Wang, Zhulun; Wanska, Malgorzata; Wehn, Paul M.; Weidner, Margaret F.; Zhang, Alex J.; Zhao, Xiaoning; Kamb, Alexander; Wickramasinghe, Dineli; Dai, Kang; McGee, Lawrence R.; Medina, Julio C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3430-3449</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors describe the structural optimization of a lead compd. that exhibits dual inhibitory activities against FLT3 and CDK4.  A series of pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidine derivs. was synthesized, and SAR anal., using cell-based assays, led to the discovery of AMG 925 (I), a potent and orally bioavailable dual inhibitor of CDK4 and FLT3, including many FLT3 mutants reported to date.  Compd. I inhibits the proliferation of a panel of human tumor cell lines including Colo205 (Rb+) and U937 (FLT3WT) and induced cell death in MOLM13 (FLT3ITD) and even in MOLM13 (FLT3ITD, D835Y), which exhibits resistance to a no. of FLT3 inhibitors currently under clin. development.  At well-tolerated doses, compd. I leads to significant growth inhibition of MOLM13 xenografts in nude mice, and the activity correlates with inhibition of STAT5 and Rb phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcJdjH0aU8KrVg90H21EOLACvtfcHk0lgB2leY7WYTrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D&md5=4047a6ea068dbde57896da520fbdf0d3</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1021%2Fjm500118j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500118j%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DGribble%26aufirst%3DM.%2BW.%26aulast%3DAlba%26aufirst%3DG.%2BQ.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DCarlson%26aufirst%3DT.%2BJ.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCho%26aufirst%3DR.%26aulast%3DConnors%26aufirst%3DR.%2BV.%26aulast%3DDeGraffenreid%26aufirst%3DM.%26aulast%3DDeignan%26aufirst%3DJ.%2BT.%26aulast%3DDuquette%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DHuard%26aufirst%3DJ.%2BN.%26aulast%3DKaizerman%26aufirst%3DJ.%26aulast%3DKeegan%26aufirst%3DK.%2BS.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLively%26aufirst%3DS.%2BE.%26aulast%3DLo%26aufirst%3DM.%2BC.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DMcMinn%26aufirst%3DD.%2BL.%26aulast%3DMihalic%26aufirst%3DJ.%2BT.%26aulast%3DModi%26aufirst%3DK.%26aulast%3DNgo%26aufirst%3DR.%26aulast%3DPattabiraman%26aufirst%3DK.%26aulast%3DPiper%26aufirst%3DD.%2BE.%26aulast%3DQueva%26aufirst%3DC.%26aulast%3DRagains%26aufirst%3DM.%2BL.%26aulast%3DSuchomel%26aufirst%3DJ.%26aulast%3DThibault%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWanska%26aufirst%3DM.%26aulast%3DWehn%26aufirst%3DP.%2BM.%26aulast%3DWeidner%26aufirst%3DM.%2BF.%26aulast%3DZhang%26aufirst%3DA.%2BJ.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DKamb%26aufirst%3DA.%26aulast%3DWickramasinghe%26aufirst%3DD.%26aulast%3DDai%26aufirst%3DK.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520of%2520AMG%2520925%252C%2520a%2520FLT3%2520and%2520CDK4%2520dual%2520kinase%2520inhibitor%2520with%2520preferential%2520affinity%2520for%2520the%2520activated%2520state%2520of%2520FLT3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D8%26spage%3D3430%26epage%3D3449%26doi%3D10.1021%2Fjm500118j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaser, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchemin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusewitt, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligiuri, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briesewitz, R.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>110</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2075</span>– <span class="NLM_lpage">2083</span>, <span class="refDoi"> DOI: 10.1182/blood-2007-02-071266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2007-02-071266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=17537993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVGjtbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=2075-2083&issue=6&author=L.+Wangauthor=J.+Wangauthor=B.+W.+Blaserauthor=A.+M.+Ducheminauthor=D.+F.+Kusewittauthor=T.+Liuauthor=M.+A.+Caligiuriauthor=R.+Briesewitz&title=Pharmacologic+inhibition+of+CDK4%2F6%3A+mechanistic+evidence+for+selective+activity+or+acquired+resistance+in+acute+myeloid+leukemia&doi=10.1182%2Fblood-2007-02-071266"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia</span></div><div class="casAuthors">Wang, Lisheng; Wang, Jie; Blaser, Bradley W.; Duchemin, Anne-Marie; Kusewitt, Donna F.; Liu, Tom; Caligiuri, Michael A.; Briesewitz, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2075-2083</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Entry into the cell cycle is mediated by cyclin-dependent kinase 4/6 (CDK4/6) activation, followed by CDK2 activation.  We found that pharmacol. inhibition of the Flt3 internal tandem duplication (ITD), a mutated receptor tyrosine kinase commonly found in patients with acute myelogenous leukemia (AML), led to the down-regulation of cyclin D2 and D3 followed by retinoblastoma protein (pRb) dephosphorylation and G1 cell-cycle arrest.  This implicated the D-cyclin-CDK4/6 complex as a downstream effector of Flt3 ITD signaling.  Indeed, single-agent PD0332991, a selective CDK4/6 inhibitor, caused sustained cell-cycle arrest in Flt3 ITD AML cell lines and prolonged survival in an in vivo model of Flt3 ITD AML.  PD0332991 caused an initial cell-cycle arrest in well-established Flt3 wild-type (wt) AML cell lines, but this was overcome by down-regulation of p27Kip and reactivation of CDK2.  This acquired resistance was not obsd. in a Flt3 ITD and a Flt3 wt sample from a patient with primary AML.  In summary, the mechanism of cell-cycle arrest after treatment of Flt3 ITD AML with a Flt3 inhibitor involves down-regulation of cyclin D2 and D3.  As such, CDK4/6 can be a therapeutic target in Flt3 ITD AML but also in primary Flt3 wt AML.  Finally, acquired resistance to CDK4/6 inhibition can arise through activation CDK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiH_wOIP8jJLVg90H21EOLACvtfcHk0lgB2leY7WYTrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVGjtbbK&md5=5f68ef6deacf3789e428731722f8c5ff</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-02-071266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-02-071266%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBlaser%26aufirst%3DB.%2BW.%26aulast%3DDuchemin%26aufirst%3DA.%2BM.%26aulast%3DKusewitt%26aufirst%3DD.%2BF.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26aulast%3DBriesewitz%26aufirst%3DR.%26atitle%3DPharmacologic%2520inhibition%2520of%2520CDK4%252F6%253A%2520mechanistic%2520evidence%2520for%2520selective%2520activity%2520or%2520acquired%2520resistance%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26issue%3D6%26spage%3D2075%26epage%3D2083%26doi%3D10.1182%2Fblood-2007-02-071266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newhall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinclair, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickramasinghe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, K.</span></span> <span> </span><span class="NLM_article-title">AMG 925 is a dual FLT3/CDK4 inhibitor with the potential to overcome FLT3 inhibitor resistance in acute myeloid leukemia</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">375</span>– <span class="NLM_lpage">383</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0388</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F1535-7163.MCT-14-0388" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=25487917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitlOjsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=375-383&issue=2&author=C.+Liauthor=L.+Liuauthor=L.+Liangauthor=Z.+Xiaauthor=Z.+Liauthor=X.+Wangauthor=L.+R.+McGeeauthor=K.+Newhallauthor=A.+Sinclairauthor=A.+Kambauthor=D.+Wickramasingheauthor=K.+Dai&title=AMG+925+is+a+dual+FLT3%2FCDK4+inhibitor+with+the+potential+to+overcome+FLT3+inhibitor+resistance+in+acute+myeloid+leukemia&doi=10.1158%2F1535-7163.MCT-14-0388"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">AMG 925 Is a Dual FLT3/CDK4 Inhibitor with the Potential to Overcome FLT3 Inhibitor Resistance in Acute Myeloid Leukemia</span></div><div class="casAuthors">Li, Cong; Liu, Liqin; Liang, Lingming; Xia, Zhen; Li, Zhihong; Wang, Xianghong; McGee, Lawrence R.; Newhall, Katie; Sinclair, Angus; Kamb, Alexander; Wickramasinghe, Dineli; Dai, Kang</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">375-383</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Resistance to FLT3 inhibitors is a serious clin. issue in treating acute myelogenous leukemia (AML).  AMG 925, a dual FLT3/CDK4 inhibitor, has been developed to overcome this resistance.  It is hypothesized that the combined inhibition of FLT3 and CDK4 may reduce occurrence of the FLT3 resistance mutations, and thereby prolong clin. responses.  To test this hypothesis, we attempted to isolate AML cell clones resistant to AMG 925 or to FLT3 inhibitors.  After a selection of over 8 mo with AMG 925, we could only isolate partially resistant clones.  No new mutations in FLT3 were found, but a 2- to 3-fold increase in total FLT3 protein was detected and believed to contribute to the partial resistance.  In contrast, selection with the FLT3 inhibitors sorafenib or AC220 (Quizartinib), led to a resistance and the appearance of a no. of mutations in FLT3 kinase domains, including the known hot spot sites D835 and F691.  However, when AC220 was combined with the CDK4 inhibitor PD0332991 (palbociclib) at 0.1 μmol/L or higher, no resistance mutations were obtained, indicating that the CDK4-inhibiting activity of AMG 925 contributed to the failure to develop drug resistance.  AMG 925 was shown to potently inhibit the FLT3 inhibitor-resistant mutation D835Y/V.  This feature of AMG 925 was also considered to contribute to the lack of resistance mutations to the compd.  Together, our data suggest that AMG 925 has the potential to reduce resistance mutations in FLT3 and may prolong clin. responses.  Mol Cancer Ther; 14(2); 375-83. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6REHZXaV0kbVg90H21EOLACvtfcHk0lgfgm3kSne5Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitlOjsbw%253D&md5=a275188c7ace129474044779a8e91702</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0388%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DXia%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DNewhall%26aufirst%3DK.%26aulast%3DSinclair%26aufirst%3DA.%26aulast%3DKamb%26aufirst%3DA.%26aulast%3DWickramasinghe%26aufirst%3DD.%26aulast%3DDai%26aufirst%3DK.%26atitle%3DAMG%2520925%2520is%2520a%2520dual%2520FLT3%252FCDK4%2520inhibitor%2520with%2520the%2520potential%2520to%2520overcome%2520FLT3%2520inhibitor%2520resistance%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26issue%3D2%26spage%3D375%26epage%3D383%26doi%3D10.1158%2F1535-7163.MCT-14-0388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragains, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coberly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenback, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksterowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alba, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Queva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickramasinghe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, K.</span></span> <span> </span><span class="NLM_article-title">Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">880</span>– <span class="NLM_lpage">889</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0858</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F1535-7163.MCT-13-0858" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=24526162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=880-889&issue=4&author=K.+Keeganauthor=C.+Liauthor=Z.+Liauthor=J.+Maauthor=M.+Ragainsauthor=S.+Coberlyauthor=D.+Hollenbackauthor=J.+Eksterowiczauthor=L.+Liangauthor=M.+Weidnerauthor=J.+Huardauthor=X.+Wangauthor=G.+Albaauthor=J.+Orfauthor=M.+C.+Loauthor=S.+Zhaoauthor=R.+Ngoauthor=A.+Chenauthor=L.+Liuauthor=T.+Carlsonauthor=C.+Quevaauthor=L.+R.+McGeeauthor=J.+Medinaauthor=A.+Kambauthor=D.+Wickramasingheauthor=K.+Dai&title=Preclinical+evaluation+of+AMG+925%2C+a+FLT3%2FCDK4+dual+kinase+inhibitor+for+treating+acute+myeloid+leukemia&doi=10.1158%2F1535-7163.MCT-13-0858"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia</span></div><div class="casAuthors">Keegan, Kathleen; Li, Cong; Li, Zhihong; Ma, Ji; Ragains, Mark; Coberly, Suzanne; Hollenback, David; Eksterowicz, John; Liang, Lingming; Weidner, Margaret; Huard, Justin; Wang, Xianghong; Alba, Grace; Orf, Jessica; Lo, Mei-Chu; Zhao, Sharon; Ngo, Rachel; Chen, Ada; Liu, Lily; Carlson, Timothy; Queva, Christophe; McGee, Lawrence R.; Medina, Julio; Kamb, Alexander; Wickramasinghe, Dineli; Dai, Kang</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">880-889</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) remains a serious unmet medical need.  Despite high remission rates with chemotherapy std.-of-care treatment, the disease eventually relapses in a major proportion of patients.  Activating Fms-like tyrosine kinase 3 (FLT3) mutations are found in approx. 30% of patients with AML.  Targeting FLT3 receptor tyrosine kinase has shown encouraging results in treating FLT3-mutated AML.  Responses, however, are not sustained and acquired resistance has been a clin. challenge.  Treatment options to overcome resistance are currently the focus of research.  We report here the preclin. evaluation of AMG 925, a potent, selective, and bioavailable FLT3/cyclin-dependent kinase 4 (CDK4) dual kinase inhibitor.  AMG 925 inhibited AML xenograft tumor growth by 96% to 99% without significant body wt. loss.  The antitumor activity of AMG 925 correlated with the inhibition of STAT5 and RB phosphorylation, the pharmacodynamic markers for inhibition of FLT3 and CDK4, resp.  In addn., AMG 925 was also found to inhibit FLT3 mutants (e.g., D835Y) that are resistant to the current FLT3 inhibitors (e.g., AC220 and sorafenib).  CDK4 is a cyclin D-dependent kinase that plays an essential central role in regulating cell proliferation in response to external growth signals.  A crit. role of the CDK4-RB pathway in cancer development has been well established.  CDK4-specific inhibitors are being developed for treating RB-pos. cancer.  AMG 925, which combines inhibition of two kinases essential for proliferation and survival of FLT3-mutated AML cells, may improve and prolong clin. responses.  Mol Cancer Ther; 13(4); 880-9. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI4p2uOyF0ObVg90H21EOLACvtfcHk0lgfgm3kSne5Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurs%253D&md5=7343fdb82e66c9115c8b018a260aadde</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0858%26sid%3Dliteratum%253Aachs%26aulast%3DKeegan%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DRagains%26aufirst%3DM.%26aulast%3DCoberly%26aufirst%3DS.%26aulast%3DHollenback%26aufirst%3DD.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DWeidner%26aufirst%3DM.%26aulast%3DHuard%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DAlba%26aufirst%3DG.%26aulast%3DOrf%26aufirst%3DJ.%26aulast%3DLo%26aufirst%3DM.%2BC.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DNgo%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DCarlson%26aufirst%3DT.%26aulast%3DQueva%26aufirst%3DC.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%26aulast%3DKamb%26aufirst%3DA.%26aulast%3DWickramasinghe%26aufirst%3DD.%26aulast%3DDai%26aufirst%3DK.%26atitle%3DPreclinical%2520evaluation%2520of%2520AMG%2520925%252C%2520a%2520FLT3%252FCDK4%2520dual%2520kinase%2520inhibitor%2520for%2520treating%2520acute%2520myeloid%2520leukemia%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26issue%3D4%26spage%3D880%26epage%3D889%26doi%3D10.1158%2F1535-7163.MCT-13-0858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikezoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furihata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishioka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeffler, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, A.</span></span> <span> </span><span class="NLM_article-title">Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>129</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2512</span>– <span class="NLM_lpage">2521</span>, <span class="refDoi"> DOI: 10.1002/ijc.25910</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1002%2Fijc.25910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=21207414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2jt77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2011&pages=2512-2521&issue=10&author=T.+Ikezoeauthor=S.+Kojimaauthor=M.+Furihataauthor=J.+Yangauthor=C.+Nishiokaauthor=A.+Takeuchiauthor=M.+Isakaauthor=H.+P.+Koefflerauthor=A.+Yokoyama&title=Expression+of+p-JAK2+predicts+clinical+outcome+and+is+a+potential+molecular+target+of+acute+myelogenous+leukemia&doi=10.1002%2Fijc.25910"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia</span></div><div class="casAuthors">Ikezoe, Takayuki; Kojima, Shinsuke; Furihata, Mutsuo; Yang, Jing; Nishioka, Chie; Takeuchi, Asako; Isaka, Mayuka; Koeffler, H. Phillip; Yokoyama, Akihito</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2512-2521</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Our study detd. if Janus kinase 2 (JAK2) was activated in acute myelogenous leukemia (AML; n = 77, excluding acute promyelocytic leukemia) by immunohistochem. (IHC) using a phosphor-specific antibody against JAK2. p-JAK2 was detectable in all cases, although its levels varied between patient samples (high levels, n = 31; low levels, n = 46).  The quantification of levels of p-JAK2 by IHC was well correlated with that assessed by Western blot analyses and fluorescence-activated cell sorting (FACS).  Levels of p-JAK2 were directly correlated with high white blood cell count (52.3 × 103/L in patients with high p-JAK2 vs. 28.3 × 103/L in patients with low p-JAK2, p < 0.01) and were inversely correlated with complete remission rates (45% in patients with high p-JAK2 vs. 78% in patients with low p-JAK2, p < 0.003).  In addn., multivariate anal. confirmed that high levels of p-JAK2 remained a significant factor for overall survival (hazard ratio = 2.213; 95% confidence interval, 1.212-4.041, p = 0.023).  Moreover, we found that AZ960, a novel and specific inhibitor of the JAK2 kinase, potently inhibited the clonogenic growth and induced apoptosis of freshly isolated AML cells from patients in assocn. with cleavage of caspase 3 and downregulation of anti-apoptotic Bcl-xL proteins.  Taken together, JAK2 may be a promising mol. target for treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9L8HwJhfH-rVg90H21EOLACvtfcHk0lg9R_qMQjhVOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2jt77N&md5=5821c50baeb0d36708c1c30ee8a38e15</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1002%2Fijc.25910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25910%26sid%3Dliteratum%253Aachs%26aulast%3DIkezoe%26aufirst%3DT.%26aulast%3DKojima%26aufirst%3DS.%26aulast%3DFurihata%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DNishioka%26aufirst%3DC.%26aulast%3DTakeuchi%26aufirst%3DA.%26aulast%3DIsaka%26aufirst%3DM.%26aulast%3DKoeffler%26aufirst%3DH.%2BP.%26aulast%3DYokoyama%26aufirst%3DA.%26atitle%3DExpression%2520of%2520p-JAK2%2520predicts%2520clinical%2520outcome%2520and%2520is%2520a%2520potential%2520molecular%2520target%2520of%2520acute%2520myelogenous%2520leukemia%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2011%26volume%3D129%26issue%3D10%26spage%3D2512%26epage%3D2521%26doi%3D10.1002%2Fijc.25910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidel, F. H.</span></span> <span> </span><span class="NLM_article-title">Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">854</span>, <span class="refDoi"> DOI: 10.3390/cells8080854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.3390%2Fcells8080854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslWntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=854&issue=8&author=F.+Pernerauthor=C.+Pernerauthor=T.+Ernstauthor=F.+H.+Heidel&title=Roles+of+JAK2+in+aging%2C+inflammation%2C+hematopoiesis+and+malignant+transformation&doi=10.3390%2Fcells8080854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation</span></div><div class="casAuthors">Perner, Florian; Perner, Caroline; Ernst, Thomas; Heidel, Florian H.</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">854</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Clonal alterations in hematopoietic cells occur during aging and are often assocd. with the establishment of a subclin. inflammatory environment.  Several age-related conditions and diseases may be initiated or promoted by these alterations.  JAK2 mutations are among the most frequently mutated genes in blood cells during aging.  The most common mutation within the JAK2 gene is JAK2-V617F that leads to constitutive activation of the kinase and thereby aberrant engagement of downstream signaling pathways.  JAK2 mutations can act as central drivers of myeloproliferative neoplasia, a pre-leukemic and age-related malignancy.  Likewise, hyperactive JAK-signaling is a hallmark of immune diseases and critically influences inflammation, coagulation and thrombosis.  In this review we aim to summarize the current knowledge on JAK2 in clonal hematopoiesis during aging, the role of JAK-signaling in inflammation and lymphocyte biol. and JAK2 function in age-related diseases and malignant transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfbCzDy7BOo7Vg90H21EOLACvtfcHk0lg9R_qMQjhVOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslWntbw%253D&md5=8433e74cbd00a65cd218101e5ca62d79</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.3390%2Fcells8080854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells8080854%26sid%3Dliteratum%253Aachs%26aulast%3DPerner%26aufirst%3DF.%26aulast%3DPerner%26aufirst%3DC.%26aulast%3DErnst%26aufirst%3DT.%26aulast%3DHeidel%26aufirst%3DF.%2BH.%26atitle%3DRoles%2520of%2520JAK2%2520in%2520aging%252C%2520inflammation%252C%2520hematopoiesis%2520and%2520malignant%2520transformation%26jtitle%3DCells%26date%3D2019%26volume%3D8%26issue%3D8%26spage%3D854%26doi%3D10.3390%2Fcells8080854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldenson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crispino, J. D.</span></span> <span> </span><span class="NLM_article-title">The Aurora kinases in cell cycle and leukemia</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1038/onc.2014.14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fonc.2014.14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=24632603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktlGmtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=537-545&issue=5&author=B.+Goldensonauthor=J.+D.+Crispino&title=The+Aurora+kinases+in+cell+cycle+and+leukemia&doi=10.1038%2Fonc.2014.14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">The aurora kinases in cell cycle and leukemia</span></div><div class="casAuthors">Goldenson, B.; Crispino, J. D.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">537-545</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The Aurora kinases, which include Aurora A (AURKA), Aurora B (AURKB) and Aurora C (AURKC), are serine/threonine kinases required for the control of mitosis (AURKA and AURKB) and meiosis (AURKC).  Since their discovery nearly 20 years ago, Aurora kinases have been studied extensively in cell and cancer biol.  Several early studies found that Aurora kinases are amplified and overexpressed at the transcript and protein level in various malignancies, including several types of leukemia.  These discoveries and others provided a rationale for the development of small-mol. inhibitors of Aurora kinases as leukemia therapies.  The first generation of Aurora kinase inhibitors did not fare well in clin. trials, owing to poor efficacy and high toxicity.  However, the creation of second-generation, highly selective Aurora kinase inhibitors has increased the enthusiasm for targeting these proteins in leukemia.  This review will describe the functions of each Aurora kinase, summarize their involvement in leukemia and discuss inhibitor development and efficacy in leukemia clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ7zN9HIe8mbVg90H21EOLACvtfcHk0lg9R_qMQjhVOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktlGmtrg%253D&md5=376deb50059c7b67d6a86c530f772649</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1038%2Fonc.2014.14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2014.14%26sid%3Dliteratum%253Aachs%26aulast%3DGoldenson%26aufirst%3DB.%26aulast%3DCrispino%26aufirst%3DJ.%2BD.%26atitle%3DThe%2520Aurora%2520kinases%2520in%2520cell%2520cycle%2520and%2520leukemia%26jtitle%3DOncogene%26date%3D2015%26volume%3D34%26issue%3D5%26spage%3D537%26epage%3D545%26doi%3D10.1038%2Fonc.2014.14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, H.</span></span> <span> </span><span class="NLM_article-title">Clinical development of CDK4/6 inhibitor for breast cancer</span>. <i>Breast Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">406</span>, <span class="refDoi"> DOI: 10.1007/s12282-017-0827-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1007%2Fs12282-017-0827-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=29392622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BC1MvmsFGqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=402-406&issue=4&author=H.+Iwata&title=Clinical+development+of+CDK4%2F6+inhibitor+for+breast+cancer&doi=10.1007%2Fs12282-017-0827-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical development of CDK4/6 inhibitor for breast cancer</span></div><div class="casAuthors">Iwata Hiroji</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">402-406</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Endocrine therapy is the mainstay of treatment for patients with estrogen receptor positive (ER+)/HER2-negative (HER2-) metastatic breast cancer (MBC).  Many clinicians consider the sequential endocrine therapy is gold standard strategy because of better outcome and the maintenance of a better quality of life (QOL) for MBC patients.  However, clinical practice shall be changed according to development of CDK4/6 inhibitor in current.  CDK4/6 is key kinase which promote the cell cycle, and especially the expression of cyclin D1 and the activation of CDK4/6 to drive breast cancer proliferation.  Currently positive data of several clinical trials using three CDK4/6 inhibitors (palbocilcib, ribociclib, abemaciclib) were published and primary endpoint were met in all phase III studies.  Therefore, practice change of endocrine therapy has been achieved in ER positive MBC.  This review will present clinical trial data, including both the efficacy and safety of CDK4/6 inhibitors for MBC, and describe the designs of the mainly ongoing clinical trials examining CDK4/6 inhibitors for the treatment of MBC and EBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRenMI_Igvwj8RAV4D_Ins_fW6udTcc2earYcNPfIuQsbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvmsFGqtA%253D%253D&md5=d74b22349f1962078da12d1768ed48a3</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1007%2Fs12282-017-0827-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12282-017-0827-3%26sid%3Dliteratum%253Aachs%26aulast%3DIwata%26aufirst%3DH.%26atitle%3DClinical%2520development%2520of%2520CDK4%252F6%2520inhibitor%2520for%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%26date%3D2018%26volume%3D25%26issue%3D4%26spage%3D402%26epage%3D406%26doi%3D10.1007%2Fs12282-017-0827-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salerno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damon, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perl, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travers, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadt, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasarskis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. P.</span></span> <span> </span><span class="NLM_article-title">Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>485</i></span> (<span class="NLM_issue">7397</span>),  <span class="NLM_fpage">260</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1038/nature11016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fnature11016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=22504184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtVeqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=485&publication_year=2012&pages=260-263&issue=7397&author=C.+C.+Smithauthor=Q.+Wangauthor=C.+S.+Chinauthor=S.+Salernoauthor=L.+E.+Damonauthor=M.+J.+Levisauthor=A.+E.+Perlauthor=K.+J.+Traversauthor=S.+Wangauthor=J.+P.+Huntauthor=P.+P.+Zarrinkarauthor=E.+E.+Schadtauthor=A.+Kasarskisauthor=J.+Kuriyanauthor=N.+P.+Shah&title=Validation+of+ITD+mutations+in+FLT3+as+a+therapeutic+target+in+human+acute+myeloid+leukaemia&doi=10.1038%2Fnature11016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukemia</span></div><div class="casAuthors">Smith, Catherine C.; Wang, Qi; Chin, Chen-Shan; Salerno, Sara; Damon, Lauren E.; Levis, Mark J.; Perl, Alexander E.; Travers, Kevin J.; Wang, Susana; Hunt, Jeremy P.; Zarrinkar, Patrick P.; Schadt, Eric E.; Kasarskis, Andrew; Kuriyan, John; Shah, Neil P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">485</span>
        (<span class="NLM_cas:issue">7397</span>),
    <span class="NLM_cas:pages">260-263</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Effective targeted cancer therapeutic development depends upon distinguishing disease-assocd. driver' mutations, which have causative roles in malignancy pathogenesis, from passenger' mutations, which are dispensable for cancer initiation and maintenance.  Translational studies of clin. active targeted therapeutics can definitively discriminate driver from passenger lesions and provide valuable insights into human cancer biol.  Activating internal tandem duplication (ITD) mutations in FLT3 (FLT3-ITD) are detected in approx. 20% of acute myeloid leukemia (AML) patients and are assocd. with a poor prognosis.  Abundant scientific and clin. evidence, including the lack of convincing clin. activity of early FLT3 inhibitors, suggests that FLT3-ITD probably represents a passenger lesion.  Here we report point mutations at three residues within the kinase domain of FLT3-ITD that confer substantial in vitro resistance to AC220 (quizartinib), an active investigational inhibitor of FLT3, KIT, PDGFRA, PDGFRB and RET; evolution of AC220-resistant substitutions at two of these amino acid positions was obsd. in eight of eight FLT3-ITD-pos. AML patients with acquired resistance to AC220.  Our findings demonstrate that FLT3-ITD can represent a driver lesion and valid therapeutic target in human AML.  AC220-resistant FLT3 kinase domain mutants represent high-value targets for future FLT3 inhibitor development efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq0PeqhlWLObVg90H21EOLACvtfcHk0lh6JT_v0A1OYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtVeqtr8%253D&md5=228dae85b08e65918f74ee8c5d20ddb0</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1038%2Fnature11016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11016%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DChin%26aufirst%3DC.%2BS.%26aulast%3DSalerno%26aufirst%3DS.%26aulast%3DDamon%26aufirst%3DL.%2BE.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26aulast%3DTravers%26aufirst%3DK.%2BJ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DSchadt%26aufirst%3DE.%2BE.%26aulast%3DKasarskis%26aufirst%3DA.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DN.%2BP.%26atitle%3DValidation%2520of%2520ITD%2520mutations%2520in%2520FLT3%2520as%2520a%2520therapeutic%2520target%2520in%2520human%2520acute%2520myeloid%2520leukaemia%26jtitle%3DNature%26date%3D2012%26volume%3D485%26issue%3D7397%26spage%3D260%26epage%3D263%26doi%3D10.1038%2Fnature11016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dumas, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naudin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Lanneree, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izac, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casetti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansier, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousseau, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufossee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pigneux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Praloran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bidet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villacreces, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guitart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milpied, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosmider, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigon, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desplat, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dusanter-Fourt, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquet, J. M.</span></span> <span> </span><span class="NLM_article-title">Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>104</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2017</span>– <span class="NLM_lpage">2027</span>, <span class="refDoi"> DOI: 10.3324/haematol.2018.205385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.3324%2Fhaematol.2018.205385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=30923103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFChtLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2019&pages=2017-2027&issue=10&author=P.+Y.+Dumasauthor=C.+Naudinauthor=S.+Martin-Lannereeauthor=B.+Izacauthor=L.+Casettiauthor=O.+Mansierauthor=B.+Rousseauauthor=A.+Artusauthor=M.+Dufosseeauthor=A.+Gieseauthor=P.+Dubusauthor=A.+Pigneuxauthor=V.+Praloranauthor=A.+Bidetauthor=A.+Villacrecesauthor=A.+Guitartauthor=N.+Milpiedauthor=O.+Kosmiderauthor=I.+Vigonauthor=V.+Desplatauthor=I.+Dusanter-Fourtauthor=J.+M.+Pasquet&title=Hematopoietic+niche+drives+FLT3-ITD+acute+myeloid+leukemia+resistance+to+quizartinib+via+STAT5-and+hypoxia-dependent+upregulation+of+AXL&doi=10.3324%2Fhaematol.2018.205385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5- and hypoxia-dependent upregulation of AXL</span></div><div class="casAuthors">Dumas, Pierre-Yves; Naudin, Cecile; Martin-Lanneree, Severine; Izac, Brigitte; Casetti, Luana; Mansier, Olivier; Rousseau, Benoit; Artus, Alexandre; Dufossee, Melody; Giese, Alban; Dubus, Pierre; Pigneux, Arnaud; Praloran, Vincent; Bidet, Audrey; Villacreces, Arnaud; Guitart, Amelie; Milpied, Noeel; Kosmider, Olivier; Vigon, Isabelle; Desplat, Vanessa; Dusanter-Fourt, Isabelle; Pasquet, Jean-Max</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2017-2027</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">1592-8721</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">Internal tandem duplication in Fms-like tyrosine kinase 3 (FLT3-ITD) is the most frequent mutation obsd. in acute myeloid leukemia (AML) and correlates with poor prognosis.  FLT3 tyrosine kinase inhibitors are promising for targeted therapy.  Here, we investigated mechanisms dampening the response to the FLT3 inhibitor quizartinib, which is specific to the hematopoietic niche.  Using AML primary samples and cell lines, we demonstrate that convergent signals from the hematopoietic microenvironment drive FLT3-ITD cell resistance to quizartinib through the expression and activation of the tyrosine kinase receptor AXL.  Indeed, cytokines sustained phosphorylation of the transcription factor STAT5 in quizartinibtreated cells, which enhanced AXL expression by direct binding of a conserved motif in its genomic sequence.  Likewise, hypoxia, another wellknown hematopoietic niche hallmark, also enhanced AXL expression.  Finally, in a xenograft mouse model, inhibition of AXL significantly increased the response of FLT3-ITD cells to quizartinib exclusively within a bone marrow environment.  These data highlight a new bypass mechanism specific to the hematopoietic niche that hampers the response to quizartinib through combined upregulation of AXL activity.  Targeting this signaling offers the prospect of a new therapy to eradicate resistant FLT3-ITD leukemic cells hidden within their specific microenvironment, thereby preventing relapses from FLT3-ITD clones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPXvYzzeCN8LVg90H21EOLACvtfcHk0lh6JT_v0A1OYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFChtLnI&md5=a25cc5bbd8707b648e34705d99f8b247</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2018.205385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2018.205385%26sid%3Dliteratum%253Aachs%26aulast%3DDumas%26aufirst%3DP.%2BY.%26aulast%3DNaudin%26aufirst%3DC.%26aulast%3DMartin-Lanneree%26aufirst%3DS.%26aulast%3DIzac%26aufirst%3DB.%26aulast%3DCasetti%26aufirst%3DL.%26aulast%3DMansier%26aufirst%3DO.%26aulast%3DRousseau%26aufirst%3DB.%26aulast%3DArtus%26aufirst%3DA.%26aulast%3DDufossee%26aufirst%3DM.%26aulast%3DGiese%26aufirst%3DA.%26aulast%3DDubus%26aufirst%3DP.%26aulast%3DPigneux%26aufirst%3DA.%26aulast%3DPraloran%26aufirst%3DV.%26aulast%3DBidet%26aufirst%3DA.%26aulast%3DVillacreces%26aufirst%3DA.%26aulast%3DGuitart%26aufirst%3DA.%26aulast%3DMilpied%26aufirst%3DN.%26aulast%3DKosmider%26aufirst%3DO.%26aulast%3DVigon%26aufirst%3DI.%26aulast%3DDesplat%26aufirst%3DV.%26aulast%3DDusanter-Fourt%26aufirst%3DI.%26aulast%3DPasquet%26aufirst%3DJ.%2BM.%26atitle%3DHematopoietic%2520niche%2520drives%2520FLT3-ITD%2520acute%2520myeloid%2520leukemia%2520resistance%2520to%2520quizartinib%2520via%2520STAT5-and%2520hypoxia-dependent%2520upregulation%2520of%2520AXL%26jtitle%3DHaematologica%26date%3D2019%26volume%3D104%26issue%3D10%26spage%3D2017%26epage%3D2027%26doi%3D10.3324%2Fhaematol.2018.205385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burslem, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Enhancing antiproliferative activity and selectivity of a FLT-3 inhibitor by proteolysis targeting chimera conversion</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>140</i></span> (<span class="NLM_issue">48</span>),  <span class="NLM_fpage">16428</span>– <span class="NLM_lpage">16432</span>, <span class="refDoi"> DOI: 10.1021/jacs.8b10320</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.8b10320" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitF2qtr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2018&pages=16428-16432&issue=48&author=G.+M.+Burslemauthor=J.+Songauthor=X.+Chenauthor=J.+Hinesauthor=C.+M.+Crews&title=Enhancing+antiproliferative+activity+and+selectivity+of+a+FLT-3+inhibitor+by+proteolysis+targeting+chimera+conversion&doi=10.1021%2Fjacs.8b10320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion</span></div><div class="casAuthors">Burslem, George M.; Song, Jayoung; Chen, Xin; Hines, John; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">16428-16432</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase FLT-3 is frequently mutated in acute myeloid leukemia; however, current small mol. inhibitors suffer from limited efficacy in the clinic.  Conversion of a FLT-3 inhibitor (quizartinib) into a proteolysis targeting chimera (PROTAC) results in a compd. that induces degrdn. of FLT-3 ITD mutant at low nanomolar concns.  Furthermore, the PROTAC is capable of inhibiting cell growth more potently than the warhead alone while inhibiting fewer off-target kinases.  This enhanced antiproliferative activity occurs, despite a slight redn. in the PROTAC's kinase inhibitory activity, via an increased level of apoptosis induction suggesting nonkinase roles for the FLT-3 ITD protein.  Addnl., the PROTAC is capable of inducing FLT-3 ITD degrdn. in vivo.  These results suggest that degrdn. of FLT-3 ITD may provide a useful method for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBxw_nAEQydLVg90H21EOLACvtfcHk0liQ63HwGLYI3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitF2qtr7P&md5=52529d0c3f49052bd2a66c893e98e694</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Fjacs.8b10320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.8b10320%26sid%3Dliteratum%253Aachs%26aulast%3DBurslem%26aufirst%3DG.%2BM.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DEnhancing%2520antiproliferative%2520activity%2520and%2520selectivity%2520of%2520a%2520FLT-3%2520inhibitor%2520by%2520proteolysis%2520targeting%2520chimera%2520conversion%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2018%26volume%3D140%26issue%3D48%26spage%3D16428%26epage%3D16432%26doi%3D10.1021%2Fjacs.8b10320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eide, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabriskie, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage Stevens, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antelope, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellore, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Than, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clair, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowler, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomicter, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senina, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szankasi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cayuela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tognon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Hare, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W.</span></span> <span> </span><span class="NLM_article-title">Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">443</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2019.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.ccell.2019.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=31543464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVSru77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2019&pages=431-443&issue=4&author=C.+A.+Eideauthor=M.+S.+Zabriskieauthor=S.+L.+Savage+Stevensauthor=O.+Antelopeauthor=N.+A.+Velloreauthor=H.+Thanauthor=A.+R.+Schultzauthor=P.+Clairauthor=A.+D.+Bowlerauthor=A.+D.+Pomicterauthor=D.+Yanauthor=A.+V.+Seninaauthor=W.+Qiangauthor=T.+W.+Kelleyauthor=P.+Szankasiauthor=M.+C.+Heinrichauthor=J.+W.+Tynerauthor=D.+Reaauthor=J.+M.+Cayuelaauthor=D.+W.+Kimauthor=C.+E.+Tognonauthor=T.+O%E2%80%99Hareauthor=B.+J.+Drukerauthor=M.+W.+Deininger&title=Combining+the+allosteric+inhibitor+asciminib+with+ponatinib+suppresses+emergence+of+and+restores+efficacy+against+highly+resistant+BCR-ABL1+mutants&doi=10.1016%2Fj.ccell.2019.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants</span></div><div class="casAuthors">Eide, Christopher A.; Zabriskie, Matthew S.; Savage Stevens, Samantha L.; Antelope, Orlando; Vellore, Nadeem A.; Than, Hein; Schultz, Anna Reister; Clair, Phillip; Bowler, Amber D.; Pomicter, Anthony D.; Yan, Dongqing; Senina, Anna V.; Qiang, Wang; Kelley, Todd W.; Szankasi, Philippe; Heinrich, Michael C.; Tyner, Jeffrey W.; Rea, Delphine; Cayuela, Jean-Michel; Kim, Dong-Wook; Tognon, Cristina E.; O'Hare, Thomas; Druker, Brian J.; Deininger, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">431-443.e5</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">BCR-ABL1 point mutation-mediated resistance to tyrosine kinase inhibitor (TKI) therapy in Philadelphia chromosome-pos. (Ph+) leukemia is effectively managed with several approved drugs, including ponatinib for BCR-ABL1T315I-mutant disease.  However, therapy options are limited for patients with leukemic clones bearing multiple BCR-ABL1 mutations.  Asciminib, an allosteric inhibitor targeting the myristoyl-binding pocket of BCR-ABL1, is active against most single mutants but ineffective against all tested compd. mutants.  We demonstrate that combining asciminib with ATP site TKIs enhances target inhibition and suppression of resistant outgrowth in Ph+ clin. isolates and cell lines.  Inclusion of asciminib restores ponatinib's effectiveness against currently untreatable compd. mutants at clin. achievable concns.  Our findings support combining asciminib with ponatinib as a treatment strategy for this molecularly defined group of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYwcxeCHYx87Vg90H21EOLACvtfcHk0liQ63HwGLYI3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVSru77M&md5=77fb1a5430c13932b2af244e8749e7ee</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2019.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2019.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DZabriskie%26aufirst%3DM.%2BS.%26aulast%3DSavage%2BStevens%26aufirst%3DS.%2BL.%26aulast%3DAntelope%26aufirst%3DO.%26aulast%3DVellore%26aufirst%3DN.%2BA.%26aulast%3DThan%26aufirst%3DH.%26aulast%3DSchultz%26aufirst%3DA.%2BR.%26aulast%3DClair%26aufirst%3DP.%26aulast%3DBowler%26aufirst%3DA.%2BD.%26aulast%3DPomicter%26aufirst%3DA.%2BD.%26aulast%3DYan%26aufirst%3DD.%26aulast%3DSenina%26aufirst%3DA.%2BV.%26aulast%3DQiang%26aufirst%3DW.%26aulast%3DKelley%26aufirst%3DT.%2BW.%26aulast%3DSzankasi%26aufirst%3DP.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DRea%26aufirst%3DD.%26aulast%3DCayuela%26aufirst%3DJ.%2BM.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DTognon%26aufirst%3DC.%2BE.%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DCombining%2520the%2520allosteric%2520inhibitor%2520asciminib%2520with%2520ponatinib%2520suppresses%2520emergence%2520of%2520and%2520restores%2520efficacy%2520against%2520highly%2520resistant%2520BCR-ABL1%2520mutants%26jtitle%3DCancer%2520Cell%26date%3D2019%26volume%3D36%26issue%3D4%26spage%3D431%26epage%3D443%26doi%3D10.1016%2Fj.ccell.2019.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teicher, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, R.</span></span> <span> </span><span class="NLM_article-title">Antibody–drug conjugates for cancer therapy</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">e254</span>– <span class="NLM_lpage">e262</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(16)30030-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2FS1470-2045%2816%2930030-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=27299281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC28XptFCnsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=e254-e262&issue=6&author=A.+Thomasauthor=B.+A.+Teicherauthor=R.+Hassan&title=Antibody%E2%80%93drug+conjugates+for+cancer+therapy&doi=10.1016%2FS1470-2045%2816%2930030-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates for cancer therapy</span></div><div class="casAuthors">Thomas, Anish; Teicher, Beverly A.; Hassan, Raffit</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e254-e262</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Antibody-drug conjugates are monoclonal antibodies conjugated to cytotoxic agents.  They use antibodies that are specific to tumor cell-surface proteins and, thus, have tumor specificity and potency not achievable with traditional drugs.  Design of effective antibody-drug conjugates for cancer therapy requires selection of an appropriate target, a monoclonal antibody against the target, potent cytotoxic effector mols., and conjugation of the monoclonal antibody to cytotoxic agents.  Substantial advances in all these aspects in the past decade have resulted in regulatory approval of ado-trastuzumab emtansine and brentuximab vedotin for clin. use.  Several promising antibody-drug conjugates are now in late-phase clin. testing.  Ongoing efforts are focused on identifying better targets, more effective cytotoxic payloads, and further improvements in antibody-drug linker technol.  Improved understanding of the mechanistic basis of antibody-drug conjugate activity will enable design of rational combination therapies with other agents, including immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5Z8wfiqGgZ7Vg90H21EOLACvtfcHk0liQ63HwGLYI3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptFCnsbc%253D&md5=375b381d7f5b23f36453aaa50d46f4b7</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2816%2930030-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252816%252930030-4%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DTeicher%26aufirst%3DB.%2BA.%26aulast%3DHassan%26aufirst%3DR.%26atitle%3DAntibody%25E2%2580%2593drug%2520conjugates%2520for%2520cancer%2520therapy%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26issue%3D6%26spage%3De254%26epage%3De262%26doi%3D10.1016%2FS1470-2045%2816%2930030-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Timeline of key advances relating to the biology and therapeutic targeting of FLT3.<a onclick="showRef(event, 'ref1 ref2 ref3 ref11 ref13 ref20 ref24 ref26 ref29 ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref11 ref13 ref20 ref24 ref26 ref29 ref30 ref31 ref32">(1−3,11,13,20,24,26,29−32)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure of FLT3 kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB">1RJB</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Primary strategy to overcome FLT3 inhibitor resistance.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Chemical structure of pexidartinib. (B) Docking of pexidartinib into FLT3 kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>). The red dashed lines represent hydrogen bonds; the carbon atoms of the residues and the ligand are shown in yellow and green, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Chemical structure of MZH29. (B) Docking of MZH29 into FLT3 kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>). The red dashed lines represent hydrogen bonds; the yellow dashed line represents π–π interactions; the carbon atoms of the residues and the ligand are shown in yellow and green, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Chemical structure of cabozantinib. (B) Docking of cabozantinib into FLT3 kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>). The red dashed lines represent hydrogen bonds; the carbon atoms of the residues and the ligand are shown in yellow and green, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Chemical structure and design strategy for compound CHMFL-FLT3-213. (B) CHMFL-FLT3-213 docked into FLT3 kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XUF">4XUF</a>). (C) Docking of CHMFL-FLT3-213 into the homology model of DFG-out conformation of FLT3-F691L mutant (site mutation from PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XUF">4XUF</a>). The red dashed lines represent hydrogen bonds; the carbon atoms of the residues and the ligand are shown in yellow and green, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Chemical structure and design strategy for compound chen-9u. (B) Compound chen-9u docked into FLT3 kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XUF">4XUF</a>). The red dashed lines represent hydrogen bonds; the carbon atoms of the residues and the ligand are shown in yellow and green, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Chemical structure and design strategy for <b>Lu-50</b>. (B) Compound <b>Lu-50</b> docked into a homology mode of FLT3 (based on the crystal structure of c-KIT, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG">1PKG</a>). The red dashed lines represent hydrogen bonds; the carbon atoms of the residues and the ligand are shown in yellow and green, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) Chemical structure of compound NCGC1481. (B) Cocrystal binding mode of the scaffold of NCGC1481 with FLT3 kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6IL3">6IL3</a>). The red dashed line represents hydrogen bonds; the carbon atoms of the residues and the ligand are shown in yellow and green, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (A) Chemical structure of compound FF-10101. (B) Binding mode of FF-10101 with FLT3 kinase (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5X02">5X02</a>). The red dashed lines represent hydrogen bonds; the yellow solid line represents covalent bonds; the carbon atoms of the residues and the ligand are shown in yellow and green, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. (A) Chemical structure and design strategy for compound Schmidt-4b. (B) Compound Schmidt-4b docked into a homology mode of FLT3 (c-KIT, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG">1PKG</a>). The red dashed lines represent hydrogen bonds; the yellow solid line represents covalent bonds; the carbon atoms of the residues and the ligand are shown in yellow and green, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Structure of related agents involved in combination therapy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Chemical structures of compounds pacritinib (SB1518, left) and Yan-14j (right).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Chemical structure of CCT241736.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Chemical structure of AMG925.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/medium/jm0c01851_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Chemical structure of NCGC1481.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c01851/20210319/images/large/jm0c01851_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01851&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i47">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85288" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85288" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 149 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosnet, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchetto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">deLapeyriere, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birnbaum, D.</span></span> <span> </span><span class="NLM_article-title">Murine FLT3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1641</span>– <span class="NLM_lpage">1650</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1656368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADyaK38XmsVKhu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1991&pages=1641-1650&issue=9&author=O.+Rosnetauthor=S.+Marchettoauthor=O.+deLapeyriereauthor=D.+Birnbaum&title=Murine+FLT3%2C+a+gene+encoding+a+novel+tyrosine+kinase+receptor+of+the+PDGFR%2FCSF1R+family"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family</span></div><div class="casAuthors">Rosnet, Olivier; Marchetto, Sylvie; DeLapeyriere, Odile; Birnbaum, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1641-50</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    </div><div class="casAbstract">Receptor-type tyrosine kinases presenting an extracellular region with 5 Ig-like domains, and strongly related by sequence similarities in the intracellular region, constitute a family of receptors involved in development and function of various cell lineages.  The mouse Flt3 gene, encoding the sixth member of this family was isolated and characterized.  The Flt3 gene possesses an open reading frame of 3000 nucleotides, and therefore appears to code for a protein of 1000 amino acids.  The deduced structure of the FLT3 protein presents all the characteristics of a receptor-type kinase of this family.  The gene is expressed in placenta, in various adult tissues including gonads and brain, and in hematopoietic cells.  The Flt3 transcript is 3.7 kb long, except in the testis, where 2 shorter post-meiotic transcripts are detected.  These results suggest a role for this novel receptor and its yet unidentified ligand in placenta, gonads and hematopoietic and nervous systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9ZZA6MOS37LVg90H21EOLACvtfcHk0ljELbRZu8hUlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XmsVKhu7Y%253D&md5=db8f1899ab6517815304a14a8e741f1f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRosnet%26aufirst%3DO.%26aulast%3DMarchetto%26aufirst%3DS.%26aulast%3DdeLapeyriere%26aufirst%3DO.%26aulast%3DBirnbaum%26aufirst%3DD.%26atitle%3DMurine%2520FLT3%252C%2520a%2520gene%2520encoding%2520a%2520novel%2520tyrosine%2520kinase%2520receptor%2520of%2520the%2520PDGFR%252FCSF1R%2520family%26jtitle%3DOncogene%26date%3D1991%26volume%3D6%26issue%3D9%26spage%3D1641%26epage%3D1650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">The roles of FLT3 in hematopoiesis and leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>100</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1532</span>– <span class="NLM_lpage">1542</span>, <span class="refDoi"> DOI: 10.1182/blood-2002-02-0492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2002-02-0492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=12176867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslyhsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2002&pages=1532-1542&issue=5&author=D.+G.+Gillilandauthor=J.+D.+Griffin&title=The+roles+of+FLT3+in+hematopoiesis+and+leukemia&doi=10.1182%2Fblood-2002-02-0492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The roles of FLT3 in hematopoiesis and leukemia</span></div><div class="casAuthors">Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1532-1542</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">FLT3 is a receptor tyrosine kinase expressed by immature hematopoietic cells and is important for the normal development of stem cells and the immune system.  The ligand for FLT3 is expressed by marrow stromal cells and other cells and synergized with other growth factors to stimulate proliferation of stem cells, progenitor cells, dendritic cells, and natural killer cells.  Mutations of FLT3 have been detected in about 30% of patients with acute myelogenous leukemia and a small no. of patients with acute lymphocytic leukemia or myelodysplastic syndrome.  Patients with FLT3 mutations tend to have a poor prognosis.  The mutations most often involve small tandem duplications of amino acids within the juxtamembrane domain of the receptor and result in constitutive tyrosine kinase activity.  Expression of a mutant FLT3 receptor in murine marrow cells results in a lethal myeloproliferative syndrome and preliminary studies suggest that mutant FLT3 cooperates with other leukemia oncogenes to confer a more aggressive phenotype.  Taken together, these results suggest that FLT3 is an attractive therapeutic target for kinase inhibitors or other approaches for patients with mutations of this gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYQc2WkC8EQbVg90H21EOLACvtfcHk0ljELbRZu8hUlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslyhsLc%253D&md5=f6d04b227f5c5baf5c22cfba6e693ff1</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1182%2Fblood-2002-02-0492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2002-02-0492%26sid%3Dliteratum%253Aachs%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DThe%2520roles%2520of%2520FLT3%2520in%2520hematopoiesis%2520and%2520leukemia%26jtitle%3DBlood%26date%3D2002%26volume%3D100%26issue%3D5%26spage%3D1532%26epage%3D1542%26doi%3D10.1182%2Fblood-2002-02-0492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosnet, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pebusque, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchetto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonnelle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toiron, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birnbaum, D.</span></span> <span> </span><span class="NLM_article-title">Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>82</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1110</span>– <span class="NLM_lpage">1119</span>, <span class="refDoi"> DOI: 10.1182/blood.V82.4.1110.1110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood.V82.4.1110.1110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=8394751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADyaK2cXhvVSj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1993&pages=1110-1119&issue=4&author=O.+Rosnetauthor=C.+Schiffauthor=M.+J.+Pebusqueauthor=S.+Marchettoauthor=C.+Tonnelleauthor=Y.+Toironauthor=F.+Birgauthor=D.+Birnbaum&title=Human+FLT3%2FFLK2+gene%3A+cDNA+cloning+and+expression+in+hematopoietic+cells&doi=10.1182%2Fblood.V82.4.1110.1110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells</span></div><div class="casAuthors">Rosnet, Olivier; Schiff, Claudine; Pebusque, Marie Josephe; Marchetto, Sylvie; Tonnelle, Cecile; Toiron, Yves; Birg, Francoise; Birnbaum, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1110-19</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    </div><div class="casAbstract">The human FLT3 cDNA was cloned from a pre-B-cell line and characterized.  The deduced amino acid sequence shows that FLT3 codes for a receptor-type tyrosine kinase of 993 residues, presenting a strong similarity with the corresponding mouse FLT3/FLK2 protein as well as with the receptors for colony-stimulating factor 1 (CSF1R/FMS) and steel locus factor (SLFR/KIT).  An anal. of the expression of the gene using amplification of reverse transcribed FLT3 mRNA by polymerase chain reaction shows that FLT3 is expressed in various lymphohematopoietic cells and tissues, including a series of immature cell lines and leukemias of lymphocytic origin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6jBgqseYA5bVg90H21EOLACvtfcHk0lh6yAc2GvdaSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhvVSj&md5=02c1749a20d00231ce7d8bb5e95ec137</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1182%2Fblood.V82.4.1110.1110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V82.4.1110.1110%26sid%3Dliteratum%253Aachs%26aulast%3DRosnet%26aufirst%3DO.%26aulast%3DSchiff%26aufirst%3DC.%26aulast%3DPebusque%26aufirst%3DM.%2BJ.%26aulast%3DMarchetto%26aufirst%3DS.%26aulast%3DTonnelle%26aufirst%3DC.%26aulast%3DToiron%26aufirst%3DY.%26aulast%3DBirg%26aufirst%3DF.%26aulast%3DBirnbaum%26aufirst%3DD.%26atitle%3DHuman%2520FLT3%252FFLK2%2520gene%253A%2520cDNA%2520cloning%2520and%2520expression%2520in%2520hematopoietic%2520cells%26jtitle%3DBlood%26date%3D1993%26volume%3D82%26issue%3D4%26spage%3D1110%26epage%3D1119%26doi%3D10.1182%2Fblood.V82.4.1110.1110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faerman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swenson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, K.</span></span> <span> </span><span class="NLM_article-title">The structural basis for autoinhibition of FLT3 by the juxtamembrane domain</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">178</span>, <span class="refDoi"> DOI: 10.1016/S1097-2765(03)00505-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2FS1097-2765%2803%2900505-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=14759363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2004&pages=169-178&issue=2&author=J.+Griffithauthor=J.+Blackauthor=C.+Faermanauthor=L.+Swensonauthor=M.+Wynnauthor=F.+Luauthor=J.+Lippkeauthor=K.+Saxena&title=The+structural+basis+for+autoinhibition+of+FLT3+by+the+juxtamembrane+domain&doi=10.1016%2FS1097-2765%2803%2900505-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis for autoinhibition of FLT3 by the juxtamembrane domain</span></div><div class="casAuthors">Griffith, James; Black, James; Faerman, Carlos; Swenson, Lora; Wynn, Michael; Lu, Fan; Lippke, Judith; Saxena, Kumkum</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-178</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">FLT3 is a type III receptor tyrosine kinase that is thought to play a key role in hematopoiesis.  Certain classes of FLT3 mutations cause constitutively activated forms of the receptor that are found in significant nos. of patients with acute myelogenous leukemia (AML).  The mutations occur either in the activation loop, for example, as point mutations of Asp835 or as internal tandem duplication (ITD) sequences in the juxtamembrane (JM) domain.  To further understand the nature of FLT3 autoinhibition and regulation, we have detd. the crystal structure of the autoinhibited form of FLT3.  This structure shows the autoinhibitory conformation of a complete JM domain in this class of receptor tyrosine kinases.  The detailed inhibitory mechanism of the JM domain is revealed, which is likely utilized by other members of type III receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJAabT6TBxpLVg90H21EOLACvtfcHk0lgQhH1kohk2RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D&md5=d1df4a37aac59f5b59ca242fc8ccd6da</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2803%2900505-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252803%252900505-7%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DJ.%26aulast%3DBlack%26aufirst%3DJ.%26aulast%3DFaerman%26aufirst%3DC.%26aulast%3DSwenson%26aufirst%3DL.%26aulast%3DWynn%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DF.%26aulast%3DLippke%26aufirst%3DJ.%26aulast%3DSaxena%26aufirst%3DK.%26atitle%3DThe%2520structural%2520basis%2520for%2520autoinhibition%2520of%2520FLT3%2520by%2520the%2520juxtamembrane%2520domain%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D13%26issue%3D2%26spage%3D169%26epage%3D178%26doi%3D10.1016%2FS1097-2765%2803%2900505-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangoc, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spolski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broxmeyer, H. E.</span></span> <span> </span><span class="NLM_article-title">Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>192</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">719</span>– <span class="NLM_lpage">728</span>, <span class="refDoi"> DOI: 10.1084/jem.192.5.719</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1084%2Fjem.192.5.719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10974037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtlegtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2000&pages=719-728&issue=5&author=S.+Zhangauthor=S.+Fukudaauthor=Y.+Leeauthor=G.+Hangocauthor=S.+Cooperauthor=R.+Spolskiauthor=W.+J.+Leonardauthor=H.+E.+Broxmeyer&title=Essential+role+of+signal+transducer+and+activator+of+transcription+%28Stat%295a+but+not+Stat5b+for+Flt3-dependent+signaling&doi=10.1084%2Fjem.192.5.719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling</span></div><div class="casAuthors">Zhang, Shuli; Fukuda, Seiji; Lee, Younghee; Hangoc, Giao; Cooper, Scott; Spolski, Rosanne; Leonard, Warren J.; Broxmeyer, Hal E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">719-728</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase Flt3 plays an important role in proliferation and survival of hematopoietic stem and progenitor cells.  Although some post-receptor signaling events of Flt3 have been characterized, the involvement of the Janus kinase/signal transducer and activator of transcription (Jak/Stat) pathway in Flt3 signaling has not been thoroughly evaluated.  To this aim, the authors examd. whether Flt3 activates the Jak/Stat pathway in Baf3/Flt3 cells, a line stably expressing human Flt3 receptor.  Stat5a, but not Stats 1-4, 5b, or 6, was potently activated by Flt3 ligand (FL) stimulation.  Interestingly, FL did not activate any Jaks.  Activation of Stat5a required the kinase activity of Flt3.  A selective role for Stat5a in the proliferative response of primary hematopoietic progenitor cells to FL was documented, as FL did not act on progenitors from marrows of Stat5a-/- mice, but did stimulate/costimulate proliferation of these cells from Stat5a+/+, Stat5b-/-, and Stat5b+/+ mice.  Thus, Stat5a is essential for at least certain effects of FL.  The authors' data also confirm that Stat5a and Stat5b are not redundant, but rather are at least partially distinctive in their function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPiElN3OIS8rVg90H21EOLACvtfcHk0lgQhH1kohk2RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtlegtrw%253D&md5=f8ba557376b2c7fe86dcd821ffb1ae97</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1084%2Fjem.192.5.719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.192.5.719%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DFukuda%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DHangoc%26aufirst%3DG.%26aulast%3DCooper%26aufirst%3DS.%26aulast%3DSpolski%26aufirst%3DR.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26aulast%3DBroxmeyer%26aufirst%3DH.%2BE.%26atitle%3DEssential%2520role%2520of%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%2520%2528Stat%25295a%2520but%2520not%2520Stat5b%2520for%2520Flt3-dependent%2520signaling%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2000%26volume%3D192%26issue%3D5%26spage%3D719%26epage%3D728%26doi%3D10.1084%2Fjem.192.5.719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gucky, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reznickova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radosova Muchova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klejova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malinkova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazgier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepsik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divoky, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystof, V.</span></span> <span> </span><span class="NLM_article-title">Discovery of <i>N</i><sup>2</sup>-(4-amino-cyclohexyl)-9-cyclopentyl-<i>N</i><sup>6</sup>-(4-morpholin-4-ylmethyl-phenyl)-9<i>H</i>-purine-2,6-diamine as a potent FLT3 kinase inhibitor for acute myeloid leukemia with FLT3 mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3855</span>– <span class="NLM_lpage">3869</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01529</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01529" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotVahsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3855-3869&issue=9&author=T.+Guckyauthor=E.+Reznickovaauthor=T.+Radosova+Muchovaauthor=R.+Jordaauthor=Z.+Klejovaauthor=V.+Malinkovaauthor=K.+Berkaauthor=V.+Bazgierauthor=H.+Ajaniauthor=M.+Lepsikauthor=V.+Divokyauthor=V.+Krystof&title=Discovery+of+N2-%284-amino-cyclohexyl%29-9-cyclopentyl-N6-%284-morpholin-4-ylmethyl-phenyl%29-9H-purine-2%2C6-diamine+as+a+potent+FLT3+kinase+inhibitor+for+acute+myeloid+leukemia+with+FLT3+mutations&doi=10.1021%2Facs.jmedchem.7b01529"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N2-(4-Amino-cyclohexyl)-9-cyclopentyl-N6-(4-morpholin-4-ylmethyl-phenyl)-9H-purine-2,6-diamine as a Potent FLT3 Kinase Inhibitor for Acute Myeloid Leukemia with FLT3 Mutations</span></div><div class="casAuthors">Gucky, Tomas; Reznickova, Eva; Radosova Muchova, Tereza; Jorda, Radek; Klejova, Zuzana; Malinkova, Veronika; Berka, Karel; Bazgier, Vaclav; Ajani, Haresh; Lepsik, Martin; Divoky, Vladimir; Krystof, Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3855-3869</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">FLT3 tyrosine kinase is a potential drug target in acute myeloid leukemia (AML) because patients with FLT3-ITD mutations respond poorly to std. cytotoxic agents and there is a clear link between the disease and the oncogenic properties of FLT3.  We present novel 2,6,9-trisubstituted purine derivs. with potent FLT3 inhibitory activity.  The lead compd. 7d displays nanomolar activity in biochem. assays and selectively blocks proliferation of AML cell lines harboring FLT3-ITD mutations, whereas other transformed and normal human cells are several orders of magnitude less sensitive.  The MV4-11 cells treated with 7d suppressed the phosphorylation of FLT3 and its downstream signaling pathways, with subsequent G1 cell cycle arrest and apoptosis.  Addnl., a single dose of 7d in mice with s.c. MV4-11 xenografts caused sustained inhibition of FLT3 and STAT5 phosphorylation over 48 h, in contrast to the shorter effect obsd. after administration of the ref. FLT3 inhibitor quizartinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ88Wx0YxwWLVg90H21EOLACvtfcHk0lgHC2UceMAsJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotVahsr0%253D&md5=cbc982a08f1905840e273e23c825a134</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01529%26sid%3Dliteratum%253Aachs%26aulast%3DGucky%26aufirst%3DT.%26aulast%3DReznickova%26aufirst%3DE.%26aulast%3DRadosova%2BMuchova%26aufirst%3DT.%26aulast%3DJorda%26aufirst%3DR.%26aulast%3DKlejova%26aufirst%3DZ.%26aulast%3DMalinkova%26aufirst%3DV.%26aulast%3DBerka%26aufirst%3DK.%26aulast%3DBazgier%26aufirst%3DV.%26aulast%3DAjani%26aufirst%3DH.%26aulast%3DLepsik%26aufirst%3DM.%26aulast%3DDivoky%26aufirst%3DV.%26aulast%3DKrystof%26aufirst%3DV.%26atitle%3DDiscovery%2520of%2520N2-%25284-amino-cyclohexyl%2529-9-cyclopentyl-N6-%25284-morpholin-4-ylmethyl-phenyl%2529-9H-purine-2%252C6-diamine%2520as%2520a%2520potent%2520FLT3%2520kinase%2520inhibitor%2520for%2520acute%2520myeloid%2520leukemia%2520with%2520FLT3%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D9%26spage%3D3855%26epage%3D3869%26doi%3D10.1021%2Facs.jmedchem.7b01529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dohner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisdorf, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomfield, C. D.</span></span> <span> </span><span class="NLM_article-title">Acute myeloid leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1136</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1056/NEJMra1406184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1056%2FNEJMra1406184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=26376137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BC283jt1Shsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=1136-1152&issue=12&author=H.+Dohnerauthor=D.+J.+Weisdorfauthor=C.+D.+Bloomfield&title=Acute+myeloid+leukemia&doi=10.1056%2FNEJMra1406184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Acute Myeloid Leukemia</span></div><div class="casAuthors">Dohner Hartmut; Weisdorf Daniel J; Bloomfield Clara D</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1136-52</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7_lmkXqa4eckU0YCbOU3EfW6udTcc2eb2_fivS__jA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283jt1Shsw%253D%253D&md5=a22a9f8b7b0e31e1084d2e76281bb35a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1406184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1406184%26sid%3Dliteratum%253Aachs%26aulast%3DDohner%26aufirst%3DH.%26aulast%3DWeisdorf%26aufirst%3DD.%2BJ.%26aulast%3DBloomfield%26aufirst%3DC.%2BD.%26atitle%3DAcute%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26issue%3D12%26spage%3D1136%26epage%3D1152%26doi%3D10.1056%2FNEJMra1406184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Short, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rytting, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J. E.</span></span> <span> </span><span class="NLM_article-title">Acute myeloid leukaemia</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>392</i></span> (<span class="NLM_issue">10147</span>),  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">606</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(18)31041-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2FS0140-6736%2818%2931041-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=30078459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ltF2jtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=392&publication_year=2018&pages=593-606&issue=10147&author=N.+J.+Shortauthor=M.+E.+Ryttingauthor=J.+E.+Cortes&title=Acute+myeloid+leukaemia&doi=10.1016%2FS0140-6736%2818%2931041-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Acute myeloid leukaemia</span></div><div class="casAuthors">Short Nicholas J; Rytting Michael E; Cortes Jorge E</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">392</span>
        (<span class="NLM_cas:issue">10147</span>),
    <span class="NLM_cas:pages">593-606</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">For several decades, few substantial therapeutic advances have been made for patients with acute myeloid leukaemia.  However, since 2017 unprecedented growth has been seen in the number of drugs available for the treatment of acute myeloid leukaemia, with several new drugs receiving regulatory approval.  In addition to advancing our therapeutic armamentarium, an increased understanding of the biology and genomic architecture of acute myeloid leukaemia has led to refined risk assessment of this disease, with consensus risk stratification guidelines now incorporating a growing number of recurrent molecular aberrations that aid in the selection of risk-adapted management strategies.  Despite this promising recent progress, the outcomes of patients with acute myeloid leukaemia remain unsatisfactory, with more than half of patients ultimately dying from their disease.  Enrolment of patients into clinical trials that evaluate novel drugs and rational combination therapies is imperative to continuing this progress and further improving the outcomes of patients with acute myeloid leukaemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-2ehJOMY27yA3UY9EwTNrfW6udTcc2eZM9nsh-1m5t7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ltF2jtA%253D%253D&md5=212ad7a55f4f9e1e1d90f2e265987f3c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2818%2931041-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252818%252931041-9%26sid%3Dliteratum%253Aachs%26aulast%3DShort%26aufirst%3DN.%2BJ.%26aulast%3DRytting%26aufirst%3DM.%2BE.%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26atitle%3DAcute%2520myeloid%2520leukaemia%26jtitle%3DLancet%26date%3D2018%26volume%3D392%26issue%3D10147%26spage%3D593%26epage%3D606%26doi%3D10.1016%2FS0140-6736%2818%2931041-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stirewalt, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radich, J. P.</span></span> <span> </span><span class="NLM_article-title">The role of FLT3 in haematopoietic malignancies</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">650</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1038/nrc1169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fnrc1169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=12951584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvVWlu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=650-665&issue=9&author=D.+L.+Stirewaltauthor=J.+P.+Radich&title=The+role+of+FLT3+in+haematopoietic+malignancies&doi=10.1038%2Fnrc1169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The role of FLT3 in hematopoietic malignancies</span></div><div class="casAuthors">Stirewalt, Derek L.; Radich, Jerald P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">650-665</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Normal haematopoietic cells use complex systems to control proliferation, differentiation and cell death.  The control of proliferation is, in part, accomplished through the ligand-induced stimulation of receptor tyrosine kinases, which signal to downstream effectors through the RAS pathway.  Recently, mutations in the FMS-like tyrosine kinase 3 (FLT3) gene, which encodes a receptor tyrosine kinase, have been found to be the most common genetic lesion in acute myeloid leukemia (AML), occurring in ∼25% of cases.  Exploring the mechanism by which these FLT3 mutations cause uncontrolled proliferation might lead to a better understanding of how cells become cancerous and provide insights for the development of new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRONPQkpemorVg90H21EOLACvtfcHk0liwHwlR_C-Hyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvVWlu7c%253D&md5=97183b7a6087fafe20bfc695f403825b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrc1169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1169%26sid%3Dliteratum%253Aachs%26aulast%3DStirewalt%26aufirst%3DD.%2BL.%26aulast%3DRadich%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520role%2520of%2520FLT3%2520in%2520haematopoietic%2520malignancies%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26issue%3D9%26spage%3D650%26epage%3D665%26doi%3D10.1038%2Fnrc1169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fromm, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erhardt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krauter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brossart, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundgen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salih, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulf, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertenstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wattad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotze, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraemer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinicke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girschikofsky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derigs, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horst, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gohring, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teleanu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullinger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thol, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidzik, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paschka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, R. F.</span></span> <span> </span><span class="NLM_article-title">Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)</span>. <i>Ann. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>96</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1993</span>– <span class="NLM_lpage">2003</span>, <span class="refDoi"> DOI: 10.1007/s00277-017-3150-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1007%2Fs00277-017-3150-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=29090343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BC1M7msVymug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2017&pages=1993-2003&issue=12&author=G.+Nagelauthor=D.+Weberauthor=E.+Frommauthor=S.+Erhardtauthor=M.+Lubbertauthor=W.+Fiedlerauthor=T.+Kindlerauthor=J.+Krauterauthor=P.+Brossartauthor=A.+Kundgenauthor=H.+R.+Salihauthor=J.+Westermannauthor=G.+Wulfauthor=B.+Hertensteinauthor=M.+Wattadauthor=K.+Gotzeauthor=D.+Kraemerauthor=T.+Heinickeauthor=M.+Girschikofskyauthor=H.+G.+Derigsauthor=H.+A.+Horstauthor=C.+Rudolphauthor=M.+Heuserauthor=G.+Gohringauthor=V.+Teleanuauthor=L.+Bullingerauthor=F.+Tholauthor=V.+I.+Gaidzikauthor=P.+Paschkaauthor=K.+Dohnerauthor=A.+Ganserauthor=H.+Dohnerauthor=R.+F.+Schlenk&title=Epidemiological%2C+genetic%2C+and+clinical+characterization+by+age+of+newly+diagnosed+acute+myeloid+leukemia+based+on+an+academic+population-based+registry+study+%28AMLSG+BiO%29&doi=10.1007%2Fs00277-017-3150-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)</span></div><div class="casAuthors">Nagel Gabriele; Fromm E; Erhardt S; Weber D; Rudolph C; Teleanu V; Bullinger L; Gaidzik V I; Paschka P; Dohner K; Dohner Hartmut; Schlenk R F; Lubbert M; Fiedler W; Kindler T; Krauter J; Brossart P; Kundgen A; Salih H R; Westermann J; Wulf G; Hertenstein B; Wattad M; Gotze K; Kraemer D; Heinicke T; Girschikofsky M; Derigs H G; Horst H A; Heuser M; Thol F; Ganser A; Gohring G; Schlenk R F</div><div class="citationInfo"><span class="NLM_cas:title">Annals of hematology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1993-2003</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We describe genetic and clinical characteristics of acute myeloid leukemia (AML) patients according to age from an academic population-based registry.  Adult patients with newly diagnosed AML at 63 centers in Germany and Austria were followed within the AMLSG BiO registry (NCT01252485).  Between January 1, 2012, and December 31, 2014, data of 3525 patients with AML (45% women) were collected.  The median age was 65 years (range 18-94).  The comparison of age-specific AML incidence rates with epidemiological cancer registries revealed excellent coverage in patients < 70 years old and good coverage up to the age of 80.  The distribution according to the European LeukemiaNet (ELN) risk categorization from 2010 was 20% favorable, 31% intermediate-1, 28% intermediate-2, and 21% adverse.  With increasing age, the relative but not the absolute prevalence of patients with ELN favorable and intermediate-1 risk (p < 0.001), with activating FLT3 mutations (p < 0.001), with ECOG performance status < 2 (p < 0.001), and with HCT-CI comorbidity index < 3 (p < 0.001) decreased.  Regarding treatment, obesity and favorable risk were associated with an intensive treatment, whereas adverse risk, higher age, and comorbidity index > 0 were associated with non-intensive treatment or best supportive care.  The AMLSG BiO registry provides reliable population-based distributions of genetic, clinical, and treatment characteristics according to age.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTfcgM0Frwgo4YPsCkJIw00fW6udTcc2eYUDYzONrhWt7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7msVymug%253D%253D&md5=3e1e417ca1378864da1bbb89c4759bb6</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs00277-017-3150-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00277-017-3150-3%26sid%3Dliteratum%253Aachs%26aulast%3DNagel%26aufirst%3DG.%26aulast%3DWeber%26aufirst%3DD.%26aulast%3DFromm%26aufirst%3DE.%26aulast%3DErhardt%26aufirst%3DS.%26aulast%3DLubbert%26aufirst%3DM.%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DKindler%26aufirst%3DT.%26aulast%3DKrauter%26aufirst%3DJ.%26aulast%3DBrossart%26aufirst%3DP.%26aulast%3DKundgen%26aufirst%3DA.%26aulast%3DSalih%26aufirst%3DH.%2BR.%26aulast%3DWestermann%26aufirst%3DJ.%26aulast%3DWulf%26aufirst%3DG.%26aulast%3DHertenstein%26aufirst%3DB.%26aulast%3DWattad%26aufirst%3DM.%26aulast%3DGotze%26aufirst%3DK.%26aulast%3DKraemer%26aufirst%3DD.%26aulast%3DHeinicke%26aufirst%3DT.%26aulast%3DGirschikofsky%26aufirst%3DM.%26aulast%3DDerigs%26aufirst%3DH.%2BG.%26aulast%3DHorst%26aufirst%3DH.%2BA.%26aulast%3DRudolph%26aufirst%3DC.%26aulast%3DHeuser%26aufirst%3DM.%26aulast%3DGohring%26aufirst%3DG.%26aulast%3DTeleanu%26aufirst%3DV.%26aulast%3DBullinger%26aufirst%3DL.%26aulast%3DThol%26aufirst%3DF.%26aulast%3DGaidzik%26aufirst%3DV.%2BI.%26aulast%3DPaschka%26aufirst%3DP.%26aulast%3DDohner%26aufirst%3DK.%26aulast%3DGanser%26aufirst%3DA.%26aulast%3DDohner%26aufirst%3DH.%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26atitle%3DEpidemiological%252C%2520genetic%252C%2520and%2520clinical%2520characterization%2520by%2520age%2520of%2520newly%2520diagnosed%2520acute%2520myeloid%2520leukemia%2520based%2520on%2520an%2520academic%2520population-based%2520registry%2520study%2520%2528AMLSG%2520BiO%2529%26jtitle%3DAnn.%2520Hematol.%26date%3D2017%26volume%3D96%26issue%3D12%26spage%3D1993%26epage%3D2003%26doi%3D10.1007%2Fs00277-017-3150-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiike, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonoda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misawa, S.</span></span> <span> </span><span class="NLM_article-title">Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1911</span>– <span class="NLM_lpage">1918</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=8946930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADyaK2s7gt1Kqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1996&pages=1911-1918&issue=12&author=M.+Nakaoauthor=S.+Yokotaauthor=T.+Iwaiauthor=H.+Kanekoauthor=S.+Horiikeauthor=K.+Kashimaauthor=Y.+Sonodaauthor=T.+Fujimotoauthor=S.+Misawa&title=Internal+tandem+duplication+of+the+FLT3+gene+found+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Internal tandem duplication of the flt3 gene found in acute myeloid leukemia</span></div><div class="casAuthors">Nakao M; Yokota S; Iwai T; Kaneko H; Horiike S; Kashima K; Sonoda Y; Fujimoto T; Misawa S</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1911-8</span>
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    </div><div class="casAbstract">We analyzed mRNA expression of the flt3 gene in 30 patients with acute myeloid leukemia (AML) and 50 with acute lymphoblastic leukemia (ALL).  Using reverse transcriptase-polymerase chain reaction (RT-PCR), expression of flt3 was observed in 61 patients; 22 (73%) with AML and 39 (78%) with ALL.  Among these, five patients with AML (one M2, two M4, and two M5) showed unexpected longer transcripts with a primer combination which could amplify the transmembrane (TM) domain through the juxtamembrane (JM) domain.  For those patients who expressed flt3 mRNA, the extracellular domain of the flt3 gene was also examined by RT-PCR, but no length abnormality was seen in this region.  We further analyzed the TM domain through the second tyrosine kinase domain by genomic amplifications.  The five patients who showed aberrant flt3 transcripts exhibited abnormal longer PCR products in addition to the germline products at a region corresponding to the JM through the first TK (TK1) domains.  Sequence analyses of the abnormal RT-PCR products demonstrated that partial sequences were tandemly duplicated.  Because all these altered transcripts were in-frame, deduced protein products could be expected.  Sequence analyses of the genomic DNA revealed that three of the five patients showed a simple internal duplication within exon 11; one had an internal duplication (26 bp) with a 4-bp insertion; and in the fifth patient, a 136-bp sequence from the 3' part of exon 11 to intron 11 and the first 16-bp sequence of exon 12 were each duplicated with 1-bp insertion.  In order to confirm the tumor specificity of these alterations, DNA samples obtained at complete remission were also analyzed in the three patients harboring an flt3 duplication, but no abnormal PCR product other than germline was detected in any of the samples.  Our results suggest that an internal tandem duplication at the JM/TK1 domains of the flt3 gene is a somatic change detected preferentially in AML, possibly containing a monocytic component.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQL5G2hUkeODSA3UY9EwTNrfW6udTcc2eYUDYzONrhWt7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s7gt1Kqsg%253D%253D&md5=da0c7f21e6c4daf68bd4b1ae38a92891</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNakao%26aufirst%3DM.%26aulast%3DYokota%26aufirst%3DS.%26aulast%3DIwai%26aufirst%3DT.%26aulast%3DKaneko%26aufirst%3DH.%26aulast%3DHoriike%26aufirst%3DS.%26aulast%3DKashima%26aufirst%3DK.%26aulast%3DSonoda%26aufirst%3DY.%26aulast%3DFujimoto%26aufirst%3DT.%26aulast%3DMisawa%26aufirst%3DS.%26atitle%3DInternal%2520tandem%2520duplication%2520of%2520the%2520FLT3%2520gene%2520found%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D1996%26volume%3D10%26issue%3D12%26spage%3D1911%26epage%3D1918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stirewalt, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopecky, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meshinchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogosova-Agadjanyan, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linsley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slovak, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willman, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radich, J. P.</span></span> <span> </span><span class="NLM_article-title">Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>107</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3724</span>– <span class="NLM_lpage">3726</span>, <span class="refDoi"> DOI: 10.1182/blood-2005-08-3453</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2005-08-3453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=16368883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD28Xkt1Giu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2006&pages=3724-3726&issue=9&author=D.+L.+Stirewaltauthor=K.+J.+Kopeckyauthor=S.+Meshinchiauthor=J.+H.+Engelauthor=E.+L.+Pogosova-Agadjanyanauthor=J.+Linsleyauthor=M.+L.+Slovakauthor=C.+L.+Willmanauthor=J.+P.+Radich&title=Size+of+FLT3+internal+tandem+duplication+has+prognostic+significance+in+patients+with+acute+myeloid+leukemia&doi=10.1182%2Fblood-2005-08-3453"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia</span></div><div class="casAuthors">Stirewalt, Derek L.; Kopecky, Kenneth J.; Meshinchi, Soheil; Engel, Julia H.; Pogosova-Agadjanyan, Era L.; Linsley, Jeremy; Slovak, Marilyn L.; Willman, Cheryl L.; Radich, Jerald P.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3724-3726</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">FLT3 internal tandem duplications (FLT3/ITDs) in the juxtamembrane domain are found in approx. 25% of acute myeloid leukemia (AML) patients, ranging in size from 3 to hundreds of nucleotides.  We examd. whether the sizes of FLT3/ITDs were assocd. with clin. outcomes in 151 AML patients enrolled in Southwest Oncol. Group studies: S9333 and S9500.  FLT3/ITDs were identified in 32% of patients (median ITD size = 39 nucleotides; range, 15-153 nucleotides).  The CR rates were 35%, 67%, and 52% for patients with large (≥ 40), small (< 40), and no ITDs, resp. (P =.19).  Increasing ITD size was assocd. with decreasing OS (estd. 5-yr OS: large = 13%, small = 26%, and no ITD = 21%, P =.072) and RFS (estd. 5-yr RFS: large = 13%, small = 27%, and no ITD = 34%, P =.017).  These studies suggest that ITD size may have prognostic significance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbTynIbwo_AbVg90H21EOLACvtfcHk0lhjoTd_wiDe7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xkt1Giu7s%253D&md5=5cfa50e4ac5aedf32d6afaab8d658c65</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-08-3453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-08-3453%26sid%3Dliteratum%253Aachs%26aulast%3DStirewalt%26aufirst%3DD.%2BL.%26aulast%3DKopecky%26aufirst%3DK.%2BJ.%26aulast%3DMeshinchi%26aufirst%3DS.%26aulast%3DEngel%26aufirst%3DJ.%2BH.%26aulast%3DPogosova-Agadjanyan%26aufirst%3DE.%2BL.%26aulast%3DLinsley%26aufirst%3DJ.%26aulast%3DSlovak%26aufirst%3DM.%2BL.%26aulast%3DWillman%26aufirst%3DC.%2BL.%26aulast%3DRadich%26aufirst%3DJ.%2BP.%26atitle%3DSize%2520of%2520FLT3%2520internal%2520tandem%2520duplication%2520has%2520prognostic%2520significance%2520in%2520patients%2520with%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2006%26volume%3D107%26issue%3D9%26spage%3D3724%26epage%3D3726%26doi%3D10.1182%2Fblood-2005-08-3453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schnittger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haferlach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alpermann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haferlach, T.</span></span> <span> </span><span class="NLM_article-title">Diversity of the juxtamembrane and TKD1 mutations (exons 13–15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data</span>. <i>Genes, Chromosomes Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">910</span>– <span class="NLM_lpage">924</span>, <span class="refDoi"> DOI: 10.1002/gcc.21975</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1002%2Fgcc.21975" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=22674490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvFOqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=910-924&issue=10&author=S.+Schnittgerauthor=U.+Bacherauthor=C.+Haferlachauthor=T.+Alpermannauthor=W.+Kernauthor=T.+Haferlach&title=Diversity+of+the+juxtamembrane+and+TKD1+mutations+%28exons+13%E2%80%9315%29+in+the+FLT3+gene+with+regards+to+mutant+load%2C+sequence%2C+length%2C+localization%2C+and+correlation+with+biological+data&doi=10.1002%2Fgcc.21975"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Diversity of the juxtamembrane and TKD1 mutations (Exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data</span></div><div class="casAuthors">Schnittger, Susanne; Bacher, Ulrike; Haferlach, Claudia; Alpermann, Tamara; Kern, Wolfgang; Haferlach, Torsten</div><div class="citationInfo"><span class="NLM_cas:title">Genes, Chromosomes & Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">910-924</span>CODEN:
                <span class="NLM_cas:coden">GCCAES</span>;
        ISSN:<span class="NLM_cas:issn">1045-2257</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">In acute myeloid leukemia (AML) mutations in the juxtamembrane and tyrosine kinase 1 domain (exons 13-15) of the FLT3 gene (FLT3-ITD/LM) are heterogeneous with respect to mutation load, size, and localization.  We characterized length and structure of these mutations by fragment anal. and sequencing in 689 AML which were identified among 3,365 (20.5%) newly diagnosed AML (1,803 males, 1,562 females; 15.8-91.8 years).  Mutations were heterogeneous in length (median: 63, range: 3-1,236 nucleotides; nt).  Most frequent were sizes of 21 (8.4%) or 24 nt (6.0%).  Ninety-one different insertion sites were obsd. (between nt 1,788 and 1,934, according to accession "FLT3 [Ensembl/Havana merge: ENSG00000122025]" with nt 1,856 (n = 41) and 1,863 (n = 35) being most frequent.  In addn., 89 different insertion end points were obsd. between nt 1,790 and 1,994.  FLT3-mutation/wild-type ratio was available in 615 patients (median, 0.80; range 0.03-181.73). 128 Patients (20.8%) had ratios <0.3, 334 (54.3%) had ratio ≥0.3 <1, 118 (19.2%) ≥1, and 35 (5.7%) showed complete loss of the FLT3-wild-type allele.  Overall (OS) and event-free (EFS) survival were better for FLT3-neg. than FLT3mut normal karyotype patients (P = 0.078 and P = 0.004, resp.) and patients with low level FLT3-mutations had significantly longer OS and EFS compared with high level mutations (FLT3-mutation/wild-type ratio ≥1) (P < 0.001 and P = 0.002, resp.).  The length of the mutation had no prognostic impact.  Mutations localized more 5' were assocd. with better outcome than more 3'mutations, but no strict assocn. to certain functional domains was detected.  In conclusion, FLT3-mutations are extremely heterogenous with mutation load being the most relevant parameter. © 2012 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvkqizY7W9trVg90H21EOLACvtfcHk0lhjoTd_wiDe7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvFOqtb8%253D&md5=1ba64ad96edcf3aca579f5b7a1861a99</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fgcc.21975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fgcc.21975%26sid%3Dliteratum%253Aachs%26aulast%3DSchnittger%26aufirst%3DS.%26aulast%3DBacher%26aufirst%3DU.%26aulast%3DHaferlach%26aufirst%3DC.%26aulast%3DAlpermann%26aufirst%3DT.%26aulast%3DKern%26aufirst%3DW.%26aulast%3DHaferlach%26aufirst%3DT.%26atitle%3DDiversity%2520of%2520the%2520juxtamembrane%2520and%2520TKD1%2520mutations%2520%2528exons%252013%25E2%2580%259315%2529%2520in%2520the%2520FLT3%2520gene%2520with%2520regards%2520to%2520mutant%2520load%252C%2520sequence%252C%2520length%252C%2520localization%252C%2520and%2520correlation%2520with%2520biological%2520data%26jtitle%3DGenes%252C%2520Chromosomes%2520Cancer%26date%3D2012%26volume%3D51%26issue%3D10%26spage%3D910%26epage%3D924%26doi%3D10.1002%2Fgcc.21975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullinger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobbe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casper, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringhoffer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Held, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brossart, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salih, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horst, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulf, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nachbaur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotze, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamparter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paschka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidzik, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teleanu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krauter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohner, K.</span></span> <span> </span><span class="NLM_article-title">Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">3441</span>– <span class="NLM_lpage">3449</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-05-578070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2014-05-578070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=25270908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitV2nsbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=3441-3449&issue=23&author=R.+F.+Schlenkauthor=S.+Kayserauthor=L.+Bullingerauthor=G.+Kobbeauthor=J.+Casperauthor=M.+Ringhofferauthor=G.+Heldauthor=P.+Brossartauthor=M.+Lubbertauthor=H.+R.+Salihauthor=T.+Kindlerauthor=H.+A.+Horstauthor=G.+Wulfauthor=D.+Nachbaurauthor=K.+Gotzeauthor=A.+Lamparterauthor=P.+Paschkaauthor=V.+I.+Gaidzikauthor=V.+Teleanuauthor=D.+Spathauthor=A.+Bennerauthor=J.+Krauterauthor=A.+Ganserauthor=H.+Dohnerauthor=K.+Dohner&title=Differential+impact+of+allelic+ratio+and+insertion+site+in+FLT3-ITD-positive+AML+with+respect+to+allogeneic+transplantation&doi=10.1182%2Fblood-2014-05-578070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation</span></div><div class="casAuthors">Schlenk, Richard F.; Kayser, Sabine; Bullinger, Lars; Kobbe, Guido; Casper, Jochen; Ringhoffer, Mark; Held, Gerhard; Brossart, Peter; Luebbert, Michael; Salih, Helmut R.; Kindler, Thomas; Horst, Heinz A.; Wulf, Gerald; Nachbaur, David; Goetze, Katharina; Lamparter, Alexander; Paschka, Peter; Gaidzik, Verena I.; Teleanu, Veronica; Spaeth, Daniela; Benner, Axel; Krauter, Juergen; Ganser, Arnold; Doehner, Hartmut; Doehner, Konstanze</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3441-3449</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The objective was to evaluate the prognostic and predictive impact of allelic ratio and insertion site (IS) of internal tandem duplications (ITDs), as well as concurrent gene mutations, with regard to postremission therapy in 323 patients with FLT3-ITD-pos. acute myeloid leukemia (AML).  Increasing FLT3-ITD allelic ratio (P = .004) and IS in the tyrosine kinase domain 1 (TKD1, P = .06) were assocd. with low complete remission (CR) rates.  After postremission therapy including intensive chemotherapy (n = 121) or autologous hematopoietic stem cell transplantation (HSCT, n = 17), an allelic ratio ≥ 0.51 was assocd. with an unfavorable relapse-free (RFS, P = .0008) and overall survival (OS, P = .004); after allogeneic HSCT (n = 93), outcome was significantly improved in patients with a high allelic ratio (RFS, P = .02; OS, P = .03), whereas no benefit was seen in patients with a low allelic ratio (RFS, P = .38; OS, P = .64).  Multivariable analyses revealed a high allelic ratio as a predictive factor for the beneficial effect of allogeneic HSCT; ITD IS in TKD1 remained an unfavorable factor, whereas no prognostic impact of concurrent gene mutations was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-3OpzDAfbwLVg90H21EOLACvtfcHk0lhjoTd_wiDe7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitV2nsbbN&md5=d505ffab0eb1820edec6d5657d17db41</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-05-578070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-05-578070%26sid%3Dliteratum%253Aachs%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26aulast%3DKayser%26aufirst%3DS.%26aulast%3DBullinger%26aufirst%3DL.%26aulast%3DKobbe%26aufirst%3DG.%26aulast%3DCasper%26aufirst%3DJ.%26aulast%3DRinghoffer%26aufirst%3DM.%26aulast%3DHeld%26aufirst%3DG.%26aulast%3DBrossart%26aufirst%3DP.%26aulast%3DLubbert%26aufirst%3DM.%26aulast%3DSalih%26aufirst%3DH.%2BR.%26aulast%3DKindler%26aufirst%3DT.%26aulast%3DHorst%26aufirst%3DH.%2BA.%26aulast%3DWulf%26aufirst%3DG.%26aulast%3DNachbaur%26aufirst%3DD.%26aulast%3DGotze%26aufirst%3DK.%26aulast%3DLamparter%26aufirst%3DA.%26aulast%3DPaschka%26aufirst%3DP.%26aulast%3DGaidzik%26aufirst%3DV.%2BI.%26aulast%3DTeleanu%26aufirst%3DV.%26aulast%3DSpath%26aufirst%3DD.%26aulast%3DBenner%26aufirst%3DA.%26aulast%3DKrauter%26aufirst%3DJ.%26aulast%3DGanser%26aufirst%3DA.%26aulast%3DDohner%26aufirst%3DH.%26aulast%3DDohner%26aufirst%3DK.%26atitle%3DDifferential%2520impact%2520of%2520allelic%2520ratio%2520and%2520insertion%2520site%2520in%2520FLT3-ITD-positive%2520AML%2520with%2520respect%2520to%2520allogeneic%2520transplantation%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26issue%3D23%26spage%3D3441%26epage%3D3449%26doi%3D10.1182%2Fblood-2014-05-578070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ley, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koboldt, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welch, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchey, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamprecht, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMichael, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dooling, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalicki-Veizer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magrini, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendl, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Link, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasson, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payton, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westervelt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graubert, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPersio, J. F.</span></span> <span> </span><span class="NLM_article-title">Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>481</i></span> (<span class="NLM_issue">7382</span>),  <span class="NLM_fpage">506</span>– <span class="NLM_lpage">510</span>, <span class="refDoi"> DOI: 10.1038/nature10738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fnature10738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=22237025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsF2jtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=481&publication_year=2012&pages=506-510&issue=7382&author=L.+Dingauthor=T.+J.+Leyauthor=D.+E.+Larsonauthor=C.+A.+Millerauthor=D.+C.+Koboldtauthor=J.+S.+Welchauthor=J.+K.+Ritcheyauthor=M.+A.+Youngauthor=T.+Lamprechtauthor=M.+D.+McLellanauthor=J.+F.+McMichaelauthor=J.+W.+Wallisauthor=C.+Luauthor=D.+Shenauthor=C.+C.+Harrisauthor=D.+J.+Doolingauthor=R.+S.+Fultonauthor=L.+L.+Fultonauthor=K.+Chenauthor=H.+Schmidtauthor=J.+Kalicki-Veizerauthor=V.+J.+Magriniauthor=L.+Cookauthor=S.+D.+McGrathauthor=T.+L.+Vickeryauthor=M.+C.+Wendlauthor=S.+Heathauthor=M.+A.+Watsonauthor=D.+C.+Linkauthor=M.+H.+Tomassonauthor=W.+D.+Shannonauthor=J.+E.+Paytonauthor=S.+Kulkarniauthor=P.+Westerveltauthor=M.+J.+Walterauthor=T.+A.+Graubertauthor=E.+R.+Mardisauthor=R.+K.+Wilsonauthor=J.+F.+DiPersio&title=Clonal+evolution+in+relapsed+acute+myeloid+leukaemia+revealed+by+whole-genome+sequencing&doi=10.1038%2Fnature10738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing</span></div><div class="casAuthors">Ding, Li; Ley, Timothy J.; Larson, David E.; Miller, Christopher A.; Koboldt, Daniel C.; Welch, John S.; Ritchey, Julie K.; Young, Margaret A.; Lamprecht, Tamara; McLellan, Michael D.; McMichael, Joshua F.; Wallis, John W.; Lu, Charles; Shen, Dong; Harris, Christopher C.; Dooling, David J.; Fulton, Robert S.; Fulton, Lucinda L.; Chen, Ken; Schmidt, Heather; Kalicki-Veizer, Joelle; Magrini, Vincent J.; Cook, Lisa; McGrath, Sean D.; Vickery, Tammi L.; Wendl, Michael C.; Heath, Sharon; Watson, Mark A.; Link, Daniel C.; Tomasson, Michael H.; Shannon, William D.; Payton, Jacqueline E.; Kulkarni, Shashikant; Westervelt, Peter; Walter, Matthew J.; Graubert, Timothy A.; Mardis, Elaine R.; Wilson, Richard K.; DiPersio, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">481</span>
        (<span class="NLM_cas:issue">7382</span>),
    <span class="NLM_cas:pages">506-510</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The sequencing of AML genomes of eight patients before and after relapse reveals two major patterns of clonal evolution, with chemotherapy appearing to have a role in both patterns.  Most patients with acute myeloid leukemia (AML) die from progressive disease after relapse, which is assocd. with clonal evolution at the cytogenetic level.  To det. the mutational spectrum assocd. with relapse, we sequenced the primary tumor and relapse genomes from eight AML patients, and validated hundreds of somatic mutations using deep sequencing; this allowed us to define clonality and clonal evolution patterns precisely at relapse.  In addn. to discovering novel, recurrently mutated genes (for example, WAC, SMC3, DIS3,DDX41 and DAXX) in AML, we also found two major clonal evolution patterns during AML relapse: (1) the founding clone in the primary tumor gained mutations and evolved into the relapse clone, or (2) a subclone of the founding clone survived initial therapy, gained addnl. mutations and expanded at relapse.  In all cases, chemotherapy failed to eradicate the founding clone.  The comparison of relapse-specific vs. primary tumor mutations in all eight cases revealed an increase in transversions, probably due to DNA damage caused by cytotoxic chemotherapy.  These data demonstrate that AML relapse is assocd. with the addn. of new mutations and clonal evolution, which is shaped, in part, by the chemotherapy that the patients receive to establish and maintain remissions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkAtZJP8nda7Vg90H21EOLACvtfcHk0lgWsRsrmMSO5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsF2jtw%253D%253D&md5=572898dafabbe7f75054c2e07bd64a74</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnature10738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10738%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DL.%26aulast%3DLey%26aufirst%3DT.%2BJ.%26aulast%3DLarson%26aufirst%3DD.%2BE.%26aulast%3DMiller%26aufirst%3DC.%2BA.%26aulast%3DKoboldt%26aufirst%3DD.%2BC.%26aulast%3DWelch%26aufirst%3DJ.%2BS.%26aulast%3DRitchey%26aufirst%3DJ.%2BK.%26aulast%3DYoung%26aufirst%3DM.%2BA.%26aulast%3DLamprecht%26aufirst%3DT.%26aulast%3DMcLellan%26aufirst%3DM.%2BD.%26aulast%3DMcMichael%26aufirst%3DJ.%2BF.%26aulast%3DWallis%26aufirst%3DJ.%2BW.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DD.%26aulast%3DHarris%26aufirst%3DC.%2BC.%26aulast%3DDooling%26aufirst%3DD.%2BJ.%26aulast%3DFulton%26aufirst%3DR.%2BS.%26aulast%3DFulton%26aufirst%3DL.%2BL.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DSchmidt%26aufirst%3DH.%26aulast%3DKalicki-Veizer%26aufirst%3DJ.%26aulast%3DMagrini%26aufirst%3DV.%2BJ.%26aulast%3DCook%26aufirst%3DL.%26aulast%3DMcGrath%26aufirst%3DS.%2BD.%26aulast%3DVickery%26aufirst%3DT.%2BL.%26aulast%3DWendl%26aufirst%3DM.%2BC.%26aulast%3DHeath%26aufirst%3DS.%26aulast%3DWatson%26aufirst%3DM.%2BA.%26aulast%3DLink%26aufirst%3DD.%2BC.%26aulast%3DTomasson%26aufirst%3DM.%2BH.%26aulast%3DShannon%26aufirst%3DW.%2BD.%26aulast%3DPayton%26aufirst%3DJ.%2BE.%26aulast%3DKulkarni%26aufirst%3DS.%26aulast%3DWestervelt%26aufirst%3DP.%26aulast%3DWalter%26aufirst%3DM.%2BJ.%26aulast%3DGraubert%26aufirst%3DT.%2BA.%26aulast%3DMardis%26aufirst%3DE.%2BR.%26aulast%3DWilson%26aufirst%3DR.%2BK.%26aulast%3DDiPersio%26aufirst%3DJ.%2BF.%26atitle%3DClonal%2520evolution%2520in%2520relapsed%2520acute%2520myeloid%2520leukaemia%2520revealed%2520by%2520whole-genome%2520sequencing%26jtitle%3DNature%26date%3D2012%26volume%3D481%26issue%3D7382%26spage%3D506%26epage%3D510%26doi%3D10.1038%2Fnature10738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwable, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandts, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tickenbrock, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sargin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdel, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller-Tidow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serve, H.</span></span> <span> </span><span class="NLM_article-title">AML-associated FLT3 kinase domain mutations show signal transduction differences compared with FLT3 ITD mutations</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>106</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.1182/blood-2004-07-2942</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2004-07-2942" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=15769897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvVWjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=265-273&issue=1&author=C.+Choudharyauthor=J.+Schwableauthor=C.+Brandtsauthor=L.+Tickenbrockauthor=B.+Sarginauthor=T.+Kindlerauthor=T.+Fischerauthor=W.+E.+Berdelauthor=C.+Muller-Tidowauthor=H.+Serve&title=AML-associated+FLT3+kinase+domain+mutations+show+signal+transduction+differences+compared+with+FLT3+ITD+mutations&doi=10.1182%2Fblood-2004-07-2942"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations</span></div><div class="casAuthors">Choudhary, Chunaram; Schwaeble, Joachim; Brandts, Christian; Tickenbrock, Lara; Sargin, Buelent; Kindler, Thomas; Fischer, Thomas; Berdel, Wolfgang E.; Mueller-Tidow, Carsten; Serve, Hubert</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">265-273</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Activating mutations of Flt3 are found in approx. 1/3 of patients with acute myeloid leukemia (AML) and are an attractive drug target.  Two classes of Flt3 mutations occur: internal tandem duplications (ITDs) in the juxtamembrane and point mutations in the tyrosine kinase domain (TKD).  We and others have shown that Flt3-ITD induced aberrant signaling including strong activation of signal transducer and activator of transcription 5 (STAT5) and repression of CCAAT/estradiol-binding protein α (c/EBPα) and Pu.1.  Here, we compared the signaling properties of Flt3-ITD vs. Flt3-TKD in myeloid progenitor cells.  We demonstrate that Flt3-TKD mutations induced autonomous growth of 32D cells in suspension cultures.  However, in contrast to Flt3-ITD and similar to wild-type Flt3 (Flt3-WT), Flt3-TKD cannot support colony formation in semisolid media.  Also, in contrast to Flt3-ITD, neither Flt3-WT nor Flt3-TKD induced activation or induction of STAT5 target genes.  Flt3-TKD also failed to repress c/EBPα and Pu.1.  No significant differences were obsd. in receptor autophosphorylation and the phosphorylation of Erk-1 and -2, Akt, and Shc.  Importantly, TKD but not ITD mutations were a log power more sensitive toward the tyrosine kinase inhibitor protein kinase C 412 (PKC412) than Flt3-WT.  In conclusion, Flt3-ITD and Flt3-TKD mutations display differences in their signaling properties that could have important implications for their transforming capacity and for the design of mutation-specific therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK50hyr7RAoLVg90H21EOLACvtfcHk0lgWsRsrmMSO5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvVWjtrw%253D&md5=a70850e3d6fe00e8316cc8d79c2d3016</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1182%2Fblood-2004-07-2942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2004-07-2942%26sid%3Dliteratum%253Aachs%26aulast%3DChoudhary%26aufirst%3DC.%26aulast%3DSchwable%26aufirst%3DJ.%26aulast%3DBrandts%26aufirst%3DC.%26aulast%3DTickenbrock%26aufirst%3DL.%26aulast%3DSargin%26aufirst%3DB.%26aulast%3DKindler%26aufirst%3DT.%26aulast%3DFischer%26aufirst%3DT.%26aulast%3DBerdel%26aufirst%3DW.%2BE.%26aulast%3DMuller-Tidow%26aufirst%3DC.%26aulast%3DServe%26aufirst%3DH.%26atitle%3DAML-associated%2520FLT3%2520kinase%2520domain%2520mutations%2520show%2520signal%2520transduction%2520differences%2520compared%2520with%2520FLT3%2520ITD%2520mutations%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26issue%3D1%26spage%3D265%26epage%3D273%26doi%3D10.1182%2Fblood-2004-07-2942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandts, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohmer, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerke, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt-Arras, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdel, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller-Tidow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serve, H.</span></span> <span> </span><span class="NLM_article-title">Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">326</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2009.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.molcel.2009.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=19854140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFWht7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2009&pages=326-339&issue=2&author=C.+Choudharyauthor=J.+V.+Olsenauthor=C.+Brandtsauthor=J.+Coxauthor=P.+N.+Reddyauthor=F.+D.+Bohmerauthor=V.+Gerkeauthor=D.+E.+Schmidt-Arrasauthor=W.+E.+Berdelauthor=C.+Muller-Tidowauthor=M.+Mannauthor=H.+Serve&title=Mislocalized+activation+of+oncogenic+RTKs+switches+downstream+signaling+outcomes&doi=10.1016%2Fj.molcel.2009.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes</span></div><div class="casAuthors">Choudhary, Chunaram; Olsen, Jesper V.; Brandts, Christian; Cox, Juergen; Reddy, Pavankumar N. G.; Boehmer, Frank D.; Gerke, Volker; Schmidt-Arras, Dirk-E.; Berdel, Wolfgang E.; Mueller-Tidow, Carsten; Mann, Matthias; Serve, Hubert</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">326-339</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inappropriate activation of oncogenic kinases at intracellular locations is frequently obsd. in human cancers, but its effects on global signaling are incompletely understood.  Here, we show that the oncogenic mutant of Flt3 (Flt3-ITD), when localized at the endoplasmic reticulum (ER), aberrantly activates STAT5 and upregulates its targets, Pim-1/2, but fails to activate PI3K and MAPK signaling.  Conversely, membrane targeting of Flt3-ITD strongly activates the MAPK and PI3K pathways, with diminished phosphorylation of STAT5.  Global phosphoproteomics quantified 12,186 phosphorylation sites, confirmed compartment-dependent activation of these pathways and discovered many addnl. components of Flt3-ITD signaling.  The differential activation of Akt and Pim kinases by ER-retained Flt3-ITD helped to identify their putative targets.  Surprisingly, we find spatial regulation of tyrosine phosphorylation patterns of the receptor itself.  Thus, intracellular activation of RTKs by oncogenic mutations in the biosynthetic route may exploit cellular architecture to initiate aberrant signaling cascades, thus evading neg. regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrovh7aN2JkVrVg90H21EOLACvtfcHk0lhi6XavtyK0hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFWht7vL&md5=3312964e2c3ad2fde98220675c8fab96</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2009.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2009.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DChoudhary%26aufirst%3DC.%26aulast%3DOlsen%26aufirst%3DJ.%2BV.%26aulast%3DBrandts%26aufirst%3DC.%26aulast%3DCox%26aufirst%3DJ.%26aulast%3DReddy%26aufirst%3DP.%2BN.%26aulast%3DBohmer%26aufirst%3DF.%2BD.%26aulast%3DGerke%26aufirst%3DV.%26aulast%3DSchmidt-Arras%26aufirst%3DD.%2BE.%26aulast%3DBerdel%26aufirst%3DW.%2BE.%26aulast%3DMuller-Tidow%26aufirst%3DC.%26aulast%3DMann%26aufirst%3DM.%26aulast%3DServe%26aufirst%3DH.%26atitle%3DMislocalized%2520activation%2520of%2520oncogenic%2520RTKs%2520switches%2520downstream%2520signaling%2520outcomes%26jtitle%3DMol.%2520Cell%26date%3D2009%26volume%3D36%26issue%3D2%26spage%3D326%26epage%3D339%26doi%3D10.1016%2Fj.molcel.2009.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abboud, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appelbaum, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bixby, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fathi, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foran, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gore, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maness, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollyea, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shami, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickland, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieduwilt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogba, N.</span></span> <span> </span><span class="NLM_article-title">Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology</span>. <i>J. Natl. Compr. Cancer Network</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">926</span>– <span class="NLM_lpage">957</span>, <span class="refDoi"> DOI: 10.6004/jnccn.2017.0116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.6004%2Fjnccn.2017.0116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=28687581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BC1cjlsFGrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=926-957&issue=7&author=M.+R.+O%E2%80%99Donnellauthor=M.+S.+Tallmanauthor=C.+N.+Abboudauthor=J.+K.+Altmanauthor=F.+R.+Appelbaumauthor=D.+A.+Arberauthor=V.+Bhattauthor=D.+Bixbyauthor=W.+Blumauthor=S.+E.+Coutreauthor=M.+De+Limaauthor=A.+T.+Fathiauthor=M.+Fiorellaauthor=J.+M.+Foranauthor=S.+D.+Goreauthor=A.+C.+Hallauthor=P.+Kropfauthor=J.+Lancetauthor=L.+J.+Manessauthor=G.+Marcucciauthor=M.+G.+Martinauthor=J.+O.+Mooreauthor=R.+Olinauthor=D.+Pekerauthor=D.+A.+Pollyeaauthor=K.+Pratzauthor=F.+Ravandiauthor=P.+J.+Shamiauthor=R.+M.+Stoneauthor=S.+A.+Stricklandauthor=E.+S.+Wangauthor=M.+Wieduwiltauthor=K.+Gregoryauthor=N.+Ogba&title=Acute+myeloid+leukemia%2C+version+3.2017%2C+NCCN+clinical+practice+guidelines+in+oncology&doi=10.6004%2Fjnccn.2017.0116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology</span></div><div class="casAuthors">O'Donnell Margaret R; Tallman Martin S; Abboud Camille N; Altman Jessica K; Appelbaum Frederick R; Arber Daniel A; Bhatt Vijaya; Bixby Dale; Blum William; Coutre Steven E; De Lima Marcos; Fathi Amir T; Fiorella Melanie; Foran James M; Gore Steven D; Hall Aric C; Kropf Patricia; Lancet Jeffrey; Maness Lori J; Marcucci Guido; Martin Michael G; Moore Joseph O; Olin Rebecca; Peker Deniz; Pollyea Daniel A; Pratz Keith; Ravandi Farhad; Shami Paul J; Stone Richard M; Strickland Stephen A; Wang Eunice S; Wieduwilt Matthew; Gregory Kristina; Ogba Ndiya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Comprehensive Cancer Network : JNCCN</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">926-957</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States.  This portion of the NCCN Guidelines for AML focuses on management and provides recommendations on the workup, diagnostic evaluation, and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2aszz8ssiQXl8icjszYl0fW6udTcc2ebHwTsREmfqv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjlsFGrtA%253D%253D&md5=6d087e673a8e9556532bdede9151f2e2</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.6004%2Fjnccn.2017.0116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.6004%252Fjnccn.2017.0116%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DM.%2BR.%26aulast%3DTallman%26aufirst%3DM.%2BS.%26aulast%3DAbboud%26aufirst%3DC.%2BN.%26aulast%3DAltman%26aufirst%3DJ.%2BK.%26aulast%3DAppelbaum%26aufirst%3DF.%2BR.%26aulast%3DArber%26aufirst%3DD.%2BA.%26aulast%3DBhatt%26aufirst%3DV.%26aulast%3DBixby%26aufirst%3DD.%26aulast%3DBlum%26aufirst%3DW.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DDe%2BLima%26aufirst%3DM.%26aulast%3DFathi%26aufirst%3DA.%2BT.%26aulast%3DFiorella%26aufirst%3DM.%26aulast%3DForan%26aufirst%3DJ.%2BM.%26aulast%3DGore%26aufirst%3DS.%2BD.%26aulast%3DHall%26aufirst%3DA.%2BC.%26aulast%3DKropf%26aufirst%3DP.%26aulast%3DLancet%26aufirst%3DJ.%26aulast%3DManess%26aufirst%3DL.%2BJ.%26aulast%3DMarcucci%26aufirst%3DG.%26aulast%3DMartin%26aufirst%3DM.%2BG.%26aulast%3DMoore%26aufirst%3DJ.%2BO.%26aulast%3DOlin%26aufirst%3DR.%26aulast%3DPeker%26aufirst%3DD.%26aulast%3DPollyea%26aufirst%3DD.%2BA.%26aulast%3DPratz%26aufirst%3DK.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DShami%26aufirst%3DP.%2BJ.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DStrickland%26aufirst%3DS.%2BA.%26aulast%3DWang%26aufirst%3DE.%2BS.%26aulast%3DWieduwilt%26aufirst%3DM.%26aulast%3DGregory%26aufirst%3DK.%26aulast%3DOgba%26aufirst%3DN.%26atitle%3DAcute%2520myeloid%2520leukemia%252C%2520version%25203.2017%252C%2520NCCN%2520clinical%2520practice%2520guidelines%2520in%2520oncology%26jtitle%3DJ.%2520Natl.%2520Compr.%2520Cancer%2520Network%26date%3D2017%26volume%3D15%26issue%3D7%26spage%3D926%26epage%3D957%26doi%3D10.6004%2Fjnccn.2017.0116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dohner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estey, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimwade, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amadori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appelbaum, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dombret, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenaux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo-Coco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niederwieser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ossenkoppele, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sierra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tien, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowenberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomfield, C. D.</span></span> <span> </span><span class="NLM_article-title">Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">424</span>– <span class="NLM_lpage">447</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-08-733196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2016-08-733196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=27895058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BC2sjht1ShsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=424-447&issue=4&author=H.+Dohnerauthor=E.+Esteyauthor=D.+Grimwadeauthor=S.+Amadoriauthor=F.+R.+Appelbaumauthor=T.+Buchnerauthor=H.+Dombretauthor=B.+L.+Ebertauthor=P.+Fenauxauthor=R.+A.+Larsonauthor=R.+L.+Levineauthor=F.+Lo-Cocoauthor=T.+Naoeauthor=D.+Niederwieserauthor=G.+J.+Ossenkoppeleauthor=M.+Sanzauthor=J.+Sierraauthor=M.+S.+Tallmanauthor=H.+F.+Tienauthor=A.+H.+Weiauthor=B.+Lowenbergauthor=C.+D.+Bloomfield&title=Diagnosis+and+management+of+AML+in+adults%3A+2017+ELN+recommendations+from+an+international+expert+panel&doi=10.1182%2Fblood-2016-08-733196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel</span></div><div class="casAuthors">Dohner Hartmut; Estey Elihu; Appelbaum Frederick R; Grimwade David; Amadori Sergio; Lo-Coco Francesco; Buchner Thomas; Dombret Herve; Ebert Benjamin L; Fenaux Pierre; Larson Richard A; Levine Ross L; Tallman Martin S; Naoe Tomoki; Niederwieser Dietger; Ossenkoppele Gert J; Sanz Miguel; Sierra Jorge; Tien Hwei-Fang; Wei Andrew H; Wei Andrew H; Lowenberg Bob; Bloomfield Clara D</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">424-447</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML.  Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations.  The recommendations include a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTjTcxQJDkes9NTrvPZP1IpfW6udTcc2ebHwTsREmfqv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjht1ShsQ%253D%253D&md5=9dc44be2424ca51a6083c9e4edd34238</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-08-733196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-08-733196%26sid%3Dliteratum%253Aachs%26aulast%3DDohner%26aufirst%3DH.%26aulast%3DEstey%26aufirst%3DE.%26aulast%3DGrimwade%26aufirst%3DD.%26aulast%3DAmadori%26aufirst%3DS.%26aulast%3DAppelbaum%26aufirst%3DF.%2BR.%26aulast%3DBuchner%26aufirst%3DT.%26aulast%3DDombret%26aufirst%3DH.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26aulast%3DFenaux%26aufirst%3DP.%26aulast%3DLarson%26aufirst%3DR.%2BA.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DLo-Coco%26aufirst%3DF.%26aulast%3DNaoe%26aufirst%3DT.%26aulast%3DNiederwieser%26aufirst%3DD.%26aulast%3DOssenkoppele%26aufirst%3DG.%2BJ.%26aulast%3DSanz%26aufirst%3DM.%26aulast%3DSierra%26aufirst%3DJ.%26aulast%3DTallman%26aufirst%3DM.%2BS.%26aulast%3DTien%26aufirst%3DH.%2BF.%26aulast%3DWei%26aufirst%3DA.%2BH.%26aulast%3DLowenberg%26aufirst%3DB.%26aulast%3DBloomfield%26aufirst%3DC.%2BD.%26atitle%3DDiagnosis%2520and%2520management%2520of%2520AML%2520in%2520adults%253A%25202017%2520ELN%2520recommendations%2520from%2520an%2520international%2520expert%2520panel%26jtitle%3DBlood%26date%3D2017%26volume%3D129%26issue%3D4%26spage%3D424%26epage%3D447%26doi%3D10.1182%2Fblood-2016-08-733196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyoi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyawaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagasaki, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimazaki, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motoji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeshita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoe, T.</span></span> <span> </span><span class="NLM_article-title">Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>97</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2434</span>– <span class="NLM_lpage">2439</span>, <span class="refDoi"> DOI: 10.1182/blood.V97.8.2434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood.V97.8.2434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=11290608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFOgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2001&pages=2434-2439&issue=8&author=Y.+Yamamotoauthor=H.+Kiyoiauthor=Y.+Nakanoauthor=R.+Suzukiauthor=Y.+Koderaauthor=S.+Miyawakiauthor=N.+Asouauthor=K.+Kuriyamaauthor=F.+Yagasakiauthor=C.+Shimazakiauthor=H.+Akiyamaauthor=K.+Saitoauthor=M.+Nishimuraauthor=T.+Motojiauthor=K.+Shinagawaauthor=A.+Takeshitaauthor=H.+Saitoauthor=R.+Uedaauthor=R.+Ohnoauthor=T.+Naoe&title=Activating+mutation+of+D835+within+the+activation+loop+of+FLT3+in+human+hematologic+malignancies&doi=10.1182%2Fblood.V97.8.2434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies</span></div><div class="casAuthors">Yamamoto, Yukiya; Kiyoi, Hitoshi; Nakano, Yasuyuki; Suzuki, Ritsuro; Kodera, Yoshihisa; Miyawaki, Shuichi; Asou, Norio; Kuriyama, Kazutaka; Yagasaki, Fumiharu; Shimazaki, Chihiro; Akiyama, Hideki; Saito, Kenji; Nishimura, Miki; Motoji, Toshiko; Shinagawa, Katsuji; Takeshita, Akihiro; Saito, Hidehiko; Ueda, Ryuzo; Ohno, Ryuzo; Naoe, Tomoki</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2434-2439</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Mutations of receptor tyrosine kinases are implicated in the constitutive activation and development of human malignancy.  An internal tandem duplication (ITD) of the juxtamembrane (JM) domain-coding sequence of the FLT3 gene (FLT3/ITD) is found in 20% of patients with acute myeloid leukemia (AML) and is strongly assocd. with leukocytosis and a poor prognosis.  On the other hand, mutations of the c-KIT gene, which have been found in mast cell leukemia and AML, are clustered in 2 distinct regions, the JM domain and D816 within the activation loop.  This study was designed to analyze the mutation of D835 of FLT3, which corresponds to D816 of c-KIT, in a large series of human hematol. malignancies.  Several kinds of missense mutations were found in 30 of the 429 (7.0%) AML cases, 1 of the 29 (3.4%) myelodysplastic syndrome (MDS) cases, and 1 of the 36 (2.8%) acute lymphocytic leukemia patients.  The D835Y mutation was most frequently found (22 of the 32 D835 mutations), followed by the D835V (5), and D835H (1), D835E (1), and D835N (1) mutations.  Of note is that D835 mutations occurred independently of FLT3/ITD.  An anal. in the 201 patients newly diagnosed with AML (excluding M3) revealed that, in contrast to the FLT3/ITD mutation, D835 mutations were not significantly related to the leukocytosis, but tended to worsen disease-free survival.  All D835-mutant FLT3 were constitutively tyrosine-phosphorylated and transformed 32D cells, suggesting these mutations were constitutively active.  These results demonstrate that the FLT3 gene is the target most frequently mutated to become constitutively active in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrydJnPT47K17Vg90H21EOLACvtfcHk0liBDwdOQCLQIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFOgtbk%253D&md5=646e1b1a04c570f4094e7d83723d47fb</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1182%2Fblood.V97.8.2434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V97.8.2434%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DKodera%26aufirst%3DY.%26aulast%3DMiyawaki%26aufirst%3DS.%26aulast%3DAsou%26aufirst%3DN.%26aulast%3DKuriyama%26aufirst%3DK.%26aulast%3DYagasaki%26aufirst%3DF.%26aulast%3DShimazaki%26aufirst%3DC.%26aulast%3DAkiyama%26aufirst%3DH.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DNishimura%26aufirst%3DM.%26aulast%3DMotoji%26aufirst%3DT.%26aulast%3DShinagawa%26aufirst%3DK.%26aulast%3DTakeshita%26aufirst%3DA.%26aulast%3DSaito%26aufirst%3DH.%26aulast%3DUeda%26aufirst%3DR.%26aulast%3DOhno%26aufirst%3DR.%26aulast%3DNaoe%26aufirst%3DT.%26atitle%3DActivating%2520mutation%2520of%2520D835%2520within%2520the%2520activation%2520loop%2520of%2520FLT3%2520in%2520human%2520hematologic%2520malignancies%26jtitle%3DBlood%26date%3D2001%26volume%3D97%26issue%3D8%26spage%3D2434%26epage%3D2439%26doi%3D10.1182%2Fblood.V97.8.2434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abu-Duhier, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodeve, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Care, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peake, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, J. T.</span></span> <span> </span><span class="NLM_article-title">Identification of novel FLT3 Asp835 mutations in adult acute myeloid leukemia</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>113</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">983</span>– <span class="NLM_lpage">988</span>, <span class="refDoi"> DOI: 10.1046/j.1365-2141.2001.02850.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1046%2Fj.1365-2141.2001.02850.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=11442493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlslalsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2001&pages=983-988&issue=4&author=F.+M.+Abu-Duhierauthor=A.+C.+Goodeveauthor=G.+A.+Wilsonauthor=R.+S.+Careauthor=I.+R.+Peakeauthor=J.+T.+Reilly&title=Identification+of+novel+FLT3+Asp835+mutations+in+adult+acute+myeloid+leukemia&doi=10.1046%2Fj.1365-2141.2001.02850.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia</span></div><div class="casAuthors">Abu-Duhier, F. M.; Goodeve, A. C.; Wilson, G. A.; Care, R. S.; Peake, I. R.; Reilly, J. T.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">983-988</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">Genomic DNA from 97 cases of adult de novo acute myeloid leukemia (AML) was screened using polymerase chain reaction (PCR) and conformation-sensitive gel electrophoresis (CSGE) for FLT3 exon 20 mutations.  Initial sequencing of four cases, representing the spectrum of CSGE abnormalities, revealed changes affecting codon Asp835 in three cases and also an intron 20 A to G change.  In order to identify all possible Asp835 alterations, as well as the frequency of the intronic change nucleotide 2541+57 A→G, the patient PCR products were digested with EcoRV and NlaIII resp.  Seven cases (7.2%) possessed a mutation affecting Asp835; these were identified, following DNA sequencing, as Asp835Tyr (n = 5), Asp835His (n = 1) and Asp835del (n = 1).  Alterations affecting Asp835 were not found in 80 normal control DNA samples.  In contrast, the nucleotide 2541+57 A→G change was shown to be a polymorphism, with an allelic frequency of 0.24 for the G and 0.76 for the A allele.  This study reports, for the first time, point mutations in the human FLT3 gene that, because of their homol. with other class III receptor tyrosine kinase mutations, probably result in constitutive activation of the receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyMMv-RBFxCbVg90H21EOLACvtfcHk0liBDwdOQCLQIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlslalsbg%253D&md5=7989d20d19f76954dbeaf2fde89d8add</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2141.2001.02850.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2141.2001.02850.x%26sid%3Dliteratum%253Aachs%26aulast%3DAbu-Duhier%26aufirst%3DF.%2BM.%26aulast%3DGoodeve%26aufirst%3DA.%2BC.%26aulast%3DWilson%26aufirst%3DG.%2BA.%26aulast%3DCare%26aufirst%3DR.%2BS.%26aulast%3DPeake%26aufirst%3DI.%2BR.%26aulast%3DReilly%26aufirst%3DJ.%2BT.%26atitle%3DIdentification%2520of%2520novel%2520FLT3%2520Asp835%2520mutations%2520in%2520adult%2520acute%2520myeloid%2520leukemia%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2001%26volume%3D113%26issue%3D4%26spage%3D983%26epage%3D988%26doi%3D10.1046%2Fj.1365-2141.2001.02850.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daver, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span> <span> </span><span class="NLM_article-title">Targeting FLT3 mutations in AML: review of current knowledge and evidence</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1038/s41375-018-0357-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fs41375-018-0357-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=30651634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVyrsbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=299-312&issue=2&author=N.+Daverauthor=R.+F.+Schlenkauthor=N.+H.+Russellauthor=M.+J.+Levis&title=Targeting+FLT3+mutations+in+AML%3A+review+of+current+knowledge+and+evidence&doi=10.1038%2Fs41375-018-0357-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting FLT3 mutations in AML: review of current knowledge and evidence</span></div><div class="casAuthors">Daver, Naval; Schlenk, Richard F.; Russell, Nigel H.; Levis, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">299-312</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Genomic investigations of acute myeloid leukemia (AML) have demonstrated that several genes are recurrently mutated, leading to new genomic classifications, predictive biomarkers, and new therapeutic targets.  Mutations of the FMS-like tyrosine kinase 3 (FLT3) gene occur in approx. 30% of all AML cases, with the internal tandem duplication (ITD) representing the most common type of FLT3 mutation (FLT3-ITD; approx. 25% of all AML cases).  FLT3-ITD is a common driver mutation that presents with a high leukemic burden and confers a poor prognosis in patients with AML.  The prognostic value of a FLT3 mutation in the tyrosine kinase domain (FLT3-TKD), which has a lower incidence in AML (approx. 7-10% of all cases), is uncertain.  Accumulating evidence demonstrates that FLT3 mutational status evolves throughout the disease continuum.  This so-called clonal evolution, together with the identification of FLT3-ITD as a neg. prognostic marker, serves to highlight the importance of FLT3-ITD testing at diagnosis and again at relapse.  Earlier identification of FLT3 mutations will help provide a better understanding of the patient's disease and enable targeted treatment that may help patients achieve longer and more durable remissions.  First-generation FLT3 inhibitors developed for clin. use are broad-spectrum, multikinase inhibitors; however, next-generation FLT3 inhibitors are more specific, more potent, and have fewer toxicities assocd. with off-target effects.  Primary and secondary acquired resistance to FLT3 inhibitors remains a challenge and provides a rationale for combining FLT3 inhibitors with other therapies, both conventional and investigational.  This review focuses on the pathol. and prognostic role of FLT3 mutations in AML, clin. classification of the disease, recent progress with next-generation FLT3 inhibitors, and mechanisms of resistance to FLT3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjK_p2nZ_9j7Vg90H21EOLACvtfcHk0lirrTWpVwtkGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVyrsbbI&md5=25ea007d2f7b670aaddeb02866f15c69</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fs41375-018-0357-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-018-0357-9%26sid%3Dliteratum%253Aachs%26aulast%3DDaver%26aufirst%3DN.%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26aulast%3DRussell%26aufirst%3DN.%2BH.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26atitle%3DTargeting%2520FLT3%2520mutations%2520in%2520AML%253A%2520review%2520of%2520current%2520knowledge%2520and%2520evidence%26jtitle%3DLeukemia%26date%3D2019%26volume%3D33%26issue%3D2%26spage%3D299%26epage%3D312%26doi%3D10.1038%2Fs41375-018-0357-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balderes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span> <span> </span><span class="NLM_article-title">Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1432</span>– <span class="NLM_lpage">1438</span>, <span class="refDoi"> DOI: 10.1038/sj.leu.2403825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fsj.leu.2403825" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=15931264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtlSjs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=1432-1438&issue=8&author=B.+Williamsauthor=A.+Atkinsauthor=H.+Zhangauthor=D.+Luauthor=X.+Jimenezauthor=H.+Liauthor=M.+N.+Wangauthor=D.+Ludwigauthor=P.+Balderesauthor=L.+Witteauthor=Y.+Liauthor=Z.+Zhu&title=Cell-based+selection+of+internalizing+fully+human+antagonistic+antibodies+directed+against+FLT3+for+suppression+of+leukemia+cell+growth&doi=10.1038%2Fsj.leu.2403825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth</span></div><div class="casAuthors">Williams, B.; Atkins, A.; Zhang, H.; Lu, D.; Jimenez, X.; Li, H.; Wang, M-N.; Ludwig, D.; Balderes, P.; Witte, L.; Li, Y.; Zhu, Z.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1432-1438</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">FMS-like tyrosine kinase 3 (FLT3) receptor is highly expressed in an array of hematol. malignancies including ∼90% of acute myelogenous leukemia (AML).  Ligand stimulation of the receptor promotes the survival and proliferation of leukemia cells.  Strategies targeting FLT3 using monoclonal antibodies may therefore constitute an effective therapeutic approach for these leukemia.  Towards this, the authors selected a naive antibody phage display library on both recombinant FLT3 receptor protein and FLT3-expressing leukemia cells using a tailored selection scheme that was designed to isolate antagonistic phage antibodies that not only interfere with receptor/ligand binding but also trigger receptor internalization upon cell surface binding.  Phage antibodies were screened first for their ability to bind to cell surface receptor and induce receptor internalization, followed by their activity in blocking ligand-receptor interaction and neutralizing ligand-stimulated receptor activation and cell proliferation.  The authors identified three fully human antibodies, EB10, A2IN, and D4-3, which bound specifically to both sol. and cell surface-expressed FLT3.  All three antibodies were shown to be internalized upon binding to cell surface-expressed receptor in a time-dependent fashion.  EB10 and D4-3 blocked ligand binding to the receptor with IC50s of 14 and 7 nM, resp.  Further, EB10 and D4-3 inhibited FLT3 ligand-induced receptor phosphorylation and cell proliferation in EOL-1 leukemia cells.  Taken together, these results suggest that both EB10 and D4-3 may represent excellent therapeutic candidates for the treatment of FLT3-expressing human leukemia, both as unmodified antibodies and as conjugates of cytotoxic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxE-FdjIl3s7Vg90H21EOLACvtfcHk0lirrTWpVwtkGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtlSjs7o%253D&md5=a331d3fb53ce026cb97dda46eab46015</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2403825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2403825%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DB.%26aulast%3DAtkins%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DJimenez%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DM.%2BN.%26aulast%3DLudwig%26aufirst%3DD.%26aulast%3DBalderes%26aufirst%3DP.%26aulast%3DWitte%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DZ.%26atitle%3DCell-based%2520selection%2520of%2520internalizing%2520fully%2520human%2520antagonistic%2520antibodies%2520directed%2520against%2520FLT3%2520for%2520suppression%2520of%2520leukemia%2520cell%2520growth%26jtitle%3DLeukemia%26date%3D2005%26volume%3D19%26issue%3D8%26spage%3D1432%26epage%3D1438%26doi%3D10.1038%2Fsj.leu.2403825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larrosa-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, M. R.</span></span> <span> </span><span class="NLM_article-title">FLT3 inhibitors in acute myeloid leukemia: current status and future directions</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">991</span>– <span class="NLM_lpage">1001</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F1535-7163.MCT-16-0876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=28576946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Shsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=991-1001&issue=6&author=M.+Larrosa-Garciaauthor=M.+R.+Baer&title=FLT3+inhibitors+in+acute+myeloid+leukemia%3A+current+status+and+future+directions&doi=10.1158%2F1535-7163.MCT-16-0876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions</span></div><div class="casAuthors">Larrosa-Garcia, Maria; Baer, Maria R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">991-1001</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase fms-like tyrosine kinase 3 (FLT3), involved in regulating survival, proliferation, and differentiation of hematopoietic stem/progenitor cells, is expressed on acute myeloid leukemia (AML) cells in most patients.  Mutations of FLT3 resulting in constitutive signaling are common in AML, including internal tandem duplication (ITD) in the juxtamembrane domain in 25% of patients and point mutations in the tyrosine kinase domain in 5%.  Patients with AML with FLT3-ITD have a high relapse rate and short relapse-free and overall survival after chemotherapy and after transplant.  A no. of inhibitors of FLT3 signaling have been identified and are in clin. trials, both alone and with chemotherapy, with the goal of improving clin. outcomes in patients with AML with FLT3 mutations.  While inhibitor monotherapy produces clin. responses, they are usually incomplete and transient, and resistance develops rapidly.  Diverse combination therapies have been suggested to potentiate the efficacy of FLT3 inhibitors and to prevent development of resistance or overcome resistance.  Combinations with epigenetic therapies, proteasome inhibitors, downstream kinase inhibitors, phosphatase activators, and other drugs that alter signaling are being explored.  This review summarizes the current status of translational and clin. research on FLT3 inhibitors in AML, and discusses novel combination approaches.  Mol Cancer Ther; 16(6); 991-1001. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvp5t3cNnh3bVg90H21EOLACvtfcHk0lirrTWpVwtkGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Shsbs%253D&md5=7105f50a6f38c3ce41be4adb82a62413</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0876%26sid%3Dliteratum%253Aachs%26aulast%3DLarrosa-Garcia%26aufirst%3DM.%26aulast%3DBaer%26aufirst%3DM.%2BR.%26atitle%3DFLT3%2520inhibitors%2520in%2520acute%2520myeloid%2520leukemia%253A%2520current%2520status%2520and%2520future%2520directions%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26issue%3D6%26spage%3D991%26epage%3D1001%26doi%3D10.1158%2F1535-7163.MCT-16-0876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J. J.</span></span> <span> </span><span class="NLM_article-title">Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">409</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1021/jm0608107</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0608107" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Cmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=409-424&issue=3&author=J.+J.+Liao&title=Molecular+recognition+of+protein+kinase+binding+pockets+for+design+of+potent+and+selective+kinase+inhibitors&doi=10.1021%2Fjm0608107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors</span></div><div class="casAuthors">Liao, Jeffrey Jie-Lou</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">409-424</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Many kinase inhibitors have failed in preclin. or clin. development because of the lack of such selectivity that induces intolerable side effects, mostly because the catalytic cleft is highly conserved in sequence and conformation.  Systematic anal. of the crystal structures of protein kinases can offer insight into the design of highly selective kinase inhibitors to overcome these effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroDTl2SBUfbbVg90H21EOLACvtfcHk0lirrTWpVwtkGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Cmsg%253D%253D&md5=77542d3ba589bd834a0d2b97a24eea05</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm0608107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0608107%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DJ.%2BJ.%26atitle%3DMolecular%2520recognition%2520of%2520protein%2520kinase%2520binding%2520pockets%2520for%2520design%2520of%2520potent%2520and%2520selective%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26issue%3D3%26spage%3D409%26epage%3D424%26doi%3D10.1021%2Fjm0608107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghiaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of resistance to FLT3 inhibitors and the role of the bone marrow microenvironment</span>. <i>Hematol Oncol Clin North Am.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.1016/j.hoc.2017.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.hoc.2017.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=28673395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BC1cjktFCmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=681-692&issue=4&author=G.+Ghiaurauthor=M.+Levis&title=Mechanisms+of+resistance+to+FLT3+inhibitors+and+the+role+of+the+bone+marrow+microenvironment&doi=10.1016%2Fj.hoc.2017.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment</span></div><div class="casAuthors">Ghiaur Gabriel; Levis Mark</div><div class="citationInfo"><span class="NLM_cas:title">Hematology/oncology clinics of North America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">681-692</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The presence of FLT3 mutations in acute myeloid leukemia (AML) carries a particularly poor prognosis, making the development of FLT3 inhibitors an imperative goal.  The last decade has seen an abundance of clinical trials using these drugs alone or in combination with chemotherapy.  This culminated with the recent approval by the US Food and Drug Administration of Midostaurin for the treatment of FLT3-mutated AML.  Initial success has been followed by the emergence of clinical resistance.  Although novel FLT3 inhibitors are being developed, studies into mechanisms of resistance raise hope of new strategies to prevent emergence of resistance and eliminate minimal residual disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRBg2yQ4XqfsTEC-75aqa5AfW6udTcc2eZqfKIjpdH1ULntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjktFCmtg%253D%253D&md5=8b20010c4ef8fa3be85964287b6bb74e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.hoc.2017.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.hoc.2017.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DGhiaur%26aufirst%3DG.%26aulast%3DLevis%26aufirst%3DM.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520FLT3%2520inhibitors%2520and%2520the%2520role%2520of%2520the%2520bone%2520marrow%2520microenvironment%26jtitle%3DHematol%2520Oncol%2520Clin%2520North%2520Am.%26date%3D2017%26volume%3D31%26issue%3D4%26spage%3D681%26epage%3D692%26doi%3D10.1016%2Fj.hoc.2017.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daver, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopleva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span> <span> </span><span class="NLM_article-title">Secondary mutations as mediators of resistance to targeted therapy in leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>125</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">3236</span>– <span class="NLM_lpage">3245</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-10-605808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2014-10-605808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=25795921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVOru73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=3236-3245&issue=21&author=N.+Daverauthor=J.+Cortesauthor=F.+Ravandiauthor=K.+P.+Patelauthor=J.+A.+Burgerauthor=M.+Konoplevaauthor=H.+Kantarjian&title=Secondary+mutations+as+mediators+of+resistance+to+targeted+therapy+in+leukemia&doi=10.1182%2Fblood-2014-10-605808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Secondary mutations as mediators of resistance to targeted therapy in leukemia</span></div><div class="casAuthors">Daver, Naval; Cortes, Jorge; Ravandi, Farhad; Patel, Keyur P.; Burger, Jan A.; Konopleva, Marina; Kantarjian, Hagop</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3236-3245</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The advent of small mol.-based targeted therapy has improved the treatment of both acute and chronic leukemias.  Resistance to small mol. inhibitors has emerged as a common theme.  The most frequent mode of acquired resistance is the acquisition of point mutations in the kinase domain.  FLT3 inhibitors have improved response rates in FLT3-mutated acute myeloid leukemia (AML).  The occurrence of the ATP-binding site and activation loop mutations confers varying degrees of resistance to the individual FLT3 inhibitors.  Second-generation FLT3 inhibitors such as crenolanib may overcome the resistance of these mutations.  Furthermore, nonmutational mechanisms of resistance such as prosurvival pathways and bone marrow signaling may be upregulated in FLT3 inhibitor-resistant AML with secondary kinase domain mutations.  More recently, point mutations conferring resistance to the Bruton tyrosine kinase inhibitor ibrutinib in chronic lymphocytic leukemia, arsenic trioxide in acute promyelocytic leukemia, and the BH3-mimetic ABT199 in lymphoma have been identified.  In chronic myeloid leukemia, the emergence of tyrosine kinase domain mutations has historically been the dominant mechanism of resistance.  The early identification of secondary point mutations and their downstream effects along with the development of second- or third-generation inhibitors and rationally designed small mol. combinations are potential strategies to overcome mutation-mediated resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN52qqT0ZLQrVg90H21EOLACvtfcHk0ljmWgN-6nfF5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVOru73N&md5=03a65603c787ea7ee0957398bfd64c0c</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-10-605808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-10-605808%26sid%3Dliteratum%253Aachs%26aulast%3DDaver%26aufirst%3DN.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DPatel%26aufirst%3DK.%2BP.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DKantarjian%26aufirst%3DH.%26atitle%3DSecondary%2520mutations%2520as%2520mediators%2520of%2520resistance%2520to%2520targeted%2520therapy%2520in%2520leukemia%26jtitle%3DBlood%26date%3D2015%26volume%3D125%26issue%3D21%26spage%3D3236%26epage%3D3245%26doi%3D10.1182%2Fblood-2014-10-605808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elshoury, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przespolewski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. S.</span></span> <span> </span><span class="NLM_article-title">Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors</span>. <i>Expert Rev. Anticancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">286</span>, <span class="refDoi"> DOI: 10.1080/14737140.2019.1573679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1080%2F14737140.2019.1573679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=30681373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFynt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=273-286&issue=3&author=A.+Elshouryauthor=A.+Przespolewskiauthor=J.+Baronauthor=E.+S.+Wang&title=Advancing+treatment+of+acute+myeloid+leukemia%3A+the+future+of+FLT3+inhibitors&doi=10.1080%2F14737140.2019.1573679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors</span></div><div class="casAuthors">Elshoury, Amro; Przespolewski, Amanda; Baron, Jeffrey; Wang, Eunice S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-286</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Mutations of the FLT3 gene are among most common genetic abnormalities occurring in acute myeloid leukemia (AML) and are assocd. with dismal prognosis.  Tremendous effort has been devoted to developing clin. effective FLT3 inhibitors.  First generation inhibitors consisted of multi-kinase inhibitors (sorafenib, lestaurtinib, midostaurin), which blocked FLT3 as well as multiple other kinase receptors.  The failure of these agents to induce durable responses led to the development of second generation FLT3 tyrosine kinase inhibitors (quizartinib, crenolinib, gilteritinib) exhibiting high potency and specificity for mutant FLT3 kinases and sustained invivo FLT3 inhibition.  These myriad FLT3 inhibitors possess diverse kinase inhibitory properties, toxicity profiles, and pharmacokinetics, which impact on their incorporation into therapeutic regimens.: This article reviews the medical literature on current and future FLT3 inhibitors for AML therapy.  We provide algorithms for which kinase inhibitor should be utilized for different FLT3 mutations (ITD±TKD) and clin. scenarios (de novo, relapsed/refractory, fit vs. unfit) and discuss novel FLT3 targeted therapeutic approaches.: Integration of clin. active FLT3 inhibitors into all stages of therapy for all individuals with FLT3 mutant AML promises to significantly improve outcomes for this poor prognosis disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWsY02GcCSXLVg90H21EOLACvtfcHk0ljmWgN-6nfF5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFynt7s%253D&md5=3b0ee9e9837357f4a82e138151b47c13</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1080%2F14737140.2019.1573679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737140.2019.1573679%26sid%3Dliteratum%253Aachs%26aulast%3DElshoury%26aufirst%3DA.%26aulast%3DPrzespolewski%26aufirst%3DA.%26aulast%3DBaron%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DE.%2BS.%26atitle%3DAdvancing%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%253A%2520the%2520future%2520of%2520FLT3%2520inhibitors%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2019%26volume%3D19%26issue%3D3%26spage%3D273%26epage%3D286%26doi%3D10.1080%2F14737140.2019.1573679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leahy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span> <span> </span><span class="NLM_article-title">Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1038/leu.2012.191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fleu.2012.191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=22858906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVCgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=48-55&issue=1&author=A.+B.+Williamsauthor=B.+Nguyenauthor=L.+Liauthor=P.+Brownauthor=M.+Levisauthor=D.+Leahyauthor=D.+Small&title=Mutations+of+FLT3%2FITD+confer+resistance+to+multiple+tyrosine+kinase+inhibitors&doi=10.1038%2Fleu.2012.191"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors</span></div><div class="casAuthors">Williams, A. B.; Nguyen, B.; Li, L.; Brown, P.; Levis, M.; Leahy, D.; Small, D.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-55</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">FMS-like tyrosine kinase 3 (FLT3) normally functions in the survival/proliferation of hematopoietic stem/progenitor cells, but its constitutive activation by internal tandem duplication (ITD) mutations correlates with a poor prognosis in AML.  The development of FLT3 tyrosine kinase inhibitors (TKI) is a promising strategy, but resistance that arises during the course of treatment caused by secondary mutations within the mutated gene itself poses a significant challenge.  In an effort to predict FLT3 resistance mutations that might develop in patients, we used satn. mutagenesis of FLT3/ITD followed by selection of transfected cells in FLT3 TKI.  We identified F621L, A627P, F691L and Y842C mutations in FLT3/ITD that confer varying levels of resistance to FLT3 TKI.  Western blotting confirmed that some FLT3 TKI were ineffective at inhibiting FLT3 autophosphorylation and signaling through MAP kinase, STAT5 and AKT in some mutants.  Balb/c mice transplanted with the FLT3/ITD Y842C mutation confirmed resistance to sorafenib in vivo but not to lestaurtinib.  These results indicate a growing no. of FLT3 mutations that are likely to be encountered in patients.  Such knowledge, combined with known remaining sensitivity to other FLT3 TKI, will be important to establish as secondary drug treatments that can be substituted when these mutants are encountered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPSwpRBLJiTbVg90H21EOLACvtfcHk0lh1u9Qwwp__Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVCgsA%253D%253D&md5=fcdbe55897826bb883841aad04b6ebda</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fleu.2012.191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2012.191%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DA.%2BB.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DBrown%26aufirst%3DP.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DLeahy%26aufirst%3DD.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DMutations%2520of%2520FLT3%252FITD%2520confer%2520resistance%2520to%2520multiple%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DLeukemia%26date%3D2013%26volume%3D27%26issue%3D1%26spage%3D48%26epage%3D55%26doi%3D10.1038%2Fleu.2012.191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, R. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z. H.</span></span> <span> </span><span class="NLM_article-title">Small-molecule Fms-like tyrosine kinase 3 inhibitors: an attractive and efficient method for the treatment of acute myeloid leukemia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">12403</span>– <span class="NLM_lpage">12428</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00696</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00696" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlOqu7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=12403-12428&issue=21&author=Y.+Zhongauthor=R.+Z.+Qiuauthor=S.+L.+Sunauthor=C.+Zhaoauthor=T.+Y.+Fanauthor=M.+Chenauthor=N.+G.+Liauthor=Z.+H.+Shi&title=Small-molecule+Fms-like+tyrosine+kinase+3+inhibitors%3A+an+attractive+and+efficient+method+for+the+treatment+of+acute+myeloid+leukemia&doi=10.1021%2Facs.jmedchem.0c00696"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia</span></div><div class="casAuthors">Zhong, Yue; Qiu, Run-Ze; Sun, Shan-Liang; Zhao, Chao; Fan, Tian-Yuan; Chen, Min; Li, Nian-Guang; Shi, Zhi-Hao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">12403-12428</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Fms-like tyrosine kinase 3 (FLT3) is an important member of the class III receptor tyrosine kinase (RTK) family, which is involved in the proliferation of hematopoietic cells and lymphocytes.  In recent years, increasing evidence have demonstrated that the activation and mutation of FLT3 is closely implicated in the occurrence and development of acute myeloid leukemia (AML).  The exploration of small-mol. inhibitors targeting FLT3 has aroused wide interest of pharmaceutical chemists and is expected to bring new hope for AML therapy.  In this review, we specifically highlighted FLT3 mediated JAK/STAT, RAS/MAPK, and PI3K/AKT/mTOR signaling.  The structural properties and biol. activities of representative FLT3 inhibitors reported from 2014 to the present were also summarized.  In addn., the major challenges in the current advance of novel FLT3 inhibitors were further analyzed, with the aim to guide future drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8JNly0RbiqrVg90H21EOLACvtfcHk0lh1u9Qwwp__Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlOqu7rP&md5=7fd352a4bb173b1303302dfa58707b56</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00696&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00696%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DQiu%26aufirst%3DR.%2BZ.%26aulast%3DSun%26aufirst%3DS.%2BL.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DFan%26aufirst%3DT.%2BY.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DN.%2BG.%26aulast%3DShi%26aufirst%3DZ.%2BH.%26atitle%3DSmall-molecule%2520Fms-like%2520tyrosine%2520kinase%25203%2520inhibitors%253A%2520an%2520attractive%2520and%2520efficient%2520method%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D21%26spage%3D12403%26epage%3D12428%26doi%3D10.1021%2Facs.jmedchem.0c00696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiyoi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawashima, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span> <span> </span><span class="NLM_article-title">FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>111</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">312</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1111/cas.14274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1111%2Fcas.14274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=31821677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFSjt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2020&pages=312-322&issue=2&author=H.+Kiyoiauthor=N.+Kawashimaauthor=Y.+Ishikawa&title=FLT3+mutations+in+acute+myeloid+leukemia%3A+Therapeutic+paradigm+beyond+inhibitor+development&doi=10.1111%2Fcas.14274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development</span></div><div class="casAuthors">Kiyoi, Hitoshi; Kawashima, Naomi; Ishikawa, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">312-322</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  FMS-like tyrosine kinase 3 (FLT3) is a type III receptor tyrosine kinase that plays an important role in hematopoietic cell survival, proliferation and differentiation.  The most clin. important point is that mutation of the FLT3 gene is the most frequent genetic alteration and a poor prognostic factor in acute myeloid leukemia (AML) patients.  There are two major types of FLT3 mutations: internal tandem duplication mutations in the juxtamembrane domain (FLT3-ITD) and point mutations or deletion in the tyrosine kinase domain (FLT3-TKD).  Both mutant FLT3 mols. are activated through ligand-independent dimerization and trans-phosphorylation.  Mutant FLT3 induces the activation of multiple intracellular signaling pathways, mainly STAT5, MAPK and AKT signals, leading to cell proliferation and anti-apoptosis.  Because high-dose chemotherapy and allogeneic hematopoietic stem cell transplantation cannot sufficiently improve the prognosis, clin. development of FLT3 kinase inhibitors expected.  Although several FLT3 inhibitors have been developed, it takes more than 20 years from the first identification of FLT3 mutations until FLT3 inhibitors become clin. available for AML patients with FLT3 mutations.  To date, three FLT3 inhibitors have been clin. approved as monotherapy or combination therapy with conventional chemotherapeutic agents in Japan and/or Europe and United states.  However, several mechanisms of resistance to FLT3 inhibitors have already become apparent during their clin. trials.  The resistance mechanisms are complex and emerging resistant clones are heterogenous.  Further basic and clin. studies are required to establish the best therapeutic strategy for AML patients with FLT3 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv_Q3ByI5dqLVg90H21EOLACvtfcHk0lh1u9Qwwp__Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFSjt7vP&md5=79c7656f1836b2deda2b8c1203ad9719</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1111%2Fcas.14274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.14274%26sid%3Dliteratum%253Aachs%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DKawashima%26aufirst%3DN.%26aulast%3DIshikawa%26aufirst%3DY.%26atitle%3DFLT3%2520mutations%2520in%2520acute%2520myeloid%2520leukemia%253A%2520Therapeutic%2520paradigm%2520beyond%2520inhibitor%2520development%26jtitle%3DCancer%2520Sci.%26date%3D2020%26volume%3D111%26issue%3D2%26spage%3D312%26epage%3D322%26doi%3D10.1111%2Fcas.14274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span> <span> </span><span class="NLM_article-title">Quizartinib (AC220): a promising option for acute myeloid leukemia</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1125</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S198950</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.2147%2FDDDT.S198950" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=31114157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVaisr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=1117-1125&author=F.+Zhouauthor=Z.+Geauthor=B.+Chen&title=Quizartinib+%28AC220%29%3A+a+promising+option+for+acute+myeloid+leukemia&doi=10.2147%2FDDDT.S198950"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Quizartinib (AC220): a promising option for acute myeloid leukemia</span></div><div class="casAuthors">Zhou, Fang; Ge, Zheng; Chen, Baoan</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1117-1125</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Quizartinib is an effective therapy for patients with FLT3-ITD acute myeloid leukemia (AML) by continuing to inhibit the activity of FLT3 gene, leading to apoptosis of tumor cells.  Multiple clin. trials have proved that it is effective in relapsed or refractory AML with an FLT3-ITD mutation.  In this review, we focus on the characteristics of FLT3/ITD mutations, the mechanism and pharmacokinetics of quizartinib, and the mechanisms of resistance to quizartinib.  We also summarize clin. experiences and adverse effects with quizartinib and recommend crucial approaches of quizartinib in the therapy of patients with newly diagnosed AML and patients with relapsed/refractory AML, particularly those with FLT3-ITD mutation.  Quizartinib presents its advantages as a very promising agent in the treatment of AML, esp. in patients with FLT3-ITD mutations.  FLT3/ITD mutation can lead to constitutive autophosphorylation of FLT3 and activation of its downstream effectors including RAS/RAF/MEK, MAPK/ERK, PI3K/AKT/mTOR and JAK/STAT5 signal pathways, while Quizartinib can inhibit these downstream pathways through specific FLT3 inhibition.  Quizartinib has received US Food and Drug Administration breakthrough therapy designation in patients with relapsed/refractory FLT3-ITD AML based on clin. trials.  A larger sample of clin. trials are needed to verify its safety and efficacy, and the efficacy of quizartinib combined with chemotherapy or allogeneic hematopoietic cell transplantation should also be estd. in clin. trials.  Meanwhile, for the side effects of quizartinib, further studies are needed to find a way to reduce its toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdQbluP81wNLVg90H21EOLACvtfcHk0liTLUWw0u7ZbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVaisr7K&md5=c172240b673571ce14933fa6de086b10</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S198950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S198950%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DGe%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DB.%26atitle%3DQuizartinib%2520%2528AC220%2529%253A%2520a%2520promising%2520option%2520for%2520acute%2520myeloid%2520leukemia%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2019%26volume%3D13%26spage%3D1117%26epage%3D1125%26doi%3D10.2147%2FDDDT.S198950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span> <span> </span><span class="NLM_article-title">Midostaurin approved for FLT3-mutated AML</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">3403</span>– <span class="NLM_lpage">3406</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-05-782292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2017-05-782292" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=28546144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFamt7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=3403-3406&issue=26&author=M.+Levis&title=Midostaurin+approved+for+FLT3-mutated+AML&doi=10.1182%2Fblood-2017-05-782292"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Midostaurin approved for FLT3-mutated AML</span></div><div class="casAuthors">Levis, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3403-3406</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Midostaurin was recently approved by the US Food and Drug Administration for the treatment of FLT3-mutant acute myeloid leukemia (AML).  This is the first drug to receive regulatory approval for AML in the United States since the year 2000.  Midostaurin is a small-mol. kinase inhibitor with activity against the receptor tyrosine kinase FLT3, and its approval will hopefully mark the beginning of an era of targeted agents for the treatment of molecularly defined subtypes of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiE1vcI_B3uLVg90H21EOLACvtfcHk0liTLUWw0u7ZbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFamt7vM&md5=8e6eda0e807f1611ef4b90d7c1959ef4</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-05-782292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-05-782292%26sid%3Dliteratum%253Aachs%26aulast%3DLevis%26aufirst%3DM.%26atitle%3DMidostaurin%2520approved%2520for%2520FLT3-mutated%2520AML%26jtitle%3DBlood%26date%3D2017%26volume%3D129%26issue%3D26%26spage%3D3403%26epage%3D3406%26doi%3D10.1182%2Fblood-2017-05-782292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knapper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilkes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hills, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavenagh, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjeldsen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunwald, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnett, A. K.</span></span> <span> </span><span class="NLM_article-title">A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1143</span>– <span class="NLM_lpage">1154</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-07-730648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2016-07-730648" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=27872058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVWgtL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=1143-1154&issue=9&author=S.+Knapperauthor=N.+Russellauthor=A.+Gilkesauthor=R.+K.+Hillsauthor=R.+E.+Galeauthor=J.+D.+Cavenaghauthor=G.+Jonesauthor=L.+Kjeldsenauthor=M.+R.+Grunwaldauthor=I.+Thomasauthor=H.+Konigauthor=M.+J.+Levisauthor=A.+K.+Burnett&title=A+randomized+assessment+of+adding+the+kinase+inhibitor+lestaurtinib+to+first-line+chemotherapy+for+FLT3-mutated+AML&doi=10.1182%2Fblood-2016-07-730648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML</span></div><div class="casAuthors">Knapper, Steven; Russell, Nigel; Gilkes, Amanda; Hills, Robert K.; Gale, Rosemary E.; Cavenagh, James D.; Jones, Gail; Kjeldsen, Lars; Grunwald, Michael R.; Thomas, Ian; Konig, Heiko; Levis, Mark J.; Burnett, Alan K.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1143-1154</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The clin. benefit of adding FMS-like tyrosine kinase-3 (FLT3)-directed small mol. therapy to std. first-line treatment of acute myeloid leukemia (AML) has not yet been established.  As part of the UK AML15 and AML17 trials, patients with previously untreated AML and confirmed FLT3-activating mutations, mostly younger than 60 years, were randomly assigned either to receive oral lestaurtinib (CEP701) or not after each of 4 cycles of induction and consolidation chemotherapy.  Lestaurtinib was commenced 2 days after completing chemotherapy and administered in cycles of up to 28 days.  The trials ran consecutively.  Primary endpoints were overall survival inAML15 and relapse-free survival in AML17; outcome data were meta-analyzed.  Five hundred patients were randomly assigned between lestaurtinib and control: 74% had FLT3-internal tandemduplicationmutations, 23% FLT3-tyrosine kinase domain pointmutations, and 2%both types.No significant differences were seen in either 5-yr overall survival (lestaurtinib 46% vs control 45%; hazard ratio, 0.90; 95% CI 0.70-1.15;P=.3) or 5-yr relapse-free survival (40% vs 36%; hazard ratio, 0.88; 95%CI 0.69-1.12;P=.3).  Exploratory subgroup anal. suggested survival benefit with lestaurtinib in patients receiving concomitant azole antifungal prophylaxis and gemtuzumab ozogamicin with the first course of chemotherapy.  Correlative studies included anal. of in vivo FLT3 inhibition by plasma inhibitory activity assay and indicated improved overall survival and significantly reduced rates of relapse in lestaurtinib-treated patients who achieved sustained greater than 85% FLT3 inhibition.  In conclusion, combining lestaurtinib with intensive chemotherapy proved feasible in younger patients with newly diagnosed FLT3-mutated AML, but yielded no overall clin. benefit.  The improved clin. outcomes seen in patients achieving sustained FLT3 inhibition encourage continued evaluation of FLT3-directed therapy alongside front-line AML treatment.  The UK AML15 and AML17 trials are registered at www.isrctn.com/ISRCTN17161961 and www.isrctn.com/ISRCTN55675535 resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZEyQZJRTBUbVg90H21EOLACvtfcHk0liTLUWw0u7ZbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVWgtL7F&md5=54c984612a70cf995de092ff91482319</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-07-730648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-07-730648%26sid%3Dliteratum%253Aachs%26aulast%3DKnapper%26aufirst%3DS.%26aulast%3DRussell%26aufirst%3DN.%26aulast%3DGilkes%26aufirst%3DA.%26aulast%3DHills%26aufirst%3DR.%2BK.%26aulast%3DGale%26aufirst%3DR.%2BE.%26aulast%3DCavenagh%26aufirst%3DJ.%2BD.%26aulast%3DJones%26aufirst%3DG.%26aulast%3DKjeldsen%26aufirst%3DL.%26aulast%3DGrunwald%26aufirst%3DM.%2BR.%26aulast%3DThomas%26aufirst%3DI.%26aulast%3DKonig%26aufirst%3DH.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DBurnett%26aufirst%3DA.%2BK.%26atitle%3DA%2520randomized%2520assessment%2520of%2520adding%2520the%2520kinase%2520inhibitor%2520lestaurtinib%2520to%2520first-line%2520chemotherapy%2520for%2520FLT3-mutated%2520AML%26jtitle%3DBlood%26date%3D2017%26volume%3D129%26issue%3D9%26spage%3D1143%26epage%3D1154%26doi%3D10.1182%2Fblood-2016-07-730648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weis, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marini, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bixby, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perissinotti, A. J.</span></span> <span> </span><span class="NLM_article-title">Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia</span>. <i>Crit Rev. Oncol Hematol</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2019.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.critrevonc.2019.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=31279288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BB3MzkslersA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2019&pages=125-138&author=T.+M.+Weisauthor=B.+L.+Mariniauthor=D.+L.+Bixbyauthor=A.+J.+Perissinotti&title=Clinical+considerations+for+the+use+of+FLT3+inhibitors+in+acute+myeloid+leukemia&doi=10.1016%2Fj.critrevonc.2019.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia</span></div><div class="casAuthors">Weis Taylor M; Marini Bernard L; Bixby Dale L; Perissinotti Anthony J</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">125-138</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Internal tandem duplications and tyrosine kinase mutations in the fms-like tyrosine kinase 3 (FLT3) receptor can occur in acute myeloid leukemia (AML) and portend a poor prognosis.  Midostaurin, a multikinase inhibitor that targets FLT3, demonstrated a survival benefit in FLT3-mutated AML in combination with front-line chemotherapy.  Despite this advancement, the use of FLT3 inhibitors in clinical practice is complicated by significant drug-drug interactions and uncertainty about optimal timing, duration, and sequencing of therapy.  As monotherapy, the utility of FLT3 inhibitors was initially limited by incomplete and transient clinical responses and the development of acquired resistance.  This led to the development of more potent and selective FLT3 inhibitors designed to overcome common resistance mechanisms.  One of these second generation FLT3 inhibitors, gilteritinib, is now FDA-approved for the treatment of relapsed or refractory AML.  Now that multiple FLT3 inhibitors are commercially available, it is important to further delineate the role of these agents in the AML population.  This review aims to provide a comprehensive overview of the role of FLT3 inhibitors in AML and apply the current literature to clinical practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLHgPcBNhpCCM8MEzWGjS9fW6udTcc2eYeDNtjbhUaubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzkslersA%253D%253D&md5=d4ae236b21409087d7226b1a6df8bd2a</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2019.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2019.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DWeis%26aufirst%3DT.%2BM.%26aulast%3DMarini%26aufirst%3DB.%2BL.%26aulast%3DBixby%26aufirst%3DD.%2BL.%26aulast%3DPerissinotti%26aufirst%3DA.%2BJ.%26atitle%3DClinical%2520considerations%2520for%2520the%2520use%2520of%2520FLT3%2520inhibitors%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DCrit%2520Rev.%2520Oncol%2520Hematol%26date%3D2019%26volume%3D141%26spage%3D125%26epage%3D138%26doi%3D10.1016%2Fj.critrevonc.2019.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLachlan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvaro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enjeti, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verrills, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dun, M. D.</span></span> <span> </span><span class="NLM_article-title">Targeting oncogenic signaling in mutant FLT3 acute myeloid leukemia: the path to least resistance</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">3198</span>, <span class="refDoi"> DOI: 10.3390/ijms19103198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.3390%2Fijms19103198" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntlymtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=3198&issue=10&author=D.+Staudtauthor=H.+C.+Murrayauthor=T.+McLachlanauthor=F.+Alvaroauthor=A.+K.+Enjetiauthor=N.+M.+Verrillsauthor=M.+D.+Dun&title=Targeting+oncogenic+signaling+in+mutant+FLT3+acute+myeloid+leukemia%3A+the+path+to+least+resistance&doi=10.3390%2Fijms19103198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting oncogenic signaling in mutant FLT3 acute myeloid leukemia: the path to least resistance</span></div><div class="casAuthors">Staudt, Dilana; Murray, Heather C.; McLachlan, Tabitha; Alvaro, Frank; Enjeti, Anoop K.; Verrills, Nicole M.; Dun, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3198/1-3198/26</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The identification of recurrent driver mutations in genes encoding tyrosine kinases has resulted in the development of molecularly-targeted treatment strategies designed to improve outcomes for patients diagnosed with acute myeloid leukemia (AML).  The receptor tyrosine kinase FLT3 is the most commonly mutated gene in AML, with internal tandem duplications within the juxtamembrane domain (FLT3-ITD) or missense mutations in the tyrosine kinase domain (FLT3-TKD) present in 30-35% of AML patients at diagnosis.  An established driver mutation and marker of poor prognosis, the FLT3 tyrosine kinase has emerged as an attractive therapeutic target, and thus, encouraged the development of FLT3 tyrosine kinase inhibitors (TKIs).  However, the therapeutic benefit of FLT3 inhibition, particularly as a monotherapy, frequently results in the development of treatment resistance and disease relapse.  Commonly, FLT3 inhibitor resistance occurs by the emergence of secondary lesions in the FLT3 gene, particularly in the second tyrosine kinase domain (TKD) at residue Asp835 (D835) to form a 'dual mutation' (ITD-D835).  Individual FLT3-ITD and FLT3-TKD mutations influence independent signaling cascades; however, little is known about which divergent signaling pathways are controlled by each of the FLT3 specific mutations, particularly in the context of patients harboring dual ITD-D835 mutations.  This review provides a comprehensive anal. of the known discrete and cooperative signaling pathways deregulated by each of the FLT3 specific mutations, as well as the therapeutic approaches that hold the most promise of more durable and personalized therapeutic approaches to improve treatments of FLT3 mutant AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpa4ET_f5LGqbVg90H21EOLACvtfcHk0lidlPa53dvxcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntlymtr8%253D&md5=534da5dfc80804ed501f8aa95454b1cc</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.3390%2Fijms19103198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19103198%26sid%3Dliteratum%253Aachs%26aulast%3DStaudt%26aufirst%3DD.%26aulast%3DMurray%26aufirst%3DH.%2BC.%26aulast%3DMcLachlan%26aufirst%3DT.%26aulast%3DAlvaro%26aufirst%3DF.%26aulast%3DEnjeti%26aufirst%3DA.%2BK.%26aulast%3DVerrills%26aufirst%3DN.%2BM.%26aulast%3DDun%26aufirst%3DM.%2BD.%26atitle%3DTargeting%2520oncogenic%2520signaling%2520in%2520mutant%2520FLT3%2520acute%2520myeloid%2520leukemia%253A%2520the%2520path%2520to%2520least%2520resistance%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26issue%3D10%26spage%3D3198%26doi%3D10.3390%2Fijms19103198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traer, E.</span></span> <span> </span><span class="NLM_article-title">Profile of quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD-positive acute myeloid leukemia: evidence to date</span>. <i>Cancer Manage. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.2147/CMAR.S196568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.2147%2FCMAR.S196568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=32021432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVCjsrnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=151-163&author=L.+Fletcherauthor=S.+K.+Joshiauthor=E.+Traer&title=Profile+of+quizartinib+for+the+treatment+of+adult+patients+with+relapsed%2Frefractory+FLT3-ITD-positive+acute+myeloid+leukemia%3A+evidence+to+date&doi=10.2147%2FCMAR.S196568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Profile of quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD-positive acute myeloid leukemia: evidence to date</span></div><div class="casAuthors">Fletcher, Luke; Joshi, Sunil K.; Traer, Elie</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Management and Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">151-163</span>CODEN:
                <span class="NLM_cas:coden">CMRACP</span>;
        ISSN:<span class="NLM_cas:issn">1179-1322</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) is a clonal hematol. neoplasm characterized by rapid, uncontrolled cell growth of immature myeloid cells (blasts).  There are numerous genetic abnormalities in AML, many of which are prognostic, but an increasing no. are targets for drug therapy.  One of the most common genetic abnormalities in AML are activating mutations in the FMS-like tyrosine kinase 3 receptor (FLT3).  As a receptor tyrosine kinase, FLT3 was the first targetable genetic abnormality in AML.  The first generation of FLT3 inhibitors were broad-spectrum kinase inhibitors that inhibited FLT3 among other proteins.  Although clin. active, first-generation FLT3 inhibitors had limited success as single agents.  This led to the development of a second generation of more selective FLT3 inhibitors.  This review focuses on quizartinib, a potent second-generation FLT3 inhibitor.  We discuss the clin. trial development, mechanisms of resistance, and the recent FDA decision to deny approval for quizartinib as a single agent in relapsed/refractory AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMBOdx7nPXwrVg90H21EOLACvtfcHk0lidlPa53dvxcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVCjsrnE&md5=06f5bc8d10d0e2d4a8cd540d5af751e2</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.2147%2FCMAR.S196568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCMAR.S196568%26sid%3Dliteratum%253Aachs%26aulast%3DFletcher%26aufirst%3DL.%26aulast%3DJoshi%26aufirst%3DS.%2BK.%26aulast%3DTraer%26aufirst%3DE.%26atitle%3DProfile%2520of%2520quizartinib%2520for%2520the%2520treatment%2520of%2520adult%2520patients%2520with%2520relapsed%252Frefractory%2520FLT3-ITD-positive%2520acute%2520myeloid%2520leukemia%253A%2520evidence%2520to%2520date%26jtitle%3DCancer%2520Manage.%2520Res.%26date%3D2020%26volume%3D12%26spage%3D151%26epage%3D163%26doi%3D10.2147%2FCMAR.S196568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perl, A. E.</span></span> <span> </span><span class="NLM_article-title">Gilteritinib: potent targeting of FLT3 mutations in AML</span>. <i>Blood Adv.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1178</span>– <span class="NLM_lpage">1191</span>, <span class="refDoi"> DOI: 10.1182/bloodadvances.2019000174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fbloodadvances.2019000174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=32208491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BB3cXis12ktrjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2020&pages=1178-1191&issue=6&author=M.+Levisauthor=A.+E.+Perl&title=Gilteritinib%3A+potent+targeting+of+FLT3+mutations+in+AML&doi=10.1182%2Fbloodadvances.2019000174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Gilteritinib: potent targeting of FLT3 mutations in AML</span></div><div class="casAuthors">Levis, Mark; Perl, Alexander E.</div><div class="citationInfo"><span class="NLM_cas:title">Blood Advances</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1178-1191</span>CODEN:
                <span class="NLM_cas:coden">BALDBA</span>;
        ISSN:<span class="NLM_cas:issn">2473-9537</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Since the discovery of FMS-like tyrosine kinase-3 (FLT3)-activating mutations as genetic drivers in acute myeloid leukemia (AML), investigators have tried to develop tyrosine kinase inhibitors that could effectively target FLT3 and alter the disease trajectory.  Giltertinib (formerly known as ASP2215) is a novel compd. that entered the field late, but moved through the developmental process with remarkable speed.  In many ways, this drug's rapid development was facilitated by the large body of knowledge gained over the years from efforts to develop other FLT3 inhibitors.  Single-agent gilteritinib, a potent and selective oral FLT3 inhibitor, improved the survival of patients with relapsed or refractory FLT3-mutated AML compared with std. chemotherapy.  This continues to validate the approach of targeting FLT3 itself and establishes a new backbone for testing combination regimens.  This review will frame the preclin. and clin. development of gilteritinib in the context of the lessons learned from its predecessors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOB-jGZCX9A7Vg90H21EOLACvtfcHk0lidlPa53dvxcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXis12ktrjK&md5=a293d32efa1833dbc74aef6cbbf06ae2</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1182%2Fbloodadvances.2019000174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fbloodadvances.2019000174%26sid%3Dliteratum%253Aachs%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26atitle%3DGilteritinib%253A%2520potent%2520targeting%2520of%2520FLT3%2520mutations%2520in%2520AML%26jtitle%3DBlood%2520Adv.%26date%3D2020%26volume%3D4%26issue%3D6%26spage%3D1178%26epage%3D1191%26doi%3D10.1182%2Fbloodadvances.2019000174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khaled, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perl, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganguly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dombret, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogge, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonas, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montesinos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radsak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sica, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arunachalam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namuyinga, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yver, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span> <span> </span><span class="NLM_article-title">Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">984</span>– <span class="NLM_lpage">997</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(19)30150-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2FS1470-2045%2819%2930150-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=31175001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFGqtrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=984-997&issue=7&author=J.+E.+Cortesauthor=S.+Khaledauthor=G.+Martinelliauthor=A.+E.+Perlauthor=S.+Gangulyauthor=N.+Russellauthor=A.+Kramerauthor=H.+Dombretauthor=D.+Hoggeauthor=B.+A.+Jonasauthor=A.+Y.+Leungauthor=P.+Mehtaauthor=P.+Montesinosauthor=M.+Radsakauthor=S.+Sicaauthor=M.+Arunachalamauthor=M.+Holmesauthor=K.+Kobayashiauthor=R.+Namuyingaauthor=N.+Geauthor=A.+Yverauthor=Y.+Zhangauthor=M.+J.+Levis&title=Quizartinib+versus+salvage+chemotherapy+in+relapsed+or+refractory+FLT3-ITD+acute+myeloid+leukaemia+%28QuANTUM-R%29%3A+a+multicentre%2C+randomised%2C+controlled%2C+open-label%2C+phase+3+trial&doi=10.1016%2FS1470-2045%2819%2930150-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial</span></div><div class="casAuthors">Cortes, Jorge E.; Khaled, Samer; Martinelli, Giovanni; Perl, Alexander E.; Ganguly, Siddhartha; Russell, Nigel; Kramer, Alwin; Dombret, Herve; Hogge, Donna; Jonas, Brian A.; Leung, Anskar Yu-Hung; Mehta, Priyanka; Montesinos, Pau; Radsak, Markus; Sica, Simona; Arunachalam, Meena; Holmes, Melissa; Kobayashi, Ken; Namuyinga, Ruth; Ge, Nanxiang; Yver, Antoine; Zhang, Yufen; Levis, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">984-997</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Patients with relapsed or refractory FLT3 internal tandem duplication (FLT3-ITD)-pos. acute myeloid leukemia have a poor prognosis, including high frequency of relapse, poorer response to salvage therapy, and shorter overall survival than those with FLT3 wild-type disease.  We aimed to assess whether single-agent quizartinib, an oral, highly potent and selective type II FLT3 inhibitor, improves overall survival vs. salvage chemotherapy.  QuANTUM-R is a randomized, controlled, phase 3 trial done at 152 hospitals and cancer centers in 19 countries.  Eligible patients aged 18 years or older with ECOG performance status 0-2 with relapsed or refractory (duration of first composite complete remission ≤6 mo) FLT3-ITD acute myeloid leukemia after std. therapy with or without allogeneic hemopoietic stem-cell transplantation were randomly assigned (2:1; permuted block size of 6; stratified by response to previous therapy and choice of chemotherapy via a phone-based and web-based interactive response system) to quizartinib (60 mg [30 mg lead-in] orally once daily) or investigator's choice of preselected chemotherapy: s.c. low-dose cytarabine (s.c. injection of cytarabine 20 mg twice daily on days 1-10 of 28-day cycles); i.v. infusions of mitoxantrone (8 mg/m2 per day), etoposide (100 mg/m2 per day), and cytarabine (1000 mg/m2 per day on days 1-5 of up to two 28-day cycles); or i.v. granulocyte colony-stimulating factor (300μg/m2 per day or 5μg/kg per day s.c. on days 1-5), fludarabine (i.v. infusion 30 mg/m2 per day on days 2-6), cytarabine (i.v. infusion 2000 mg/m2 per day on days 2-6), and idarubicin (i.v. infusion 10 mg/m2 per day on days 2-4 in up to two 28-day cycles).  Patients proceeding to hemopoietic stem-cell transplantation after quizartinib could resume quizartinib after hemopoietic stem-cell transplantation.  The primary endpoint was overall survival in the intention-to-treat population.  This trial is registered with ClinicalTrials.gov, no. NCT02039726, and follow-up is ongoing.  Between May 7, 2014, and Sept 13, 2017, 367 patients were enrolled, of whom 245 were randomly allocated to quizartinib and 122 to chemotherapy.  Four patients in the quizartinib group and 28 in the chemotherapy group were not treated.  Median follow-up was 23.5 mo (IQR 15.4-32.3).  Overall survival was longer for quizartinib than for chemotherapy (hazard ratio 0.76 [95% CI 0.58-0.98; p = 0.02]).  Median overall survival was 6.2 mo (5.3-7.2) in the quizartinib group and 4.7 mo (4.0-5.5) in the chemotherapy group.  The most common non-haematol. grade 3-5 treatment-emergent adverse events (within ≤30 days of last dose or >30 days if suspected to be a treatment-related event) for quizartinib (241 patients) and chemotherapy (94 patients) were sepsis or septic shock (46 patients [19%] for quizartinib vs 18 [19%] for chemotherapy), pneumonia (29 [12%] vs eight [9%]), and hypokalemia (28 [12%] vs eight [9%]).  The most frequent treatment-related serious adverse events were febrile neutropenia (18 patients [7%]), sepsis or septic shock (11 [5%]), QT prolongation (five [2%]), and nausea (five [2%]) in the quizartinib group, and febrile neutropenia (five [5%]), sepsis or septic shock (four [4%]), pneumonia (two [2%]), and pyrexia (two [2%]) in the chemotherapy group.  Grade 3 QT prolongation in the quizartinib group was uncommon (eight [3%] by central reading, ten [4%] by investigator report); no grade 4 events occurred.  There were 80 (33%) treatment-emergent deaths in the quizartinib group (31 [13%] of which were due to adverse events) and 16 (17%) in the chemotherapy group (nine [10%] of which were due to adverse events).  Treatment with quizartinib had a survival benefit vs. salvage chemotherapy and had a manageable safety profile in patients with rapidly proliferative disease and very poor prognosis.  Quizartinib could be considered a new std. of care.  Given that there are only a few available treatment options, this study highlights the value of targeting the FLT3-ITD driver mutation with a highly potent and selective FLT3 inhibitor.Daiichi Sankyo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGcMb6SW1_b7Vg90H21EOLACvtfcHk0lhkPm0rXIAjPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFGqtrzM&md5=63619aa2e4ea4fcc29b74d2aef43f224</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2819%2930150-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252819%252930150-0%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26aulast%3DKhaled%26aufirst%3DS.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26aulast%3DGanguly%26aufirst%3DS.%26aulast%3DRussell%26aufirst%3DN.%26aulast%3DKramer%26aufirst%3DA.%26aulast%3DDombret%26aufirst%3DH.%26aulast%3DHogge%26aufirst%3DD.%26aulast%3DJonas%26aufirst%3DB.%2BA.%26aulast%3DLeung%26aufirst%3DA.%2BY.%26aulast%3DMehta%26aufirst%3DP.%26aulast%3DMontesinos%26aufirst%3DP.%26aulast%3DRadsak%26aufirst%3DM.%26aulast%3DSica%26aufirst%3DS.%26aulast%3DArunachalam%26aufirst%3DM.%26aulast%3DHolmes%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DK.%26aulast%3DNamuyinga%26aufirst%3DR.%26aulast%3DGe%26aufirst%3DN.%26aulast%3DYver%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26atitle%3DQuizartinib%2520versus%2520salvage%2520chemotherapy%2520in%2520relapsed%2520or%2520refractory%2520FLT3-ITD%2520acute%2520myeloid%2520leukaemia%2520%2528QuANTUM-R%2529%253A%2520a%2520multicentre%252C%2520randomised%252C%2520controlled%252C%2520open-label%252C%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2019%26volume%3D20%26issue%3D7%26spage%3D984%26epage%3D997%26doi%3D10.1016%2FS1470-2045%2819%2930150-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandrekar, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanford, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laumann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomfield, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiede, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prior, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo-Coco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klisovic, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sierra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandwein, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Witte, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niederwieser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appelbaum, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medeiros, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krauter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serve, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehninger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amadori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohner, H.</span></span> <span> </span><span class="NLM_article-title">Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">464</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1614359</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1056%2FNEJMoa1614359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=28644114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlyksrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=454-464&issue=5&author=R.+M.+Stoneauthor=S.+J.+Mandrekarauthor=B.+L.+Sanfordauthor=K.+Laumannauthor=S.+Geyerauthor=C.+D.+Bloomfieldauthor=C.+Thiedeauthor=T.+W.+Priorauthor=K.+Dohnerauthor=G.+Marcucciauthor=F.+Lo-Cocoauthor=R.+B.+Klisovicauthor=A.+Weiauthor=J.+Sierraauthor=M.+A.+Sanzauthor=J.+M.+Brandweinauthor=T.+de+Witteauthor=D.+Niederwieserauthor=F.+R.+Appelbaumauthor=B.+C.+Medeirosauthor=M.+S.+Tallmanauthor=J.+Krauterauthor=R.+F.+Schlenkauthor=A.+Ganserauthor=H.+Serveauthor=G.+Ehningerauthor=S.+Amadoriauthor=R.+A.+Larsonauthor=H.+Dohner&title=Midostaurin+plus+chemotherapy+for+acute+myeloid+leukemia+with+a+FLT3+mutation&doi=10.1056%2FNEJMoa1614359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation</span></div><div class="casAuthors">Stone, R. M.; Mandrekar, S. J.; Sanford, B. L.; Laumann, K.; Geyer, S.; Bloomfield, C. D.; Thiede, C.; Prior, T. W.; Dohner, K.; Marcucci, G.; Lo-Coco, F.; Klisovic, R. B.; Wei, A.; Sierra, J.; Sanz, M. A.; Brandwein, J. M.; de Witte, T.; Niederwieser, D.; Appelbaum, F. R.; Medeiros, B. C.; Tallman, M. S.; Krauter, J.; Schlenk, R. F.; Ganser, A.; Serve, H.; Ehninger, G.; Amadori, S.; Larson, R. A.; Dohner, H.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">454-464</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes.  We conducted a phase 3 trial to det. whether the addn. of midostaurin - an oral multitargeted kinase inhibitor that is active in patients with a FLT3 mutation - to std. chemotherapy would prolong overall survival in this population.  Methods: We screened 3277 patients, 18 to 59 years of age, who had newly diagnosed AML for FLT3 mutations.  Patients were randomly assigned to receive std. chemotherapy (induction therapy with daunorubicin and cytarabine and consolidation therapy with high-dose cytarabine) plus either midostaurin or placebo; those who were in remission after consolidation therapy entered a maintenance phase in which they received either midostaurin or placebo.  Randomization was stratified according to subtype of FLT3 mutation: point mutation in the tyrosine kinase domain (TKD) or internal tandem duplication (ITD) mutation with either a high ratio (>0.7) or a low ratio (0.05 to 0.7) of mutant to wild-type alleles (ITD [high] and ITD [low], resp.).  Allogeneic transplantation was allowed.  The primary end point was overall survival.  Results: A total of 717 patients underwent randomization; 360 were assigned to the midostaurin group, and 357 to the placebo group.  The FLT3 subtype was ITD (high) in 214 patients, ITD (low) in 341 patients, and TKD in 162 patients.  The treatment groups were well balanced with respect to age, race, FLT3 subtype, cytogenetic risk, and blood counts but not with respect to sex (51.7% in the midostaurin group vs. 59.4% in the placebo group were women, P = 0.04).  Overall survival was significantly longer in the midostaurin group than in the placebo group (hazard ratio for death, 0.78; one-sided P = 0.009), as was event-free survival (hazard ratio for event or death, 0.78; one-sided P = 0.002).  In both the primary anal. and an anal. in which data for patients who underwent transplantation were censored, the benefit of midostaurin was consistent across all FLT3 subtypes.  The rate of severe adverse events was similar in the two groups.  Conclusions: The addn. of the multitargeted kinase inhibitor midostaurin to std. chemotherapy significantly prolonged overall and event-free survival among patients with AML and a FLT3 mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9IT8JULCk7bVg90H21EOLACvtfcHk0lhkPm0rXIAjPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlyksrbK&md5=9b0b003122a307b4d92f05826745cb8c</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1614359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1614359%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DMandrekar%26aufirst%3DS.%2BJ.%26aulast%3DSanford%26aufirst%3DB.%2BL.%26aulast%3DLaumann%26aufirst%3DK.%26aulast%3DGeyer%26aufirst%3DS.%26aulast%3DBloomfield%26aufirst%3DC.%2BD.%26aulast%3DThiede%26aufirst%3DC.%26aulast%3DPrior%26aufirst%3DT.%2BW.%26aulast%3DDohner%26aufirst%3DK.%26aulast%3DMarcucci%26aufirst%3DG.%26aulast%3DLo-Coco%26aufirst%3DF.%26aulast%3DKlisovic%26aufirst%3DR.%2BB.%26aulast%3DWei%26aufirst%3DA.%26aulast%3DSierra%26aufirst%3DJ.%26aulast%3DSanz%26aufirst%3DM.%2BA.%26aulast%3DBrandwein%26aufirst%3DJ.%2BM.%26aulast%3Dde%2BWitte%26aufirst%3DT.%26aulast%3DNiederwieser%26aufirst%3DD.%26aulast%3DAppelbaum%26aufirst%3DF.%2BR.%26aulast%3DMedeiros%26aufirst%3DB.%2BC.%26aulast%3DTallman%26aufirst%3DM.%2BS.%26aulast%3DKrauter%26aufirst%3DJ.%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26aulast%3DGanser%26aufirst%3DA.%26aulast%3DServe%26aufirst%3DH.%26aulast%3DEhninger%26aufirst%3DG.%26aulast%3DAmadori%26aufirst%3DS.%26aulast%3DLarson%26aufirst%3DR.%2BA.%26aulast%3DDohner%26aufirst%3DH.%26atitle%3DMidostaurin%2520plus%2520chemotherapy%2520for%2520acute%2520myeloid%2520leukemia%2520with%2520a%2520FLT3%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26issue%3D5%26spage%3D454%26epage%3D464%26doi%3D10.1056%2FNEJMoa1614359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heidel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solem, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breitenbuecher, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipka, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiede, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandts, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serve, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roesel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giles, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehninger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, T.</span></span> <span> </span><span class="NLM_article-title">Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>107</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">300</span>, <span class="refDoi"> DOI: 10.1182/blood-2005-06-2469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2005-06-2469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=16150941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsVGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2006&pages=293-300&issue=1&author=F.+Heidelauthor=F.+K.+Solemauthor=F.+Breitenbuecherauthor=D.+B.+Lipkaauthor=S.+Kasperauthor=M.+H.+Thiedeauthor=C.+Brandtsauthor=H.+Serveauthor=J.+Roeselauthor=F.+Gilesauthor=E.+Feldmanauthor=G.+Ehningerauthor=G.+J.+Schillerauthor=S.+Nimerauthor=R.+M.+Stoneauthor=Y.+Wangauthor=T.+Kindlerauthor=P.+S.+Cohenauthor=C.+Huberauthor=T.+Fischer&title=Clinical+resistance+to+the+kinase+inhibitor+PKC412+in+acute+myeloid+leukemia+by+mutation+of+Asn-676+in+the+FLT3+tyrosine+kinase+domain&doi=10.1182%2Fblood-2005-06-2469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain</span></div><div class="casAuthors">Heidel, Florian; Solem, Fian K.; Breitenbuecher, Frank; Lipka, Daniel B.; Kasper, Stefan; Thiede, M. H.; Brandts, Christian; Serve, Hubert; Roesel, Johannes; Giles, Francis; Feldman, Eric; Ehninger, Gerhard; Schille, Gary J.; Nimer, Stephen; Stone, Richard M.; Wang, Yanfeng; Kindler, Thomas; Cohen, Pamela S.; Huber, Christoph; Fischer, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">293-300</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Activating mutations in the FLT3 tyrosine kinase (TK) occur in approx. 35% of patients with acute myeloid leukemia (AML).  Therefore, targeting mutated FLT3 is an attractive therapeutic strategy, and early clin. trials testing FLT3 TK inhibitors (TKI) showed measurable clin. responses.  Most of these responses were transient; however, in a subset of patients blast recurrence was preceded by an interval of prolonged remission.  The etiol. of clin. resistance to FLT3-TKI in AML is unclear but is of major significance for the development of future therapeutic strategies.  We searched for mechanisms of resistance in 6 patients with AML who had relapses upon PKC412 treatment.  In an index AML patient, an algorithm of analyses was applied using clin. material.  In vivo and in vitro investigation of primary blasts at relapse revealed persistent TK phosphorylation of FLT3 despite sufficient PKC412 serum levels.  Through addnl. mol. analyses, we identified a single amino acid substitution at position 676 (N676K) within the FLT3 kinase domain as the sole cause of resistance of PKC412 in this patient.  Reconstitution expts. expressing the N676K mutant in 32D cells demonstrated that FLT3-ITD-N676K was sufficient to confer an intermediate level of resistance to PKC412 in vitro.  These studies point out that a genetically complex malignancy such as AML may retain dependence on a single oncogenic signal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNW2s1mxXfzLVg90H21EOLACvtfcHk0lhxMXUhnL1BQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsVGlsQ%253D%253D&md5=be1fc50b4c74553a330fa9bd48cb2a22</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-06-2469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-06-2469%26sid%3Dliteratum%253Aachs%26aulast%3DHeidel%26aufirst%3DF.%26aulast%3DSolem%26aufirst%3DF.%2BK.%26aulast%3DBreitenbuecher%26aufirst%3DF.%26aulast%3DLipka%26aufirst%3DD.%2BB.%26aulast%3DKasper%26aufirst%3DS.%26aulast%3DThiede%26aufirst%3DM.%2BH.%26aulast%3DBrandts%26aufirst%3DC.%26aulast%3DServe%26aufirst%3DH.%26aulast%3DRoesel%26aufirst%3DJ.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DFeldman%26aufirst%3DE.%26aulast%3DEhninger%26aufirst%3DG.%26aulast%3DSchiller%26aufirst%3DG.%2BJ.%26aulast%3DNimer%26aufirst%3DS.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKindler%26aufirst%3DT.%26aulast%3DCohen%26aufirst%3DP.%2BS.%26aulast%3DHuber%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DT.%26atitle%3DClinical%2520resistance%2520to%2520the%2520kinase%2520inhibitor%2520PKC412%2520in%2520acute%2520myeloid%2520leukemia%2520by%2520mutation%2520of%2520Asn-676%2520in%2520the%2520FLT3%2520tyrosine%2520kinase%2520domain%26jtitle%3DBlood%26date%3D2006%26volume%3D107%26issue%3D1%26spage%3D293%26epage%3D300%26doi%3D10.1182%2Fblood-2005-06-2469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alvarado, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luthra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Manero, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopleva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrov, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreeff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J. E.</span></span> <span> </span><span class="NLM_article-title">Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>120</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">2142</span>– <span class="NLM_lpage">2149</span>, <span class="refDoi"> DOI: 10.1002/cncr.28705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1002%2Fcncr.28705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=24737502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFSmtrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2014&pages=2142-2149&issue=14&author=Y.+Alvaradoauthor=H.+M.+Kantarjianauthor=R.+Luthraauthor=F.+Ravandiauthor=G.+Borthakurauthor=G.+Garcia-Maneroauthor=M.+Konoplevaauthor=Z.+Estrovauthor=M.+Andreeffauthor=J.+E.+Cortes&title=Treatment+with+FLT3+inhibitor+in+patients+with+FLT3-mutated+acute+myeloid+leukemia+is+associated+with+development+of+secondary+FLT3-tyrosine+kinase+domain+mutations&doi=10.1002%2Fcncr.28705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations</span></div><div class="casAuthors">Alvarado, Yesid; Kantarjian, Hagop M.; Luthra, Rajyalakshmi; Ravandi, Farhad; Borthakur, Gautam; Garcia-Manero, Guillermo; Konopleva, Marina; Estrov, Zeev; Andreeff, Michael; Cortes, Jorge E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2142-2149</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND : FLT3-internal tandem duplication (ITD) mutations are found in approx. 30% of patients with acute myeloid leukemia (AML).  FLT3 inhibitors have shown clin. activity in AML with FLT3-ITD, but responses are usually short-lived.  METHODS : This study examd. 69 FLT3-mutated patients with AML, who were treated with different FLT3 inhibitors to analyze emergence of new mutations.  RESULTS : At baseline, 87% of patients had an ITD mutation, 7% had a D835/I836 mutation, and 6% had combined ITD and D835/I836 mutations.  Responses occurred in 32% of patients, all with FLT3-ITD; none of the patients with D835/I836 or ITD+D835/I836 responded.  Mutational assessment at the time of FLT3 inhibitor discontinuation showed that 68% of patients were unchanged, 10% had become undetectable, and 22% of patients progressed from a single ITD to have combined ITD+D835/I836 mutations.  In those patients with unchanged FLT3 mutation at progression, the median survival was 5 mo, whereas in those with undetectable and with combined ITD+D835/I836 mutations, the median survival was 7 mo, resp.  CONCLUSIONS : These data confirm in vitro observations that a secondary tyrosine kinase domain mutation may arise after the use of FLT3 inhibitors in patients with single FLT3-ITD mutated AML, a phenomenon that is assocd. with resistance and a poor prognosis.  Cancer 2014;120:2142-2149. © 2014 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6wrXS8kVYurVg90H21EOLACvtfcHk0lhxMXUhnL1BQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFSmtrzN&md5=b16b32e2b79500ca3dabb70a1d9b0a3a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fcncr.28705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.28705%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarado%26aufirst%3DY.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DLuthra%26aufirst%3DR.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DAndreeff%26aufirst%3DM.%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26atitle%3DTreatment%2520with%2520FLT3%2520inhibitor%2520in%2520patients%2520with%2520FLT3-mutated%2520acute%2520myeloid%2520leukemia%2520is%2520associated%2520with%2520development%2520of%2520secondary%2520FLT3-tyrosine%2520kinase%2520domain%2520mutations%26jtitle%3DCancer%26date%3D2014%26volume%3D120%26issue%3D14%26spage%3D2142%26epage%3D2149%26doi%3D10.1002%2Fcncr.28705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stecula, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. P.</span></span> <span> </span><span class="NLM_article-title">FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2390</span>– <span class="NLM_lpage">2392</span>, <span class="refDoi"> DOI: 10.1038/leu.2015.165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fleu.2015.165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=26108694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Wrtb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=2390-2392&issue=12&author=C.+C.+Smithauthor=K.+Linauthor=A.+Steculaauthor=A.+Saliauthor=N.+P.+Shah&title=FLT3+D835+mutations+confer+differential+resistance+to+type+II+FLT3+inhibitors&doi=10.1038%2Fleu.2015.165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors</span></div><div class="casAuthors">Smith, C. C.; Lin, K.; Stecula, A.; Sali, A.; Shah, N. P.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2390-2392</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activating mutations in FLT3 occur in ∼30% of adult acute myeloid leukemia, primarily consisting of internal tandem duplication (ITD) mutations (∼25%) and point mutations in the tyrosine kinase domain (∼5%), commonly at the activation loop residue D835.  Secondary kinase domain mutations in FLT3-ITD, particularly at the D835 residue are frequently assocd. with acquired clin. resistance to effective FLT3 tyrosine kinase inhibitors (TKIs).  Mol. docking studies have suggested that D835 mutations primarily confer resistance by stabilizing an active Asp-Phe-Gly in ('DFG-in') kinase conformation unfavorable to the binding of type II FLT3 TKIs, which target a 'DFG-out' inactive conformation.  We profiled the activity of active type II FLT3 TKIs against D835 kinase domain mutants that have been clin. detected to date.  We found that type II inhibitors (quizartinib, sorafenib, ponatinib and PLX3397) retain activity against specific D835 substitutions.  Modeling studies suggest that bulky hydrophobic substitutions (D835Y/V/I/F) at this residue are particularly resistant, whereas mutations that preserve interactions between D835 and S838 are relatively sensitive (D835E/N).  All mutants retain sensitivity to the type I inhibitor crenolanib.  These results suggest that patients with relatively sensitive D835 mutations should be included in clin. trials of type II FLT3 TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQhZ7jQYhBcbVg90H21EOLACvtfcHk0lhxMXUhnL1BQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Wrtb%252FJ&md5=f6de44ca15604b8429a5dab811fe8eeb</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.165%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DStecula%26aufirst%3DA.%26aulast%3DSali%26aufirst%3DA.%26aulast%3DShah%26aufirst%3DN.%2BP.%26atitle%3DFLT3%2520D835%2520mutations%2520confer%2520differential%2520resistance%2520to%2520type%2520II%2520FLT3%2520inhibitors%26jtitle%3DLeukemia%26date%3D2015%26volume%3D29%26issue%3D12%26spage%3D2390%26epage%3D2392%26doi%3D10.1038%2Fleu.2015.165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melgar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolanos, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hueneman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawa, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyt, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunderlich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perentesis, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starczynowski, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span> <span> </span><span class="NLM_article-title">Targeting AML-associated FLT3 mutations with a type I kinase inhibitor</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>130</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">2017</span>– <span class="NLM_lpage">2023</span>, <span class="refDoi"> DOI: 10.1172/JCI127907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1172%2FJCI127907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=32149729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsFGlurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2020&pages=2017-2023&issue=4&author=L.+M.+Jonesauthor=K.+Melgarauthor=L.+Bolanosauthor=K.+Huenemanauthor=M.+M.+Walkerauthor=J.+K.+Jiangauthor=K.+M.+Wilsonauthor=X.+Zhangauthor=J.+Shenauthor=F.+Jiangauthor=P.+Sutterauthor=A.+Wangauthor=X.+Xuauthor=G.+J.+Tawaauthor=S.+B.+Hoytauthor=M.+Wunderlichauthor=E.+O%E2%80%99Brienauthor=J.+P.+Perentesisauthor=D.+T.+Starczynowskiauthor=C.+J.+Thomas&title=Targeting+AML-associated+FLT3+mutations+with+a+type+I+kinase+inhibitor&doi=10.1172%2FJCI127907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting AML-associated FLT3 mutations with a type I kinase inhibitor</span></div><div class="casAuthors">Jones, LaQuita M.; Melgar, Katelyn; Bolanos, Lyndsey; Hueneman, Kathleen; Walker, Morgan M.; Jiang, Jian-Kang; Wilson, Kelli M.; Zhang, Xiaohu; Shen, Jian; Jiang, Fan; Sutter, Patrick; Wang, Amy; Xu, Xin; Tawa, Gregory J.; Hoyt, Scott B.; Wunderlich, Mark; O'Brien, Eric; Perentesis, John P.; Starczynowski, Daniel T.; Thomas, Craig J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2017-2023</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">1558-8238</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Tyrosine kinase domain (TKD) mutations contribute to acquired resistance to FMS-like tyrosine kinase 3 (FLT3) inhibitors used to treat FLT3-mutant acute myeloid leukemia (AML).  We report a cocrystal structure of FLT3 with a type I inhibitor, NCGC1481, that retained potent binding and activity against FLT3 TKD and gatekeeper mutations.  Relative to the current generation of advanced FLT3 inhibitors, NCGC1481 exhibited superior antileukemic activity against the common, clin. relevant FLT3-mutant AML cells in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU_p8IYcvTBrVg90H21EOLACvtfcHk0liofZ6WpYsdGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsFGlurk%253D&md5=d1c6d0eb4baf22ef9d3da642a3f71e45</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1172%2FJCI127907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI127907%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DL.%2BM.%26aulast%3DMelgar%26aufirst%3DK.%26aulast%3DBolanos%26aufirst%3DL.%26aulast%3DHueneman%26aufirst%3DK.%26aulast%3DWalker%26aufirst%3DM.%2BM.%26aulast%3DJiang%26aufirst%3DJ.%2BK.%26aulast%3DWilson%26aufirst%3DK.%2BM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DSutter%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DTawa%26aufirst%3DG.%2BJ.%26aulast%3DHoyt%26aufirst%3DS.%2BB.%26aulast%3DWunderlich%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DE.%26aulast%3DPerentesis%26aufirst%3DJ.%2BP.%26aulast%3DStarczynowski%26aufirst%3DD.%2BT.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26atitle%3DTargeting%2520AML-associated%2520FLT3%2520mutations%2520with%2520a%2520type%2520I%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2020%26volume%3D130%26issue%3D4%26spage%3D2017%26epage%3D2023%26doi%3D10.1172%2FJCI127907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasater, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damon, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendleton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasarskis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carias, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matusow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spevak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. P.</span></span> <span> </span><span class="NLM_article-title">Characterizing and overriding the structural mechanism of the quizartinib-resistant FLT3 ″gatekeeper″ F691L mutation with PLX3397</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">668</span>– <span class="NLM_lpage">679</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F2159-8290.CD-15-0060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=25847190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2MXps1Cgsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=668-679&issue=6&author=C.+C.+Smithauthor=C.+Zhangauthor=K.+C.+Linauthor=E.+A.+Lasaterauthor=Y.+Zhangauthor=E.+Massiauthor=L.+E.+Damonauthor=M.+Pendletonauthor=A.+Bashirauthor=R.+Sebraauthor=A.+Perlauthor=A.+Kasarskisauthor=R.+Shellooeauthor=G.+Tsangauthor=H.+Cariasauthor=B.+Powellauthor=E.+A.+Burtonauthor=B.+Matusowauthor=J.+Zhangauthor=W.+Spevakauthor=P.+N.+Ibrahimauthor=M.+H.+Leauthor=H.+H.+Hsuauthor=G.+Habetsauthor=B.+L.+Westauthor=G.+Bollagauthor=N.+P.+Shah&title=Characterizing+and+overriding+the+structural+mechanism+of+the+quizartinib-resistant+FLT3+%E2%80%B3gatekeeper%E2%80%B3+F691L+mutation+with+PLX3397&doi=10.1158%2F2159-8290.CD-15-0060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397</span></div><div class="casAuthors">Smith, Catherine C.; Zhang, Chao; Lin, Kimberly C.; Lasater, Elisabeth A.; Zhang, Ying; Massi, Evan; Damon, Lauren E.; Pendleton, Matthew; Bashir, Ali; Sebra, Robert; Perl, Alexander; Kasarskis, Andrew; Shellooe, Rafe; Tsang, Garson; Carias, Heidi; Powell, Ben; Burton, Elizabeth A.; Matusow, Bernice; Zhang, Jiazhong; Spevak, Wayne; Ibrahim, Prabha N.; Le, Mai H.; Hsu, Henry H.; Habets, Gaston; West, Brian L.; Bollag, Gideon; Shah, Neil P.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">668-679</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PLX3397 inhibits the growth of quizartinib-resistant FLT3-ITD+ AML cells expressing the gatekeeper F691L mutation in vitro and in vivo, but not cells expressing kinase domain mutations in the FLT3 activation loop.  Tyrosine kinase domain mutations are a common cause of acquired clin. resistance to tyrosine kinase inhibitors (TKI) used to treat cancer, including the FLT3 inhibitor quizartinib.  Mutation of kinase "gatekeeper" residues, which control access to an allosteric pocket adjacent to the ATP-binding site, has been frequently implicated in TKI resistance.  The mol. underpinnings of gatekeeper mutation-mediated resistance are incompletely understood.  We report the first cocrystal structure of FLT3 with the TKI quizartinib, which demonstrates that quizartinib binding relies on essential edge-to-face arom. interactions with the gatekeeper F691 residue, and F830 within the highly conserved Asp-Phe-Gly motif in the activation loop.  This reliance makes quizartinib critically vulnerable to gatekeeper and activation loop substitutions while minimizing the impact of mutations elsewhere.  Moreover, we identify PLX3397, a novel FLT3 inhibitor that retains activity against the F691L mutant due to a binding mode that depends less vitally on specific interactions with the gatekeeper position.  Significance: We report the first cocrystal structure of FLT3 with a kinase inhibitor, elucidating the structural mechanism of resistance due to the gatekeeper F691L mutation.  PLX3397 is a novel FLT3 inhibitor with in vitro activity against this mutation but is vulnerable to kinase domain mutations in the FLT3 activation loop.  Cancer Discov; 5(6); 668-79. cpr2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9oYwTJ6cznrVg90H21EOLACvtfcHk0liofZ6WpYsdGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXps1Cgsb4%253D&md5=7e76b2892a49a6e4701f534fce212ca4</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0060%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DK.%2BC.%26aulast%3DLasater%26aufirst%3DE.%2BA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DMassi%26aufirst%3DE.%26aulast%3DDamon%26aufirst%3DL.%2BE.%26aulast%3DPendleton%26aufirst%3DM.%26aulast%3DBashir%26aufirst%3DA.%26aulast%3DSebra%26aufirst%3DR.%26aulast%3DPerl%26aufirst%3DA.%26aulast%3DKasarskis%26aufirst%3DA.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DCarias%26aufirst%3DH.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DMatusow%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DLe%26aufirst%3DM.%2BH.%26aulast%3DHsu%26aufirst%3DH.%2BH.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DShah%26aufirst%3DN.%2BP.%26atitle%3DCharacterizing%2520and%2520overriding%2520the%2520structural%2520mechanism%2520of%2520the%2520quizartinib-resistant%2520FLT3%2520%25E2%2580%25B3gatekeeper%25E2%2580%25B3%2520F691L%2520mutation%2520with%2520PLX3397%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26issue%3D6%26spage%3D668%26epage%3D679%26doi%3D10.1158%2F2159-8290.CD-15-0060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Natan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharbanda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolais, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, D. A.</span></span> <span> </span><span class="NLM_article-title">The STAT5 inhibitor pimozide displays efficacy in models of acute myelogenous leukemia driven by FLT3 mutations</span>. <i>Genes Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">7–8</span>),  <span class="NLM_fpage">503</span>– <span class="NLM_lpage">511</span>, <span class="refDoi"> DOI: 10.1177/1947601912466555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1177%2F1947601912466555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=23264850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtleitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=503-511&issue=7%E2%80%938&author=E.+A.+Nelsonauthor=S.+R.+Walkerauthor=M.+Xiangauthor=E.+Weisbergauthor=M.+Bar-Natanauthor=R.+Barrettauthor=S.+Liuauthor=S.+Kharbandaauthor=A.+L.+Christieauthor=M.+Nicolaisauthor=J.+D.+Griffinauthor=R.+M.+Stoneauthor=A.+L.+Kungauthor=D.+A.+Frank&title=The+STAT5+inhibitor+pimozide+displays+efficacy+in+models+of+acute+myelogenous+leukemia+driven+by+FLT3+mutations&doi=10.1177%2F1947601912466555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The STAT5 inhibitor pimozide displays efficacy in models of acute myelogenous leukemia driven by FLT3 mutations</span></div><div class="casAuthors">Nelson, Erik A.; Walker, Sarah R.; Xiang, Michael; Weisberg, Ellen; Bar-Natan, Michal; Barrett, Rosemary; Liu, Suiyang; Kharbanda, Surender; Christie, Amanda L.; Nicolais, Maria; Griffin, James D.; Stone, Richard M.; Kung, Andrew L.; Frank, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">503-511, 9</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Activation of the transcription factor STAT5 is essential for the pathogenesis of acute myelogenous leukemia (AML) contg. the FLT3 internal tandem duplication (ITD) mutation.  FLT3 ITD is a constitutively active tyrosine kinase that drives the activation of STAT5, leading to the growth and survival of AML cells.  Although there has been some success in identifying tyrosine kinase inhibitors that block the function of FLT3 ITD, there remains a continued need for effective treatment of this disease.  We have identified the psychotropic drug pimozide as an effective inhibitor of STAT5 function.  Pimozide inhibits the tyrosine phosphorylation of STAT5, leading to the death of AML cells through the induction of apoptosis.  Pimozide shows a combinatorial effect with the tyrosine kinase inhibitors midostaurin (PKC412) and sunitinib in the inhibition of STAT5 tyrosine phosphorylation and the induction of apoptosis.  Significantly, pimozide reduces the tumor burden in a mouse model of FLT3-driven AML.  Therefore, identifying STAT5 inhibitors may provide a new avenue for the treatment of AML, and these may be effective alone or in combination with tyrosine kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY6fwT1Dx0qrVg90H21EOLACvtfcHk0liw1hZs3WCCfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtleitLs%253D&md5=c6a237d42ce26413f162b3eac9571c3f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1177%2F1947601912466555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601912466555%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DE.%2BA.%26aulast%3DWalker%26aufirst%3DS.%2BR.%26aulast%3DXiang%26aufirst%3DM.%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DBar-Natan%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DKharbanda%26aufirst%3DS.%26aulast%3DChristie%26aufirst%3DA.%2BL.%26aulast%3DNicolais%26aufirst%3DM.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DFrank%26aufirst%3DD.%2BA.%26atitle%3DThe%2520STAT5%2520inhibitor%2520pimozide%2520displays%2520efficacy%2520in%2520models%2520of%2520acute%2520myelogenous%2520leukemia%2520driven%2520by%2520FLT3%2520mutations%26jtitle%3DGenes%2520Cancer%26date%3D2012%26volume%3D3%26issue%3D7%25E2%2580%25938%26spage%3D503%26epage%3D511%26doi%3D10.1177%2F1947601912466555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindblad, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordero, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puissant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macaulay, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabir, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallon-Christersson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haraldsson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemann, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levander, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmaier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietras, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronnstrand, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazi, J. U.</span></span> <span> </span><span class="NLM_article-title">Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">39</span>),  <span class="NLM_fpage">5119</span>– <span class="NLM_lpage">5131</span>, <span class="refDoi"> DOI: 10.1038/onc.2016.41</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fonc.2016.41" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=26999641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC28XksVykurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=5119-5131&issue=39&author=O.+Lindbladauthor=E.+Corderoauthor=A.+Puissantauthor=L.+Macaulayauthor=A.+Ramosauthor=N.+N.+Kabirauthor=J.+Sunauthor=J.+Vallon-Christerssonauthor=K.+Haraldssonauthor=M.+T.+Hemannauthor=A.+Borgauthor=F.+Levanderauthor=K.+Stegmaierauthor=K.+Pietrasauthor=L.+Ronnstrandauthor=J.+U.+Kazi&title=Aberrant+activation+of+the+PI3K%2FmTOR+pathway+promotes+resistance+to+sorafenib+in+AML&doi=10.1038%2Fonc.2016.41"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML</span></div><div class="casAuthors">Lindblad, O.; Cordero, E.; Puissant, A.; Macaulay, L.; Ramos, A.; Kabir, N. N.; Sun, J.; Vallon-Christersson, J.; Haraldsson, K.; Hemann, M. T.; Borg, Aa; Levander, F.; Stegmaier, K.; Pietras, K.; Roennstrand, L.; Kazi, J. U.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">5119-5131</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Therapy directed against oncogenic FLT3 has been shown to induce response in patients with acute myeloid leukemia (AML), but these responses are almost always transient.  To address the mechanism of FLT3 inhibitor resistance, we generated two resistant AML cell lines by sustained treatment with the FLT3 inhibitor sorafenib.  Parental cell lines carry the FLT3-ITD (tandem duplication) mutation and are highly responsive to FLT3 inhibitors, whereas resistant cell lines display resistance to multiple FLT3 inhibitors.  Sanger sequencing and protein mass-spectrometry did not identify any acquired mutations in FLT3 in the resistant cells.  Moreover, sorafenib treatment effectively blocked FLT3 activation in resistant cells, whereas it was unable to block colony formation or cell survival, suggesting that the resistant cells are no longer FLT3 dependent.  Gene expression anal. of sensitive and resistant cell lines, as well as of blasts from patients with sorafenib-resistant AML, suggested an enrichment of the PI3K/mTOR pathway in the resistant phenotype, which was further supported by next-generation sequencing and phospho-specific-antibody array anal.  Furthermore, a selective PI3K/mTOR inhibitor, gedatolisib, efficiently blocked proliferation, colony and tumor formation, and induced apoptosis in resistant cell lines.  Gedatolisib significantly extended survival of mice in a sorafenib-resistant AML patient-derived xenograft model.  Taken together, our data suggest that aberrant activation of the PI3K/mTOR pathway in FLT3-ITD-dependent AML results in resistance to drugs targeting FLT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCfp1049FgsbVg90H21EOLACvtfcHk0liw1hZs3WCCfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksVykurw%253D&md5=94a7570e240d12c506af0850819c77d9</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fonc.2016.41&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2016.41%26sid%3Dliteratum%253Aachs%26aulast%3DLindblad%26aufirst%3DO.%26aulast%3DCordero%26aufirst%3DE.%26aulast%3DPuissant%26aufirst%3DA.%26aulast%3DMacaulay%26aufirst%3DL.%26aulast%3DRamos%26aufirst%3DA.%26aulast%3DKabir%26aufirst%3DN.%2BN.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DVallon-Christersson%26aufirst%3DJ.%26aulast%3DHaraldsson%26aufirst%3DK.%26aulast%3DHemann%26aufirst%3DM.%2BT.%26aulast%3DBorg%26aufirst%3DA.%26aulast%3DLevander%26aufirst%3DF.%26aulast%3DStegmaier%26aufirst%3DK.%26aulast%3DPietras%26aufirst%3DK.%26aulast%3DRonnstrand%26aufirst%3DL.%26aulast%3DKazi%26aufirst%3DJ.%2BU.%26atitle%3DAberrant%2520activation%2520of%2520the%2520PI3K%252FmTOR%2520pathway%2520promotes%2520resistance%2520to%2520sorafenib%2520in%2520AML%26jtitle%3DOncogene%26date%3D2016%26volume%3D35%26issue%3D39%26spage%3D5119%26epage%3D5131%26doi%3D10.1038%2Fonc.2016.41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottomly, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segerdell, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilmot, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McWeeney, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eide, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nechiporuk, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Searles, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Follit, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lind, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Manero, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buelow, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyner, J. W.</span></span> <span> </span><span class="NLM_article-title">Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">244</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-08263-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fs41467-018-08263-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=30651561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BB3cjit1GisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=244&issue=1&author=H.+Zhangauthor=S.+Savageauthor=A.+R.+Schultzauthor=D.+Bottomlyauthor=L.+Whiteauthor=E.+Segerdellauthor=B.+Wilmotauthor=S.+K.+McWeeneyauthor=C.+A.+Eideauthor=T.+Nechiporukauthor=A.+Carlosauthor=R.+Hensonauthor=C.+Linauthor=R.+Searlesauthor=H.+Hoauthor=Y.+L.+Lamauthor=R.+Sweatauthor=C.+Follitauthor=V.+Jainauthor=E.+Lindauthor=G.+Borthakurauthor=G.+Garcia-Maneroauthor=F.+Ravandiauthor=H.+M.+Kantarjianauthor=J.+Cortesauthor=R.+Collinsauthor=D.+R.+Buelowauthor=S.+D.+Bakerauthor=B.+J.+Drukerauthor=J.+W.+Tyner&title=Clinical+resistance+to+crenolanib+in+acute+myeloid+leukemia+due+to+diverse+molecular+mechanisms&doi=10.1038%2Fs41467-018-08263-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms</span></div><div class="casAuthors">Zhang Haijiao; Savage Samantha; Schultz Anna Reister; Nechiporuk Tamilla; Tyner Jeffrey W; Zhang Haijiao; Savage Samantha; Schultz Anna Reister; Eide Christopher A; Nechiporuk Tamilla; Druker Brian J; Tyner Jeffrey W; Bottomly Daniel; White Libbey; Segerdell Erik; Wilmot Beth; McWeeney Shannon K; Eide Christopher A; Druker Brian J; Carlos Amy; Henson Rachel; Lin Chenwei; Searles Robert; Ho Hoang; Lam Yee Ling; Sweat Richard; Follit Courtney; Jain Vinay; Lind Evan; Borthakur Gautam; Garcia-Manero Guillermo; Ravandi Farhad; Kantarjian Hagop M; Cortes Jorge; Collins Robert; Buelow Daelynn R; Baker Sharyn D</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">244</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">FLT3 mutations are prevalent in AML patients and confer poor prognosis.  Crenolanib, a potent type I pan-FLT3 inhibitor, is effective against both internal tandem duplications and resistance-conferring tyrosine kinase domain mutations.  While crenolanib monotherapy has demonstrated clinical benefit in heavily pretreated relapsed/refractory AML patients, responses are transient and relapse eventually occurs.  Here, to investigate the mechanisms of crenolanib resistance, we perform whole exome sequencing of AML patient samples before and after crenolanib treatment.  Unlike other FLT3 inhibitors, crenolanib does not induce FLT3 secondary mutations, and mutations of the FLT3 gatekeeper residue are infrequent.  Instead, mutations of NRAS and IDH2 arise, mostly as FLT3-independent subclones, while TET2 and IDH1 predominantly co-occur with FLT3-mutant clones and are enriched in crenolanib poor-responders.  The remaining patients exhibit post-crenolanib expansion of mutations associated with epigenetic regulators, transcription factors, and cohesion factors, suggesting diverse genetic/epigenetic mechanisms of crenolanib resistance.  Drug combinations in experimental models restore crenolanib sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1TvmXT9vLcb5oR8RchjrrfW6udTcc2eZ_GFwqmdOfuLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjit1GisA%253D%253D&md5=8e3b63a5ef84182a0df6229bd5c99bc9</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-08263-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-08263-x%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSavage%26aufirst%3DS.%26aulast%3DSchultz%26aufirst%3DA.%2BR.%26aulast%3DBottomly%26aufirst%3DD.%26aulast%3DWhite%26aufirst%3DL.%26aulast%3DSegerdell%26aufirst%3DE.%26aulast%3DWilmot%26aufirst%3DB.%26aulast%3DMcWeeney%26aufirst%3DS.%2BK.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DNechiporuk%26aufirst%3DT.%26aulast%3DCarlos%26aufirst%3DA.%26aulast%3DHenson%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DSearles%26aufirst%3DR.%26aulast%3DHo%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DY.%2BL.%26aulast%3DSweat%26aufirst%3DR.%26aulast%3DFollit%26aufirst%3DC.%26aulast%3DJain%26aufirst%3DV.%26aulast%3DLind%26aufirst%3DE.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DBuelow%26aufirst%3DD.%2BR.%26aulast%3DBaker%26aufirst%3DS.%2BD.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26atitle%3DClinical%2520resistance%2520to%2520crenolanib%2520in%2520acute%2520myeloid%2520leukemia%2520due%2520to%2520diverse%2520molecular%2520mechanisms%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26issue%3D1%26spage%3D244%26doi%3D10.1038%2Fs41467-018-08263-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Puissant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenouille, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pikman, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassil, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazi, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luciano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronnstrand, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aster, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galinsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeAngelo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemann, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmaier, K.</span></span> <span> </span><span class="NLM_article-title">SYK is a critical regulator of FLT3 in acute myeloid leukemia</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">226</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2014.01.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.ccr.2014.01.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=24525236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitlCisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=226-242&issue=2&author=A.+Puissantauthor=N.+Fenouilleauthor=G.+Alexeauthor=Y.+Pikmanauthor=C.+F.+Bassilauthor=S.+Mehtaauthor=J.+Duauthor=J.+U.+Kaziauthor=F.+Lucianoauthor=L.+Ronnstrandauthor=A.+L.+Kungauthor=J.+C.+Asterauthor=I.+Galinskyauthor=R.+M.+Stoneauthor=D.+J.+DeAngeloauthor=M.+T.+Hemannauthor=K.+Stegmaier&title=SYK+is+a+critical+regulator+of+FLT3+in+acute+myeloid+leukemia&doi=10.1016%2Fj.ccr.2014.01.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia</span></div><div class="casAuthors">Puissant, Alexandre; Fenouille, Nina; Alexe, Gabriela; Pikman, Yana; Bassil, Christopher F.; Mehta, Swapnil; Du, Jinyan; Kazi, Julhash U.; Luciano, Frederic; Ronnstrand, Lars; Kung, Andrew L.; Aster, Jon C.; Galinsky, Ilene; Stone, Richard M.; De Angelo, Daniel J.; Hemann, Michael T.; Stegmaier, Kimberly</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">226-242</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Cooperative dependencies between mutant oncoproteins and wild-type proteins are crit. in cancer pathogenesis and therapy resistance.  Although spleen tyrosine kinase (SYK) has been implicated in hematol. malignancies, it is rarely mutated.  We used kinase activity profiling to identify collaborators of SYK in acute myeloid leukemia (AML) and detd. that FMS-like tyrosine kinase 3 (FLT3) is transactivated by SYK via direct binding.  Highly activated SYK is predominantly found in FLT3-ITD pos. AML and cooperates with FLT3-ITD to activate MYC transcriptional programs.  FLT3-ITD AML cells are more vulnerable to SYK suppression than FLT3 wild-type counterparts.  In a FLT3-ITD in vivo model, SYK is indispensable for myeloproliferative disease (MPD) development, and SYK overexpression promotes overt transformation to AML and resistance to FLT3-ITD-targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLCsPtJvlk9bVg90H21EOLACvtfcHk0lgGLtR9byzGCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitlCisrw%253D&md5=a529b289d6d920b2506df30c658b4d0e</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2014.01.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2014.01.022%26sid%3Dliteratum%253Aachs%26aulast%3DPuissant%26aufirst%3DA.%26aulast%3DFenouille%26aufirst%3DN.%26aulast%3DAlexe%26aufirst%3DG.%26aulast%3DPikman%26aufirst%3DY.%26aulast%3DBassil%26aufirst%3DC.%2BF.%26aulast%3DMehta%26aufirst%3DS.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DKazi%26aufirst%3DJ.%2BU.%26aulast%3DLuciano%26aufirst%3DF.%26aulast%3DRonnstrand%26aufirst%3DL.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DAster%26aufirst%3DJ.%2BC.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DHemann%26aufirst%3DM.%2BT.%26aulast%3DStegmaier%26aufirst%3DK.%26atitle%3DSYK%2520is%2520a%2520critical%2520regulator%2520of%2520FLT3%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D25%26issue%3D2%26spage%3D226%26epage%3D242%26doi%3D10.1016%2Fj.ccr.2014.01.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Green, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciel, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hospital, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazed, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilorge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paubelle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacquel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zylbersztejn, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decroocq, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulain, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sujobert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacque, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">So, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosmider, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auberger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermine, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstock, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacombe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayeux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanasse, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moura, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouscary, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamburini, J.</span></span> <span> </span><span class="NLM_article-title">Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia</span>. <i>Sci. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">e1500221</span>, <span class="refDoi"> DOI: 10.1126/sciadv.1500221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1126%2Fsciadv.1500221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=26601252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtl2itrnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=e1500221&issue=8&author=A.+S.+Greenauthor=T.+T.+Macielauthor=M.+A.+Hospitalauthor=C.+Yinauthor=F.+Mazedauthor=E.+C.+Townsendauthor=S.+Pilorgeauthor=M.+Lambertauthor=E.+Paubelleauthor=A.+Jacquelauthor=F.+Zylbersztejnauthor=J.+Decroocqauthor=L.+Poulainauthor=P.+Sujobertauthor=N.+Jacqueauthor=K.+Adamauthor=J.+C.+Soauthor=O.+Kosmiderauthor=P.+Aubergerauthor=O.+Hermineauthor=D.+M.+Weinstockauthor=C.+Lacombeauthor=P.+Mayeuxauthor=G.+J.+Vanasseauthor=A.+Y.+Leungauthor=I.+C.+Mouraauthor=D.+Bouscaryauthor=J.+Tamburini&title=Pim+kinases+modulate+resistance+to+FLT3+tyrosine+kinase+inhibitors+in+FLT3-ITD+acute+myeloid+leukemia&doi=10.1126%2Fsciadv.1500221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia</span></div><div class="casAuthors">Green, Alexa S.; Maciel, Thiago T.; Hospital, Marie-Anne; Yin, Chae; Mazed, Fetta; Townsend, Elizabeth C.; Pilorge, Sylvain; Lambert, Mireille; Paubelle, Etienne; Jacquel, Arnaud; Zylbersztejn, Florence; Decroocq, Justine; Poulain, Laury; Sujobert, Pierre; Jacque, Nathalie; Adam, Kevin; So, Jason C. C.; Kosmider, Olivier; Auberger, Patrick; Hermine, Olivier; Weinstock, David M.; Lacombe, Catherine; Mayeux, Patrick; Vanasse, Gary J.; Leung, Anskar Y.; Moura, Ivan C.; Bouscary, Didier; Tamburini, Jerome</div><div class="citationInfo"><span class="NLM_cas:title">Science Advances</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e1500221/1-e1500221/13</span>CODEN:
                <span class="NLM_cas:coden">SACDAF</span>;
        ISSN:<span class="NLM_cas:issn">2375-2548</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) is frequently detected in acute myeloid leukemia (AML) patients and is assocd. with a dismal long-term prognosis.  FLT3 tyrosine kinase inhibitors provide shortterm disease control, but relapse invariably occurs within months.  Pim protein kinases are oncogenic FLT3-ITD targets expressed in AML cells.  We show that increased Pim kinase expression is found in relapse samples from AML patients treated with FLT3 inhibitors.  Ectopic Pim-2 expression induces resistance to FLT3 inhibition in both FLT3- ITD-induced myeloproliferative neoplasm and AML models in mice.  Strikingly, we found that Pim kinases govern FLT3-ITD signaling and that their pharmacol. or genetic inhibition restores cell sensitivity to FLT3 inhibitors.  Finally, dual inhibition of FLT3 and Pimkinases eradicates FLT3-ITD+ cells including primary AML cells.  Concomitant Pim and FLT3 inhibition represents a promising new avenue for AML therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT6JcWV2N-6bVg90H21EOLACvtfcHk0lgGLtR9byzGCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtl2itrnM&md5=16641fd4236f453104f40e6e80e20b13</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1126%2Fsciadv.1500221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciadv.1500221%26sid%3Dliteratum%253Aachs%26aulast%3DGreen%26aufirst%3DA.%2BS.%26aulast%3DMaciel%26aufirst%3DT.%2BT.%26aulast%3DHospital%26aufirst%3DM.%2BA.%26aulast%3DYin%26aufirst%3DC.%26aulast%3DMazed%26aufirst%3DF.%26aulast%3DTownsend%26aufirst%3DE.%2BC.%26aulast%3DPilorge%26aufirst%3DS.%26aulast%3DLambert%26aufirst%3DM.%26aulast%3DPaubelle%26aufirst%3DE.%26aulast%3DJacquel%26aufirst%3DA.%26aulast%3DZylbersztejn%26aufirst%3DF.%26aulast%3DDecroocq%26aufirst%3DJ.%26aulast%3DPoulain%26aufirst%3DL.%26aulast%3DSujobert%26aufirst%3DP.%26aulast%3DJacque%26aufirst%3DN.%26aulast%3DAdam%26aufirst%3DK.%26aulast%3DSo%26aufirst%3DJ.%2BC.%26aulast%3DKosmider%26aufirst%3DO.%26aulast%3DAuberger%26aufirst%3DP.%26aulast%3DHermine%26aufirst%3DO.%26aulast%3DWeinstock%26aufirst%3DD.%2BM.%26aulast%3DLacombe%26aufirst%3DC.%26aulast%3DMayeux%26aufirst%3DP.%26aulast%3DVanasse%26aufirst%3DG.%2BJ.%26aulast%3DLeung%26aufirst%3DA.%2BY.%26aulast%3DMoura%26aufirst%3DI.%2BC.%26aulast%3DBouscary%26aufirst%3DD.%26aulast%3DTamburini%26aufirst%3DJ.%26atitle%3DPim%2520kinases%2520modulate%2520resistance%2520to%2520FLT3%2520tyrosine%2520kinase%2520inhibitors%2520in%2520FLT3-ITD%2520acute%2520myeloid%2520leukemia%26jtitle%3DSci.%2520Adv.%26date%3D2015%26volume%3D1%26issue%3D8%26spage%3De1500221%26doi%3D10.1126%2Fsciadv.1500221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galkin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnett, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span> <span> </span><span class="NLM_article-title">FLT3 ligand impedes the efficacy of FLT3 inhibitors <i>in vitro</i> and <i>in vivo</i></span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>117</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3286</span>– <span class="NLM_lpage">3293</span>, <span class="refDoi"> DOI: 10.1182/blood-2010-01-266742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2010-01-266742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=21263155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslams70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=3286-3293&issue=12&author=T.+Satoauthor=X.+Yangauthor=S.+Knapperauthor=P.+Whiteauthor=B.+D.+Smithauthor=S.+Galkinauthor=D.+Smallauthor=A.+Burnettauthor=M.+Levis&title=FLT3+ligand+impedes+the+efficacy+of+FLT3+inhibitors+in+vitro+and+in+vivo&doi=10.1182%2Fblood-2010-01-266742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo</span></div><div class="casAuthors">Sato, Takashi; Yang, Xiaochuan; Knapper, Steven; White, Paul; Smith, B. Douglas; Galkin, Steven; Small, Donald; Burnett, Alan; Levis, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3286-3293</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">We examd. in vivo FLT3 inhibition in acute myeloid leukemia patients treated with chemotherapy followed by the FLT3 inhibitor lestaurtinib, comparing newly diagnosed acute myeloid leukemia patients with relapsed patients.  Because we noted that in vivo FLT3 inhibition by lestaurtinib was less effective in the relapsed patients compared with the newly diagnosed patients, we investigated whether plasma FLT3 ligand (FL) levels could influence the efficacy of FLT3 inhibition in these patients.  After intensive chemotherapy, FL levels rose to a mean of 488 pg/mL on day 15 of induction therapy for newly diagnosed patients, whereas they rose to a mean of 1148 pg/mL in the relapsed patients.  FL levels rose even higher with successive courses of chemotherapy, to a mean of 3251 pg/mL after the fourth course.  In vitro, exogenous FL at concns. similar to those obsd. in patients mitigated FLT3 inhibition and cytotoxicity for each of 5 different FLT3 inhibitors (lestaurtinib, midostaurin, sorafenib, KW-2449, and AC220).  The dramatic increase in FL level after chemotherapy represents a possible obstacle to inhibiting FLT3 in this clin. setting.  These findings could have important implications regarding the design and outcome of trials of FLT3 inhibitors and furthermore suggest a rationale for targeting FL as a therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZGxLbAzmoObVg90H21EOLACvtfcHk0lhVaVeHiQaXng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslams70%253D&md5=0cc4092386152ccdafb174772165e5a9</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-01-266742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-01-266742%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DKnapper%26aufirst%3DS.%26aulast%3DWhite%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DGalkin%26aufirst%3DS.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DBurnett%26aufirst%3DA.%26aulast%3DLevis%26aufirst%3DM.%26atitle%3DFLT3%2520ligand%2520impedes%2520the%2520efficacy%2520of%2520FLT3%2520inhibitors%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26issue%3D12%26spage%3D3286%26epage%3D3293%26doi%3D10.1182%2Fblood-2010-01-266742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daley, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galinsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N.</span></span> <span> </span><span class="NLM_article-title">Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2233</span>– <span class="NLM_lpage">2244</span>, <span class="refDoi"> DOI: 10.1038/leu.2012.96</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fleu.2012.96" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=22469781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSgurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=2233-2244&issue=10&author=E.+Weisbergauthor=Q.+Liuauthor=E.+Nelsonauthor=A.+L.+Kungauthor=A.+L.+Christieauthor=R.+Bronsonauthor=M.+Sattlerauthor=T.+Sandaauthor=Z.+Zhaoauthor=W.+Hurauthor=C.+Mitsiadesauthor=R.+Smithauthor=J.+F.+Daleyauthor=R.+Stoneauthor=I.+Galinskyauthor=J.+D.+Griffinauthor=N.+Gray&title=Using+combination+therapy+to+override+stromal-mediated+chemoresistance+in+mutant+FLT3-positive+AML%3A+synergism+between+FLT3+inhibitors%2C+dasatinib%2Fmulti-targeted+inhibitors+and+JAK+inhibitors&doi=10.1038%2Fleu.2012.96"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors</span></div><div class="casAuthors">Weisberg, E.; Liu, Q.; Nelson, Erik; Kung, A. L.; Christie, A. L.; Bronson, R.; Sattler, M.; Sanda, T.; Zhao, Z.; Hur, W.; Mitsiades, C.; Smith, R.; Daley, J. F.; Stone, R.; Galinsky, I.; Griffin, J. D.; Gray, N.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2233-2244</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) progenitors are frequently characterized by activating mutations in the receptor tyrosine kinase Fms-like tyrosine kinase-3 (FLT3).  Protein tyrosine kinases are integral components of signaling cascades that have a role in both FLT3-mediated transformation as well as viability pathways that are advantageous to leukemic cell survival.  The bone marrow microenvironment can diminish AML sensitivity to tyrosine kinase inhibitors.  We hypothesized that inhibition of protein kinases in addn. to FLT3 may be effective in overriding drug resistance in AML.  We used a cell-based model mimicking stromal protection as part of an unbiased high-throughput chem. screen to identify kinase inhibitors with the potential to override microenvironment-mediated drug resistance in mutant FLT3-pos. AML.  Several related multi-targeted kinase inhibitors, including dasatinib, with the capability of reversing microenvironment-induced resistance to FLT3 inhibition were identified and validated.  We validated synergy in vitro and demonstrated effective combination potential in vivo.  In particular Janus kinase inhibitors were effective in overriding stromal protection and potentiating FLT3 inhibition in primary AML and cell lines.  These results hint at a novel concept of using combination therapy to override drug resistance in mutant FLT3-pos. AML in the bone marrow niche and suppress or eradicate residual disease.  Leukemia (2012) 26, 2233-2244; doi:10.1038/leu.2012.96; published online 1 May 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr06E1HAXSPQrVg90H21EOLACvtfcHk0lhVaVeHiQaXng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSgurfN&md5=8bb4fcb2f4d911f1c32057b94d450419</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fleu.2012.96&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2012.96%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DNelson%26aufirst%3DE.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DChristie%26aufirst%3DA.%2BL.%26aulast%3DBronson%26aufirst%3DR.%26aulast%3DSattler%26aufirst%3DM.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DMitsiades%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DDaley%26aufirst%3DJ.%2BF.%26aulast%3DStone%26aufirst%3DR.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DGray%26aufirst%3DN.%26atitle%3DUsing%2520combination%2520therapy%2520to%2520override%2520stromal-mediated%2520chemoresistance%2520in%2520mutant%2520FLT3-positive%2520AML%253A%2520synergism%2520between%2520FLT3%2520inhibitors%252C%2520dasatinib%252Fmulti-targeted%2520inhibitors%2520and%2520JAK%2520inhibitors%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26issue%3D10%26spage%3D2233%26epage%3D2244%26doi%3D10.1038%2Fleu.2012.96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundy-Bosse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitman, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bearss, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligiuri, M. A.</span></span> <span> </span><span class="NLM_article-title">Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2382</span>– <span class="NLM_lpage">2389</span>, <span class="refDoi"> DOI: 10.1038/leu.2015.147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fleu.2015.147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=26172401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOisrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=2382-2389&issue=12&author=I.+K.+Parkauthor=B.+Mundy-Bosseauthor=S.+P.+Whitmanauthor=X.+Zhangauthor=S.+L.+Warnerauthor=D.+J.+Bearssauthor=W.+Blumauthor=G.+Marcucciauthor=M.+A.+Caligiuri&title=Receptor+tyrosine+kinase+Axl+is+required+for+resistance+of+leukemic+cells+to+FLT3-targeted+therapy+in+acute+myeloid+leukemia&doi=10.1038%2Fleu.2015.147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia</span></div><div class="casAuthors">Park, I.-K.; Mundy-Bosse, B.; Whitman, S. P.; Zhang, X.; Warner, S. L.; Bearss, D. J.; Blum, W.; Marcucci, G.; Caligiuri, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2382-2389</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In acute myeloid leukemia (AML), about 25-30% of patients harbor a constitutively active receptor tyrosine kinase (RTK) FLT3 encoded by a FLT3 allele harboring internal tandem duplication (FLT3-ITD) mutation.  The presence of FLT3-ITD correlates with poor prognosis in AML and it makes FLT3 an attractive therapeutic target in AML.  Unfortunately, to date small-mol. inhibitors of FLT3 have resulted in only partial and transient clin. responses with residual leukemic blasts resistant to FLT3 inhibitors detected in blood or bone marrow.  In this study, we investigated whether the RTK Axl is responsible for resistance of FLT3-ITD+ AML cells to PKC412 and AC220, FLT3 inhibitors currently under clin. trials for FLT3-ITD+ AML patients.  Upon treatment with PKC412 or AC220, phosphorylation of Axl was significantly enhanced in the FLT3-ITD+ MV4-11 AML cell line and in primary blasts from a FLT3-ITD+ AML patient.  Consistently, a PKC412-resistant AML cell line and PKC412-resistant primary blasts from FLT3-ITD+ AML patients had significantly higher levels of constitutively phosphorylated Axl and total Axl when compared with a PKC412-sensitive AML cell line and PKC412-sensitive primary blasts from FLT3-ITD+ AML patients.  We also found that resistance of AML cells against the FLT3 inhibitor PKC412 and AC220 was substantially diminished by the inhibition of Axl via a small-mol. inhibitor TP-0903, a sol. receptor Axl fusion protein Axl-Fc or knockdown of Axl gene expression by shRNA.  Collectively, our study suggests that Axl is required for resistance of FLT3-ITD+ AML cells against the FLT3 inhibitor PKC412 and AC220, and that inhibition of Axl activation may overcome resistance to FLT3-targeted therapy in FLT3-ITD+ AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeDvBUXvGLubVg90H21EOLACvtfcHk0lhVaVeHiQaXng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOisrvI&md5=a9f83832544a12ccdb85215e9e26cabc</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.147%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DI.%2BK.%26aulast%3DMundy-Bosse%26aufirst%3DB.%26aulast%3DWhitman%26aufirst%3DS.%2BP.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26aulast%3DBlum%26aufirst%3DW.%26aulast%3DMarcucci%26aufirst%3DG.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26atitle%3DReceptor%2520tyrosine%2520kinase%2520Axl%2520is%2520required%2520for%2520resistance%2520of%2520leukemic%2520cells%2520to%2520FLT3-targeted%2520therapy%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2015%26volume%3D29%26issue%3D12%26spage%3D2382%26epage%3D2389%26doi%3D10.1038%2Fleu.2015.147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erba, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baccarani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cripe, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meloni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godley, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amadori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiktor-Jedrzejczak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juliusson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litzow, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersdorf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremmel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bensen-Kennedy, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. D.</span></span> <span> </span><span class="NLM_article-title">Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>117</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3294</span>– <span class="NLM_lpage">3301</span>, <span class="refDoi"> DOI: 10.1182/blood-2010-08-301796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2010-08-301796" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=21270442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslams7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=3294-3301&issue=12&author=M.+Levisauthor=F.+Ravandiauthor=E.+S.+Wangauthor=M.+R.+Baerauthor=A.+Perlauthor=S.+Coutreauthor=H.+Erbaauthor=R.+K.+Stuartauthor=M.+Baccaraniauthor=L.+D.+Cripeauthor=M.+S.+Tallmanauthor=G.+Meloniauthor=L.+A.+Godleyauthor=A.+A.+Langstonauthor=S.+Amadoriauthor=I.+D.+Lewisauthor=A.+Naglerauthor=R.+Stoneauthor=K.+Yeeauthor=A.+Advaniauthor=D.+Douerauthor=W.+Wiktor-Jedrzejczakauthor=G.+Juliussonauthor=M.+R.+Litzowauthor=S.+Petersdorfauthor=M.+Sanzauthor=H.+M.+Kantarjianauthor=T.+Satoauthor=L.+Tremmelauthor=D.+M.+Bensen-Kennedyauthor=D.+Smallauthor=B.+D.+Smith&title=Results+from+a+randomized+trial+of+salvage+chemotherapy+followed+by+lestaurtinib+for+patients+with+FLT3+mutant+AML+in+first+relapse&doi=10.1182%2Fblood-2010-08-301796"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse</span></div><div class="casAuthors">Levis, Mark; Ravandi, Farhad; Wang, Eunice S.; Baer, Maria R.; Perl, Alexander; Coutre, Steven; Erba, Harry; Stuart, Robert K.; Baccarani, Michele; Cripe, Larry D.; Tallman, Martin S.; Meloni, Giovanna; Godley, Lucy A.; Langston, Amelia A.; Amadori, Sergio; Lewis, Ian D.; Nagler, Arnon; Stone, Richard; Yee, Karen; Advani, Anjali; Douer, Dan; Wiktor-Jedrzejczak, W.; Juliusson, Gunnar; Litzow, Mark R.; Petersdorf, Stephen; Sanz, Miguel; Kantarjian, Hagop M.; Sato, Takashi; Tremmel, Lothar; Bensen-Kennedy, Debra M.; Small, Donald; Smith, B. Douglas</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3294-3301</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">In a randomized trial of therapy for FMS-like tyrosine kinase-3 (FLT3) mutant acute myeloid leukemia in first relapse, 224 patients received chemotherapy alone or followed by 80 mg of the FLT3 inhibitor lestaurtinib twice daily.  Endpoints included complete remission or complete remission with incomplete platelet recovery (CR/CRp), overall survival, safety, and tolerability.  Correlative studies included pharmacokinetics and anal. of in vivo FLT3 inhibition.  There were 29 patients with CR/CRp in the lestaurtinib arm and 23 in the control arm (26% vs 21%; P = .35), and no difference in overall survival between the 2 arms.  There was evidence of toxicity in the lestaurtinib-treated patients, particularly those with plasma levels in excess of 20μM.  In the lestaurtinib arm, FLT3 inhibition was highly correlated with remission rate, but target inhibition on day 15 was achieved in only 58% of patients receiving lestaurtinib.  Given that such a small proportion of patients on this trial achieved sustained FLT3 inhibition in vivo, any conclusions regarding the efficacy of combining FLT3 inhibition with chemotherapy are limited.  Overall, lestaurtinib treatment after chemotherapy did not increase response rates or prolong survival of patients with FLT3 mutant acute myeloid leukemia in first relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNtYr30842srVg90H21EOLACvtfcHk0liFLs4buQ2t4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslams7o%253D&md5=7e3647298bb0ee66ac72786f103d8f3b</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-08-301796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-08-301796%26sid%3Dliteratum%253Aachs%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DE.%2BS.%26aulast%3DBaer%26aufirst%3DM.%2BR.%26aulast%3DPerl%26aufirst%3DA.%26aulast%3DCoutre%26aufirst%3DS.%26aulast%3DErba%26aufirst%3DH.%26aulast%3DStuart%26aufirst%3DR.%2BK.%26aulast%3DBaccarani%26aufirst%3DM.%26aulast%3DCripe%26aufirst%3DL.%2BD.%26aulast%3DTallman%26aufirst%3DM.%2BS.%26aulast%3DMeloni%26aufirst%3DG.%26aulast%3DGodley%26aufirst%3DL.%2BA.%26aulast%3DLangston%26aufirst%3DA.%2BA.%26aulast%3DAmadori%26aufirst%3DS.%26aulast%3DLewis%26aufirst%3DI.%2BD.%26aulast%3DNagler%26aufirst%3DA.%26aulast%3DStone%26aufirst%3DR.%26aulast%3DYee%26aufirst%3DK.%26aulast%3DAdvani%26aufirst%3DA.%26aulast%3DDouer%26aufirst%3DD.%26aulast%3DWiktor-Jedrzejczak%26aufirst%3DW.%26aulast%3DJuliusson%26aufirst%3DG.%26aulast%3DLitzow%26aufirst%3DM.%2BR.%26aulast%3DPetersdorf%26aufirst%3DS.%26aulast%3DSanz%26aufirst%3DM.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DSato%26aufirst%3DT.%26aulast%3DTremmel%26aufirst%3DL.%26aulast%3DBensen-Kennedy%26aufirst%3DD.%2BM.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26atitle%3DResults%2520from%2520a%2520randomized%2520trial%2520of%2520salvage%2520chemotherapy%2520followed%2520by%2520lestaurtinib%2520for%2520patients%2520with%2520FLT3%2520mutant%2520AML%2520in%2520first%2520relapse%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26issue%3D12%26spage%3D3294%26epage%3D3301%26doi%3D10.1182%2Fblood-2010-08-301796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyoi, H.</span></span> <span> </span><span class="NLM_article-title">Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">30</span>),  <span class="NLM_fpage">47018</span>– <span class="NLM_lpage">47032</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.10147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.18632%2Foncotarget.10147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=27331411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BC2s7isFKhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=47018-47032&issue=30&author=F.+Chenauthor=Y.+Ishikawaauthor=A.+Akashiauthor=T.+Naoeauthor=H.+Kiyoi&title=Co-expression+of+wild-type+FLT3+attenuates+the+inhibitory+effect+of+FLT3+inhibitor+on+FLT3+mutated+leukemia+cells&doi=10.18632%2Foncotarget.10147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells</span></div><div class="casAuthors">Chen Fangli; Ishikawa Yuichi; Akashi Akimi; Kiyoi Hitoshi; Naoe Tomoki</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">47018-47032</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">FLT3 mutation is found in about 30% of acute myeloid leukemia (AML) patients and is associated with a poor prognosis.  Several FLT3 inhibitors are undergoing investigation, while their clinical efficacies were lower than expected and several resistant mechanisms to FLT3 inhibitors have been demonstrated.  Although most AML cells harboring FLT3 mutation co-express wild-type (Wt)-FLT3, it is not fully understood how Wt-FLT3 expression is associated with the resistance to FLT3 inhibitors.  In this study, we elucidated a resistant mechanism by which FL-dependent Wt-FLT3 activation reduced inhibitory effects of FLT3 inhibitors.  We demonstrated that FL-stimulation much more strongly reduced growth inhibitory effects of FLT3 inhibitors on Wt- and mutant-FLT3 co-expressing cells than sole mutant-FLT3 expressing cells both in vitro and in vivo.  It was also confirmed that FL impaired the anti-leukemia effects of FLT3 inhibitors on primary AML cells.  We elucidated that FL impeded the inhibitory effects of FLT3 inhibitors mainly through the activation of Wt-FLT3, but not mutated FLT3, in the Wt- and ITD-FLT3 co-expressing cells.  Furthermore, FL-induced activation of Wt-FLT3-MAPK axis was the dominant pathway for the resistance, and the glycosylation of Wt-FLT3 was also vital for FL-dependent kinase activation and following resistance to FLT3 inhibitors.  Thus, we clarified the importance of co-expressing Wt-FLT3 in resistance to FLT3 inhibitors.  These findings provide us with important implications for clinical application and new strategies to improve clinical outcomes of FLT3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRyBiRvpDlPv_SAs_PE1QvifW6udTcc2ebAdadKUvEsJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7isFKhtQ%253D%253D&md5=95b7de22ecd33946cb95e4b22f68fe78</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.10147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.10147%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DF.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAkashi%26aufirst%3DA.%26aulast%3DNaoe%26aufirst%3DT.%26aulast%3DKiyoi%26aufirst%3DH.%26atitle%3DCo-expression%2520of%2520wild-type%2520FLT3%2520attenuates%2520the%2520inhibitory%2520effect%2520of%2520FLT3%2520inhibitor%2520on%2520FLT3%2520mutated%2520leukemia%2520cells%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26issue%3D30%26spage%3D47018%26epage%3D47032%26doi%3D10.18632%2Foncotarget.10147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Traer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javidi-Sharifi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunlap, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">English, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacsovics, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span> <span> </span><span class="NLM_article-title">FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">6471</span>– <span class="NLM_lpage">6482</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-3569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F0008-5472.CAN-15-3569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=27671675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVCjt7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=6471-6482&issue=22&author=E.+Traerauthor=J.+Martinezauthor=N.+Javidi-Sharifiauthor=A.+Agarwalauthor=J.+Dunlapauthor=I.+Englishauthor=T.+Kovacsovicsauthor=J.+W.+Tynerauthor=M.+Wongauthor=B.+J.+Druker&title=FGF2+from+marrow+microenvironment+promotes+resistance+to+FLT3+inhibitors+in+acute+myeloid+leukemia&doi=10.1158%2F0008-5472.CAN-15-3569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia</span></div><div class="casAuthors">Traer, Elie; Martinez, Jacqueline; Javidi-Sharifi, Nathalie; Agarwal, Anupriya; Dunlap, Jennifer; English, Isabel; Kovacsovics, Tibor; Tyner, Jeffrey W.; Wong, Melissa; Druker, Brian J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6471-6482</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Potent FLT3 inhibitors, such as quizartinib (AC220), have shown promise in treating acute myeloid leukemia (AML) contg. FLT3 internal tandem duplication (ITD) mutations.  However, responses are not durable and resistance develops within months.  In this study, we outline a two-step model of resistance whereby extrinsic microenvironmental proteins FLT3 ligand (FL) and fibroblast growth factor 2 (FGF2) protect FLT3-ITD+ MOLM14 cells from AC220, providing time for subsequent accumulation of ligand-independent resistance mechanisms.  FL directly attenuated AC220 inhibition of FLT3, consistent with previous reports.  Conversely, FGF2 promoted resistance through activation of FGFR1 and downstream MAPK effectors; these resistant cells responded synergistically to combinatorial inhibition of FGFR1 and FLT3.  Removing FL or FGF2 from ligand-dependent resistant cultures transiently restored sensitivity to AC220, but accelerated acquisition of secondary resistance via reactivation of FLT3 and RAS/MAPK signaling.  FLT3-ITD AML patients treated with AC220 developed increased FGF2 expression in marrow stromal cells, which peaked prior to overt clin. relapse and detection of resistance mutations.  Overall, these results support a strategy of early combination therapy to target early survival signals from the bone marrow microenvironment, in particular FGF2, to improve the depth of response in FLT3-ITD AML.  Cancer Res; 76(22); 6471-82. cpr2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW1JQ4QAjsZbVg90H21EOLACvtfcHk0ljhhPXhnJaoxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVCjt7rE&md5=ad8ad0fc77302b1d31d5927e25c51604</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-3569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-3569%26sid%3Dliteratum%253Aachs%26aulast%3DTraer%26aufirst%3DE.%26aulast%3DMartinez%26aufirst%3DJ.%26aulast%3DJavidi-Sharifi%26aufirst%3DN.%26aulast%3DAgarwal%26aufirst%3DA.%26aulast%3DDunlap%26aufirst%3DJ.%26aulast%3DEnglish%26aufirst%3DI.%26aulast%3DKovacsovics%26aufirst%3DT.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DWong%26aufirst%3DM.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DFGF2%2520from%2520marrow%2520microenvironment%2520promotes%2520resistance%2520to%2520FLT3%2520inhibitors%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26issue%3D22%26spage%3D6471%26epage%3D6482%26doi%3D10.1158%2F0008-5472.CAN-15-3569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. J.</span></span> <span> </span><span class="NLM_article-title">Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors</span>. <i>Blood Adv.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">908</span>– <span class="NLM_lpage">916</span>, <span class="refDoi"> DOI: 10.1182/bloodadvances.2018022921</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fbloodadvances.2018022921" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=30898762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1ahs7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2019&pages=908-916&issue=6&author=Y.+T.+Changauthor=D.+Hernandezauthor=S.+Alonsoauthor=M.+Gaoauthor=M.+Suauthor=G.+Ghiaurauthor=M.+J.+Levisauthor=R.+J.+Jones&title=Role+of+CYP3A4+in+bone+marrow+microenvironment-mediated+protection+of+FLT3%2FITD+AML+from+tyrosine+kinase+inhibitors&doi=10.1182%2Fbloodadvances.2018022921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors</span></div><div class="casAuthors">Chang, Yu-Ting; Hernandez, Daniela; Alonso, Salvador; Gao, Minling; Su, Meng; Ghiaur, Gabriel; Levis, Mark J.; Jones, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">Blood Advances</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">908-916</span>CODEN:
                <span class="NLM_cas:coden">BALDBA</span>;
        ISSN:<span class="NLM_cas:issn">2473-9537</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">An intriguing aspect of the clin. activity of FMS-like tyrosine kinase 3 inhibitors (FLT3 TKIs) is their apparent higher activity against peripheral blasts from FLT3/internal tandem duplication (ITD) acute myeloid leukemia than marrow disease in the same patients.  Accordingly, studies showed that the bone marrow microenvironment plays a role in FLT3 TKI resistance, although the underlying mechanisms are unclear.  We recently identified a previously undescribed mechanism by which the bone marrow microenvironment can contribute to drug resistance: expression of cytochrome P 450 enzymes (CYPs).  In fact, bone marrow stromal cells (BMSCs) expressed most CYPs, including CYP3A4.  Because hepatic CYP3A4 plays a role in the inactivation of several FLT3 TKIs, we explored the potential role of CYP3A4 in bone marrow microenvironment-mediated FLT3 TKI resistance.  We found that CYP3A4 plays a major role in BMSC-mediated inhibition in the activity of 3 different FLT3 TKIs (sorafenib, quizartinib, and gilteritinib) against FLT3/ITD acute myeloid leukemia (AML).  Furthermore, clarithromycin, a clin. active CYP3A4 inhibitor, significantly reversed the protective effects of BMSCs.  We show, for the first time, that bone marrow stromal CYP3A4 contributes to FLT3 TKI resistance in the bone marrow.  These results suggest that combining FLT3 TKIs with CYP3A4 inhibitors could be a promising strategy toward improving the activity of FLT3 TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiUvvLQPJXqrVg90H21EOLACvtfcHk0ljhhPXhnJaoxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1ahs7%252FM&md5=b6e068417dec6eaa20321697024c31fe</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1182%2Fbloodadvances.2018022921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fbloodadvances.2018022921%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DY.%2BT.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DAlonso%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DGhiaur%26aufirst%3DG.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DJones%26aufirst%3DR.%2BJ.%26atitle%3DRole%2520of%2520CYP3A4%2520in%2520bone%2520marrow%2520microenvironment-mediated%2520protection%2520of%2520FLT3%252FITD%2520AML%2520from%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBlood%2520Adv.%26date%3D2019%26volume%3D3%26issue%3D6%26spage%3D908%26epage%3D916%26doi%3D10.1182%2Fbloodadvances.2018022921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, W.</span></span> <span> </span><span class="NLM_article-title">MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">913</span>– <span class="NLM_lpage">921</span>, <span class="refDoi"> DOI: 10.1038/leu.2016.297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fleu.2016.297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=27773927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCjt7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=913-921&issue=4&author=B.+Xuauthor=Y.+Zhaoauthor=X.+Wangauthor=P.+Gongauthor=W.+Ge&title=MZH29+is+a+novel+potent+inhibitor+that+overcomes+drug+resistance+FLT3+mutations+in+acute+myeloid+leukemia&doi=10.1038%2Fleu.2016.297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia</span></div><div class="casAuthors">Xu, B.; Zhao, Y.; Wang, X.; Gong, P.; Ge, W.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">913-921</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">More than one-third of patients with acute myeloid leukemia (AML) harbor aberrant mutations in Fms-like tyrosine kinase 3 (FLT3).  Among them, the internal tandem duplication (ITD) mutation predicts poor prognosis.  MZH29 is a novel FLT3 inhibitor synthesized in our lab. that showed that cellular and kinase assays sustained inhibitory effects on wild-type and mutant FLT3, including the FLT3-ITD, FLT3-D835H/Y/V and FLT3-K663Q mutants.  More importantly, MZH29 retained its potent inhibitory effect against the FLT3-ITD/F691L mutation, a drug resistance mutation against the well-known FLT3 inhibitor, AC220.  MZH29 is a type II FLT3 inhibitor that tolerated the F691L mutation in mol. docking studies.  Oral administration of 10 mg/kg MZH29 caused complete tumor regression and extended survival in a mouse model of AML with less toxicity.  Subsequent proteomics study revealed less proteome perturbation in the MZH29-treated group than in the AC220-treated group.  MZH29 demonstrates potential and potent novel FLT3 inhibitory effects for the treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqypie-S2V6M7Vg90H21EOLACvtfcHk0ljhhPXhnJaoxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCjt7fI&md5=76a4ff225ff13fc14e810826e75572fc</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1038%2Fleu.2016.297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2016.297%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DGe%26aufirst%3DW.%26atitle%3DMZH29%2520is%2520a%2520novel%2520potent%2520inhibitor%2520that%2520overcomes%2520drug%2520resistance%2520FLT3%2520mutations%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2017%26volume%3D31%26issue%3D4%26spage%3D913%26epage%3D921%26doi%3D10.1038%2Fleu.2016.297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fathi, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blonquist, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amrein, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballen, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMasters, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avigan, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobbs, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behnan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Som, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rae, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishman, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuberg, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span> <span> </span><span class="NLM_article-title">Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>124</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">306</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1002/cncr.31038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1002%2Fcncr.31038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=28960265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1Wgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2018&pages=306-314&issue=2&author=A.+T.+Fathiauthor=T.+M.+Blonquistauthor=D.+Hernandezauthor=P.+C.+Amreinauthor=K.+K.+Ballenauthor=M.+McMastersauthor=D.+E.+Aviganauthor=R.+Joyceauthor=E.+K.+Loganauthor=G.+Hobbsauthor=A.+M.+Brunnerauthor=C.+Josephauthor=A.+M.+Perryauthor=M.+Burkeauthor=T.+Behnanauthor=J.+Fosterauthor=M.+K.+Bergeronauthor=J.+A.+Moranauthor=A.+Y.+Ramosauthor=T.+T.+Somauthor=J.+Raeauthor=K.+M.+Fishmanauthor=K.+L.+McGregorauthor=C.+Connollyauthor=D.+S.+Neubergauthor=M.+J.+Levis&title=Cabozantinib+is+well+tolerated+in+acute+myeloid+leukemia+and+effectively+inhibits+the+resistance-conferring+FLT3%2Ftyrosine+kinase+domain%2FF691+mutation&doi=10.1002%2Fcncr.31038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation</span></div><div class="casAuthors">Fathi, Amir T.; Blonquist, Traci M.; Hernandez, Daniela; Amrein, Philip C.; Ballen, Karen K.; McMasters, Malgorzata; Avigan, David E.; Joyce, Robin; Logan, Emma K.; Hobbs, Gabriela; Brunner, Andrew M.; Joseph, Christelle; Perry, Ashley M.; Burke, Meghan; Behnan, Tanya; Foster, Julia; Bergeron, Meghan K.; Moran, Jenna A.; Ramos, Aura Y.; Som, Tina T.; Rae, Jessica; Fishman, Kaitlyn M.; McGregor, Kristin L.; Connolly, Christine; Neuberg, Donna S.; Levis, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">306-314</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND : Cabozantinib, a tyrosine kinase inhibitor of FMS-like tyrosine kinase 3 (FLT3), MET, AXL, vascular endothelial growth factor receptor, and KIT, is approved for use in multiple malignancies.  We assessed the safety and tolerability of cabozantinib in AML, given up-regulation of multiple relevant pathways.  METHODS : Adults were eligible if they were 18 years old or older with relapsed/refractory AML or if they were 70 years old or older with newly diagnosed AML but were ineligible for conventional therapy.  Cabozantinib was administered in 28-day cycles, and dose escalation occurred via cohorts.  A pharmacodynamic evaluation of serial plasma samples via a plasma inhibitory assay (PIA) was used to assess FLT3-inhibitory activity in FLT3-mutant cell lines.  RESULTS : Among 18 patients enrolled, 5 were found to harbor FLT3/ITD mutations.  Sixteen patients (89%) had relapsed/refractory AML, and most were treated with 2 or more lines of prior treatment.  No dose-limiting toxicities (DLTs) were detected at the first dose level (40 mg daily), but 2 patients experienced DLTs at the next level (60 mg daily).  The remaining patients were then dosed at 40 mg daily, the max. tolerated dose (MTD).  Addnl. grade 2 or higher toxicities, possibly/probably related to cabozantinib, included fatigue, nausea, transaminitis, and electrolyte imbalance.  No patients had a marrow response according to formal criteria, but 4 had peripheral blast redns.; 2 of these 4 patients transiently cleared circulating blasts.  One patient experienced a redn. in marrow blasts, and 1 had stable disease.  The FLT3-inhibitory activity of plasma samples, as assessed with the PIA, revealed potent and sustained inhibition in FLT3/ITD and, notably, F691 tyrosine kinase domain (TKD)-mutant cells.  CONCLUSIONS : Cabozantinib is well tolerated in AML patients at an MTD of 40 mg daily and is a potent inhibitor of FLT3/ITD- and F691 TKD-altered tyrosine kinases.  Cancer 2018;124:306-14. © 2017 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF-_oxC3SsXbVg90H21EOLACvtfcHk0lisiC94Ial-fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1Wgsg%253D%253D&md5=ad24e48ef3222951bc1c8e3d445b4b8f</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2Fcncr.31038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.31038%26sid%3Dliteratum%253Aachs%26aulast%3DFathi%26aufirst%3DA.%2BT.%26aulast%3DBlonquist%26aufirst%3DT.%2BM.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DAmrein%26aufirst%3DP.%2BC.%26aulast%3DBallen%26aufirst%3DK.%2BK.%26aulast%3DMcMasters%26aufirst%3DM.%26aulast%3DAvigan%26aufirst%3DD.%2BE.%26aulast%3DJoyce%26aufirst%3DR.%26aulast%3DLogan%26aufirst%3DE.%2BK.%26aulast%3DHobbs%26aufirst%3DG.%26aulast%3DBrunner%26aufirst%3DA.%2BM.%26aulast%3DJoseph%26aufirst%3DC.%26aulast%3DPerry%26aufirst%3DA.%2BM.%26aulast%3DBurke%26aufirst%3DM.%26aulast%3DBehnan%26aufirst%3DT.%26aulast%3DFoster%26aufirst%3DJ.%26aulast%3DBergeron%26aufirst%3DM.%2BK.%26aulast%3DMoran%26aufirst%3DJ.%2BA.%26aulast%3DRamos%26aufirst%3DA.%2BY.%26aulast%3DSom%26aufirst%3DT.%2BT.%26aulast%3DRae%26aufirst%3DJ.%26aulast%3DFishman%26aufirst%3DK.%2BM.%26aulast%3DMcGregor%26aufirst%3DK.%2BL.%26aulast%3DConnolly%26aufirst%3DC.%26aulast%3DNeuberg%26aufirst%3DD.%2BS.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26atitle%3DCabozantinib%2520is%2520well%2520tolerated%2520in%2520acute%2520myeloid%2520leukemia%2520and%2520effectively%2520inhibits%2520the%2520resistance-conferring%2520FLT3%252Ftyrosine%2520kinase%2520domain%252FF691%2520mutation%26jtitle%3DCancer%26date%3D2018%26volume%3D124%26issue%3D2%26spage%3D306%26epage%3D314%26doi%3D10.1002%2Fcncr.31038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3–122) as a potent and orally available FLT3 kinase inhibitor for FLT3-ITD positive acute myeloid leukemia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">9625</span>– <span class="NLM_lpage">9638</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01611</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01611" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGnsL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9625-9638&issue=24&author=X.+Liauthor=A.+Wangauthor=K.+Yuauthor=Z.+Qiauthor=C.+Chenauthor=W.+Wangauthor=C.+Huauthor=H.+Wuauthor=J.+Wuauthor=Z.+Zhaoauthor=J.+Liuauthor=F.+Zouauthor=L.+Wangauthor=B.+Wangauthor=W.+Wangauthor=S.+Zhangauthor=J.+Liuauthor=Q.+Liu&title=Discovery+of+%28R%29-1-%283-%284-amino-3-%284-phenoxyphenyl%29-1H-pyrazolo%5B3%2C4-d%5Dpyrimidin-1-yl%29piperidin-1-yl%29-2-%28dimethylamino%29ethanone+%28CHMFL-FLT3%E2%80%93122%29+as+a+potent+and+orally+available+FLT3+kinase+inhibitor+for+FLT3-ITD+positive+acute+myeloid+leukemia&doi=10.1021%2Facs.jmedchem.5b01611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia</span></div><div class="casAuthors">Li, Xixiang; Wang, Aoli; Yu, Kailin; Qi, Ziping; Chen, Cheng; Wang, Wenchao; Hu, Chen; Wu, Hong; Wu, Jiaxin; Zhao, Zheng; Liu, Juan; Zou, Fengming; Wang, Li; Wang, Beilei; Wang, Wei; Zhang, Shanchun; Liu, Jing; Liu, Qingsong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9625-9638</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">FLT3-ITD mutant has been obsd. in about 30% of AML patients and extensively studied as a drug discovery target.  On the basis of the structure of PCI-32765 (ibrutinib), a BTK kinase inhibitor that was recently reported to bear FLT3 kinase activity through a structure-guided drug design approach, the authors have discovered compd. 18 (CHMFL-FLT3-122, I), which displayed an IC50 of 40 nM against FLT3 kinase and achieved selectivity over BTK kinase (over 10-fold).  It significantly inhibited the proliferation of FLT3-ITD pos. AML cancer cell lines MV4-11 (GIC50 = 22 nM), MOLM13/14 (GIC50 = 21 nM/42 nM).  More importantly, compd. 18 demonstrated 170-fold selectivity between FLT3 kinase and c-KIT kinase (GIC50 = 11 nM vs. 1900 nM) in the TEL-fusion isogenic BaF3 cells indicating a potential to avoid the FLT3/c-KIT dual inhibition induced myelosuppression toxicity.  In the cellular context it strongly affected FLT3-ITD mediated signaling pathways and induced apoptosis by arresting the cell cycle into the G0/G1 phase.  In the in vivo studies compd. 18 demonstrated a good bioavailability (30%) and significantly suppressed the tumor growth in MV4-11 cell inoculated xenograft model (50 mg/kg) without exhibiting obvious toxicity.  Compd. 18 might be a potential drug candidate for FLT3-ITD pos. AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotxBPmnbEZ17Vg90H21EOLACvtfcHk0lisiC94Ial-fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGnsL%252FJ&md5=f0d6f5f767f35c4aed3b20c02de06e86</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01611%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DQi%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520%2528R%2529-1-%25283-%25284-amino-3-%25284-phenoxyphenyl%2529-1H-pyrazolo%255B3%252C4-d%255Dpyrimidin-1-yl%2529piperidin-1-yl%2529-2-%2528dimethylamino%2529ethanone%2520%2528CHMFL-FLT3%25E2%2580%2593122%2529%2520as%2520a%2520potent%2520and%2520orally%2520available%2520FLT3%2520kinase%2520inhibitor%2520for%2520FLT3-ITD%2520positive%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D24%26spage%3D9625%26epage%3D9638%26doi%3D10.1021%2Facs.jmedchem.5b01611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-(4-(4-amino-3-(4-(2-morpholinoethoxy)phenyl)-1<i>H</i>-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a highly potent type II FLT3 kinase inhibitor capable of overcoming a variety of FLT3 kinase mutants in FLT3-ITD positive AML</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">8407</span>– <span class="NLM_lpage">8424</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00840</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00840" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOmu7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8407-8424&issue=20&author=A.+Wangauthor=X.+Liauthor=C.+Chenauthor=H.+Wuauthor=Z.+Qiauthor=C.+Huauthor=K.+Yuauthor=J.+Wuauthor=J.+Liuauthor=X.+Liuauthor=Z.+Huauthor=W.+Wangauthor=W.+Wangauthor=W.+Wangauthor=L.+Wangauthor=B.+Wangauthor=Q.+Liuauthor=L.+Liauthor=J.+Geauthor=T.+Renauthor=S.+Zhangauthor=R.+Xiaauthor=J.+Liuauthor=Q.+Liu&title=Discovery+of+1-%284-%284-amino-3-%284-%282-morpholinoethoxy%29phenyl%29-1H-pyrazolo%5B3%2C4-d%5Dpyrimidin-1-yl%29phenyl%29-3-%285-%28tert-butyl%29isoxazol-3-yl%29urea+%28CHMFL-FLT3-213%29+as+a+highly+potent+type+II+FLT3+kinase+inhibitor+capable+of+overcoming+a+variety+of+FLT3+kinase+mutants+in+FLT3-ITD+positive+AML&doi=10.1021%2Facs.jmedchem.7b00840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML</span></div><div class="casAuthors">Wang, Aoli; Li, Xixiang; Chen, Cheng; Wu, Hong; Qi, Ziping; Hu, Chen; Yu, Kailin; Wu, Jiaxin; Liu, Juan; Liu, Xiaochuan; Hu, Zhenquan; Wang, Wei; Wang, Wenliang; Wang, Wenchao; Wang, Li; Wang, Beilei; Liu, Qingwang; Li, Lili; Ge, Jian; Ren, Tao; Zhang, Shanchun; Xia, Ruixiang; Liu, Jing; Liu, Qingsong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8407-8424</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">FLT3-ITD mutant has been obsd. in about 30% of AML patients and extensively studied as a drug discovery target.  On the basis of our previous study that ibrutinib exhibited selective and moderate inhibitory activity against FLT3-ITD pos. AML cells, through a structure-guided drug design approach, we have discovered a new type II FLT3 kinase inhibitor, compd. I (CHMFL-FLT3-213), which exhibited highly potent inhibitory effects against FLT3-ITD mutant and assocd. oncogenic mutations (including FLT3-D835Y/H/V, FLT3-ITD-D835Y/I/N/A/G/Del, and FLT3-ITD-F691L).  In the cellular context I strongly affected FLT3-ITD mediated signaling pathways and induced apoptosis by arresting cell cycle into G0/G1 phase.  In the in vivo studies I demonstrated an acceptable bioavailability (F = 19%) and significantly suppressed the tumor growth in MV4-11 cell inoculated xenograft model (15 mg kg-1 day-1, TGI = 97%) without exhibiting obvious toxicity.  Compd. I might be a potential drug candidate for FLT3-ITD pos. AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1tbOp_Bxu-LVg90H21EOLACvtfcHk0lgVCOSZPu-4YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOmu7fN&md5=e4f3a47069f8ea615a3e1543b24a19b9</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00840%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DQi%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DXia%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%25201-%25284-%25284-amino-3-%25284-%25282-morpholinoethoxy%2529phenyl%2529-1H-pyrazolo%255B3%252C4-d%255Dpyrimidin-1-yl%2529phenyl%2529-3-%25285-%2528tert-butyl%2529isoxazol-3-yl%2529urea%2520%2528CHMFL-FLT3-213%2529%2520as%2520a%2520highly%2520potent%2520type%2520II%2520FLT3%2520kinase%2520inhibitor%2520capable%2520of%2520overcoming%2520a%2520variety%2520of%2520FLT3%2520kinase%2520mutants%2520in%2520FLT3-ITD%2520positive%2520AML%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D20%26spage%3D8407%26epage%3D8424%26doi%3D10.1021%2Facs.jmedchem.7b00840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Identification of pyrrolo[2,3- d]pyrimidine-based derivatives as potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3) inhibitors for treating acute myelogenous leukemia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">4158</span>– <span class="NLM_lpage">4173</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00223</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00223" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms1ajt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4158-4173&issue=8&author=X.+Yuanauthor=Y.+Chenauthor=W.+Zhangauthor=J.+Heauthor=L.+Leiauthor=M.+Tangauthor=J.+Liuauthor=M.+Liauthor=C.+Douauthor=T.+Yangauthor=L.+Yangauthor=S.+Yangauthor=Y.+Weiauthor=A.+Pengauthor=T.+Niuauthor=M.+Xiangauthor=H.+Yeauthor=L.+Chen&title=Identification+of+pyrrolo%5B2%2C3-+d%5Dpyrimidine-based+derivatives+as+potent+and+orally+effective+Fms-like+tyrosine+receptor+kinase+3+%28FLT3%29+inhibitors+for+treating+acute+myelogenous+leukemia&doi=10.1021%2Facs.jmedchem.9b00223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Pyrrolo[2,3-d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia</span></div><div class="casAuthors">Yuan, Xue; Chen, Yong; Zhang, Wanhua; He, Jun; Lei, Lei; Tang, Minghai; Liu, Jiang; Li, Muzhou; Dou, Caixia; Yang, Tao; Yang, Linyu; Yang, Shengyong; Wei, Yuquan; Peng, Aihua; Niu, Ting; Xiang, Mingli; Ye, Haoyu; Chen, Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4158-4173</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of pyrrolo[2,3-d]pyrimidine derivs. were prepd. and optimized for cytotoxic activities against FLT3-ITD mutant cancer cells.  Among them, compd. I possessed nanomolar FLT3 inhibitory activities and subnanomolar inhibitory activities against MV4-11 and Molm-13 cells.  It also showed excellent inhibitory activities in FLT3-ITD-D835V and FLT3-ITD-F691L cells which were resistant to quizartinib.  Furthermore, I exhibited over 40-fold selectivity toward FLT3 relative to c-Kit kinase, which might reduce myelosuppression toxicity.  Cellular assays demonstrated that I inhibited phosphorylated FLT3 and downstream signaling factors and also induced cell cycle arrest in the G0/G1 stage and apoptosis in MV4-11 and Molm-13 cells.  Oral administration of I at 10 mg/kg could achieve rapid tumor extinction in the MV4-11 xenograft model and significantly inhibit the tumor growth in the MOLM-13 xenograft model with a tumor growth inhibitory rate of 96% without obvious toxicity.  Addnl., I demonstrated high bioavailability (F = 59.5%) and suitable eliminated half-life time (T1/2 = 2.06 h), suggesting that I may be a potent candidate for treating acute myelogenous leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc5FKDBj_PA7Vg90H21EOLACvtfcHk0lgVCOSZPu-4YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms1ajt7s%253D&md5=37666941adb79cb2a5d8a4115ddd2519</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00223%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DLei%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DDou%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DA.%26aulast%3DNiu%26aufirst%3DT.%26aulast%3DXiang%26aufirst%3DM.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DIdentification%2520of%2520pyrrolo%255B2%252C3-%2520d%255Dpyrimidine-based%2520derivatives%2520as%2520potent%2520and%2520orally%2520effective%2520Fms-like%2520tyrosine%2520receptor%2520kinase%25203%2520%2528FLT3%2529%2520inhibitors%2520for%2520treating%2520acute%2520myelogenous%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D8%26spage%3D4158%26epage%3D4173%26doi%3D10.1021%2Facs.jmedchem.9b00223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-((7<i>H</i>-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase inhibitor with potentially high efficiency against acute myelocytic leukemia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1499</span>– <span class="NLM_lpage">1518</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01261</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01261" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1499-1518&issue=4&author=Y.+Wangauthor=Y.+Zhiauthor=Q.+Jinauthor=S.+Luauthor=G.+Linauthor=H.+Yuanauthor=T.+Yangauthor=Z.+Wangauthor=C.+Yaoauthor=J.+Lingauthor=H.+Guoauthor=T.+Liauthor=J.+Jinauthor=B.+Liauthor=L.+Zhangauthor=Y.+Chenauthor=T.+Lu&title=Discovery+of+4-%28%287H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29amino%29-N-%284-%28%284-methylpiperazin-1-yl%29methyl%29phenyl%29-1H-pyrazole-3-carboxamide+%28FN-1501%29%2C+an+FLT3-+and+CDK-Kinase+inhibitor+with+potentially+high+efficiency+against+acute+myelocytic+leukemia&doi=10.1021%2Facs.jmedchem.7b01261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia</span></div><div class="casAuthors">Wang, Yue; Zhi, Yanle; Jin, Qiaomei; Lu, Shuai; Lin, Guowu; Yuan, Haoliang; Yang, Taotao; Wang, Zhanwei; Yao, Chao; Ling, Jun; Guo, Hao; Li, Tonghui; Jin, Jianlin; Li, Baoquan; Zhang, Li; Chen, Yadong; Lu, Tao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1499-1518</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 1-H-pyrazole-3-carboxamide derivs. have been designed and synthesized that exhibit excellent FLT3 and CDK inhibition and antiproliferative activities.  A structure-activity-relationship study illustrates that the incorporation of a pyrimidine-fused heterocycle at position 4 of the pyrazole is crit. for FLT3 and CDK inhibition.  Compd. 50 (FN-1501), which possesses potent inhibitory activities against FLT3, CDK2, CDK4, and CDK6 with IC50 values in the nanomolar range, shows antiproliferative activities against MV4-11 cells (IC50: 0.008 μM), which correlates with the suppression of retinoblastoma phosphorylation, FLT3, ERK, AKT, and STAT5 and the onset of apoptosis.  Acute-toxicity studies in mice show that compd. I (LD50: 186 mg/kg) is safer than AT7519 (32 mg/kg).  In MV4-11 xenografts in a nude-mouse model, compd. I can induce tumor regression at the dose of 15 mg/kg, which is more efficient than cytarabine (50 mg/kg).  Taken together, these results demonstrate the potential of this unique compd. for further development into a drug applied in acute-myeloid-leukemia (AML) therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfX9S4QkGccbVg90H21EOLACvtfcHk0lggvBS1Glm5LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyqurg%253D&md5=2757ad7559e655c5d96f0a8af8c74aa5</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01261%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhi%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DC.%26aulast%3DLing%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DT.%26atitle%3DDiscovery%2520of%25204-%2528%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%2529-N-%25284-%2528%25284-methylpiperazin-1-yl%2529methyl%2529phenyl%2529-1H-pyrazole-3-carboxamide%2520%2528FN-1501%2529%252C%2520an%2520FLT3-%2520and%2520CDK-Kinase%2520inhibitor%2520with%2520potentially%2520high%2520efficiency%2520against%2520acute%2520myelocytic%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D4%26spage%3D1499%26epage%3D1518%26doi%3D10.1021%2Facs.jmedchem.7b01261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of the selective and efficacious inhibitors of FLT3 mutations</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.ejmech.2018.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=29894944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFaltbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2018&pages=303-315&author=Y.+Zhiauthor=B.+Liauthor=C.+Yaoauthor=H.+Liauthor=P.+Chenauthor=J.+Baoauthor=T.+Qinauthor=Y.+Wangauthor=T.+Luauthor=S.+Lu&title=Discovery+of+the+selective+and+efficacious+inhibitors+of+FLT3+mutations&doi=10.1016%2Fj.ejmech.2018.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the selective and efficacious inhibitors of FLT3 mutations</span></div><div class="casAuthors">Zhi, Yanle; Li, Baoquan; Yao, Chao; Li, Hongmei; Chen, Puzhou; Bao, Jiyin; Qin, Tianren; Wang, Yue; Lu, Tao; Lu, Shuai</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">303-315</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Fms-like tyrosine kinase 3 (FLT3) is among the most frequently mutated protein in acute myeloid leukemia (AML), which has been confirmed as an important drug target for AML chemotherapy.  Starting from the lead compd. LT-106-175, a series of 1-H-pyrazole-3-carboxamide derivs. were synthesized to improve the FLT3 inhibitory potency and selectivity.  Among them, compd. 50 (4-((2-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)amino)-N-(4-(piperazin-1-yl)phenyl)-1H-pyrazole-3-carboxamide) was identified as a highly potent and selective FLT3 inhibitor (IC50 = 0.213 nM), which showed equal activities against various mutants of FLT3 including FLT3 (ITD)-D835V and FLT3 (ITD)-F691L that is resistant to quizartinib.  Compd. 50 also exhibited efficacy against the human AML cell line MV4-11 (IC50 = 16.1 nM) harboring FLT3-ITD mutants.  Inversely, compd. 50 displayed no cytotoxicity to FLT3-independent cells, and the biochem. analyses showed that its effects were related to the inhibition of FLT3 signal pathways.  Addnl., compd. 50 induced apoptosis in MV4-11 cell as demonstrated by flow cytometry.  Moreover, compd. 50 showed enhanced metabolic stability.  Altogether, it was concluded that compd. 50 could be a promising FLT3 inhibitor for further developing therapeutic remedy of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUFIlbd1kxabVg90H21EOLACvtfcHk0lggvBS1Glm5LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFaltbzJ&md5=8b82ebdbf00f4693a7e7b94b32c9f1b7</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DZhi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DYao%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DBao%26aufirst%3DJ.%26aulast%3DQin%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520the%2520selective%2520and%2520efficacious%2520inhibitors%2520of%2520FLT3%2520mutations%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D155%26spage%3D303%26epage%3D315%26doi%3D10.1016%2Fj.ejmech.2018.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Melgar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolanos, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hueneman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunderlich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorimer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abendroth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyt, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Famulare, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulloy, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perentesis, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starczynowski, D. T.</span></span> <span> </span><span class="NLM_article-title">Overcoming adaptive therapy resistance in AML by targeting immune response pathways</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">508</span>),  <span class="NLM_fpage">eaaw8828</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aaw8828</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1126%2Fscitranslmed.aaw8828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=31484791" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=eaaw8828&issue=508&author=K.+Melgarauthor=M.+M.+Walkerauthor=L.+M.+Jonesauthor=L.+C.+Bolanosauthor=K.+Huenemanauthor=M.+Wunderlichauthor=J.+K.+Jiangauthor=K.+M.+Wilsonauthor=X.+Zhangauthor=P.+Sutterauthor=A.+Wangauthor=X.+Xuauthor=K.+Choiauthor=G.+Tawaauthor=D.+Lorimerauthor=J.+Abendrothauthor=E.+O%E2%80%99Brienauthor=S.+B.+Hoytauthor=E.+Bermanauthor=C.+A.+Famulareauthor=J.+C.+Mulloyauthor=R.+L.+Levineauthor=J.+P.+Perentesisauthor=C.+J.+Thomasauthor=D.+T.+Starczynowski&title=Overcoming+adaptive+therapy+resistance+in+AML+by+targeting+immune+response+pathways&doi=10.1126%2Fscitranslmed.aaw8828"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaw8828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaw8828%26sid%3Dliteratum%253Aachs%26aulast%3DMelgar%26aufirst%3DK.%26aulast%3DWalker%26aufirst%3DM.%2BM.%26aulast%3DJones%26aufirst%3DL.%2BM.%26aulast%3DBolanos%26aufirst%3DL.%2BC.%26aulast%3DHueneman%26aufirst%3DK.%26aulast%3DWunderlich%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DJ.%2BK.%26aulast%3DWilson%26aufirst%3DK.%2BM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSutter%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DChoi%26aufirst%3DK.%26aulast%3DTawa%26aufirst%3DG.%26aulast%3DLorimer%26aufirst%3DD.%26aulast%3DAbendroth%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DE.%26aulast%3DHoyt%26aufirst%3DS.%2BB.%26aulast%3DBerman%26aufirst%3DE.%26aulast%3DFamulare%26aufirst%3DC.%2BA.%26aulast%3DMulloy%26aufirst%3DJ.%2BC.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DPerentesis%26aufirst%3DJ.%2BP.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DStarczynowski%26aufirst%3DD.%2BT.%26atitle%3DOvercoming%2520adaptive%2520therapy%2520resistance%2520in%2520AML%2520by%2520targeting%2520immune%2520response%2520pathways%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2019%26volume%3D11%26issue%3D508%26spage%3Deaaw8828%26doi%3D10.1126%2Fscitranslmed.aaw8828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Kinase inhibitors: the road ahead</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fnrd.2018.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=29545548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1cXks12ktbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=353-377&issue=5&author=F.+M.+Fergusonauthor=N.+S.+Gray&title=Kinase+inhibitors%3A+the+road+ahead&doi=10.1038%2Fnrd.2018.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase inhibitors: the road ahead</span></div><div class="casAuthors">Ferguson, Fleur M.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">353-377</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinase signaling pathways have been successfully targeted to inhibit proliferation and angiogenesis for cancer therapy.  However, kinase deregulation has been firmly demonstrated to play an essential role in virtually all major disease areas.  Kinase inhibitor drug discovery programs have recently broadened their focus to include an expanded range of kinase targets and therapeutic areas.  In this Review, we provide an overview of the novel targets, biol. processes and disease areas that kinase-targeting small mols. are being developed against, highlight the assocd. challenges and assess the strategies and technologies that are enabling efficient generation of highly optimized kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZPospb1TP7Vg90H21EOLACvtfcHk0lggvBS1Glm5LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXks12ktbg%253D&md5=34e42911d8a70301905460c3507e737a</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.21%26sid%3Dliteratum%253Aachs%26aulast%3DFerguson%26aufirst%3DF.%2BM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DKinase%2520inhibitors%253A%2520the%2520road%2520ahead%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26issue%3D5%26spage%3D353%26epage%3D377%26doi%3D10.1038%2Fnrd.2018.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harki, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummond, K. M.</span></span> <span> </span><span class="NLM_article-title">Covalent modifiers: a chemical perspective on the reactivity of alpha,beta-unsaturated carbonyls with thiols via hetero-michael addition reactions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">839</span>– <span class="NLM_lpage">885</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC28XitV2rtbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=839-885&issue=3&author=P.+A.+Jacksonauthor=J.+C.+Widenauthor=D.+A.+Harkiauthor=K.+M.+Brummond&title=Covalent+modifiers%3A+a+chemical+perspective+on+the+reactivity+of+alpha%2Cbeta-unsaturated+carbonyls+with+thiols+via+hetero-michael+addition+reactions&doi=10.1021%2Facs.jmedchem.6b00788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions</span></div><div class="casAuthors">Jackson, Paul A.; Widen, John C.; Harki, Daniel A.; Brummond, Kay M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">839-885</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Although Michael acceptors display a potent and broad spectrum of bioactivity, they have largely been ignored in drug discovery because of their presumed indiscriminate reactivity.  As such, a dearth of information exists relevant to the thiol reactivity of natural products and their analogs possessing this moiety.  In the midst of recently approved acrylamide-contg. drugs, it is clear that a good understanding of the hetero-Michael addn. reaction and the relative reactivities of biol. thiols with Michael acceptors under physiol. conditions is needed for the design and use of these compds. as biol. tools and potential therapeutics.  This Perspective provides information that will contribute to this understanding, such as kinetics of thiol addn. reactions, bioactivities, as well as steric and electronic factors that influence the electrophilicity and reversibility of Michael acceptors.  This Perspective is focused on α,β-unsatd. carbonyls given their preponderance in bioactive natural products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn4jDqxoos17Vg90H21EOLACvtfcHk0ljONkUwle-2ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitV2rtbnM&md5=36d3be5bf688c4e4a8cf4bcf42073009</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00788%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DP.%2BA.%26aulast%3DWiden%26aufirst%3DJ.%2BC.%26aulast%3DHarki%26aufirst%3DD.%2BA.%26aulast%3DBrummond%26aufirst%3DK.%2BM.%26atitle%3DCovalent%2520modifiers%253A%2520a%2520chemical%2520perspective%2520on%2520the%2520reactivity%2520of%2520alpha%252Cbeta-unsaturated%2520carbonyls%2520with%2520thiols%2520via%2520hetero-michael%2520addition%2520reactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D3%26spage%3D839%26epage%3D885%26doi%3D10.1021%2Facs.jmedchem.6b00788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gehringer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Emerging and re-emerging warheads for targeted covalent Inhibitors: applications in medicinal chemistry and chemical biology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5673</span>– <span class="NLM_lpage">5724</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01153</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01153" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFKiur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5673-5724&issue=12&author=M.+Gehringerauthor=S.+A.+Laufer&title=Emerging+and+re-emerging+warheads+for+targeted+covalent+Inhibitors%3A+applications+in+medicinal+chemistry+and+chemical+biology&doi=10.1021%2Facs.jmedchem.8b01153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology</span></div><div class="casAuthors">Gehringer, Matthias; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5673-5724</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Targeted covalent inhibitors (TCIs) are designed to bind poorly conserved amino acids by means of reactive groups, the so-called warheads.  Currently, targeting noncatalytic cysteine residues with acrylamides and other α,β-unsatd. carbonyl compds. is the predominant strategy in TCI development.  The recent ascent of covalent drugs has stimulated considerable efforts to characterize alternative warheads for the covalent-reversible and irreversible engagement of noncatalytic cysteine residues as well as other amino acids.  This Perspective article provides an overview of warheads-beyond α,β-unsatd. amides-recently used in the design of targeted covalent ligands.  Promising reactive groups that have not yet demonstrated their utility in TCI development are also highlighted.  Special emphasis is placed on the discussion of reactivity and of case studies illustrating applications in medicinal chem. and chem. biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDhc4PWV293LVg90H21EOLACvtfcHk0ljONkUwle-2ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFKiur%252FL&md5=4623733558ff99aadebfc13950b816ad</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01153%26sid%3Dliteratum%253Aachs%26aulast%3DGehringer%26aufirst%3DM.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DEmerging%2520and%2520re-emerging%2520warheads%2520for%2520targeted%2520covalent%2520Inhibitors%253A%2520applications%2520in%2520medicinal%2520chemistry%2520and%2520chemical%2520biology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D12%26spage%3D5673%26epage%3D5724%26doi%3D10.1021%2Facs.jmedchem.8b01153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lonsdale, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of targeted covalent inhibitors</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3816</span>– <span class="NLM_lpage">3830</span>, <span class="refDoi"> DOI: 10.1039/C7CS00220C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1039%2FC7CS00220C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=29620097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVGiurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2018&pages=3816-3830&issue=11&author=R.+Lonsdaleauthor=R.+A.+Ward&title=Structure-based+design+of+targeted+covalent+inhibitors&doi=10.1039%2FC7CS00220C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of targeted covalent inhibitors</span></div><div class="casAuthors">Lonsdale, Richard; Ward, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3816-3830</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Covalent inhibition is a rapidly growing discipline within drug discovery.  Many historical covalent inhibitors were discovered by serendipity, with such a mechanism of action often regarded as undesirable due to potential toxicity issues.  Recent progress has seen a major shift in this outlook, as covalent inhibition shows promise for targets where previous efforts to identify non-covalent small mol. inhibitors have failed.  Targeted covalent inhibitors (TCIs) can offer drug discovery scientists the ability to increase the potency and/or selectivity of small mol. inhibitors, by attachment of reactive functional groups designed to covalently bind to specific sites in a target.  In this tutorial review we introduce the broader concept of covalent inhibition, discuss the potential benefits and challenges of such an approach, and provide an overview of the current status of the field.  We also describe some strategies and computational tools to enable successful covalent drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnSIGMuS3vm7Vg90H21EOLACvtfcHk0ljONkUwle-2ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVGiurs%253D&md5=a7e31b23cf8ecfcad1397ad10ea10b7b</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1039%2FC7CS00220C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7CS00220C%26sid%3Dliteratum%253Aachs%26aulast%3DLonsdale%26aufirst%3DR.%26aulast%3DWard%26aufirst%3DR.%2BA.%26atitle%3DStructure-based%2520design%2520of%2520targeted%2520covalent%2520inhibitors%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2018%26volume%3D47%26issue%3D11%26spage%3D3816%26epage%3D3830%26doi%3D10.1039%2FC7CS00220C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Angst, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gessier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janser, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walchli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beerli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littlewood-Evans, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuesslein-Hildesheim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieczorek, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheufler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinniger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerlin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funhoff, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cenni, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of LOU064 (remibrutinib), a potent and highly selective covalent inhibitor of Bruton’s tyrosine kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">5102</span>– <span class="NLM_lpage">5118</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01916</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01916" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjs1KiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=5102-5118&issue=10&author=D.+Angstauthor=F.+Gessierauthor=P.+Janserauthor=A.+Vulpettiauthor=R.+Walchliauthor=C.+Beerliauthor=A.+Littlewood-Evansauthor=J.+Dawsonauthor=B.+Nuesslein-Hildesheimauthor=G.+Wieczorekauthor=S.+Gutmannauthor=C.+Scheuflerauthor=A.+Hinnigerauthor=A.+Zimmerlinauthor=E.+G.+Funhoffauthor=R.+Pulzauthor=B.+Cenni&title=Discovery+of+LOU064+%28remibrutinib%29%2C+a+potent+and+highly+selective+covalent+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1021%2Facs.jmedchem.9b01916"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase</span></div><div class="casAuthors">Angst, Daniela; Gessier, Francois; Janser, Philipp; Vulpetti, Anna; Walchli, Rudolf; Beerli, Christian; Littlewood-Evans, Amanda; Dawson, Janet; Nuesslein-Hildesheim, Barbara; Wieczorek, Grazyna; Gutmann, Sascha; Scheufler, Clemens; Hinniger, Alexandra; Zimmerlin, Alfred; Funhoff, Enrico G.; Pulz, Robert; Cenni, Bruno</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5102-5118</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases.  The use of currently marketed covalent BTK inhibitors is limited to oncol. indications based on their suboptimal kinase selectivity.  We describe the discovery and preclin. profile of LOU064 (remibrutinib, 25), a potent, highly selective covalent BTK inhibitor.  LOU064 exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for a best-in-class covalent BTK inhibitor for the treatment of autoimmune diseases.  It demonstrates potent in vivo target occupancy with an EC90 of 1.6 mg/kg and dose-dependent efficacy in rat collagen-induced arthritis.  LOU064 is currently being tested in phase 2 clin. studies for chronic spontaneous urticaria and Sjoegren's syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBR_esJ38IMrVg90H21EOLACvtfcHk0lijNNgjzcAD9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjs1KiurY%253D&md5=9122b310c294d6071ae7cd73cdb91b3d</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01916%26sid%3Dliteratum%253Aachs%26aulast%3DAngst%26aufirst%3DD.%26aulast%3DGessier%26aufirst%3DF.%26aulast%3DJanser%26aufirst%3DP.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DWalchli%26aufirst%3DR.%26aulast%3DBeerli%26aufirst%3DC.%26aulast%3DLittlewood-Evans%26aufirst%3DA.%26aulast%3DDawson%26aufirst%3DJ.%26aulast%3DNuesslein-Hildesheim%26aufirst%3DB.%26aulast%3DWieczorek%26aufirst%3DG.%26aulast%3DGutmann%26aufirst%3DS.%26aulast%3DScheufler%26aufirst%3DC.%26aulast%3DHinniger%26aufirst%3DA.%26aulast%3DZimmerlin%26aufirst%3DA.%26aulast%3DFunhoff%26aufirst%3DE.%2BG.%26aulast%3DPulz%26aufirst%3DR.%26aulast%3DCenni%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520LOU064%2520%2528remibrutinib%2529%252C%2520a%2520potent%2520and%2520highly%2520selective%2520covalent%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D10%26spage%3D5102%26epage%3D5118%26doi%3D10.1021%2Facs.jmedchem.9b01916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin
Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elzinga, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westhouse, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catlett, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pokross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allentoff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of branebrutinib (BMS-986195): a strategy for identifying a highly potent and selective covalent inhibitor providing rapid <i>in vivo</i> inactivation of Bruton’s tyrosine kinase (BTK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3228</span>– <span class="NLM_lpage">3250</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00167</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00167" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXls1aks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3228-3250&issue=7&author=S.+H.+Wattersonauthor=Q.+Liuauthor=M.+Beaudoin%0ABertrandauthor=D.+G.+Battauthor=L.+Liauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=L.+Chengauthor=M.+T.+Obermeierauthor=R.+Mooreauthor=Z.+Yangauthor=R.+Vickeryauthor=P.+A.+Elzingaauthor=L.+Discenzaauthor=C.+D%E2%80%99Arienzoauthor=K.+M.+Gilloolyauthor=T.+L.+Taylorauthor=C.+Pulicicchioauthor=Y.+Zhangauthor=E.+Heimrichauthor=K.+W.+McIntyreauthor=Q.+Ruanauthor=R.+A.+Westhouseauthor=I.+M.+Catlettauthor=N.+Zhengauthor=C.+Chaudhryauthor=J.+Daiauthor=M.+A.+Galellaauthor=A.+J.+Tebbenauthor=M.+Pokrossauthor=J.+Liauthor=R.+Zhaoauthor=D.+Smithauthor=R.+Rampullaauthor=A.+Allentoffauthor=M.+A.+Wallaceauthor=A.+Mathurauthor=L.+Salter-Cidauthor=J.+E.+Macorauthor=P.+H.+Carterauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+A.+Tino&title=Discovery+of+branebrutinib+%28BMS-986195%29%3A+a+strategy+for+identifying+a+highly+potent+and+selective+covalent+inhibitor+providing+rapid+in+vivo+inactivation+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29&doi=10.1021%2Facs.jmedchem.9b00167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK)</span></div><div class="casAuthors">Watterson, Scott H.; Liu, Qingjie; Beaudoin Bertrand, Myra; Batt, Douglas G.; Li, Ling; Pattoli, Mark A.; Skala, Stacey; Cheng, Lihong; Obermeier, Mary T.; Moore, Robin; Yang, Zheng; Vickery, Rodney; Elzinga, Paul A.; Discenza, Lorell; D'Arienzo, Celia; Gillooly, Kathleen M.; Taylor, Tracy L.; Pulicicchio, Claudine; Zhang, Yifan; Heimrich, Elizabeth; McIntyre, Kim W.; Ruan, Qian; Westhouse, Richard A.; Catlett, Ian M.; Zheng, Naiyu; Chaudhry, Charu; Dai, Jun; Galella, Michael A.; Tebben, Andrew J.; Pokross, Matt; Li, Jianqing; Zhao, Rulin; Smith, Daniel; Rampulla, Richard; Allentoff, Alban; Wallace, Michael A.; Mathur, Arvind; Salter-Cid, Luisa; Macor, John E.; Carter, Percy H.; Fura, Aberra; Burke, James R.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3228-3250</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a non-receptor tyrosine kinase, is a member of the Tec family of kinases and is essential for B cell receptor (BCR) mediated signaling.  BTK also plays a crit. role in the downstream signaling pathways for the Fcγ receptor in monocytes, the Fcε receptor in granulocytes, and the RANK receptor in osteoclasts.  As a result, pharmacol. inhibition of BTK is anticipated to provide an effective strategy for the clin. treatment of autoimmune diseases such as rheumatoid arthritis and lupus.  This article will outline the evolution of our strategy to identify a covalent, irreversible inhibitor of BTK that has the intrinsic potency, selectivity, and pharmacokinetic properties necessary to provide a rapid rate of inactivation systemically following a very low dose.  With excellent in vivo efficacy and a very desirable tolerability profile, 5a (branebrutinib, BMS-986195) has advanced into clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGr5oQEoebirVg90H21EOLACvtfcHk0lijNNgjzcAD9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXls1aks7w%253D&md5=2d521ec7c06d503f940cb44d381af58d</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00167%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DElzinga%26aufirst%3DP.%2BA.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DWesthouse%26aufirst%3DR.%2BA.%26aulast%3DCatlett%26aufirst%3DI.%2BM.%26aulast%3DZheng%26aufirst%3DN.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DPokross%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DAllentoff%26aufirst%3DA.%26aulast%3DWallace%26aufirst%3DM.%2BA.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%2520branebrutinib%2520%2528BMS-986195%2529%253A%2520a%2520strategy%2520for%2520identifying%2520a%2520highly%2520potent%2520and%2520selective%2520covalent%2520inhibitor%2520providing%2520rapid%2520in%2520vivo%2520inactivation%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D7%26spage%3D3228%26epage%3D3250%26doi%3D10.1021%2Facs.jmedchem.9b00167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lelais, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epple, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, Y. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anumolu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badiger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juarez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manuia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groessl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasibhatla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isbell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spraggon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P. Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of (R,E)-<i>N</i>-(7-chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1<i>H</i>-benzo[d]imid azol-2-yl)-2-methylisonicotinamide (EGF816), a novel, potent, and WT sparing covalent inhibitor of oncogenic (L858R, ex19del) and resistant (T790M) EGFR mutants for the treatment of EGFR mutant non-small-cell lung cancers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">6671</span>– <span class="NLM_lpage">6689</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01985</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01985" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOgu77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6671-6689&issue=14&author=G.+Lelaisauthor=R.+Eppleauthor=T.+H.+Marsiljeauthor=Y.+O.+Longauthor=M.+McNeillauthor=B.+Chenauthor=W.+Luauthor=J.+Anumoluauthor=S.+Badigerauthor=B.+Bursulayaauthor=M.+DiDonatoauthor=R.+Fongauthor=J.+Juarezauthor=J.+Liauthor=M.+Manuiaauthor=D.+E.+Masonauthor=P.+Gordonauthor=T.+Groesslauthor=K.+Johnsonauthor=Y.+Jiaauthor=S.+Kasibhatlaauthor=C.+Liauthor=J.+Isbellauthor=G.+Spraggonauthor=S.+Benderauthor=P.+Y.+Michellys&title=Discovery+of+%28R%2CE%29-N-%287-chloro-1-%281-%5B4-%28dimethylamino%29but-2-enoyl%5Dazepan-3-yl%29-1H-benzo%5Bd%5Dimid+azol-2-yl%29-2-methylisonicotinamide+%28EGF816%29%2C+a+novel%2C+potent%2C+and+WT+sparing+covalent+inhibitor+of+oncogenic+%28L858R%2C+ex19del%29+and+resistant+%28T790M%29+EGFR+mutants+for+the+treatment+of+EGFR+mutant+non-small-cell+lung+cancers&doi=10.1021%2Facs.jmedchem.5b01985"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers</span></div><div class="casAuthors">Lelais, Gerald; Epple, Robert; Marsilje, Thomas H.; Long, Yun O.; McNeill, Matthew; Chen, Bei; Lu, Wenshuo; Anumolu, Jaganmohan; Badiger, Sangamesh; Bursulaya, Badry; DiDonato, Michael; Fong, Rina; Juarez, Jose; Li, Jie; Manuia, Mari; Mason, Daniel E.; Gordon, Perry; Groessl, Todd; Johnson, Kevin; Jia, Yong; Kasibhatla, Shailaja; Li, Chun; Isbell, John; Spraggon, Glen; Bender, Steven; Michellys, Pierre-Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6671-6689</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Over the past decade, first and second generation EGFR inhibitors have significantly improved outcomes for lung cancer patients with activating mutations in EGFR.  However, both resistance through a secondary T790M mutation at the gatekeeper residue and dose-limiting toxicities from wild-type (WT) EGFR inhibition ultimately limit the full potential of these therapies to control mutant EGFR-driven tumors and new therapies are urgently needed.  Herein, we describe our approach toward the discovery of 47 (EGF816, nazartinib), a novel, covalent mutant-selective EGFR inhibitor with equipotent activity on both oncogenic and T790M-resistant EGFR mutations.  Through mol. docking studies we converted a mutant-selective high-throughput screening hit (7) into a no. of targeted covalent EGFR inhibitors with equipotent activity across mutants EGFR and good WT-EGFR selectivity.  We used an abbreviated in vivo efficacy study for prioritizing compds. with good tolerability and efficacy that ultimately led to the selection of 47 as the clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpcKsqbwkyp7Vg90H21EOLACvtfcHk0ljTwc5u4m56Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOgu77P&md5=c106545d878ab3d675644b47099668a0</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01985%26sid%3Dliteratum%253Aachs%26aulast%3DLelais%26aufirst%3DG.%26aulast%3DEpple%26aufirst%3DR.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DLong%26aufirst%3DY.%2BO.%26aulast%3DMcNeill%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DAnumolu%26aufirst%3DJ.%26aulast%3DBadiger%26aufirst%3DS.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DFong%26aufirst%3DR.%26aulast%3DJuarez%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DManuia%26aufirst%3DM.%26aulast%3DMason%26aufirst%3DD.%2BE.%26aulast%3DGordon%26aufirst%3DP.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DKasibhatla%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DIsbell%26aufirst%3DJ.%26aulast%3DSpraggon%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26atitle%3DDiscovery%2520of%2520%2528R%252CE%2529-N-%25287-chloro-1-%25281-%255B4-%2528dimethylamino%2529but-2-enoyl%255Dazepan-3-yl%2529-1H-benzo%255Bd%255Dimid%2520azol-2-yl%2529-2-methylisonicotinamide%2520%2528EGF816%2529%252C%2520a%2520novel%252C%2520potent%252C%2520and%2520WT%2520sparing%2520covalent%2520inhibitor%2520of%2520oncogenic%2520%2528L858R%252C%2520ex19del%2529%2520and%2520resistant%2520%2528T790M%2529%2520EGFR%2520mutants%2520for%2520the%2520treatment%2520of%2520EGFR%2520mutant%2520non-small-cell%2520lung%2520cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D14%26spage%3D6671%26epage%3D6689%26doi%3D10.1021%2Facs.jmedchem.5b01985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brameld, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venetsanakos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaStant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughhead, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karr, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerritsen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J. O.</span></span> <span> </span><span class="NLM_article-title">Discovery of the irreversible covalent FGFR inhibitor 8-(3-(4-acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8<i>H</i>)-one (PRN1371) for the treatment of solid tumors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">6516</span>– <span class="NLM_lpage">6527</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00360</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00360" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVykt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6516-6527&issue=15&author=K.+A.+Brameldauthor=T.+D.+Owensauthor=E.+Vernerauthor=E.+Venetsanakosauthor=J.+M.+Bradshawauthor=V.+T.+Phanauthor=D.+Tamauthor=K.+Leungauthor=J.+Shuauthor=J.+LaStantauthor=D.+G.+Loughheadauthor=T.+Tonauthor=D.+E.+Karrauthor=M.+E.+Gerritsenauthor=D.+M.+Goldsteinauthor=J.+O.+Funk&title=Discovery+of+the+irreversible+covalent+FGFR+inhibitor+8-%283-%284-acryloylpiperazin-1-yl%29propyl%29-6-%282%2C6-dichloro-3%2C5-dimethoxyphenyl%29-2-%28methylamino%29pyrido%5B2%2C3-d%5Dpyrimidin-7%288H%29-one+%28PRN1371%29+for+the+treatment+of+solid+tumors&doi=10.1021%2Facs.jmedchem.7b00360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors</span></div><div class="casAuthors">Brameld, Ken A.; Owens, Timothy D.; Verner, Erik; Venetsanakos, Eleni; Bradshaw, J. Michael; Phan, Vernon T.; Tam, Danny; Leung, Kwan; Shu, Jin; LaStant, Jacob; Loughhead, David G.; Ton, Tony; Karr, Dane E.; Gerritsen, Mary E.; Goldstein, David M.; Funk, Jens Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6516-6527</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aberrant signaling of the FGF/FGFR pathway occurs frequently in cancers and is an oncogenic driver in many solid tumors.  Clin. validation of FGFR as a therapeutic target has been demonstrated in bladder, liver, lung, breast, and gastric cancers.  Our goal was to develop an irreversible covalent inhibitor of FGFR1-4 for use in oncol. indications.  An irreversible covalent binding mechanism imparts many desirable pharmacol. benefits including high potency, selectivity, and prolonged target inhibition.  Herein we report the structure-based design, medicinal chem. optimization, and unique ADME assays of our irreversible covalent drug discovery program which culminated in the discovery of compd. 34 (PRN1371), a highly selective and potent FGFR1-4 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpklTuvm1niy7Vg90H21EOLACvtfcHk0ljTwc5u4m56Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVykt7fK&md5=987069b645d5e0e36ccda5e5c81520b9</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00360%26sid%3Dliteratum%253Aachs%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DVenetsanakos%26aufirst%3DE.%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26aulast%3DPhan%26aufirst%3DV.%2BT.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLeung%26aufirst%3DK.%26aulast%3DShu%26aufirst%3DJ.%26aulast%3DLaStant%26aufirst%3DJ.%26aulast%3DLoughhead%26aufirst%3DD.%2BG.%26aulast%3DTon%26aufirst%3DT.%26aulast%3DKarr%26aufirst%3DD.%2BE.%26aulast%3DGerritsen%26aufirst%3DM.%2BE.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26atitle%3DDiscovery%2520of%2520the%2520irreversible%2520covalent%2520FGFR%2520inhibitor%25208-%25283-%25284-acryloylpiperazin-1-yl%2529propyl%2529-6-%25282%252C6-dichloro-3%252C5-dimethoxyphenyl%2529-2-%2528methylamino%2529pyrido%255B2%252C3-d%255Dpyrimidin-7%25288H%2529-one%2520%2528PRN1371%2529%2520for%2520the%2520treatment%2520of%2520solid%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D15%26spage%3D6516%26epage%3D6527%26doi%3D10.1021%2Facs.jmedchem.7b00360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery of an orally available Janus kinase 3 selective covalent inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">1054</span>– <span class="NLM_lpage">1066</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01823</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01823" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjs1Ghug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1054-1066&issue=2&author=L.+Shiauthor=Z.+Zhongauthor=X.+Liauthor=Y.+Zhouauthor=Z.+Pan&title=Discovery+of+an+orally+available+Janus+kinase+3+selective+covalent+inhibitor&doi=10.1021%2Facs.jmedchem.8b01823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Orally Available Janus Kinase 3 Selective Covalent Inhibitor</span></div><div class="casAuthors">Shi, Liyang; Zhong, Zhenpeng; Li, Xitao; Zhou, Yiqing; Pan, Zhengying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1054-1066</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">JAK family kinases are important mediators of immune cell signaling and Janus Kinase 3 (JAK3) has long been indicated as a potential target for autoimmune disorders.  Intensive efforts to develop highly selective JAK3 inhibitors have been underway for many years.  However, because of JAK3's strong binding preference to ATP (ATP), a no. of inhibitors exhibit large gaps between enzymic and cellular potency, which hampers efforts to dissect the roles of JAK3 in cellular settings.  Using a targeted covalent inhibitor approach, we discovered compd. 32, which overcame ATP competition (1 mM) in the enzymic assay, and demonstrated significantly improved inhibitory activity for JAK3-dependent signaling in mouse CTLL-2 and human peripheral blood mononuclear cells.  Compd. 32 also exhibited high selectivity within the JAK family and good pharmacokinetic properties.  Thus, it may serve as a highly valuable tool mol. to study the overlapping roles of JAK family kinases in complex biol. settings.  Our study also suggested that for covalent kinase inhibitors, esp. those targeting kinases with low Km ATP values, the reversible interactions between mols. and proteins should be carefully optimized to improve the overall potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZd2JO9l7Q4LVg90H21EOLACvtfcHk0ljUiN24zEhGZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjs1Ghug%253D%253D&md5=17792310c69501e5a645a63b79aa4826</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01823%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DL.%26aulast%3DZhong%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DPan%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520an%2520orally%2520available%2520Janus%2520kinase%25203%2520selective%2520covalent%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D2%26spage%3D1054%26epage%3D1066%26doi%3D10.1021%2Facs.jmedchem.8b01823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amegadzie, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frohn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopecky, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minatti, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickrell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegmund, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tegley, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walton, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurz, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achanta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiki, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volak, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zech, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipford, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cee, V. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of a covalent inhibitor of KRAS(G12C) (AMG 510) for the treatment of solid tumors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">52</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01180</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01180" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlGitrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=52-65&issue=1&author=B.+A.+Lanmanauthor=J.+R.+Allenauthor=J.+G.+Allenauthor=A.+K.+Amegadzieauthor=K.+S.+Ashtonauthor=S.+K.+Bookerauthor=J.+J.+Chenauthor=N.+Chenauthor=M.+J.+Frohnauthor=G.+Goodmanauthor=D.+J.+Kopeckyauthor=L.+Liuauthor=P.+Lopezauthor=J.+D.+Lowauthor=V.+Maauthor=A.+E.+Minattiauthor=T.+T.+Nguyenauthor=N.+Nishimuraauthor=A.+J.+Pickrellauthor=A.+B.+Reedauthor=Y.+Shinauthor=A.+C.+Siegmundauthor=N.+A.+Tamayoauthor=C.+M.+Tegleyauthor=M.+C.+Waltonauthor=H.+L.+Wangauthor=R.+P.+Wurzauthor=M.+Xueauthor=K.+C.+Yangauthor=P.+Achantaauthor=M.+D.+Bartbergerauthor=J.+Canonauthor=L.+S.+Hollisauthor=J.+D.+McCarterauthor=C.+Mohrauthor=K.+Rexauthor=A.+Y.+Saikiauthor=T.+San+Miguelauthor=L.+P.+Volakauthor=K.+H.+Wangauthor=D.+A.+Whittingtonauthor=S.+G.+Zechauthor=J.+R.+Lipfordauthor=V.+J.+Cee&title=Discovery+of+a+covalent+inhibitor+of+KRAS%28G12C%29+%28AMG+510%29+for+the+treatment+of+solid+tumors&doi=10.1021%2Facs.jmedchem.9b01180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors</span></div><div class="casAuthors">Lanman, Brian A.; Allen, Jennifer R.; Allen, John G.; Amegadzie, Albert K.; Ashton, Kate S.; Booker, Shon K.; Chen, Jian Jeffrey; Chen, Ning; Frohn, Michael J.; Goodman, Guy; Kopecky, David J.; Liu, Longbin; Lopez, Patricia; Low, Jonathan D.; Ma, Vu; Minatti, Ana E.; Nguyen, Thomas T.; Nishimura, Nobuko; Pickrell, Alexander J.; Reed, Anthony B.; Shin, Youngsook; Siegmund, Aaron C.; Tamayo, Nuria A.; Tegley, Christopher M.; Walton, Mary C.; Wang, Hui-Ling; Wurz, Ryan P.; Xue, May; Yang, Kevin C.; Achanta, Pragathi; Bartberger, Michael D.; Canon, Jude; Hollis, L. Steven; McCarter, John D.; Mohr, Christopher; Rex, Karen; Saiki, Anne Y.; San Miguel, Tisha; Volak, Laurie P.; Wang, Kevin H.; Whittington, Douglas A.; Zech, Stephan G.; Lipford, J. Russell; Cee, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">52-65</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">KRASG12C has emerged as a promising target in the treatment of solid tumors.  Covalent inhibitors targeting the mutant cysteine-12 residue have been shown to disrupt signaling by this long-"undruggable" target; however clin. viable inhibitors have yet to be identified.  Here, we report efforts to exploit a cryptic pocket (H95/Y96/Q99) we identified in KRASG12C to identify inhibitors suitable for clin. development.  Structure-based design efforts leading to the identification of a novel quinazolinone scaffold are described, along with optimization efforts that overcame a configurational stability issue arising from restricted rotation about an axially chiral biaryl bond.  Biopharmaceutical optimization of the resulting leads culminated in the identification of AMG 510, a highly potent, selective, and well-tolerated KRASG12C inhibitor currently in phase I clin. trials (NCT03600883).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGeWqRRXX6lbVg90H21EOLACvtfcHk0ljUiN24zEhGZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlGitrrK&md5=d973189be70bb913020edb4989f6ba7d</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01180%26sid%3Dliteratum%253Aachs%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DAllen%26aufirst%3DJ.%2BR.%26aulast%3DAllen%26aufirst%3DJ.%2BG.%26aulast%3DAmegadzie%26aufirst%3DA.%2BK.%26aulast%3DAshton%26aufirst%3DK.%2BS.%26aulast%3DBooker%26aufirst%3DS.%2BK.%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26aulast%3DChen%26aufirst%3DN.%26aulast%3DFrohn%26aufirst%3DM.%2BJ.%26aulast%3DGoodman%26aufirst%3DG.%26aulast%3DKopecky%26aufirst%3DD.%2BJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLopez%26aufirst%3DP.%26aulast%3DLow%26aufirst%3DJ.%2BD.%26aulast%3DMa%26aufirst%3DV.%26aulast%3DMinatti%26aufirst%3DA.%2BE.%26aulast%3DNguyen%26aufirst%3DT.%2BT.%26aulast%3DNishimura%26aufirst%3DN.%26aulast%3DPickrell%26aufirst%3DA.%2BJ.%26aulast%3DReed%26aufirst%3DA.%2BB.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DSiegmund%26aufirst%3DA.%2BC.%26aulast%3DTamayo%26aufirst%3DN.%2BA.%26aulast%3DTegley%26aufirst%3DC.%2BM.%26aulast%3DWalton%26aufirst%3DM.%2BC.%26aulast%3DWang%26aufirst%3DH.%2BL.%26aulast%3DWurz%26aufirst%3DR.%2BP.%26aulast%3DXue%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DK.%2BC.%26aulast%3DAchanta%26aufirst%3DP.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DCanon%26aufirst%3DJ.%26aulast%3DHollis%26aufirst%3DL.%2BS.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DMohr%26aufirst%3DC.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DSaiki%26aufirst%3DA.%2BY.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DVolak%26aufirst%3DL.%2BP.%26aulast%3DWang%26aufirst%3DK.%2BH.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DZech%26aufirst%3DS.%2BG.%26aulast%3DLipford%26aufirst%3DJ.%2BR.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26atitle%3DDiscovery%2520of%2520a%2520covalent%2520inhibitor%2520of%2520KRAS%2528G12C%2529%2520%2528AMG%2520510%2529%2520for%2520the%2520treatment%2520of%2520solid%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D1%26spage%3D52%26epage%3D65%26doi%3D10.1021%2Facs.jmedchem.9b01180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamaura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurokawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujikawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Date, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terada, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyoi, H.</span></span> <span> </span><span class="NLM_article-title">A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>131</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-05-786657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2017-05-786657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=29187377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1CqsbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2018&pages=426-438&issue=4&author=T.+Yamauraauthor=T.+Nakataniauthor=K.+Udaauthor=H.+Oguraauthor=W.+Shinauthor=N.+Kurokawaauthor=K.+Saitoauthor=N.+Fujikawaauthor=T.+Dateauthor=M.+Takasakiauthor=D.+Teradaauthor=A.+Hiraiauthor=A.+Akashiauthor=F.+Chenauthor=Y.+Adachiauthor=Y.+Ishikawaauthor=F.+Hayakawaauthor=S.+Hagiwaraauthor=T.+Naoeauthor=H.+Kiyoi&title=A+novel+irreversible+FLT3+inhibitor%2C+FF-10101%2C+shows+excellent+efficacy+against+AML+cells+with+FLT3+mutations&doi=10.1182%2Fblood-2017-05-786657"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations</span></div><div class="casAuthors">Yamaura, Takeshi; Nakatani, Toshiyuki; Uda, Ken; Ogura, Hayato; Shin, Wigyon; Kurokawa, Naoya; Saito, Koichi; Fujikawa, Norie; Date, Tomomi; Takasaki, Masaru; Terada, Daisuke; Hirai, Atsushi; Akashi, Akimi; Chen, Fangli; Adachi, Yoshiya; Ishikawa, Yuichi; Hayakawa, Fumihiko; Hagiwara, Shinji; Naoe, Tomoki; Kiyoi, Hitoshi</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">426-438</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">An activating mutation of Fms-like tyrosine kinase 3 (FLT3) is the most frequent genetic alteration assocd. with poor prognosis in acute myeloid leukemia (AML).  Although many FLT3 inhibitors have been clin. developed, no first-generation inhibitors have demonstrated clin. efficacy by monotherapy, due to poor pharmacokinetics or unfavorable safety profiles possibly assocd. with low selectivity against FLT3 kinase.  Recently, a selective FLT3 inhibitor, quizartinib, demonstrated favorable outcomes in clin. studies.  However, several resistant mutations emerged during the disease progression.  To overcome these problems, we developed a novel FLT3 inhibitor, FF-10101, designed to possess selective and irreversible FLT3 inhibition.  The co-crystal structure of FLT3 protein bound to FF-10101 revealed the formation of a covalent bond between FF-10101 and the cysteine residue at 695 of FLT3.  The unique binding brought high selectivity and inhibitory activity against FLT3 kinase.  FF-10101 showed potent growth inhibitory effects on human AML cell lines harboring FLT3 internal tandem duplication (FLT3-ITD), MOLM-13, MOLM-14, and MV4-11, and all tested types of mutant FLT3-expressing 32D cells including quizartinib-resistant mutations at D835, Y842, and F691 residues in the FLT3 kinase domain.  In mouse s.c. implantation models, orally administered FF-10101 showed significant growth inhibitory effect on FLT3-ITD-D835Y- and FLT3-ITD-F691L-expressing 32D cells.  Furthermore, FF-10101 potently inhibited growth of primary AML cells harboring either FLT3-ITD or FLT3-D835 mutation in vitro and in vivo.  These results indicate that FF-10101 is a promising agent for the treatment of patients with AML with FLT3 mutations, including the activation loop mutations clin. identified as quizartinib-resistant mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrNdcWgLnPALVg90H21EOLACvtfcHk0lggx3zZIQ1Mcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1CqsbnE&md5=6812be0253e393c018ad5f7b47b9ec02</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-05-786657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-05-786657%26sid%3Dliteratum%253Aachs%26aulast%3DYamaura%26aufirst%3DT.%26aulast%3DNakatani%26aufirst%3DT.%26aulast%3DUda%26aufirst%3DK.%26aulast%3DOgura%26aufirst%3DH.%26aulast%3DShin%26aufirst%3DW.%26aulast%3DKurokawa%26aufirst%3DN.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DFujikawa%26aufirst%3DN.%26aulast%3DDate%26aufirst%3DT.%26aulast%3DTakasaki%26aufirst%3DM.%26aulast%3DTerada%26aufirst%3DD.%26aulast%3DHirai%26aufirst%3DA.%26aulast%3DAkashi%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DAdachi%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DHayakawa%26aufirst%3DF.%26aulast%3DHagiwara%26aufirst%3DS.%26aulast%3DNaoe%26aufirst%3DT.%26aulast%3DKiyoi%26aufirst%3DH.%26atitle%3DA%2520novel%2520irreversible%2520FLT3%2520inhibitor%252C%2520FF-10101%252C%2520shows%2520excellent%2520efficacy%2520against%2520AML%2520cells%2520with%2520FLT3%2520mutations%26jtitle%3DBlood%26date%3D2018%26volume%3D131%26issue%3D4%26spage%3D426%26epage%3D438%26doi%3D10.1182%2Fblood-2017-05-786657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bensinger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubba, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cremer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohl, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wassmer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engemann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmaier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, B.</span></span> <span> </span><span class="NLM_article-title">Virtual screening identifies irreversible FMS-like tyrosine kinase 3 inhibitors with activity toward resistance-conferring mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2428</span>– <span class="NLM_lpage">2446</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01714</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01714" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisl2lsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2428-2446&issue=5&author=D.+Bensingerauthor=D.+Stubbaauthor=A.+Cremerauthor=V.+Kohlauthor=T.+Wassmerauthor=J.+Stuckertauthor=V.+Engemannauthor=K.+Stegmaierauthor=K.+Schmitzauthor=B.+Schmidt&title=Virtual+screening+identifies+irreversible+FMS-like+tyrosine+kinase+3+inhibitors+with+activity+toward+resistance-conferring+mutations&doi=10.1021%2Facs.jmedchem.8b01714"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations</span></div><div class="casAuthors">Bensinger, Dennis; Stubba, Daniel; Cremer, Anjali; Kohl, Vanessa; Wassmer, Theresa; Stuckert, Johanna; Engemann, Victoria; Stegmaier, Kimberly; Schmitz, Katja; Schmidt, Boris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2428-2446</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The use of covalent irreversible binding inhibitors is an established concept for drug development.  Usually, the discovery of new irreversible kinase inhibitors occurs serendipitously, showing that efficient rational approaches for the rapid discovery of new drugs are needed.  Herein, the authors report a virtual screening strategy that led to the discovery of irreversible inhibitors of FMS-like tyrosine kinase 3 (FLT3) involved in the pathogenesis of acute myeloid leukemia.  A virtual screening library was designed to target the highly conserved Cys828 residue preceding the DFG motif by modification of reported reversible inhibitors with chem. reactive groups.  Prospective covalent docking allowed the identification of two lead series, resulting in a massive increase in inhibition of kinase activity and cell viability by irreversible inhibitors compared to the corresponding reversible scaffolds.  Lead compd. I (BSc5371) displays superior cytotoxicity in FLT3-dependent cell lines to compds. in recent clin. trials and overcomes drug-resistant mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquy_8BkIpJILVg90H21EOLACvtfcHk0lggx3zZIQ1Mcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisl2lsro%253D&md5=336bed5b86809d78cfaf8b74d934ef68</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01714%26sid%3Dliteratum%253Aachs%26aulast%3DBensinger%26aufirst%3DD.%26aulast%3DStubba%26aufirst%3DD.%26aulast%3DCremer%26aufirst%3DA.%26aulast%3DKohl%26aufirst%3DV.%26aulast%3DWassmer%26aufirst%3DT.%26aulast%3DStuckert%26aufirst%3DJ.%26aulast%3DEngemann%26aufirst%3DV.%26aulast%3DStegmaier%26aufirst%3DK.%26aulast%3DSchmitz%26aufirst%3DK.%26aulast%3DSchmidt%26aufirst%3DB.%26atitle%3DVirtual%2520screening%2520identifies%2520irreversible%2520FMS-like%2520tyrosine%2520kinase%25203%2520inhibitors%2520with%2520activity%2520toward%2520resistance-conferring%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D5%26spage%3D2428%26epage%3D2446%26doi%3D10.1021%2Facs.jmedchem.8b01714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daver, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinardo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pemmaraju, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Manero, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrajoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popat, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosing, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderlini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span> <span> </span><span class="NLM_article-title">Clinical characteristics and outcomes in patients with acute promyelocytic leukemia and hyperleucocytosis</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>168</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">646</span>– <span class="NLM_lpage">653</span>, <span class="refDoi"> DOI: 10.1111/bjh.13189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1111%2Fbjh.13189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=25312977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitlOjs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2015&pages=646-653&issue=5&author=N.+Daverauthor=H.+Kantarjianauthor=G.+Marcucciauthor=S.+Pierceauthor=M.+Brandtauthor=C.+Dinardoauthor=N.+Pemmarajuauthor=G.+Garcia-Maneroauthor=S.+O%E2%80%99Brienauthor=A.+Ferrajoliauthor=S.+Verstovsekauthor=U.+Popatauthor=C.+Hosingauthor=P.+Anderliniauthor=G.+Borthakurauthor=T.+Kadiaauthor=J.+Cortesauthor=F.+Ravandi&title=Clinical+characteristics+and+outcomes+in+patients+with+acute+promyelocytic+leukemia+and+hyperleucocytosis&doi=10.1111%2Fbjh.13189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis</span></div><div class="casAuthors">Daver, Naval; Kantarjian, Hagop; Marcucci, Guido; Pierce, Sherry; Brandt, Mark; Dinardo, Courtney; Pemmaraju, Naveen; Garcia-Manero, Guillermo; O'Brien, Susan; Ferrajoli, Alessandra; Verstovsek, Srdan; Popat, Uday; Hosing, Chitra; Anderlini, Paolo; Borthakur, Gautam; Kadia, Tapan; Cortes, Jorge; Ravandi, Farhad</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">646-653</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary: The clin. characteristics, treatment options and outcomes in patients with acute promyelocytic leukemia (APL) and hyperleucocytosis remain poorly defined.  This study reviewed 242 consecutive patients with APL; 29 patients (12%) had a white blood cell count (WBC) ≥ 50 × 109/l at presentation (median WBC 85·5 × 109/l).  Patients with hyperleucocytosis had inferior complete remission (CR) rates (69% vs. 88%; P = 0·004) and higher 4-wk mortality (24% vs. 9%; P = 0·018) compared to patients without hyperleucocytosis.  We noted a trend towards inferior 3-yr disease-free survival (DFS) (69% vs. 80%; P = 0·057) and inferior 3-yr overall survival (OS) (74% vs. 92%; P = 0·2) for patients with hyperleucocytosis.  Leukapheresis was performed in 11 (38%) of the 29 patients with hyperleucocytosis.  CR rate and 3-yr OS were not significantly improved in patients who received leukapheresis.  CR rate and 3-yr OS for the 15 patients with hyperleucocytosis treated with all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) plus cytotoxic therapy (idarubicin or gemtuzumab ozogamicin) combinations were 100% and 100% vs. 57% and 35% for the 14 patients treated with non-ATRA/ATO combinations (P = 0·004 and P = 0·002).  Leukapheresis does not improve the outcomes in patients with APL presenting with hyperleucocytosis.  ATRA/ATO-based combinations are superior to other regimens in these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryVkJHaNGBWLVg90H21EOLACvtfcHk0lggx3zZIQ1Mcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitlOjs70%253D&md5=c53c1fb35e1fbfc0ec12ddb0140f3ebd</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1111%2Fbjh.13189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.13189%26sid%3Dliteratum%253Aachs%26aulast%3DDaver%26aufirst%3DN.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DMarcucci%26aufirst%3DG.%26aulast%3DPierce%26aufirst%3DS.%26aulast%3DBrandt%26aufirst%3DM.%26aulast%3DDinardo%26aufirst%3DC.%26aulast%3DPemmaraju%26aufirst%3DN.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DFerrajoli%26aufirst%3DA.%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DPopat%26aufirst%3DU.%26aulast%3DHosing%26aufirst%3DC.%26aulast%3DAnderlini%26aufirst%3DP.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DKadia%26aufirst%3DT.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DRavandi%26aufirst%3DF.%26atitle%3DClinical%2520characteristics%2520and%2520outcomes%2520in%2520patients%2520with%2520acute%2520promyelocytic%2520leukemia%2520and%2520hyperleucocytosis%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2015%26volume%3D168%26issue%3D5%26spage%3D646%26epage%3D653%26doi%3D10.1111%2Fbjh.13189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandy, M.</span></span> <span> </span><span class="NLM_article-title">Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>92</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">994</span>– <span class="NLM_lpage">995</span>, <span class="refDoi"> DOI: 10.3324/haematol.10802</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.3324%2Fhaematol.10802" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=17606455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFGqu7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2007&pages=994-995&issue=7&author=V.+Mathewsauthor=M.+Thomasauthor=V.+M.+Srivastavaauthor=B.+Georgeauthor=A.+Srivastavaauthor=M.+Chandy&title=Impact+of+FLT3+mutations+and+secondary+cytogenetic+changes+on+the+outcome+of+patients+with+newly+diagnosed+acute+promyelocytic+leukemia+treated+with+a+single+agent+arsenic+trioxide+regimen&doi=10.3324%2Fhaematol.10802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen</span></div><div class="casAuthors">Mathews, Vikram; Thomas, Maria; Srivastava, Vivi M.; George, Biju; Srivastava, Alok; Chandy, Mammen</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">994-995</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">0390-6078</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">Ninety-eight newly diagnosed cases of PML-RARα pos. APL were treated with a regimen of single agent ATO.  FLT3 activating mutations were seen in 33% and an addnl. cytogenetic finding was noted in 23.2%.  FLT3 activating mutations were significantly assocd. with a bcr3 PML-RARα isoform (p = 0.012) and a delay in achieving a mol. remission (p = 0.022).  Neither FLT3 activating mutations nor secondary cytogenetic changes had an impact on clin. outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyjF_niTK9BbVg90H21EOLACvtfcHk0lgnZZEEk4R-MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFGqu7vE&md5=808914d910f31c37950491b98411e63b</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.10802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.10802%26sid%3Dliteratum%253Aachs%26aulast%3DMathews%26aufirst%3DV.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DSrivastava%26aufirst%3DV.%2BM.%26aulast%3DGeorge%26aufirst%3DB.%26aulast%3DSrivastava%26aufirst%3DA.%26aulast%3DChandy%26aufirst%3DM.%26atitle%3DImpact%2520of%2520FLT3%2520mutations%2520and%2520secondary%2520cytogenetic%2520changes%2520on%2520the%2520outcome%2520of%2520patients%2520with%2520newly%2520diagnosed%2520acute%2520promyelocytic%2520leukemia%2520treated%2520with%2520a%2520single%2520agent%2520arsenic%2520trioxide%2520regimen%26jtitle%3DHaematologica%26date%3D2007%26volume%3D92%26issue%3D7%26spage%3D994%26epage%3D995%26doi%3D10.3324%2Fhaematol.10802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabrilove, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waxman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Y.</span></span> <span> </span><span class="NLM_article-title">Arsenic trioxide and sorafenib induce synthetic lethality of FLT3-ITD acute myeloid leukemia cells</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1871</span>– <span class="NLM_lpage">1880</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-17-0298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F1535-7163.MCT-17-0298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=29959200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit12qtLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=1871-1880&issue=9&author=R.+Wangauthor=Y.+Liauthor=P.+Gongauthor=J.+Gabriloveauthor=S.+Waxmanauthor=Y.+Jing&title=Arsenic+trioxide+and+sorafenib+induce+synthetic+lethality+of+FLT3-ITD+acute+myeloid+leukemia+cells&doi=10.1158%2F1535-7163.MCT-17-0298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Arsenic trioxide and sorafenib induce synthetic lethality of FLT3-ITD acute myeloid leukemia cells</span></div><div class="casAuthors">Wang, Rui; Lie, Ying; Gong, Ping; Gabrilove, Janice; Waxman, Samuel; Jing, Yongkui</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1871-1880</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) with Fms-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutation is notoriously hard to treat.  We identified two drugs that together form an effective combination therapy against FLT3-ITD AML.  One of the drugs, Sorafenib, an inhibitor of FLT3-ITD and other kinase activity, produces an impressive but short-lived remission in FLT3-ITD AML patients.  The second, arsenic trioxide (ATO), at therapeutically achievable concns., reduces the level of FLT3-ITD and Mcl-1 proteins, and induces apoptosis in leukemic cell lines and in primary cells expressing FLT3-ITD.  We linked this relative sensitivity to ATO to low levels of reduced glutathione.  While producing proapoptotic effects, ATO treatment also has an unwanted effect whereby it causes the accumulation of the phosphorylated (inactive) form of glycogen synthase kinase 3β, a kinase necessary for apoptosis.  When ATO is combined with Sorafenib, GSK-3β is activated, Mcl-1 is further reduced, and proapoptotic proteins Bak and Bax are activated.  Mice xenografted with FLT3-ITD MOLM13 cell line treated with the Sorafenib/ATO combination have significantly improved survival.  This combination has potential to improve the therapeutic outcome of FLT3-ITD targeted therapy of AML patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSa8hhWaOsyrVg90H21EOLACvtfcHk0lgnZZEEk4R-MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit12qtLrL&md5=092c29dab1f5e12e30fc97bebf4b9222</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0298%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DGabrilove%26aufirst%3DJ.%26aulast%3DWaxman%26aufirst%3DS.%26aulast%3DJing%26aufirst%3DY.%26atitle%3DArsenic%2520trioxide%2520and%2520sorafenib%2520induce%2520synthetic%2520lethality%2520of%2520FLT3-ITD%2520acute%2520myeloid%2520leukemia%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26issue%3D9%26spage%3D1871%26epage%3D1880%26doi%3D10.1158%2F1535-7163.MCT-17-0298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Breitenbuecher, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markova, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carius, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauder, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohmer, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronnstrand, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, T.</span></span> <span> </span><span class="NLM_article-title">A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>113</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">4063</span>– <span class="NLM_lpage">4073</span>, <span class="refDoi"> DOI: 10.1182/blood-2007-11-126664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2007-11-126664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=19144992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsVWrtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=4063-4073&issue=17&author=F.+Breitenbuecherauthor=B.+Markovaauthor=S.+Kasperauthor=B.+Cariusauthor=T.+Stauderauthor=F.+D.+Bohmerauthor=K.+Massonauthor=L.+Ronnstrandauthor=C.+Huberauthor=T.+Kindlerauthor=T.+Fischer&title=A+novel+molecular+mechanism+of+primary+resistance+to+FLT3-kinase+inhibitors+in+AML&doi=10.1182%2Fblood-2007-11-126664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML</span></div><div class="casAuthors">Breitenbuecher, Frank; Markova, Boyka; Kasper, Stefan; Carius, Birgit; Stauder, Torsten; Boehmer, Frank D.; Masson, Kristina; Roennstrand, Lars; Huber, Christoph; Kindler, Thomas; Fischer, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4063-4073</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Currently, FLT3 tyrosine kinase inhibitors (TKIs) are emerging as the most promising drug therapy to overcome the dismal prognosis of acute myelogenous leukemia (AML) patients harboring internal tandem duplications (ITDs) of FLT3.  However, up-front drug resistance occurs in approx. 30% of patients, and mol. mechanisms of resistance are poorly understood.  Here, we have uncovered a novel mechanism of primary resistance to FLT3 TKIs in AML: an FLT3 receptor harboring a nonjuxtamembrane ITD atypically integrating into the β-2 sheet of the first kinase domain (FLT3_ITD627E) induces dramatic up-regulation of the anti-apoptotic myeloid cell leukemia 1 protein (MCL-1).  Using RNA interference technol., deregulated MCL-1 protein expression was shown to play a major role in conferring the resistance phenotype of 32D_ITD627E cells.  Enhanced and sustained binding of the adaptor protein GRB-2 to the FLT3_ITD627E receptor is involved in MCL-1 up-regulation and is independent from TKI (PKC412)-induced inhibition of the receptor kinase.  Thus, we describe a new mechanism of primary resistance to TKIs, which operates by reprogramming local and distant signal transduction events of the FLT3 tyrosine kinase.  The data presented suggest that particular ITDs of FLT3 may be assocd. with rewired signaling and differential responsiveness to TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkDPfslG_wk7Vg90H21EOLACvtfcHk0lgnZZEEk4R-MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsVWrtr8%253D&md5=a741ab3c322f5ac83712fa097bf22704</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-11-126664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-11-126664%26sid%3Dliteratum%253Aachs%26aulast%3DBreitenbuecher%26aufirst%3DF.%26aulast%3DMarkova%26aufirst%3DB.%26aulast%3DKasper%26aufirst%3DS.%26aulast%3DCarius%26aufirst%3DB.%26aulast%3DStauder%26aufirst%3DT.%26aulast%3DBohmer%26aufirst%3DF.%2BD.%26aulast%3DMasson%26aufirst%3DK.%26aulast%3DRonnstrand%26aufirst%3DL.%26aulast%3DHuber%26aufirst%3DC.%26aulast%3DKindler%26aufirst%3DT.%26aulast%3DFischer%26aufirst%3DT.%26atitle%3DA%2520novel%2520molecular%2520mechanism%2520of%2520primary%2520resistance%2520to%2520FLT3-kinase%2520inhibitors%2520in%2520AML%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26issue%3D17%26spage%3D4063%26epage%3D4073%26doi%3D10.1182%2Fblood-2007-11-126664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Q.</span></span> <span> </span><span class="NLM_article-title">Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1833</span>, <span class="refDoi"> DOI: 10.1038/s41467-020-15290-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fs41467-020-15290-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=32286255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntFOiu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1833&issue=1&author=M.+Yinauthor=Y.+Guoauthor=R.+Huauthor=W.+L.+Caiauthor=Y.+Liauthor=S.+Peiauthor=H.+Sunauthor=C.+Pengauthor=J.+Liauthor=R.+Yeauthor=Q.+Yangauthor=N.+Wangauthor=Y.+Taoauthor=X.+Chenauthor=Q.+Yan&title=Potent+BRD4+inhibitor+suppresses+cancer+cell-macrophage+interaction&doi=10.1038%2Fs41467-020-15290-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction</span></div><div class="casAuthors">Yin, Mingzhu; Guo, Ying; Hu, Rui; Cai, Wesley L.; Li, Yao; Pei, Shiyao; Sun, Hongyin; Peng, Cong; Li, Jiali; Ye, Rui; Yang, Qiaohong; Wang, Nenghui; Tao, Yongguang; Chen, Xiang; Yan, Qin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1833</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Small mol. inhibitor of the bromodomain and extraterminal domain (BET) family proteins is a promising option for cancer treatment.  However, current BET inhibitors are limited by their potency or oral bioavailability.  Here we report the discovery and characterization of NHWD-870, a BET inhibitor that is more potent than three major clin. stage BET inhibitors BMS-986158, OTX-015, and GSK-525762.  NHWD-870 causes tumor shrinkage or significantly suppresses tumor growth in nine xenograft or syngeneic models.  In addn. to its ability to downregulate c-MYC and directly inhibit tumor cell proliferation, NHWD-870 blocks the proliferation of tumor assocd. macrophages (TAMs) through multiple mechanisms, partly by reducing the expression and secretion of macrophage colony-stimulating factor CSF1 by tumor cells.  NHWD-870 inhibits CSF1 expression through suppressing BRD4 and its target HIF1α.  Taken together, these results reveal a mechanism by which BRD4 inhibition suppresses tumor growth, and support further development of NHWD-870 to treat solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTJ-5bp_10QrVg90H21EOLACvtfcHk0liLJoBK-Vs2xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntFOiu70%253D&md5=20b5ac123381a3ca75164a5e53a64c18</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1038%2Fs41467-020-15290-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-020-15290-0%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DR.%26aulast%3DCai%26aufirst%3DW.%2BL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DPei%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DTao%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DYan%26aufirst%3DQ.%26atitle%3DPotent%2520BRD4%2520inhibitor%2520suppresses%2520cancer%2520cell-macrophage%2520interaction%26jtitle%3DNat.%2520Commun.%26date%3D2020%26volume%3D11%26issue%3D1%26spage%3D1833%26doi%3D10.1038%2Fs41467-020-15290-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fiskus, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devaraj, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leveque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portier, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhalla, K. N.</span></span> <span> </span><span class="NLM_article-title">BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2315</span>– <span class="NLM_lpage">2327</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F1535-7163.MCT-14-0258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=25053825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yisb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2315-2327&issue=10&author=W.+Fiskusauthor=S.+Sharmaauthor=J.+Qiauthor=B.+Shahauthor=S.+G.+Devarajauthor=C.+Levequeauthor=B.+P.+Portierauthor=S.+Iyerauthor=J.+E.+Bradnerauthor=K.+N.+Bhalla&title=BET+protein+antagonist+JQ1+is+synergistically+lethal+with+FLT3+tyrosine+kinase+inhibitor+%28TKI%29+and+overcomes+resistance+to+FLT3-TKI+in+AML+cells+expressing+FLT-ITD&doi=10.1158%2F1535-7163.MCT-14-0258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD</span></div><div class="casAuthors">Fiskus, Warren; Sharma, Sunil; Qi, Jun; Shah, Bhavin; Devaraj, Santhana G. T.; Leveque, Christopher; Portier, Bryce P.; Iyer, Swaminathan; Bradner, James E.; Bhalla, Kapil N.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2315-2327</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Recently, treatment with bromodomain and extraterminal protein antagonist (BA) such as JQ1 has been shown to inhibit growth and induce apoptosis of human acute myelogenous leukemia (AML) cells, including those expressing FLT3-ITD.  Here, we demonstrate that cotreatment with JQ1 and the FLT3 tyrosine kinase inhibitor (TKI) ponatinib or AC220 synergistically induce apoptosis of cultured and primary CD34+ human AML blast progenitor cells (BPC) expressing FLT3-ITD.  Concomitantly, as compared with each agent alone, cotreatment with JQ1 and the FLT3-TKI caused greater attenuation of c-MYC, BCL2, and CDK4/6.  Simultaneously, cotreatment with JQ1 and the FLT3-TKI increased the levels of p21, BIM, and cleaved PARP, as well as mediated marked attenuation of p-STAT5, p-AKT, and p-ERK1/2 levels in AML BPCs.  Conversely, cotreatment with JQ1 and FLT3-TKI was significantly less active against CD34+ normal bone marrow progenitor cells.  Knockdown of BRD4 by short hairpin RNA also sensitized AML cells to FLT3-TKI.  JQ1 treatment induced apoptosis of mouse Ba/F3 cells ectopically expressing FLT3-ITD with or without FLT3-TKI-resistant mutations F691L and D835V.  Compared with the parental human AML FLT3-ITD-expressing MOLM13, MOLM13-TKIR cells resistant to AC220 were markedly more sensitive to JQ1-induced apoptosis.  Furthermore, cotreatment with JQ1 and the pan-histone deacetylase inhibitor (HDI) panobinostat synergistically induced apoptosis of FLT3-TKI-resistant MOLM13-TKIR and MV4-11-TKIR cells.  Collectively, these findings support the rationale for detg. the in vivo activity of combined therapy with BA and FLT3-TKI against human AML cells expressing FLT3-ITD or with BA and HDI against AML cells resistant to FLT3-TKI.  Mol Cancer Ther; 13(10); 2315-27. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9PTZkTs8dmLVg90H21EOLACvtfcHk0liLJoBK-Vs2xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yisb%252FI&md5=86b07b19b740ed314bd042a472507766</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0258%26sid%3Dliteratum%253Aachs%26aulast%3DFiskus%26aufirst%3DW.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DB.%26aulast%3DDevaraj%26aufirst%3DS.%2BG.%26aulast%3DLeveque%26aufirst%3DC.%26aulast%3DPortier%26aufirst%3DB.%2BP.%26aulast%3DIyer%26aufirst%3DS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DBhalla%26aufirst%3DK.%2BN.%26atitle%3DBET%2520protein%2520antagonist%2520JQ1%2520is%2520synergistically%2520lethal%2520with%2520FLT3%2520tyrosine%2520kinase%2520inhibitor%2520%2528TKI%2529%2520and%2520overcomes%2520resistance%2520to%2520FLT3-TKI%2520in%2520AML%2520cells%2520expressing%2520FLT-ITD%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26issue%3D10%26spage%3D2315%26epage%3D2327%26doi%3D10.1158%2F1535-7163.MCT-14-0258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Tilburg, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milde, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ecker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hielscher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenk, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhl, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riehl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruhwald, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pekrun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieland, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flotho, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kordes, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruhn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linderkamp, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahm, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freitag, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burhenne, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foerster, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meid, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karapanagiotou-Schenkel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span> <span> </span><span class="NLM_article-title">Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia</span>. <i>Clin. Epigenet.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">188</span>, <span class="refDoi"> DOI: 10.1186/s13148-019-0775-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1186%2Fs13148-019-0775-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=31823832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVyktbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=188&issue=1&author=C.+M.+van%0ATilburgauthor=T.+Mildeauthor=R.+Wittauthor=J.+Eckerauthor=T.+Hielscherauthor=A.+Seitzauthor=J.+P.+Schenkauthor=J.+L.+Buhlauthor=D.+Riehlauthor=M.+C.+Fruhwaldauthor=A.+Pekrunauthor=C.+Rossigauthor=R.+Wielandauthor=C.+Flothoauthor=U.+Kordesauthor=B.+Gruhnauthor=T.+Simonauthor=C.+Linderkampauthor=F.+Sahmauthor=L.+Taylorauthor=A.+Freitagauthor=J.+Burhenneauthor=K.+I.+Foersterauthor=A.+D.+Meidauthor=S.+M.+Pfisterauthor=I.+Karapanagiotou-Schenkelauthor=O.+Witt&title=Phase+I%2FII+intra-patient+dose+escalation+study+of+vorinostat+in+children+with+relapsed+solid+tumor%2C+lymphoma%2C+or+leukemia&doi=10.1186%2Fs13148-019-0775-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia</span></div><div class="casAuthors">van Tilburg, Cornelis M.; Milde, Till; Witt, Ruth; Ecker, Jonas; Hielscher, Thomas; Seitz, Angelika; Schenk, Jens-Peter; Buhl, Juliane L.; Riehl, Dennis; Fruehwald, Michael C.; Pekrun, Arnulf; Rossig, Claudia; Wieland, Regina; Flotho, Christian; Kordes, Uwe; Gruhn, Bernd; Simon, Thorsten; Linderkamp, Christin; Sahm, Felix; Taylor, Lenka; Freitag, Angelika; Burhenne, Juergen; Foerster, Kathrin I.; Meid, Andreas D.; Pfister, Stefan M.; Karapanagiotou-Schenkel, Irini; Witt, Olaf</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Epigenetics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">188</span>CODEN:
                <span class="NLM_cas:coden">CELPCI</span>;
        ISSN:<span class="NLM_cas:issn">1868-7083</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">In the current pediatric trial, we applied an intra-patient dose escalation design.  The purpose of this trial was to det. a safe dose recommendation (SDR) of single-agent vorinostat for intra-patient dose escalation, pharmacokinetic analyses (PK), and activity evaluation in children (3-18 years) with relapsed or therapy-refractory malignancies.  Results: A phase I intra-patient dose (de)escalation was performed until individual max. tolerated dose (MTD).  The starting dose was 180 mg/m2/day with weekly dose escalations of 50 mg/m2 until DLT/max. dose.  After MTD detn., patients seamlessly continued in phase II with disease assessments every 3 mo.  An SDR of 130 mg/m2/day was detd. (max., 580 mg/m2/day). n = 46/50 (92%) patients experienced treatment-related AEs which were mostly reversible and included thrombocytopenia, fatigue, nausea, diarrhea, anemia, and vomiting. n = 6/50 (12%) had treatment-related SAEs.  Five patients achieved prolonged disease control (> 12 mo) and showed a higher Cmax (> 270 ng/mL) and MTDs.  Conclusion: An SDR of 130 mg/m2/day for individual dose escalation was detd.  Higher drug exposure was assocd. with responses and long-term disease stabilization with manageable toxicity.  Patients with low expression of plasma cytokine levels at baseline were able to tolerate higher doses of vorinostat and benefited from treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAK3quYz2RfrVg90H21EOLACvtfcHk0liLJoBK-Vs2xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVyktbfF&md5=7b89e399083307382870d15a844e11ef</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1186%2Fs13148-019-0775-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13148-019-0775-1%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BTilburg%26aufirst%3DC.%2BM.%26aulast%3DMilde%26aufirst%3DT.%26aulast%3DWitt%26aufirst%3DR.%26aulast%3DEcker%26aufirst%3DJ.%26aulast%3DHielscher%26aufirst%3DT.%26aulast%3DSeitz%26aufirst%3DA.%26aulast%3DSchenk%26aufirst%3DJ.%2BP.%26aulast%3DBuhl%26aufirst%3DJ.%2BL.%26aulast%3DRiehl%26aufirst%3DD.%26aulast%3DFruhwald%26aufirst%3DM.%2BC.%26aulast%3DPekrun%26aufirst%3DA.%26aulast%3DRossig%26aufirst%3DC.%26aulast%3DWieland%26aufirst%3DR.%26aulast%3DFlotho%26aufirst%3DC.%26aulast%3DKordes%26aufirst%3DU.%26aulast%3DGruhn%26aufirst%3DB.%26aulast%3DSimon%26aufirst%3DT.%26aulast%3DLinderkamp%26aufirst%3DC.%26aulast%3DSahm%26aufirst%3DF.%26aulast%3DTaylor%26aufirst%3DL.%26aulast%3DFreitag%26aufirst%3DA.%26aulast%3DBurhenne%26aufirst%3DJ.%26aulast%3DFoerster%26aufirst%3DK.%2BI.%26aulast%3DMeid%26aufirst%3DA.%2BD.%26aulast%3DPfister%26aufirst%3DS.%2BM.%26aulast%3DKarapanagiotou-Schenkel%26aufirst%3DI.%26aulast%3DWitt%26aufirst%3DO.%26atitle%3DPhase%2520I%252FII%2520intra-patient%2520dose%2520escalation%2520study%2520of%2520vorinostat%2520in%2520children%2520with%2520relapsed%2520solid%2520tumor%252C%2520lymphoma%252C%2520or%2520leukemia%26jtitle%3DClin.%2520Epigenet.%26date%3D2019%26volume%3D11%26issue%3D1%26spage%3D188%26doi%3D10.1186%2Fs13148-019-0775-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fiskus, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pranpat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bali, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumaraswamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyapalle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giles, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhalla, K.</span></span> <span> </span><span class="NLM_article-title">Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>108</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">645</span>– <span class="NLM_lpage">652</span>, <span class="refDoi"> DOI: 10.1182/blood-2005-11-4639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2005-11-4639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=16537804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFehtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=645-652&issue=2&author=W.+Fiskusauthor=M.+Pranpatauthor=P.+Baliauthor=M.+Balasisauthor=S.+Kumaraswamyauthor=S.+Boyapalleauthor=K.+Rochaauthor=J.+Wuauthor=F.+Gilesauthor=P.+W.+Manleyauthor=P.+Atadjaauthor=K.+Bhalla&title=Combined+effects+of+novel+tyrosine+kinase+inhibitor+AMN107+and+histone+deacetylase+inhibitor+LBH589+against+Bcr-Abl-expressing+human+leukemia+cells&doi=10.1182%2Fblood-2005-11-4639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells</span></div><div class="casAuthors">Fiskus, Warren; Pranpat, Michael; Bali, Purva; Balasis, Maria; Kumaraswamy, Sandhya; Boyapalle, Sandhya; Rocha, Kathy; Wu, Jie; Giles, Francis; Manley, Paul W.; Atadja, Peter; Bhalla, Kapil</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">645-652</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">AMN107 (Novartis Pharmaceuticals, Basel, Switzerland) has potent in vitro and in vivo activity against the unmutated and most common mutant forms of Bcr-Abl.  Treatment with the histone deacetylase inhibitor LBH589 (Novartis) depletes Bcr-Abl levels.  We detd. the effects of AMN107 and/or LBH589 in Bcr-Abl-expressing human K562 and LAMA-84 cells, as well as in primary chronic myelogenous leukemia (CML) cells.  AMN107 was more potent than imatinib mesylate (IM) in inhibiting Bcr-Abl tyrosine kinase (TK) activity and attenuating p-STAT5, p-AKT, Bcl-xL, and c-Myc levels in K562 and LAMA-84 cells.  Cotreatment with LBH589 and AMN107 exerted synergistic apoptotic effects with more attenuation of p-STAT5, p-ERK1/2, c-Myc, and Bcl-xL and increases in p27 and Bim levels.  LBH589 attenuated Bcr-Abl levels and induced apoptosis of mouse pro-B BaF3 cells contg. ectopic expression of Bcr-Abl or the IM-resistant, point-mutant Bcr-AblT315l and Bcr-AblE255K.  Treatment with LBH589 also depleted Bcr-Abl levels and induced apoptosis of IM-resistant primary human CML cells, including those with expression of Bcr-AblT315l.  As compared with either agent alone, cotreatment with AMN107 and LBH589 induced more loss of cell viability of primary IM-resistant CML cells.  Thus, cotreatment with LBH589 and AMN107 is active against cultured or primary IM-resistant CML cells, including those with expression of Bcr-AblT315l.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGzSAxnzx4SrVg90H21EOLACvtfcHk0lj89DK8XqxUrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFehtbk%253D&md5=cc73f2b19bbc3bbd8cbac6b8c24c994f</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-11-4639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-11-4639%26sid%3Dliteratum%253Aachs%26aulast%3DFiskus%26aufirst%3DW.%26aulast%3DPranpat%26aufirst%3DM.%26aulast%3DBali%26aufirst%3DP.%26aulast%3DBalasis%26aufirst%3DM.%26aulast%3DKumaraswamy%26aufirst%3DS.%26aulast%3DBoyapalle%26aufirst%3DS.%26aulast%3DRocha%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DBhalla%26aufirst%3DK.%26atitle%3DCombined%2520effects%2520of%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520AMN107%2520and%2520histone%2520deacetylase%2520inhibitor%2520LBH589%2520against%2520Bcr-Abl-expressing%2520human%2520leukemia%2520cells%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26issue%3D2%26spage%3D645%26epage%3D652%26doi%3D10.1182%2Fblood-2005-11-4639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hof, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fichtner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henze, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Stackelberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shalapour, S.</span></span> <span> </span><span class="NLM_article-title">Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-kappaB</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1445</span>– <span class="NLM_lpage">1457</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-1511</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F1078-0432.CCR-12-1511" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=23357978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFKktrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1445-1457&issue=6&author=L.+Bastianauthor=J.+Hofauthor=M.+Pfauauthor=I.+Fichtnerauthor=C.+Eckertauthor=G.+Henzeauthor=J.+Pradaauthor=A.+von+Stackelbergauthor=K.+Seegerauthor=S.+Shalapour&title=Synergistic+activity+of+bortezomib+and+HDACi+in+preclinical+models+of+B-cell+precursor+acute+lymphoblastic+leukemia+via+modulation+of+p53%2C+PI3K%2FAKT%2C+and+NF-kappaB&doi=10.1158%2F1078-0432.CCR-12-1511"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-κB</span></div><div class="casAuthors">Bastian, Lorenz; Hof, Jana; Pfau, Madlen; Fichtner, Iduna; Eckert, Cornelia; Henze, Guenter; Prada, Javier; von Stackelberg, Arend; Seeger, Karl; Shalapour, Shabnam</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1445-1457</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Relapse of disease and subsequent resistance to established therapies remains a major challenge in the treatment of childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL).  New therapeutic options, such as proteasome and histone deacetylase inhibitors (HDACi) with a toxicity profile differing from that of conventional cytotoxic agents, are needed for these extensively pretreated patients.  Exptl. Design: Antiproliferative and proapoptotic effects of combined HDACi/proteasome inhibitor treatments were analyzed using BCP-ALL monocultures, cocultures with primary mesenchymal stroma cells from patients with ALL, and xenograft mouse models.  The underlying mol. mechanisms assocd. with combined treatment were detd. by gene expression profiling and protein validation.  Results: We identified the proteasome inhibitor bortezomib as a promising combination partner for HDACi due to the substantial synergistic antileukemic activity in BCP-ALL cells after concomitant application.  This effect was maintained or even increased in the presence of chemotherapeutic agents.  The synergistic effect of combined HDACi/BTZ treatment was assocd. with the regulation of genes involved in cell cycle, JUN/MAPK, PI3K/AKT, p53, ubiquitin/proteasome, and NF-κB pathways.  We obsd. an activation of NF-κB after bortezomib treatment and the induction of apoptosis-related NF-κB target genes such as TNFαRs after concomitant treatment, indicating a possible involvement of NF-κB as proapoptotic mediator.  In this context, significantly lower NF-κB subunits gene expression was detected in leukemia cells from patients who developed a relapse during frontline chemotherapy, compared with those who relapsed after cessation of frontline therapy.  Conclusion: These results provide a rationale for the integration of HDACi/BTZ combinations into current childhood BCP-ALL treatment protocols.  Clin Cancer Res; 19(6); 1445-57. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB99eJz7h77bVg90H21EOLACvtfcHk0lj89DK8XqxUrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFKktrk%253D&md5=1ba986aa293b8726bb4757ea8f147d3f</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-1511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-1511%26sid%3Dliteratum%253Aachs%26aulast%3DBastian%26aufirst%3DL.%26aulast%3DHof%26aufirst%3DJ.%26aulast%3DPfau%26aufirst%3DM.%26aulast%3DFichtner%26aufirst%3DI.%26aulast%3DEckert%26aufirst%3DC.%26aulast%3DHenze%26aufirst%3DG.%26aulast%3DPrada%26aufirst%3DJ.%26aulast%3Dvon%2BStackelberg%26aufirst%3DA.%26aulast%3DSeeger%26aufirst%3DK.%26aulast%3DShalapour%26aufirst%3DS.%26atitle%3DSynergistic%2520activity%2520of%2520bortezomib%2520and%2520HDACi%2520in%2520preclinical%2520models%2520of%2520B-cell%2520precursor%2520acute%2520lymphoblastic%2520leukemia%2520via%2520modulation%2520of%2520p53%252C%2520PI3K%252FAKT%252C%2520and%2520NF-kappaB%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26issue%3D6%26spage%3D1445%26epage%3D1457%26doi%3D10.1158%2F1078-0432.CCR-12-1511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span> <span> </span><span class="NLM_article-title">FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD<sup>+</sup> acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>135</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">1472</span>– <span class="NLM_lpage">1483</span>, <span class="refDoi"> DOI: 10.1182/blood.2019003538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood.2019003538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=32315388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BB38zns12kug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2020&pages=1472-1483&issue=17&author=J.+Longauthor=M.+Y.+Jiaauthor=W.+Y.+Fangauthor=X.+J.+Chenauthor=L.+L.+Muauthor=Z.+Y.+Wangauthor=Y.+Shenauthor=R.+F.+Xiangauthor=L.+N.+Wangauthor=L.+Wangauthor=C.+H.+Jiangauthor=J.+L.+Jiangauthor=W.+J.+Zhangauthor=Y.+D.+Sunauthor=L.+Changauthor=W.+H.+Gaoauthor=Y.+Wangauthor=J.+M.+Liauthor=D.+L.+Hongauthor=A.+B.+Liangauthor=J.+Hu&title=FLT3+inhibition+upregulates+HDAC8+via+FOXO+to+inactivate+p53+and+promote+maintenance+of+FLT3-ITD%2B+acute+myeloid+leukemia&doi=10.1182%2Fblood.2019003538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia</span></div><div class="casAuthors">Long Jun; Zhang Wen-Jun; Liang Ai-Bin; Long Jun; Jia Ming-Yuan; Fang Wei-Yue; Chen Xin-Jie; Wang Zhong-Yu; Xiang Ru-Fang; Wang Li-Ning; Wang Ling; Jiang Chuan-He; Jiang Jie-Ling; Sun Yi-Dan; Chang Li; Gao Wen-Hui; Wang Ying; Li Jun-Min; Hu Jiong; Jia Ming-Yuan; Fang Wei-Yue; Chen Xin-Jie; Wang Ying; Mu Li-Li; Hong Deng-Li; Shen Yan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1472-1483</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Internal tandem duplication (ITD) mutations within the FMS-like receptor tyrosine kinase-3 (FLT3) can be found in up to 25% to 30% of acute myeloid leukemia (AML) patients and confer a poor prognosis.  Although FLT3 tyrosine kinase inhibitors (TKIs) have shown clinical responses, they cannot eliminate primitive FLT3-ITD+ AML cells, which are potential sources of relapse.  Therefore, elucidating the mechanisms underlying FLT3-ITD+ AML maintenance and drug resistance is essential to develop novel effective treatment strategies.  Here, we demonstrate that FLT3 inhibition induces histone deacetylase 8 (HDAC8) upregulation through FOXO1- and FOXO3-mediated transactivation in FLT3-ITD+ AML cells.  Upregulated HDAC8 deacetylates and inactivates p53, leading to leukemia maintenance and drug resistance upon TKI treatment.  Genetic or pharmacological inhibition of HDAC8 reactivates p53, abrogates leukemia maintenance, and significantly enhances TKI-mediated elimination of FLT3-ITD+ AML cells.  Importantly, in FLT3-ITD+ AML patient-derived xenograft models, the combination of FLT3 TKI (AC220) and an HDAC8 inhibitor (22d) significantly inhibits leukemia progression and effectively reduces primitive FLT3-ITD+ AML cells.  Moreover, we extend these findings to an AML subtype harboring another tyrosine kinase-activating mutation.  In conclusion, our study demonstrates that HDAC8 upregulation is an important mechanism to resist TKIs and promote leukemia maintenance and suggests that combining HDAC8 inhibition with TKI treatment could be a promising strategy to treat FLT3-ITD+ AML and other tyrosine kinase mutation-harboring leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLBFLp-jEpumGmni0r9GoKfW6udTcc2eaGgMJx8MUA4bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38zns12kug%253D%253D&md5=a68a319748e3483ac7b69faeb2770ed2</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1182%2Fblood.2019003538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.2019003538%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DJ.%26aulast%3DJia%26aufirst%3DM.%2BY.%26aulast%3DFang%26aufirst%3DW.%2BY.%26aulast%3DChen%26aufirst%3DX.%2BJ.%26aulast%3DMu%26aufirst%3DL.%2BL.%26aulast%3DWang%26aufirst%3DZ.%2BY.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DR.%2BF.%26aulast%3DWang%26aufirst%3DL.%2BN.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DC.%2BH.%26aulast%3DJiang%26aufirst%3DJ.%2BL.%26aulast%3DZhang%26aufirst%3DW.%2BJ.%26aulast%3DSun%26aufirst%3DY.%2BD.%26aulast%3DChang%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DW.%2BH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%2BM.%26aulast%3DHong%26aufirst%3DD.%2BL.%26aulast%3DLiang%26aufirst%3DA.%2BB.%26aulast%3DHu%26aufirst%3DJ.%26atitle%3DFLT3%2520inhibition%2520upregulates%2520HDAC8%2520via%2520FOXO%2520to%2520inactivate%2520p53%2520and%2520promote%2520maintenance%2520of%2520FLT3-ITD%252B%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2020%26volume%3D135%26issue%3D17%26spage%3D1472%26epage%3D1483%26doi%3D10.1182%2Fblood.2019003538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishioka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikezoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeffler, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, A.</span></span> <span> </span><span class="NLM_article-title">MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1382</span>– <span class="NLM_lpage">1392</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2008.02.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.leukres.2008.02.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=18394702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvF2qtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2008&pages=1382-1392&issue=9&author=C.+Nishiokaauthor=T.+Ikezoeauthor=J.+Yangauthor=S.+Takeuchiauthor=H.+P.+Koefflerauthor=A.+Yokoyama&title=MS-275%2C+a+novel+histone+deacetylase+inhibitor+with+selectivity+against+HDAC1%2C+induces+degradation+of+FLT3+via+inhibition+of+chaperone+function+of+heat+shock+protein+90+in+AML+cells&doi=10.1016%2Fj.leukres.2008.02.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells</span></div><div class="casAuthors">Nishioka, Chie; Ikezoe, Takayuki; Yang, Jing; Takeuchi, Seisho; Koeffler, H. Phillip; Yokoyama, Akihito</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1382-1392</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">This study explored the effect of MS-275, a novel histone deacetylase inhibitor (HDACI), against a variety of human leukemia cells with defined genetic alterations.  MS-275 profoundly induced growth arrest of acute myelogenous leukemia (AML) MOLM13 and biphenotypic leukemia MV4-11 cells, which possess internal tandem duplication mutation in the fms-like tyrosine kinase 3 (FLT3) gene (FLT3-ITD), with IC50s less than 1 μM, as measured by 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay on day two of culture.  Exposure of these cells to MS-275 decreased levels of total, as well as, phosphorylated forms of FLT3, resulting in inactivation of its downstream signal pathways, including Akt, ERK, and STAT5.  Further studies found that MS-275 induced acetylation of heat shock protein 90 (HSP90) in conjunction with ubiquitination of FLT3, leading to degrdn. of FLT3 proteins in these cells.  This was blunted by treatment with the proteasome inhibitor bortezomib, confirming that FLT was degraded via ubiquitin/proteasome pathway.  Moreover, we found that further inhibition of MEK/ERK signaling potentiated the action of MS-275 in leukemia cells.  Taken together, MS-275 may be useful for treatment of individuals with leukemia possessing activating mutation of FLT3 gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFFu5NS0Ijg7Vg90H21EOLACvtfcHk0li9KfdoTn9fuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvF2qtb0%253D&md5=b7af7f332be3efcac4f117470376e6ca</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2008.02.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2008.02.018%26sid%3Dliteratum%253Aachs%26aulast%3DNishioka%26aufirst%3DC.%26aulast%3DIkezoe%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DTakeuchi%26aufirst%3DS.%26aulast%3DKoeffler%26aufirst%3DH.%2BP.%26aulast%3DYokoyama%26aufirst%3DA.%26atitle%3DMS-275%252C%2520a%2520novel%2520histone%2520deacetylase%2520inhibitor%2520with%2520selectivity%2520against%2520HDAC1%252C%2520induces%2520degradation%2520of%2520FLT3%2520via%2520inhibition%2520of%2520chaperone%2520function%2520of%2520heat%2520shock%2520protein%252090%2520in%2520AML%2520cells%26jtitle%3DLeuk.%2520Res.%26date%3D2008%26volume%3D32%26issue%3D9%26spage%3D1382%26epage%3D1392%26doi%3D10.1016%2Fj.leukres.2008.02.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietschmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohmer, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinzel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, O. H.</span></span> <span> </span><span class="NLM_article-title">Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1412</span>– <span class="NLM_lpage">1421</span>, <span class="refDoi"> DOI: 10.1038/leu.2010.114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fleu.2010.114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=20508617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVSmurzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=1412-1421&issue=8&author=M.+Buchwaldauthor=K.+Pietschmannauthor=J.+P.+Mullerauthor=F.+D.+Bohmerauthor=T.+Heinzelauthor=O.+H.+Kramer&title=Ubiquitin+conjugase+UBCH8+targets+active+FMS-like+tyrosine+kinase+3+for+proteasomal+degradation&doi=10.1038%2Fleu.2010.114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation</span></div><div class="casAuthors">Buchwald, M.; Pietschmann, K.; Mueller, J. P.; Boehmer, F. D.; Heinzel, T.; Kraemer, O. H.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1412-1421</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The class III receptor tyrosine kinase FMS-like tyrosine kinase 3 (FLT3) regulates normal hematopoiesis and immunol. functions.  Nonetheless, constitutively active mutant FLT3 (FLT3-ITD) causally contributes to transformation and is assocd. with poor prognosis of acute myeloid leukemia (AML) patients.  Histone deacetylase inhibitors (HDACi) can counteract deregulated gene expression profiles and decrease oncoprotein stability, which renders them candidate drugs for AML treatment.  However, these drugs have pleiotropic effects and it is often unclear how they correct oncogenic transcriptomes and proteomes.  We report here that treatment of AML cells with the HDACi LBH589 induces the ubiquitin-conjugating enzyme UBCH8 and degrdn. of FLT3-ITD.  Gain- and loss-of-function approaches show that UBCH8 and the ubiquitin-ligase SIAH1 phys. interact with and target FLT3-ITD for proteasomal degrdn.  These ubiquitinylating enzymes though have a significantly lesser effect on wild-type FLT3.  Furthermore, physiol. and pharmacol. stimulation of FLT3 phosphorylation, inhibition of FLT3-ITD autophosphorylation and anal. of kinase-inactive FLT3-ITD revealed that tyrosine phosphorylation dets. degrdn. of FLT3 and FLT3-ITD by the proteasome.  These results provide novel insights into antileukemic activities of HDACi and position UBCH8, which have been implicated primarily in processes in the nucleus, as a previously unrecognized important modulator of FLT3-ITD stability and leukemic cell survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLyKAo8s7C0bVg90H21EOLACvtfcHk0li9KfdoTn9fuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVSmurzE&md5=1e7a09004da360e385f01ecfb9178157</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2Fleu.2010.114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2010.114%26sid%3Dliteratum%253Aachs%26aulast%3DBuchwald%26aufirst%3DM.%26aulast%3DPietschmann%26aufirst%3DK.%26aulast%3DMuller%26aufirst%3DJ.%2BP.%26aulast%3DBohmer%26aufirst%3DF.%2BD.%26aulast%3DHeinzel%26aufirst%3DT.%26aulast%3DKramer%26aufirst%3DO.%2BH.%26atitle%3DUbiquitin%2520conjugase%2520UBCH8%2520targets%2520active%2520FMS-like%2520tyrosine%2520kinase%25203%2520for%2520proteasomal%2520degradation%26jtitle%3DLeukemia%26date%3D2010%26volume%3D24%26issue%3D8%26spage%3D1412%26epage%3D1421%26doi%3D10.1038%2Fleu.2010.114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pietschmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolck, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spielberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polzer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiekermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bug, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinzel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohmer, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, O. H.</span></span> <span> </span><span class="NLM_article-title">Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2373</span>– <span class="NLM_lpage">2383</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F1535-7163.MCT-12-0129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=22942377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1CksrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=2373-2383&issue=11&author=K.+Pietschmannauthor=H.+A.+Bolckauthor=M.+Buchwaldauthor=S.+Spielbergauthor=H.+Polzerauthor=K.+Spiekermannauthor=G.+Bugauthor=T.+Heinzelauthor=F.+D.+Bohmerauthor=O.+H.+Kramer&title=Breakdown+of+the+FLT3-ITD%2FSTAT5+axis+and+synergistic+apoptosis+induction+by+the+histone+deacetylase+inhibitor+panobinostat+and+FLT3-specific+inhibitors&doi=10.1158%2F1535-7163.MCT-12-0129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Breakdown of the FLT3-ITD/STAT5 Axis and Synergistic Apoptosis Induction by the Histone Deacetylase Inhibitor Panobinostat and FLT3-Specific Inhibitors</span></div><div class="casAuthors">Pietschmann, Kristin; Bolck, Hella Anna; Buchwald, Marc; Spielberg, Steffi; Polzer, Harald; Spiekermann, Karsten; Bug, Gesine; Heinzel, Thorsten; Boehmer, Frank-Dietmar; Kraemer, Oliver H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2373-2383</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activating mutations of the class III receptor tyrosine kinase FLT3 are the most frequent mol. aberration in acute myeloid leukemia (AML).  Mutant FLT3 accelerates proliferation, suppresses apoptosis, and correlates with poor prognosis.  Therefore, it is a promising therapeutic target.  Here, the authors show that RNA interference against FLT3 with an internal tandem duplication (FLT3-ITD) potentiates the efficacy of the histone deacetylase inhibitor (HDACi) panobinostat (LBH589) against AML cells expressing FLT3-ITD.  Similar to RNA interference, tyrosine kinase inhibitors (TKI; AC220/cpd.102/PKC412) in combination with LBH589 exhibit superior activity against AML cells.  Median dose-effect analyses of drug-induced apoptosis rates of AML cells (MV4-11 and MOLM-13) revealed combination index (CI) values indicating strong synergism.  AC220, the most potent and FLT3-specific TKI, shows highest synergism with LBH589 in the low nanomolar range.  A 4-h exposure to LBH589 + AC220 already generates more than 50% apoptosis after 24 h.  Different cell lines lacking FLT3-ITD as well as normal peripheral blood mononuclear cells are not significantly affected by LBH589 + TKI, showing the specificity of this treatment regimen.  Immunoblot analyses show that LBH589 + TKI induce apoptosis via degrdn. of FLT3-ITD and its prosurvival target STAT5.  Previously, the authors showed the LBH589-induced proteasomal degrdn. of FLT3-ITD.  Here, the authors show that activated caspase-3 also contributes to the degrdn. of FLT3-ITD and that STAT5 is a direct target of this protease.  The authors' data strongly emphasize HDACi/TKI drug combinations as promising modality for the treatment of FLT3-ITD-pos. AMLs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobrrwTwrumvLVg90H21EOLACvtfcHk0li9KfdoTn9fuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1CksrfF&md5=cd0825ddafad9c60143015f1d69deaa9</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0129%26sid%3Dliteratum%253Aachs%26aulast%3DPietschmann%26aufirst%3DK.%26aulast%3DBolck%26aufirst%3DH.%2BA.%26aulast%3DBuchwald%26aufirst%3DM.%26aulast%3DSpielberg%26aufirst%3DS.%26aulast%3DPolzer%26aufirst%3DH.%26aulast%3DSpiekermann%26aufirst%3DK.%26aulast%3DBug%26aufirst%3DG.%26aulast%3DHeinzel%26aufirst%3DT.%26aulast%3DBohmer%26aufirst%3DF.%2BD.%26aulast%3DKramer%26aufirst%3DO.%2BH.%26atitle%3DBreakdown%2520of%2520the%2520FLT3-ITD%252FSTAT5%2520axis%2520and%2520synergistic%2520apoptosis%2520induction%2520by%2520the%2520histone%2520deacetylase%2520inhibitor%2520panobinostat%2520and%2520FLT3-specific%2520inhibitors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26issue%3D11%26spage%3D2373%26epage%3D2383%26doi%3D10.1158%2F1535-7163.MCT-12-0129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bali, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigua, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishvanath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scuto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annavarapu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiskus, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moscinski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhalla, K.</span></span> <span> </span><span class="NLM_article-title">Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT3</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">4991</span>– <span class="NLM_lpage">4997</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-0210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F1078-0432.CCR-04-0210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=15297399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtlSitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=4991-4997&issue=15&author=P.+Baliauthor=P.+Georgeauthor=P.+Cohenauthor=J.+Taoauthor=F.+Guoauthor=C.+Siguaauthor=A.+Vishvanathauthor=A.+Scutoauthor=S.+Annavarapuauthor=W.+Fiskusauthor=L.+Moscinskiauthor=P.+Atadjaauthor=K.+Bhalla&title=Superior+activity+of+the+combination+of+histone+deacetylase+inhibitor+LAQ824+and+the+FLT-3+kinase+inhibitor+PKC412+against+human+acute+myelogenous+leukemia+cells+with+mutant+FLT3&doi=10.1158%2F1078-0432.CCR-04-0210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 Kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3</span></div><div class="casAuthors">Bali, Purva; George, Prince; Cohen, Pamela; Tao, Jianguo; Guo, Fei; Sigua, Celia; Vishvanath, Anasuya; Scuto, Anna; Annavarapu, Srinivas; Fiskus, Warren; Moscinski, Lynn; Atadja, Peter; Bhalla, Kapil</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4991-4997</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mutant FLT-3 receptor tyrosine kinase is a client protein of the mol. chaperone heat shock protein 90 and is commonly present and contributes to the leukemia phenotype in acute myelogenous leukemia (AML).  LAQ824, a cinnamyl hydroxamate histone deacetylase inhibitor, is known to induce acetylation and inhibition of heat shock protein 90.  Here, we detd. the effects of LAQ824 and/or PKC412 (a FLT-3 kinase inhibitor) on the levels of mutant FLT-3 and its downstream signaling, as well as growth arrest and cell-death of cultured and primary human AML cells.  The effect of LAQ824 and/or PKC412 treatment was detd. on the levels of FLT-3 and phosphorylated (p)-FLT-3, on downstream pro-growth and pro-survival effectors, e.g., p-STAT5, p-AKT, and p-extracellular signal-regulated kinase (ERK) 1/2, and on the cell cycle status and apoptosis in the cultured MV4-11 and primary AML cells with mutant FLT-3.  Treatment with LAQ824 promoted proteasomal degrdn. and attenuation of the levels of FLT-3 and p-FLT-3, assocd. with cell cycle G1-phase accumulation and apoptosis of MV4-11 cells.  This was accompanied by attenuation of p-STAT5, p-AKT, and p-ERK1/2 levels.  STAT-5 DNA-binding activity and the levels of c-Myc and oncostatin M were also down-regulated.  Cotreatment with LAQ824 and PKC412 synergistically induced apoptosis of MV4-11 cells and induced more apoptosis of the primary AML cells expressing mutant FLT-3.  This was also assocd. with more attenuation of p-FLT-3, p-AKT, p-ERK1/2, and p-STAT5.  The combination of LAQ824 and PKC412 is highly active against human AML cells with mutant FLT-3, which merits in vivo studies of the combination against human AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPJeLfYNFiTbVg90H21EOLACvtfcHk0ljoWVR-O-7NrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtlSitrs%253D&md5=375c881c176bfec9a1ddf8b5616d576d</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-0210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-0210%26sid%3Dliteratum%253Aachs%26aulast%3DBali%26aufirst%3DP.%26aulast%3DGeorge%26aufirst%3DP.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DTao%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DF.%26aulast%3DSigua%26aufirst%3DC.%26aulast%3DVishvanath%26aufirst%3DA.%26aulast%3DScuto%26aufirst%3DA.%26aulast%3DAnnavarapu%26aufirst%3DS.%26aulast%3DFiskus%26aufirst%3DW.%26aulast%3DMoscinski%26aufirst%3DL.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DBhalla%26aufirst%3DK.%26atitle%3DSuperior%2520activity%2520of%2520the%2520combination%2520of%2520histone%2520deacetylase%2520inhibitor%2520LAQ824%2520and%2520the%2520FLT-3%2520kinase%2520inhibitor%2520PKC412%2520against%2520human%2520acute%2520myelogenous%2520leukemia%2520cells%2520with%2520mutant%2520FLT3%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26issue%3D15%26spage%3D4991%26epage%3D4997%26doi%3D10.1158%2F1078-0432.CCR-04-0210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radany, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. Y.</span></span> <span> </span><span class="NLM_article-title">Suberoylanilide hydroxamic acid induces hypersensitivity to radiation therapy in acute myelogenous leukemia cells expressing constitutively active FLT3 mutants</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">e84515</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0084515</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1371%2Fjournal.pone.0084515" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=24367670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFelsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e84515&issue=12&author=X.+Chenauthor=E.+H.+Radanyauthor=P.+Wongauthor=S.+Maauthor=K.+Wuauthor=B.+Wangauthor=J.+Y.+Wong&title=Suberoylanilide+hydroxamic+acid+induces+hypersensitivity+to+radiation+therapy+in+acute+myelogenous+leukemia+cells+expressing+constitutively+active+FLT3+mutants&doi=10.1371%2Fjournal.pone.0084515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Suberoylanilide hydroxamic acid induces hypersensitivity to radiation therapy in acute myelogenous leukemia cells expressing constitutively active FLT3 mutants</span></div><div class="casAuthors">Chen, Xufeng; Radany, Eric H.; Wong, Patty; Ma, Shenglin; Wu, Kan; Wang, Bing; Wong, Jeffrey Y. C.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e84515/1-e84515/14, 14 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDIs) have shown promise as candidate radiosensitizer for many types of cancers.  However, the mechanisms of action are not well understood, and whether they could have clin. impact on radiotherapy for leukemia is unclear.  In this study, we demonstrate that suberoylanilide hydroxamic acid (SAHA) can increase radiosensitivity of acute myeloid leukemia (AML) cells through posttranslational modification of Rad51 protein responses and selective inhibition of the homol.-directed repair (HDR) pathway.  Our data also showed that AML cells with mutant, constitutively active FMS-like tyrosine kinase-3 (FLT3) were more radiation sensitive, caused by compromised non-homologous end joining (NHEJ) repair.  Furthermore, SAHA-induced radiosensitization were enhanced in AML cells with expression of these FLT3 mutants.  The results of this study suggest that SAHA, a recently approved HDI in clin. trials, may act as a candidate component for novel conditioning regimens to improve efficacy for AML patients undergoing radiotherapy and chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrzXL5huZIy7Vg90H21EOLACvtfcHk0ljoWVR-O-7NrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFelsb8%253D&md5=49e370ef178feae3db7bf0534211d754</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0084515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0084515%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DRadany%26aufirst%3DE.%2BH.%26aulast%3DWong%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWong%26aufirst%3DJ.%2BY.%26atitle%3DSuberoylanilide%2520hydroxamic%2520acid%2520induces%2520hypersensitivity%2520to%2520radiation%2520therapy%2520in%2520acute%2520myelogenous%2520leukemia%2520cells%2520expressing%2520constitutively%2520active%2520FLT3%2520mutants%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26issue%3D12%26spage%3De84515%26doi%3D10.1371%2Fjournal.pone.0084515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiaang, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">e83160</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0083160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1371%2Fjournal.pone.0083160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=24416160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFOjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e83160&issue=1&author=W.+H.+Linauthor=T.+K.+Yehauthor=W.+T.+Jiaangauthor=K.+J.+Yenauthor=C.+H.+Chenauthor=C.+T.+Huangauthor=S.+C.+Yenauthor=S.+Y.+Hsiehauthor=L.+H.+Chouauthor=C.+P.+Chenauthor=C.+H.+Chiuauthor=L.+C.+Kaoauthor=Y.+S.+Chaoauthor=C.+T.+Chenauthor=J.+T.+Hsu&title=Evaluation+of+the+antitumor+effects+of+BPR1J-340%2C+a+potent+and+selective+FLT3+inhibitor%2C+alone+or+in+combination+with+an+HDAC+inhibitor%2C+vorinostat%2C+in+AML+cancer&doi=10.1371%2Fjournal.pone.0083160"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer</span></div><div class="casAuthors">Lin, Wen-Hsing; Yeh, Teng-Kuang; Jiaang, Weir-Torn; Yen, Kuei-Jung; Chen, Chun-Hwa; Huang, Chin-Ting; Yen, Shih-Chieh; Hsieh, Shu-Yi; Chou, Ling-Hui; Chen, Ching-Ping; Chiu, Chun-Hsien; Kao, Li-Chun; Chao, Yu-Sheng; Chen, Chiung-Tong; Hsu, John T.-A.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e83160/1-e83160/9, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Overexpression or/and activating mutation of FLT3 kinase play a major driving role in the pathogenesis of acute myeloid leukemia (AML).  Hence, pharmacol. inhibitors of FLT3 are of therapeutic potential for AML treatment.  In this study, BPR1J-340 was identified as a novel potent FLT3 inhibitor by biochem. kinase activity (IC50 approx. 25 nM) and cellular proliferation (GC50 approx. 5 nM) assays.  BPR1J-340 inhibited the phosphorylation of FLT3 and STAT5 and triggered apoptosis in FLT3-ITD+ AML cells.  The pharmacokinetic parameters of BPR1J-340 in rats were detd.  BPR1J-340 also demonstrated pronounced tumor growth inhibition and regression in FLT3-ITD+ AML murine xenograft models.  The combination treatment of the HDAC inhibitor vorinostat (SAHA) with BPR1J-340 synergistically induced apoptosis via Mcl-1 down-regulation in MOLM-13 AML cells, indicating that the combination of selective FLT3 kinase inhibitors and HDAC inhibitors could exhibit clin. benefit in AML therapy.  Our results suggest that BPR1J-340 may be further developed in the preclin. and clin. studies as therapeutics in AML treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppUyYs9NC-LbVg90H21EOLACvtfcHk0ljoWVR-O-7NrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFOjsrc%253D&md5=d16dce70aa0d0978df3570db62559b90</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0083160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0083160%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DW.%2BH.%26aulast%3DYeh%26aufirst%3DT.%2BK.%26aulast%3DJiaang%26aufirst%3DW.%2BT.%26aulast%3DYen%26aufirst%3DK.%2BJ.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DHuang%26aufirst%3DC.%2BT.%26aulast%3DYen%26aufirst%3DS.%2BC.%26aulast%3DHsieh%26aufirst%3DS.%2BY.%26aulast%3DChou%26aufirst%3DL.%2BH.%26aulast%3DChen%26aufirst%3DC.%2BP.%26aulast%3DChiu%26aufirst%3DC.%2BH.%26aulast%3DKao%26aufirst%3DL.%2BC.%26aulast%3DChao%26aufirst%3DY.%2BS.%26aulast%3DChen%26aufirst%3DC.%2BT.%26aulast%3DHsu%26aufirst%3DJ.%2BT.%26atitle%3DEvaluation%2520of%2520the%2520antitumor%2520effects%2520of%2520BPR1J-340%252C%2520a%2520potent%2520and%2520selective%2520FLT3%2520inhibitor%252C%2520alone%2520or%2520in%2520combination%2520with%2520an%2520HDAC%2520inhibitor%252C%2520vorinostat%252C%2520in%2520AML%2520cancer%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26issue%3D1%26spage%3De83160%26doi%3D10.1371%2Fjournal.pone.0083160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. S.</span></span> <span> </span><span class="NLM_article-title">PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">e19798</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0019798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1371%2Fjournal.pone.0019798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=21589872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtlKksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e19798&issue=5&author=J.+Zhouauthor=C.+Biauthor=W.+J.+Chngauthor=L.+L.+Cheongauthor=S.+C.+Liuauthor=S.+Maharaauthor=K.+G.+Tayauthor=Q.+Zengauthor=J.+Liauthor=K.+Guoauthor=C.+P.+Tanauthor=H.+Yuauthor=D.+H.+Albertauthor=C.+S.+Chen&title=PRL-3%2C+a+metastasis+associated+tyrosine+phosphatase%2C+is+involved+in+FLT3-ITD+signaling+and+implicated+in+anti-AML+therapy&doi=10.1371%2Fjournal.pone.0019798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy</span></div><div class="casAuthors">Zhou, Jianbiao; Bi, Chonglei; Chng, Wee-Joo; Cheong, Lip-Lee; Liu, Shaw-Cheng; Mahara, Sylvia; Tay, Kian-Ghee; Zeng, Qi; Li, Jie; Guo, Ke; Tan, Cheng Peow Bobby; Yu, Hanry; Albert, Daniel H.; Chen, Chien-Shing</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e19798</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Combination with other small mol. drugs represents a promising strategy to improve therapeutic efficacy of FLT3 inhibitors in the clinic.  We demonstrated that combining ABT-869, a FLT3 inhibitor, with SAHA, a HDAC inhibitor, led to synergistic killing of the AML cells with FLT3 mutations and suppression of colony formation.  We identified a core gene signature that is uniquely induced by the combination treatment in 2 different leukemia cell lines.  Among these, we showed that downregulation of PTP4A3 (PRL-3) played a role in this synergism.  PRL-3 is downstream of FLT3 signaling and ectopic expression of PRL-3 conferred therapeutic resistance through upregulation of STAT (signal transducers and activators of transcription) pathway activity and anti-apoptotic Mcl-1 protein.  PRL-3 interacts with HDAC4 and SAHA downregulates PRL-3 via a proteasome dependent pathway.  In addn., PRL-3 protein was identified in 47% of AML cases, but was absent in myeloid cells in normal bone marrows.  Our results suggest such combination therapies may significantly improve the therapeutic efficacy of FLT3 inhibitors.  PRL-3 plays a potential pathol. role in AML and it might be a useful therapeutic target in AML, and warrant clin. investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjpYGhMVUgIbVg90H21EOLACvtfcHk0lgxhK1dqul1CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtlKksrw%253D&md5=a31d6fabae78504afd1549b8bf110e6a</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0019798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0019798%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DBi%26aufirst%3DC.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DCheong%26aufirst%3DL.%2BL.%26aulast%3DLiu%26aufirst%3DS.%2BC.%26aulast%3DMahara%26aufirst%3DS.%26aulast%3DTay%26aufirst%3DK.%2BG.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DK.%26aulast%3DTan%26aufirst%3DC.%2BP.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DChen%26aufirst%3DC.%2BS.%26atitle%3DPRL-3%252C%2520a%2520metastasis%2520associated%2520tyrosine%2520phosphatase%252C%2520is%2520involved%2520in%2520FLT3-ITD%2520signaling%2520and%2520implicated%2520in%2520anti-AML%2520therapy%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26issue%3D5%26spage%3De19798%26doi%3D10.1371%2Fjournal.pone.0019798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z. X.</span></span> <span> </span><span class="NLM_article-title">Crotonoside exhibits selective post-inhibition effect in AML cells via inhibition of FLT3 and HDAC3/6</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">61</span>),  <span class="NLM_fpage">103087</span>– <span class="NLM_lpage">103099</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.20710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.18632%2Foncotarget.20710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=29262547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BC1Mzjs1antw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=103087-103099&issue=61&author=Y.+Z.+Liauthor=S.+Yuauthor=P.+A.+Yanauthor=D.+Y.+Gongauthor=F.+L.+Wuauthor=Z.+Heauthor=Y.+Y.+Yuanauthor=A.+Y.+Zhaoauthor=X.+Tangauthor=R.+Q.+Zhangauthor=C.+Pengauthor=Z.+X.+Cao&title=Crotonoside+exhibits+selective+post-inhibition+effect+in+AML+cells+via+inhibition+of+FLT3+and+HDAC3%2F6&doi=10.18632%2Foncotarget.20710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Crotonoside exhibits selective post-inhibition effect in AML cells via inhibition of FLT3 and HDAC3/6</span></div><div class="casAuthors">Li Yu-Zhi; Yu Si; Yan Pei-Ao; Gong Dao-Yin; Tang Xue; Zhang Ruo-Qi; Peng Cheng; Cao Zhi-Xing; Wu Fang-Li; He Zhi; Yuan Yu-Yao; Zhao An-Yan</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">61</span>),
    <span class="NLM_cas:pages">103087-103099</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Targeted therapies for the treatment of acute myeloid leukemia (AML), specifically the FLT3 inhibitors, have shown promising results.  Nevertheless, it is very unlikely that inhibitors which target a single pathway will provide long-term disease control.  Here, we report the characterization of crotonoside, a natural product extracted from Chinese medicinal herb, Croton, for the treatment of AML via inhibition of FLT3 and HDAC3/6.  In vitro, crotonoside exhibited selective inhibition in AML cells.  In vivo, crotonoside treatment at 70 and 35 mg/kg/d produced significant AML tumor inhibition rates of 93.5% and 73.6%, respectively.  Studies on the anti-AML mechanism of crotonoside demonstrated a significant inhibition of FLT3 signaling, cell cycle arrest in G0/G1 phase, and apoptosis.  In contrast to classic FLT3 inhibitor; sunitinib, crotonoside was able to selectively suppress the expression of HDAC3 and HDAC6 without altering the expression of other HDAC isoforms.  Inhibitors of HDAC3 and HDAC6; RGFP966 and HPOB, respectively, also exhibited selective inhibition in AML cells.  Furthermore, we established novel signaling pathways including HDAC3/NF-κB-p65 and HDAC6/c-Myc besides FLT3/c-Myc which are aberrantly regulated in the progression of AML.  In addition, crotonoside alone or the combination of sunitinib/RFP966/HPOB exhibited a significant post-inhibition effect in AML cells by the inhibition of FLT3 and HDAC3/6.  Inhibitors targeting the FLT3 and HDAC3/6 might provide a more effective treatment strategy for AML.  Taken together, the present study suggests that crotonoside could be a promising candidate for the treatment of AML, and deserves further investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJ7MGLt-1wSEQ0lWbKiCflfW6udTcc2eZwVAADlrTbNrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mzjs1antw%253D%253D&md5=353a8403064b1a9ce553d76d712cfe88</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.20710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.20710%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%2BZ.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DYan%26aufirst%3DP.%2BA.%26aulast%3DGong%26aufirst%3DD.%2BY.%26aulast%3DWu%26aufirst%3DF.%2BL.%26aulast%3DHe%26aufirst%3DZ.%26aulast%3DYuan%26aufirst%3DY.%2BY.%26aulast%3DZhao%26aufirst%3DA.%2BY.%26aulast%3DTang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DR.%2BQ.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DZ.%2BX.%26atitle%3DCrotonoside%2520exhibits%2520selective%2520post-inhibition%2520effect%2520in%2520AML%2520cells%2520via%2520inhibition%2520of%2520FLT3%2520and%2520HDAC3%252F6%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D61%26spage%3D103087%26epage%3D103099%26doi%3D10.18632%2Foncotarget.20710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganguly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajkhowa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gocke, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konig, H.</span></span> <span> </span><span class="NLM_article-title">The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1025</span>– <span class="NLM_lpage">1032</span>, <span class="refDoi"> DOI: 10.1038/leu.2015.346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fleu.2015.346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=26686245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC28Xps1Snug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=1025-1032&issue=5&author=E.+Changauthor=S.+Gangulyauthor=T.+Rajkhowaauthor=C.+D.+Gockeauthor=M.+Levisauthor=H.+Konig&title=The+combination+of+FLT3+and+DNA+methyltransferase+inhibition+is+synergistically+cytotoxic+to+FLT3%2FITD+acute+myeloid+leukemia+cells&doi=10.1038%2Fleu.2015.346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells</span></div><div class="casAuthors">Chang, E.; Ganguly, S.; Rajkhowa, T.; Gocke, C. D.; Levis, M.; Konig, H.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1025-1032</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Effective treatment regimens for elderly acute myeloid leukemia (AML) patients harboring internal tandem duplication mutations in the FMS-like tyrosine kinase-3 (FLT3) gene (FLT3/ITD) are lacking and represent a significant unmet need.  Recent data on the effects of FLT3 tyrosine kinase inhibitors on FLT3/ITD+ AML showed promising clin. activity, including in elderly patients.  DNA methyltransferase (DNMT) inhibitors such as decitabine (5-aza-2-deoxycytidine, DEC) and 5-azacitidine (AZA) demonstrated clin. benefit in AML, are well tolerated and are assocd. with minimal increases in FLT3 ligand, which can represent a potential resistance mechanism to FLT3 inhibitors.  In addn., both FLT3 and DNMT inhibition are assocd. with the induction of terminal differentiation of myeloid blasts.  Consequently, there is a strong theor. rationale for combining FLT3 and DNMT inhibition for FLT3/ITD+ AML.  We therefore sought to study the anti-leukemic effects of DEC, AZA and FLT3 inhibitors, either as single agents or in combination, on AML cell lines and primary cells derived from newly diagnosed and relapsed AML patients.  Our studies indicate that combined treatment using FLT3 inhibition and hypomethylation confers synergistic anti-leukemic effects, including apoptosis, growth inhibition and differentiation.  The simultaneous administration of AZA and FLT3 inhibition appears to be the most efficacious combination in this regard.  These drugs may provide a novel therapeutic approach for FLT3/ITD+ AML, in particular for older patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsoMdnpAgygrVg90H21EOLACvtfcHk0lhW-QFVh8u9Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xps1Snug%253D%253D&md5=c7b5c4d85f330db28f6bb7a9388370f2</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.346%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DE.%26aulast%3DGanguly%26aufirst%3DS.%26aulast%3DRajkhowa%26aufirst%3DT.%26aulast%3DGocke%26aufirst%3DC.%2BD.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DKonig%26aufirst%3DH.%26atitle%3DThe%2520combination%2520of%2520FLT3%2520and%2520DNA%2520methyltransferase%2520inhibition%2520is%2520synergistically%2520cytotoxic%2520to%2520FLT3%252FITD%2520acute%2520myeloid%2520leukemia%2520cells%26jtitle%3DLeukemia%26date%3D2016%26volume%3D30%26issue%3D5%26spage%3D1025%26epage%3D1032%26doi%3D10.1038%2Fleu.2015.346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lubbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruter, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmoor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germing, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuendgen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rethwisch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platzbecker, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galm, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brugger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heil, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackanson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagemeijer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijermans, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohner, H.</span></span> <span> </span><span class="NLM_article-title">A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>97</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">401</span>, <span class="refDoi"> DOI: 10.3324/haematol.2011.048231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.3324%2Fhaematol.2011.048231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=22058219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BC383nsFSrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2012&pages=393-401&issue=3&author=M.+Lubbertauthor=B.+H.+Ruterauthor=R.+Clausauthor=C.+Schmoorauthor=M.+Schmidauthor=U.+Germingauthor=A.+Kuendgenauthor=V.+Rethwischauthor=A.+Ganserauthor=U.+Platzbeckerauthor=O.+Galmauthor=W.+Bruggerauthor=G.+Heilauthor=B.+Hackansonauthor=B.+Deschlerauthor=K.+Dohnerauthor=A.+Hagemeijerauthor=P.+W.+Wijermansauthor=H.+Dohner&title=A+multicenter+phase+II+trial+of+decitabine+as+first-line+treatment+for+older+patients+with+acute+myeloid+leukemia+judged+unfit+for+induction+chemotherapy&doi=10.3324%2Fhaematol.2011.048231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy</span></div><div class="casAuthors">Lubbert Michael; Ruter Bjorn H; Claus Rainer; Schmoor Claudia; Schmid Mathias; Germing Ulrich; Kuendgen Andrea; Rethwisch Volker; Ganser Arnold; Platzbecker Uwe; Galm Oliver; Brugger Wolfram; Heil Gerhard; Hackanson Bjorn; Deschler Barbara; Dohner Konstanze; Hagemeijer Anne; Wijermans Pierre W; Dohner Hartmut</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">393-401</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The treatment of acute myeloid leukemia of older, medically non-fit patients still poses a highly unmet clinical need, and only few large, prospective studies have been performed in this setting.  Given the established activity of hypomethylating agents such as 5-aza-2'-deoxycytidine (decitabine) in myelodysplastic syndromes and acute myeloid leukemia with 20-30% bone marrow blasts, we investigated whether this drug is also active in patients with more than 30% blasts.  DESIGN AND METHODS:  To evaluate the efficacy and toxicity of decitabine in patients over 60 years old with untreated acute myeloid leukemia ineligible for induction chemotherapy, 227 patients (median age, 72 years), many with comorbidities, adverse cytogenetics and/or preceding myelodysplastic syndrome were treated with this hypomethylating agent.  During the initial decitabine treatment (135 mg/m(2) total dose infused intravenously over 72 hours every 6 weeks), a median of two cycles was administered (range, 1-4).  All-trans retinoic acid was administered to 100 patients during course 2.  Fifty-two patients who completed four cycles of treatment subsequently received a median of five maintenance courses (range, 1-19) with a lower dose of decitabine (20 mg/m(2)) infused over 1 hour on 3 consecutive days every 4-6 weeks.  RESULTS:  The complete and partial remission rate was 26%, 95% CI (20%, 32%), and an antileukemic effect was noted in 26% of patients.  Response rates did not differ between patients with or without adverse cytogenetics; patients with monosomal karyotypes also responded.  The median overall survival from the start of decitabine treatment was 5.5 months (range, 0-57.5+) and the 1-year survival rate was 28%, 95%CI (22%,34%).  Toxicities were predominantly hematologic.  CONCLUSIONS:  Decitabine is well tolerated by older, medically non-fit patients with acute myeloid leukemia; myelosuppression is the major toxicity.  The response rate and overall survival were not adversely influenced by poor-risk cytogenetics or myelodysplastic syndrome.  Because of these encouraging results, randomized studies evaluating single-agent decitabine versus conventional treatment are warranted.  The study is registered with the German Clinical Trials Registry, number DRKS00000069.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTewgQWGB3nkO98rul4nhSdfW6udTcc2ebv1OehfUGs8rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383nsFSrtA%253D%253D&md5=be52b886b97d95c66f3d803ccba55985</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2011.048231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2011.048231%26sid%3Dliteratum%253Aachs%26aulast%3DLubbert%26aufirst%3DM.%26aulast%3DRuter%26aufirst%3DB.%2BH.%26aulast%3DClaus%26aufirst%3DR.%26aulast%3DSchmoor%26aufirst%3DC.%26aulast%3DSchmid%26aufirst%3DM.%26aulast%3DGerming%26aufirst%3DU.%26aulast%3DKuendgen%26aufirst%3DA.%26aulast%3DRethwisch%26aufirst%3DV.%26aulast%3DGanser%26aufirst%3DA.%26aulast%3DPlatzbecker%26aufirst%3DU.%26aulast%3DGalm%26aufirst%3DO.%26aulast%3DBrugger%26aufirst%3DW.%26aulast%3DHeil%26aufirst%3DG.%26aulast%3DHackanson%26aufirst%3DB.%26aulast%3DDeschler%26aufirst%3DB.%26aulast%3DDohner%26aufirst%3DK.%26aulast%3DHagemeijer%26aufirst%3DA.%26aulast%3DWijermans%26aufirst%3DP.%2BW.%26aulast%3DDohner%26aufirst%3DH.%26atitle%3DA%2520multicenter%2520phase%2520II%2520trial%2520of%2520decitabine%2520as%2520first-line%2520treatment%2520for%2520older%2520patients%2520with%2520acute%2520myeloid%2520leukemia%2520judged%2520unfit%2520for%2520induction%2520chemotherapy%26jtitle%3DHaematologica%26date%3D2012%26volume%3D97%26issue%3D3%26spage%3D393%26epage%3D401%26doi%3D10.3324%2Fhaematol.2011.048231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Jamal, H. A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mat Jusoh, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johan, M. F.</span></span> <span> </span><span class="NLM_article-title">Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">869</span>, <span class="refDoi"> DOI: 10.1186/s12885-015-1695-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1186%2Fs12885-015-1695-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=26547689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVGlsLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=869&author=H.+A.+N.+Al-Jamalauthor=S.+A.+Mat+Jusohauthor=R.+Hassanauthor=M.+F.+Johan&title=Enhancing+SHP-1+expression+with+5-azacytidine+may+inhibit+STAT3+activation+and+confer+sensitivity+in+lestaurtinib+%28CEP-701%29-resistant+FLT3-ITD+positive+acute+myeloid+leukemia&doi=10.1186%2Fs12885-015-1695-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia</span></div><div class="casAuthors">Al-Jamal, Hamid Ali Nagi; Jusoh, Siti Asmaa Mat; Hassan, Rosline; Johan, Muhammad Farid</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">869/1-869/11</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Tumor-suppressor genes are inactivated by methylation in several cancers including acute myeloid leukemia (AML).  Src homol.-2 (SH2)-contg. protein-tyrosine phosphatase 1 (SHP-1) is a neg. regulator of the JAK/STAT pathway.  Transcriptional silencing of SHP-1 plays a crit. role in the development and progression of cancers through STAT3 activation. 5-Azacytidine (5-Aza) is a DNA methyltransferase inhibitor that causes DNA demethylation resulting in re-expression of silenced SHP-1.  Lestaurtinib (CEP-701) is a multi-targeted tyrosine kinase inhibitor that potently inhibits FLT3 tyrosine kinase and induces hematol. remission in AML patients harboring the internal tandem duplication of the FLT3 gene (FLT3-ITD).  However, the majority of patients in clin. trials developed resistance to CEP-701.  Therefore, the aim of this study, was to assess the effect of re-expression of SHP-1 on sensitivity to CEP-701 in resistant AML cells.  Methods: Resistant cells harboring the FLT3-ITD were developed by overexposure of MV4-11 to CEP-701, and the effects of 5-Aza treatment were investigated.  Apoptosis and cytotoxicity of CEP-701 were detd. using Annexin V and MTS assays, resp.  Gene expression was performed by quant. real-time PCR.  STATs activity was examd. by western blotting and the methylation profile of SHP-1 was studied using MS-PCR and pyrosequencing anal.  Repeated-measures ANOVA and Kruskal-Wallis tests were used for statistical anal.  Results: The cytotoxic dose of CEP-701 on resistant cells was significantly higher in comparison with parental and MV4-11R-cep + 5-Aza cells (p = 0.004).  The resistant cells showed a significant higher viability and lower apoptosis compared with other cells (p < 0.001).  Expression of SHP-1 was 7-fold higher in MV4-11R-cep + 5-Aza cells compared to parental and resistant cells (p = 0.011).  STAT3 was activated in resistant cells.  Methylation of SHP-1 was significantly decreased in MV4-11R-cep + 5-Aza cells (p = 0.002).  Conclusions: The restoration of SHP-1 expression induces sensitivity towards CEP-701 and could serve as a target in the treatment of AML.  Our findings support the hypothesis that, the tumor-suppressor effect of SHP-1 is lost due to epigenetic silencing and its re-expression might play an important role in re-inducing sensitivity to TKIs.  Thus, SHP-1 is a plausible candidate for a role in the development of CEP-701 resistance in FLT3-ITD+ AML patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRvpZF_EfRyrVg90H21EOLACvtfcHk0lhW-QFVh8u9Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVGlsLrM&md5=edfd98edbe255dd426424ef67aaf401b</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1186%2Fs12885-015-1695-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-015-1695-x%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Jamal%26aufirst%3DH.%2BA.%2BN.%26aulast%3DMat%2BJusoh%26aufirst%3DS.%2BA.%26aulast%3DHassan%26aufirst%3DR.%26aulast%3DJohan%26aufirst%3DM.%2BF.%26atitle%3DEnhancing%2520SHP-1%2520expression%2520with%25205-azacytidine%2520may%2520inhibit%2520STAT3%2520activation%2520and%2520confer%2520sensitivity%2520in%2520lestaurtinib%2520%2528CEP-701%2529-resistant%2520FLT3-ITD%2520positive%2520acute%2520myeloid%2520leukemia%26jtitle%3DBMC%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D869%26doi%3D10.1186%2Fs12885-015-1695-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alattar, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunwald, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudek, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajkhowa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richie, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daver, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Manero, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faderl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nazha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopleva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellasala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreeff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span> <span> </span><span class="NLM_article-title">Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT3 internal tandem duplication mutation</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>121</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">4655</span>– <span class="NLM_lpage">4662</span>, <span class="refDoi"> DOI: 10.1182/blood-2013-01-480228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2013-01-480228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=23613521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpsFWktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2013&pages=4655-4662&issue=23&author=F.+Ravandiauthor=M.+L.+Alattarauthor=M.+R.+Grunwaldauthor=M.+A.+Rudekauthor=T.+Rajkhowaauthor=M.+A.+Richieauthor=S.+Pierceauthor=N.+Daverauthor=G.+Garcia-Maneroauthor=S.+Faderlauthor=A.+Nazhaauthor=M.+Konoplevaauthor=G.+Borthakurauthor=J.+Burgerauthor=T.+Kadiaauthor=S.+Dellasalaauthor=M.+Andreeffauthor=J.+Cortesauthor=H.+Kantarjianauthor=M.+Levis&title=Phase+2+study+of+azacytidine+plus+sorafenib+in+patients+with+acute+myeloid+leukemia+and+FLT3+internal+tandem+duplication+mutation&doi=10.1182%2Fblood-2013-01-480228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation</span></div><div class="casAuthors">Ravandi, Farhad; Alattar, Mona Lisa; Grunwald, Michael R.; Rudek, Michelle A.; Rajkhowa, Trivikram; Richie, Mary Ann; Pierce, Sherry; Daver, Naval; Garcia-Manero, Guillermo; Faderl, Stefan; Nazha, Aziz; Konopleva, Marina; Borthakur, Gautam; Burger, Jan; Kadia, Tapan; Dellasala, Sara; Andreeff, Michael; Cortes, Jorge; Kantarjian, Hagop; Levis, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4655-4662</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Patients received 5-azacytidine (AZA) 75 mg/m2 i.v. daily for 7 days and sorafenib 400 mg orally twice daily continuously; cycles were repeated at ∼1-mo intervals.  Forty-three acute myeloid leukemia (AML) patients with a median age of 64 years (range, 24-87 years) were enrolled; 37 were evaluable for response.  FMS-like tyrosine kinase-3 (FLT3)-internal tandem duplication (ITD) mutation was detected in 40 (93%) patients, with a median allelic ratio of 0.32 (range, 0.009-0.93).  They had received a median of 2 prior treatment regimens (range, 0-7); 9 had failed prior therapy with a FLT3 kinase inhibitor.  The response rate was 46%, including 10 (27%) complete response with incomplete count recovery (CRi), 6 (16%) complete responses (CR), and 1 (3%) partial response.  The median time to achieve CR/CRi was 2 cycles (range, 1-4), and the median duration of CR/CRi was 2.3 mo (range, 1-14.3 mo).  Sixty-four percent of patients achieved adequate (defined as >85%) FLT3 inhibition during their first cycle of therapy.  The degree of FLT3 inhibition correlated with plasma sorafenib concns.  FLT3 ligand levels did not rise to levels seen in prior studies of patients receiving cytotoxic chemotherapy.  The combination of AZA and sorafenib is effective for patients with relapsed AML and FLT-3-ITD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx7FK4wFoKk7Vg90H21EOLACvtfcHk0lgsdp-4CtrU-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpsFWktbo%253D&md5=cb763c746906ccd682cbe8faa5ec6f67</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-01-480228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-01-480228%26sid%3Dliteratum%253Aachs%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DAlattar%26aufirst%3DM.%2BL.%26aulast%3DGrunwald%26aufirst%3DM.%2BR.%26aulast%3DRudek%26aufirst%3DM.%2BA.%26aulast%3DRajkhowa%26aufirst%3DT.%26aulast%3DRichie%26aufirst%3DM.%2BA.%26aulast%3DPierce%26aufirst%3DS.%26aulast%3DDaver%26aufirst%3DN.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DFaderl%26aufirst%3DS.%26aulast%3DNazha%26aufirst%3DA.%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DBurger%26aufirst%3DJ.%26aulast%3DKadia%26aufirst%3DT.%26aulast%3DDellasala%26aufirst%3DS.%26aulast%3DAndreeff%26aufirst%3DM.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DLevis%26aufirst%3DM.%26atitle%3DPhase%25202%2520study%2520of%2520azacytidine%2520plus%2520sorafenib%2520in%2520patients%2520with%2520acute%2520myeloid%2520leukemia%2520and%2520FLT3%2520internal%2520tandem%2520duplication%2520mutation%26jtitle%3DBlood%26date%3D2013%26volume%3D121%26issue%3D23%26spage%3D4655%26epage%3D4662%26doi%3D10.1182%2Fblood-2013-01-480228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daver, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohanian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNardo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrov, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrajoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Manero, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopleva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreeff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pemmaraju, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabbour, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarado, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinsoy, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span> <span> </span><span class="NLM_article-title">The combination of quizartinib with azacitidine or Low dose cytarabine is highly active in patients (Pts) with FLT3-ITD mutated myeloid leukemias: interim report of a phase I/II trial</span>. <i>Clinical Lymphoma Myeloma and Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">S3</span>, <span class="refDoi"> DOI: 10.1016/j.clml.2017.09.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.clml.2017.09.027" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=S3&issue=10&author=M.+Swaminathanauthor=H.+Kantarjianauthor=N.+Daverauthor=G.+Borthakurauthor=M.+Ohanianauthor=T.+Kadiaauthor=C.+DiNardoauthor=N.+Jainauthor=Z.+Estrovauthor=A.+Ferrajoliauthor=G.+Garcia-Maneroauthor=M.+Konoplevaauthor=M.+Andreeffauthor=N.+Pemmarajuauthor=E.+Jabbourauthor=Y.+Alvaradoauthor=W.+Wierdaauthor=M.+R.+Pinsoyauthor=F.+Ravandiauthor=J.+Cortes&title=The+combination+of+quizartinib+with+azacitidine+or+Low+dose+cytarabine+is+highly+active+in+patients+%28Pts%29+with+FLT3-ITD+mutated+myeloid+leukemias%3A+interim+report+of+a+phase+I%2FII+trial&doi=10.1016%2Fj.clml.2017.09.027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.clml.2017.09.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clml.2017.09.027%26sid%3Dliteratum%253Aachs%26aulast%3DSwaminathan%26aufirst%3DM.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DDaver%26aufirst%3DN.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DOhanian%26aufirst%3DM.%26aulast%3DKadia%26aufirst%3DT.%26aulast%3DDiNardo%26aufirst%3DC.%26aulast%3DJain%26aufirst%3DN.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DFerrajoli%26aufirst%3DA.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DAndreeff%26aufirst%3DM.%26aulast%3DPemmaraju%26aufirst%3DN.%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DAlvarado%26aufirst%3DY.%26aulast%3DWierda%26aufirst%3DW.%26aulast%3DPinsoy%26aufirst%3DM.%2BR.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DThe%2520combination%2520of%2520quizartinib%2520with%2520azacitidine%2520or%2520Low%2520dose%2520cytarabine%2520is%2520highly%2520active%2520in%2520patients%2520%2528Pts%2529%2520with%2520FLT3-ITD%2520mutated%2520myeloid%2520leukemias%253A%2520interim%2520report%2520of%2520a%2520phase%2520I%252FII%2520trial%26jtitle%3DClinical%2520Lymphoma%2520Myeloma%2520and%2520Leukemia%26date%3D2017%26volume%3D17%26issue%3D10%26spage%3DS3%26doi%3D10.1016%2Fj.clml.2017.09.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dowling, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakikhani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantus, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span> <span> </span><span class="NLM_article-title">Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10804</span>– <span class="NLM_lpage">10812</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-2310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F0008-5472.CAN-07-2310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=18006825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlSls7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=10804-10812&issue=22&author=R.+J.+Dowlingauthor=M.+Zakikhaniauthor=I.+G.+Fantusauthor=M.+Pollakauthor=N.+Sonenberg&title=Metformin+inhibits+mammalian+target+of+rapamycin-dependent+translation+initiation+in+breast+cancer+cells&doi=10.1158%2F0008-5472.CAN-07-2310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin Inhibits Mammalian Target of Rapamycin-Dependent Translation Initiation in Breast Cancer Cells</span></div><div class="casAuthors">Dowling, Ryan J. O.; Zakikhani, Mahvash; Fantus, I. George; Pollak, Michael; Sonenberg, Nahum</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10804-10812</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Metformin is used for the treatment of type 2 diabetes because of its ability to lower blood glucose.  The effects of metformin are explained by the activation of AMP-activated protein kinase (AMPK), which regulates cellular energy metab.  Recently, we showed that metformin inhibits the growth of breast cancer cells through the activation of AMPK.  Here, we show that metformin inhibits translation initiation.  In MCF-7 breast cancer cells, metformin treatment led to a 30% decrease in global protein synthesis.  Metformin caused a dose-dependent specific decrease in cap-dependent translation, with a maximal inhibition of 40%.  Polysome profile anal. showed an inhibition of translation initiation as metformin treatment of MCF-7 cells led to a shift of mRNAs from heavy to light polysomes and a concomitant increase in the amt. of 80S ribosomes.  The decrease in translation caused by metformin was assocd. with mammalian target of rapamycin (mTOR) inhibition, and a decrease in the phosphorylation of S6 kinase, ribosomal protein S6, and eIF4E-binding protein 1.  The effects of metformin on translation were mediated by AMPK, as treatment of cells with the AMPK inhibitor compd. C prevented the inhibition of translation.  Furthermore, translation in MDA-MB-231 cells, which lack the AMPK kinase LKB1, and in tuberous sclerosis complex 2 null (TSC2-/-) mouse embryonic fibroblasts was unaffected by metformin, indicating that LKB1 and TSC2 are involved in the mechanism of action of metformin.  These results show that metformin-mediated AMPK activation leads to inhibition of mTOR and a redn. in translation initiation, thus providing a possible mechanism of action of metformin in the inhibition of cancer cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJqVcwq27NFbVg90H21EOLACvtfcHk0lgsdp-4CtrU-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlSls7fI&md5=3a7bcbef8eda124f387ceb5526a3efb4</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-2310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-2310%26sid%3Dliteratum%253Aachs%26aulast%3DDowling%26aufirst%3DR.%2BJ.%26aulast%3DZakikhani%26aufirst%3DM.%26aulast%3DFantus%26aufirst%3DI.%2BG.%26aulast%3DPollak%26aufirst%3DM.%26aulast%3DSonenberg%26aufirst%3DN.%26atitle%3DMetformin%2520inhibits%2520mammalian%2520target%2520of%2520rapamycin-dependent%2520translation%2520initiation%2520in%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26issue%3D22%26spage%3D10804%26epage%3D10812%26doi%3D10.1158%2F0008-5472.CAN-07-2310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W.</span></span> <span> </span><span class="NLM_article-title">Metformin inhibits the proliferation of A431 cells by modulating the PI3K/Akt signaling pathway</span>. <i>Exp. Ther. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1401</span>– <span class="NLM_lpage">1406</span>, <span class="refDoi"> DOI: 10.3892/etm.2015.2220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.3892%2Fetm.2015.2220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=25780442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnvValsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=1401-1406&issue=4&author=Y.+Liuauthor=Y.+Zhangauthor=K.+Jiaauthor=Y.+Dongauthor=W.+Ma&title=Metformin+inhibits+the+proliferation+of+A431+cells+by+modulating+the+PI3K%2FAkt+signaling+pathway&doi=10.3892%2Fetm.2015.2220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin inhibits the proliferation of A431 cells by modulating the PI3K/Akt signaling pathway</span></div><div class="casAuthors">Liu, Yingshan; Zhang, Yan; Jia, Kun; Dong, Yuhao; Ma, Weiyuan</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and Therapeutic Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1401-1406</span>CODEN:
                <span class="NLM_cas:coden">ETMXA2</span>;
        ISSN:<span class="NLM_cas:issn">1792-0981</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The ability of metformin, an antidiabetic drug with wide applications, to inhibit tumor cell growth has recently been discovered.  The PI3K/Akt signaling pathway has been found to play an important role in the survival, proliferation and apoptosis of tumor cells.  The aim of the present study was to explore the effect of metformin on the proliferation of A431 human squamous cell carcinoma cells and the underlying mol. mechanisms.  A431 cells in the logarithmic growth phase were treated with 0, 15, 30, 45 and 60 mM metformin for 12, 24 and 36 h, resp.  Cell morphol. with 45 mM metformin treatment for 24 h was obsd. under a microscope.  The proliferation of A431 cells was detected by the Cell Counting kit-8 colorimetric method.  The mRNA expression levels of PI3K and Akt were detected by reverse transcription-polymerase chain reaction (RT-PCR).  The protein expression levels of PI3K, Akt and phosphorylated (p)-Akt were detected by western blot anal.  Metformin treatment caused morphol. change in A431 cells and inhibited their proliferation in a significant time- and dose-dependent manner.  RT-PCR results showed that the mRNA expression of PI3K was inhibited by metformin in a time- and dose-dependent manner (P<0.05).  However, there was no significant change in the mRNA expression of Akt following metformin treatment (P>0.05).  Western blotting results showed that the protein expression levels of PI3K and p-Akt were inhibited by metformin in a time- and dose-dependent manner (P<0.05).  In conclusion, metformin significantly inhibited the proliferation of A431 cells in the current study, which may be strongly assocd. with the inhibition of the PI3K/Akt signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr663vfSlEIhrVg90H21EOLACvtfcHk0lh8TPmBPdKgCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnvValsr4%253D&md5=f54c303907ea5ca73bc84e99cf70c242</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.3892%2Fetm.2015.2220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fetm.2015.2220%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DW.%26atitle%3DMetformin%2520inhibits%2520the%2520proliferation%2520of%2520A431%2520cells%2520by%2520modulating%2520the%2520PI3K%252FAkt%2520signaling%2520pathway%26jtitle%3DExp.%2520Ther.%2520Med.%26date%3D2015%26volume%3D9%26issue%3D4%26spage%3D1401%26epage%3D1406%26doi%3D10.3892%2Fetm.2015.2220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span> <span> </span><span class="NLM_article-title">Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1421</span>– <span class="NLM_lpage">1427</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2015.09.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.leukres.2015.09.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=26505133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslSjsb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2015&pages=1421-1427&issue=12&author=F.+Wangauthor=Z.+Liuauthor=J.+Zengauthor=H.+Zhuauthor=J.+Liauthor=X.+Chengauthor=T.+Jiangauthor=L.+Zhangauthor=C.+Zhangauthor=T.+Chenauthor=T.+Liuauthor=Y.+Jia&title=Metformin+synergistically+sensitizes+FLT3-ITD-positive+acute+myeloid+leukemia+to+sorafenib+by+promoting+mTOR-mediated+apoptosis+and+autophagy&doi=10.1016%2Fj.leukres.2015.09.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy</span></div><div class="casAuthors">Wang, Fangfang; Liu, Zuofeng; Zeng, Jisha; Zhu, Hongyan; Li, Jingjing; Cheng, Xiaomin; Jiang, Tao; Zhang, Li; Zhang, Chuanfen; Chen, Tie; Liu, Ting; Jia, Yongqian</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1421-1427</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Mutations of Fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD), accounting for approx. 30% of patients with acute myeloid leukemia (AML), results in poor therapeutic efficacy and short survival.  Sorafenib, an oral multikinase inhibitor, can inhibit FLT3 and improve clin. outcome of FLT3 mutated leukemia.  Our current studies have shown that, the antidiabetic drug metformin also exerts anti-leukemic effect by activating p-AMPK and synergistically sensitizes FLT3 mutated AML to sorafenib.  Both agents suppress cell proliferation in a dose-dependent manner and induce apoptosis via cell cycle arrest, but does not obviously modulate autophagy marker, light chain 3 (LC3).  Mechanistically, in the presence of metformin, the anticancer potential of sorafenib, accompanying with increased LC3 levels, is found to be synergistically enhanced with the remarkably reduced protein expression of the mTOR/p70S6K/4EBP1 pathway, while not appreciably altering cell cycle.  Overall, these results show metformin in aid of sorafenib may represent a promising and attractive strategy for the treatment of FLT3-ITD mutated AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1PhDpLHlTjLVg90H21EOLACvtfcHk0lh8TPmBPdKgCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslSjsb%252FI&md5=c9f09d1129f9c72f86d126f9831a2bd9</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2015.09.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2015.09.016%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DZeng%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DJia%26aufirst%3DY.%26atitle%3DMetformin%2520synergistically%2520sensitizes%2520FLT3-ITD-positive%2520acute%2520myeloid%2520leukemia%2520to%2520sorafenib%2520by%2520promoting%2520mTOR-mediated%2520apoptosis%2520and%2520autophagy%26jtitle%3DLeuk.%2520Res.%26date%3D2015%26volume%3D39%26issue%3D12%26spage%3D1421%26epage%3D1427%26doi%3D10.1016%2Fj.leukres.2015.09.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. J.</span></span> <span> </span><span class="NLM_article-title">The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2017.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.leukres.2017.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=29232592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFGlsrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2018&pages=14-19&author=H.+H.+Zhuauthor=Z.+P.+Guoauthor=J.+S.+Jiaauthor=Q.+Jiangauthor=H.+Jiangauthor=X.+J.+Huang&title=The+impact+of+oral+arsenic+and+all-trans-retinoic+acid+on+coagulopathy+in+acute+promyelocytic+leukemia&doi=10.1016%2Fj.leukres.2017.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia</span></div><div class="casAuthors">Zhu, Hong-Hu; Guo, Zhi-Ping; Jia, Jin-Song; Jiang, Qian; Jiang, Hao; Huang, Xiao-Jun</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14-19</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The aim of our study was to evaluate the impact of oral arsenic (the realgar-indigo naturalis formula, RIF) and all-trans retinoic acid (ATRA) on coagulopathy in acute promyelocytic leukemia (APL) compared with i.v. arsenic trioxide (ATO) and ATRA during induction.  Mitoxantrone was added to all the patients at a dose of 1.4 mg/m2 per day for 5-7 days.  D-dimer levels, prothrombin time (PT), fibrinogen (Fbg) levels and the platelet count were comparably analyzed among 83 newly diagnosed APL patients treated with RIF (n = 45) or with ATO (n = 38).  Since induction therapy with RIF and ATRA, the median levels of Fbg, PT and platelets were recovered to the normal range within 4 days, 10 days and 28 days, resp.  The last day of platelet and plasma transfusion was day 12 (range: 0-24 days) and day 3 (range: 0-27 days), resp.  Among the 42 patients with a disseminated intravascular coagulation (DIC) score = 4, the consumption of transfused platelets was less in the RIF group than that in the ATO group (P = 0.037).  In the 17 patients with a DIC score <4, prompt recovery of Fbg levels (P = 0.028) was obsd. in the RIF group compared with that in the ATO group (P = 0.401).  RIF and ATO showed similar effects on the recovery of coagulopathy in APL patients.  RIF had a potential beneficial effect in accelerating the recovery of thrombocytopenia and hypofibrinogenemia for subclin. DIC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaPZ3N9Bihf7Vg90H21EOLACvtfcHk0lh8TPmBPdKgCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFGlsrfL&md5=87885249348fc3492fa2a6a8c5cd660b</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2017.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2017.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DH.%2BH.%26aulast%3DGuo%26aufirst%3DZ.%2BP.%26aulast%3DJia%26aufirst%3DJ.%2BS.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DX.%2BJ.%26atitle%3DThe%2520impact%2520of%2520oral%2520arsenic%2520and%2520all-trans-retinoic%2520acid%2520on%2520coagulopathy%2520in%2520acute%2520promyelocytic%2520leukemia%26jtitle%3DLeuk.%2520Res.%26date%3D2018%26volume%3D65%26spage%3D14%26epage%3D19%26doi%3D10.1016%2Fj.leukres.2017.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">All-trans retinoic acid exerts selective anti-FLT3-ITD acute myeloid leukemia efficacy through downregulating Chk1 kinase</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>473</i></span>,  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2019.12.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.canlet.2019.12.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=31904486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BB3cXotVemtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=473&publication_year=2020&pages=130-138&author=W.+Wangauthor=Z.+Jiangauthor=L.+Wangauthor=A.+Wangauthor=J.+Liuauthor=C.+Chenauthor=K.+Yuauthor=F.+Zouauthor=W.+Wangauthor=J.+Liuauthor=Q.+Liu&title=All-trans+retinoic+acid+exerts+selective+anti-FLT3-ITD+acute+myeloid+leukemia+efficacy+through+downregulating+Chk1+kinase&doi=10.1016%2Fj.canlet.2019.12.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">All-trans retinoic acid exerts selective anti-FLT3-ITD acute myeloid leukemia efficacy through downregulating Chk1 kinase</span></div><div class="casAuthors">Wang, Wenliang; Jiang, Zongru; Wang, Li; Wang, Aoli; Liu, Juan; Chen, Cheng; Yu, Kailin; Zou, Fengming; Wang, Wenchao; Liu, Jing; Liu, Qingsong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">473</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">130-138</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">All-trans retinoic acid (ATRA) is known to be a potent inhibitor of FLT3-ITD acute myeloid leukemia (AML) cells, although the exact mechanism remains unclear.  In this work, we report that ATRA causes fatal mitotic catastrophe in FLT3-ITD AML cells by degrading Chk1 kinase, and therefore preventing DNA damage repair.  In order to explore a further enhancement in the inhibitory effect of ATRA on FLT3-ITD AML cells, we investigated the suitability of a combination of ATRA and DNA damage drug SN38.  In vitro expts. showed that this combinatorial approach effectively inhibited the proliferation of FLT3-ITD cells and induced cell apoptosis in AML.  In vivo expts. confirmed that the combination could substantially improve the anti-tumor effect of SN38.  Taken together, our results indicate that ATRA down-regulates Chk1 in FLT3-ITD AML cells, and the combination of ATRA and SN38 significantly improves the anti-tumor effect of either ATRA or SN38 when used alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKcigTNTfpvbVg90H21EOLACvtfcHk0lgIASlDyeEEoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXotVemtr4%253D&md5=64cdca227a01b66ea4375c0be20ed337</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2019.12.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2019.12.045%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DZou%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DAll-trans%2520retinoic%2520acid%2520exerts%2520selective%2520anti-FLT3-ITD%2520acute%2520myeloid%2520leukemia%2520efficacy%2520through%2520downregulating%2520Chk1%2520kinase%26jtitle%3DCancer%2520Lett.%26date%3D2020%26volume%3D473%26spage%3D130%26epage%3D138%26doi%3D10.1016%2Fj.canlet.2019.12.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenblatt, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirley, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffield, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruner, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aplan, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span> <span> </span><span class="NLM_article-title">All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD<sup>+</sup> leukemia stem cells <i>in vitro</i> and <i>in vivo</i></span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">2867</span>– <span class="NLM_lpage">2878</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-05-646786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2015-05-646786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=27103744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1ars7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=2867-2878&issue=23&author=H.+S.+Maauthor=S.+M.+Greenblattauthor=C.+M.+Shirleyauthor=A.+S.+Duffieldauthor=J.+K.+Brunerauthor=L.+Liauthor=B.+Nguyenauthor=E.+Jungauthor=P.+D.+Aplanauthor=G.+Ghiaurauthor=R.+J.+Jonesauthor=D.+Small&title=All-trans+retinoic+acid+synergizes+with+FLT3+inhibition+to+eliminate+FLT3%2FITD%2B+leukemia+stem+cells+in+vitro+and+in+vivo&doi=10.1182%2Fblood-2015-05-646786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo</span></div><div class="casAuthors">Ma, Hayley S.; Greenblatt, Sarah M.; Shirley, Courtney M.; Duffield, Amy S.; Bruner, J. Kyle; Li, Li; Nguyen, Bao; Jung, Eric; Aplan, Peter D.; Ghiaur, Gabriel; Jones, Richard J.; Small, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2867-2878</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">FMS-like tyrosine kinase 3 (FLT3)-mutant acute myeloid leukemia (AML) portends a poor prognosis, and ineffective targeting of the leukemic stem cell (LSC) population remains one of several obstacles in treating this disease.  All-trans retinoic acid (ATRA) has been used in several clin. trials for the treatment of nonpromyelocytic AML with limited clin. activity obsd.  FLT3 tyrosine kinase inhibitors (TKIs) used as monotherapy also achieve limited clin. responses and are thus far unable to affect cure rates in AML patients.  We explored the efficacy of combining ATRA and FLT3 TKIs to eliminate FLT3/internal tandem duplication (ITD)+ LSCs.  Our studies reveal highly synergistic drug activity, preferentially inducing apoptosis in FLT3/ITD+ cell lines and patient samples.  Colony-forming unit assays further demonstrate decreased clonogenicity of FLT3/ITD+ cells upon treatment with ATRA and TKI.  Most importantly, the drug combination depletes FLT3/ITD+ LSCs in a genetic mouse model of AML, and prolongs survival of leukemic mice.  Furthermore, engraftment of primary FLT3/ITD+ patient samples is reduced in mice following treatment with FLT3 TKI and ATRA in combination, with evidence of cellular differentiation occurring in vivo.  Mechanistically, we provide evidence that the synergism of ATRA and FLT3 TKIs is at least in part due to the observation that FLT3 TKI treatment upregulates the antiapoptotic protein Bcl6, limiting the drug's apoptotic effect.  However, cotreatment with ATRA reduces Bcl6 expression to baseline levels through suppression of interleukin-6 receptor signaling.  These studies provide evidence of the potential of this drug combination to eliminate FLT3/ITD+ LSCs and reduce the rate of relapse in AML patients with FLT3 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZPpO6zBVIsLVg90H21EOLACvtfcHk0lgIASlDyeEEoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1ars7zE&md5=4f0e624bfcb71998230c304074beda38</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-05-646786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-05-646786%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DH.%2BS.%26aulast%3DGreenblatt%26aufirst%3DS.%2BM.%26aulast%3DShirley%26aufirst%3DC.%2BM.%26aulast%3DDuffield%26aufirst%3DA.%2BS.%26aulast%3DBruner%26aufirst%3DJ.%2BK.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DJung%26aufirst%3DE.%26aulast%3DAplan%26aufirst%3DP.%2BD.%26aulast%3DGhiaur%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DR.%2BJ.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DAll-trans%2520retinoic%2520acid%2520synergizes%2520with%2520FLT3%2520inhibition%2520to%2520eliminate%2520FLT3%252FITD%252B%2520leukemia%2520stem%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26issue%3D23%26spage%3D2867%26epage%3D2878%26doi%3D10.1182%2Fblood-2015-05-646786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guenounou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delabesse, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recher, C.</span></span> <span> </span><span class="NLM_article-title">Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations</span>. <i>Eur. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>93</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">536</span>, <span class="refDoi"> DOI: 10.1111/ejh.12334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1111%2Fejh.12334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=24689895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFCqu7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2014&pages=533-536&issue=6&author=S.+Guenounouauthor=E.+Delabesseauthor=C.+Recher&title=Sorafenib+plus+all-trans+retinoic+acid+for+AML+patients+with+FLT3-ITD+and+NPM1+mutations&doi=10.1111%2Fejh.12334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations</span></div><div class="casAuthors">Guenounou, Sarah; Delabesse, Eric; Recher, Christian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Haematology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">533-536</span>CODEN:
                <span class="NLM_cas:coden">EJHAEC</span>;
        ISSN:<span class="NLM_cas:issn">0902-4441</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Knowledge of the mol. basis of acute myeloid leukemia has increased considerably in the past few years, and therapies targeting specific mol. defects of this disease are intensively investigated.  Patients with both NPM1 and FLT3-ITD mutations encompass 20% of cytogenetically normal AML.  The multikinase and FLT3 inhibitor, sorafenib, has shown some efficacy in patients with relapsed FLT3-ITD+ AML.  In addn., it is suggested that all-trans retinoic acid (ATRA) used in combination with chemotherapy has shown to improve outcome of patients harboring NPM1 mutations.  We report here the clin. course of three patients with refractory or relapsed FLT3-ITD+/NPM1+ AML who achieved significant response upon sorafenib and ATRA combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJW3OjlJDixbVg90H21EOLACvtfcHk0lgIASlDyeEEoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFCqu7nM&md5=266b24a8c5b745a24af876b34ea56526</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1111%2Fejh.12334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fejh.12334%26sid%3Dliteratum%253Aachs%26aulast%3DGuenounou%26aufirst%3DS.%26aulast%3DDelabesse%26aufirst%3DE.%26aulast%3DRecher%26aufirst%3DC.%26atitle%3DSorafenib%2520plus%2520all-trans%2520retinoic%2520acid%2520for%2520AML%2520patients%2520with%2520FLT3-ITD%2520and%2520NPM1%2520mutations%26jtitle%3DEur.%2520J.%2520Haematol.%26date%3D2014%26volume%3D93%26issue%3D6%26spage%3D533%26epage%3D536%26doi%3D10.1111%2Fejh.12334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Speers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsimelzon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrick, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culhane, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quackenbush, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilsenbeck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P.</span></span> <span> </span><span class="NLM_article-title">Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">6327</span>– <span class="NLM_lpage">6340</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-1107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F1078-0432.CCR-09-1107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=19808870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlyqsLfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=6327-6340&issue=20&author=C.+Speersauthor=A.+Tsimelzonauthor=K.+Sextonauthor=A.+M.+Herrickauthor=C.+Gutierrezauthor=A.+Culhaneauthor=J.+Quackenbushauthor=S.+Hilsenbeckauthor=J.+Changauthor=P.+Brown&title=Identification+of+novel+kinase+targets+for+the+treatment+of+estrogen+receptor-negative+breast+cancer&doi=10.1158%2F1078-0432.CCR-09-1107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer</span></div><div class="casAuthors">Speers, Corey; Tsimelzon, Anna; Sexton, Krystal; Herrick, Ashley M.; Gutierrez, Carolina; Culhane, Aedin; Quackenbush, John; Hilsenbeck, Susan; Chang, Jenny; Brown, Powel</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6327-6340</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Previous gene expression profiling studies of breast cancer have focused on the entire genome to identify genes differentially expressed between estrogen receptor (ER) α-pos. and ER-α-neg. cancers.  Exptl. Design: Here, the authors used gene expression microarray profiling to identify a distinct kinase gene expression profile that identifies ER-neg. breast tumors and subsets ER-neg. breast tumors into four distinct subtypes.  Results: Based on the types of kinases expressed in these clusters, the authors identify a cell cycle regulatory subset, a S6 kinase pathway cluster, an immunomodulatory kinase-expressing cluster, and a mitogen-activated protein kinase pathway cluster.  Furthermore, the authors show that this specific kinase profile is validated using independent sets of human tumors and is also seen in a panel of breast cancer cell lines.  Kinase expression knockdown studies show that many of these kinases are essential for the growth of ER-neg., but not ER-pos., breast cancer cell lines.  Finally, survival anal. of patients with breast cancer shows that the S6 kinase pathway signature subtype of ER-neg. cancers confers an extremely poor prognosis, whereas patients whose tumors express high levels of immunomodulatory kinases have a significantly better prognosis.  Conclusions: This study identifies a list of kinases that are prognostic and may serve as druggable targets for the treatment of ER-neg. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_rbJqzatV3bVg90H21EOLACvtfcHk0lidy_e0I0pQ8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlyqsLfK&md5=5c3d1bc319129b47ae96fe07b635c29a</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-1107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-1107%26sid%3Dliteratum%253Aachs%26aulast%3DSpeers%26aufirst%3DC.%26aulast%3DTsimelzon%26aufirst%3DA.%26aulast%3DSexton%26aufirst%3DK.%26aulast%3DHerrick%26aufirst%3DA.%2BM.%26aulast%3DGutierrez%26aufirst%3DC.%26aulast%3DCulhane%26aufirst%3DA.%26aulast%3DQuackenbush%26aufirst%3DJ.%26aulast%3DHilsenbeck%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DP.%26atitle%3DIdentification%2520of%2520novel%2520kinase%2520targets%2520for%2520the%2520treatment%2520of%2520estrogen%2520receptor-negative%2520breast%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26issue%3D20%26spage%3D6327%26epage%3D6340%26doi%3D10.1158%2F1078-0432.CCR-09-1107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dozier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Didier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamburini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manenti, S.</span></span> <span> </span><span class="NLM_article-title">Targeting CHK1 inhibits cell proliferation in FLT3-ITD positive acute myeloid leukemia</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1342</span>– <span class="NLM_lpage">1349</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2014.08.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.leukres.2014.08.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=25281057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFGltLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2014&pages=1342-1349&issue=11&author=L.+L.+Yuanauthor=A.+Greenauthor=L.+Davidauthor=C.+Dozierauthor=C.+Recherauthor=C.+Didierauthor=J.+Tamburiniauthor=S.+Manenti&title=Targeting+CHK1+inhibits+cell+proliferation+in+FLT3-ITD+positive+acute+myeloid+leukemia&doi=10.1016%2Fj.leukres.2014.08.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CHK1 inhibits cell proliferation in FLT3-ITD positive acute myeloid leukemia</span></div><div class="casAuthors">Yuan, Ling Li; Green, Alexa; David, Laure; Dozier, Christine; Recher, Christian; Didier, Christine; Tamburini, Jerome; Manenti, Stephane</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1342-1349</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">CHK1 Ser/Thr kinase, a well characterized regulator of DNA damage response, is also involved in normal cell cycle progression.  In this study, we investigate how CHK1 participates to proliferation of acute myeloid leukemia cells expressing the mutated FLT3-ITD tyrosine kinase receptor.  Pharmacol. inhibition of CHK1 as well as its shRNA mediated down regulation reduced the proliferation rate of FLT-ITD expressing leukemic cell lines in a cytostatic manner.  Flow cytometry anal. revealed no accumulation in a specific phase of the cell cycle upon CHK1 inhibition.  Accordingly, lentiviral-mediated CHK1 overexpression increased the proliferation rate of FLT3-ITD expressing cells, as judged by cell viability and [3H] thymidine incorporation expts.  By contrast, expression of a ser280 mutant did not, suggesting that phosphorylation of this residue is an important determinant of CHK1 proliferative function.  Clonogenic growth of primary leukemic cells from patients in semi-solid medium was reduced upon CHK1 inhibition, confirming the data obtained with leukemic established cell lines.  Surprisingly, 3 out of 4 CHK1 inhibitory compds. tested in this study were also potent inhibitors of the FLT3-ITD tyrosine kinase receptor.  Altogether, these data identify CHK1 as a regulator of FLT3-ITD-pos. leukemic cells proliferation, and they open interesting perspectives in terms of new therapeutic strategies for these pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXfsrSR7FvhLVg90H21EOLACvtfcHk0lidy_e0I0pQ8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFGltLfL&md5=98e88982e5d5142c10993192e2abba9b</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2014.08.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2014.08.020%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DL.%2BL.%26aulast%3DGreen%26aufirst%3DA.%26aulast%3DDavid%26aufirst%3DL.%26aulast%3DDozier%26aufirst%3DC.%26aulast%3DRecher%26aufirst%3DC.%26aulast%3DDidier%26aufirst%3DC.%26aulast%3DTamburini%26aufirst%3DJ.%26aulast%3DManenti%26aufirst%3DS.%26atitle%3DTargeting%2520CHK1%2520inhibits%2520cell%2520proliferation%2520in%2520FLT3-ITD%2520positive%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeuk.%2520Res.%26date%3D2014%26volume%3D38%26issue%3D11%26spage%3D1342%26epage%3D1349%26doi%3D10.1016%2Fj.leukres.2014.08.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimal, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansat-De
Mas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dozier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamburini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Didier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manenti, S.</span></span> <span> </span><span class="NLM_article-title">Pim kinases phosphorylate Chk1 and regulate its functions in acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1038/leu.2013.168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fleu.2013.168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=23748345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsl2jt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=293-301&issue=2&author=L.+L.+Yuanauthor=A.+S.+Greenauthor=S.+Bertoliauthor=F.+Grimalauthor=V.+Mansat-De%0AMasauthor=C.+Dozierauthor=J.+Tamburiniauthor=C.+Recherauthor=C.+Didierauthor=S.+Manenti&title=Pim+kinases+phosphorylate+Chk1+and+regulate+its+functions+in+acute+myeloid+leukemia&doi=10.1038%2Fleu.2013.168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Pim kinases phosphorylate Chk1 and regulate its functions in acute myeloid leukemia</span></div><div class="casAuthors">Yuan, L. L.; Green, A. S.; Bertoli, S.; Grimal, F.; Mansat-De Mas, V.; Dozier, C.; Tamburini, J.; Recher, C.; Didier, C.; Manenti, S.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">293-301</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Phosphorylation by Akt on Ser 280 was reported to induce cytoplasmic retention and inactivation of CHK1 with consequent genetic instability in PTEN-/- cells.  In acute myeloid leukemia cells carrying the FLT3-internal tandem duplication (ITD) mutation, we obsd. high rates of FLT3-ITD-dependent CHK1 Ser 280 phosphorylation.  Pharmacol. inhibition and RNA interference identified Pim1/2, not Akt, as effectors of this phosphorylation.  Pim1 catalyzed Ser 280 phosphorylation in vitro and ectopic expression of Pim1/2-induced CHK1 phosphorylation.  Ser 280 phosphorylation did not modify CHK1 localization, but facilitated its cell cycle and resistance functions in leukemic cells.  FLT3, PIM or CHK1 inhibitors synergized with DNA-damaging agents to induce apoptosis, allowing cells to bypass the etoposide-induced G2/M arrest.  Consistently, etoposide-induced CHK1-dependent phosphorylations of CDC25C on Ser 216 and histone H3 on Thr11 were decreased upon FLT3 inhibition.  Accordingly, ectopic expression of CHK1 improved the resistance of FLT3-ITD cells and maintained histone H3 phosphorylation in response to DNA damage, whereas expression of unphosphorylated Ser 280Ala mutant did not.  Finally, FLT3- and Pim-dependent phosphorylation of CHK1 on Ser 280 was confirmed in primary blasts from patients.  These results identify a new pathway involved in the resistance of FLT3-ITD leukemic cells to genotoxic agents, and they constitute the first report of CHK1 Ser 280 regulation in myeloid malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRb_6wUbp7YrVg90H21EOLACvtfcHk0lidy_e0I0pQ8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsl2jt7w%253D&md5=bec5f52a33e196a13350b18a3b920e5e</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1038%2Fleu.2013.168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2013.168%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DL.%2BL.%26aulast%3DGreen%26aufirst%3DA.%2BS.%26aulast%3DBertoli%26aufirst%3DS.%26aulast%3DGrimal%26aufirst%3DF.%26aulast%3DMansat-De%2BMas%26aufirst%3DV.%26aulast%3DDozier%26aufirst%3DC.%26aulast%3DTamburini%26aufirst%3DJ.%26aulast%3DRecher%26aufirst%3DC.%26aulast%3DDidier%26aufirst%3DC.%26aulast%3DManenti%26aufirst%3DS.%26atitle%3DPim%2520kinases%2520phosphorylate%2520Chk1%2520and%2520regulate%2520its%2520functions%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2014%26volume%3D28%26issue%3D2%26spage%3D293%26epage%3D301%26doi%3D10.1038%2Fleu.2013.168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lilly, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span> <span> </span><span class="NLM_article-title">Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>105</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1759</span>– <span class="NLM_lpage">1767</span>, <span class="refDoi"> DOI: 10.1182/blood-2004-05-2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2004-05-2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=15498859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsVGjs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=1759-1767&issue=4&author=K.+T.+Kimauthor=K.+Bairdauthor=J.+Y.+Ahnauthor=P.+Meltzerauthor=M.+Lillyauthor=M.+Levisauthor=D.+Small&title=Pim-1+is+up-regulated+by+constitutively+activated+FLT3+and+plays+a+role+in+FLT3-mediated+cell+survival&doi=10.1182%2Fblood-2004-05-2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival</span></div><div class="casAuthors">Kim, Kyu-Tae; Baird, Kristin; Ahn, Joon-Young; Meltzer, Paul; Lilly, Michael; Levis, Mark; Small, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1759-1767</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Constitutively activating internal tandem duplication (ITD) mutations of the receptor tyrosine kinase FLT3 (Fms-like tyrosine kinase 3) play an important role in leukemogenesis, and their presence is assocd. with poor prognosis in acute myeloid leukemia (AML).  To better understand FLT3 signaling in leukemogenesis, the authors have examd. the changes in gene expression induced by FLT3/ITD or constitutively activated wild-type FLT3 expression.  Microarrays were used with RNA harvested before and after inhibition of FLT3 signaling.  Pim-1 was one of the most significantly down-regulated genes upon FLT3 inhibition.  Pim-1 is a proto-oncogene and is known to be up-regulated by signal transducer and activator of transcription 5 (STAT5), which itself is a downstream target of FLT3 signaling.  Quant. polymerase chain reaction (QPCR) confirmed the microarray results and demonstrated approx. 10-fold decreases in Pim-1 expression in response to FLT3 inhibition.  Pim-1 protein also decreased rapidly in parallel with decreasing autophosphorylation activity of FLT3.  Enforced expression of either the 44-kDa or 33-kDa Pim-1 isotypes resulted in increased resistance to FLT3 inhibition-mediated cytotoxicity and apoptosis.  In contrast, expression of a dominant-neg. Pim-1 construct accelerated cytotoxicity in response to FLT3 inhibition and inhibited colony growth of FLT3/ITD-transformed BaF3 cells.  These findings demonstrate that constitutively activated FLT3 signaling up-regulates Pim-1 expression in leukemia cells.  This up-regulation contributes to the proliferative and antiapoptotic pathways induced by FLT3 signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqaPXq1gUo1bVg90H21EOLACvtfcHk0lhSWXM7wEVxcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsVGjs7k%253D&md5=003846bdd51d90c5efc2613954b3b185</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1182%2Fblood-2004-05-2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2004-05-2006%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BT.%26aulast%3DBaird%26aufirst%3DK.%26aulast%3DAhn%26aufirst%3DJ.%2BY.%26aulast%3DMeltzer%26aufirst%3DP.%26aulast%3DLilly%26aufirst%3DM.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DPim-1%2520is%2520up-regulated%2520by%2520constitutively%2520activated%2520FLT3%2520and%2520plays%2520a%2520role%2520in%2520FLT3-mediated%2520cell%2520survival%26jtitle%3DBlood%26date%3D2005%26volume%3D105%26issue%3D4%26spage%3D1759%26epage%3D1767%26doi%3D10.1182%2Fblood-2004-05-2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burcu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linn, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, M. R.</span></span> <span> </span><span class="NLM_article-title">Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">e74653</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0074653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1371%2Fjournal.pone.0074653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=24040307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVGiu7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e74653&issue=9&author=K.+Natarajanauthor=Y.+Xieauthor=M.+Burcuauthor=D.+E.+Linnauthor=Y.+Qiuauthor=M.+R.+Baer&title=Pim-1+kinase+phosphorylates+and+stabilizes+130+kDa+FLT3+and+promotes+aberrant+STAT5+signaling+in+acute+myeloid+leukemia+with+FLT3+internal+tandem+duplication&doi=10.1371%2Fjournal.pone.0074653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication</span></div><div class="casAuthors">Natarajan, Karthika; Xie, Yingqiu; Burcu, Mehmet; Linn, Douglas E.; Qiu, Yun; Baer, Maria R.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e74653</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The type III receptor tyrosine kinase fms-like tyrosine kinase 3 (FLT3) is expressed on both normal hematopoietic stem cells and acute myeloid leukemia (AML) cells and regulates their proliferation.  Internal tandem duplication (ITD) mutation of FLT3 is present in a third of AML cases, results in constitutive activation and aberrant signaling of FLT3, and is assocd. with adverse treatment outcomes.  While wild-type (WT) FLT3 is predominantly a 150 kDa complex glycosylated cell surface protein, FLT3-ITD is partially retained in the endoplasmic reticulum as a 130 kDa underglycosylated species assocd. with the chaperones calnexin and heat shock protein (HSP) 90, and mediates aberrant STAT5 signaling, which upregulates the oncogenic serine/threonine kinase Pim-1.  FLT3 contains a Pim-1 substrate consensus serine phosphorylation site, and we hypothesized that it might be a Pim-1 substrate.  Pim-1 was indeed found to directly interact with and serine-phosphorylate FLT3.  Pim-1 inhibition decreased the expression and half-life of 130 kDa FLT3, with partial abrogation by proteasome inhibition, in assocn. with decreased FLT3 binding to calnexin and HSP90, and increased 150 kDa FLT3 expression and half-life, with abrogation by inhibition of glycosylation.  These findings were consistent with Pim-1 stabilizing FLT3-ITD as a 130 kDa species assocd. with calnexin and HSP90 and inhibiting its glycosylation to form the 150 kDa species.  Pim-1 knockdown effects were similar.  Pim-1 inhibition also decreased phosphorylation of FLT3 at tyrosine 591 and of STAT5, and expression of Pim-1 itself, consistent with inhibition of the FLT3-ITD-STAT5 signaling pathway.  Finally, Pim-1 inhibition synergized with FLT3 inhibition in inducing apoptosis of FLT3-ITD cells.  This is, to our knowledge, the first demonstration of a role of Pim-1 in a pos. feedback loop promoting aberrant signaling in malignant cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr42kk5fFOnOrVg90H21EOLACvtfcHk0lhSWXM7wEVxcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVGiu7vI&md5=01126b1c9bb585e6c514e85c0cd7a637</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0074653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0074653%26sid%3Dliteratum%253Aachs%26aulast%3DNatarajan%26aufirst%3DK.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DBurcu%26aufirst%3DM.%26aulast%3DLinn%26aufirst%3DD.%2BE.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DBaer%26aufirst%3DM.%2BR.%26atitle%3DPim-1%2520kinase%2520phosphorylates%2520and%2520stabilizes%2520130%2520kDa%2520FLT3%2520and%2520promotes%2520aberrant%2520STAT5%2520signaling%2520in%2520acute%2520myeloid%2520leukemia%2520with%2520FLT3%2520internal%2520tandem%2520duplication%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26issue%3D9%26spage%3De74653%26doi%3D10.1371%2Fjournal.pone.0074653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kapoor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doshi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapidus, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathias, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trotta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davila, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tron, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrotti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, M. R.</span></span> <span> </span><span class="NLM_article-title">Concurrent inhibition of Pim and FLT3 kinases enhances apoptosis of FLT3-ITD acute myeloid leukemia cells through increased Mcl-1 proteasomal degradation</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">234</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-1629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F1078-0432.CCR-17-1629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=29074603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVWntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=234-247&issue=1&author=S.+Kapoorauthor=K.+Natarajanauthor=P.+R.+Baldwinauthor=K.+A.+Doshiauthor=R.+G.+Lapidusauthor=T.+J.+Mathiasauthor=M.+Scarpaauthor=R.+Trottaauthor=E.+Davilaauthor=M.+Krausauthor=D.+Huszarauthor=A.+E.+Tronauthor=D.+Perrottiauthor=M.+R.+Baer&title=Concurrent+inhibition+of+Pim+and+FLT3+kinases+enhances+apoptosis+of+FLT3-ITD+acute+myeloid+leukemia+cells+through+increased+Mcl-1+proteasomal+degradation&doi=10.1158%2F1078-0432.CCR-17-1629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation</span></div><div class="casAuthors">Kapoor, Shivani; Natarajan, Karthika; Baldwin, Patrick R.; Doshi, Kshama A.; Lapidus, Rena G.; Mathias, Trevor J.; Scarpa, Mario; Trotta, Rossana; Davila, Eduardo; Kraus, Manfred; Huszar, Dennis; Tron, Adriana E.; Perrotti, Danilo; Baer, Maria R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">234-247</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) is present in 30% of acute myeloid leukemia (AML), and these patients have short disease-free survival.  FLT3 inhibitors have limited and transient clin. activity, and concurrent treatment with inhibitors of parallel or downstream signaling may improve responses.  The oncogenic serine/threonine kinase Pim-1 is upregulated downstream of FLT3-ITD and also promotes its signaling in a pos. feedback loop, suggesting benefit of combined Pim and FLT3 inhibition.  Combinations of clin. active Pim and FLT3 inhibitors were studied in vitro and in vivo.  Concurrent treatment with the pan-Pim inhibitor AZD1208 and FLT3 inhibitors at clin. applicable concns. abrogated in vitro growth of FLT3-ITD, but not wild-type FLT3 (FLT3-WT), cell lines.  AZD1208 cotreatment increased FLT3 inhibitor-induced apoptosis of FLT3-ITD, but not FLT3-WT, cells measured by sub-G1 fraction, annexin V labeling, mitochondrial membrane potential, and PARP and caspase-3 cleavage.  Concurrent treatment with AZD1208 and the FLT3 inhibitor quizartinib decreased growth of MV4-11 cells, with FLT3-ITD, in mouse xenografts, and prolonged survival, enhanced apoptosis of FLT3-ITD primary AML blasts, but not FLT3-WT blasts or remission marrow cells, and decreased FLT3-ITD AML blast colony formation.  Mechanistically, AZD1208 and quizartinib cotreatment decreased expression of the antiapoptotic protein Mcl-1.  Decrease in Mcl-1 protein expression was abrogated by treatment with the proteasome inhibitor MG132, and was preceded by downregulation of the Mcl-1 deubiquitinase USP9X, a novel mechanism of Mcl-1 regulation in AML.  The data support clin. testing of Pim and FLT3 inhibitor combination therapy for FLT3-ITD AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqej4YfGVBGLVg90H21EOLACvtfcHk0lhSWXM7wEVxcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVWntg%253D%253D&md5=f20b78a3d8a7a5f14d3256219e4a83eb</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-1629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-1629%26sid%3Dliteratum%253Aachs%26aulast%3DKapoor%26aufirst%3DS.%26aulast%3DNatarajan%26aufirst%3DK.%26aulast%3DBaldwin%26aufirst%3DP.%2BR.%26aulast%3DDoshi%26aufirst%3DK.%2BA.%26aulast%3DLapidus%26aufirst%3DR.%2BG.%26aulast%3DMathias%26aufirst%3DT.%2BJ.%26aulast%3DScarpa%26aufirst%3DM.%26aulast%3DTrotta%26aufirst%3DR.%26aulast%3DDavila%26aufirst%3DE.%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DHuszar%26aufirst%3DD.%26aulast%3DTron%26aufirst%3DA.%2BE.%26aulast%3DPerrotti%26aufirst%3DD.%26aulast%3DBaer%26aufirst%3DM.%2BR.%26atitle%3DConcurrent%2520inhibition%2520of%2520Pim%2520and%2520FLT3%2520kinases%2520enhances%2520apoptosis%2520of%2520FLT3-ITD%2520acute%2520myeloid%2520leukemia%2520cells%2520through%2520increased%2520Mcl-1%2520proteasomal%2520degradation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26issue%3D1%26spage%3D234%26epage%3D247%26doi%3D10.1158%2F1078-0432.CCR-17-1629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parlati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouffet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackinnon, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshaies, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of an inhibitor of the proteasome subunit rpn11</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1343</span>– <span class="NLM_lpage">1361</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01379</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01379" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisVGlsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1343-1361&issue=4&author=C.+Perezauthor=J.+Liauthor=F.+Parlatiauthor=M.+Rouffetauthor=Y.+Maauthor=A.+L.+Mackinnonauthor=T.+F.+Chouauthor=R.+J.+Deshaiesauthor=S.+M.+Cohen&title=Discovery+of+an+inhibitor+of+the+proteasome+subunit+rpn11&doi=10.1021%2Facs.jmedchem.6b01379"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Inhibitor of the Proteasome Subunit Rpn11</span></div><div class="casAuthors">Perez, Christian; Li, Jing; Parlati, Francesco; Rouffet, Matthieu; Ma, Yuyong; Mackinnon, Andrew L.; Chou, Tsui-Fen; Deshaies, Raymond J.; Cohen, Seth M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1343-1361</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The proteasome plays a crucial role in degrdn. of normal proteins that happen to be constitutively or inducibly unstable, and in this capacity it plays a regulatory role.  Addnl., it degrades abnormal/damaged/mutant/misfolded proteins, which serves a quality-control function.  Inhibitors of the proteasome have been validated in the treatment of multiple myeloma, with several FDA-approved therapeutics.  Rpn11 is a Zn2+-dependent metallo-isopeptidase that hydrolyzes ubiquitin from tagged proteins that are trafficked to the proteasome for degrdn.  A fragment-based drug discovery (FBDD) approach was utilized to identify fragments with activity against Rpn11.  Screening of a library of metal-binding pharmacophores (MBPs) revealed that 8-thioquinoline (8TQ, IC50 value ∼2.5 μM) displayed strong inhibition of Rpn11.  Further synthetic elaboration of 8TQ yielded a small mol. compd. I (IC50 value ∼300 nM) that is a potent and selective inhibitor of Rpn11 that blocks proliferation of tumor cells in culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVoqv0GBUXK7Vg90H21EOLACvtfcHk0lib_OsZhtD1vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisVGlsLk%253D&md5=375924a352599bba41888915b77e2159</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01379%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DRouffet%26aufirst%3DM.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DMackinnon%26aufirst%3DA.%2BL.%26aulast%3DChou%26aufirst%3DT.%2BF.%26aulast%3DDeshaies%26aufirst%3DR.%2BJ.%26aulast%3DCohen%26aufirst%3DS.%2BM.%26atitle%3DDiscovery%2520of%2520an%2520inhibitor%2520of%2520the%2520proteasome%2520subunit%2520rpn11%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D4%26spage%3D1343%26epage%3D1361%26doi%3D10.1021%2Facs.jmedchem.6b01379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larrue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saland, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boutzen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joffre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hospital, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamburini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delabesse, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manenti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarry, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recher, C.</span></span> <span> </span><span class="NLM_article-title">Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">882</span>– <span class="NLM_lpage">892</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-05-646497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2015-05-646497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=26286850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1KjtrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=882-892&issue=7&author=C.+Larrueauthor=E.+Salandauthor=H.+Boutzenauthor=F.+Vergezauthor=M.+Davidauthor=C.+Joffreauthor=M.+A.+Hospitalauthor=J.+Tamburiniauthor=E.+Delabesseauthor=S.+Manentiauthor=J.+E.+Sarryauthor=C.+Recher&title=Proteasome+inhibitors+induce+FLT3-ITD+degradation+through+autophagy+in+AML+cells&doi=10.1182%2Fblood-2015-05-646497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells</span></div><div class="casAuthors">Larrue, Clement; Saland, Estelle; Boutzen, Helena; Vergez, Francois; David, Marion; Joffre, Carine; Hospital, Marie-Anne; Tamburini, Jerome; Delabesse, Eric; Manenti, Stephane; Sarry, Jean Emmanuel; Recher, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">882-892</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Internal tandem duplication of the Fms-like tyrosine kinase-3 receptor (FLT3) internal tandem duplication (ITD) is found in 30% of acute myeloid leukemia (AML) and is assocd. with a poor outcome.  In addn. to tyrosine kinase inhibitors, therapeutic strategies that modulate the expression of FLT3-ITD are also promising.  We show that AML samples bearing FLT3-ITD mutations are more sensitive to proteasome inhibitors than wild-type samples and this sensitivity is strongly correlated with a higher FLT3-ITD allelic burden.  Using pharmacol. inhibitors of autophagy, specific downregulation of key autophagy proteins including Vps34, autophagy gene (Atg)5, Atg12, Atg13, biochem., and microscopy studies, we demonstrated that proteasome inhibitors induced cytotoxic autophagy in AML cells.  FLT3-ITD mols. were detectable within autophagosomes after bortezomib treatment indicating that autophagy induction was responsible for the early degrdn. of FLT3-ITD, which preceded the inhibition of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), PI3K/AKT, and STAT5 pathways, and subsequent activation of cell death.  Moreover, proteasome inhibitors overcome resistance to quizartinib induced by mutations in the kinase domain of FLT3, suggesting that these compoundsmay prevent the emergence of mutant clones arising from tyrosine kinase inhibitor treatments.  In xenograft mice models, bortezomib stimulated the conversion of LC3-I to LC3-II, indicating induction of autophagy in vivo, downregulated FLT3-ITD protein expression and improved overall survival.  Therefore, selecting patients according to FLT3-ITD mutations could be anewwayto detect a significant clin. activity of proteasome inhibitors in AML patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotz1aMaqxvG7Vg90H21EOLACvtfcHk0lib_OsZhtD1vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1KjtrzP&md5=0f71d67246259ff440b9da749df29447</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-05-646497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-05-646497%26sid%3Dliteratum%253Aachs%26aulast%3DLarrue%26aufirst%3DC.%26aulast%3DSaland%26aufirst%3DE.%26aulast%3DBoutzen%26aufirst%3DH.%26aulast%3DVergez%26aufirst%3DF.%26aulast%3DDavid%26aufirst%3DM.%26aulast%3DJoffre%26aufirst%3DC.%26aulast%3DHospital%26aufirst%3DM.%2BA.%26aulast%3DTamburini%26aufirst%3DJ.%26aulast%3DDelabesse%26aufirst%3DE.%26aulast%3DManenti%26aufirst%3DS.%26aulast%3DSarry%26aufirst%3DJ.%2BE.%26aulast%3DRecher%26aufirst%3DC.%26atitle%3DProteasome%2520inhibitors%2520induce%2520FLT3-ITD%2520degradation%2520through%2520autophagy%2520in%2520AML%2520cells%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26issue%3D7%26spage%3D882%26epage%3D892%26doi%3D10.1182%2Fblood-2015-05-646497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatnagar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garzon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canning, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devine, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klisovic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcucci, G.</span></span> <span> </span><span class="NLM_article-title">Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia</span>. <i>Leuk. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2100</span>– <span class="NLM_lpage">2108</span>, <span class="refDoi"> DOI: 10.3109/10428194.2015.1135435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.3109%2F10428194.2015.1135435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=26784138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFKhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=2100-2108&issue=9&author=A.+R.+Walkerauthor=H.+Wangauthor=K.+Walshauthor=B.+Bhatnagarauthor=S.+Vasuauthor=R.+Garzonauthor=R.+Canningauthor=S.+Geyerauthor=Y.+Z.+Wuauthor=S.+M.+Devineauthor=R.+Klisovicauthor=W.+Blumauthor=G.+Marcucci&title=Midostaurin%2C+bortezomib+and+MEC+in+relapsed%2Frefractory+acute+myeloid+leukemia&doi=10.3109%2F10428194.2015.1135435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia</span></div><div class="casAuthors">Walker, Alison R.; Wang, Hongyan; Walsh, Katherine; Bhatnagar, Bhavana; Vasu, Sumithira; Garzon, Ramiro; Canning, Renee; Geyer, Susan; Wu, Yue-Zhong; Devine, Steven M.; Klisovic, Rebecca; Blum, William; Marcucci, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2100-2108</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1029-2403</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Targeting aberrant tyrosine kinase activity may impact clin. outcome in acute myeloid leukemia (AML).  We conducted a phase I study of the tyrosine kinase inhibitor midostaurin with bortezomib alone and in combination with chemotherapy in patients with AML.  Patients on dose levels 1 and 2 (DL1 & 2) received midostaurin 50 mg bid and escalating doses of bortezomib (1 to 1.3 mg/m2).  Patients on DL3 or higher received midostaurin and bortezomib following chemotherapy with mitoxantrone, etoposide, cytarabine (MEC).  None of the patients enrolled to DL1 & 2 had dose-limiting toxicities (DLTs) or a clin. response.  Among patients enrolled to DL3 or higher, DLTs were peripheral neuropathy, decrease in ejection fraction and diarrhea.  A 56.5% CR rate and 82.5% overall response rate (CR + CR with incomplete neutrophil or platelet count recovery) were obsd.  The midostaurin/bortezomib/MEC combination is active in refractory/relapsed AML, but is assocd. with expected drug-related toxicities (NCT01174888).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY3jHRB7_JQrVg90H21EOLACvtfcHk0lgn08ypjGmpFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFKhtrY%253D&md5=29a42c74b9da814d367152a0d78ebd90</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.3109%2F10428194.2015.1135435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10428194.2015.1135435%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DA.%2BR.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWalsh%26aufirst%3DK.%26aulast%3DBhatnagar%26aufirst%3DB.%26aulast%3DVasu%26aufirst%3DS.%26aulast%3DGarzon%26aufirst%3DR.%26aulast%3DCanning%26aufirst%3DR.%26aulast%3DGeyer%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DY.%2BZ.%26aulast%3DDevine%26aufirst%3DS.%2BM.%26aulast%3DKlisovic%26aufirst%3DR.%26aulast%3DBlum%26aufirst%3DW.%26aulast%3DMarcucci%26aufirst%3DG.%26atitle%3DMidostaurin%252C%2520bortezomib%2520and%2520MEC%2520in%2520relapsed%252Frefractory%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2016%26volume%3D57%26issue%3D9%26spage%3D2100%26epage%3D2108%26doi%3D10.3109%2F10428194.2015.1135435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, S. M.</span></span> <span> </span><span class="NLM_article-title">Alteration of the MT1 melatonin receptor gene and its expression in primary human breast tumors and breast cancer cell lines</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>118</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1007/s10549-008-0220-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1007%2Fs10549-008-0220-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=18979234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Ons7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2009&pages=293-305&issue=2&author=L.+Laiauthor=L.+Yuanauthor=Q.+Chengauthor=C.+Dongauthor=L.+Maoauthor=S.+M.+Hill&title=Alteration+of+the+MT1+melatonin+receptor+gene+and+its+expression+in+primary+human+breast+tumors+and+breast+cancer+cell+lines&doi=10.1007%2Fs10549-008-0220-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Alteration of the MT1 melatonin receptor gene and its expression in primary human breast tumors and breast cancer cell lines</span></div><div class="casAuthors">Lai, Ling; Yuan, Lin; Cheng, Qi; Dong, Chunmin; Mao, Lulu; Hill, Steven Marc</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">293-305</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The MT1 melatonin receptor is bound and activated by the pineal hormone melatonin.  This G protein-coupled melatonin receptor is expressed in human breast tumor cell lines, and when activated, mediates the growth-suppressive and steroid hormone/nuclear receptor modulatory actions of melatonin on breast tumor cells.  In the current studies, we have examd. the expression of the MT1 receptor in breast cancer cell lines and primary human breast tumors and correlated MT1 receptor expression with the deletion, rearrangement and amplification of the MT1 gene and established markers of breast cancer such as tumor size, stage, estrogen receptor alpha (ERα) and progesterone receptor (PR) expression.  Theses studies suggest amplification of the MT1 gene in some breast tumors and an inverse correlation with ERα, PR and MT1 protein expression.  Furthermore, these approaches employing immunohistochem. and immunofluorescent/confocal microscopic studies demonstrate that the MT1 receptor is localized to the caveoli and that MT1 expression in MCF-7 breast cancer cells can be repressed by estradiol and melatonin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTLKjLnW2DArVg90H21EOLACvtfcHk0lgn08ypjGmpFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Ons7zP&md5=7f60f4169056958cf5131f96fb87b9b1</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1007%2Fs10549-008-0220-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-008-0220-1%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DQ.%26aulast%3DDong%26aufirst%3DC.%26aulast%3DMao%26aufirst%3DL.%26aulast%3DHill%26aufirst%3DS.%2BM.%26atitle%3DAlteration%2520of%2520the%2520MT1%2520melatonin%2520receptor%2520gene%2520and%2520its%2520expression%2520in%2520primary%2520human%2520breast%2520tumors%2520and%2520breast%2520cancer%2520cell%2520lines%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2009%26volume%3D118%26issue%3D2%26spage%3D293%26epage%3D305%26doi%3D10.1007%2Fs10549-008-0220-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plaimee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weerapreeyakul, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barusrux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johns, N. P.</span></span> <span> </span><span class="NLM_article-title">Melatonin potentiates cisplatin-induced apoptosis and cell cycle arrest in human lung adenocarcinoma cells</span>. <i>Cell Proliferation</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1111/cpr.12158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1111%2Fcpr.12158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=25580987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslWgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2015&pages=67-77&issue=1&author=P.+Plaimeeauthor=N.+Weerapreeyakulauthor=S.+Barusruxauthor=N.+P.+Johns&title=Melatonin+potentiates+cisplatin-induced+apoptosis+and+cell+cycle+arrest+in+human+lung+adenocarcinoma+cells&doi=10.1111%2Fcpr.12158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin potentiates cisplatin-induced apoptosis and cell cycle arrest in human lung adenocarcinoma cells</span></div><div class="casAuthors">Plaimee, P.; Weerapreeyakul, N.; Barusrux, S.; Johns, N. P.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Proliferation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-77</span>CODEN:
                <span class="NLM_cas:coden">CPROEM</span>;
        ISSN:<span class="NLM_cas:issn">0960-7722</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Objectives : Melatonin produces anti-cancer effects via several mechanisms, including by induction of apoptosis.  In this way, it has been shown to be of use, in combination with chemotherapeutic drugs, for cancer treatment.  The study described here has evaluated effects of melatonin on cytotoxicity, apoptosis and cell cycle arrest induced with the chemotherapeutic agent cisplatin, in human lung adenocarcinoma cisplatin-sensitive cell line (SK-LU-1), which previously had only limit data.  Materials and methods : Cells of the SK-LU-1 line were treated with melatonin alone at 1-5 mm concn. or cisplatin alone 10-200 μm, for 48 h in culture.  Cytotoxicity was measured by MTT redn. assay.  Apoptosis induction was detected by annexin V/PI staining using flow cytometric anal. and DAPI nuclear staining.  Change in mitochondrial membrane potential (ΔΨm) was quantified using DiOC6(3) reagent and activities of caspases-3/7 were also investigated.  DNA fractions were measured using propidium iodide (PI) staining.  Results : Melatonin or cisplatin alone had 50% (IC50) cytotoxicity at 5 mm or 34 μm concns. resp.  Combination of 1 or 2 mm melatonin and cisplatin significantly augmented cytotoxicity of cisplatin by reducing its IC50 to 11 and 4 μm, resp.  Consistently, combined treatment increased population of apoptotic cells by elevating mitochondrial membrane depolarization, activating caspases-3/7 and inducing cell cycle arrest in the S phase, compared to treatment with cisplatin alone.  Conclusion : These data demonstrate that melatonin enhanced cisplatin-induced cytotoxicity and apoptosis in SK-LU-1 lung cancer cells.  SK-LU-1 cell population growth inhibition was mediated by cell cycle arrest in the S phase.  These findings suggest that melatonin has the potential to be used for NSCLC treatment in combination with a chemotherapeutic agent such as cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOwyaIbAwG6bVg90H21EOLACvtfcHk0lh1xbhNDXUsaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslWgsQ%253D%253D&md5=6533ab83ae36d7d2c61dad01130bdcb2</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1111%2Fcpr.12158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcpr.12158%26sid%3Dliteratum%253Aachs%26aulast%3DPlaimee%26aufirst%3DP.%26aulast%3DWeerapreeyakul%26aufirst%3DN.%26aulast%3DBarusrux%26aufirst%3DS.%26aulast%3DJohns%26aufirst%3DN.%2BP.%26atitle%3DMelatonin%2520potentiates%2520cisplatin-induced%2520apoptosis%2520and%2520cell%2520cycle%2520arrest%2520in%2520human%2520lung%2520adenocarcinoma%2520cells%26jtitle%3DCell%2520Proliferation%26date%3D2015%26volume%3D48%26issue%3D1%26spage%3D67%26epage%3D77%26doi%3D10.1111%2Fcpr.12158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krestinina, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fadeev, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomovsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baburina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobyakova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akatov, V.</span></span> <span> </span><span class="NLM_article-title">Melatonin can strengthen the effect of retinoic acid in HL-60 cells</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2873</span>, <span class="refDoi"> DOI: 10.3390/ijms19102873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.3390%2Fijms19102873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntVKku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=2873&issue=10&author=O.+Krestininaauthor=R.+Fadeevauthor=A.+Lomovskyauthor=Y.+Baburinaauthor=M.+Kobyakovaauthor=V.+Akatov&title=Melatonin+can+strengthen+the+effect+of+retinoic+acid+in+HL-60+cells&doi=10.3390%2Fijms19102873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin can strengthen the effect of retinoic acid in HL-60 cells</span></div><div class="casAuthors">Krestinina, Olga; Fadeev, Roman; Lomovsky, Alexey; Baburina, Yulia; Kobyakova, Margarita; Akatov, Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2873/1-2873/13</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Melatonin is produced by the pineal gland.  It can be regarded as an anticancer agent and used for combined therapy, owing to its oncostatic, antioxidant, and immunoregulatory activities.  Retinoic acid is widely used for the treatment of acute promyelocytic leukemia; however, it has adverse effects on the human organism.  We investigated the effect of melatonin and reduced concns. of retinoic acid on the activation of proliferation in acute promyelocytic leukemiaon a cell model HL-60.  The combined effect of these compds. leads to a redn. in the no. of cells by 70% and the index of mitotic activity by 64%.  Combined treatment with melatonin and retinoic acid decreased the expression of the Bcl-2.  The mitochondrial isoform VDAC1 can be a target in the treatment of different tumors.  The combined effect of and retinoic acid at a low concn. (10 nM) decreased VDAC1 expression.  Melatonin in combination with retinoic acid produced a similar effect on the expression of the translocator protein.  The copptn. of VDAC with 2',3'-cyclonucleotide-3'-phosphodiesterase implies a possible role of its in cancer development.  The combined effect of retinoic acid and melatonin decreased the activity of the electron transport chain complexes.  The changes in the activation of proliferation in HL-60 cells, the mitotic index, and Bcl-2 expression under combined effect of retinoic acid (10 nM) with melatonin (1 mM) are similar to changes that are induced by 1 μM retinoic acid.  Our results suggest that MEL is able to improve the action the other chemotherapeutic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRIZPiXu93trVg90H21EOLACvtfcHk0lh1xbhNDXUsaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntVKku7s%253D&md5=dbf9c36fca75b7651d10a61094de49b7</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.3390%2Fijms19102873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19102873%26sid%3Dliteratum%253Aachs%26aulast%3DKrestinina%26aufirst%3DO.%26aulast%3DFadeev%26aufirst%3DR.%26aulast%3DLomovsky%26aufirst%3DA.%26aulast%3DBaburina%26aufirst%3DY.%26aulast%3DKobyakova%26aufirst%3DM.%26aulast%3DAkatov%26aufirst%3DV.%26atitle%3DMelatonin%2520can%2520strengthen%2520the%2520effect%2520of%2520retinoic%2520acid%2520in%2520HL-60%2520cells%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26issue%3D10%26spage%3D2873%26doi%3D10.3390%2Fijms19102873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosales-Corral, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, D. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acuna-Castroviejo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span> <span> </span><span class="NLM_article-title">Melatonin, a full service anti-cancer agent: inhibition of initiation, progression and metastasis</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">843</span>, <span class="refDoi"> DOI: 10.3390/ijms18040843</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.3390%2Fijms18040843" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFGjs7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=843&issue=4&author=R.+J.+Reiterauthor=S.+A.+Rosales-Corralauthor=D.+X.+Tanauthor=D.+Acuna-Castroviejoauthor=L.+Qinauthor=S.+F.+Yangauthor=K.+Xu&title=Melatonin%2C+a+full+service+anti-cancer+agent%3A+inhibition+of+initiation%2C+progression+and+metastasis&doi=10.3390%2Fijms18040843"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin, a full service anti-cancer agent: inhibition of initiation, progression and metastasis</span></div><div class="casAuthors">Reiter, Russel J.; Rosales-Corral, Sergio A.; Tan, Dun-Xian; Acuna-Castroviejo, Dario; Qin, Lilan; Yang, Shun-Fa; Xu, Kexin</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">843/1-843/47</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">There is highly credible evidence that melatonin mitigates cancer at the initiation, progression and metastasis phases.  In many cases, the mol. mechanisms underpinning these inhibitory actions have been proposed.  What is rather perplexing, however, is the large no. of processes by which melatonin reportedly restrains cancer development and growth.  These diverse actions suggest that what is being obsd. are merely epiphenomena of an underlying more fundamental action of melatonin that remains to be disclosed.  Some of the arresting actions of melatonin on cancer are clearly membrane receptor-mediated while others are membrane receptor-independent and involve direct intracellular actions of this ubiquitously-distributed mol.  While the emphasis of melatonin/cancer research has been on the role of the indoleamine in restraining breast cancer, this is changing quickly with many cancer types having been shown to be susceptible to inhibition by melatonin.  There are several facets of this research which could have immediate applications at the clin. level.  Many studies have shown that melatonin's co-administration improves the sensitivity of cancers to inhibition by conventional drugs.  Even more important are the findings that melatonin renders cancers previously totally resistant to treatment sensitive to these same therapies.  Melatonin also inhibits mol. processes assocd. with metastasis by limiting the entrance of cancer cells into the vascular system and preventing them from establishing secondary growths at distant sites.  This is of particular importance since cancer metastasis often significantly contributes to death of the patient.  Another area that deserves addnl. consideration is related to the capacity of melatonin in reducing the toxic consequences of anti-cancer drugs while increasing their efficacy.  Although this information has been available for more than a decade, it has not been adequately exploited at the clin. level.  Even if the only beneficial actions of melatonin in cancer patients are its ability to attenuate acute and long-term drug toxicity, melatonin should be used to improve the phys. wellbeing of the patients.  The exptl. findings, however, suggest that the advantages of using melatonin as a co-treatment with conventional cancer therapies would far exceed improvements in the wellbeing of the patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozdzwNs8nI5bVg90H21EOLACvtfcHk0lh1xbhNDXUsaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFGjs7bP&md5=1bb28bdff4aa4e971c76c069cc72f341</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.3390%2Fijms18040843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18040843%26sid%3Dliteratum%253Aachs%26aulast%3DReiter%26aufirst%3DR.%2BJ.%26aulast%3DRosales-Corral%26aufirst%3DS.%2BA.%26aulast%3DTan%26aufirst%3DD.%2BX.%26aulast%3DAcuna-Castroviejo%26aufirst%3DD.%26aulast%3DQin%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DS.%2BF.%26aulast%3DXu%26aufirst%3DK.%26atitle%3DMelatonin%252C%2520a%2520full%2520service%2520anti-cancer%2520agent%253A%2520inhibition%2520of%2520initiation%252C%2520progression%2520and%2520metastasis%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26issue%3D4%26spage%3D843%26doi%3D10.3390%2Fijms18040843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tian, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Manero, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span> <span> </span><span class="NLM_article-title">Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3768</span>– <span class="NLM_lpage">3779</span>, <span class="refDoi"> DOI: 10.7150/thno.34327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.7150%2Fthno.34327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=31281512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1ertLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=3768-3779&issue=13&author=T.+Tianauthor=J.+Liauthor=Y.+Liauthor=Y.+X.+Luauthor=Y.+L.+Tangauthor=H.+Wangauthor=F.+Zhengauthor=D.+Shiauthor=Q.+Longauthor=M.+Chenauthor=G.+Garcia-Maneroauthor=Y.+Huauthor=L.+Qinauthor=W.+Deng&title=Melatonin+enhances+sorafenib-induced+cytotoxicity+in+FLT3-ITD+acute+myeloid+leukemia+cells+by+redox+modification&doi=10.7150%2Fthno.34327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification</span></div><div class="casAuthors">Tian, Tian; Li, Jiajun; Li, Yizhuo; Lu, Yun-Xin; Tang, Yan-Lai; Wang, Hua; Zheng, Fufu; Shi, Dingbo; Long, Qian; Chen, Miao; Garcia-Manero, Guillermo; Hu, Yumin; Qin, Lijun; Deng, Wuguo</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3768-3779</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) with an internal tandem duplication in Fms-related tyrosine kinase 3 (FLT3-ITD) is identified as a subgroup with poor outcome and intrinsic resistance to chemotherapy and therefore urgent need for development of novel therapeutic strategies.  The antitumor effects of melatonin alone or combined with sorafenib were evaluated via flow cytometry and immunoblotting assays in FLT-ITD AML cells.  Also, the ex vivo and in vivo models were used to test the synergistic effects of melatonin and sorafenib against leukemia with FLT3/ITD mutation.  Our study shows for the first time that melatonin inhibits proliferation and induces apoptosis in FLT3/ITD-pos. leukemia cells.  Mechanistically, melatonin preferentially causes overprodn. of reactive oxygen species (ROS) and ultimately massive cell death in FLT3-ITD AML cells.  Moreover, melatonin significantly enhances the cytotoxicity induced by the FLT3 tyrosine kinase inhibitor sorafenib in AML cells with FLT3/ITD through redox modification.  Importantly, combination of melatonin and sorafenib exhibited highly synergistic therapeutic activity in MV4-11 xenografts and a murine model bearing FLT3/ITD leukemia.  This study indicates that melatonin, alone or in combination with sorafenib, has potential to improve the therapeutic outcome of AML patients with FLT3-ITD mutation that merits further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSlsD6-46i5rVg90H21EOLACvtfcHk0lhcSOT2yWoq9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1ertLjE&md5=ad88dd7b7f757bc568e06142486c39e7</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.7150%2Fthno.34327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.34327%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DY.%2BX.%26aulast%3DTang%26aufirst%3DY.%2BL.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DF.%26aulast%3DShi%26aufirst%3DD.%26aulast%3DLong%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DQin%26aufirst%3DL.%26aulast%3DDeng%26aufirst%3DW.%26atitle%3DMelatonin%2520enhances%2520sorafenib-induced%2520cytotoxicity%2520in%2520FLT3-ITD%2520acute%2520myeloid%2520leukemia%2520cells%2520by%2520redox%2520modification%26jtitle%3DTheranostics%26date%3D2019%26volume%3D9%26issue%3D13%26spage%3D3768%26epage%3D3779%26doi%3D10.7150%2Fthno.34327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dun, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panicker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mashkani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Don, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toop, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lock, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guthridge, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashman, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skelding, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enjeti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verrills, N. M.</span></span> <span> </span><span class="NLM_article-title">Activation of protein phosphatase 2A in FLT3<sup>+</sup> acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">30</span>),  <span class="NLM_fpage">47465</span>– <span class="NLM_lpage">47478</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.10167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.18632%2Foncotarget.10167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=27329844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BC2s7isFeguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=47465-47478&issue=30&author=A.+M.+Smithauthor=M.+D.+Dunauthor=E.+M.+Leeauthor=C.+Harrisonauthor=R.+Kahlauthor=H.+Flanaganauthor=N.+Panickerauthor=B.+Mashkaniauthor=A.+S.+Donauthor=J.+Morrisauthor=H.+Toopauthor=R.+B.+Lockauthor=J.+A.+Powellauthor=D.+Thomasauthor=M.+A.+Guthridgeauthor=A.+Mooreauthor=L.+K.+Ashmanauthor=K.+A.+Skeldingauthor=A.+Enjetiauthor=N.+M.+Verrills&title=Activation+of+protein+phosphatase+2A+in+FLT3%2B+acute+myeloid+leukemia+cells+enhances+the+cytotoxicity+of+FLT3+tyrosine+kinase+inhibitors&doi=10.18632%2Foncotarget.10167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors</span></div><div class="casAuthors">Smith Amanda M; Dun Matthew D; Harrison Celeste; Kahl Richard; Flanagan Hayley; Panicker Nikita; Mashkani Baratali; Ashman Leonie K; Skelding Kathryn A; Enjeti Anoop; Verrills Nicole M; Smith Amanda M; Dun Matthew D; Harrison Celeste; Kahl Richard; Flanagan Hayley; Panicker Nikita; Mashkani Baratali; Ashman Leonie K; Skelding Kathryn A; Enjeti Anoop; Verrills Nicole M; Smith Amanda M; Lee Erwin M; Lock Richard B; Mashkani Baratali; Don Anthony S; Morris Jonathan; Toop Hamish; Powell Jason A; Thomas Daniel; Thomas Daniel; Guthridge Mark A; Moore Andrew; Enjeti Anoop</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">47465-47478</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Constitutive activation of the receptor tyrosine kinase Fms-like tyrosine kinase 3 (FLT3), via co-expression of its ligand or by genetic mutation, is common in acute myeloid leukemia (AML).  In this study we show that FLT3 activation inhibits the activity of the tumor suppressor, protein phosphatase 2A (PP2A).  Using BaF3 cells transduced with wildtype or mutant FLT3, we show that FLT3-induced PP2A inhibition sensitizes cells to the pharmacological PP2A activators, FTY720 and AAL(S).  FTY720 and AAL(S) induced cell death and inhibited colony formation of FLT3 activated cells.  Furthermore, PP2A activators reduced the phosphorylation of ERK and AKT, downstream targets shared by both FLT3 and PP2A, in FLT3/ITD+ BaF3 and MV4-11 cell lines.  PP2A activity was lower in primary human bone marrow derived AML blasts compared to normal bone marrow, with blasts from FLT3-ITD patients displaying lower PP2A activity than WT-FLT3 blasts.  Reduced PP2A activity was associated with hyperphosphorylation of the PP2A catalytic subunit, and reduced expression of PP2A structural and regulatory subunits.  AML patient blasts were also sensitive to cell death induced by FTY720 and AAL(S), but these compounds had minimal effect on normal CD34+ bone marrow derived monocytes.  Finally, PP2A activating compounds displayed synergistic effects when used in combination with tyrosine kinase inhibitors in FLT3-ITD+ cells.  A combination of Sorafenib and FTY720 was also synergistic in the presence of a protective stromal microenvironment.  Thus combining a PP2A activating compound and a FLT3 inhibitor may be a novel therapeutic approach for treating AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTxTjCLYqx9S2xpATR2EQURfW6udTcc2eZ9F-gF1uLBzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7isFeguw%253D%253D&md5=691727b8e4d3b270933bdda014f6a7f7</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.10167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.10167%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DDun%26aufirst%3DM.%2BD.%26aulast%3DLee%26aufirst%3DE.%2BM.%26aulast%3DHarrison%26aufirst%3DC.%26aulast%3DKahl%26aufirst%3DR.%26aulast%3DFlanagan%26aufirst%3DH.%26aulast%3DPanicker%26aufirst%3DN.%26aulast%3DMashkani%26aufirst%3DB.%26aulast%3DDon%26aufirst%3DA.%2BS.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DToop%26aufirst%3DH.%26aulast%3DLock%26aufirst%3DR.%2BB.%26aulast%3DPowell%26aufirst%3DJ.%2BA.%26aulast%3DThomas%26aufirst%3DD.%26aulast%3DGuthridge%26aufirst%3DM.%2BA.%26aulast%3DMoore%26aufirst%3DA.%26aulast%3DAshman%26aufirst%3DL.%2BK.%26aulast%3DSkelding%26aufirst%3DK.%2BA.%26aulast%3DEnjeti%26aufirst%3DA.%26aulast%3DVerrills%26aufirst%3DN.%2BM.%26atitle%3DActivation%2520of%2520protein%2520phosphatase%25202A%2520in%2520FLT3%252B%2520acute%2520myeloid%2520leukemia%2520cells%2520enhances%2520the%2520cytotoxicity%2520of%2520FLT3%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26issue%3D30%26spage%3D47465%26epage%3D47478%26doi%3D10.18632%2Foncotarget.10167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKenzie, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pippa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eide, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oddo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sears, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitek, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odero, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span> <span> </span><span class="NLM_article-title">Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2092</span>– <span class="NLM_lpage">2103</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-2575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F1078-0432.CCR-13-2575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=24436473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtl2msLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2092-2103&issue=8&author=A.+Agarwalauthor=R.+J.+MacKenzieauthor=R.+Pippaauthor=C.+A.+Eideauthor=J.+Oddoauthor=J.+W.+Tynerauthor=R.+Searsauthor=M.+P.+Vitekauthor=M.+D.+Oderoauthor=D.+J.+Christensenauthor=B.+J.+Druker&title=Antagonism+of+SET+using+OP449+enhances+the+efficacy+of+tyrosine+kinase+inhibitors+and+overcomes+drug+resistance+in+myeloid+leukemia&doi=10.1158%2F1078-0432.CCR-13-2575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia</span></div><div class="casAuthors">Agarwal, Anupriya; MacKenzie, Ryan J.; Pippa, Raffaella; Eide, Christopher A.; Oddo, Jessica; Tyner, Jeffrey W.; Sears, Rosalie; Vitek, Michael P.; Odero, Maria D.; Christensen, Dale J.; Druker, Brian J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2092-2103</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The SET oncoprotein, a potent inhibitor of the protein phosphatase 2A (PP2A), is overexpressed in leukemia.  We evaluated the efficacy of SET antagonism in chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) cell lines, a murine leukemia model, and primary patient samples using OP449, a specific, cell-penetrating peptide that antagonizes SET's inhibition of PP2A.  Exptl. Design: In vitro cytotoxicity and specificity of OP449 in CML and AML cell lines and primary samples were measured using proliferation, apoptosis, and clonogenic assays.  Efficacy of target inhibition by OP449 was evaluated by immunoblotting and PP2A assay.  In vivo antitumor efficacy of OP449 was measured in human HL-60 xenografted murine model.  Results: We obsd. that OP449 inhibited growth of CML cells including those from patients with blastic phase disease and patients harboring highly drug-resistant BCR-ABL1 mutations.  Combined treatment with OP449 and ABL1 tyrosine kinase inhibitors was significantly more cytotoxic to K562 cells and primary CD34+ CML cells.  SET protein levels remained unchanged with OP449 treatment, but BCR-ABL1-mediated downstream signaling was significantly inhibited with the degrdn. of key signaling mols. such as BCR-ABL1, STAT5, and AKT.  Similarly, AML cell lines and primary patient samples with various genetic lesions showed inhibition of cell growth after treatment with OP449 alone or in combination with resp. kinase inhibitors.  Finally, OP449 reduced the tumor burden of mice xenografted with human leukemia cells.  Conclusions: We demonstrate a novel therapeutic paradigm of SET antagonism using OP449 in combination with tyrosine kinase inhibitors for the treatment of CML and AML.  Clin Cancer Res; 20(8); 2092-103. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPqhh_v9-eq7Vg90H21EOLACvtfcHk0lhcSOT2yWoq9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtl2msLY%253D&md5=22aab4e8cb861c5be37a596dbf6ce8e7</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-2575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-2575%26sid%3Dliteratum%253Aachs%26aulast%3DAgarwal%26aufirst%3DA.%26aulast%3DMacKenzie%26aufirst%3DR.%2BJ.%26aulast%3DPippa%26aufirst%3DR.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DOddo%26aufirst%3DJ.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DSears%26aufirst%3DR.%26aulast%3DVitek%26aufirst%3DM.%2BP.%26aulast%3DOdero%26aufirst%3DM.%2BD.%26aulast%3DChristensen%26aufirst%3DD.%2BJ.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DAntagonism%2520of%2520SET%2520using%2520OP449%2520enhances%2520the%2520efficacy%2520of%2520tyrosine%2520kinase%2520inhibitors%2520and%2520overcomes%2520drug%2520resistance%2520in%2520myeloid%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26issue%3D8%26spage%3D2092%26epage%3D2103%26doi%3D10.1158%2F1078-0432.CCR-13-2575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gondek, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huso, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foerster, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchionni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGovern, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peacock, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merchant, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsui, W.</span></span> <span> </span><span class="NLM_article-title">Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">291</span>),  <span class="NLM_fpage">291ra96</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aaa5731</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1126%2Fscitranslmed.aaa5731" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=26062848" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=291ra96&issue=291&author=Y.+Limauthor=L.+Gondekauthor=L.+Liauthor=Q.+Wangauthor=H.+Maauthor=E.+Changauthor=D.+L.+Husoauthor=S.+Foersterauthor=L.+Marchionniauthor=K.+McGovernauthor=D.+N.+Watkinsauthor=C.+D.+Peacockauthor=M.+Levisauthor=B.+D.+Smithauthor=A.+A.+Merchantauthor=D.+Smallauthor=W.+Matsui&title=Integration+of+Hedgehog+and+mutant+FLT3+signaling+in+myeloid+leukemia&doi=10.1126%2Fscitranslmed.aaa5731"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaa5731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaa5731%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DY.%26aulast%3DGondek%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DChang%26aufirst%3DE.%26aulast%3DHuso%26aufirst%3DD.%2BL.%26aulast%3DFoerster%26aufirst%3DS.%26aulast%3DMarchionni%26aufirst%3DL.%26aulast%3DMcGovern%26aufirst%3DK.%26aulast%3DWatkins%26aufirst%3DD.%2BN.%26aulast%3DPeacock%26aufirst%3DC.%2BD.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DMerchant%26aufirst%3DA.%2BA.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DMatsui%26aufirst%3DW.%26atitle%3DIntegration%2520of%2520Hedgehog%2520and%2520mutant%2520FLT3%2520signaling%2520in%2520myeloid%2520leukemia%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2015%26volume%3D7%26issue%3D291%26spage%3D291ra96%26doi%3D10.1126%2Fscitranslmed.aaa5731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohl, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullinger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rucker, F. G.</span></span> <span> </span><span class="NLM_article-title">New targeted agents in acute myeloid leukemia: new hope on the rise</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1983</span>, <span class="refDoi"> DOI: 10.3390/ijms20081983</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.3390%2Fijms20081983" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFKjt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1983&issue=8&author=S.+R.+Bohlauthor=L.+Bullingerauthor=F.+G.+Rucker&title=New+targeted+agents+in+acute+myeloid+leukemia%3A+new+hope+on+the+rise&doi=10.3390%2Fijms20081983"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">New targeted agents in acute myeloid leukemia: new hope on the rise</span></div><div class="casAuthors">Bohl, Stephan R.; Bullinger, Lars; Ruecker, Frank G.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1983</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The therapeutic approach for acute myeloid leukemia (AML) remains challenging, since over the last four decades a stagnation in std. cytotoxic treatment has been obsd.  But within recent years, remarkable advances in the understanding of the mol. heterogeneity and complexity of this disease have led to the identification of novel therapeutic targets.  In the last two years, seven new targeted agents (midostaurin, gilteritinib, enasidenib, ivosidenib, glasdegib, venetoclax and gemtuzumab ozogamicin) have received US Food and Drug Administration (FDA) approval for the treatment of AML.  These drugs did not just prove to have a clin. benefit as single agents but have esp. improved AML patient outcomes if they are combined with conventional therapy.  In this review, we will focus on currently approved and promising upcoming agents and we will discuss controversial aspects and limitations of targeted treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQK8hg1LfxhbVg90H21EOLACvtfcHk0lgXelfi7J0LnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFKjt7o%253D&md5=f698f250c6c5edcfd8b871016ebbe75e</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.3390%2Fijms20081983&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20081983%26sid%3Dliteratum%253Aachs%26aulast%3DBohl%26aufirst%3DS.%2BR.%26aulast%3DBullinger%26aufirst%3DL.%26aulast%3DRucker%26aufirst%3DF.%2BG.%26atitle%3DNew%2520targeted%2520agents%2520in%2520acute%2520myeloid%2520leukemia%253A%2520new%2520hope%2520on%2520the%2520rise%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26issue%3D8%26spage%3D1983%26doi%3D10.3390%2Fijms20081983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, S.</span></span> <span> </span><span class="NLM_article-title">Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">13</span>, <span class="refDoi"> DOI: 10.1186/1756-8722-4-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1186%2F1756-8722-4-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=21453545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltV2htLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=13&author=S.+Takahashi&title=Downstream+molecular+pathways+of+FLT3+in+the+pathogenesis+of+acute+myeloid+leukemia%3A+biology+and+therapeutic+implications&doi=10.1186%2F1756-8722-4-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications</span></div><div class="casAuthors">Takahashi, Shinichiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  FLT3 is a type III receptor tyrosine kinase.  Mutations of FLT3 comprise one of the most frequently identified types of genetic alterations in acute myeloid leukemia.  One-third of acute myeloid leukemia patients have mutations of this gene, and the majority of these mutations involve an internal tandem duplication in the juxtamembrane region of FLT3, leading to constitutive activation of downstream signaling pathways and aberrant cell growth.  This review summarizes the current understanding of the effects of the downstream mol. signaling pathways after FLT3 activation, with a particular focus on the effects on transcription factors.  Moreover, this review describes novel FLT3-targeted therapies, as well as efficient combination therapies for FLT3-mutated leukemia cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSWuiPhmUfabVg90H21EOLACvtfcHk0lgXelfi7J0LnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltV2htLk%253D&md5=c9fc883616d38b64a3ce16dc1c9f28cb</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-4-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-4-13%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DS.%26atitle%3DDownstream%2520molecular%2520pathways%2520of%2520FLT3%2520in%2520the%2520pathogenesis%2520of%2520acute%2520myeloid%2520leukemia%253A%2520biology%2520and%2520therapeutic%2520implications%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2011%26volume%3D4%26spage%3D13%26doi%3D10.1186%2F1756-8722-4-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohi, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sternberg, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neel, B. G.</span></span> <span> </span><span class="NLM_article-title">Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3130</span>– <span class="NLM_lpage">3135</span>, <span class="refDoi"> DOI: 10.1073/pnas.0400063101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1073%2Fpnas.0400063101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=14976243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitlWhtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=3130-3135&issue=9&author=M.+G.+Mohiauthor=C.+Boultonauthor=T.+L.+Guauthor=D.+W.+Sternbergauthor=D.+Neubergauthor=J.+D.+Griffinauthor=D.+G.+Gillilandauthor=B.+G.+Neel&title=Combination+of+rapamycin+and+protein+tyrosine+kinase+%28PTK%29+inhibitors+for+the+treatment+of+leukemias+caused+by+oncogenic+PTKs&doi=10.1073%2Fpnas.0400063101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs</span></div><div class="casAuthors">Mohi, M. Golam; Boulton, Christina; Gu, Ting-Lei; Sternberg, David W.; Neuberg, Donna; Griffin, James D.; Gilliland, D. Gary; Neel, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3130-3135</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Abnormal protein tyrosine kinases (PTKs) cause many human leukemias.  For example, BCR/ABL causes chronic myelogenous leukemia (CML), whereas FLT3 mutations contribute to the pathogenesis of acute myelogenous leukemia.  The ABL inhibitor Imatinib (Gleevec, STI571) has remarkable efficacy for treating chronic phase CML, and FLT3 inhibitors (e.g., PKC412) show similar promise in preclin. studies.  However, resistance to PTK inhibitors is a major emerging problem that may limit long-term therapeutic efficacy.  Development of rational combination therapies will probably be required to effect cures of these and other neoplastic disorders.  Here, we report that the mTOR inhibitor rapamycin synergizes with Imatinib against BCR/ABL-transformed myeloid and lymphoid cells and increases survival in a murine CML model.  Rapamycin/Imatinib combinations also inhibit Imatinib-resistant mutants of BCR/ABL, and rapamycin plus PKC412 synergistically inhibits cells expressing PKC412-sensitive or -resistant leukemogenic FLT3 mutants.  Biochem. analyses raise the possibility that inhibition of 4E-BP1 phosphorylation may be particularly important for the synergistic effects of PTK inhibitor/rapamycin combinations.  Addn. of a mitogen-activated protein kinase kinase inhibitor to rapamycin or rapamycin plus PTK inhibitor further increases efficacy.  Our results suggest that simultaneous targeting of more than one signaling pathway required by leukemogenic PTKs may improve the treatment of primary and relapsed CML and/or acute myelogenous leukemia caused by FLT3 mutations.  Similar strategies may be useful for treating solid tumors assocd. with mutant and/or overexpressed PTKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFh_qyVxb2rrVg90H21EOLACvtfcHk0lh7J2JWhWsfQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitlWhtL0%253D&md5=fdf6c963832e6a9eab8bbb964d9db5a4</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0400063101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0400063101%26sid%3Dliteratum%253Aachs%26aulast%3DMohi%26aufirst%3DM.%2BG.%26aulast%3DBoulton%26aufirst%3DC.%26aulast%3DGu%26aufirst%3DT.%2BL.%26aulast%3DSternberg%26aufirst%3DD.%2BW.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26atitle%3DCombination%2520of%2520rapamycin%2520and%2520protein%2520tyrosine%2520kinase%2520%2528PTK%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520leukemias%2520caused%2520by%2520oncogenic%2520PTKs%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26issue%3D9%26spage%3D3130%26epage%3D3135%26doi%3D10.1073%2Fpnas.0400063101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolais, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galinsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N.</span></span> <span> </span><span class="NLM_article-title">Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">e56473</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0056473</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1371%2Fjournal.pone.0056473" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=23437141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjs12ns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e56473&issue=2&author=E.+Weisbergauthor=Q.+Liuauthor=X.+Zhangauthor=E.+Nelsonauthor=M.+Sattlerauthor=F.+Liuauthor=M.+Nicolaisauthor=J.+Zhangauthor=C.+Mitsiadesauthor=R.+W.+Smithauthor=R.+Stoneauthor=I.+Galinskyauthor=A.+Nonamiauthor=J.+D.+Griffinauthor=N.+Gray&title=Selective+Akt+inhibitors+synergize+with+tyrosine+kinase+inhibitors+and+effectively+override+stroma-associated+cytoprotection+of+mutant+FLT3-positive+AML+cells&doi=10.1371%2Fjournal.pone.0056473"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells</span></div><div class="casAuthors">Weisberg, Ellen; Liu, Qingsong; Zhang, Xin; Nelson, Erik; Sattler, Martin; Liu, Feiyang; Nicolais, Maria; Zhang, Jianming; Mitsiades, Constantine; Smith, Robert W.; Stone, Richard; Galinsky, Ilene; Nonami, Atsushi; Griffin, James D.; Gray, Nathanael</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e56473</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Objectives: Tyrosine kinase inhibitor (TKI)-treated acute myeloid leukemia (AML) patients commonly show rapid and significant peripheral blood blast cell redn., however a marginal decrease in bone marrow blasts.  This suggests a protective environment and highlights the demand for a better understanding of stromal:leukemia cell communication.  As a strategy to improve clin. efficacy, we searched for novel agents capable of potentiating the stroma-diminished effects of TKI treatment of mutant FLT3-expressing cells.  Methods: We designed a combinatorial high throughput drug screen using well-characterized kinase inhibitor-focused libraries to identify novel kinase inhibitors capable of overriding stromal-mediated resistance to TKIs, such as PKC412 and AC220.  Std. liq. culture proliferation assays, cell cycle and apoptosis anal., and immunoblotting were carried out with cell lines or primary AML to validate putative candidates from the screen and characterize the mechanism(s) underlying obsd. synergy.  Results and Conclusions: Our study led to the observation of synergy between selective Akt inhibitors and FLT3 inhibitors against mutant FLT3-pos. AML in either the absence or presence of stroma.  Our findings are consistent with evidence that Akt activation is characteristic of mutant FLT3-transformed cells, as well as obsd. residual Akt activity following FLT3 inhibitor treatment.  In conclusion, our study highlights the potential importance of Akt as a signaling factor in leukemia survival, and supports the use of the co-culture chem. screen to identify agents able to potentiate TKI anti-leukemia activity in a cytoprotective microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoghH_zJn-FM7Vg90H21EOLACvtfcHk0lh7J2JWhWsfQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjs12ns7k%253D&md5=195d2a5870780230bdfdad9da26cd501</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0056473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0056473%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DNelson%26aufirst%3DE.%26aulast%3DSattler%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DNicolais%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DMitsiades%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DR.%2BW.%26aulast%3DStone%26aufirst%3DR.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DNonami%26aufirst%3DA.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DGray%26aufirst%3DN.%26atitle%3DSelective%2520Akt%2520inhibitors%2520synergize%2520with%2520tyrosine%2520kinase%2520inhibitors%2520and%2520effectively%2520override%2520stroma-associated%2520cytoprotection%2520of%2520mutant%2520FLT3-positive%2520AML%2520cells%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26issue%3D2%26spage%3De56473%26doi%3D10.1371%2Fjournal.pone.0056473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamorska-Dyga, A.</span></span> <span> </span><span class="NLM_article-title">Syk inhibitors in clinical development for hematological malignancies</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">145</span>, <span class="refDoi"> DOI: 10.1186/s13045-017-0512-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1186%2Fs13045-017-0512-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=28754125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2gsrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=145&issue=1&author=D.+Liuauthor=A.+Mamorska-Dyga&title=Syk+inhibitors+in+clinical+development+for+hematological+malignancies&doi=10.1186%2Fs13045-017-0512-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Syk inhibitors in clinical development for hematological malignancies</span></div><div class="casAuthors">Liu, Delong; Mamorska-Dyga, Aleksandra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">145/1-145/7</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Spleen tyrosine kinase (Syk) is a cytosolic non-receptor protein tyrosine kinase (PTK) and is mainly expressed in hematopoietic cells.  Syk was recognized as a crit. element in the B-cell receptor signaling pathway.  Syk is also a key component in signal transduction from other immune receptors like Fc receptors and adhesion receptors.  Several oral Syk inhibitors including fostamatinib (R788), entospletinib (GS-9973), cerdulatinib (PRT062070), and TAK-659 are being assessed in clin. trials.  The second generation compd., entospletinib, showed promising results in clin. trials against B-cell malignancies, mainly chronic lymphoid leukemia.  Syk inhibitors are being evaluated in combination regimens in multiple malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI4gAk4MLv-7Vg90H21EOLACvtfcHk0ljC41oqxFdEtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2gsrbJ&md5=ed423c793913414c2966af15bd4457c4</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1186%2Fs13045-017-0512-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-017-0512-1%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DMamorska-Dyga%26aufirst%3DA.%26atitle%3DSyk%2520inhibitors%2520in%2520clinical%2520development%2520for%2520hematological%2520malignancies%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2017%26volume%3D10%26issue%3D1%26spage%3D145%26doi%3D10.1186%2Fs13045-017-0512-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Megias-Vericat, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballesta-Lopez, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barragan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Cuadron, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montesinos, P.</span></span> <span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors for acute myeloid leukemia: a step toward disease control?</span>. <i>Blood Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">100675</span>, <span class="refDoi"> DOI: 10.1016/j.blre.2020.100675</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.blre.2020.100675" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=32147087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkslClur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2020&pages=100675&author=J.+E.+Megias-Vericatauthor=O.+Ballesta-Lopezauthor=E.+Barraganauthor=D.+Martinez-Cuadronauthor=P.+Montesinos&title=Tyrosine+kinase+inhibitors+for+acute+myeloid+leukemia%3A+a+step+toward+disease+control%3F&doi=10.1016%2Fj.blre.2020.100675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control</span></div><div class="casAuthors">Megias-Vericat, Juan Eduardo; Ballesta-Lopez, Octavio; Barragan, Eva; Martinez-Cuadron, David; Montesinos, Pau</div><div class="citationInfo"><span class="NLM_cas:title">Blood Reviews</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">100675</span>CODEN:
                <span class="NLM_cas:coden">BLOREB</span>;
        ISSN:<span class="NLM_cas:issn">0268-960X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Dysregulation of tyrosine kinases (TKs) may play a role in leukemogenesis by promoting survival and proliferation of acute myeloid leukemia (AML) cells.  In AML, the main TKs mutations are produced in Fms-like tyrosine kinase 3 (FLT3), KIT and Janus kinase (JAK) genes, and with less frequency in BCR-ABL.  The striking results with TK Inhibitors (TKIs) therapy in BCR-ABL1 chronic myeloid leukemias has paved the way for its clin. development in AML.  However, the AML biol. complexity seems to prevent TKI therapy from being proposed as a strong shift in the treatment paradigm and prognosis.  While some FLT3 inhibitors have shown efficacy in well-designed studies, an increasing no. of AML patients are being treated with TKIs as a new std. of care, compassionate use, or in clin. trials.  We will review the current clin. evidence concerning the use of TKIs in different subsets of AML (BCR-ABL1, Core Binding Factor, FLT3 mutated, and FLT3 wild-type) to address the main topics concerning these targeted therapies for AML: 1) optimal place (upfront, relapsed/refractory or maintenance); 2) monotherapy or combination; 3) efficacy in TK mutated vs. wild-type patients; 4) differences between selective and multi-targeted TKIs.  In the next years, clin. trials and real-world data will help answer these questions and establish the impact of TKIs on outcomes of AML patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_GLCI_CMJlLVg90H21EOLACvtfcHk0ljC41oqxFdEtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkslClur0%253D&md5=42fffc2fef25f79d95324b1944fc4718</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.blre.2020.100675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.blre.2020.100675%26sid%3Dliteratum%253Aachs%26aulast%3DMegias-Vericat%26aufirst%3DJ.%2BE.%26aulast%3DBallesta-Lopez%26aufirst%3DO.%26aulast%3DBarragan%26aufirst%3DE.%26aulast%3DMartinez-Cuadron%26aufirst%3DD.%26aulast%3DMontesinos%26aufirst%3DP.%26atitle%3DTyrosine%2520kinase%2520inhibitors%2520for%2520acute%2520myeloid%2520leukemia%253A%2520a%2520step%2520toward%2520disease%2520control%253F%26jtitle%3DBlood%2520Rev.%26date%3D2020%26volume%3D44%26spage%3D100675%26doi%3D10.1016%2Fj.blre.2020.100675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuromitsu, S.</span></span> <span> </span><span class="NLM_article-title">Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">556</span>– <span class="NLM_lpage">565</span>, <span class="refDoi"> DOI: 10.1007/s10637-017-0470-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1007%2Fs10637-017-0470-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=28516360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvV2isrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=556-565&issue=5&author=M.+Moriauthor=N.+Kanekoauthor=Y.+Uenoauthor=M.+Yamadaauthor=R.+Tanakaauthor=R.+Saitoauthor=I.+Shimadaauthor=K.+Moriauthor=S.+Kuromitsu&title=Gilteritinib%2C+a+FLT3%2FAXL+inhibitor%2C+shows+antileukemic+activity+in+mouse+models+of+FLT3+mutated+acute+myeloid+leukemia&doi=10.1007%2Fs10637-017-0470-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia</span></div><div class="casAuthors">Mori, Masamichi; Kaneko, Naoki; Ueno, Yoko; Yamada, Masaki; Tanaka, Ruriko; Saito, Rika; Shimada, Itsuro; Mori, Kenichi; Kuromitsu, Sadao</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">556-565</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Advances in the understanding of the mol. basis for acute myeloid leukemia (AML) have generated new potential targets for treatment.  Fms-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in AML and mutations in this gene are assocd. with poor overall survival.  AXL plays a role in the activation of FLT3 and has been implicated in the pathogenesis of AML.  The studies reported here evaluated the ability of a novel FLT3/AXL inhibitor, gilteritinib, to block mutated FLT3 in cellular and animal models of AML.  Initial kinase studies showed that gilteritinib, a type I tyrosine kinase inhibitor, was highly selective for both FLT3 and AXL while having weak activity against c-KIT.  Gilteritinib demonstrated potent inhibitory activity against the internal tandem duplication (FLT3-ITD) and FLT3-D835Y point mutations in cellular assays using MV4-11 and MOLM-13 cells as well as Ba/F3 cells expressing mutated FLT3.  Gilteritinib also inhibited FLT3-F691 mutations, although to a lesser degree, in these assays.  Furthermore, gilteritinib decreased the phosphorylation levels of FLT3 and its downstream targets in both cellular and animal models.  In vivo, gilteritinib was distributed at high levels in xenografted tumors after oral administration.  The decreased FLT3 activity and high intratumor distribution of gilteritinib translated to tumor regression and improved survival in xenograft and intra-bone marrow transplantation models of FLT3-driven AML.  No overt toxicity was seen in mouse models treated with gilteritinib.  These results indicate that gilteritinib may be an important next-generation FLT3 inhibitor for use in the treatment of FLT3 mutation-pos. AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMaOcOB0-DOrVg90H21EOLACvtfcHk0ljC41oqxFdEtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvV2isrc%253D&md5=ffdf8ee1887cd2c6623dda70bb98a464</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1007%2Fs10637-017-0470-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-017-0470-z%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DM.%26aulast%3DKaneko%26aufirst%3DN.%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DYamada%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DR.%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DShimada%26aufirst%3DI.%26aulast%3DMori%26aufirst%3DK.%26aulast%3DKuromitsu%26aufirst%3DS.%26atitle%3DGilteritinib%252C%2520a%2520FLT3%252FAXL%2520inhibitor%252C%2520shows%2520antileukemic%2520activity%2520in%2520mouse%2520models%2520of%2520FLT3%2520mutated%2520acute%2520myeloid%2520leukemia%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2017%26volume%3D35%26issue%3D5%26spage%3D556%26epage%3D565%26doi%3D10.1007%2Fs10637-017-0470-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amalini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia</span>. <i>Blood Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">e44</span>, <span class="refDoi"> DOI: 10.1038/bcj.2011.43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fbcj.2011.43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=22829080" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=e44&issue=11&author=S.+Hartauthor=K.+C.+Gohauthor=V.+Novotny-Diermayrauthor=Y.+C.+Tanauthor=B.+Madanauthor=C.+Amaliniauthor=L.+C.+Ongauthor=B.+Khengauthor=A.+Cheongauthor=J.+Zhouauthor=W.+J.+Chngauthor=J.+M.+Wood&title=Pacritinib+%28SB1518%29%2C+a+JAK2%2FFLT3+inhibitor+for+the+treatment+of+acute+myeloid+leukemia&doi=10.1038%2Fbcj.2011.43"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2011.43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2011.43%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DS.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DAmalini%26aufirst%3DC.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DKheng%26aufirst%3DB.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DPacritinib%2520%2528SB1518%2529%252C%2520a%2520JAK2%252FFLT3%2520inhibitor%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%2520Cancer%2520J.%26date%3D2011%26volume%3D1%26issue%3D11%26spage%3De44%26doi%3D10.1038%2Fbcj.2011.43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buelow, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phelps, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mims, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behbehani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blachly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klisovic, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garzon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatnagar, B.</span></span> <span> </span><span class="NLM_article-title">Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">349</span>, <span class="refDoi"> DOI: 10.1007/s10637-019-00786-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1007%2Fs10637-019-00786-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=31102119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFert7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=340-349&issue=2&author=J.+Y.+Jeonauthor=Q.+Zhaoauthor=D.+R.+Buelowauthor=M.+Phelpsauthor=A.+R.+Walkerauthor=A.+S.+Mimsauthor=S.+Vasuauthor=G.+Behbehaniauthor=J.+Blachlyauthor=W.+Blumauthor=R.+B.+Klisovicauthor=J.+C.+Byrdauthor=R.+Garzonauthor=S.+D.+Bakerauthor=B.+Bhatnagar&title=Preclinical+activity+and+a+pilot+phase+I+study+of+pacritinib%2C+an+oral+JAK2%2FFLT3+inhibitor%2C+and+chemotherapy+in+FLT3-ITD-positive+AML&doi=10.1007%2Fs10637-019-00786-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positve AML</span></div><div class="casAuthors">Jeon, Jae Yoon; Zhao, Qiuhong; Buelow, Daelynn R.; Phelps, Mitch; Walker, Alison R.; Mims, Alice S.; Vasu, Sumithira; Behbehani, Gregory; Blachly, James; Blum, William; Klisovic, Rebecca B.; Byrd, John C.; Garzon, Ramiro; Baker, Sharyn D.; Bhatnagar, Bhavana</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">340-349</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Activating FLT3 internal tandem duplication (FLT3-ITD) mutations in acute myeloid leukemia (AML) assoc. with inferior outcomes.  We detd. that pacritinib, a JAK2/FLT3 inhibitor, has in vitro activity against FLT3-ITD and tyrosine kinase domain (TKD) mutations.  Therefore, we conducted a phase I study of pacritinib in combination with chemotherapy in AML patients with FLT3 mutations to det. the pharmacokinetics and preliminary toxicity and clin. activity.  Pacritinib was administered at a dose of 100 mg or 200 mg twice daily following a 3 + 3 dose-escalation in combination with cytarabine and daunorubicin (cohort A) or with decitabine induction (cohort B).  A total of thirteen patients were enrolled (five in cohort A; eight in cohort B).  Dose limiting toxicities include hemolytic anemia and grade 3 QTc prolongation in two patients who received 100 mg.  Complete remission was achieved in two patients in cohort A, one of whom had a minor D835Y clone at baseline.  One patient in cohort B achieved morphol. leukemia free state.  Seven patients (two in cohort A; five in cohort B) had stable disease.  In conclusion, pacritinib, an inhibitor of FLT3-ITD and resistant-conferring TKD mutations, was well tolerated and demonstrated preliminary anti-leukemic activity in combination with chemotherapy in patients with FLT3 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_5v94xwTkvbVg90H21EOLACvtfcHk0lg17NRznWldsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFert7jM&md5=8bd832581ae6d52b56fb0df21074be16</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1007%2Fs10637-019-00786-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-019-00786-4%26sid%3Dliteratum%253Aachs%26aulast%3DJeon%26aufirst%3DJ.%2BY.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DBuelow%26aufirst%3DD.%2BR.%26aulast%3DPhelps%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DA.%2BR.%26aulast%3DMims%26aufirst%3DA.%2BS.%26aulast%3DVasu%26aufirst%3DS.%26aulast%3DBehbehani%26aufirst%3DG.%26aulast%3DBlachly%26aufirst%3DJ.%26aulast%3DBlum%26aufirst%3DW.%26aulast%3DKlisovic%26aufirst%3DR.%2BB.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DGarzon%26aufirst%3DR.%26aulast%3DBaker%26aufirst%3DS.%2BD.%26aulast%3DBhatnagar%26aufirst%3DB.%26atitle%3DPreclinical%2520activity%2520and%2520a%2520pilot%2520phase%2520I%2520study%2520of%2520pacritinib%252C%2520an%2520oral%2520JAK2%252FFLT3%2520inhibitor%252C%2520and%2520chemotherapy%2520in%2520FLT3-ITD-positive%2520AML%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2020%26volume%3D38%26issue%3D2%26spage%3D340%26epage%3D349%26doi%3D10.1007%2Fs10637-019-00786-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">111590</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.ejmech.2019.111590" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=31408808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFyjsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2019&pages=111590&author=Y.+Liauthor=T.+Yeauthor=L.+Xuauthor=Y.+Dongauthor=Y.+Luoauthor=C.+Wangauthor=Y.+Hanauthor=K.+Chenauthor=M.+Qinauthor=Y.+Liuauthor=Y.+Zhao&title=Discovery+of+4-piperazinyl-2-aminopyrimidine+derivatives+as+dual+inhibitors+of+JAK2+and+FLT3&doi=10.1016%2Fj.ejmech.2019.111590"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3</span></div><div class="casAuthors">Li, Yingxiu; Ye, Tianyu; Xu, Le; Dong, Yuhong; Luo, Yong; Wang, Chu; Han, Yufei; Chen, Ke; Qin, Mingze; Liu, Yajing; Zhao, Yanfang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111590</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Hybridization strategy is an effective strategy to obtain multi-target inhibitors in drug design.  In this study, we assembled the pharmacophores of momelotinib and tandutinib to get a series of 4-piperazinyl-2-aminopyrimidine derivs.  All compds. were tested for the inhibition of JAK2 and FLT3 enzymes, of which, compds. with potent enzyme activities were assayed for antiproliferative activities against three cancer cell lines (HEL, MV4-11, and HL60).  The structure-activity relationship studies were conducted through variations in two regions, the "A" Ph ring and "B" Ph ring.  Compd. 14j showed the most balanced in vitro inhibitory activity against JAK2 and FLT3 (JAK2 IC50 = 27 nM, FLT3 IC50 = 30 nM), and it also showed potent inhibition against the above tested cell lines.  In the cellular context, 14j strongly induced apoptosis by arresting cell cycle in the G1/S phase, and was selected as a promising JAK2/FLT3 dual inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs61BoDk0-lbVg90H21EOLACvtfcHk0lg17NRznWldsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFyjsLnO&md5=787f97231f5494a8f85f581521486b25</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111590%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DQin%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DY.%26atitle%3DDiscovery%2520of%25204-piperazinyl-2-aminopyrimidine%2520derivatives%2520as%2520dual%2520inhibitors%2520of%2520JAK2%2520and%2520FLT3%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D181%26spage%3D111590%26doi%3D10.1016%2Fj.ejmech.2019.111590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bavetsias, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crumpler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atrash, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faisal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosmopoulou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheldrake, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Haven Brandon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayliss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linardopoulos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span> <span> </span><span class="NLM_article-title">Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">8721</span>– <span class="NLM_lpage">8734</span>, <span class="refDoi"> DOI: 10.1021/jm300952s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300952s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVOhsrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8721-8734&issue=20&author=V.+Bavetsiasauthor=S.+Crumplerauthor=C.+Sunauthor=S.+Averyauthor=B.+Atrashauthor=A.+Faisalauthor=A.+S.+Mooreauthor=M.+Kosmopoulouauthor=N.+Brownauthor=P.+W.+Sheldrakeauthor=K.+Bushauthor=A.+Henleyauthor=G.+Boxauthor=M.+Valentiauthor=A.+de+Haven+Brandonauthor=F.+I.+Raynaudauthor=P.+Workmanauthor=S.+A.+Ecclesauthor=R.+Baylissauthor=S.+Linardopoulosauthor=J.+Blagg&title=Optimization+of+imidazo%5B4%2C5-b%5Dpyridine-based+kinase+inhibitors%3A+identification+of+a+dual+FLT3%2FAurora+kinase+inhibitor+as+an+orally+bioavailable+preclinical+development+candidate+for+the+treatment+of+acute+myeloid+leukemia&doi=10.1021%2Fjm300952s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Imidazo[4,5-b]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia</span></div><div class="casAuthors">Bavetsias, Vassilios; Crumpler, Simon; Sun, Chongbo; Avery, Sian; Atrash, Butrus; Faisal, Amir; Moore, Andrew S.; Kosmopoulou, Magda; Brown, Nathan; Sheldrake, Peter W.; Bush, Katherine; Henley, Alan; Box, Gary; Valenti, Melanie; Brandon, Alexis de Haven; Raynaud, Florence I.; Workman, Paul; Eccles, Suzanne A.; Bayliss, Richard; Linardopoulos, Spiros; Blagg, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8721-8734</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Optimization of the imidazo[4,5-b]pyridine-based series of Aurora kinase inhibitors led to the identification of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine (I), a potent inhibitor of Aurora kinases (Aurora-A Kd = 7.5 nM, Aurora-B Kd = 48 nM), FLT3 kinase (Kd = 6.2 nM), and FLT3 mutants including FLT3-ITD (Kd = 38 nM) and FLT3(D835Y) (Kd = 14 nM).  FLT3-ITD causes constitutive FLT3 kinase activation and is detected in 20-35% of adults and 15% of children with acute myeloid leukemia (AML), conferring a poor prognosis in both age groups.  In an in vivo setting, I strongly inhibited the growth of a FLT3-ITD-pos. AML human tumor xenograft (MV4-11) following oral administration, with in vivo biomarker modulation and plasma free drug exposures consistent with dual FLT3 and Aurora kinase inhibition.  Compd. I, an orally bioavailable dual FLT3 and Aurora kinase inhibitor, was selected as a preclin. development candidate for the treatment of human malignancies, in particular AML, in adults and children.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr33FrCMOQBC7Vg90H21EOLACvtfcHk0lh3UquoQONNAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVOhsrzK&md5=4fcd67f24f682f6421d058723b9e89df</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1021%2Fjm300952s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300952s%26sid%3Dliteratum%253Aachs%26aulast%3DBavetsias%26aufirst%3DV.%26aulast%3DCrumpler%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DAvery%26aufirst%3DS.%26aulast%3DAtrash%26aufirst%3DB.%26aulast%3DFaisal%26aufirst%3DA.%26aulast%3DMoore%26aufirst%3DA.%2BS.%26aulast%3DKosmopoulou%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DN.%26aulast%3DSheldrake%26aufirst%3DP.%2BW.%26aulast%3DBush%26aufirst%3DK.%26aulast%3DHenley%26aufirst%3DA.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3Dde%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DBayliss%26aufirst%3DR.%26aulast%3DLinardopoulos%26aufirst%3DS.%26aulast%3DBlagg%26aufirst%3DJ.%26atitle%3DOptimization%2520of%2520imidazo%255B4%252C5-b%255Dpyridine-based%2520kinase%2520inhibitors%253A%2520identification%2520of%2520a%2520dual%2520FLT3%252FAurora%2520kinase%2520inhibitor%2520as%2520an%2520orally%2520bioavailable%2520preclinical%2520development%2520candidate%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D20%26spage%3D8721%26epage%3D8734%26doi%3D10.1021%2Fjm300952s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moore, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faisal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, G. W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miraki-Moud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bavetsias, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallsworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Haven Brandon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xavier, C. P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stronge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, A. D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taussig, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linardopoulos, S.</span></span> <span> </span><span class="NLM_article-title">Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736</span>. <i>Blood Adv.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1478</span>– <span class="NLM_lpage">1491</span>, <span class="refDoi"> DOI: 10.1182/bloodadvances.2019000986</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fbloodadvances.2019000986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=32282883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BB3cXis12ksr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2020&pages=1478-1491&issue=7&author=A.+S.+Mooreauthor=A.+Faisalauthor=G.+W.+Y.+Makauthor=F.+Miraki-Moudauthor=V.+Bavetsiasauthor=M.+Valentiauthor=G.+Boxauthor=A.+Hallsworthauthor=A.+de+Haven+Brandonauthor=C.+P.+R.+Xavierauthor=R.+Strongeauthor=A.+D.+J.+Pearsonauthor=J.+Blaggauthor=F.+I.+Raynaudauthor=R.+Chopraauthor=S.+A.+Ecclesauthor=D.+C.+Taussigauthor=S.+Linardopoulos&title=Quizartinib-resistant+FLT3-ITD+acute+myeloid+leukemia+cells+are+sensitive+to+the+FLT3-Aurora+kinase+inhibitor+CCT241736&doi=10.1182%2Fbloodadvances.2019000986"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736</span></div><div class="casAuthors">Moore, Andrew S.; Faisal, Amir; Mak, Grace W. Y.; Miraki-Moud, Farideh; Bavetsias, Vassilios; Valenti, Melanie; Box, Gary; Hallsworth, Albert; Brandon, Alexis de Haven; Xavier, Cristina P. R.; Stronge, Randal; Pearson, Andrew D. J.; Blagg, Julian; Raynaud, Florence I.; Chopra, Rajesh; Eccles, Suzanne A.; Taussig, David C.; Linardopoulos, Spiros</div><div class="citationInfo"><span class="NLM_cas:title">Blood Advances</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1478-1491</span>CODEN:
                <span class="NLM_cas:coden">BALDBA</span>;
        ISSN:<span class="NLM_cas:issn">2473-9537</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Internal tandem duplication of FLT3 (FLT3-ITD) is one of the most common somatic mutations in acute myeloid leukemia (AML); it causes constitutive activation of FLT3 kinase and is assocd. with high relapse rates and poor survival.  Small-mol. inhibition of FLT3 represents an attractive therapeutic strategy for this subtype of AML, although resistance from secondary FLT3 tyrosine kinase domain (FLT3-TKD) mutations is an emerging clin. problem.  CCT241736 is an orally bioavailable, selective, and potent dual inhibitor of FLT3 and Aurora kinases.  FLT3-ITD+ cells with secondary FLT3-TKD mutations have high in vitro relative resistance to the FLT3 inhibitors quizartinib and sorafenib, but not to CCT241736.  The mechanism of action of CCT241736 results in significant in vivo efficacy, with inhibition of tumor growth obsd. in efficacy studies in FLT3-ITD and FLT3-ITD-TKD human tumor xenograft models.  The efficacy of CCT241736 was also confirmed in primary samples from AML patients, including those with quizartinib-resistant disease, which induces apoptosis through inhibition of both FLT3 and Aurora kinases.  The unique combination of CCT241736 properties based on robust potency, dual selectivity, and significant in vivo activity indicate that CCT241736 is a bona fide clin. drug candidate for FLT3-ITD and TKD AML patients with resistance to current drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3khkwzjI8mbVg90H21EOLACvtfcHk0lhMO2zG39OwOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXis12ksr3K&md5=a911f89f608c505eeb6ffcfd14113bfc</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1182%2Fbloodadvances.2019000986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fbloodadvances.2019000986%26sid%3Dliteratum%253Aachs%26aulast%3DMoore%26aufirst%3DA.%2BS.%26aulast%3DFaisal%26aufirst%3DA.%26aulast%3DMak%26aufirst%3DG.%2BW.%2BY.%26aulast%3DMiraki-Moud%26aufirst%3DF.%26aulast%3DBavetsias%26aufirst%3DV.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DHallsworth%26aufirst%3DA.%26aulast%3Dde%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DXavier%26aufirst%3DC.%2BP.%2BR.%26aulast%3DStronge%26aufirst%3DR.%26aulast%3DPearson%26aufirst%3DA.%2BD.%2BJ.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DChopra%26aufirst%3DR.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DTaussig%26aufirst%3DD.%2BC.%26aulast%3DLinardopoulos%26aufirst%3DS.%26atitle%3DQuizartinib-resistant%2520FLT3-ITD%2520acute%2520myeloid%2520leukemia%2520cells%2520are%2520sensitive%2520to%2520the%2520FLT3-Aurora%2520kinase%2520inhibitor%2520CCT241736%26jtitle%3DBlood%2520Adv.%26date%3D2020%26volume%3D4%26issue%3D7%26spage%3D1478%26epage%3D1491%26doi%3D10.1182%2Fbloodadvances.2019000986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksterowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribble, M. W.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alba, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connors, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeGraffenreid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deignan, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquette, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huard, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaizerman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lively, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMinn, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihalic, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattabiraman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piper, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Queva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragains, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suchomel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wanska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehn, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickramasinghe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3430</span>– <span class="NLM_lpage">3449</span>, <span class="refDoi"> DOI: 10.1021/jm500118j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500118j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3430-3449&issue=8&author=Z.+Liauthor=X.+Wangauthor=J.+Eksterowiczauthor=M.+W.+Gribbleauthor=G.+Q.+Albaauthor=M.+Ayresauthor=T.+J.+Carlsonauthor=A.+Chenauthor=X.+Chenauthor=R.+Choauthor=R.+V.+Connorsauthor=M.+DeGraffenreidauthor=J.+T.+Deignanauthor=J.+Duquetteauthor=P.+Fanauthor=B.+Fisherauthor=J.+Fuauthor=J.+N.+Huardauthor=J.+Kaizermanauthor=K.+S.+Keeganauthor=C.+Liauthor=K.+Liauthor=Y.+Liauthor=L.+Liangauthor=W.+Liuauthor=S.+E.+Livelyauthor=M.+C.+Loauthor=J.+Maauthor=D.+L.+McMinnauthor=J.+T.+Mihalicauthor=K.+Modiauthor=R.+Ngoauthor=K.+Pattabiramanauthor=D.+E.+Piperauthor=C.+Quevaauthor=M.+L.+Ragainsauthor=J.+Suchomelauthor=S.+Thibaultauthor=N.+Walkerauthor=X.+Wangauthor=Z.+Wangauthor=M.+Wanskaauthor=P.+M.+Wehnauthor=M.+F.+Weidnerauthor=A.+J.+Zhangauthor=X.+Zhaoauthor=A.+Kambauthor=D.+Wickramasingheauthor=K.+Daiauthor=L.+R.+McGeeauthor=J.+C.+Medina&title=Discovery+of+AMG+925%2C+a+FLT3+and+CDK4+dual+kinase+inhibitor+with+preferential+affinity+for+the+activated+state+of+FLT3&doi=10.1021%2Fjm500118j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3</span></div><div class="casAuthors">Li, Zhihong; Wang, Xianghong; Eksterowicz, John; Gribble, Michael W.; Alba, Grace Q.; Ayres, Merrill; Carlson, Timothy J.; Chen, Ada; Chen, Xiaoqi; Cho, Robert; Connors, Richard V.; DeGraffenreid, Michael; Deignan, Jeffrey T.; Duquette, Jason; Fan, Pingchen; Fisher, Benjamin; Fu, Jiasheng; Huard, Justin N.; Kaizerman, Jacob; Keegan, Kathleen S.; Li, Cong; Li, Kexue; Li, Yunxiao; Liang, Lingming; Liu, Wen; Lively, Sarah E.; Lo, Mei-Chu; Ma, Ji; McMinn, Dustin L.; Mihalic, Jeffrey T.; Modi, Kriti; Ngo, Rachel; Pattabiraman, Kanaka; Piper, Derek E.; Queva, Christophe; Ragains, Mark L.; Suchomel, Julia; Thibault, Steve; Walker, Nigel; Wang, Xiaodong; Wang, Zhulun; Wanska, Malgorzata; Wehn, Paul M.; Weidner, Margaret F.; Zhang, Alex J.; Zhao, Xiaoning; Kamb, Alexander; Wickramasinghe, Dineli; Dai, Kang; McGee, Lawrence R.; Medina, Julio C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3430-3449</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors describe the structural optimization of a lead compd. that exhibits dual inhibitory activities against FLT3 and CDK4.  A series of pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidine derivs. was synthesized, and SAR anal., using cell-based assays, led to the discovery of AMG 925 (I), a potent and orally bioavailable dual inhibitor of CDK4 and FLT3, including many FLT3 mutants reported to date.  Compd. I inhibits the proliferation of a panel of human tumor cell lines including Colo205 (Rb+) and U937 (FLT3WT) and induced cell death in MOLM13 (FLT3ITD) and even in MOLM13 (FLT3ITD, D835Y), which exhibits resistance to a no. of FLT3 inhibitors currently under clin. development.  At well-tolerated doses, compd. I leads to significant growth inhibition of MOLM13 xenografts in nude mice, and the activity correlates with inhibition of STAT5 and Rb phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcJdjH0aU8KrVg90H21EOLACvtfcHk0lhMO2zG39OwOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D&md5=4047a6ea068dbde57896da520fbdf0d3</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1021%2Fjm500118j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500118j%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DGribble%26aufirst%3DM.%2BW.%26aulast%3DAlba%26aufirst%3DG.%2BQ.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DCarlson%26aufirst%3DT.%2BJ.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCho%26aufirst%3DR.%26aulast%3DConnors%26aufirst%3DR.%2BV.%26aulast%3DDeGraffenreid%26aufirst%3DM.%26aulast%3DDeignan%26aufirst%3DJ.%2BT.%26aulast%3DDuquette%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DHuard%26aufirst%3DJ.%2BN.%26aulast%3DKaizerman%26aufirst%3DJ.%26aulast%3DKeegan%26aufirst%3DK.%2BS.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLively%26aufirst%3DS.%2BE.%26aulast%3DLo%26aufirst%3DM.%2BC.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DMcMinn%26aufirst%3DD.%2BL.%26aulast%3DMihalic%26aufirst%3DJ.%2BT.%26aulast%3DModi%26aufirst%3DK.%26aulast%3DNgo%26aufirst%3DR.%26aulast%3DPattabiraman%26aufirst%3DK.%26aulast%3DPiper%26aufirst%3DD.%2BE.%26aulast%3DQueva%26aufirst%3DC.%26aulast%3DRagains%26aufirst%3DM.%2BL.%26aulast%3DSuchomel%26aufirst%3DJ.%26aulast%3DThibault%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWanska%26aufirst%3DM.%26aulast%3DWehn%26aufirst%3DP.%2BM.%26aulast%3DWeidner%26aufirst%3DM.%2BF.%26aulast%3DZhang%26aufirst%3DA.%2BJ.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DKamb%26aufirst%3DA.%26aulast%3DWickramasinghe%26aufirst%3DD.%26aulast%3DDai%26aufirst%3DK.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520of%2520AMG%2520925%252C%2520a%2520FLT3%2520and%2520CDK4%2520dual%2520kinase%2520inhibitor%2520with%2520preferential%2520affinity%2520for%2520the%2520activated%2520state%2520of%2520FLT3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D8%26spage%3D3430%26epage%3D3449%26doi%3D10.1021%2Fjm500118j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaser, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchemin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusewitt, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligiuri, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briesewitz, R.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>110</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2075</span>– <span class="NLM_lpage">2083</span>, <span class="refDoi"> DOI: 10.1182/blood-2007-02-071266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1182%2Fblood-2007-02-071266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=17537993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVGjtbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=2075-2083&issue=6&author=L.+Wangauthor=J.+Wangauthor=B.+W.+Blaserauthor=A.+M.+Ducheminauthor=D.+F.+Kusewittauthor=T.+Liuauthor=M.+A.+Caligiuriauthor=R.+Briesewitz&title=Pharmacologic+inhibition+of+CDK4%2F6%3A+mechanistic+evidence+for+selective+activity+or+acquired+resistance+in+acute+myeloid+leukemia&doi=10.1182%2Fblood-2007-02-071266"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia</span></div><div class="casAuthors">Wang, Lisheng; Wang, Jie; Blaser, Bradley W.; Duchemin, Anne-Marie; Kusewitt, Donna F.; Liu, Tom; Caligiuri, Michael A.; Briesewitz, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2075-2083</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Entry into the cell cycle is mediated by cyclin-dependent kinase 4/6 (CDK4/6) activation, followed by CDK2 activation.  We found that pharmacol. inhibition of the Flt3 internal tandem duplication (ITD), a mutated receptor tyrosine kinase commonly found in patients with acute myelogenous leukemia (AML), led to the down-regulation of cyclin D2 and D3 followed by retinoblastoma protein (pRb) dephosphorylation and G1 cell-cycle arrest.  This implicated the D-cyclin-CDK4/6 complex as a downstream effector of Flt3 ITD signaling.  Indeed, single-agent PD0332991, a selective CDK4/6 inhibitor, caused sustained cell-cycle arrest in Flt3 ITD AML cell lines and prolonged survival in an in vivo model of Flt3 ITD AML.  PD0332991 caused an initial cell-cycle arrest in well-established Flt3 wild-type (wt) AML cell lines, but this was overcome by down-regulation of p27Kip and reactivation of CDK2.  This acquired resistance was not obsd. in a Flt3 ITD and a Flt3 wt sample from a patient with primary AML.  In summary, the mechanism of cell-cycle arrest after treatment of Flt3 ITD AML with a Flt3 inhibitor involves down-regulation of cyclin D2 and D3.  As such, CDK4/6 can be a therapeutic target in Flt3 ITD AML but also in primary Flt3 wt AML.  Finally, acquired resistance to CDK4/6 inhibition can arise through activation CDK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiH_wOIP8jJLVg90H21EOLACvtfcHk0lg0X3RCmPdIuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVGjtbbK&md5=5f68ef6deacf3789e428731722f8c5ff</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-02-071266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-02-071266%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBlaser%26aufirst%3DB.%2BW.%26aulast%3DDuchemin%26aufirst%3DA.%2BM.%26aulast%3DKusewitt%26aufirst%3DD.%2BF.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26aulast%3DBriesewitz%26aufirst%3DR.%26atitle%3DPharmacologic%2520inhibition%2520of%2520CDK4%252F6%253A%2520mechanistic%2520evidence%2520for%2520selective%2520activity%2520or%2520acquired%2520resistance%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26issue%3D6%26spage%3D2075%26epage%3D2083%26doi%3D10.1182%2Fblood-2007-02-071266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newhall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinclair, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickramasinghe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, K.</span></span> <span> </span><span class="NLM_article-title">AMG 925 is a dual FLT3/CDK4 inhibitor with the potential to overcome FLT3 inhibitor resistance in acute myeloid leukemia</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">375</span>– <span class="NLM_lpage">383</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0388</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F1535-7163.MCT-14-0388" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=25487917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitlOjsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=375-383&issue=2&author=C.+Liauthor=L.+Liuauthor=L.+Liangauthor=Z.+Xiaauthor=Z.+Liauthor=X.+Wangauthor=L.+R.+McGeeauthor=K.+Newhallauthor=A.+Sinclairauthor=A.+Kambauthor=D.+Wickramasingheauthor=K.+Dai&title=AMG+925+is+a+dual+FLT3%2FCDK4+inhibitor+with+the+potential+to+overcome+FLT3+inhibitor+resistance+in+acute+myeloid+leukemia&doi=10.1158%2F1535-7163.MCT-14-0388"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">AMG 925 Is a Dual FLT3/CDK4 Inhibitor with the Potential to Overcome FLT3 Inhibitor Resistance in Acute Myeloid Leukemia</span></div><div class="casAuthors">Li, Cong; Liu, Liqin; Liang, Lingming; Xia, Zhen; Li, Zhihong; Wang, Xianghong; McGee, Lawrence R.; Newhall, Katie; Sinclair, Angus; Kamb, Alexander; Wickramasinghe, Dineli; Dai, Kang</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">375-383</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Resistance to FLT3 inhibitors is a serious clin. issue in treating acute myelogenous leukemia (AML).  AMG 925, a dual FLT3/CDK4 inhibitor, has been developed to overcome this resistance.  It is hypothesized that the combined inhibition of FLT3 and CDK4 may reduce occurrence of the FLT3 resistance mutations, and thereby prolong clin. responses.  To test this hypothesis, we attempted to isolate AML cell clones resistant to AMG 925 or to FLT3 inhibitors.  After a selection of over 8 mo with AMG 925, we could only isolate partially resistant clones.  No new mutations in FLT3 were found, but a 2- to 3-fold increase in total FLT3 protein was detected and believed to contribute to the partial resistance.  In contrast, selection with the FLT3 inhibitors sorafenib or AC220 (Quizartinib), led to a resistance and the appearance of a no. of mutations in FLT3 kinase domains, including the known hot spot sites D835 and F691.  However, when AC220 was combined with the CDK4 inhibitor PD0332991 (palbociclib) at 0.1 μmol/L or higher, no resistance mutations were obtained, indicating that the CDK4-inhibiting activity of AMG 925 contributed to the failure to develop drug resistance.  AMG 925 was shown to potently inhibit the FLT3 inhibitor-resistant mutation D835Y/V.  This feature of AMG 925 was also considered to contribute to the lack of resistance mutations to the compd.  Together, our data suggest that AMG 925 has the potential to reduce resistance mutations in FLT3 and may prolong clin. responses.  Mol Cancer Ther; 14(2); 375-83. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6REHZXaV0kbVg90H21EOLACvtfcHk0lg0X3RCmPdIuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitlOjsbw%253D&md5=a275188c7ace129474044779a8e91702</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0388%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DXia%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DNewhall%26aufirst%3DK.%26aulast%3DSinclair%26aufirst%3DA.%26aulast%3DKamb%26aufirst%3DA.%26aulast%3DWickramasinghe%26aufirst%3DD.%26aulast%3DDai%26aufirst%3DK.%26atitle%3DAMG%2520925%2520is%2520a%2520dual%2520FLT3%252FCDK4%2520inhibitor%2520with%2520the%2520potential%2520to%2520overcome%2520FLT3%2520inhibitor%2520resistance%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26issue%3D2%26spage%3D375%26epage%3D383%26doi%3D10.1158%2F1535-7163.MCT-14-0388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragains, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coberly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenback, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksterowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alba, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Queva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickramasinghe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, K.</span></span> <span> </span><span class="NLM_article-title">Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">880</span>– <span class="NLM_lpage">889</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0858</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1158%2F1535-7163.MCT-13-0858" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=24526162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=880-889&issue=4&author=K.+Keeganauthor=C.+Liauthor=Z.+Liauthor=J.+Maauthor=M.+Ragainsauthor=S.+Coberlyauthor=D.+Hollenbackauthor=J.+Eksterowiczauthor=L.+Liangauthor=M.+Weidnerauthor=J.+Huardauthor=X.+Wangauthor=G.+Albaauthor=J.+Orfauthor=M.+C.+Loauthor=S.+Zhaoauthor=R.+Ngoauthor=A.+Chenauthor=L.+Liuauthor=T.+Carlsonauthor=C.+Quevaauthor=L.+R.+McGeeauthor=J.+Medinaauthor=A.+Kambauthor=D.+Wickramasingheauthor=K.+Dai&title=Preclinical+evaluation+of+AMG+925%2C+a+FLT3%2FCDK4+dual+kinase+inhibitor+for+treating+acute+myeloid+leukemia&doi=10.1158%2F1535-7163.MCT-13-0858"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia</span></div><div class="casAuthors">Keegan, Kathleen; Li, Cong; Li, Zhihong; Ma, Ji; Ragains, Mark; Coberly, Suzanne; Hollenback, David; Eksterowicz, John; Liang, Lingming; Weidner, Margaret; Huard, Justin; Wang, Xianghong; Alba, Grace; Orf, Jessica; Lo, Mei-Chu; Zhao, Sharon; Ngo, Rachel; Chen, Ada; Liu, Lily; Carlson, Timothy; Queva, Christophe; McGee, Lawrence R.; Medina, Julio; Kamb, Alexander; Wickramasinghe, Dineli; Dai, Kang</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">880-889</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) remains a serious unmet medical need.  Despite high remission rates with chemotherapy std.-of-care treatment, the disease eventually relapses in a major proportion of patients.  Activating Fms-like tyrosine kinase 3 (FLT3) mutations are found in approx. 30% of patients with AML.  Targeting FLT3 receptor tyrosine kinase has shown encouraging results in treating FLT3-mutated AML.  Responses, however, are not sustained and acquired resistance has been a clin. challenge.  Treatment options to overcome resistance are currently the focus of research.  We report here the preclin. evaluation of AMG 925, a potent, selective, and bioavailable FLT3/cyclin-dependent kinase 4 (CDK4) dual kinase inhibitor.  AMG 925 inhibited AML xenograft tumor growth by 96% to 99% without significant body wt. loss.  The antitumor activity of AMG 925 correlated with the inhibition of STAT5 and RB phosphorylation, the pharmacodynamic markers for inhibition of FLT3 and CDK4, resp.  In addn., AMG 925 was also found to inhibit FLT3 mutants (e.g., D835Y) that are resistant to the current FLT3 inhibitors (e.g., AC220 and sorafenib).  CDK4 is a cyclin D-dependent kinase that plays an essential central role in regulating cell proliferation in response to external growth signals.  A crit. role of the CDK4-RB pathway in cancer development has been well established.  CDK4-specific inhibitors are being developed for treating RB-pos. cancer.  AMG 925, which combines inhibition of two kinases essential for proliferation and survival of FLT3-mutated AML cells, may improve and prolong clin. responses.  Mol Cancer Ther; 13(4); 880-9. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI4p2uOyF0ObVg90H21EOLACvtfcHk0lgKeCx4qPHLgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurs%253D&md5=7343fdb82e66c9115c8b018a260aadde</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0858%26sid%3Dliteratum%253Aachs%26aulast%3DKeegan%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DRagains%26aufirst%3DM.%26aulast%3DCoberly%26aufirst%3DS.%26aulast%3DHollenback%26aufirst%3DD.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DWeidner%26aufirst%3DM.%26aulast%3DHuard%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DAlba%26aufirst%3DG.%26aulast%3DOrf%26aufirst%3DJ.%26aulast%3DLo%26aufirst%3DM.%2BC.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DNgo%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DCarlson%26aufirst%3DT.%26aulast%3DQueva%26aufirst%3DC.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%26aulast%3DKamb%26aufirst%3DA.%26aulast%3DWickramasinghe%26aufirst%3DD.%26aulast%3DDai%26aufirst%3DK.%26atitle%3DPreclinical%2520evaluation%2520of%2520AMG%2520925%252C%2520a%2520FLT3%252FCDK4%2520dual%2520kinase%2520inhibitor%2520for%2520treating%2520acute%2520myeloid%2520leukemia%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26issue%3D4%26spage%3D880%26epage%3D889%26doi%3D10.1158%2F1535-7163.MCT-13-0858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikezoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furihata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishioka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeffler, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, A.</span></span> <span> </span><span class="NLM_article-title">Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>129</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2512</span>– <span class="NLM_lpage">2521</span>, <span class="refDoi"> DOI: 10.1002/ijc.25910</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1002%2Fijc.25910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=21207414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2jt77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2011&pages=2512-2521&issue=10&author=T.+Ikezoeauthor=S.+Kojimaauthor=M.+Furihataauthor=J.+Yangauthor=C.+Nishiokaauthor=A.+Takeuchiauthor=M.+Isakaauthor=H.+P.+Koefflerauthor=A.+Yokoyama&title=Expression+of+p-JAK2+predicts+clinical+outcome+and+is+a+potential+molecular+target+of+acute+myelogenous+leukemia&doi=10.1002%2Fijc.25910"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia</span></div><div class="casAuthors">Ikezoe, Takayuki; Kojima, Shinsuke; Furihata, Mutsuo; Yang, Jing; Nishioka, Chie; Takeuchi, Asako; Isaka, Mayuka; Koeffler, H. Phillip; Yokoyama, Akihito</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2512-2521</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Our study detd. if Janus kinase 2 (JAK2) was activated in acute myelogenous leukemia (AML; n = 77, excluding acute promyelocytic leukemia) by immunohistochem. (IHC) using a phosphor-specific antibody against JAK2. p-JAK2 was detectable in all cases, although its levels varied between patient samples (high levels, n = 31; low levels, n = 46).  The quantification of levels of p-JAK2 by IHC was well correlated with that assessed by Western blot analyses and fluorescence-activated cell sorting (FACS).  Levels of p-JAK2 were directly correlated with high white blood cell count (52.3 × 103/L in patients with high p-JAK2 vs. 28.3 × 103/L in patients with low p-JAK2, p < 0.01) and were inversely correlated with complete remission rates (45% in patients with high p-JAK2 vs. 78% in patients with low p-JAK2, p < 0.003).  In addn., multivariate anal. confirmed that high levels of p-JAK2 remained a significant factor for overall survival (hazard ratio = 2.213; 95% confidence interval, 1.212-4.041, p = 0.023).  Moreover, we found that AZ960, a novel and specific inhibitor of the JAK2 kinase, potently inhibited the clonogenic growth and induced apoptosis of freshly isolated AML cells from patients in assocn. with cleavage of caspase 3 and downregulation of anti-apoptotic Bcl-xL proteins.  Taken together, JAK2 may be a promising mol. target for treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9L8HwJhfH-rVg90H21EOLACvtfcHk0lgKeCx4qPHLgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2jt77N&md5=5821c50baeb0d36708c1c30ee8a38e15</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1002%2Fijc.25910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25910%26sid%3Dliteratum%253Aachs%26aulast%3DIkezoe%26aufirst%3DT.%26aulast%3DKojima%26aufirst%3DS.%26aulast%3DFurihata%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DNishioka%26aufirst%3DC.%26aulast%3DTakeuchi%26aufirst%3DA.%26aulast%3DIsaka%26aufirst%3DM.%26aulast%3DKoeffler%26aufirst%3DH.%2BP.%26aulast%3DYokoyama%26aufirst%3DA.%26atitle%3DExpression%2520of%2520p-JAK2%2520predicts%2520clinical%2520outcome%2520and%2520is%2520a%2520potential%2520molecular%2520target%2520of%2520acute%2520myelogenous%2520leukemia%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2011%26volume%3D129%26issue%3D10%26spage%3D2512%26epage%3D2521%26doi%3D10.1002%2Fijc.25910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidel, F. H.</span></span> <span> </span><span class="NLM_article-title">Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">854</span>, <span class="refDoi"> DOI: 10.3390/cells8080854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.3390%2Fcells8080854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslWntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=854&issue=8&author=F.+Pernerauthor=C.+Pernerauthor=T.+Ernstauthor=F.+H.+Heidel&title=Roles+of+JAK2+in+aging%2C+inflammation%2C+hematopoiesis+and+malignant+transformation&doi=10.3390%2Fcells8080854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation</span></div><div class="casAuthors">Perner, Florian; Perner, Caroline; Ernst, Thomas; Heidel, Florian H.</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">854</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Clonal alterations in hematopoietic cells occur during aging and are often assocd. with the establishment of a subclin. inflammatory environment.  Several age-related conditions and diseases may be initiated or promoted by these alterations.  JAK2 mutations are among the most frequently mutated genes in blood cells during aging.  The most common mutation within the JAK2 gene is JAK2-V617F that leads to constitutive activation of the kinase and thereby aberrant engagement of downstream signaling pathways.  JAK2 mutations can act as central drivers of myeloproliferative neoplasia, a pre-leukemic and age-related malignancy.  Likewise, hyperactive JAK-signaling is a hallmark of immune diseases and critically influences inflammation, coagulation and thrombosis.  In this review we aim to summarize the current knowledge on JAK2 in clonal hematopoiesis during aging, the role of JAK-signaling in inflammation and lymphocyte biol. and JAK2 function in age-related diseases and malignant transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfbCzDy7BOo7Vg90H21EOLACvtfcHk0lgKeCx4qPHLgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslWntbw%253D&md5=8433e74cbd00a65cd218101e5ca62d79</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.3390%2Fcells8080854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells8080854%26sid%3Dliteratum%253Aachs%26aulast%3DPerner%26aufirst%3DF.%26aulast%3DPerner%26aufirst%3DC.%26aulast%3DErnst%26aufirst%3DT.%26aulast%3DHeidel%26aufirst%3DF.%2BH.%26atitle%3DRoles%2520of%2520JAK2%2520in%2520aging%252C%2520inflammation%252C%2520hematopoiesis%2520and%2520malignant%2520transformation%26jtitle%3DCells%26date%3D2019%26volume%3D8%26issue%3D8%26spage%3D854%26doi%3D10.3390%2Fcells8080854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldenson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crispino, J. D.</span></span> <span> </span><span class="NLM_article-title">The Aurora kinases in cell cycle and leukemia</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1038/onc.2014.14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fonc.2014.14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=24632603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktlGmtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=537-545&issue=5&author=B.+Goldensonauthor=J.+D.+Crispino&title=The+Aurora+kinases+in+cell+cycle+and+leukemia&doi=10.1038%2Fonc.2014.14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">The aurora kinases in cell cycle and leukemia</span></div><div class="casAuthors">Goldenson, B.; Crispino, J. D.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">537-545</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The Aurora kinases, which include Aurora A (AURKA), Aurora B (AURKB) and Aurora C (AURKC), are serine/threonine kinases required for the control of mitosis (AURKA and AURKB) and meiosis (AURKC).  Since their discovery nearly 20 years ago, Aurora kinases have been studied extensively in cell and cancer biol.  Several early studies found that Aurora kinases are amplified and overexpressed at the transcript and protein level in various malignancies, including several types of leukemia.  These discoveries and others provided a rationale for the development of small-mol. inhibitors of Aurora kinases as leukemia therapies.  The first generation of Aurora kinase inhibitors did not fare well in clin. trials, owing to poor efficacy and high toxicity.  However, the creation of second-generation, highly selective Aurora kinase inhibitors has increased the enthusiasm for targeting these proteins in leukemia.  This review will describe the functions of each Aurora kinase, summarize their involvement in leukemia and discuss inhibitor development and efficacy in leukemia clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ7zN9HIe8mbVg90H21EOLACvtfcHk0lgnA8WlV_pQRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktlGmtrg%253D&md5=376deb50059c7b67d6a86c530f772649</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1038%2Fonc.2014.14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2014.14%26sid%3Dliteratum%253Aachs%26aulast%3DGoldenson%26aufirst%3DB.%26aulast%3DCrispino%26aufirst%3DJ.%2BD.%26atitle%3DThe%2520Aurora%2520kinases%2520in%2520cell%2520cycle%2520and%2520leukemia%26jtitle%3DOncogene%26date%3D2015%26volume%3D34%26issue%3D5%26spage%3D537%26epage%3D545%26doi%3D10.1038%2Fonc.2014.14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, H.</span></span> <span> </span><span class="NLM_article-title">Clinical development of CDK4/6 inhibitor for breast cancer</span>. <i>Breast Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">406</span>, <span class="refDoi"> DOI: 10.1007/s12282-017-0827-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1007%2Fs12282-017-0827-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=29392622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A280%3ADC%252BC1MvmsFGqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=402-406&issue=4&author=H.+Iwata&title=Clinical+development+of+CDK4%2F6+inhibitor+for+breast+cancer&doi=10.1007%2Fs12282-017-0827-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical development of CDK4/6 inhibitor for breast cancer</span></div><div class="casAuthors">Iwata Hiroji</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">402-406</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Endocrine therapy is the mainstay of treatment for patients with estrogen receptor positive (ER+)/HER2-negative (HER2-) metastatic breast cancer (MBC).  Many clinicians consider the sequential endocrine therapy is gold standard strategy because of better outcome and the maintenance of a better quality of life (QOL) for MBC patients.  However, clinical practice shall be changed according to development of CDK4/6 inhibitor in current.  CDK4/6 is key kinase which promote the cell cycle, and especially the expression of cyclin D1 and the activation of CDK4/6 to drive breast cancer proliferation.  Currently positive data of several clinical trials using three CDK4/6 inhibitors (palbocilcib, ribociclib, abemaciclib) were published and primary endpoint were met in all phase III studies.  Therefore, practice change of endocrine therapy has been achieved in ER positive MBC.  This review will present clinical trial data, including both the efficacy and safety of CDK4/6 inhibitors for MBC, and describe the designs of the mainly ongoing clinical trials examining CDK4/6 inhibitors for the treatment of MBC and EBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRenMI_Igvwj8RAV4D_Ins_fW6udTcc2eYHdCEqpdk5I7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvmsFGqtA%253D%253D&md5=d74b22349f1962078da12d1768ed48a3</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1007%2Fs12282-017-0827-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12282-017-0827-3%26sid%3Dliteratum%253Aachs%26aulast%3DIwata%26aufirst%3DH.%26atitle%3DClinical%2520development%2520of%2520CDK4%252F6%2520inhibitor%2520for%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%26date%3D2018%26volume%3D25%26issue%3D4%26spage%3D402%26epage%3D406%26doi%3D10.1007%2Fs12282-017-0827-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salerno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damon, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perl, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travers, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadt, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasarskis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. P.</span></span> <span> </span><span class="NLM_article-title">Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>485</i></span> (<span class="NLM_issue">7397</span>),  <span class="NLM_fpage">260</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1038/nature11016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1038%2Fnature11016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=22504184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtVeqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=485&publication_year=2012&pages=260-263&issue=7397&author=C.+C.+Smithauthor=Q.+Wangauthor=C.+S.+Chinauthor=S.+Salernoauthor=L.+E.+Damonauthor=M.+J.+Levisauthor=A.+E.+Perlauthor=K.+J.+Traversauthor=S.+Wangauthor=J.+P.+Huntauthor=P.+P.+Zarrinkarauthor=E.+E.+Schadtauthor=A.+Kasarskisauthor=J.+Kuriyanauthor=N.+P.+Shah&title=Validation+of+ITD+mutations+in+FLT3+as+a+therapeutic+target+in+human+acute+myeloid+leukaemia&doi=10.1038%2Fnature11016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukemia</span></div><div class="casAuthors">Smith, Catherine C.; Wang, Qi; Chin, Chen-Shan; Salerno, Sara; Damon, Lauren E.; Levis, Mark J.; Perl, Alexander E.; Travers, Kevin J.; Wang, Susana; Hunt, Jeremy P.; Zarrinkar, Patrick P.; Schadt, Eric E.; Kasarskis, Andrew; Kuriyan, John; Shah, Neil P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">485</span>
        (<span class="NLM_cas:issue">7397</span>),
    <span class="NLM_cas:pages">260-263</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Effective targeted cancer therapeutic development depends upon distinguishing disease-assocd. driver' mutations, which have causative roles in malignancy pathogenesis, from passenger' mutations, which are dispensable for cancer initiation and maintenance.  Translational studies of clin. active targeted therapeutics can definitively discriminate driver from passenger lesions and provide valuable insights into human cancer biol.  Activating internal tandem duplication (ITD) mutations in FLT3 (FLT3-ITD) are detected in approx. 20% of acute myeloid leukemia (AML) patients and are assocd. with a poor prognosis.  Abundant scientific and clin. evidence, including the lack of convincing clin. activity of early FLT3 inhibitors, suggests that FLT3-ITD probably represents a passenger lesion.  Here we report point mutations at three residues within the kinase domain of FLT3-ITD that confer substantial in vitro resistance to AC220 (quizartinib), an active investigational inhibitor of FLT3, KIT, PDGFRA, PDGFRB and RET; evolution of AC220-resistant substitutions at two of these amino acid positions was obsd. in eight of eight FLT3-ITD-pos. AML patients with acquired resistance to AC220.  Our findings demonstrate that FLT3-ITD can represent a driver lesion and valid therapeutic target in human AML.  AC220-resistant FLT3 kinase domain mutants represent high-value targets for future FLT3 inhibitor development efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq0PeqhlWLObVg90H21EOLACvtfcHk0lgnA8WlV_pQRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtVeqtr8%253D&md5=228dae85b08e65918f74ee8c5d20ddb0</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1038%2Fnature11016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11016%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DChin%26aufirst%3DC.%2BS.%26aulast%3DSalerno%26aufirst%3DS.%26aulast%3DDamon%26aufirst%3DL.%2BE.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26aulast%3DTravers%26aufirst%3DK.%2BJ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DSchadt%26aufirst%3DE.%2BE.%26aulast%3DKasarskis%26aufirst%3DA.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DN.%2BP.%26atitle%3DValidation%2520of%2520ITD%2520mutations%2520in%2520FLT3%2520as%2520a%2520therapeutic%2520target%2520in%2520human%2520acute%2520myeloid%2520leukaemia%26jtitle%3DNature%26date%3D2012%26volume%3D485%26issue%3D7397%26spage%3D260%26epage%3D263%26doi%3D10.1038%2Fnature11016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dumas, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naudin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Lanneree, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izac, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casetti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansier, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousseau, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufossee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pigneux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Praloran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bidet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villacreces, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guitart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milpied, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosmider, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigon, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desplat, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dusanter-Fourt, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquet, J. M.</span></span> <span> </span><span class="NLM_article-title">Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>104</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2017</span>– <span class="NLM_lpage">2027</span>, <span class="refDoi"> DOI: 10.3324/haematol.2018.205385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.3324%2Fhaematol.2018.205385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=30923103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFChtLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2019&pages=2017-2027&issue=10&author=P.+Y.+Dumasauthor=C.+Naudinauthor=S.+Martin-Lannereeauthor=B.+Izacauthor=L.+Casettiauthor=O.+Mansierauthor=B.+Rousseauauthor=A.+Artusauthor=M.+Dufosseeauthor=A.+Gieseauthor=P.+Dubusauthor=A.+Pigneuxauthor=V.+Praloranauthor=A.+Bidetauthor=A.+Villacrecesauthor=A.+Guitartauthor=N.+Milpiedauthor=O.+Kosmiderauthor=I.+Vigonauthor=V.+Desplatauthor=I.+Dusanter-Fourtauthor=J.+M.+Pasquet&title=Hematopoietic+niche+drives+FLT3-ITD+acute+myeloid+leukemia+resistance+to+quizartinib+via+STAT5-and+hypoxia-dependent+upregulation+of+AXL&doi=10.3324%2Fhaematol.2018.205385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5- and hypoxia-dependent upregulation of AXL</span></div><div class="casAuthors">Dumas, Pierre-Yves; Naudin, Cecile; Martin-Lanneree, Severine; Izac, Brigitte; Casetti, Luana; Mansier, Olivier; Rousseau, Benoit; Artus, Alexandre; Dufossee, Melody; Giese, Alban; Dubus, Pierre; Pigneux, Arnaud; Praloran, Vincent; Bidet, Audrey; Villacreces, Arnaud; Guitart, Amelie; Milpied, Noeel; Kosmider, Olivier; Vigon, Isabelle; Desplat, Vanessa; Dusanter-Fourt, Isabelle; Pasquet, Jean-Max</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2017-2027</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">1592-8721</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">Internal tandem duplication in Fms-like tyrosine kinase 3 (FLT3-ITD) is the most frequent mutation obsd. in acute myeloid leukemia (AML) and correlates with poor prognosis.  FLT3 tyrosine kinase inhibitors are promising for targeted therapy.  Here, we investigated mechanisms dampening the response to the FLT3 inhibitor quizartinib, which is specific to the hematopoietic niche.  Using AML primary samples and cell lines, we demonstrate that convergent signals from the hematopoietic microenvironment drive FLT3-ITD cell resistance to quizartinib through the expression and activation of the tyrosine kinase receptor AXL.  Indeed, cytokines sustained phosphorylation of the transcription factor STAT5 in quizartinibtreated cells, which enhanced AXL expression by direct binding of a conserved motif in its genomic sequence.  Likewise, hypoxia, another wellknown hematopoietic niche hallmark, also enhanced AXL expression.  Finally, in a xenograft mouse model, inhibition of AXL significantly increased the response of FLT3-ITD cells to quizartinib exclusively within a bone marrow environment.  These data highlight a new bypass mechanism specific to the hematopoietic niche that hampers the response to quizartinib through combined upregulation of AXL activity.  Targeting this signaling offers the prospect of a new therapy to eradicate resistant FLT3-ITD leukemic cells hidden within their specific microenvironment, thereby preventing relapses from FLT3-ITD clones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPXvYzzeCN8LVg90H21EOLACvtfcHk0lglz_186aFgCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFChtLnI&md5=a25cc5bbd8707b648e34705d99f8b247</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2018.205385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2018.205385%26sid%3Dliteratum%253Aachs%26aulast%3DDumas%26aufirst%3DP.%2BY.%26aulast%3DNaudin%26aufirst%3DC.%26aulast%3DMartin-Lanneree%26aufirst%3DS.%26aulast%3DIzac%26aufirst%3DB.%26aulast%3DCasetti%26aufirst%3DL.%26aulast%3DMansier%26aufirst%3DO.%26aulast%3DRousseau%26aufirst%3DB.%26aulast%3DArtus%26aufirst%3DA.%26aulast%3DDufossee%26aufirst%3DM.%26aulast%3DGiese%26aufirst%3DA.%26aulast%3DDubus%26aufirst%3DP.%26aulast%3DPigneux%26aufirst%3DA.%26aulast%3DPraloran%26aufirst%3DV.%26aulast%3DBidet%26aufirst%3DA.%26aulast%3DVillacreces%26aufirst%3DA.%26aulast%3DGuitart%26aufirst%3DA.%26aulast%3DMilpied%26aufirst%3DN.%26aulast%3DKosmider%26aufirst%3DO.%26aulast%3DVigon%26aufirst%3DI.%26aulast%3DDesplat%26aufirst%3DV.%26aulast%3DDusanter-Fourt%26aufirst%3DI.%26aulast%3DPasquet%26aufirst%3DJ.%2BM.%26atitle%3DHematopoietic%2520niche%2520drives%2520FLT3-ITD%2520acute%2520myeloid%2520leukemia%2520resistance%2520to%2520quizartinib%2520via%2520STAT5-and%2520hypoxia-dependent%2520upregulation%2520of%2520AXL%26jtitle%3DHaematologica%26date%3D2019%26volume%3D104%26issue%3D10%26spage%3D2017%26epage%3D2027%26doi%3D10.3324%2Fhaematol.2018.205385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burslem, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Enhancing antiproliferative activity and selectivity of a FLT-3 inhibitor by proteolysis targeting chimera conversion</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>140</i></span> (<span class="NLM_issue">48</span>),  <span class="NLM_fpage">16428</span>– <span class="NLM_lpage">16432</span>, <span class="refDoi"> DOI: 10.1021/jacs.8b10320</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.8b10320" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitF2qtr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2018&pages=16428-16432&issue=48&author=G.+M.+Burslemauthor=J.+Songauthor=X.+Chenauthor=J.+Hinesauthor=C.+M.+Crews&title=Enhancing+antiproliferative+activity+and+selectivity+of+a+FLT-3+inhibitor+by+proteolysis+targeting+chimera+conversion&doi=10.1021%2Fjacs.8b10320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion</span></div><div class="casAuthors">Burslem, George M.; Song, Jayoung; Chen, Xin; Hines, John; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">16428-16432</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase FLT-3 is frequently mutated in acute myeloid leukemia; however, current small mol. inhibitors suffer from limited efficacy in the clinic.  Conversion of a FLT-3 inhibitor (quizartinib) into a proteolysis targeting chimera (PROTAC) results in a compd. that induces degrdn. of FLT-3 ITD mutant at low nanomolar concns.  Furthermore, the PROTAC is capable of inhibiting cell growth more potently than the warhead alone while inhibiting fewer off-target kinases.  This enhanced antiproliferative activity occurs, despite a slight redn. in the PROTAC's kinase inhibitory activity, via an increased level of apoptosis induction suggesting nonkinase roles for the FLT-3 ITD protein.  Addnl., the PROTAC is capable of inducing FLT-3 ITD degrdn. in vivo.  These results suggest that degrdn. of FLT-3 ITD may provide a useful method for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBxw_nAEQydLVg90H21EOLACvtfcHk0liUNAJz4WrxeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitF2qtr7P&md5=52529d0c3f49052bd2a66c893e98e694</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Fjacs.8b10320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.8b10320%26sid%3Dliteratum%253Aachs%26aulast%3DBurslem%26aufirst%3DG.%2BM.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DEnhancing%2520antiproliferative%2520activity%2520and%2520selectivity%2520of%2520a%2520FLT-3%2520inhibitor%2520by%2520proteolysis%2520targeting%2520chimera%2520conversion%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2018%26volume%3D140%26issue%3D48%26spage%3D16428%26epage%3D16432%26doi%3D10.1021%2Fjacs.8b10320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eide, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabriskie, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage Stevens, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antelope, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellore, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Than, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clair, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowler, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomicter, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senina, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szankasi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cayuela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tognon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Hare, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W.</span></span> <span> </span><span class="NLM_article-title">Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">443</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2019.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2Fj.ccell.2019.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=31543464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVSru77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2019&pages=431-443&issue=4&author=C.+A.+Eideauthor=M.+S.+Zabriskieauthor=S.+L.+Savage+Stevensauthor=O.+Antelopeauthor=N.+A.+Velloreauthor=H.+Thanauthor=A.+R.+Schultzauthor=P.+Clairauthor=A.+D.+Bowlerauthor=A.+D.+Pomicterauthor=D.+Yanauthor=A.+V.+Seninaauthor=W.+Qiangauthor=T.+W.+Kelleyauthor=P.+Szankasiauthor=M.+C.+Heinrichauthor=J.+W.+Tynerauthor=D.+Reaauthor=J.+M.+Cayuelaauthor=D.+W.+Kimauthor=C.+E.+Tognonauthor=T.+O%E2%80%99Hareauthor=B.+J.+Drukerauthor=M.+W.+Deininger&title=Combining+the+allosteric+inhibitor+asciminib+with+ponatinib+suppresses+emergence+of+and+restores+efficacy+against+highly+resistant+BCR-ABL1+mutants&doi=10.1016%2Fj.ccell.2019.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants</span></div><div class="casAuthors">Eide, Christopher A.; Zabriskie, Matthew S.; Savage Stevens, Samantha L.; Antelope, Orlando; Vellore, Nadeem A.; Than, Hein; Schultz, Anna Reister; Clair, Phillip; Bowler, Amber D.; Pomicter, Anthony D.; Yan, Dongqing; Senina, Anna V.; Qiang, Wang; Kelley, Todd W.; Szankasi, Philippe; Heinrich, Michael C.; Tyner, Jeffrey W.; Rea, Delphine; Cayuela, Jean-Michel; Kim, Dong-Wook; Tognon, Cristina E.; O'Hare, Thomas; Druker, Brian J.; Deininger, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">431-443.e5</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">BCR-ABL1 point mutation-mediated resistance to tyrosine kinase inhibitor (TKI) therapy in Philadelphia chromosome-pos. (Ph+) leukemia is effectively managed with several approved drugs, including ponatinib for BCR-ABL1T315I-mutant disease.  However, therapy options are limited for patients with leukemic clones bearing multiple BCR-ABL1 mutations.  Asciminib, an allosteric inhibitor targeting the myristoyl-binding pocket of BCR-ABL1, is active against most single mutants but ineffective against all tested compd. mutants.  We demonstrate that combining asciminib with ATP site TKIs enhances target inhibition and suppression of resistant outgrowth in Ph+ clin. isolates and cell lines.  Inclusion of asciminib restores ponatinib's effectiveness against currently untreatable compd. mutants at clin. achievable concns.  Our findings support combining asciminib with ponatinib as a treatment strategy for this molecularly defined group of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYwcxeCHYx87Vg90H21EOLACvtfcHk0lizkko4HtC78Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVSru77M&md5=77fb1a5430c13932b2af244e8749e7ee</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2019.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2019.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DZabriskie%26aufirst%3DM.%2BS.%26aulast%3DSavage%2BStevens%26aufirst%3DS.%2BL.%26aulast%3DAntelope%26aufirst%3DO.%26aulast%3DVellore%26aufirst%3DN.%2BA.%26aulast%3DThan%26aufirst%3DH.%26aulast%3DSchultz%26aufirst%3DA.%2BR.%26aulast%3DClair%26aufirst%3DP.%26aulast%3DBowler%26aufirst%3DA.%2BD.%26aulast%3DPomicter%26aufirst%3DA.%2BD.%26aulast%3DYan%26aufirst%3DD.%26aulast%3DSenina%26aufirst%3DA.%2BV.%26aulast%3DQiang%26aufirst%3DW.%26aulast%3DKelley%26aufirst%3DT.%2BW.%26aulast%3DSzankasi%26aufirst%3DP.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DRea%26aufirst%3DD.%26aulast%3DCayuela%26aufirst%3DJ.%2BM.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DTognon%26aufirst%3DC.%2BE.%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DCombining%2520the%2520allosteric%2520inhibitor%2520asciminib%2520with%2520ponatinib%2520suppresses%2520emergence%2520of%2520and%2520restores%2520efficacy%2520against%2520highly%2520resistant%2520BCR-ABL1%2520mutants%26jtitle%3DCancer%2520Cell%26date%3D2019%26volume%3D36%26issue%3D4%26spage%3D431%26epage%3D443%26doi%3D10.1016%2Fj.ccell.2019.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teicher, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, R.</span></span> <span> </span><span class="NLM_article-title">Antibody–drug conjugates for cancer therapy</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">e254</span>– <span class="NLM_lpage">e262</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(16)30030-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=10.1016%2FS1470-2045%2816%2930030-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=27299281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;key=1%3ACAS%3A528%3ADC%252BC28XptFCnsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=e254-e262&issue=6&author=A.+Thomasauthor=B.+A.+Teicherauthor=R.+Hassan&title=Antibody%E2%80%93drug+conjugates+for+cancer+therapy&doi=10.1016%2FS1470-2045%2816%2930030-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates for cancer therapy</span></div><div class="casAuthors">Thomas, Anish; Teicher, Beverly A.; Hassan, Raffit</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e254-e262</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Antibody-drug conjugates are monoclonal antibodies conjugated to cytotoxic agents.  They use antibodies that are specific to tumor cell-surface proteins and, thus, have tumor specificity and potency not achievable with traditional drugs.  Design of effective antibody-drug conjugates for cancer therapy requires selection of an appropriate target, a monoclonal antibody against the target, potent cytotoxic effector mols., and conjugation of the monoclonal antibody to cytotoxic agents.  Substantial advances in all these aspects in the past decade have resulted in regulatory approval of ado-trastuzumab emtansine and brentuximab vedotin for clin. use.  Several promising antibody-drug conjugates are now in late-phase clin. testing.  Ongoing efforts are focused on identifying better targets, more effective cytotoxic payloads, and further improvements in antibody-drug linker technol.  Improved understanding of the mechanistic basis of antibody-drug conjugate activity will enable design of rational combination therapies with other agents, including immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5Z8wfiqGgZ7Vg90H21EOLACvtfcHk0lizkko4HtC78Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptFCnsbc%253D&md5=375b381d7f5b23f36453aaa50d46f4b7</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2816%2930030-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252816%252930030-4%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DTeicher%26aufirst%3DB.%2BA.%26aulast%3DHassan%26aufirst%3DR.%26atitle%3DAntibody%25E2%2580%2593drug%2520conjugates%2520for%2520cancer%2520therapy%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26issue%3D6%26spage%3De254%26epage%3De262%26doi%3D10.1016%2FS1470-2045%2816%2930030-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB','PDB','1RJB'); return false;">PDB: 1RJB</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7','PDB','4RT7'); return false;">PDB: 4RT7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XUF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XUF','PDB','4XUF'); return false;">PDB: 4XUF</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG','PDB','1PKG'); return false;">PDB: 1PKG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6IL3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6IL3','PDB','6IL3'); return false;">PDB: 6IL3</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5X02" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5X02','PDB','5X02'); return false;">PDB: 5X02</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01851&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-6%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01851%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01851" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67992dcf9ce31949","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
